PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Shukolyukov, A; Lugmair, GW				Shukolyukov, A; Lugmair, GW			Isotopic evidence for the Cretaceous-Tertiary impactor and its type	SCIENCE			English	Article							EARLY SOLAR-SYSTEM; BOUNDARY; SEDIMENTS; CHROMIUM; EXTINCTIONS; ABUNDANCES; METAL	High-precision mass spectrometric analysis of chromium in sediment samples from the Cretaceous-Tertiary (K-T) boundary coincident with the extinction of numerous organisms on Earth confirms the cosmic origin of the K-T phenomenon. The isotopic composition of chromium in K-T boundary samples from Stevns Klint, Denmark, and Caravaca, Spain, is different from that of Earth and indicates its extraterrestrial source. The chromium isotopic signature is consistent with a carbonaceous chondrite-type impactor. The observed differences in the chromium isotopic composition among various meteorite classes can serve as a diagnostic tool for deciphering the nature of impactors that have collided with Earth during its history.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Max Planck Inst Chem Cosmochem, D-55020 Mainz, Germany	University of California System; University of California San Diego; Scripps Institution of Oceanography; Max Planck Society	Shukolyukov, A (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.							ALVAREZ LW, 1980, SCIENCE, V208, P1095, DOI 10.1126/science.208.4448.1095; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; BIRCK JL, 1985, GEOPHYS RES LETT, V12, P745, DOI 10.1029/GL012i011p00745; BROWNLEE DE, 1977, COMETS ASTEROIDS MET, P137; DIA A, 1989, CHEM GEOL, V75, P291, DOI 10.1016/0009-2541(89)90002-8; EUGSTER O, 1985, EARTH PLANET SC LETT, V74, P27, DOI 10.1016/0012-821X(85)90163-3; Farley KA, 1998, SCIENCE, V280, P1250, DOI 10.1126/science.280.5367.1250; GALER SJG, 1989, GEOPHYS RES LETT, V16, P1302; HILDEBRAND AR, 1991, GEOLOGY, V19, P867, DOI 10.1130/0091-7613(1991)019<0867:CCAPCT>2.3.CO;2; HILLS JG, 1981, ASTRON J, V86, P1730, DOI 10.1086/113058; HUTCHEON ID, 1992, LUNAR PLANET SCI, V23, P565; KYTE FT, 1980, NATURE, V288, P651, DOI 10.1038/288651a0; KYTE FT, 1985, EARTH PLANET SC LETT, V73, P183, DOI 10.1016/0012-821X(85)90067-6; KYTE FT, 1996, GEOL SOC AM SPEC PAP, V307, P389; KYTE FT, IN PRESS NATURE; LUCK JM, 1983, SCIENCE, V222, P613, DOI 10.1126/science.222.4624.613; LUGMAIR GW, IN PRESS GEOCHIM COS; NYQUIST LE, 1997, LUNAR PLANET SCI, V28, P1033; OFFICER CB, 1987, NATURE, V326, P143, DOI 10.1038/326143a0; PAPANASTASSIOU DA, 1986, ASTROPHYS J, V308, pL27, DOI 10.1086/184737; Podosek FA, 1997, METEORIT PLANET SCI, V32, P617, DOI 10.1111/j.1945-5100.1997.tb01547.x; RAMPINO MR, 1984, NATURE, V308, P709, DOI 10.1038/308709a0; ROTARU M, 1990, LPSC, V21, P1037; RUSSELL DA, 1979, ANNU REV EARTH PL SC, V7, P163, DOI 10.1146/annurev.ea.07.050179.001115; Schuraytz BC, 1996, SCIENCE, V271, P1573, DOI 10.1126/science.271.5255.1573; SCHURAYTZ BC, 1998, LUN PLAN SCI C, V29, P1935; SHIELDS WR, 1966, J RES NBS A PHYS CH, VA 70, P193, DOI 10.6028/jres.070A.016; Taylor S.R., 1985, CONTINENTAL CRUST IT, V94, P57	29	171	176	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					927	929		10.1126/science.282.5390.927	http://dx.doi.org/10.1126/science.282.5390.927			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794759				2022-12-24	WOS:000076727300044
J	Stratigos, AJ; Arndt, KA; Dover, JS				Stratigos, AJ; Arndt, KA; Dover, JS			Advances in cutaneous aesthetic surgery	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LIPOSUCTION; IMPLANTS; TERM; SKIN		Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Dermatol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Dover, JS (corresponding author), Beth Israel Deaconess Med Ctr, Cosmet Surg & Laser Ctr, 25 Boylston St,Suite 104, Chestnut Hill, MA 02167 USA.							ADAMSON PA, 1990, J OTOLARYNGOL, V19, P267; Bernstein LJ, 1997, DERMATOL SURG, V23, P519, DOI 10.1111/j.1524-4725.1997.tb00677.x; Carruthers A, 1996, J AM ACAD DERMATOL, V34, P788, DOI 10.1016/S0190-9622(96)90016-X; CLARK DP, 1989, J AM ACAD DERMATOL, V21, P992, DOI 10.1016/S0190-9622(89)70288-7; Fitzpatrick RE, 1996, ARCH DERMATOL, V132, P395, DOI 10.1001/archderm.132.4.395; Goldberg DJ, 1998, DERMATOL SURG, V24, P619, DOI 10.1111/j.1524-4725.1998.tb04217.x; Grover R, 1998, BRIT J PLAST SURG, V51, P8, DOI 10.1016/S0007-1226(97)90090-4; Hruza GJ, 1996, ARCH DERMATOL, V132, P451, DOI 10.1001/archderm.132.4.451; Kauvar ANB, 1996, DERMATOL SURG, V22, P343, DOI 10.1111/j.1524-4725.1996.tb00328.x; KELLY K, 1998, LASERS SURG MED S, V10, P38; KLEIN JA, 1990, DERMATOL CLIN, V8, P425, DOI 10.1016/S0733-8635(18)30474-1; Maxwell GP, 1998, PLAST RECONSTR SURG, V101, P189, DOI 10.1097/00006534-199801000-00034; MOLE B, 1992, PLAST RECONSTR SURG, V90, P200, DOI 10.1097/00006534-199290020-00007; Olenius M, 1998, AESTHET PLAST SURG, V22, P97, DOI 10.1007/s002669900172; PINSKI KS, 1992, J DERMATOL SURG ONC, V18, P179, DOI 10.1111/j.1524-4725.1992.tb02795.x; West TB, 1998, DERMATOL SURG, V24, P510, DOI 10.1111/j.1524-4725.1998.tb04198.x; ZUBER M, 1993, NEUROLOGY, V43, P1715, DOI 10.1212/WNL.43.9.1715	17	2	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1397	1398		10.1001/jama.280.16.1397	http://dx.doi.org/10.1001/jama.280.16.1397			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9800989				2022-12-24	WOS:000076546900018
J	Christie, JD; Rosen, IM; Bellini, LM; Inglesby, TV; Lindsay, J; Alper, A; Asch, DA				Christie, JD; Rosen, IM; Bellini, LM; Inglesby, TV; Lindsay, J; Alper, A; Asch, DA			Prescription drug use and self-prescription among resident physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH-CARE	Context.-Self-prescription is common among practicing physicians, but little is known about the practice among resident physicians. Objective.-To determine prescription drug use and self-prescription among US resident physicians. Design and Setting.-Anonymous mail survey of all resident physicians in 4 US categorical internal medicine training programs in February 1997. Main Outcome Measures.-Self-reported use of health care services and prescription medications and how they were obtained. Results.-A total of 316 (83%) of 381 residents responded; 244 residents (78%) reported using at least 1 prescription medicine and 162 residents (52%) reported self-prescribing medications. Twenty-five percent of all medications and 42% of self-prescribed medications were obtained from a sample cabinet; 7% of all medications and 11% of self-prescribed medications were obtained directly from a pharmaceutical company representative. Conclusions.-Self-prescription is common among resident physicians. Although self-prescription is difficult to evaluate, the source of these medications and the lack of oversight of medication use raise questions about the practice.	Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Ctr Bioeth, Philadelphia, PA 19104 USA; Vet Affairs Med Ctr, Philadelphia, PA USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA USA; Tulane Univ, Sch Med, Dept Med, New Orleans, LA 70112 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; Johns Hopkins University; Stanford University; Tulane University	Asch, DA (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, 3641 Locust Walk, Philadelphia, PA 19104 USA.			Asch, David/0000-0002-7970-286X				Allibone A, 1981, J R Coll Gen Pract, V31, P728; Asch DA, 1996, EPIDEMIOLOGY, V7, P550, DOI 10.1097/00001648-199609000-00020; CHAMBERS R, 1992, BRIT J GEN PRACT, V42, P153; CHAMBERS RM, 1993, FAM PRACT, V10, P416, DOI 10.1093/fampra/10.4.416; MCCAULIFFE WE, 1986, NEW ENGL J MED, V315, P805; Selley P, 1988, Health Trends, V20, P128; WACHTEL TJ, 1995, J GEN INTERN MED, V10, P261, DOI 10.1007/BF02599883; Westfall JM, 1997, JAMA-J AM MED ASSOC, V278, P141, DOI 10.1001/jama.278.2.141	8	60	60	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1253	1255		10.1001/jama.280.14.1253	http://dx.doi.org/10.1001/jama.280.14.1253			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786376	Bronze			2022-12-24	WOS:000076357900032
J	Zareba, W; Moss, AJ; Schwartz, PJ; Vincent, GM; Robinson, JL; Priori, SG; Benhorin, J; Locati, EH; Towbin, JA; Keating, MT; Lehmann, MH; Hall, WJ				Zareba, W; Moss, AJ; Schwartz, PJ; Vincent, GM; Robinson, JL; Priori, SG; Benhorin, J; Locati, EH; Towbin, JA; Keating, MT; Lehmann, MH; Hall, WJ		Int Long-QT Syndrome Registry Res Grp	Influence of the genotype on the clinical course of the long-QT syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARDIAC POTASSIUM CURRENT; HEART-RATE; MUTATIONS; GENE; ARRHYTHMIAS; INTERVAL; PATTERNS; FAMILIES; MODELS; SCN5A	Background The congenital long-QT syndrome, caused by mutations in cardiac potassium-channel genes (KVLQT1 at the LOT1 locus and HERG at the LQT2 locus) and the sodium-channel gene (SCN5A at the LQT3 locus), has distinct repolarization patterns on electrocardiography, but it is not known whether the genotype influences the clinical course of the disease. Methods We determined the genotypes of 541 of 1378 members of 38 families enrolled in the International Long-QT Syndrome Registry: 112 had mutations at the LOT1 locus, 72 had mutations at the LQT2 locus, and 62 had mutations at the LQT3 locus. We determined the cumulative probability and lethality of cardiac events (syncope, aborted cardiac arrest, or sudden death) occurring from birth through the age of 40 years according to genotype in the 246 gene carriers and in all 1378 members of the families studied. Results The frequency of cardiac events was higher among subjects with mutations at the LQT1 locus (63 percent) or the LQT2 locus (46 percent) than among subjects with mutations at the LQT3 locus (18 percent) (P<0.001 for the comparison of all three groups). In a multivariate Cox analysis, the genotype and the QT interval corrected for heart rate were significant independent predictors of a first cardiac event. The cumulative mortality through the age of 40 among members of the three groups of families studied was similar; however, the likelihood of dying during a cardiac event was significantly higher (P<0.001) among families with mutations at the LQT3 locus (20 percent) than among those with mutations at the LQT1 locus (4 percent) or the LQT2 locus (4 percent). Conclusions The genotype of the long-QT syndrome influences the clinical course. The risk of cardiac events is significantly higher among subjects with mutations at the LQT1 or LQT2 locus than among those with mutations at the LQT3 locus. Although cumulative mortality is similar regardless of the genotype, the percentage of cardiac events that are lethal is significantly higher in families with mutations at the LQT3 locus. (N Engl J Med 1998;339: 960-5.) (C)1998, Massachusetts Medical Society.	Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Community & Prevent Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY 14642 USA; Univ Milan, Ctr Fisiol Clin & Ipertens, Milan, Italy; Osped Maggiore, Ist Ricovero & Cura Carattene Sci, Milan, Italy; Univ Pavia, Dept Cardiol, I-27100 Pavia, Italy; Policlin San Matteo, Ist Ricovero & Cura Carattene Sci, I-27100 Pavia, Italy; LDS Hosp, Salt Lake City, UT USA; Mol Cardiol Fdn S Maugeri, Pavia, Italy; Univ Perugia, Dept Cardiol, I-06100 Perugia, Italy; Hebrew Univ Jerusalem, Bikur Cholim Hosp, Jerusalem, Israel; Texas Childrens Hosp, Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Univ Utah, Howard Hughes Med Inst, Salt Lake City, UT USA; Sinai Hosp, Arrhythmia Ctr, Detroit, MI 48235 USA	University of Rochester; University of Rochester; University of Rochester; University of Milan; University of Pavia; IRCCS Fondazione San Matteo; University of Perugia; Hebrew University of Jerusalem; Baylor College of Medicine; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	Zareba, W (corresponding author), Univ Rochester, Med Ctr, Heart Res Follow Up Program, Box 653, Rochester, NY 14642 USA.		Priori, Silvia G/ABH-6894-2020; napolitano, carlo/ABI-4608-2020; Locati, Emanuela Teresina/AAW-3821-2020; Napolitano, Carlo/K-4760-2016; Towbin, Jeffrey A./J-5595-2019; Schwartz, Peter J/J-4267-2016; Priori, Silvia G G/A-6116-2014	Priori, Silvia G/0000-0001-6877-0288; napolitano, carlo/0000-0002-7643-4628; Locati, Emanuela Teresina/0000-0002-4488-0455; Napolitano, Carlo/0000-0002-7643-4628; Towbin, Jeffrey A./0000-0002-6585-714X; Schwartz, Peter J/0000-0003-0367-1048; Priori, Silvia G G/0000-0001-6877-0288; Medina, Aharon/0000-0002-0274-1406	NHLBI NIH HHS [HL-51618, HL-33843] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033843, R01HL051618] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALI RH, 1997, PACING CLIN ELECTROP, V20, P1072; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BOYLE MB, 1987, NATURE, V330, P373, DOI 10.1038/330373a0; COX DR, 1972, J R STAT SOC B, V34, P187; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Drici MD, 1996, CIRCULATION, V94, P1471, DOI 10.1161/01.CIR.94.6.1471; ElSherif N, 1996, CIRC RES, V79, P474, DOI 10.1161/01.RES.79.3.474; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lehmann MH, 1997, J AM COLL CARDIOL, V29, P93, DOI 10.1016/S0735-1097(96)00454-8; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; MOSS AJ, 1995, CIRCULATION, V92, P2929, DOI 10.1161/01.CIR.92.10.2929; ROMANO C, 1963, Clin Pediatr (Bologna), V45, P656; ROSERO SZ, 1997, ANN NONINVAS ELECTRO, V2, P274, DOI DOI 10.1111/j.1542-474X.1997.tb00336.x; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; SCHWARTZ PJ, 1993, CIRCULATION, V88, P782, DOI 10.1161/01.CIR.88.2.782; SCHWARTZ PJ, 1997, CIRCULATION S1, V96, P212; Shimizu W, 1997, CIRCULATION, V96, P2038, DOI 10.1161/01.CIR.96.6.2038; SHIMIZU W, 1997, CIRCULATION, V96, P554; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARD O C, 1964, J Ir Med Assoc, V54, P103; ZAREBA W, 1995, J AM COLL CARDIOL, V26, P1685, DOI 10.1016/0735-1097(95)60383-2	29	528	548	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					960	965		10.1056/NEJM199810013391404	http://dx.doi.org/10.1056/NEJM199810013391404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753711				2022-12-24	WOS:000076186900004
J	Dix, P				Dix, P			Access to the dead: the role of relatives in the aftermath of disaster	LANCET			English	Article											Dix, P (corresponding author), 7 Firwood Close, Woking GU21 1UQ, Surrey, England.								0	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1061	1062		10.1016/S0140-6736(98)06491-5	http://dx.doi.org/10.1016/S0140-6736(98)06491-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759773				2022-12-24	WOS:000076121800053
J	Le Good, JA; Ziegler, WH; Parekh, DB; Alessi, DR; Cohen, P; Parker, PJ				Le Good, JA; Ziegler, WH; Parekh, DB; Alessi, DR; Cohen, P; Parker, PJ			Protein kinase C isotypes controlled by phosphoinositide 3-kinase through the protein kinase PDK1	SCIENCE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; PKC-DELTA; EXPRESSION; ALPHA; ACTIVATION	Phosphorylation sites in members of the protein kinase A (PKA), PKG, and PKC kinase subfamily are conserved. Thus, the PKB kinase PDK1 may be responsible for the phosphorylation of PKC isotypes. PDK1 phosphorylated the activation Loop sites of PKC zeta and PKC delta in vitro and in a phosphoinositide 3-kinase (PI 3-kinase)-dependent manner in vivo in human embryonic kidney (293) cells. All members of the PKC family tested formed complexes with PDK1, PDK1-dependent phosphorylation of PKC delta in vitro was stimulated by combined PKC and PDK1 activators. The activation Loop phosphorylation of PKC delta in response to serum stimulation of cells was PI 3-kinase-dependent and was enhanced by PDK1 coexpression.	Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England; Univ Dundee, Inst Med Sci, Dept Biochem, Dundee DD1 4HN, Scotland	Cancer Research UK; University of Dundee	Parker, PJ (corresponding author), Imperial Canc Res Fund, Prot Phosphorylat Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Parker, Peter j/D-5192-2013	parker, peter/0000-0002-6218-2933; Ziegler, Wolfgang H./0000-0003-4529-1916; Le Good, Jessie/0000-0002-6332-9239; Alessi, Dario/0000-0002-2140-9185				Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; FLINT AJ, 1990, SCIENCE, V249, P408, DOI 10.1126/science.2377895; Garcia-Paramio P, 1998, BIOCHEM J, V333, P631, DOI 10.1042/bj3330631; GOODE NT, 1994, FEBS LETT, V340, P145, DOI 10.1016/0014-5793(94)80190-8; Hansra G, 1996, J BIOL CHEM, V271, P32785, DOI 10.1074/jbc.271.51.32785; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGOOD JA, UNPUB; MANIATIS T, 1989, MOL CLONIG LAB MANUA; Moriya S, 1996, P NATL ACAD SCI USA, V93, P151, DOI 10.1073/pnas.93.1.151; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; OLIVIER AR, 1994, J BIOL CHEM, V269, P2758; ORR JW, 1994, J BIOL CHEM, V269, P27715; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; STABEL S, 1991, METHOD ENZYMOL, V200, P670; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; WHELAN DH, 1998, SCIENCE, V279, P710; ZIEGLER W, UNPUB	22	955	980	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	1998	281	5385					2042	2045		10.1126/science.281.5385.2042	http://dx.doi.org/10.1126/science.281.5385.2042			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748166				2022-12-24	WOS:000076161800060
J	Sutton, RB; Fasshauer, D; Jahn, R; Brunger, AT				Sutton, RB; Fasshauer, D; Jahn, R; Brunger, AT			Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 angstrom resolution	NATURE			English	Article							MEMBRANE-FUSION COMPLEX; MACROMOLECULAR STRUCTURES; CLOSTRIDIAL NEUROTOXINS; COILED COILS; IN-VITRO; PROTEIN; SYNTAXIN; SNAP-25; PHASES; GLYCOPROTEIN	The evolutionarily conserved SNARE proteins and their complexes are involved in the fusion of vesicles with their target membranes; however, the overall organization and structural details of these complexes are unknown. Here we report the X-ray crystal structure at 2.4 Angstrom resolution of a core synaptic fusion complex containing syntaxin-1A, synaptobrevin-II and SNAP-25B. The structure reveals a highly twisted and parallel four-helix bundle that differs from the bundles described for the haemagglutinin and HIV/SIV gp41 membrane-fusion proteins. Conserved leucine-zipper-like layers are found at the centre of the synaptic fusion complex. Embedded within these leucine-ripper layers is an ionic layer consisting of an arginine and three glutamine residues contributed from each of the four alpha-helices. These residues are highly conserved across the entire SNARE family. The regions flanking the leucine-zipper-like layers contain a hydrophobic core similar to that of more general four-helix-bundle proteins. The surface of the synaptic fusion complex is highly grooved and possesses distinct hydrophilic, hydrophobic and charged regions. These characteristics may be important for membrane fusion and for the binding of regulatory factors affecting neurotransmission.	Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Max Planck Inst Biophys Chem, Dept Neurobiol, D-37077 Gottingen, Germany	Howard Hughes Medical Institute; Yale University; Yale University; Max Planck Society	Brunger, AT (corresponding author), Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA.	brunger@laplace.csb	Fasshauer, Dirk/B-1563-2013	Fasshauer, Dirk/0000-0002-1040-4282; Brunger, Axel/0000-0001-5121-2036; Jahn, Reinhard/0000-0003-1542-3498				BERNARD A, 1995, CURR PROTOCOL PROTEI, P1; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; Bricogne G, 1997, METHOD ENZYMOL, V276, P361, DOI 10.1016/S0076-6879(97)76069-5; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burling FT, 1996, SCIENCE, V271, P72, DOI 10.1126/science.271.5245.72; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fasshauer D, 1998, BIOCHEMISTRY-US, V37, P10354, DOI 10.1021/bi980542h; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Fasshauer D, 1997, J BIOL CHEM, V272, P4582, DOI 10.1074/jbc.272.7.4582; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; Hao JC, 1997, J NEUROSCI, V17, P1596; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JAHN R, 1994, ANN NY ACAD SCI, V733, P245, DOI 10.1111/j.1749-6632.1994.tb17274.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JORGENSEN WL, 1988, J AM CHEM SOC, V110, P1657, DOI 10.1021/ja00214a001; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; LEAHY DJ, 1994, PROTEINS, V19, P48, DOI 10.1002/prot.340190107; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PANNU NS, IN PRESS ACTA CRYS D; PHILLIPS JC, 1980, ACTA CRYSTALLOGR A, V36, P856, DOI 10.1107/S0567739480001817; Read RJ, 1997, METHOD ENZYMOL, V277, P110, DOI 10.1016/S0076-6879(97)77009-5; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rice LM, 1997, FEBS LETT, V415, P49, DOI 10.1016/S0014-5793(97)01091-0; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Saifee O, 1998, MOL BIOL CELL, V9, P1235, DOI 10.1091/mbc.9.6.1235; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Weimbs T, 1998, TRENDS CELL BIOL, V8, P260, DOI 10.1016/S0962-8924(98)01285-9; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; YONG K, 1990, ACTA CRYSTALLOGR A, V46, P41	50	1832	1888	0	149	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					347	353		10.1038/26412	http://dx.doi.org/10.1038/26412			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759724				2022-12-24	WOS:000076083800043
J	Ushikubi, F; Segi, E; Sugimoto, Y; Murata, T; Matsuoka, T; Kobayashi, T; Hizaki, H; Tuboi, K; Katsuyama, M; Ichikawa, A; Tanaka, T; Yoshida, N; Narumiya, S				Ushikubi, F; Segi, E; Sugimoto, Y; Murata, T; Matsuoka, T; Kobayashi, T; Hizaki, H; Tuboi, K; Katsuyama, M; Ichikawa, A; Tanaka, T; Yoshida, N; Narumiya, S			Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3	NATURE			English	Article							PROSTANOID RECEPTORS; NEURAL MEDIATOR; NERVOUS-SYSTEM; FEVER; MECHANISM; EICOSANOIDS	Fever, a hallmark of disease, is elicited by exogenous pyrogens, that is, cellular components, such as lipopolysaccharide (LPS), of infectious organisms, as well as by non-infectious inflammatory insults. Both stimulate the production of cytokines, such as interleukin (IL)-1 beta, that act on the brain as endogenous pyrogens'. Fever can be suppressed by aspirin-like anti-inflammatory drugs. As these drugs share the ability to inhibit prostaglandin biosynthesis(2), it is thought that a prostaglandin is important in fever generation. Prostaglandin E-2 (PGE(2)) may be a neural mediator of fever(3), but this has been much debated(1,4-7). PGE, acts by interacting with four subtypes of PGE receptor, the EP1, EP2, EP3 and EP4 receptors(8). Here we generate mice lacking each of these receptors by homologous recombination. Only mice lacking the EP3 receptor fail to show a febrile response to PGE(2) and to either IL-1 beta or LPS. Our results establish that PGE(2) mediates fever generation in response to both exogenous and endogenous pyrogens by acting at the EP3 receptor.	Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan; Kyoto Univ, Dept Pharmaceut Sci, Dept Physiol Chem, Kyoto 6068315, Japan; Osaka Med Ctr Maternal & Child Hlth, Res Inst, Div Mol & Cellular Immunol, Osaka 5941101, Japan	Kyoto University; Kyoto University	Narumiya, S (corresponding author), Kyoto Univ, Fac Med, Dept Pharmacol, Kyoto 6068315, Japan.	snaru@mfour.med.kyoto-u.ac.jp	Tanaka, Takashi/O-8254-2015; Sugimoto, Yukihiko/AAV-6470-2021	Sugimoto, Yukihiko/0000-0001-6973-932X; Segi-Nishida, Eri/0000-0002-0803-6513; Murata, Takahiko/0000-0003-0132-5424				ALEXANDER SJ, 1989, PFLUG ARCH EUR J PHY, V413, P451, DOI 10.1007/BF00594172; BISHAI I, 1987, CAN J PHYSIOL PHARM, V65, P2225, DOI 10.1139/y87-352; CRANSTON WI, 1976, J PHYSIOL-LONDON, V259, P239, DOI 10.1113/jphysiol.1976.sp011464; DAVATELIS G, 1989, SCIENCE, V243, P1066, DOI 10.1126/science.2646711; DIPAULI R, 1972, J IMMUNOL, V109, P394; KATSUURA G, 1990, AM J PHYSIOL, V258, pE163, DOI 10.1152/ajpendo.1990.258.1.E163; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; KLUGER MJ, 1991, PHYSIOL REV, V71, P93, DOI 10.1152/physrev.1991.71.1.93; KOZAK W, 1995, AM J PHYSIOL-REG I, V269, pR969, DOI 10.1152/ajpregu.1995.269.5.R969; Meng FY, 1997, J EXP MED, V185, P1661, DOI 10.1084/jem.185.9.1661; MILTON AS, 1970, J PHYSIOL-LONDON, V207, pP76; MILTON AS, 1989, ANN NY ACAD SCI, V559, P392; MITCHELL D, 1986, YALE J BIOL MED, V59, P159; MORLEY RM, 1990, AM J PHYSIOL, V258, pR1064, DOI 10.1152/ajpregu.1990.258.4.R1064; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nguyen MT, 1997, NATURE, V390, P78, DOI 10.1038/36342; SAPER CB, 1994, NEW ENGL J MED, V330, P1880; Segi E, 1998, BIOCHEM BIOPH RES CO, V246, P7, DOI 10.1006/bbrc.1998.8461; STITT JT, 1986, YALE J BIOL MED, V59, P137; SUGIMOTO Y, 1994, NEUROSCIENCE, V62, P919, DOI 10.1016/0306-4522(94)90483-9; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; USHIKUBI F, 1995, J LIPID MEDIAT CELL, V12, P343, DOI 10.1016/0929-7855(95)00022-I; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; ZAMPRONIO AR, 1994, AM J PHYSIOL, V266, pR1670, DOI 10.1152/ajpregu.1994.266.5.R1670; ZHENG H, 1995, IMMUNITY, V3, P9, DOI 10.1016/1074-7613(95)90154-X	27	536	564	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					281	284		10.1038/26233	http://dx.doi.org/10.1038/26233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751056				2022-12-24	WOS:000075974600052
J	Albertsen, PC; Hanley, JA; Gleason, DF; Barry, MJ				Albertsen, PC; Hanley, JA; Gleason, DF; Barry, MJ			Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; MORTALITY; ANTIGEN	Context.-The appropriate therapy for men with localized prostate cancer is uncertain. Until results of clinical trials are available, men and their physicians need guidance. Objective.-To estimate survival based on a competing risk analysis stratified by age at diagnosis and histologic findings for men diagnosed as having clinically localized prostate cancer and who were managed conservatively. Design.-Retrospective cohort study, Setting.-Connecticut Tumor Registry. Patients.-A total of 767 men with localized prostate cancer diagnosed between 1971 and 1984, aged 55 to 74 years at diagnosis, either not treated or treated with immediate pr delayed hormonal therapy, and followed up for 10 to 20 years after diagnosis. Main Outcome Measures.-Estimates of the probability of dying from prostate cancer or other competing hazards, Results.-Men with tumors that have Gleason scores of 2 to 4, 5, 6, 7, and 8 to 10 face a 4% to 7%, 6% to 11%, 18% to 30%, 42% to 70%, and 60% to 87% chance, respectively, of dying from prostate cancer within 15 years of diagnosis depending on their age at diagnosis, Conclusions.-Men whose prostate biopsy specimens show Gleason score 2 to 4 disease face a minimal risk of death from prostate cancer within 15 years of diagnosis, Conversely, men whose biopsy specimens show Gleason score 7 to 10 disease face a high risk of death from prostate cancer when treated conservatively, even when cancer is diagnosed as late as age 74 years, Men with Gleason score 5 or 6 tumors face a modest risk of death from prostate cancer that increases slowly over at least 15 years of follow-up.	Univ Connecticut, Ctr Hlth, Div Urol, Farmington, CT 06030 USA; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA	University of Connecticut; McGill University; Harvard University; Massachusetts General Hospital	Albertsen, PC (corresponding author), Univ Connecticut, Ctr Hlth, Div Urol, 263 Farmington Ave, Farmington, CT 06030 USA.				AHRQ HHS [HS 08397] Funding Source: Medline; NCRR NIH HHS [M01 RR06192] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008397] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALBERTSEN PC, 1995, JAMA-J AM MED ASSOC, V274, P626, DOI 10.1001/jama.274.8.626; AUS G, 1995, J UROLOGY, V154, P460, DOI 10.1016/S0022-5347(01)67074-5; BAGSHAW MA, 1994, J UROLOGY, V152, P1781, DOI 10.1016/S0022-5347(17)32385-6; Blasko JC, 1996, UROL CLIN N AM, V23, P633, DOI 10.1016/S0094-0143(05)70342-6; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; Cowen ME, 1996, JAMA-J AM MED ASSOC, V275, P31; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; Epstein JI, 1996, AM J SURG PATHOL, V20, P286, DOI 10.1097/00000478-199603000-00004; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gerber GS, 1996, JAMA-J AM MED ASSOC, V276, P615; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; Holland, 1975, DISCRETE MULTIVARIAT, P123; HUGOSSON J, 1995, J UROLOGY, V154, P2115, DOI 10.1016/S0022-5347(01)66710-7; Johansson JE, 1997, JAMA-J AM MED ASSOC, V277, P467, DOI 10.1001/jama.277.6.467; Kalbfleisch J, 1980, STAT ANAL FAILURE TI, P168; Landis SH, 1998, CA-CANCER J CLIN, V48, P6, DOI 10.3322/canjclin.48.1.6; MURPHY GP, 1982, J UROLOGY, V127, P928, DOI 10.1016/S0022-5347(17)54135-X; STENBACK M, 1995, ACTA ONCOL S4, V34, P62; Swanson G, 1996, JAMA-J AM MED ASSOC, V275, P31, DOI 10.1001/jama.1996.03530250035012; Walsh PC, 1997, JAMA-J AM MED ASSOC, V277, P497, DOI 10.1001/jama.277.6.497	22	516	533	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					975	980		10.1001/jama.280.11.975	http://dx.doi.org/10.1001/jama.280.11.975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749479	Bronze			2022-12-24	WOS:000075891400030
J	Behringer, W; Kittler, H; Sterz, F; Domanovits, H; Schoerkhuber, W; Holzer, M; Mullner, M; Laggner, AN				Behringer, W; Kittler, H; Sterz, F; Domanovits, H; Schoerkhuber, W; Holzer, M; Mullner, M; Laggner, AN			Cumulative epinephrine dose during cardiopulmonary resuscitation and neurologic outcome	ANNALS OF INTERNAL MEDICINE			English	Article						epinephrine; neurologic manifestations; cardiopulmonary resuscitation; dose-response relationship, drug; outcome and process assessment (health care)	HOSPITAL CARDIAC-ARREST; VENTRICULAR-FIBRILLATION; BLOOD-FLOW; PERFUSION-PRESSURE; STANDARD; CPR; MODEL; NOREPINEPHRINE; IMPROVES; SEVERITY	Background: Epinephrine is the drug of choice in advanced cardiac life support, but it can have deleterious side effects after restoration of spontaneous circulation. Objective: To investigate the association between the cumulative epinephrine dose used in advanced cardiac life support and neurologic outcome after cardiac arrest. Design: Retrospective cohort study. Setting: University hospital. Patients: Adults admitted to the emergency department with witnessed, nontraumatic, normothermic ventricular fibrillation cardiac arrest and unsuccessful initial defibrillation. Measurements: Functional neurologic outcome was regularly assessed by cerebral performance category (CPC) within 6 months after cardiac arrest. A CPC of 1 or 2 was defined as favorable recovery. Results: Among 178 enrolled patients, the median cumulative epinephrine dose administered was 4 mg (range, 0 to 50 mg). In 151 patients (84%), spontaneous circulation was restored; 63 of these 151 patients (42%) had favorable neurologic recovery. Patients with an unfavorable CPC received a significantly higher cumulative dose of epinephrine than did patients with a favorable CPC (4 mg compared with 1 mg; P < 0.001). This finding persisted after stratification by duration of resuscitation. After possible cofounders were controlled for, the cumulative epinephrine dose remained an independent predictor of unfavorable neurologic outcome. Conclusions: The results indicate that an increasing cumulative dose of epinephrine administered during resuscitation is independently associated with unfavorable neurologic outcome after ventricular fibrillation cardiac arrest.	Univ Vienna, Sch Med, Vienna, Austria	University of Vienna	Sterz, F (corresponding author), Vienna Gen Hosp, Univ Clin, Dept Emergency Med, Waehringerguertel 18-20-6-D, A-1090 Vienna, Austria.		Kittler, Harald/K-7574-2013; Kittler, Harald/AAK-1502-2020	KITTLER, HARALD/0000-0002-0051-8016				Altman D.G., 1991, PRACTICAL STATISTIC; *AM HEART ASS, 1992, JAMA-J AM MED ASSOC, V268, P2205; [Anonymous], 1986, Am J Emerg Med, V4, P72; BARTON C, 1991, ANN EMERG MED, V20, P722, DOI 10.1016/S0196-0644(05)80830-3; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BEER RJ, 1994, RESUSCITATION, V27, P189, DOI 10.1016/0300-9572(94)90032-9; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1992, NEW ENGL J MED, V327, P1051, DOI 10.1056/NEJM199210083271503; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; BROWN CG, 1990, RESUSCITATION, V19, P1, DOI 10.1016/0300-9572(90)90094-U; BRUNETTE DD, 1990, ANN EMERG MED, V19, P8, DOI 10.1016/S0196-0644(05)82130-4; CALLAHAM M, 1991, JAMA-J AM MED ASSOC, V265, P1117, DOI 10.1001/jama.265.9.1117; CALLAHAM M, 1992, JAMA-J AM MED ASSOC, V268, P2667, DOI 10.1001/jama.268.19.2667; CHOUX C, 1995, RESUSCITATION, V29, P3, DOI 10.1016/0300-9572(94)00810-3; Crile G, 1906, J EXP MED, V8, P713, DOI 10.1084/jem.8.6.713; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; DITCHEY RV, 1988, CIRCULATION, V78, P382, DOI 10.1161/01.CIR.78.2.382; EISENBERG MS, 1990, ANN EMERG MED, V19, P1249, DOI 10.1016/S0196-0644(05)82283-8; GOETTING MG, 1991, ANN EMERG MED, V20, P22, DOI 10.1016/S0196-0644(05)81112-6; Hallstrom AP, 1996, CIRCULATION, V93, P2019, DOI 10.1161/01.CIR.93.11.2019; JENNETT B, 1975, LANCET, V1, P480; LINDNER KH, 1989, CRIT CARE MED, V17, P437, DOI 10.1097/00003246-198905000-00012; LINDNER KH, 1992, RESUSCITATION, V24, P147, DOI 10.1016/0300-9572(92)90021-4; LINDNER KH, 1991, AM J EMERG MED, V9, P27, DOI 10.1016/0735-6757(91)90008-8; LITTLE RA, 1985, Q J MED, V54, P133; LIVESAY JJ, 1978, J THORAC CARDIOV SUR, V76, P244; LONGSTRETH WT, 1983, NEW ENGL J MED, V308, P1378, DOI 10.1056/NEJM198306093082302; MARTENS PR, 1993, RESUSCITATION, V25, P227, DOI 10.1016/0300-9572(93)90119-B; MARWICK TH, 1988, LANCET, V2, P66; MULLER CP, 1989, EXP HEMATOL, V17, P1; NG AY, 1990, AM J EMERG MED, V8, P87, DOI 10.1016/0735-6757(90)90190-B; OLSON DW, 1989, ANN EMERG MED, V18, P250, DOI 10.1016/S0196-0644(89)80408-1; ONEIL BJ, 1994, CRIT CARE MED, V22, P194, DOI 10.1097/00003246-199402000-00006; PARADIS NA, 1991, JAMA-J AM MED ASSOC, V265, P1139, DOI 10.1001/jama.265.9.1139; PEPE PE, 1993, CRIT CARE MED, V21, P1838, DOI 10.1097/00003246-199312000-00009; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1962, JAMA-J AM MED ASSOC, V182, P283; REDDING JS, 1968, JAMA-J AM MED ASSOC, V203, P93; RITTER G, 1985, AM HEART J, V110, P932, DOI 10.1016/0002-8703(85)90187-5; RIVERS EP, 1994, CHEST, V106, P1499, DOI 10.1378/chest.106.5.1499; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; RUBERTSSON S, 1995, CRIT CARE MED, V23, P1984, DOI 10.1097/00003246-199512000-00007; Schindler MB, 1996, NEW ENGL J MED, V335, P1473, DOI 10.1056/NEJM199611143352001; STIELL IG, 1992, NEW ENGL J MED, V327, P1045, DOI 10.1056/NEJM199210083271502; STUEVEN HA, 1989, RESUSCITATION, V17, pS71, DOI 10.1016/0300-9572(89)90092-0; SUGA H, 1983, CIRC RES, V53, P306, DOI 10.1161/01.RES.53.3.306; TANG W, 1991, CIRCULATION, V84, P2101, DOI 10.1161/01.CIR.84.5.2101; TANG WC, 1995, CIRCULATION, V92, P3089, DOI 10.1161/01.CIR.92.10.3089; WORTSMAN J, 1993, CRIT CARE MED, V21, P692, DOI 10.1097/00003246-199305000-00012	49	102	108	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					450	456		10.7326/0003-4819-129-6-199809150-00004	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735082				2022-12-24	WOS:000075892100003
J	Greenough, A				Greenough, A			Gains and losses from dexamethasone for neonatal chronic lung disease	LANCET			English	Editorial Material							RESPIRATORY-DISTRESS SYNDROME; BRONCHOPULMONARY DYSPLASIA; CONTROLLED TRIAL; PRETERM INFANTS; FOLLOW-UP; POSTNATAL DEXAMETHASONE; THERAPY		Guys Kings & St Thomass Sch Med, Dept Child Hlth, London SE5 9RS, England	University of London; King's College London	Greenough, A (corresponding author), Guys Kings & St Thomass Sch Med, Dept Child Hlth, London SE5 9RS, England.							Bancalari E, 1998, EUR J PEDIATR, V157, pS31, DOI 10.1007/PL00014290; Bhuta T, 1998, ARCH DIS CHILD-FETAL, V79, pF26, DOI 10.1136/fn.79.1.F26; BROZANSKI BS, 1995, J PEDIATR-US, V126, P769, DOI 10.1016/S0022-3476(95)70410-8; CUMMINGS JJ, 1989, NEW ENGL J MED, V320, P1505, DOI 10.1056/NEJM198906083202301; DAgostino RB, 1995, CLIN PHARMACOL THER, V58, P605, DOI 10.1016/0009-9236(95)90016-0; Dimitriou G, 1997, EUR J PEDIATR, V156, P51; GREENOUGH A, 1992, EUR J PEDIATR, V151, P134, DOI 10.1007/BF01958959; JONES R, 1991, PEDIATRICS, V88, P421; JONES R, 1995, PEDIATRICS, V96, P897; Kovacs L, 1998, ACTA PAEDIATR, V87, P792, DOI 10.1080/080352598750013905; MAMMEL MC, 1987, DEV PHARMACOL THERAP, V10, P1; MASSARO D, 1986, AM J PHYSIOL, V251, pR218, DOI 10.1152/ajpregu.1986.251.2.R218; OSHEA TM, 1993, AM J DIS CHILD, V147, P658, DOI 10.1001/archpedi.1993.02160300064024; Rastogi A, 1996, PEDIATRICS, V98, P204; SAHEBJAMI H, 1989, EXP LUNG RES, V15, P961, DOI 10.3109/01902148909069638; SANDERS RJ, 1994, PEDIATR RES, V36, P122, DOI 10.1203/00006450-199407001-00022; Shinwell ES, 1996, ARCH DIS CHILD-FETAL, V74, pF33, DOI 10.1136/fn.74.1.F33; TSCHANZ SA, 1995, BIOL NEONATE, V68, P229; Yeh TF, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.5.e7; Yeh TF, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e3	20	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					835	836		10.1016/S0140-6736(05)60002-5	http://dx.doi.org/10.1016/S0140-6736(05)60002-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742974				2022-12-24	WOS:000075857300004
J	Glickman, MH; Rubin, DM; Coux, O; Wefes, I; Pfeifer, G; Cjeka, Z; Baumeister, W; Fried, VA; Finley, D				Glickman, MH; Rubin, DM; Coux, O; Wefes, I; Pfeifer, G; Cjeka, Z; Baumeister, W; Fried, VA; Finley, D			A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3	CELL			English	Article							INITIATION-FACTOR EIF3; 20S PROTEASOME; MULTICATALYTIC PROTEASE; DEPENDENT PROTEASES; 20-S PROTEASOME; 11-S REGULATOR; SUBUNITS; COMPLEX; YEAST; PURIFICATION	The proteasome consists of a 20S proteolytic core particle (CP) and a 19S regulatory particle (RP), which selects ubiquitinated substrates for translocation into the CP. An eight-subunit subcomplex of the RP, the lid, can be dissociated from proteasomes prepared from a deletion mutant for Rpn10, an RP subunit. A second subcomplex, the base, contains all six proteasomal ATPases and links the RP to the CP. The base is sufficient to activate the CP for degradation of peptides or a nonubiquitinated protein, whereas the lid is required for ubiquitin-dependent degradation. By electron microscopy, the base and the lid correspond to the proximal and distal masses of the RP, respectively. The lid subunits share sequence motifs with components of the COPS/signalosome complex and eIF3, suggesting that these functionally diverse particles have a common evolutionary ancestry.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; New York Med Coll, Dept Cell Biol, Valhalla, NY 10595 USA; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Harvard University; Harvard Medical School; New York Medical College; Max Planck Society	Finley, D (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Coux, Olivier/P-6847-2019; Coux, Olivier/B-3406-2010	Coux, Olivier/0000-0001-8455-3849; Coux, Olivier/0000-0001-8455-3849; Glickman, Michael/0000-0002-1222-8104	NIGMS NIH HHS [GM43601] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043601, R01GM043601] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, PROTEIN SCI, V7, P1250, DOI 10.1002/pro.5560070521; Asano K, 1997, J BIOL CHEM, V272, P1101, DOI 10.1074/jbc.272.2.1101; Asano K, 1997, J BIOL CHEM, V272, P27042, DOI 10.1074/jbc.272.43.27042; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Beyer A, 1997, PROTEIN SCI, V6, P2043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; Chamovitz DA, 1998, NATO ADV SCI I H-CEL, V104, P83; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; Fenton WA, 1997, PROTEIN SCI, V6, P743; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; Finley D, 1998, TRENDS BIOCHEM SCI, V23, P244, DOI 10.1016/S0968-0004(98)01222-5; Fu HY, 1998, J BIOL CHEM, V273, P1970, DOI 10.1074/jbc.273.4.1970; Fujimuro M, 1998, FEBS LETT, V423, P149, DOI 10.1016/S0014-5793(98)00084-2; Glickman MH, 1998, MOL CELL BIOL, V18, P3149, DOI 10.1128/MCB.18.6.3149; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Haracska L, 1997, FEBS LETT, V412, P331, DOI 10.1016/S0014-5793(97)00808-9; HEINEMEYER W, 1994, BIOCHEMISTRY-US, V33, P12229, DOI 10.1021/bi00206a028; Hershey J, 1996, BIOCHIMIE, V78, P903, DOI 10.1016/S0300-9084(97)86711-9; HERSHKO A, 1998, IN PRESS ANN REV BIO; HOFFMAN L, 1994, J BIOL CHEM, V269, P16890; Hofmann K, 1998, TRENDS BIOCHEM SCI, V23, P204, DOI 10.1016/S0968-0004(98)01217-1; Kisselev AF, 1998, J BIOL CHEM, V273, P1982, DOI 10.1074/jbc.273.4.1982; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; MA CP, 1994, J BIOL CHEM, V269, P3539; MA CP, 1992, BIOCHIM BIOPHYS ACTA, V1119, P303, DOI 10.1016/0167-4838(92)90218-3; MA CP, 1992, J BIOL CHEM, V267, P10515; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Rubin DM, 1998, EMBO J, V17, P4909, DOI 10.1093/emboj/17.17.4909; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Suzuki CK, 1997, TRENDS BIOCHEM SCI, V22, P118, DOI 10.1016/S0968-0004(97)01020-7; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wei N, 1998, CURR BIOL, V8, P919, DOI 10.1016/S0960-9822(07)00372-7; Wolf S, 1998, J MOL BIOL, V277, P13, DOI 10.1006/jmbi.1997.1589; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	47	711	728	0	26	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					615	623		10.1016/S0092-8674(00)81603-7	http://dx.doi.org/10.1016/S0092-8674(00)81603-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741626	Bronze			2022-12-24	WOS:000075851900009
J	Powell, JE; Esteve, J; Mann, JR; Parker, L; Frappaz, D; Michaelis, J; Kerbl, R; Mutz, ID; Stiller, CA				Powell, JE; Esteve, J; Mann, JR; Parker, L; Frappaz, D; Michaelis, J; Kerbl, R; Mutz, ID; Stiller, CA		Sense	Neuroblastoma in Europe: differences in the pattern of disease in the UK	LANCET			English	Article							MORTALITY	Background Neuroblastoma is a major contributor to childhood cancer mortality, but its prognosis varies with age and stage of disease, and some tumours regress spontaneously. Urinary screening programmes or clinical examination may detect the disease before symptoms appear, but the benefit of early diagnosis is uncertain. We examined the incidence, pattern, and presentation of neuroblastoma in four European countries. Method Population-based incidence rates were derived for France, Austria, Germany, and the UK. Age, sex, and stage distribution were analysed by Mantel-Haenszel techniques and Poisson regression. The proportion of incidental diagnoses (cases without symptoms found at routine health checks or during investigation of other disorders) and mortality rates were also compared. Findings Between 1987 and 1991, 1672 cases of neuroblastoma were diagnosed in children under 15 years old (France, 624; Austria, 69;Germany, 493; UK, 486). Age-standardised annual incidence was significantly lower in the UK (10.1/million) than in France (12.5) and Germany (11.4). In the UK a deficit of low-stage disease in infants was accompanied by an excess of stage IV in older children. The UK had significantly fewer incidental diagnoses (8%) than Austria (27%) and Germany (34%). UK mortality rates were significantly higher than German or French rates. Interpretation In the UK, neuroblastoma diagnosis is delayed, possibly because of a less rigorous system of health checks for children. Although some overdiagnosis occurs in mainland Europe, our data suggest that in the UK some low-stage cases, undetected in infancy, may later present as advanced disease. This finding has implications for screening programmes and organisation of routine surveillance of infant health in the UK.	Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England; Int Agcy Res Canc, F-69372 Lyon, France; Birmingham Childrens Hosp NHS Trust, Dept Oncol, Birmingham, W Midlands, England; Univ Newcastle Upon Tyne, Childrens Canc Unit, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Ctr Leon Berard, F-69373 Lyon, France; Johannes Gutenberg Universitat Mainz, Inst Med Stat & Dokumentat, Mainz, Germany; Graz Univ, Dept Paediat, A-8010 Graz, Austria; Landeskrankenhauses, Kinderabstellung, Leoben, Austria; Childhood Canc Res Grp, Oxford, England	University of Birmingham; World Health Organization; International Agency for Research on Cancer (IARC); Newcastle University - UK; UNICANCER; Centre Leon Berard; Johannes Gutenberg University of Mainz; University of Graz; University of Oxford	Powell, JE (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, Birmingham B15 2TT, W Midlands, England.			Stiller, Charles/0000-0002-3006-7869; PARKER, LOUISE/0000-0002-5188-8113				ABUHARB M, 1994, ARCH DIS CHILD, V71, P3, DOI 10.1136/adc.71.1.3; ARMATA J, 1994, ARCH DIS CHILD, V70, P253, DOI 10.1136/adc.70.3.253; BERNSTEIN ML, 1992, J CLIN ONCOL, V10, P323, DOI 10.1200/JCO.1992.10.2.323; BERTHOLD F, 1991, AM J PEDIAT HEMATOL, V13, P8; Bessho F, 1996, LANCET, V348, P1672, DOI 10.1016/S0140-6736(05)65814-X; CARLSEN NTL, 1991, AM J PAEDIAT HEMATOL, V14, P103; Craft AW, 1996, EUR J CANCER, V32A, P1540, DOI 10.1016/0959-8049(96)00152-9; Dezateux C, 1995, J Med Screen, V2, P200; ESTEVE J, 1995, BRIT J CANCER, V71, P1125, DOI 10.1038/bjc.1995.219; Esteve J., 1994, IARC SCI PUBLICATION, V128; Gao RN, 1997, CANCER CAUSE CONTROL, V8, P745, DOI 10.1023/A:1018483405637; KAATSCH P, 1995, EUR J CANCER, V31A, P993, DOI 10.1016/0959-8049(95)00091-7; LACOUR B, 1995, CANC ENFANT LORRAINE; Morgan M, 1989, Health Visit, V62, P244; Nishi M, 1997, INT J CANCER, V71, P552, DOI 10.1002/(SICI)1097-0215(19970516)71:4<552::AID-IJC8>3.0.CO;2-T; Parkin D. M, 1988, IARC SCI PUBLICATION, V87; SAWADA T, 1992, AM J PEDIAT HEMATOL, V14, P320; SCHWARTZ AD, 1974, J PEDIATR-US, V85, P760, DOI 10.1016/S0022-3476(74)80336-7; SMELLIE JM, 1994, BRIT MED J, V308, P1193, DOI 10.1136/bmj.308.6938.1193; STILLER CA, 1992, INT J CANCER, V52, P538, DOI 10.1002/ijc.2910520407; STILLER CA, 1993, EUR J CANCER, V29A, P1008, DOI 10.1016/S0959-8049(05)80213-8; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; Woods WG, 1996, LANCET, V348, P1682, DOI 10.1016/S0140-6736(96)06020-5; WOODS WG, 1992, PEDIATRICS, V89, P114	24	44	44	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					682	687		10.1016/S0140-6736(97)11239-9	http://dx.doi.org/10.1016/S0140-6736(97)11239-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728983				2022-12-24	WOS:000075729700011
J	Ward, HJ				Ward, HJ			Uric acid as an independent risk factor in the treatment of hypertension	LANCET			English	Editorial Material									Univ Calif Los Angeles, Div Nephrol & Hypertens, Los Angeles, CA 90059 USA; Drew Sch Med, Los Angeles, CA 90059 USA	University of California System; University of California Los Angeles	Ward, HJ (corresponding author), Univ Calif Los Angeles, Div Nephrol & Hypertens, Los Angeles, CA 90059 USA.							Alderman M.H., 1998, AM J HYPERTENS, V2, p16A; BARDENHEUER HJ, 1994, CARDIOVASC RES, V28, P656, DOI 10.1093/cvr/28.5.656; CAPPUCCIO FP, 1993, JAMA-J AM MED ASSOC, V270, P354, DOI 10.1001/jama.270.3.354; DESCHEERDER IK, 1991, AM J CARDIOL, V68, P392, DOI 10.1016/0002-9149(91)90838-C; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; JOHNSON WD, 1991, AM HEART J, V121, P20, DOI 10.1016/0002-8703(91)90950-M; Lacy F, 1998, J HYPERTENS, V16, P291, DOI 10.1097/00004872-199816030-00006; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; SELBY JV, 1990, AM J EPIDEMIOL, V131, P1017, DOI 10.1093/oxfordjournals.aje.a115593	9	122	137	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					670	671		10.1016/S0140-6736(05)60816-1	http://dx.doi.org/10.1016/S0140-6736(05)60816-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728978				2022-12-24	WOS:000075729700006
J	Emanuel, LL				Emanuel, LL			Facing requests for physician-assisted suicide - Toward a practical and principled clinical skill set	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACTIVE EUTHANASIA; PATIENT REQUESTS; MEDICAL-CARE; RESUSCITATE; HYDRATION; NUTRITION; ATTITUDES; DECISIONS; ORDERS; STATE	Requests for physician-assisted suicide are not a new phenomenon, and many physicians are likely to face this challenging situation. This article proposes for professionals an 8-step approach to respond to requests for physician-assisted suicide. The approach seeks to identify and treat the root causes of the request and aims to present a plan for consistent application of a set of clinical skills. Justification for the steps requires only 2 noncontentious principles: the patient should be free of unwanted intervention, and the physician is obligated to provide suffering patients with comfort care. Care based on these 2 principles alone does not include physician-assisted suicide. The approach does, however, justify patient refusal of oral intake in specific circumstances. The approach could resolve a majority of requests for physician-assisted suicide and should be tested further for clinical efficacy.	Amer Med Assoc, Inst Eth, Chicago, IL 60610 USA	American Medical Association	Emanuel, LL (corresponding author), Amer Med Assoc, Inst Eth, 515 N State St, Chicago, IL 60610 USA.							Alpert HR, 1998, J GEN INTERN MED, V13, P175, DOI 10.1046/j.1525-1497.1998.00052.x; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; Baron CH, 1996, HARVARD J LEGIS, V33, P1; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLOCH SD, 1994, ARCH INTERN MED, V154, P2039, DOI 10.1001/archinte.154.18.2039; Brody H, 1997, NEW ENGL J MED, V336, P652, DOI 10.1056/NEJM199702273360910; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; Edelstein L., 1967, ANCIENT MED; Emanuel EJ, 1998, LANCET, V351, P21, DOI 10.1016/S0140-6736(98)90329-4; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; EMANUEL EJ, 1988, AM J MED, V84, P291, DOI 10.1016/0002-9343(88)90428-7; EMANUEL EJ, 1998, ANN M 1998 AM SOC CL; EMANUEL L, 1995, JAMA-J AM MED ASSOC, V274, P501, DOI 10.1001/jama.274.6.501; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; Emanuel LL, 1995, HASTINGS CENT REP, V25, pS14, DOI 10.2307/3527851; EMANUEL LL, 1996, CONT INTERNAL MED, V8, P10; EMANUEL LL, 1998, REGULATING WE DIE; GILLIGAN T, 1995, CHEST, V108, P1407, DOI 10.1378/chest.108.5.1407; Glick SM, 1997, AM J MED, V102, P294, DOI 10.1016/S0002-9343(97)00016-8; Gloth F M 3rd, 1994, Md Med J, V43, P511; Gostin LO, 1997, JAMA-J AM MED ASSOC, V278, P1523, DOI 10.1001/jama.278.18.1523; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; KAMISAR Y, 1993, HASTINGS CENT REP, V23, P32, DOI 10.2307/3563366; Kamisar Y, 1998, MINN LAW REV, V82, P895; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Koenig HG, 1996, ARCH INTERN MED, V156, P2240, DOI 10.1001/archinte.156.19.2240; KOUENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064; MCCANN RM, 1994, JAMA-J AM MED ASSOC, V272, P1263, DOI 10.1001/jama.272.16.1263; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; MOORE FD, 1997, HARVARD ALUMNI M SEP, P3; Orentlicher D, 1997, NEW ENGL J MED, V337, P1236, DOI 10.1056/NEJM199710233371713; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; Quill TE, 1997, NEW ENGL J MED, V337, P1768, DOI 10.1056/NEJM199712113372413; Quill TE, 1997, JAMA-J AM MED ASSOC, V278, P2099, DOI 10.1001/jama.278.23.2099; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Rousseau P, 1996, ARCH INTERN MED, V156, P1785, DOI 10.1001/archinte.156.16.1785; SAUNDERS CM, 1978, MANAGEMENT TERMINAL, P194; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; STANLEY J, 1997, QUEST DIE DIGNITY; *SUPPORT PRINC INV, 1996, JAMA-J AM MED ASSOC, V275, P1232, DOI DOI 10.1001/JAMA.1995.03530200027032; Tulsky JA, 1996, ARCH INTERN MED, V156, P1285, DOI 10.1001/archinte.156.12.1285; van der Maas PJ, 1995, JAMA-J AM MED ASSOC, V273, P1411, DOI 10.1001/jama.273.18.1411; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1997, AM MED NEWS     0113, V40, P56; 1997, AM MED NEWS     0113, V40, P3	46	62	62	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					643	647		10.1001/jama.280.7.643	http://dx.doi.org/10.1001/jama.280.7.643			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110ME	9718058				2022-12-24	WOS:000075384300035
J	Jiang, Y; Ma, W; Wan, Y; Kozasa, T; Hattori, S; Huang, XY				Jiang, Y; Ma, W; Wan, Y; Kozasa, T; Hattori, S; Huang, XY			The G protein G alpha 12 stimulates Bruton's tyrosine kinase and a rasGAP through a conserved PH/BM domain	NATURE			English	Article							GTPASE-ACTIVATING PROTEIN; BETA-GAMMA-SUBUNITS; RAT-BRAIN; RECEPTOR; PURIFICATION; CASCADE; FAMILY; CELLS	Heterotrimeric guanine-nucleotide-binding proteins (G proteins) are signal transducers that relay messages from many receptors on the cell surface to modulate various cellular processes(1-4). The direct downstream effecters of G proteins consist of the signalling molecules that are activated by their physical interactions with a G alpha or G beta gamma subunit. Effecters that interact directly with G alpha 12 G, proteins have yet to be identified(5,6). Here we show that G alpha 12 binds directly to, and stimulates the activity of, Bruton's tyrosine kinase (Btk) and a Res GTPase-activating protein, Gap1(m), in vitro and in; vivo. G alpha 12 interacts with a conserved domain, composed of the pleckstrin-homology domain and the adjacent Btk motif, that is present in both Btk and Gap1(m). Our results are, to our knowledge, the first to identify direct effecters for G alpha 12 and to show that there is a direct link between heterotrimeric and monomeric G proteins.	Cornell Univ, Coll Med, Dept Physiol, New York, NY 10021 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Natl Inst Neurosci, Div Biochem & Cellular Biol, Tokyo 187, Japan	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; National Center for Neurology & Psychiatry - Japan	Huang, XY (corresponding author), Cornell Univ, Coll Med, Dept Physiol, 1300 York Ave, New York, NY 10021 USA.							Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BOUME HR, 1990, NATURE, V348, P125; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Dhanasekaran N, 1996, CELL SIGNAL, V8, P235, DOI 10.1016/0898-6568(96)00048-4; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Harhammer R, 1996, BIOCHEM J, V319, P165, DOI 10.1042/bj3190165; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; MACKAWA M, 1994, MOL CELL BIOL, V14, P6879; MAEKAWA M, 1993, J BIOL CHEM, V268, P22948; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; VIHINEN M, 1995, IMMUNOL TODAY, V16, P460, DOI 10.1016/0167-5699(95)80027-1; VIHINEN M, 1994, FEBS LETT, V350, P263, DOI 10.1016/0014-5793(94)00783-7; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	26	153	156	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					808	813		10.1038/27454	http://dx.doi.org/10.1038/27454			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796816				2022-12-24	WOS:000076607400059
J	Murakami, I; Cavanagh, P				Murakami, I; Cavanagh, P			A jitter after-effect reveals motion-based stabilization of vision	NATURE			English	Article							EYE-MOVEMENTS; PERCEPTION; POSITION; FIELD; SENSITIVITY; DIRECTION	A shaky hand holding a video camera invariably turns a treasured moment into an annoying, jittery memento. More recent consumer cameras thoughtfully offer stabilization mechanisms to compensate for our unsteady grip. Our eyes face a similar challenge in that they are constantly making small movements even when we try to maintain a fixed gaze(1). What should be substantial, distracting jitter passes completely unseen. Position changes from large eye movements (saccades) seem to be corrected on the basis of extraretinal signals such as the motor commands sent to the eye muscle(2-5), and the resulting motion responses seem to be simply switched off(6,7). But this approach is impracticable for incessant, small displacements, and here we describe a novel visual illusion that reveals a compensation mechanism based on visual motion signals. Observers were adapted to a patch of dynamic random noise and then viewed a larger pattern of static random noise. The static noise in the unadapted regions then appeared to 'jitter' coherently in random directions. Several observations indicate that this visual jitter directly reflects fixational eye movements. We propose a model that accounts for this illusion as well as the stability of the visual world during small and/or slow eye movements such as fixational drift, smooth pursuit and low-amplitude mechanical vibrations of the eyes.	Harvard Univ, Dept Psychol, Cambridge, MA 02138 USA	Harvard University	Murakami, I (corresponding author), Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA.							ABRAHAMS VC, 1979, CAN J PHYSIOL PHARM, V57, P359, DOI 10.1139/y79-054; ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; ANSTIS SM, 1976, VISION RES, V16, P1391, DOI 10.1016/0042-6989(76)90157-7; BADCOCK DR, 1990, NATURE, V343, P554, DOI 10.1038/343554a0; BARLOW HB, 1963, NATURE, V200, P1347, DOI 10.1038/2001347a0; BURR DC, 1982, J PHYSIOL-LONDON, V333, P1; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FIORENTINI A, 1982, EXP BRAIN RES, V48, P113; Haarmeier T, 1997, NATURE, V389, P849, DOI 10.1038/39872; HANSEN RM, 1977, VISION RES, V17, P919, DOI 10.1016/0042-6989(77)90067-0; HARDAGE L, 1995, VISION RES, V35, P757, DOI 10.1016/0042-6989(94)00167-K; MATIN L, 1982, SCIENCE, V216, P198, DOI 10.1126/science.7063881; NAKAYAMA K, 1981, VISION RES, V21, P427, DOI 10.1016/0042-6989(81)90089-4; POST RB, 1985, PERCEPTION, V14, P631, DOI 10.1068/p140631; RAMACHANDRAN VS, 1991, NATURE, V350, P699, DOI 10.1038/350699a0; RAMACHANDRAN VS, 1993, VISION RES, V33, P717, DOI 10.1016/0042-6989(93)90191-X; Seiffert AE, 1998, VISION RES, V38, P3569, DOI 10.1016/S0042-6989(98)00035-2; SHEEDY JE, 1981, AM J OPTOM PHYS OPT, V58, P149; SHIOIRI S, 1989, VISION RES, V29, P915, DOI 10.1016/0042-6989(89)90106-5; SKAVENSKI AA, 1972, PERCEPT PSYCHOPHYS, V11, P287, DOI 10.3758/BF03210380; STEINBACH MJ, 1987, VISION RES, V27, P1737, DOI 10.1016/0042-6989(87)90103-9; TANAKA K, 1986, J NEUROSCI, V6, P134; Tyler CW, 1998, PERCEPTION, V27, P203, DOI 10.1068/p270203; Von Grunau Michael, 1992, Spatial Vision, V6, P303, DOI 10.1163/156856892X00145; von Helmholtz H., 1866, HDB PHYSL OPTIK; Yarbus A.L., 1967, EYE MOVEMENTS VISION, DOI 10.1007/978-1-4899-5379-7; ZAIDI Q, 1991, PERCEPTION, V20, P703, DOI 10.1068/p200703	27	81	81	1	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					798	801		10.1038/27435	http://dx.doi.org/10.1038/27435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	132AL	9796813				2022-12-24	WOS:000076607400056
J	Barr, H				Barr, H			Gastrointestinal tumours: let there be light	LANCET			English	Editorial Material							HIGH-GRADE DYSPLASIA; ND-YAG LASER; PHOTODYNAMIC THERAPY; ESOPHAGEAL CANCER; BARRETTS-ESOPHAGUS; MULTICENTER; JAPANESE		Gloucestershire Royal & Cranfield Univ, Inst Med Sci, Gloucester Gastroenterol Grp, Gloucester GL1 3NN, England	Cranfield University	Barr, H (corresponding author), Gloucestershire Royal & Cranfield Univ, Inst Med Sci, Gloucester Gastroenterol Grp, Gloucester GL1 3NN, England.							BARR H, 1987, PHOTOCHEM PHOTOBIOL, V46, P795, DOI 10.1111/j.1751-1097.1987.tb04850.x; Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; BARR H, 1990, BRIT J SURG, V77, P93, DOI 10.1002/bjs.1800770132; Ell C, 1998, GUT, V43, P345, DOI 10.1136/gut.43.3.345; Gossner L, 1998, GASTROENTEROLOGY, V114, P448, DOI 10.1016/S0016-5085(98)70527-X; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROSJEAN P, 1998, EUR J SURG ONCOL, V24, P234; Hayata Y, 1996, LASER MED SCI, V11, P255, DOI 10.1007/BF02134916; HEIER SK, 1995, GASTROENTEROLOGY, V109, P63, DOI 10.1016/0016-5085(95)90269-4; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P507, DOI 10.1016/S0016-5107(95)70002-1; Ortner MAEJ, 1998, GASTROENTEROLOGY, V114, P536, DOI 10.1016/S0016-5085(98)70537-2; Overholt BF, 1997, GASTROINTEST ENDOSC, V45, P206, DOI 10.1016/S1052-5157(18)30308-8; Schlemper RJ, 1997, LANCET, V349, P1725, DOI 10.1016/S0140-6736(96)12249-2; SIBILLE A, 1995, GASTROENTEROLOGY, V108, P337, DOI 10.1016/0016-5085(95)90058-6	15	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 17	1998	352	9136					1242	1244		10.1016/S0140-6736(05)70484-0	http://dx.doi.org/10.1016/S0140-6736(05)70484-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788451				2022-12-24	WOS:000076573800005
J	Schwartz, RS				Schwartz, RS			Direct visualization of antigen-specific cytotoxic T cells - A new insight into immune defenses	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103	3	8	11	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 8	1998	339	15					1076	1078		10.1056/NEJM199810083391510	http://dx.doi.org/10.1056/NEJM199810083391510			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	126LL	9761811				2022-12-24	WOS:000076294800010
J	Alter, DA; Basinski, ASH; Naylor, CD				Alter, DA; Basinski, ASH; Naylor, CD			A survey of provider experiences and perceptions of preferential access to cardiovascular care in Ontario, Canada	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; ARTERY BYPASS-SURGERY; UNITED-STATES; CORONARY ANGIOGRAPHY; SOCIOECONOMIC-STATUS; CARDIAC PROCEDURES; HEALTH; SERVICES	Background: The public health insurance system in Canada is predicated on equal access to care for persons in need. Objective: To determine the views and experiences of Ontario physicians and hospital administrators in providing patients with preferential access to specialized cardiovascular care on the basis of nonclinical factors. Design: Survey with self-administered questionnaire. Setting: Ontario, Canada. Participants: All Ontario cardiologists (n = 268), cardiac surgeons (n = 68), and hospital chief executives (n = 218) and random samples of internists (n = 300) and family physicians (n = 300). Measurements: Elicited responses (yes or no) to questions on whether and why preferential access occurred and whether the respondents had been personally involved in such a situation. Results: After undeliverable surveys and respondents no longer involved with acute care were excluded, the eligible response rate was 71.3% (788 of 1105 respondents). More than 80% of physicians and 53% of hospital chief executives had been personally involved in managing a patient who had received preferential access on the basis of factors other than medical need. Patients deemed most likely to receive such treatment were those with personal ties to the treating physicians (93% [95% CI, 91% to 95%]), high-profile public figures (85% [CI, 82% to 87%]), and politicians (83% [CI, 80% to 86%]), Physicians were significantly more likely than chief executives to indicate that hospital board members (81% and 68%; P < 0.001) and donors to hospital foundations (63% and 42%; P < 0.001) would receive preferential access. Most respondents indicated that preferential access was more likely to be provided if patients or families were well informed, aggressive, or potentially litigious. The survey did not permit estimation of the frequency of episodes of preferential access. Conclusions: Although equality of access is a cornerstone principle of Canada's universal health care system, some access to specialized cardiovascular services occurs preferentially on the basis of factors other than clinical need. The actual magnitude and consequences of this phenomenon remain unknown.	Univ Toronto, Toronto, ON, Canada; Sunnybrook Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada	University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Naylor, CD (corresponding author), Sunnybrook Hlth Sci Ctr, G-106,2075 Bayview Ave, N York, ON M4N 3M5, Canada.							ANDERSON GM, 1993, JAMA-J AM MED ASSOC, V269, P1661; BADGLEY RF, 1992, CANADIAN HLTH CARE S, P193; BLUSTEIN J, 1993, JAMA-J AM MED ASSOC, V270, P344, DOI 10.1001/jama.270.3.344; COS JL, 1994, J GEN INTERN MED, V9, P674, DOI 10.1007/BF02599007; ENTERLINE PE, 1973, NEW ENGL J MED, V289, P1174, DOI 10.1056/NEJM197311292892206; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GATSONIS CA, 1995, MED CARE, V33, P625, DOI 10.1097/00005650-199506000-00005; Gerdtham UG, 1997, HEALTH ECON, V6, P303, DOI 10.1002/(SICI)1099-1050(199705)6:3<303::AID-HEC270>3.0.CO;2-P; GUADAGNOLI E, 1995, NEW ENGL J MED, V333, P573, DOI 10.1056/NEJM199508313330908; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; MCISAAC W, 1997, J HEALTH SERV RES PO, V2, P4; NAVARRORUBIO MD, 1995, AM J PREV MED, V11, P256, DOI 10.1016/S0749-3797(18)30455-0; Naylor C D, 1992, Health Econ, V1, P19, DOI 10.1002/hec.4730010106; NAYLOR CD, 1995, CAN J CARDIOL, V11, P670; NAYLOR CD, 1995, LANCET, V346, P1605, DOI 10.1016/S0140-6736(95)91934-1; NAYLOR CD, 1991, HEALTH AFFAIR, V10, P110, DOI 10.1377/hlthaff.10.3.110; Payne N, 1997, BRIT MED J, V314, P257, DOI 10.1136/bmj.314.7076.257; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; Roos NP, 1997, MILBANK Q, V75, P89, DOI 10.1111/1468-0009.00045; SHIN AY, 1998, THESIS U TORONTO TOR; SULLIVAN P, 1990, CAN MED ASSOC J, V142, P50; UGNAT AM, 1994, CAN MED ASSOC J, V151, P575	23	27	27	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					567	572		10.7326/0003-4819-129-7-199810010-00011	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	123KN	9758578				2022-12-24	WOS:000076124500009
J	Ganzini, L; Johnston, WS; McFarland, BH; Tolle, SW; Lee, MA				Ganzini, L; Johnston, WS; McFarland, BH; Tolle, SW; Lee, MA			Attitudes of patients with amyotrophic lateral sclerosis and their care givers toward assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOPELESSNESS; LIFE; ILL; OUTPATIENTS; EUTHANASIA; DEPRESSION; FAMILIES; QUALITY; HISTORY; IMPACT	Background and Methods Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that causes gradual paralysis, respiratory failure, and death, usually within three to five years after it has been diagnosed. Between 1995 and 1997, we surveyed patients with this disease in Oregon and Washington, as well as their family care givers, in order to determine their attitudes toward assisted suicide. Patients were considered to be willing to contemplate assisted suicide if they agreed with the statement, "Under some circumstances I would consider taking a prescription for a medicine whose sole purpose was to end my life," and disagreed with the statement, "I would never request or take a prescription for a medication whose sole purpose was to end my life." The Oregon Death with Dignity Act, which legalized physician-assisted suicide, was approved by Oregon voters in 1994 but did not go into effect until October 1997, after data collection for this study had been completed. Results Of 140 eligible persons with ALS, 100 (71 percent) agreed to participate in the study, as did 91 family care givers. The mean age of the patients with ALS was 54 years; the mean duration of illness since the diagnosis was 2.8 years. Fifty-six patients (56 percent) said they would consider assisted suicide, and 44 of the 56 agreed with the statement, "If physician-assisted suicide were legal, I would request a lethal prescription from a physician." One patient would have taken the medication immediately, and 36 would have kept it for future use. As compared with the patients who were opposed to assisted suicide, those who would consider it were mure likely to be men, had a higher level of education, were less likely to be religious, had higher scores for hopelessness, and rated their quality of life as lower. In 66 of 91 instances (73 percent), care givers and patients had the same attitude toward assisted suicide. Conclusions In Oregon and Washington, a majority of persons with ALS whom we surveyed would consider assisted suicide. Many would request a prescription for a lethal dose of medication well before they intended to use it. (N Engl J Med 1998;339: 967-73.) (C)1998, Massachusetts Medical Society.	Vet Affairs Med Ctr, Mental Hlth Div P 7 1DMH, Portland, OR 97207 USA; Oregon Hlth Sci Univ, Dept Psychiat, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Ctr Eth Hlth Care, Portland, OR 97201 USA; Providence ElderPlace, Portland, OR USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Ganzini, L (corresponding author), Vet Affairs Med Ctr, Mental Hlth Div P 7 1DMH, Portland, OR 97207 USA.		Johnston, Wendy S/E-2491-2013	Johnston, Wendy S/0000-0002-4330-5563; McFarland, Bentson/0000-0001-9149-5616				ARMITAGE P, 1987, STAT METHOS MED RES; BATTIN MP, 1995, ACAD MED, V70, P583; BECK AT, 1990, AM J PSYCHIAT, V147, P190; BECK AT, 1974, J CONSULT CLIN PSYCH, V42, P861, DOI 10.1037/h0037562; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; Breitbart W, 1996, AM J PSYCHIAT, V153, P238; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CARALIS PV, 1993, J CLIN ETHIC, V4, P155; CASSEL C, 1980, DIAGNOSIS TREATMENT, P325; Cherny N I, 1994, J Palliat Care, V10, P71; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Covinsky KE, 1996, ARCH INTERN MED, V156, P1737, DOI 10.1001/archinte.156.15.1737; Emanuel EJ, 1996, LANCET, V347, P1805, DOI 10.1016/S0140-6736(96)91621-9; Fleiss J. L., 1981, STAT METHODS RATES P, V2; HENDIN H, 1997, SEDUCED DEATH DOCTOR; LEE BC, 1997, OREGON HLTH LAW MANU, V2; Lord F. M., 1968, STAT THEORIES MENTAL; MASSIE MJ, 1994, J PAIN SYMPTOM MANAG, V9, P325, DOI 10.1016/0885-3924(94)90192-9; MILTON N, 1995, ISSUES LAW MED, V11, P123; MINKOFF K, 1973, AM J PSYCHIAT, V130, P455; Moberg D. O., 1965, OLDER PEOPLE THEIR S, P125; PEARLMAN RA, 1991, J GERONTOL, V46, pM31, DOI 10.1093/geronj/46.2.M31; RINGEL SP, 1993, NEUROLOGY, V43, P1316, DOI 10.1212/WNL.43.7.1316; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; ZARIT SH, 1980, GERONTOLOGIST, V20, P649, DOI 10.1093/geront/20.6.649	29	231	232	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					967	973		10.1056/NEJM199810013391406	http://dx.doi.org/10.1056/NEJM199810013391406			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124MW	9753713	Bronze			2022-12-24	WOS:000076186900006
J	Xia, XM; Fakler, B; Rivard, A; Wayman, G; Johnson-Pais, T; Keen, JE; Ishii, T; Hirschberg, B; Bond, CT; Lutsenko, S; Maylie, J; Adelman, JP				Xia, XM; Fakler, B; Rivard, A; Wayman, G; Johnson-Pais, T; Keen, JE; Ishii, T; Hirschberg, B; Bond, CT; Lutsenko, S; Maylie, J; Adelman, JP			Mechanism of calcium gating in small-conductance calcium-activated potassium channels	NATURE			English	Article							GATED ION CHANNELS; CALMODULIN-BINDING; PROTEIN-KINASE; RECEPTORS; BRAIN; SUBUNITS; IDENTIFICATION; MUSCLE	The slow afterhyperpolarization that follows an action potential is generated by the activation of small-conductance calcium-activated potassium channels (SK channels). The slow afterhyperpolarization limits the bring frequency of repetitive action potentials (spike-frequency adaption) and is essential for normal neurotransmission(1-3). SK channels are voltage-independent and activated by submicromolar concentrations of intracellular calcium(1). They are high-affinity calcium sensors that transduce fluctuations in intracellular calcium concentrations into changes in membrane potential. Here we study the mechanism of calcium gating and find that SK channels are not gated by calcium binding directly to the channel alpha-subunits. Instead, the functional SK channels are heteromeric complexes with calmodulin, which is constitutively associated with the alpha-subunits in a calcium-independent manner. Our data support a model in which calcium gating of SK channels is mediated by binding of calcium to calmodulin and subsequent conformational alterations in the channel protein.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Biochem & Biol Sci, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA; Univ Tuebingen, Dept Physiol, Tuebingen, Germany	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Eberhard Karls University of Tubingen	Adelman, JP (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, L474, Portland, OR 97201 USA.							ADELMAN JP, 1995, CURR OPIN NEUROBIOL, V5, P286, DOI 10.1016/0959-4388(95)80040-9; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHIEN YH, 1984, MOL CELL BIOL, V4, P507, DOI 10.1128/MCB.4.3.507; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLBRAN RJ, 1988, J BIOL CHEM, V263, P18145; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FISCHER TH, 1987, BIOCHEMISTRY-US, V26, P8024, DOI 10.1021/bi00398a070; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; HERB A, 1992, NEURON, V8, P775, DOI 10.1016/0896-6273(92)90098-X; Hille B., 1992, IONIC CHANNELS EXCIT; HINRICHSEN RD, 1986, SCIENCE, V232, P503, DOI 10.1126/science.2421410; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; LANCASTER B, 1991, J NEUROSCI, V11, P23; LANGOSCH D, 1988, P NATL ACAD SCI USA, V85, P7394, DOI 10.1073/pnas.85.19.7394; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MACONOCHIE DJ, 1994, NEURON, V12, P61, DOI 10.1016/0896-6273(94)90152-X; MIYANO O, 1992, J BIOL CHEM, V267, P1198; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; Oliver D, 1998, BIOPHYS J, V74, P2318, DOI 10.1016/S0006-3495(98)77941-X; PERSECHINI A, 1989, TRENDS NEUROSCI, V12, P462, DOI 10.1016/0166-2236(89)90097-0; PICTON C, 1980, EUR J BIOCHEM, V111, P553, DOI 10.1111/j.1432-1033.1980.tb04971.x; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; SAH P, 1995, J NEUROPHYSIOL, V74, P1772, DOI 10.1152/jn.1995.74.4.1772; SCHATZMANN HJ, 1982, MEMBRANE TRANSPORT C, P41; Schreiber M, 1997, BIOPHYS J, V73, P1355, DOI 10.1016/S0006-3495(97)78168-2; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; WYLIE DC, 1988, CALMODULIN, P1	30	707	721	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					503	507		10.1038/26758	http://dx.doi.org/10.1038/26758			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774106				2022-12-24	WOS:000076212200057
J	Levy, JA				Levy, JA			Caution: should we be treating HIV infection early?	LANCET			English	Editorial Material							VIRUS TYPE-1 INFECTION; RESPONSES; CELLS; AIDS		Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Levy, JA (corresponding author), Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA.							ALLET B, 1998, LANCET, V351, P1958; Angel JB, 1998, J INFECT DIS, V177, P898, DOI 10.1086/515244; Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; Blackbourn DJ, 1996, P NATL ACAD SCI USA, V93, P13125, DOI 10.1073/pnas.93.23.13125; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; Carpenter CCJ, 1998, JAMA-J AM MED ASSOC, V280, P78, DOI 10.1001/jama.280.1.78; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; LEVY JA, 1995, LANCET, V345, P1619, DOI 10.1016/S0140-6736(95)90121-3; Levy JA, 1996, SCIENCE, V271, P670, DOI 10.1126/science.271.5249.670; Levy JA, 1996, JAMA-J AM MED ASSOC, V276, P161, DOI 10.1001/jama.276.2.161; LEVY JA, 1993, AIDS, V7, P1401, DOI 10.1097/00002030-199311000-00001; LEVY JA, 1998, HIV PATHOENESIS AIDS; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; Miller KD, 1998, LANCET, V351, P871, DOI 10.1016/S0140-6736(97)11518-5; Montaner JSG, 1998, AIDS, V12, P1398, DOI 10.1097/00002030-199811000-00028; Ogg GS, 1998, SCIENCE, V279, P2103, DOI 10.1126/science.279.5359.2103; Rosenberg ES, 1997, SCIENCE, V278, P1447, DOI 10.1126/science.278.5342.1447; ROWLANDJONES SL, 1995, CURR OPIN IMMUNOL, V7, P448, DOI 10.1016/0952-7915(95)80087-5; Shearer GM, 1996, IMMUNOL TODAY, V17, P21, DOI 10.1016/0167-5699(96)80564-0; STRANFORD S, UNPUB HIV EXPOSED UN; Tenner-Racz K, 1998, J EXP MED, V187, P949, DOI 10.1084/jem.187.6.949	23	51	51	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 19	1998	352	9132					982	983		10.1016/S0140-6736(98)05391-4	http://dx.doi.org/10.1016/S0140-6736(98)05391-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752836				2022-12-24	WOS:000076002200041
J	Maclure, M; Dormuth, C; Naumann, T; McCormack, J; Rangno, R; Whiteside, C; Wright, JM				Maclure, M; Dormuth, C; Naumann, T; McCormack, J; Rangno, R; Whiteside, C; Wright, JM			Influences of educational interventions and adverse news about calcium-channel blockers on first-line prescribing of antihypertensive drugs to elderly people in British Columbia	LANCET			English	Article							ESSENTIAL-HYPERTENSION; RISK; MANAGEMENT; SOCIETY; TRIALS	Background The way in which dissemination of evidence changes medical practice needs td be better understood. Controversy about calcium-channel blockers (CCB) in the past 3 years has provided a natural experiment, enabling assessment of the impact of media stories, a national warning letter, a teleconference, small group workshops, and newsletters on first-line prescribing of antihypertensive drugs. Methods We included all physicians (4403) in British Columbia who prescribed a thiazide diuretic, beta-blocker, inhibitor of angiotensin-converting enzyme (ACE), or CCB as the first antihypertensive agent for 36 507 residents aged 66 years and over, with no previous or concurrent sign of underlying cardiovascular disease. We used a database covering all prescriptions to elderly people to measure the change in proportion of newly treated patients who received each class of drug as first-line therapy. We used a matched cohort design for assessment of the teleconference and workshops, a randomised community design for the newsletters, and time-series analysis for the media impacts. Findings The proportion of patients who received a CCB as first-line therapy declined gradually from 22% in early 1994 to 15% in late 1996. This proportion was not affected by two waves of adverse news about CCBs in 1995, but fell by 5% for 5 months and by 3% for 1 month after two waves in 1996. The proportion of patients who received either a CCB or an ACE inhibitor as first-fine therapy, contrary to guidelines, was still 42% overall in 1996. The workshops and newsletters were followed by shifts from first-line CCB to first-line thiazide prescribing. Interpretation Changes in prescribing practices occur gradually with the accumulation of small impacts from educational interventions and lay media attention.	British Columbia Minist Hlth, Victoria, BC V8W 3C8, Canada; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Univ Victoria, Dept Econ, Victoria, BC V8W 2Y2, Canada; Lions Gate Hosp, N Vancouver, BC, Canada; Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada; Univ British Columbia, Dept Pharmacol & Therapeut, Vancouver, BC V6T 1W5, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ British Columbia, Dept Family Practice, Vancouver, BC, Canada	Harvard University; Harvard T.H. Chan School of Public Health; University of Victoria; University of British Columbia; University of British Columbia; University of British Columbia; University of British Columbia	Maclure, M (corresponding author), British Columbia Minist Hlth, 1515 Blanshard St, Victoria, BC V8W 3C8, Canada.	mmaclure@bcsc02.gov.bc.ca		Dormuth, Colin/0000-0001-8577-8783; McCormack, James/0000-0002-7801-5515				Barnett AA, 1996, LANCET, V347, P313; Borhani NO, 1996, JAMA-J AM MED ASSOC, V276, P785, DOI 10.1001/jama.276.10.785; Dean M, 1996, LANCET, V348, P951, DOI 10.1016/S0140-6736(05)65348-2; FREEMANTLE N, 1998, COCHRANE LIB; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; *HLTH PROT BRANCH, 1996, DEAR DOCTOR, V44, P1; INSUA JT, 1994, ANN INTERN MED, V121, P355, DOI 10.7326/0003-4819-121-5-199409010-00008; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P1577, DOI 10.1001/jama.275.20.1577; LAMAS GA, 1992, NEW ENGL J MED, V327, P241, DOI 10.1056/NEJM199207233270405; MARWICK C, 1996, JAMA-J AM MED ASSOC, V275, P638; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Myers MG, 1996, CAN MED ASSOC J, V155, P772; OGILVIE RI, 1993, CAN MED ASSOC J, V149, P575; OXMAN AD, 1995, CAN MED ASSOC J, V153, P1423; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; PAHOR M, 1996, AM J HYPERTENS, V9, P1429; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; PSATY BZ, 1995, CIRCULATION, V91, P925; REUTER, 1995, VANCOUVER SUN   0311, pA15; ROTHMAN K, 1986, MODERN EPIDEMIOLOGY, P173; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SOUMERAI SB, 1992, MILBANK Q, V70, P155, DOI 10.2307/3350088; *THER IN, 1995, THERAPEUTICS LETT, V8; *THER IN, 1995, THERAPEUTICS LETT, V7; THOMSON MA, 1998, COCHRANE LIB; *WHO, 1993, J HYPERTENS, V11, P906	30	58	58	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					943	948		10.1016/S0140-6736(97)11390-3	http://dx.doi.org/10.1016/S0140-6736(97)11390-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752816				2022-12-24	WOS:000076002200009
J	Nedivi, E; Wu, GY; Cline, HT				Nedivi, E; Wu, GY; Cline, HT			Promotion of dendritic growth by CPG15, an activity-induced signaling molecule	SCIENCE			English	Article							RECEPTOR TYROSINE KINASES; GANGLION-CELL DENDRITES; STRIATE CORTEX; OPTIC TECTUM; NEURONS; EXPRESSION; CLONING; LIGANDS; CAMKII; FROGS	Activity-independent and activity-dependent mechanisms work in concert to regulate neuronal growth, ensuring the formation of accurate synaptic connections. CPG15, a protein regulated by synaptic activity, functions as a cell-surface growth-promoting molecule in vivo. In Xenopus laevis, CPG15 enhanced dendritic arbor growth in projection neurons, with no effect on interneurons. CPG15 controlled growth of neighboring neuron's through an intercellular signaling mechanism that requires, its glycosylphosphatidylinositol link. CPG15 may represent a new class of activity-regulated, membrane-bound, growth-promoting proteins that permit exquisite spatial and temporal control of neuronal structure.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Nedivi, E (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.		Nedivi, Elly/ABC-9923-2021	/0000-0002-1710-0767	NEI NIH HHS [R29 EY011894, R29 EY011894-04] Funding Source: Medline; NATIONAL EYE INSTITUTE [R29EY011894] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANTAL M, 1986, J COMP NEUROL, V246, P238, DOI 10.1002/cne.902460208; BODNARENKO SR, 1993, NATURE, V364, P144, DOI 10.1038/364144a0; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; KATZ LC, 1988, J NEUROSCI, V8, P3160; KOSSEL A, 1995, J NEUROSCI, V15, P3913; LUND JS, 1991, J COMP NEUROL, V309, P129, DOI 10.1002/cne.903090109; MACKETT M, 1985, DNA CLONING PRACTICA; MATSUMOTO N, 1986, J COMP PHYSIOL A, V159, P721, DOI 10.1007/BF00603726; Naeve GS, 1997, P NATL ACAD SCI USA, V94, P2648, DOI 10.1073/pnas.94.6.2648; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Nedivi E, 1996, P NATL ACAD SCI USA, V93, P2048, DOI 10.1073/pnas.93.5.2048; NEDIVI E, UNPUB; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; PANDEY A, 1995, CURR BIOL, V5, P986, DOI 10.1016/S0960-9822(95)00195-3; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; SAMBROOK J, 1989, MOL CLONIGN LAB MANU; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHOLL DA, 1953, J ANAT, V87, P387; TIEMAN SB, 1982, J COMP NEUROL, V211, P353, DOI 10.1002/cne.902110403; WONG ROL, 1991, J NEUROBIOL, V22, P685, DOI 10.1002/neu.480220704; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; Wu GY, 1998, SCIENCE, V279, P222, DOI 10.1126/science.279.5348.222; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	28	166	175	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1863	1866		10.1126/science.281.5384.1863	http://dx.doi.org/10.1126/science.281.5384.1863			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743502	Green Accepted			2022-12-24	WOS:000076007100057
J	Plath, K; Mothes, W; Wilkinson, BM; Stirling, CJ; Rapoport, TA				Plath, K; Mothes, W; Wilkinson, BM; Stirling, CJ; Rapoport, TA			Signal sequence recognition in posttranslational protein transport across the yeast ER membrane	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; SEC PROTEINS; TRANSLOCATION; COMPLEX; POLYPEPTIDES; COMPONENT; DOMAINS; KAR2P; BIP	We have analyzed how the signal sequence of prepor-alpha-factor is recognized during the first step of posttranslational protein transport into the yeast endoplasmic reticulum. Cross-linking studies indicate that the signal sequence interacts in a Kar2p- and ATP-independent reaction with Sec61p, the multispanning membrane component of the protein-conducting channel, by intercalation into transmembrane domains 2 and 7. While bound to Sec61p, the signal sequence forms a helix that is contacted on one side by Sec62p and Sec71p. The binding site is located at the interface of the protein channel and the lipid bilayer. Signal sequence recognition in cotranslational translocation in mammals appears to occur similarly. These results suggest a general mechanism by which the signal sequence could open the channel for polypeptide transport.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; University of Manchester	Rapoport, TA (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.			Plath, Kathrin/0000-0001-7796-3372	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054238] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54238] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1991, NATURE, V349, P806, DOI 10.1038/349806a0; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; ITO K, 1995, ADV CELL MOL BIOL M, V4, P35; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; Lyman SK, 1997, CELL, V88, P85, DOI 10.1016/S0092-8674(00)81861-9; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Matlack KES, 1997, SCIENCE, V277, P938, DOI 10.1126/science.277.5328.938; Mothes W, 1998, J CELL BIOL, V142, P355, DOI 10.1083/jcb.142.2.355; MURPHY CK, 1994, P NATL ACAD SCI USA, V91, P2557, DOI 10.1073/pnas.91.7.2557; MUSCH A, 1992, CELL, V69, P343, DOI 10.1016/0092-8674(92)90414-8; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; SAKO T, 1991, J BACTERIOL, V173, P2289, DOI 10.1128/JB.173.7.2289-2296.1991; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; Voigt S, 1996, J CELL BIOL, V134, P25, DOI 10.1083/jcb.134.1.25; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549	21	273	278	3	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					795	807		10.1016/S0092-8674(00)81738-9	http://dx.doi.org/10.1016/S0092-8674(00)81738-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753326	Bronze			2022-12-24	WOS:000076021200012
J	Rongo, C; Whitfield, CW; Rodal, A; Kim, SK; Kaplan, JM				Rongo, C; Whitfield, CW; Rodal, A; Kim, SK; Kaplan, JM			LIN-10 is a shared component of the polarized protein localization pathways in neurons and epithelia	CELL			English	Article							GLR-1 GLUTAMATE-RECEPTOR; ELEGANS VULVAR INDUCTION; PDZ-DOMAIN PROTEIN; C-ELEGANS; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; FASCICLIN-II; GENE; CHANNEL; RECOGNITION	We tested the model that neurons and epithelial cells use a shared mechanism for polarized protein sorting by comparing the pathways for localizing basolateral and postsynaptic proteins in C. elegans. GLR-1 glutamate receptors are localized to postsynaptic elements of central synapses and, when ectopically expressed, to basolateral membranes of epithelial cells. Proper localization of GLR-1 in both neurons and epithelia requires the PDZ protein LIN-10, defining LIN-10 as a shared component of the basolateral and postsynaptic localization pathways. Changing the GLR-1 carboxyterminal sequence from a group I PDZ-binding consensus (-TAV) to a group II consensus (-FYV) restores GLR-1 synaptic localization in lin-10 mutants. Thus, these interneurons utilize at least two separate postsynaptic localization pathways.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	University of California System; University of California Berkeley; Stanford University	Kaplan, JM (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NINDS NIH HHS [NS32196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032196] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Borg JP, 1996, MOL CELL BIOL, V16, P6229; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CHALFIE M, 1985, J NEUROSCI, V5, P956; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HART AC, 1995, NATURE, V378, P82, DOI 10.1038/378082a0; Hein R, 1996, CURR BIOL, V6, P178, DOI 10.1016/S0960-9822(02)00450-5; Hoskins R, 1996, DEVELOPMENT, V122, P97; Isaacson JS, 1998, NEURON, V20, P749, DOI 10.1016/S0896-6273(00)81013-2; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Keller P, 1997, J CELL SCI, V110, P3001; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Sheng M, 1997, BIOESSAYS, V19, P847, DOI 10.1002/bies.950191004; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Thomas U, 1997, NEURON, V19, P787, DOI 10.1016/S0896-6273(00)80961-7; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	32	212	226	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1998	94	6					751	759		10.1016/S0092-8674(00)81734-1	http://dx.doi.org/10.1016/S0092-8674(00)81734-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753322	Bronze			2022-12-24	WOS:000076021200008
J	Wang, XQ; Lin, XL; Loy, JA; Tang, J; Zhang, XJC				Wang, XQ; Lin, XL; Loy, JA; Tang, J; Zhang, XJC			Crystal structure of the catalytic domain of human plasmin complexed with streptokinase	SCIENCE			English	Article							ALPHA-CHYMOTRYPSIN; ACTIVATION; GENE; STAPHYLOKINASE; IDENTIFICATION; STABILITY; PROTEASES; PROENZYME; SEQUENCE; ZYMOGEN	Streptokinase is a plasminogen activator widely used in treating blood-clotting disorders. Complexes of streptokinase with human plasminogen can hydrolytically activate other plasminogen molecules to plasmin, which then dissolves blood clots. A similar binding activation mechanism also occurs in some key steps of blood coagulation. The crystal structure of streptokinase complexed with the catalytic unit of human plasmin was solved at 2.9 angstroms. The amino-terminal domain of streptokinase in the complex is hypothesized to enhance the substrate recognition. The carboxyl-terminal domain of streptokinase, which binds near the activation Loop of plasminogen, is Likely responsible for the contact activation of plasminogen in the complex.	Oklahoma Med Res Fdn, Crystallog Program, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Prot Studies Program, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA	Oklahoma Medical Research Foundation; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center	Zhang, XJC (corresponding author), Oklahoma Med Res Fdn, Crystallog Program, 825 NE 13th St, Oklahoma City, OK 73104 USA.				NHLBI NIH HHS [HL 60626] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060626] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachmann F., 1994, HEMOSTASIS THROMBOSI, V3rd, P1592; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASTELLINO FJ, 1979, TRENDS BIOCHEM SCI, V4, P1, DOI 10.1016/0968-0004(79)90235-4; ConejeroLara F, 1996, PROTEIN SCI, V5, P2583, DOI 10.1002/pro.5560051221; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; DAWSON KM, 1994, BIOCHEMISTRY-US, V33, P12042, DOI 10.1021/bi00206a005; de la Cadena RA, 1994, HEMOSTASIS THROMBOSI, P219; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; GANU VS, 1982, INT J PEPT PROT RES, V20, P421; Grella DK, 1997, BLOOD, V89, P1585, DOI 10.1182/blood.V89.5.1585.1585_1585_1589; HAREL M, 1991, BIOCHEMISTRY-US, V30, P5217, DOI 10.1021/bi00235a015; ICHINOSE A, 1991, P NATL ACAD SCI USA, V88, P115, DOI 10.1073/pnas.88.1.115; JACKSON KW, 1982, BIOCHEMISTRY-US, V21, P6620, DOI 10.1021/bi00269a001; JACKSON KW, 1986, BIOCHEMISTRY-US, V25, P108, DOI 10.1021/bi00349a016; Jespers L, 1998, BIOCHEMISTRY-US, V37, P6380, DOI 10.1021/bi972807i; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamba D, 1996, J MOL BIOL, V258, P117, DOI 10.1006/jmbi.1996.0238; Lee SH, 1997, BIOCHEM MOL BIOL INT, V41, P199; LIN XL, 1994, METHOD ENZYMOL, V241, P195; LIN XL, ADV EXP MED BIOL, V306, P255; MALKE H, 1985, GENE, V34, P357, DOI 10.1016/0378-1119(85)90145-3; MCCLINTOCK DK, 1971, BIOCHEM BIOPH RES CO, V43, P694, DOI 10.1016/0006-291X(71)90670-X; Medved LV, 1996, EUR J BIOCHEM, V239, P333, DOI 10.1111/j.1432-1033.1996.0333u.x; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nassar N, 1996, NAT STRUCT BIOL, V3, P723, DOI 10.1038/nsb0896-723; Nihalani D, 1998, PROTEIN SCI, V7, P637, DOI 10.1002/pro.5560070313; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; PETERSEN TE, 1990, J BIOL CHEM, V265, P6104; Rabijns A, 1997, NAT STRUCT BIOL, V4, P357, DOI 10.1038/nsb0597-357; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REED GL, 1995, BIOCHEMISTRY-US, V34, P10266, DOI 10.1021/bi00032a021; Renatus M, 1997, BIOCHEMISTRY-US, V36, P13483, DOI 10.1021/bi971129x; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; ROBBINS KC, 1981, METHOD ENZYMOL, V80, P379; RODRIGUEZ P, 1995, EUR J BIOCHEM, V229, P83, DOI 10.1111/j.1432-1033.1995.tb20441.x; SCHIMMEL P, 1989, ACCOUNTS CHEM RES, V22, P232, DOI 10.1021/ar00163a001; SCHLOTT B, 1994, BBA-PROTEIN STRUCT M, V1204, P235, DOI 10.1016/0167-4838(94)90013-2; SHI GY, 1990, THROMB RES, V58, P317, DOI 10.1016/0049-3848(90)90101-H; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, V3, P191; Tachias K, 1997, J BIOL CHEM, V272, P28; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; VILLIERS CL, 1985, P NATL ACAD SCI USA, V82, P4477, DOI 10.1073/pnas.82.13.4477; Young KC, 1998, J BIOL CHEM, V273, P3110, DOI 10.1074/jbc.273.5.3110; YOUNG KC, 1995, J BIOL CHEM, V270, P29601, DOI 10.1074/jbc.270.49.29601; ZHANG XJ, 1995, J APPL CRYSTALLOGR, V28, P624, DOI 10.1107/S0021889895001063	48	194	212	1	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1662	1665		10.1126/science.281.5383.1662	http://dx.doi.org/10.1126/science.281.5383.1662			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733510				2022-12-24	WOS:000075856500043
J	Sampath, K; Rubinstein, AL; Cheng, AHS; Liang, JO; Fekany, K; Solnica-Krezel, L; Korzh, V; Halpern, ME; Wright, CVE				Sampath, K; Rubinstein, AL; Cheng, AHS; Liang, JO; Fekany, K; Solnica-Krezel, L; Korzh, V; Halpern, ME; Wright, CVE			Induction of the zebrafish ventral brain and floorplate requires cyclops/nodal signalling	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; DEVELOPING SPINAL-CORD; ACTIVIN-A; EXPRESSION; MIDLINE; PLATE; FOREBRAIN; DIFFERENTIATION; ASYMMETRY; PATTERN	Zebrafish cyclops (cyc) mutations cause deficiencies in the dorsal mesendoderm(1,2) and ventral neural tube(3,4), leading to neural defects and cyclopia(5,6). Here we report that cyc encodes a transforming growth factor-beta (TGF-beta)-related intercellular signalling molecule that is similar to mouse nodal(7). cyc is expressed in dorsal mesendoderm at gastrulation and in the prechordal plate until early somitogenesis. Expression reappears transiently in the left lateral-plate mesoderm, and in an unprecedented asymmetric pattern in the left forebrain. Injection of cyc RNA non-autonomously restores sonic hedgehog-expressing cells of the ventral brain and floorplate that are absent in cyc mutants, whereas inducing activities are abolished by cyc(m294), a mutation of a conserved cysteine in the mature ligand. Our results indicate that cyc provides an essential non-cell-autonomous signal at gastrulation, leading to induction of the floorplate and ventral brain.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Mol Biol, Nashville, TN 37232 USA; Natl Univ Singapore, Inst Mol Agrobiol, Singapore 117604, Singapore; Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA	Vanderbilt University; Vanderbilt University; National University of Singapore; Carnegie Institution for Science	Wright, CVE (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.		Korzh, Vladimir P/H-1596-2011	Korzh, Vladimir P/0000-0002-6580-7986; Sampath, Karuna/0000-0002-0729-1977				ARTINGER KB, 1993, NEURON, V11, P1147, DOI 10.1016/0896-6273(93)90227-I; Brand M, 1996, DEVELOPMENT, V123, P129; Butler A. B., 1996, HODOS H COMP VERTEBR; Chen JN, 1997, DEVELOPMENT, V124, P4373; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; FELDMAN B, IN PRESS NATURE; Halpern ME, 1997, DEV BIOL, V187, P154, DOI 10.1006/dbio.1997.8605; HATTA K, 1994, P NATL ACAD SCI USA, V91, P2061, DOI 10.1073/pnas.91.6.2061; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; MASON AJ, 1994, MOL ENDOCRINOL, V8, P325, DOI 10.1210/me.8.3.325; Pera EM, 1997, DEVELOPMENT, V124, P4153; PITUELLO F, 1995, P NATL ACAD SCI USA, V92, P6952, DOI 10.1073/pnas.92.15.6952; POSTLETHWAIT JH, 1994, SCIENCE, V264, P699, DOI 10.1126/science.8171321; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; Schier AF, 1996, DEVELOPMENT, V123, P165; Strahle U, 1997, Genes Funct, V1, P131; Talbot WS, 1998, GENETICS, V148, P373; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; TOYAMA R, 1995, DEVELOPMENT, V121, P383; Varlet I, 1997, CURR OPIN GENET DEV, V7, P519, DOI 10.1016/S0959-437X(97)80080-9; VARLET J, 1997, COLD SPRING HAR S QU, V62, P105; WARGA RM, 1996, THESIS U TUBINGEN; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	32	399	408	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					185	189		10.1038/26020	http://dx.doi.org/10.1038/26020			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744278				2022-12-24	WOS:000075829900045
J	Monks, CRF; Freiberg, BA; Kupfer, H; Sciaky, N; Kupfer, A				Monks, CRF; Freiberg, BA; Kupfer, H; Sciaky, N; Kupfer, A			Three-dimensional segregation of supramolecular activation clusters in T cells	NATURE			English	Article							SIGNAL-TRANSDUCTION; B-CELLS; MEMBRANE; ADHESION; PROTEINS	Activation of T cells by antigen-presenting Cells (APCs) depends on the complex integration of signals that are delivered by multiple antigen receptors. Most receptor-proximal activation events in T cells(1,2) were identified using multivalent anti-receptor antibodies, eliminating the need to use the more complex APCs. As the physiological membrane-associated ligands ori the APC and the activating antibodies probably trigger the same biochemical pathways, it is unknown why the antibodies, even at saturating concentrations, fail to trigger some of the physiological T-cell responses(3). Here we study, at the level of the single cell, the responses of T cells to native ligands. We used a digital imaging system and analysed the three-dimensional distribution of receptors and intracellular proteins that cluster at the contacts between T cells and APCs during antigen-specific interactions(3,4). Surprisingly, instead of showing uniform oligomerization, these proteins clustered into segregated three-dimensional domains within the cell contacts. The antigen-specific formation of these new, spatially segregated supramolecular activation clusters may generate appropriate physiological responses and may explain the high sensitivity of the T cells to antigen.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Cellular & Struct Biol, Denver, CO 80262 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kupfer, A (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.							ANDERSON MS, 1993, J EXP MED, V178, P1959, DOI 10.1084/jem.178.6.1959; Dittel BN, 1997, J IMMUNOL, V158, P4065; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; HIRAOKA Y, 1990, BIOPHYS J, V57, P325, DOI 10.1016/S0006-3495(90)82534-0; KUPFER A, 1990, J MOL CELL IMMUNOL, V4, P317; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; KUPFER H, 1994, J EXP MED, V179, P1507, DOI 10.1084/jem.179.5.1507; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MCCLOSKEY MA, 1986, J CELL BIOL, V102, P2185, DOI 10.1083/jcb.102.6.2185; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PODACK ER, 1991, ANNU REV CELL BIOL, V7, P479, DOI 10.1146/annurev.cellbio.7.1.479; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SINGER SJ, 1992, SCIENCE, V255, P1671, DOI 10.1126/science.1313187; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	16	1890	1938	0	95	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					82	86		10.1038/25764	http://dx.doi.org/10.1038/25764			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738502				2022-12-24	WOS:000075722200051
J	Shivers, SC; Wang, XN; Li, WG; Joseph, E; Messina, J; Glass, LF; DeConti, R; Cruse, CW; Berman, C; Fenske, NA; Lyman, GH; Reintgen, DS				Shivers, SC; Wang, XN; Li, WG; Joseph, E; Messina, J; Glass, LF; DeConti, R; Cruse, CW; Berman, C; Fenske, NA; Lyman, GH; Reintgen, DS			Molecular staging of malignant melanoma - Correlation with clinical outcome	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LYMPH-NODE METASTASES; POLYMERASE CHAIN-REACTION; MONOCLONAL-ANTIBODIES; CUTANEOUS MELANOMA; PROGNOSTIC VALUE; SENTINEL NODE; TUMOR-CELLS; BONE-MARROW; 4 MM; CANCER	Context.-For most solid tumors, the metastatic status of regional lymph nodes is the strongest predictor of relapse and survival. However, routine pathological examination of lymph nodes may underestimate the number of patients with melanoma who have nodal metastases, Objective.-To determine the clinical significance of a highly sensitive molecular assay for occult nodal metastases for the staging of patients with melanoma, Design.-A prospective cohort study of consecutive patients in which lymphatic mapping and sentinel lymph node (SLN) biopsy were performed on 114 melanoma patients with clinical stage I and stage II disease. The SLNs were bivalved, and half of each specimen was submitted for routine pathological examination, The other half was submitted for molecular detection of submicroscopic metastases using a reverse transcriptase-polymerase chain reaction (RT-PCR) assay for tyrosinase messenger RNA as a marker for the presence of melanoma cells. Patient followup averaged 28 months. Setting.-A major university-based melanoma referral center at a National Cancer Institute-designated cancer center. Patients.-A total of 114 patients with newly diagnosed cutaneous malignant melanoma who were at risk for regional nodal metastases, Main Outcome Measure.-Melanoma recurrence and overall survival. Results.-Twenty-three patients (20%) had pathologically positive SLNs, and all of these patients were also RT-PCR positive. Of the 91 pathologically negative patients, 44 were RT-PCR negative and 47 were RT-PCR positive. There was a recurrence rate among 14 (61%) of the 23 patients who were both pathologically and RT-PCR positive and a recurrence rate among 1 (2%) of 44 patients who were both pathologically and RT-PCR negative. For patients who were upstaged by the molecular assay (pathologically negative, RT-PCR positive), there was a recurrence rate among 6 (13%) of 47 patients. The differences in recurrence rates and overall survival between the pathologically negative, RT-PCR-negative and pathologically negative, RT-PCR-positive patient groups were statistically significant (P=.02 for disease-free survival and for overall survival). In both univariate and multivariate regression analyses, the histological and RT-PCR status of the SLNs were the best predictors of disease-free survival. Conclusions.-The use of an RT-PCR assay for detection of submicroscopic melanoma metastases in SLNs improved the prediction of melanoma recurrence and overall survival over routine pathological examination.	Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Cutaneous Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Dept Surg, Tampa, FL 33612 USA; Univ S Florida, Dept Lab Med & Pathol, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA; Univ S Florida, Dept Radiol, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Reintgen, DS (corresponding author), Univ S Florida, H Lee Moffit Canc Ctr & Res Inst, Cutaneous Oncol Program, 12902 Magnolia dr, Tampa, FL 33612 USA.	doug@moffitt.usf.edu	Shivers, Steve/E-6438-2013; Shivers, Steven/AAE-9288-2022; Lyman, Gary H/K-5227-2019	Shivers, Steve/0000-0001-9538-4016; Lyman, Gary H/0000-0002-0823-8086				Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; BALCH CM, 1992, CUTANEOUS MELANOMA, P188; BERMAN CG, 1992, ANN PLAS SURG, V28, P29, DOI 10.1097/00000637-199201000-00010; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; CHO KH, 1990, CANCER, V66, P765, DOI 10.1002/1097-0142(19900815)66:4<765::AID-CNCR2820660428>3.0.CO;2-M; COCHRAN AJ, 1988, AM J SURG PATHOL, V12, P612, DOI 10.1097/00000478-198808000-00002; COX DR, 1972, J R STAT SOC B, V34, P187; Fields KK, 1996, J CLIN ONCOL, V14, P1868, DOI 10.1200/JCO.1996.14.6.1868; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; GREENSON JK, 1994, CANCER-AM CANCER SOC, V73, P563, DOI 10.1002/1097-0142(19940201)73:3<563::AID-CNCR2820730311>3.0.CO;2-D; HELLER R, 1993, SEMIN SURG ONCOL, V9, P285; HELLER R, 1991, ARCH SURG-CHICAGO, V126, P1455; Izbicki JR, 1997, NEW ENGL J MED, V337, P1188, DOI 10.1056/NEJM199710233371702; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; Maehara Y, 1996, SURGERY, V119, P397, DOI 10.1016/S0039-6060(96)80138-3; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Messina J L, 1997, J Fla Med Assoc, V84, P153; MORENO JG, 1992, CANCER RES, V52, P6110; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; MOSS TJ, 1991, NEW ENGL J MED, V324, P219, DOI 10.1056/NEJM199101243240403; Noguchi S, 1996, AM J PATHOL, V148, P649; NORMAN J, 1991, AM J SURG, V162, P432, DOI 10.1016/0002-9610(91)90255-C; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; REINTGEN DS, 1987, ARCH SURG-CHICAGO, V122, P1338; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; ROSS MI, 1993, SEMIN SURG ONCOL, V9, P219; UREN RF, 1993, J NUCL MED, V34, P1435; VERONESI U, 1988, NEW ENGL J MED, V318, P1159, DOI 10.1056/NEJM198805053181804; WALTS AE, 1988, AM J CLIN PATHOL, V90, P77, DOI 10.1093/ajcp/90.1.77; WANG XN, 1994, ANN SURG, V220, P768, DOI 10.1097/00000658-199412000-00010; WONG JH, 1991, ANN SURG, V214, P637, DOI 10.1097/00000658-199111000-00015; Wood DP, 1997, J CLIN ONCOL, V15, P3451, DOI 10.1200/JCO.1997.15.12.3451	36	264	268	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1410	1415		10.1001/jama.280.16.1410	http://dx.doi.org/10.1001/jama.280.16.1410			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9801000	Bronze			2022-12-24	WOS:000076546900035
J	Chu, S; DeRisi, J; Eisen, M; Mulholland, J; Botstein, D; Brown, PO; Herskowitz, I				Chu, S; DeRisi, J; Eisen, M; Mulholland, J; Botstein, D; Brown, PO; Herskowitz, I			The transcriptional program of sporulation in budding yeast	SCIENCE			English	Article							SISTER-CHROMATID COHESION; SPORE WALL MATURATION; MEIOSIS-SPECIFIC GENE; MAP KINASE CASCADE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; REPRESSOR UME6; EXPRESSION; ELEMENT	Diploid cells of budding yeast produce haploid cells through the developmental program of sporulation, which consists of meiosis and spore morphogenesis. DNA microarrays containing nearly every yeast gene were used to assay changes in gene expression during sporulation. At Least seven distinct temporal patterns of induction were observed. The transcription factor Ndt80 appeared to be important for induction of a Large group of genes at the end of meiotic prophase, Consensus sequences known or proposed to be responsible for temporal regulation could be identified solely from analysis of sequences of coordinately expressed genes. The temporal expression pattern provided clues to potential functions of hundreds of previously uncharacterized genes, some of which have vertebrate homologs that may function during gametogenesis.	Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; University of California System; University of California San Francisco; Stanford University; Stanford University	Brown, PO (corresponding author), Stanford Univ, Howard Hughes Med Inst, Sch Med, Dept Biochem, Stanford, CA 94305 USA.	pbrown@cmgm.stanford.edu; ira@cgl.ucsf.edu		Eisen, Michael/0000-0002-7528-738X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018738, R37AI018738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046406, R01GM046406] Funding Source: NIH RePORTER; NIAID NIH HHS [AI18738] Funding Source: Medline; NIGMS NIH HHS [GM46406] Funding Source: Medline; CGH CDC HHS [GH00450] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CGH CDC HHS		BIGGINS S, UNPUB; BRIZA P, 1990, GENE DEV, V4, P1775, DOI 10.1101/gad.4.10.1775; BUCKINGHAM LE, 1990, P NATL ACAD SCI USA, V87, P9406, DOI 10.1073/pnas.87.23.9406; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; BYERS B, 1975, J BACTERIOL, V124, P511, DOI 10.1128/JB.124.1.511-523.1975; Byers B, 1981, MOL BIOL YEAST SACCH, P59; Caro LHP, 1997, YEAST, V13, P1477, DOI 10.1002/(SICI)1097-0061(199712)13:15<1477::AID-YEA184>3.0.CO;2-L; CHAN CSM, 1993, GENETICS, V135, P677; CHOI KY, 1994, CELL, V78, P499; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; CHU SC, UNPUB; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; EISEN MB, UNPUB; ESPOSITO RE, 1972, MOL GEN GENET, V114, P241, DOI 10.1007/BF01788893; Esposito RE, 1981, MOL BIOL YEAST SACCH; Friesen H, 1997, MOL CELL BIOL, V17, P123, DOI 10.1128/MCB.17.1.123; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GLOTZER M, 1995, CURR BIOL, V5, P970, DOI 10.1016/S0960-9822(95)00190-4; Hales KG, 1997, CELL, V90, P121, DOI 10.1016/S0092-8674(00)80319-0; HEPWORTH SR, 1995, MOL CELL BIOL, V15, P3934; Horie S, 1998, MOL CELL BIOL, V18, P2118, DOI 10.1128/MCB.18.4.2118; IRELAND LS, 1994, EMBO J, V13, P3812, DOI 10.1002/j.1460-2075.1994.tb06692.x; Jackson JC, 1996, NUCLEIC ACIDS RES, V24, P1322, DOI 10.1093/nar/24.7.1322; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; Kohonen T., 1997, SELF ORGANIZING MAPS; Kovalenko OV, 1996, P NATL ACAD SCI USA, V93, P2958, DOI 10.1073/pnas.93.7.2958; Kratzer S, 1997, MOL MICROBIOL, V26, P631, DOI 10.1046/j.1365-2958.1997.5611937.x; KRISAK L, 1994, GENE DEV, V8, P2151, DOI 10.1101/gad.8.18.2151; Kupiec M., 1997, MOL CELLULAR BIOL YE, P889; LAW DTS, 1988, MOL CELL BIOL, V8, P912, DOI 10.1128/MCB.8.2.912; Lydall D, 1996, NATURE, V383, P840, DOI 10.1038/383840a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MATSUBARA N, 1995, MOL REPROD DEV, V41, P407, DOI 10.1002/mrd.1080410403; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; MIYAKAWA I, 1984, J CELL SCI, V66, P21; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MOLNAR M, 1995, GENETICS, V141, P61; MULHOLLAND JH, UNPUB; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; Ozsarac N, 1997, MOL CELL BIOL, V17, P1152, DOI 10.1128/MCB.17.3.1152; Page AW, 1997, CURR OPIN GENET DEV, V7, P23, DOI 10.1016/S0959-437X(97)80105-0; PALMER DK, 1990, CHROMOSOMA, V100, P32, DOI 10.1007/BF00337600; Patton EE, 1998, TRENDS GENET, V14, P236, DOI 10.1016/S0168-9525(98)01473-5; PRINTEN JA, 1994, GENETICS, V138, P609; Roeder AD, 1996, GENETICS, V144, P445; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; RubinBejerano I, 1996, MOL CELL BIOL, V16, P2518; Sambrook EE., 1989, MOL CLONING LAB MANU; SCHILD D, 1978, CHROMOSOMA, V70, P109, DOI 10.1007/BF00292220; Sherman F., 1986, METHODS YEAST GENETI; SIMCHEN G, 1974, GENETICS, V76, P745; SPELLMAN P, COMMUNICATION; Townsley FM, 1998, TRENDS CELL BIOL, V8, P238, DOI 10.1016/S0962-8924(98)01268-9; WADA Y, 1992, J BIOL CHEM, V267, P18665; XU LZ, 1995, MOL CELL BIOL, V15, P6572; Yanai A, 1997, ONCOGENE, V14, P2943, DOI 10.1038/sj.onc.1201144	60	1438	1502	1	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					699	705		10.1126/science.282.5389.699	http://dx.doi.org/10.1126/science.282.5389.699			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784122				2022-12-24	WOS:000076607500041
J	Sasazuki, T; Juji, T; Morishima, Y; Kinukawa, N; Kashiwabara, H; Inoko, H; Yoshida, T; Kimura, A; Akaza, T; Kamikawaji, N; Kodera, Y; Takaku, F				Sasazuki, T; Juji, T; Morishima, Y; Kinukawa, N; Kashiwabara, H; Inoko, H; Yoshida, T; Kimura, A; Akaza, T; Kamikawaji, N; Kodera, Y; Takaku, F		Japan Marrow Donor Program	Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW-TRANSPLANTATION; VERSUS-HOST DISEASE; HEMATOLOGIC MALIGNANCIES; HUMAN RECIPIENTS; NATURAL-KILLER; LEUKEMIA; GRAFT; JAPANESE; RECEPTORS; HLA-DRB1	Background The requirements with respect to HLA compatibility and the relative importance of matching for individual class I and class II HLA alleles in the transplantation of hematopoietic stem cells from unrelated donors have not yet been established. Methods We performed retrospective DNA typing of alleles at 11 polymorphic loci of HLA genes in 440 recipients of hematopoietic stem cells from unrelated donors who were serologically identical with their respective recipients for HLA-A, B, and DR antigens. Of these recipients, 80 percent had leukemia; the rest had lymphoma, marrow failure, or a congenital disorder. Results Multivariate analysis showed that incompatibility for HLA-A alleles and incompatibility for HLA-C alleles were independent risk factors for severe acute graft-versus-host disease (GVHD) (HLA-A, P=0.006; HLA-C, P=0.001). Mismatching of HLA-A, but not of HLA-C, alleles was an independent risk factor for death (P<0.001). Mismatching of HLA-C alleles was a significant risk factor for relapse of leukemia (P=0.035). HLA-B disparity was a significant risk factor for both GVHD and death in the univariate analysis, but not in the multivariate analysis. Disparities in class II HLA alleles of the DRB1, DQA1, DQB1, DPA1, and DPB1 loci were not identified as significant risk factors for acute GVHD or death in the multivariate analysis. Conclusions Genomic typing of class I HLA alleles adds substantially to the success of transplantation of hematopoietic stem cells from unrelated donors, even if the donors are serologically identical to their recipients with respect to HLA-A, B, and DR antigens. (N Engl J Med 1998;339:1177-85.) (C) 1998, Massachusetts Medical Society.	Kyushu Univ, Med Inst Bioregulat, Dept Genet, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Dept Med Informat, Fukuoka 812, Japan; Japanese Red Cross Cent Blood Ctr, Tokyo, Japan; Aichi Canc Ctr Hosp, Dept Hematol & Chemotherapy, Nagoya, Aichi 464, Japan; Sakura Natl Hosp, Dept Surg, Chiba, Japan; Tokai Univ, Sch Med, Dept Genet Informat, Div Mol Life Sci, Kanagawa, Japan; Showa Univ, Sch Med, Dept Microbiol & Immunol, Tokyo 142, Japan; Tokyo Med & Dent Univ, Med Res Inst, Div Adult Dis, Dept Tissue Physiol, Tokyo 113, Japan; Nagoya First Hosp, Japanese Red Cross, Dept Internal Med, Nagoya, Aichi, Japan; Jichi Med Sch, Tochigi, Japan	Kyushu University; Kyushu University; Japanese Red Cross Medical Center; Aichi Cancer Center; Tokai University; Showa University; Tokyo Medical & Dental University (TMDU); Japanese Red Cross Medical Center; Red Cross Nagoya Daiichi Hospital; Jichi Medical University	Sasazuki, T (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Genet, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.							Ando H, 1996, TISSUE ANTIGENS, V48, P55, DOI 10.1111/j.1399-0039.1996.tb02606.x; BEATTY PG, 1993, BLOOD, V81, P249; Bodmer JG, 1997, TISSUE ANTIGENS, V49, P297, DOI 10.1111/j.1399-0039.1997.tb02759.x; BORTIN MM, 1992, JAMA-J AM MED ASSOC, V268, P607; CHAMPLIN RE, 1984, CANCER TREAT REP, V68, P145; COX DR, 1972, J R STAT SOC B, V34, P187; Date Y, 1996, TISSUE ANTIGENS, V47, P93, DOI 10.1111/j.1399-0039.1996.tb02520.x; DAVIES SM, 1995, BLOOD, V86, P1636, DOI 10.1182/blood.V86.4.1636.bloodjournal8641636; Dixon W. J., 1992, BMDP STAT SOFTWARE M; Dupont B, 1997, IMMUNOL REV, V157, P5, DOI 10.1111/j.1600-065X.1997.tb00970.x; Fleischhauer K, 1997, TISSUE ANTIGENS, V50, P208; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; Hansen JA, 1997, IMMUNOL REV, V157, P141, DOI 10.1111/j.1600-065X.1997.tb00979.x; HAUCH M, 1990, BLOOD, V75, P2250; HIRABAYASHI N, 1995, TRANSPLANT P, V27, P1380; HOROWITZ MM, 1990, BLOOD, V75, P555; HOWS JM, 1986, BLOOD, V68, P1322; INOKO H, 1993, HDB HLA TYPING TECHN, P9; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KIMURA A, 1992, TISSUE ANTIGENS, V40, P5, DOI 10.1111/j.1399-0039.1992.tb01951.x; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; KIMURA A, 1992, HLA 1991, V1, P511; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MATSUBARA K, 1992, HUM IMMUNOL, V35, P132, DOI 10.1016/0198-8859(92)90021-E; MCCULLOUGH J, 1986, TRANSFUSION, V26, P315, DOI 10.1046/j.1537-2995.1986.26486262737.x; MCELLIGOTT MC, 1986, TRANSFUSION, V26, P309, DOI 10.1046/j.1537-2995.1986.26486262736.x; Moretta A, 1997, CURR OPIN IMMUNOL, V9, P694, DOI 10.1016/S0952-7915(97)80051-9; Moretta A, 1997, IMMUNOL REV, V155, P105, DOI 10.1111/j.1600-065X.1997.tb00943.x; MORISHIMA Y, 1989, BLOOD, V74, P2252, DOI 10.1182/blood.V74.6.2252.2252; Naruse TK, 1997, TISSUE ANTIGENS, V49, P152, DOI 10.1111/j.1399-0039.1997.tb02729.x; OREILLY RJ, 1983, BLOOD, V62, P941; PETERSDORF EW, 1993, BLOOD, V81, P1923; Petersdorf EW, 1996, P NATL ACAD SCI USA, V93, P15358, DOI 10.1073/pnas.93.26.15358; PETERSDORF EW, 1995, BLOOD, V86, P1606, DOI 10.1182/blood.V86.4.1606.bloodjournal8641606; Reyburn H, 1997, IMMUNOL REV, V155, P119, DOI 10.1111/j.1600-065X.1997.tb00944.x; SANTAMARIA, 1994, BLOOD, V83, P3834; SANTAMARIA P, 1994, BLOOD, V83, P280; Speiser DE, 1996, BLOOD, V87, P4455, DOI 10.1182/blood.V87.10.4455.bloodjournal87104455; SPENCER A, 1995, TRANSPLANTATION, V59, P1302, DOI 10.1097/00007890-199505000-00014; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; THOMAS ED, 1983, J CLIN ONCOL, V1, P517, DOI 10.1200/JCO.1983.1.9.517; Tokunaga K, 1997, IMMUNOGENETICS, V46, P199, DOI 10.1007/s002510050262; WEIDEN PL, 1979, NEW ENGL J MED, V300, P1068, DOI 10.1056/NEJM197905103001902; Yasunaga S, 1996, TISSUE ANTIGENS, V47, P37, DOI 10.1111/j.1399-0039.1996.tb02512.x	45	419	435	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1177	1185		10.1056/NEJM199810223391701	http://dx.doi.org/10.1056/NEJM199810223391701			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780337				2022-12-24	WOS:000076532400001
J	Gurwitz, JH; Gore, JM; Goldberg, RJ; Barron, HV; Breen, T; Rundle, AC; Sloan, MA; French, W; Rogers, WJ				Gurwitz, JH; Gore, JM; Goldberg, RJ; Barron, HV; Breen, T; Rundle, AC; Sloan, MA; French, W; Rogers, WJ		Participants Natl Registry Myocardial Infarc	Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; tissue plasminogen activator; hemorrhage; cerebral; hypertension; angioplasty; transluminal; percutaneous coronary	THROMBOLYTIC THERAPY; STROKE; TRIAL	Background: The efficacy of thrombolytic therapy in reducing mortality from acute myocardial infarction has been unequivocally shown. However, thrombolysis is related to bleeding complications, including intracranial hemorrhage. Objective: To determine the frequency of and risk factors for intracranial hemorrhage after recombinant tissue-type plasminogen activator (tPA) given for acute myocardial infarction in patients receiving usual care. Design: Large national registry of patients who have had acute myocardial infarction. Setting: 1484 U.S. hospitals. Patients: 71 073 patients who had had acute myocardial infarction from 1 June 1994 to 30 September 1996, received tPA as the initial reperfusion strategy, and did not receive a second dose of any thrombolytic agent. Measurement: Intracranial hemorrhage confirmed by computed tomography or magnetic resonance imaging. Results: 673 patients (0.95%) were reported to have had intracranial hemorrhage during hospitalization for acute myocardial infarction; 625 patients (0.88%) had the event confirmed by computed tomography or magnetic resonance imaging. Of the 625 patients with confirmed intracranial hemorrhage, 331 (53%) died during hospitalization. An additional 158 patients (25.3%) who survived to hospital discharge had residual neurologic deficit. In multivariable models for the main effects of candidate risk factors, older age, female sex, black ethnicity, systolic blood pressure of 140 mm Hg or more, diastolic blood pressure of 100 mm Hg or more, history of stroke, tPA dose more than 1.5 mg/kg, and lower body weight were significantly associated with intracranial hemorrhage. Conclusions: Intracranial hemorrhage is a rare but serious complication of tPA in patients with acute myocardial infarction. Appropriate drug dosing may reduce the risk for this complication. Other therapies, such as primary coronary angioplasty, may be preferable in patients with acute myocardial infarction who have a history of stroke.	Univ Massachusetts, Sch Med, Meyers Primary Care Inst, Worcester, MA 01608 USA; Fallon Healthcare Syst, Worcester, MA 01608 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Genentech Inc, Med Affairs, San Francisco, CA 94080 USA; Harbin Clin, Dept Neurosci, Rome, GA 30165 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Univ Alabama Birmingham, Med Ctr, Birmingham, AL 35294 USA	University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; Roche Holding; Genentech; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Alabama System; University of Alabama Birmingham	Gurwitz, JH (corresponding author), Univ Massachusetts, Sch Med, Meyers Primary Care Inst, 100 Cent St, Worcester, MA 01608 USA.							[Anonymous], 1997, PHYS DESK REF, P1723; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Becker, 1995, J Thromb Thrombolysis, V2, P231; Berkowitz SD, 1997, CIRCULATION, V95, P2508, DOI 10.1161/01.CIR.95.11.2508; Betriu A, 1997, NEW ENGL J MED, V336, P1621; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Gurwitz JH, 1997, JAMA-J AM MED ASSOC, V277, P1723, DOI 10.1001/jama.277.21.1723; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; KLEIMAN NS, 1993, CIRCULATION, V88, P17; Krumholz HM, 1997, JAMA-J AM MED ASSOC, V277, P1683, DOI 10.1001/jama.277.21.1683; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	17	162	167	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					597	+		10.7326/0003-4819-129-8-199810150-00002	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786806				2022-12-24	WOS:000076431800001
J	Kato, Y; Tapping, RI; Huang, S; Watson, MH; Ulevitch, RJ; Lee, JD				Kato, Y; Tapping, RI; Huang, S; Watson, MH; Ulevitch, RJ; Lee, JD			Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor	NATURE			English	Article							ACTIVATED PROTEIN-KINASES; SIGNAL-TRANSDUCTION; EXPRESSION; PATHWAY; GENE; TRANSFORMATION; REARRANGEMENT; SYSTEM; ORIGIN; JUN	Epidermal growth factor (EGF) induces cell proliferation in a variety of cell types by binding to a prototype transmembrane tyrosine kinase receptor(1,2). Ligation of this receptor by EGF activates Erk1 and Erk2, members of the mitogen-activated protein (MAP) kinase family, through a Res-dependent signal transduction pathway(3-5). Despite our detailed understanding of these events, the exact mechanism by which EGF causes cells to proliferate is unclear. Big MAP kinase (Bmk1), also known as Erk5, is a member of the MAP kinase family that is activated in cells in response to oxidative stress, hyperosmolarity and treatment with serum(6,7). Here we show that EGF is a potent activator of Bmk1. In contrast to Erk1/2, EGF-mediated activation of Bmk1 occurs independently of Ras and requires the MAP-kinase kinase Mek5. Expression of a dominant-negative form of Bmk1 blocks EGF-induced cell proliferation and prevents cells from entering the S phase of the cell cycle. These results demonstrate that Bmk1 is part of a distinct MAP-kinase signalling pathway that is required for EGF-induced cell proliferation and progression through the cell cycle.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Lee, JD (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jdlee@scripps.edu	Ulevitch, Richard J/Q-3393-2017					Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586; Barr MM, 1996, MOL CELL BIOL, V16, P5597; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HOY CA, 1989, CYTOMETRY, V10, P718, DOI 10.1002/cyto.990100608; Huang S, 1997, IMMUNITY, V6, P739, DOI 10.1016/S1074-7613(00)80449-5; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; JOMARY C, 1994, FEBS LETT, V347, P117, DOI 10.1016/0014-5793(94)00512-5; KASTAN MB, 1991, CANCER RES, V51, P6304; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; MERLINO GT, 1984, SCIENCE, V224, P417, DOI 10.1126/science.6200934; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SOULE HD, 1990, CANCER RES, V50, P6075; STEIN GS, 1994, LAB HDB, P282; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	29	348	364	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					713	716		10.1038/27234	http://dx.doi.org/10.1038/27234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790194				2022-12-24	WOS:000076472600056
J	Bliss, TVP				Bliss, TVP			Neuroscience - The saturation debate	SCIENCE			English	Editorial Material							LONG-TERM POTENTIATION; SYNAPTIC ENHANCEMENT; WATER MAZE; ACQUISITION; TASK		Natl Inst Med Res, Div Neurophysiol, London NW7 1AA, England	MRC National Institute for Medical Research	Bliss, TVP (corresponding author), Natl Inst Med Res, Div Neurophysiol, Mill Hill, London NW7 1AA, England.							BARNES CA, 1994, J NEUROSCI, V14, P5793; BLISS TVP, 1993, HIPPOCAMPUS, V3, P123, DOI 10.1002/hipo.450030203; CAIN DP, 1993, HIPPOCAMPUS, V3, P153, DOI 10.1002/hipo.450030208; CASTRO CA, 1989, NATURE, V342, P545, DOI 10.1038/342545a0; JEFFERY KJ, 1993, HIPPOCAMPUS, V3, P133, DOI 10.1002/hipo.450030205; KOROL DL, 1993, HIPPOCAMPUS, V3, P127, DOI 10.1002/hipo.450030204; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P563; Moser EI, 1998, SCIENCE, V281, P2038, DOI 10.1126/science.281.5385.2038; Petersen CCH, 1998, P NATL ACAD SCI USA, V95, P4732, DOI 10.1073/pnas.95.8.4732; ROBINSON GB, 1992, HIPPOCAMPUS, V2, P389, DOI 10.1002/hipo.450020406; SUTHERLAND RJ, 1993, HIPPOCAMPUS, V3, P141, DOI 10.1002/hipo.450030206	11	9	10	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					1975	1976		10.1126/science.281.5385.1975	http://dx.doi.org/10.1126/science.281.5385.1975			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9767047				2022-12-24	WOS:000076161800039
J	Pestova, TV; Borukhov, SI; Hellen, CUT				Pestova, TV; Borukhov, SI; Hellen, CUT			Eukaryotic ribosomes require initiation factors 1 and 1A to locate initiation codons	NATURE			English	Article							MAMMALIAN PROTEIN-SYNTHESIS; AMINO-ACID-SEQUENCE; RABBIT RETICULOCYTES; BINDING PROTEIN; MESSENGER-RNA; TRANSLATION; MECHANISM; ENTRY; SUI1; PURIFICATION	The scanning model of translation initiation is a coherent description of how eukaryotic ribosomes reach the initiation codon after being recruited to the capped 5' end of messenger RNA. Five eukaryotic initiation factors (eIF 2, 3, 4A, 4B and 4F) with established functions have been assumed to be sufficient to mediate this process. Here we report that eIF1 and eIF1A are also both essential for translation initiation. In their absence, 43S ribosomal preinitiation complexes incubated with ATP, eIF4A, eIF4B and eIF4F bind exclusively to the cap-proximal region but are unable to reach the initiation codon. Individually, eIF1A enhances formation of this cap-proximal complex, and eIF1 weakly promotes formation of a 48S ribosomal compiler at the Initiation codon. These proteins act synergistically to mediate assembly of ribosomal initiation complexes at the Initiation codon and dissociate aberrant complexes from the mRNA.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Brooklyn, NY 11203 USA; Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Moscow 119899, Russia	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Lomonosov Moscow State University	Pestova, TV (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	tpestova@netmail.hscbklyn.edu						ANTHONY DD, 1992, J BIOL CHEM, V267, P1554; BENNE R, 1978, J BIOL CHEM, V253, P3078; Chaudhuri J, 1997, J BIOL CHEM, V272, P7883, DOI 10.1074/jbc.272.12.7883; CHEN CY, 1995, SCIENCE, V268, P415, DOI 10.1126/science.7536344; Cui Y, 1998, MOL CELL BIOL, V18, P1506, DOI 10.1128/MCB.18.3.1506; DEVER TE, 1994, J BIOL CHEM, V269, P3212; EVSTAFIEVA AG, 1991, NUCLEIC ACIDS RES, V19, P665, DOI 10.1093/nar/19.3.665; FIELDS C, 1994, BIOCHEM BIOPH RES CO, V198, P288, DOI 10.1006/bbrc.1994.1040; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; JACKSON RJ, 1996, TRANSLATIONAL CONTRO, P71; KAMINSKI A, 1990, EMBO J, V9, P3753, DOI 10.1002/j.1460-2075.1990.tb07588.x; KASPERAITIS MAM, 1995, FEBS LETT, V365, P47, DOI 10.1016/0014-5793(95)00427-B; KEMPER WM, 1976, J BIOL CHEM, V251, P5551; KOZAK M, 1978, CELL, V15, P1109, DOI 10.1016/0092-8674(78)90039-9; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Merrick WC., 1996, TRANSLATION CONTROL, P31; Pestova TV, 1998, GENE DEV, V12, P67, DOI 10.1101/gad.12.1.67; Pestova TV, 1996, MOL CELL BIOL, V16, P6870; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; SCHREIER MH, 1977, J MOL BIOL, V116, P727, DOI 10.1016/0022-2836(77)90268-6; THOMAS A, 1980, EUR J BIOCHEM, V107, P39, DOI 10.1111/j.1432-1033.1980.tb04621.x; THOMAS A, 1980, FEBS LETT, V116, P67, DOI 10.1016/0014-5793(80)80530-8; TRACHSEL H, 1977, J MOL BIOL, V116, P755, DOI 10.1016/0022-2836(77)90269-8; WEI CL, 1995, J BIOL CHEM, V270, P5764, DOI 10.1074/jbc.270.11.5764; WEI CL, 1995, J BIOL CHEM, V270, P22788, DOI 10.1074/jbc.270.39.22788; YOON HJ, 1992, MOL CELL BIOL, V12, P248, DOI 10.1128/MCB.12.1.248	26	315	319	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					854	859		10.1038/29703	http://dx.doi.org/10.1038/29703			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732867				2022-12-24	WOS:000075611800037
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			A Frankenstein experiment	SCIENCE			English	Article									Medsite Commun, Boston, MA 01945 USA		Sikorski, R (corresponding author), Medsite Commun, Boston, MA 01945 USA.							Wakayama T, 1998, NAT BIOTECHNOL, V16, P639, DOI 10.1038/nbt0798-639	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1163	1164						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735033				2022-12-24	WOS:000075531200041
J	Bado, A; Levasseur, S; Attoub, S; Kermorgant, S; Laigneau, JP; Bortoluzzi, MN; Moizo, L; Lehy, T; Guerre-Millo, M; Le Marchand-Brustel, Y; Lewin, MJM				Bado, A; Levasseur, S; Attoub, S; Kermorgant, S; Laigneau, JP; Bortoluzzi, MN; Moizo, L; Lehy, T; Guerre-Millo, M; Le Marchand-Brustel, Y; Lewin, MJM			The stomach is a source of leptin	NATURE			English	Article							OBESE GENE-PRODUCT; ADIPOSE-TISSUE; FOOD-INTAKE; CHOLECYSTOKININ; EXPRESSION; RATS; MICE; INHIBITION; INCREASE; ADIPOCYTES	The circulating peptide leptin, which is the product of the ob gene(1), provides feedback information on the size of fat stores to central Ob receptors(2,3) that control food intake and body-weight homeostasis(4-6). Leptin has so far been reported to be secreted only by adipocytes(1) and the placenta(7). Here we show that leptin messenger RNA and leptin protein are present in rat gastric epithelium, and that cells in the glands of the gastric fundic mucosa are immunoreactive for leptin, The physiological function of this previously unsuspected source of leptin is unknown. However, both feeding and administration of CCK-8 (the biologically active carboxy-terminal end of cholecystokinin) result in a rapid and large decrease in both leptin cell immunoreactivity and the leptin content of the fundic epithelium, with a concomitant increase in the concentration of leptin in the plasma. These results indicate that gastric leptin may be involved in early CCK-mediated effects activated by food intake, possibly including satiety.	Univ Paris 07, INSERM, U10, IFR2 Cellules Epitheliales,Hop Bichat, F-75018 Paris, France; Fac Med Nice, INSERM, U145, F-06107 Nice, France; Inst Biomed Cordeliers, INSERM, U465, F-75006 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Lewin, MJM (corresponding author), Univ Paris 07, INSERM, U10, IFR2 Cellules Epitheliales,Hop Bichat, 170 Blvd Ney, F-75018 Paris, France.	mjmlewin@bichat.inserm.fr	Guerre-Millo, Michele/G-7253-2017; Attoub, Samir/N-6852-2018; BADO, Andre/G-3408-2013; Kermorgant, Stephanie/AAB-4931-2020	Kermorgant, Stephanie/0000-0001-5921-479X; BADO, Andre/0000-0002-8007-1460				Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; BADO A, 1994, YALE J BIOL MED, V67, P113; Barrachina MD, 1997, P NATL ACAD SCI USA, V94, P10455, DOI 10.1073/pnas.94.19.10455; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; BUFFA R, 1976, GASTROENTEROLOGY, V70, P528; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; DUGAIL I, 1988, BIOCHEM J, V254, P483, DOI 10.1042/bj2540483; GIBBS J, 1973, NATURE, V245, P323, DOI 10.1038/245323a0; HAINAULT I, 1991, J CLIN INVEST, V87, P1127, DOI 10.1172/JCI115077; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hardie LJ, 1996, BIOCHEM BIOPH RES CO, V223, P660, DOI 10.1006/bbrc.1996.0951; KOULISCHER D, 1982, REGUL PEPTIDES, V4, P127, DOI 10.1016/0167-0115(82)90080-5; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levy R, 1997, BIOCHEM BIOPH RES CO, V237, P98, DOI 10.1006/bbrc.1997.7086; LIDDLE RA, 1984, GASTROENTEROLOGY, V87, P542; MACDOUGALD OA, 1995, P NATL ACAD SCI USA, V92, P9034, DOI 10.1073/pnas.92.20.9034; Mantzoros CS, 1996, DIABETES, V45, P909, DOI 10.2337/diabetes.45.7.909; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Matson CA, 1997, PEPTIDES, V18, P1275, DOI 10.1016/S0196-9781(97)00138-1; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Rose C, 1996, NATURE, V380, P403, DOI 10.1038/380403a0; SALADIN R, 1995, NATURE, V377, P527, DOI 10.1038/377527a0; SMITH GP, 1981, SCIENCE, V213, P1036, DOI 10.1126/science.7268408; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Trayhurn P, 1996, BIOCHEM BIOPH RES CO, V228, P605, DOI 10.1006/bbrc.1996.1704; Wang YH, 1997, AM J PHYSIOL-REG I, V273, pR833, DOI 10.1152/ajpregu.1997.273.2.R833; Weigle DS, 1997, J CLIN ENDOCR METAB, V82, P561, DOI 10.1210/jc.82.2.561; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	29	940	983	0	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1998	394	6695					790	793		10.1038/29547	http://dx.doi.org/10.1038/29547			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723619				2022-12-24	WOS:000075503600048
J	Gonzalez-Ruiz, A; Wright, SG				Gonzalez-Ruiz, A; Wright, SG			Disparate amoebae	LANCET			English	Editorial Material							NONPATHOGENIC ENTAMOEBA-HISTOLYTICA; DIAGNOSIS; ZYMODEMES; DYSENTERY		Whittington Hosp, Dept Microbiol, London N19 5NF, England; Hosp Trop Dis, London, England	University of London; University College London; University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Gonzalez-Ruiz, A (corresponding author), Whittington Hosp, Dept Microbiol, London N19 5NF, England.							AGUIRRE A, 1995, T ROY SOC TROP MED H, V89, P187, DOI 10.1016/0035-9203(95)90488-3; BLANC DS, 1992, J PROTOZOOL, V39, P471, DOI 10.1111/j.1550-7408.1992.tb04834.x; BRUMPT E, 1925, B ACAD MED PARIS, V94, P942; CLARK CG, 1991, MOL BIOCHEM PARASIT, V49, P297, DOI 10.1016/0166-6851(91)90073-F; DIAMOND LS, 1993, J EUKARYOT MICROBIOL, V40, P340, DOI 10.1111/j.1550-7408.1993.tb04926.x; GATHIRAM V, 1987, S AFR MED J, V72, P669; GONZALEZRUIZ A, 1994, J CLIN MICROBIOL, V32, P964, DOI 10.1128/JCM.32.4.964-970.1994; GONZALEZRUIZ A, 1994, J CLIN PATHOL, V47, P236, DOI 10.1136/jcp.47.3.236; HAQUE R, 1993, J INFECT DIS, V167, P247, DOI 10.1093/infdis/167.1.247; MARTINEZ.A, 1973, NATURE-NEW BIOL, V245, P186, DOI 10.1038/newbio245186a0; RUIZPALACIOS GM, 1992, ARCHIVES OF MEDICAL RESEARCH, VOL 23, NO 2, P289; SARGEAUNT PG, 1978, T ROY SOC TROP MED H, V72, P519, DOI 10.1016/0035-9203(78)90174-8; TEIG MK, 1997, T ROY SOC TROP MED H, V91, P506; WHO, 1997, WKLY EPIDEMIOL REC R, V72, P97	14	19	19	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1998	351	9117					1672	1673		10.1016/S0140-6736(05)77735-7	http://dx.doi.org/10.1016/S0140-6736(05)77735-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734879				2022-12-24	WOS:000074088900003
J	Khurana, KK; Kivelson, MG; Stevenson, DJ; Schubert, G; Russell, CT; Walker, RJ; Polanskey, C				Khurana, KK; Kivelson, MG; Stevenson, DJ; Schubert, G; Russell, CT; Walker, RJ; Polanskey, C			Induced magnetic fields as evidence for subsurface oceans in Europa and Callisto	NATURE			English	Article							INTERNAL STRUCTURE; OUTER PLANETS; GANYMEDE; SIGNATURE; WATER; IO	The Galileo spacecraft has been orbiting Jupiter since 7 December 1995, and encounters one of the four galilean satellites-Io, Europa, Ganymede and Callisto-on each orbit. Initial results from the spacecraft's magnetometer(1,2) have indicated that neither Europe nor Callisto have an appreciable internal magnetic field, in contrast to Ganymede(3) and possibly Io(4). Here we report perturbations of the external magnetic fields (associated with Jupiter's inner magnetosphere) in the vicinity of both Europe and Callisto. We interpret these perturbations as arising from induced magnetic fields, generated by the moons in response to the periodically varying plasma environment. Electromagnetic induction requires eddy currents to now within the moons, and our calculations show that the most probable explanation is that there are layers of significant electrical conductivity just beneath the surfaces of both moons. We argue that these conducting layers may best be explained by the presence of salty liquid-water oceans, for which there is already indirect geological evidence(5,6) in the case of Europa.	Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Khurana, KK (corresponding author), Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA.		Kivelson, Margaret G/I-9019-2012; Russell, Christopher T/E-7745-2012	Kivelson, Margaret G/0000-0003-3859-8581; Russell, Christopher T/0000-0003-1639-8298; Khurana, Krishan/0000-0002-2856-1171				Anderson JD, 1996, NATURE, V384, P541, DOI 10.1038/384541a0; Anderson JD, 1998, SCIENCE, V280, P1573, DOI 10.1126/science.280.5369.1573; ANDERSON JG, IN PRESS SCIENCE; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; COLBURN DS, 1985, ICARUS, V63, P39, DOI 10.1016/0019-1035(85)90019-3; CONNERNEY JEP, 1993, J GEOPHYS RES-PLANET, V98, P18659, DOI 10.1029/93JE00980; Durham WB, 1997, J GEOPHYS RES-PLANET, V102, P16293, DOI 10.1029/97JE00916; Ip WH, 1996, ICARUS, V120, P317, DOI 10.1006/icar.1996.0052; JACKSON JD, 1975, CLASSICAL ELECTRODYN, P338; KARGEL JS, 1996, LUNAR PLANET SCI C, V27, P643; KHURANA KK, 1989, J GEOPHYS RES, V94, P5241, DOI 10.1029/JA094iA05p05241; Khurana KK, 1997, NATURE, V387, P262, DOI 10.1038/387262a0; Khurana KK, 1997, J GEOPHYS RES-SPACE, V102, P11295, DOI 10.1029/97JA00563; KIRK RL, 1987, ICARUS, V69, P91, DOI 10.1016/0019-1035(87)90009-1; Kivelson MG, 1996, SCIENCE, V273, P337, DOI 10.1126/science.273.5273.337; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; Kivelson MG, 1996, NATURE, V384, P537, DOI 10.1038/384537a0; KIVELSON MG, UNPUB J GEOPHYS RES; Kliore AJ, 1997, SCIENCE, V277, P355, DOI 10.1126/science.277.5324.355; McCord TB, 1998, SCIENCE, V280, P1242, DOI 10.1126/science.280.5367.1242; MONTGOMERY RB, 1963, AM I PHYSICS HDB, P125; NEUBAUER FM, 1980, J GEOPHYS RES-SPACE, V85, P1171, DOI 10.1029/JA085iA03p01171; Neubauer FM, 1998, J GEOPHYS RES-PLANET, V103, P19843, DOI 10.1029/97JE03370; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Owen CJ, 1996, GEOPHYS RES LETT, V23, P1263, DOI 10.1029/96GL01354; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PARKINSON WD, 1993, INTRO GEOMAGNETISM, P308; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; Schubert G, 1996, NATURE, V384, P544, DOI 10.1038/384544a0; Schubert G., 1986, SATELLITES, P224; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STEVENSON DJ, 1996, P EUR C SAN JUAN CAP, P69	34	392	402	2	105	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					777	780		10.1038/27394	http://dx.doi.org/10.1038/27394			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796812				2022-12-24	WOS:000076607400049
J	Secor, SM; Diamond, J				Secor, SM; Diamond, J			A vertebrate model of extreme physiological regulation	NATURE			English	Article							BURMESE PYTHONS; MOLURUS	Investigation of vertebrate regulatory biology is restricted by the modest response amplitudes In mammalian model species that derive from a lifestyle of frequent small meals. By contrast, ambush-hunting snakes eat huge meals after long intervals. In juvenile pythons during feeding, there are large and rapid increases In metabolism and secretion, In the activation of enzymes and transporter proteins, and in tissue growth. These responses enable an economic hypothesis concerning the evolution of regulation to be tested. Combined with other experimental advantages, these features recommend juvenile pythons as the equivalent of a squid axon in vertebrate regulatory biology.	Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Secor, SM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA.	python@ucla.edu						Conlon JM, 1997, PEPTIDES, V18, P1505, DOI 10.1016/S0196-9781(97)00232-5; Conlon JM, 1997, REGUL PEPTIDES, V71, P191; DIAMOND P, 1985, AM J PHYSIOL, V248, pE75, DOI 10.1152/ajpendo.1985.248.1.E75; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Field J, 1939, J CELL COMPAR PHYSL, V14, P143, DOI 10.1002/jcp.1030140202; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Greene H, 1997, SNAKES EVOLUTION MYS; JANES DN, 1995, PHYSIOL ZOOL, V68, P1029, DOI 10.1086/physzool.68.6.30163792; Kleiber M., 1961, FIRE LIFE INTRO ANIM; POPE CH, 1961, GIANT SNAKES; Secor SM, 1997, AM J PHYSIOL-REG I, V272, pR902, DOI 10.1152/ajpregu.1997.272.3.R902; Secor SM, 1997, PHYSIOL ZOOL, V70, P202, DOI 10.1086/639578; SECOR SM, 1994, ECOLOGY, V75, P1600, DOI 10.2307/1939621; SECOR SM, 1994, AM J PHYSIOL, V266, pG695, DOI 10.1152/ajpgi.1994.266.4.G695; SECOR SM, 1995, HERPETOLOGICAL MONOGRAPHS, NO 9, 1995, P169, DOI 10.2307/1467004; SECOR SM, 1995, J EXP BIOL, V198, P1313	16	208	216	2	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 15	1998	395	6703					659	662		10.1038/27131	http://dx.doi.org/10.1038/27131			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790187				2022-12-24	WOS:000076472600041
J	Monane, M; Matthias, DM; Nagle, BA; Kelly, MA				Monane, M; Matthias, DM; Nagle, BA; Kelly, MA			Improving prescribing patterns for the elderly through an online drug utilization review intervention - A system linking the physician, pharmacist, and computer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INAPPROPRIATE MEDICATION USE; EXPLICIT CRITERIA	Context.- Pharmacotherapy is among the most powerful interventions to improve health outcomes in the elderly. However, since some medications are less appropriate for older patients, systems approaches to improving pharmacy care may be an effective way to reduce inappropriate medication use. Objective.-To determine whether a computerized drug utilization review (DUR) database linked to a telepharmacy intervention can improve suboptimal medication use in the elderly. Design.-Population-based cohort design, April 1, 1996, through March 31, 1997, Setting.-Ambulatory care. Patients.-A total of 23 269 patients aged 65 years acid older throughout the United States receiving prescription drug benefits from a large pharmaceutical benefits manager during a 12-month period. Intervention.- Evaluation of provider prescribing through a computerized online DUR database using explicit criteria to identify potentially inappropriate drug use in the elderly. Computer alerts triggered telephone calls to physicians by pharmacists with training in geriatrics, whereby principles of geriatric pharmacology were discussed along with therapeutic substitution options. Main Outcome Measures.-Contact rate with physicians and change rate to suggested drug regimen. Results.-A total of 43 007 alerts were triggered. From a total of 43 007 telepharmacy calls generated by the alerts, we were able to reach 19 368 physicians regarding 24 266 alerts (56%). Rate of change to a more appropriate therapeutic agent was 24% (5860), but ranged from 40% for long half-life benzodiazepines to 2% to 7% for drugs that theoretically were contraindicated by patients' self-reported history. Except for rate of change of beta-blockers in patients with chronic obstructive pulmonary disease, all rates of change were significantly greater than the expected baseline 2% rate of change. Conclusions.-Using a system integrating computers, pharmacists, and physicians, our large-scale intervention improved prescribing patterns and quality of care and thus provides a population-based approach to advance geriatric clinical pharmacology. Future research should focus on the demonstration of improved health outcomes resulting from improved prescribing choices for the elderly.	Merck Medco Managed Care LLC, Dept Med Affairs, Montvale, NJ 07645 USA; Merck Medco Managed Care LLC, Dept Hlth & Utilizat Management, Montvale, NJ 07645 USA		Monane, M (corresponding author), Merck Medco Managed Care LLC, Dept Med Affairs, 100 Summit Ave, Montvale, NJ 07645 USA.	mark_monane@merck.com						BAUM C, 1984, JAMA-J AM MED ASSOC, V251, P1293, DOI 10.1001/jama.251.10.1293; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; BEERS MH, 1992, ANN INTERN MED, V117, P684, DOI 10.7326/0003-4819-117-8-684; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; *GEN ACC OFF, 1995, GAOHEHS95152; GROVES RE, 1985, AM J HOSP PHARM, V42, P316, DOI 10.1093/ajhp/42.2.316; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; Hanlon JT, 1995, THERAPEUTICS ELDERLY, P212; LINDLEY CM, 1992, AGE AGEING, V21, P294, DOI 10.1093/ageing/21.4.294; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; Monane M, 1996, AM J PUBLIC HEALTH, V86, P1805, DOI 10.2105/AJPH.86.12.1805; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P302; SARTOR F, 1995, AM J EPIDEMIOL, V141, P782, DOI 10.1093/oxfordjournals.aje.a117502; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; STEWART RB, 1994, DRUG AGING, V4, P449, DOI 10.2165/00002512-199404060-00002; STEWART RB, 1989, MED CLIN N AM, V73, P1551, DOI 10.1016/S0025-7125(16)30616-2; STUCK AE, 1994, ARCH INTERN MED, V154, P2195; WILCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292	22	154	164	1	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1249	1252		10.1001/jama.280.14.1249	http://dx.doi.org/10.1001/jama.280.14.1249			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	127NR	9786375	Bronze			2022-12-24	WOS:000076357900031
J	Blaas, HG; Eik-Nes, SH; Berg, S; Torp, H				Blaas, HG; Eik-Nes, SH; Berg, S; Torp, H			In-vivo three-dimensional ultrasound reconstructions of embryos and early fetuses	LANCET			English	Article							LONGITUDINAL ULTRASOUND; VOLUME ESTIMATION; HUMAN BRAIN; GESTATION; ULTRASONOGRAPHY	Background Three-dimensional (3D) imaging of the living human embryo has become possible in the monitoring of embryological development, as described by classic human embryology. We aimed to create 3D images of organs in embryos on early pregnancy. Methods We used a specially developed 7.5 MHz annular array 3D transvaginal probe to examine embryos. We included 34 women at 7-10 weeks' gestation. We measured the crown-rump length (CRL) of the embryos and fetuses and transferred the 3D ultrasound data to an external computer for further processing to calculate volume. Findings The CRLs ranged from 9.3 mm to 39.0 mm. The quality of the images of the embryos and fetuses made it possible to outline in detail the outer contours and the contours of the brain cavities, and the calculated volumes corresponded well to the descriptions from classic human embryology. Interpretation Our 3D imaging system allowed visualisation of structures of less than 10 mm. Therefore, development and abnormal development of fetuses can be monitored.	Univ Trondheim Hosp, Dept Obstet & Gynaecol, Natl Ctr Fetal Med, N-7006 Trondheim, Norway; Univ Trondheim, Dept Physiol & Biomed Engn, N-7034 Trondheim, Norway	Norwegian University of Science & Technology (NTNU)	Blaas, HG (corresponding author), Univ Trondheim Hosp, Dept Obstet & Gynaecol, Natl Ctr Fetal Med, N-7006 Trondheim, Norway.							[Anonymous], 1920, CONTRIBUTIONS EMBRYO; BLAAS HG, 1995, ULTRASOUND OBST GYN, V5, P151, DOI 10.1046/j.1469-0705.1995.05030151.x; BLAAS HG, 1995, ULTRASOUND OBST GYN, V5, P228, DOI 10.1046/j.1469-0705.1995.05040228.x; BLAAS HG, 1994, ULTRASOUND OBST GYN, V4, P183, DOI 10.1046/j.1469-0705.1994.04030183.x; BLAAS HG, 1995, ULTRASOUND OBST GYN, V6, P240, DOI 10.1046/j.1469-0705.1995.06040240.x; Born G, 1883, ARCH MIKROSK ANAT, V22, P584, DOI 10.1007/bf02952679; BRINKLEY JF, 1982, AM J OBSTET GYNECOL, V144, P715, DOI 10.1016/0002-9378(82)90443-4; DRUMM JE, 1977, AM J ANAT, V148, P555, DOI 10.1002/aja.1001480410; ELGAMMAL S, 1987, NEW FRONTIERS BRAIN, P46; GAUNT PN, 1978, 3 DIMENSIONAL RECONS, P63; GILJA OH, 1994, ULTRASOUND MED BIOL, V20, P157, DOI 10.1016/0301-5629(94)90080-9; GILJA OH, 1995, ULTRASOUND MED BIOL, V21, P25, DOI 10.1016/0301-5629(94)00082-4; His W., 1880, ANATOMIE MENSCHLICHE; HIS W, 1890, ABHANDL KS GESELLSCH, V29, P3; His W., 1887, ANAT ANZEIGER, V2, P382; JENKINS GB, 1921, CONTRIB EMBRYOL CARN, V13, P41; JIRASEK JE, 1966, AM J OBSTET GYNECOL, V96, P868, DOI 10.1016/0002-9378(66)90684-3; Kostovic I., 1990, HUMANEMBRYOLOGIE, P381; MEBAN C, 1983, J ANAT, V137, P217; MULLER F, 1990, ANAT EMBRYOL, V182, P375, DOI 10.1007/BF02433497; O'Rahilly R., 1994, EMBRYONIC HUMAN BRAI; O'Rahilly R., 1987, DEV STAGES HUMAN EMB; ORAHILLY R, 1990, AM J ANAT, V189, P285, DOI 10.1002/aja.1001890402; ORAHILLY R, 1992, HUMAN EMBRYOLOGY TER; RICCABONA M, 1995, ULTRASCHALL KLIN PRA, V10, P35; THUNE N, 1996, EUR J ULTRASOUND, V3, P83; TIMORTRITSCH IE, 1990, J CLIN ULTRASOUND, V18, P286, DOI 10.1002/jcu.1870180412; TIMORTRITSCH IE, 1988, AM J OBSTET GYNECOL, V159, P678	28	106	107	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1182	1186		10.1016/S0140-6736(98)03227-9	http://dx.doi.org/10.1016/S0140-6736(98)03227-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777835				2022-12-24	WOS:000076415400010
J	Parcy, F; Nilsson, O; Busch, MA; Lee, I; Weigel, D				Parcy, F; Nilsson, O; Busch, MA; Lee, I; Weigel, D			A genetic framework for floral patterning	NATURE			English	Article							POLYCOMB-GROUP GENE; HOMEOTIC GENE; ARABIDOPSIS-THALIANA; ORGAN IDENTITY; INFLORESCENCE DEVELOPMENT; ECTOPIC EXPRESSION; FLOWER DEVELOPMENT; MERISTEM IDENTITY; LEAFY; TRANSCRIPTION	The initial steps of newer development involve two classes of consecutively acting regulatory genes. Meristem-identity genes, which act early to control the initiation of flowers, are expressed throughout the incipient floral primordium. Homeotic genes, which act later to specify the identify of individual floral organs, are expressed in distinct domains within the flower. The link between the two classes of genes has remained unknown so far. Here we show that the meristem-identity gene LEAN has a role in controlling homeotic genes that is separable from its role in specifying floral fate. On the basis of our observation that LEAFY activates different homeotic genes through distinct mechanisms, we propose a genetic framework for the control of floral patterning.	Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	weigel@salk.edu	Parcy, François/G-9177-2011; parcy, francois/A-6031-2009; Weigel, Detlef/AAR-3312-2021; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022	Parcy, François/0000-0003-2191-500X; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Nilsson, Ove/0000-0002-1033-1909				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; COUSENS DJ, 1989, EMBO J, V8, P2337, DOI 10.1002/j.1460-2075.1989.tb08361.x; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; GUSTAFSOBROWN C, 1996, THESIS U CALIFORNIA; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; HANTKE SS, 1995, DEVELOPMENT, V121, P27; HEMPEL FD, 1994, PLANTA, V192, P276, DOI 10.1007/BF01089045; Hempel FD, 1997, DEVELOPMENT, V124, P3845; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JACKSON D, 1994, DEVELOPMENT, V120, P405; Jimenez G, 1996, EMBO J, V15, P7088, DOI 10.1002/j.1460-2075.1996.tb01100.x; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; Krizek BA, 1996, DEVELOPMENT, V122, P11; Kumar A, 1998, P NATL ACAD SCI USA, V95, P2417, DOI 10.1073/pnas.95.5.2417; Lee EA, 1997, KOREAN J GENETIC, V19, P95; LEVIN JZ, 1995, PLANT CELL, V7, P529, DOI 10.1105/tpc.7.5.529; LIU ZC, 1995, DEVELOPMENT, V121, P975; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; MCBRIDE KE, 1990, PLANT MOL BIOL, V14, P269, DOI 10.1007/BF00018567; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NILSSON O, IN PRESS GENETICS; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; Sze JY, 1997, DEVELOPMENT, V124, P1159; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; WILKINSON MD, 1995, PLANT CELL, V7, P1485, DOI 10.1105/tpc.7.9.1485; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123	49	388	430	2	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1998	395	6702					561	566		10.1038/26903	http://dx.doi.org/10.1038/26903			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783581				2022-12-24	WOS:000076362900037
J	Nightingale, SL				Nightingale, SL			Off-label use of Haemophilus vaccine in combination with DTaP vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-24	WOS:000076210800007
J	Stambolic, V; Suzuki, A; de la Pompa, JL; Brothers, GM; Mirtsos, C; Sasaki, T; Ruland, J; Penninger, JM; Siderovski, DP; Mak, TW				Stambolic, V; Suzuki, A; de la Pompa, JL; Brothers, GM; Mirtsos, C; Sasaki, T; Ruland, J; Penninger, JM; Siderovski, DP; Mak, TW			Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN	CELL			English	Article							PROTEIN-KINASE-B; BREAST CARCINOMAS; PROSTATE-CANCER; GROWTH; GENE; PHOSPHATASE; MUTATIONS; AKT; IDENTIFICATION; ACTIVATION	PTEN is a tumor suppressor with sequence homology to protein tyrosine phosphatases and the cytoskeletal protein tensin. mPTEN-mutant mouse embryos display regions of increased proliferation. In contrast, mPTEN-deficient immortalized mouse embryonic fibroblasts exhibit decreased sensitivity to cell death in response to a number of apoptotic stimuli, accompanied by constitutively elevated activity and phosphorylation of protein kinase B/Akt, a crucial regulator of cell survival. Expression of exogenous PTEN in mutant cells restores both their sensitivity to agonist-induced apoptosis and normal pattern of PKB/Akt phosphorylation. Furthermore, PTEN negatively regulates intracellular levels of phosphatidylinositol (3,4,5) trisphosphate in cells and dephosphorylates it in vitro. Our results show that PTEN may exert its role as a tumor suppressor by negatively regulating the PI3'K/PKB/Akt signaling pathway.	Amgen Inst, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Mak, TW (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON, Canada.	tmak@oci.utoronto.ca	De La Pompa, José Luis/F-9719-2014; Siderovski, David Peter/AAA-9603-2019; Suzuki, Akira/GYD-6697-2022; Ruland, Jürgen/Q-6680-2018; Penninger, Josef M/I-6860-2013	De La Pompa, José Luis/0000-0001-6761-7265; Siderovski, David Peter/0000-0002-0688-8210; Suzuki, Akira/0000-0002-5950-8808; Ruland, Jürgen/0000-0002-8381-3597; Penninger, Josef M/0000-0002-8194-3777; Stambolic, Vuk/0000-0001-8853-3239; Sasaki, Takehiko/0000-0003-1837-3748				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; AHMED NN, 1993, ONCOGENE, V8, P1957; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BELLACOSA A, 1995, INT J CANCER, V64, P280, DOI 10.1002/ijc.2910640412; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BIGNER SH, 1988, CANCER RES, V48, P405; Cairns P, 1997, CANCER RES, V57, P4997; CHAFFANET M, 1992, EUR J CANCER, V28A, P11, DOI 10.1016/0959-8049(92)90374-B; Cheney IW, 1998, CANCER RES, V58, P2331; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; DUKEK H, 1997, SCIENCE, V275, P661; Eng C, 1998, INT J ONCOL, V12, P701; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDMAN A, 1998, CELLS LAB MANUAL; Hausler P, 1998, EUR J IMMUNOL, V28, P57, DOI 10.1002/(SICI)1521-4141(199801)28:01<57::AID-IMMU57>3.0.CO;2-8; HAYASHI Y, 1988, J HISTOCHEM CYTOCHEM, V36, P511, DOI 10.1177/36.5.3282006; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Mishina Y, 1995, GENE DEV, V9, P3027, DOI 10.1101/gad.9.24.3027; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rhei E, 1997, CANCER RES, V57, P3657; Sasaki T, 1996, BIOCHEM J, V315, P1035, DOI 10.1042/bj3151035; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; Smits A, 1998, HISTOL HISTOPATHOL, V13, P511, DOI 10.14670/HH-13.511; SNOW MHL, 1977, J EMBRYOL EXP MORPH, V42, P293; STAAL SP, 1988, J EXP MED, V167, P1259, DOI 10.1084/jem.167.3.1259; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; TAKAHASHI JA, 1992, J NEUROSURG, V76, P792, DOI 10.3171/jns.1992.76.5.0792; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Ulrich E, 1998, ONCOGENE, V16, P825, DOI 10.1038/sj.onc.1201842; Welch H, 1998, J BIOL CHEM, V273, P11248, DOI 10.1074/jbc.273.18.11248	58	2007	2117	3	138	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					29	39		10.1016/S0092-8674(00)81780-8	http://dx.doi.org/10.1016/S0092-8674(00)81780-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778245	Bronze			2022-12-24	WOS:000076242300008
J	Bruchez, M; Moronne, M; Gin, P; Weiss, S; Alivisatos, AP				Bruchez, M; Moronne, M; Gin, P; Weiss, S; Alivisatos, AP			Semiconductor nanocrystals as fluorescent biological labels	SCIENCE			English	Article							QUANTUM DOTS; MICROSCOPY; DNA; NANOPARTICLES	Semiconductor nanocrystals were prepared for use as fluorescent probes in biological staining and diagnostics. Compared with conventional fluorophores, the nanocrystals have a narrow, tunable. symmetric emission spectrum and are photochemically stable. The advantages of the broad, continuous excitation spectrum were demonstrated in a dual-emission, single-excitation labeling experiment on mouse fibroblasts. These nanocrystal probes are thus complementary and in some cases may be superior to existing fluorophores.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Phys Biosci Div, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Weiss, S (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, 1 Cyclotron Rd, Berkeley, CA 94720 USA.		weiss, shimon/B-4164-2009; Alivisatos, Paul/N-8863-2015; 周, 伊静/I-4058-2018; Bruchez, Marcel P/C-2271-2009	weiss, shimon/0000-0002-0720-5426; Alivisatos, Paul/0000-0001-6895-9048; Bruchez, Marcel P/0000-0002-7370-4848				Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; BEVERLOO HB, 1990, CYTOMETRY, V11, P784, DOI 10.1002/cyto.990110704; Correa-Duarte MA, 1998, CHEM PHYS LETT, V286, P497, DOI 10.1016/S0009-2614(98)00012-8; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; Elghanian R, 1997, SCIENCE, V277, P1078, DOI 10.1126/science.277.5329.1078; EYCHMULLER A, 1993, CHEM PHYS LETT, V208, P59, DOI 10.1016/0009-2614(93)80076-2; Guzelian AA, 1996, J PHYS CHEM-US, V100, P7212, DOI 10.1021/jp953719f; Hermann R, 1996, HISTOCHEM CELL BIOL, V106, P31; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; JU JY, 1995, P NATL ACAD SCI USA, V92, P4347, DOI 10.1073/pnas.92.10.4347; Lackie PM, 1996, HISTOCHEM CELL BIOL, V106, P9; Liz-Marzan LM, 1996, LANGMUIR, V12, P4329, DOI 10.1021/la9601871; MILTENYI S, 1990, CYTOMETRY, V11, P231, DOI 10.1002/cyto.990110203; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; NIRMAL M, 1995, PHYS REV LETT, V75, P3728, DOI 10.1103/PhysRevLett.75.3728; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; Peng XG, 1997, J AM CHEM SOC, V119, P7019, DOI 10.1021/ja970754m; Roederer M, 1996, CYTOMETRY, V24, P191, DOI 10.1002/(SICI)1097-0320(19960701)24:3<191::AID-CYTO1>3.0.CO;2-L; Roederer M, 1997, CYTOMETRY, V29, P328, DOI 10.1002/(SICI)1097-0320(19971201)29:4<328::AID-CYTO10>3.0.CO;2-W; SEVEUS L, 1992, CYTOMETRY, V13, P329, DOI 10.1002/cyto.990130402; WAGGONER A, 1995, METHOD ENZYMOL, V246, P362; WILCHEK M, 1989, TRENDS BIOCHEM SCI, V14, P408, DOI 10.1016/0968-0004(89)90289-2	25	7806	8395	58	2699	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2013	2016		10.1126/science.281.5385.2013	http://dx.doi.org/10.1126/science.281.5385.2013			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748157				2022-12-24	WOS:000076161800051
J	Mizushima, N; Noda, T; Yoshimori, T; Tanaka, Y; Ishii, T; George, MD; Klionsky, DJ; Ohsumi, M; Ohsumi, Y				Mizushima, N; Noda, T; Yoshimori, T; Tanaka, Y; Ishii, T; George, MD; Klionsky, DJ; Ohsumi, M; Ohsumi, Y			A protein conjugation system essential for autophagy	NATURE			English	Article							NUCLEAR-PORE COMPLEX; SACCHAROMYCES-CEREVISIAE; YEAST; DEGRADATION; MECHANISMS; VACUOLE; RANGAP1; MUTANTS; GTPASE	Autophagy is a process for the bulk degradation of proteins, in which cytoplasmic components of the cell are enclosed by double-membrane structures known as autophagosomes for delivery to lysosomes or vacuoles for degradation(1-4). This process is crucial for survival during starvation and cell differentiation. No molecules have been identified that are involved in autophagy in higher eukaryotes. We have isolated 14 autophagy-defective (apg) mutants of the yeast Saccharomyces cerevisiae(5) and examined the autophagic process at the molecular level(6-9). We show here that a unique covalent-modification system is essential for autophagy to occur. The carboxy-terminal glycine residue of Apg12, a 186-amino-acid protein, is conjugated to a lysine at residue 149 of Apg5, a 294-amino-acid protein. Of the apg mutants, we found that apg7 and apg10 were unable to form an Apg5/Apg12 conjugate. By cloning APG7, we discovered that Apg7 is a ubiquitin-E1-like enzyme. This conjugation can be reconstituted in vitro and depends on ATP. To our knowledge, this is the first report of a protein unrelated to ubiquitin that uses a ubiquitination-like conjugation system. Furthermore, Apg5 and Apg12, have mammalian homologues, suggesting that this new modification system is conserved from yeast to mammalian cells.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Teikyo Univ Sci & Technol, Dept Biosci, Yamanashi 4090193, Japan; Univ Calif Davis, Microbiol Sect, Livermore, CA 95616 USA	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); University of California System; University of California Davis	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan.		Ohsumi, Yoshinori/C-6449-2009; Mizushima, Noboru/C-3635-2009; Noda, Takeshi/B-7240-2008	Ohsumi, Yoshinori/0000-0003-2384-2166; Mizushima, Noboru/0000-0002-6258-6444; Noda, Takeshi/0000-0003-3581-7961				Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Finkbeiner WE, 1992, TREATISE PULMONARY T, V1, P633; Funakoshi T, 1997, GENE, V192, P207, DOI 10.1016/S0378-1119(97)00031-0; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; Kametaka S, 1996, GENE, V178, P139, DOI 10.1016/0378-1119(96)00354-X; KAMETAKA S, IN PRESS J BIOL CHEM; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; OSAKA E, IN PRESS GENES DEV; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Weissman AM, 1997, IMMUNOL TODAY, V18, P189, DOI 10.1016/S0167-5699(97)84666-X	29	1220	1271	5	298	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					395	398		10.1038/26506	http://dx.doi.org/10.1038/26506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759731				2022-12-24	WOS:000076083800057
J	Bertka, CM; Fei, YW				Bertka, CM; Fei, YW			Implications of Mars Pathfinder data for the accretion history of the terrestrial planets	SCIENCE			English	Article							HIGH-PRESSURE; INTERIOR STRUCTURE; CORE FORMATION; EARTH	Accretion models of the terrestrial planets often assume planetary bulk compositions with nonvolatile element abundance ratios equivalent to those of C1 carbonaceous chondrites. The moment of inertia factor of Mars reported by the Pathfinder team is inconsistent with a bulk planet C1 Fe/Si ratio or Fe content, which suggests that C1 chondrite accretion models are insufficient to explain the formation of Mars and the other terrestrial planets. Future planetary accretion models will have to account for variations in bulk Fe/Si ratios among the terrestrial planets.	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA; Carnegie Inst Washington, Ctr High Pressure Res, Washington, DC 20015 USA	Carnegie Institution for Science; Carnegie Institution for Science	Bertka, CM (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.		Fei, Yingwei/F-3709-2011	Fei, Yingwei/0000-0001-9955-5353				BADDING JV, 1992, HIGH PRESSURE RES AP; Bertka CM, 1998, EARTH PLANET SC LETT, V157, P79, DOI 10.1016/S0012-821X(98)00030-2; Bills BG, 1995, J GEOPHYS RES-PLANET, V100, P26305, DOI 10.1029/95JE02776; Clayton RN, 1996, GEOCHIM COSMOCHIM AC, V60, P1999, DOI 10.1016/0016-7037(96)00074-9; DREIBUS G, 1985, METEORITICS, V20, P367; DREIBUS G, 1997, RUSSIAN GEOL GEOPHYS, V38, P287; FEI Y, COMMUNICATION; Folkner WM, 1997, SCIENCE, V278, P1749, DOI 10.1126/science.278.5344.1749; GANAPATHY R, 1979, ORIGIN EARTH MOON; GANAPATHY R, 1974, P LUNAR PLANET SCI C, V2, P1181; GANAPATHY R, 1977, GEOCHEM J, V11, P111; Hillgren VJ, 1996, GEOCHIM COSMOCHIM AC, V60, P2257, DOI 10.1016/0016-7037(96)00079-8; KAULA WM, 1979, GEOPHYS RES LETT, V6, P194, DOI 10.1029/GL006i003p00194; KURAMOTO K, 1994, LUM PLAN SCI C, V25, P759; Li J, 1996, NATURE, V381, P686, DOI 10.1038/381686a0; OHTANI E, 1992, GEOPHYS RES LETT, V19, P2239, DOI 10.1029/92GL02369; Righter K, 1996, ICARUS, V124, P513, DOI 10.1006/icar.1996.0227; RINGWOOD AE, 1971, NATURE, V234, P89, DOI 10.1038/234089a0; RINGWOOD AE, 1959, GEOCHIM COSMOCHIM AC, V15, P257, DOI 10.1016/0016-7037(59)90062-6; Sohl F, 1997, J GEOPHYS RES-PLANET, V102, P1613, DOI 10.1029/96JE03419; THIBAULT Y, 1995, GEOCHIM COSMOCHIM AC, V59, P9911; TREIMAN AH, 1986, GEOCHIM COSMOCHIM AC, V50, P1071, DOI 10.1016/0016-7037(86)90389-3; UREY HC, 1952, PLANETS; WANKE H, 1988, PHILOS T R SOC A, V325, P545, DOI 10.1098/rsta.1988.0067; WASSON JT, 1988, PHILOS T R SOC A, V325, P535, DOI 10.1098/rsta.1988.0066; WETHERILL GW, 1994, GEOCHIM COSMOCHIM AC, V58, P4513, DOI 10.1016/0016-7037(94)90352-2; WOOD BJ, 1993, EARTH PLANET SC LETT, V117, P593, DOI 10.1016/0012-821X(93)90105-I; Zharkov V. N., 1996, Solar System Research, V30, P456	28	60	63	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1838	1840		10.1126/science.281.5384.1838	http://dx.doi.org/10.1126/science.281.5384.1838			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743493				2022-12-24	WOS:000076007100048
J	Herbein, G; Mahlknecht, U; Batliwalla, F; Gregersen, P; Pappas, T; Butler, J; O'Brien, WA; Verdin, E				Herbein, G; Mahlknecht, U; Batliwalla, F; Gregersen, P; Pappas, T; Butler, J; O'Brien, WA; Verdin, E			Apoptosis of CD8(+) T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; INFECTION; PROGRESSION; PHENOTYPE; ENTRY; AIDS; DISEASE; DEATH; CCR5	CD8-positive T cells are thought to play an important role in the control of infection by human immunodeficiency virus (HIV) as a result of their cytotoxic activity and by releasing soluble factors(1,2) in AIDS patients, the absolute number bf CD8(+) T lymphocytes is decreased in peripheral blood(3,4) and their turnover rate Is increased, suggesting that there is more cell renewal and cell death occurring(5). Anti-retroviral therapy raises CD8(+) T-cell counts in HIV-infected patients(6-8). Here we report that the death rate of CD8(+) T cells by apoptosis increased markedly during HIV infection of peripheral blood mononuclear cells in vitro. Apoptosis is induced in a dose-dependent manner by recombinant envelope glycoprotein gp120 from HIV strain X4, or by stromal-derived factor-1 (SDF-1), the physiological ligand of the chemokine receptor CXCR4. Apoptosis is mediated by the interaction between tumour-necrosis factor-alpha bound to the membrane of macrophages (mbTNF) and a receptor on CD8(+) T cells (TNF-receptor II, or TNFRII). The expression of both of these cell surface proteins is upregulated by HIV infection or by treatment with recombinant gp120 or SDF-1. Apoptosis of CD8(+) T cells isolated from HIV-infected patients is also mediated by macrophages through the interaction between mbTNF and TNFRII. These results indicate that the increased turnover of CD8(+) T cells in HIV-infected subjects is mediated by the HIV envelope protein through the CXCR4 chemokine receptor.	Picower Inst Med Res, Manhasset, NY 11010 USA; Univ Texas, Med Branch, Dept Med, Div Infect Dis, Galveston, TX 77555 USA; N Shore Univ Hosp, Cornell Univ Med Coll, Dept Med, Div Biol & Human Genet, Manhasset, NY 11030 USA; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA	Northwell Health; University of Texas System; University of Texas Medical Branch Galveston; Cornell University; Northwell Health; North Shore University Hospital; University of California System; University of California San Francisco; The J David Gladstone Institutes	Verdin, E (corresponding author), Picower Inst Med Res, Manhasset, NY 11010 USA.		Verdin, Eric/AAB-7999-2019	Verdin, Eric/0000-0003-3703-3183				Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; COLLIN M, 1994, J GEN VIROL, V75, P1597, DOI 10.1099/0022-1317-75-7-1597; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; DAAR ES, 1995, AIDS RES HUM RETROV, V11, P3, DOI 10.1089/aid.1995.11.3; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Feinberg MB, 1997, CURR BIOL, V7, pR136, DOI 10.1016/S0960-9822(97)70072-1; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLER RA, 1992, CELL, V70, P47; Herbein G, 1998, J VIROL, V72, P660, DOI 10.1128/JVI.72.1.660-670.1998; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; Levy JA, 1996, IMMUNOL TODAY, V17, P217, DOI 10.1016/0167-5699(96)10011-6; MACKEWICZ CE, 1994, CLIN IMMUNOL IMMUNOP, V73, P80, DOI 10.1006/clin.1994.1172; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; Pakker NG, 1998, NAT MED, V4, P208, DOI 10.1038/nm0298-208; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; SARIN A, 1994, J IMMUNOL, V153, P862; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Simmons G, 1996, J VIROL, V70, P8355, DOI 10.1128/JVI.70.12.8355-8360.1996; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; WU MX, 1995, P NATL ACAD SCI USA, V92, P1525, DOI 10.1073/pnas.92.5.1525; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	26	350	362	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					189	194		10.1038/26026	http://dx.doi.org/10.1038/26026			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744279				2022-12-24	WOS:000075829900046
J	Jura, M; Turner, J				Jura, M; Turner, J			A mysterious dust clump in a disk around an evolved binary star system	NATURE			English	Article							RED-RECTANGLE NEBULA; CIRCUMSTELLAR ENVELOPES; CARBON STARS; EVOLUTION; GRAINS	The discovery of planets in orbit around the pulsar PSR1257+12 (ref. 1) shows that planets may form around post-main-sequence stars(2). Other evolved stars, such as HD44179 (an evolved star which is part of the binary system that has expelled the gas and dust that make the Red Rectangle nebula), possess gravitationally bound orbiting dust disks(3,4). It is possible that planets might form from gravitational collapse in such disks(5). Here we report high-angular-resolution observations at millimetre and submillimetre wavelengths of the dusk disk associated with the Red Rectangle. We find a dust clump with an estimated mass near that of Jupiter in the outer region of the disk. The clump is larger than our Solar System, and far beyond where planet formation would normally be expected, so its nature is at present unclear.	Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Jura, M (corresponding author), Univ Calif Los Angeles, Dept Phys & Astron, Los Angeles, CA 90095 USA.							ARTYMOWICZ P, 1991, ASTROPHYS J, V370, pL35, DOI 10.1086/185971; BANIT M, 1993, ASTROPHYS J, V415, P779, DOI 10.1086/173201; COHEN M, 1975, ASTROPHYS J, V196, P179, DOI 10.1086/153403; Cruzalebes P, 1996, ASTRON ASTROPHYS SUP, V116, P597, DOI 10.1051/aas:1996137; Greaves JS, 1997, ASTRON ASTROPHYS, V327, P342; Hora JL, 1996, ASTRON J, V112, P2064, DOI 10.1086/118163; Jura M, 1997, ASTROPHYS J, V474, P741, DOI 10.1086/303476; JURA M, 1995, ASTROPHYS J, V453, P721, DOI 10.1086/176433; Jura M, 1997, ASTROPHYS J, V485, P341, DOI 10.1086/304421; KOLYKHALOV PI, 1981, SOV ASTRON LETT, V6, P357; Lopez B, 1997, ASTRON ASTROPHYS, V322, P868; MATHIS JS, 1992, ASTRON ASTROPHYS, V259, pL39; OLOFSSON H, 1993, ASTROPHYS J SUPPL S, V87, P267, DOI 10.1086/191804; POLLACK JB, 1994, ASTROPHYS J, V421, P615, DOI 10.1086/173677; RODDIER F, 1995, ASTROPHYS J, V443, P249, DOI 10.1086/175520; SITKO ML, 1981, ASTROPHYS J, V247, P1024, DOI 10.1086/159112; Smail I, 1997, ASTROPHYS J, V490, pL5, DOI 10.1086/311017; VANDERVEEN WECJ, 1994, ASTRON ASTROPHYS, V285, P551; WAELKENS C, 1992, ASTRON ASTROPHYS, V256, pL15; WALKENS C, 1996, ASTRON ASTROPHYS, V314, pL17; WALMSLEY CM, 1991, ASTRON ASTROPHYS, V248, P555; Waters LBFM, 1998, NATURE, V391, P868, DOI 10.1038/36052; WATERS LBFM, 1992, ASTRON ASTROPHYS, V262, pL37; WATERS LBFM, 1993, ASTRON ASTROPHYS, V269, P242; WOLSZCZAN A, 1992, NATURE, V355, P145, DOI 10.1038/355145a0	25	25	25	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					144	145		10.1038/25938	http://dx.doi.org/10.1038/25938			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744271				2022-12-24	WOS:000075829900032
J	Vargas, M; Kashefi, K; Blunt-Harris, EL; Lovley, DR				Vargas, M; Kashefi, K; Blunt-Harris, EL; Lovley, DR			Microbiological evidence for Fe(III) reduction on early Earth	NATURE			English	Article							SP-NOV; FE(III)-REDUCING BACTERIA; GEN-NOV; IRON; LIFE; SUBSURFACE; ORIGIN; DEEP; ENVIRONMENTS; BIOSPHERE	It is generally considered(1) that sulphur reduction was one of the earliest forms of microbial respiration, because the known microorganisms that are most closely related to the last common ancestor of modern life are primarily anaerobic, sulphur-reducing hyperthermophiles(2-4). However, geochemical evidence indicates that Fe(III) is more likely than sulphur to have been the first external electron acceptor of global significance in microbial metabolism(5-7) Here we show that Archaea and Bacteria that are most closely related to the last common ancestor can reduce Fe(III) to Fe(II) and conserve energy to support growth from this respiration. Surprisingly, even Thermotoga maritima, previously considered to have only a fermentative metabolism, could grow as a respiratory organism when Fe(III) was provided as an electron acceptor. These results provide microbiological evidence that Fe(III) reduction could have been an important process on early Earth and suggest that microorganisms might contribute to Fe(III) reduction in modern hot biospheres. Furthermore, our discovery that hyperthermophiles that had previously been thought to require sulphur for cultivation can instead be grown without the production of toxic and corrosive sulphide, should aid biochemical investigations of these poorly understood organisms.	Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst	Lovley, DR (corresponding author), Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.	dlovley@microbio.u.mass.edu						ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; Barns SM, 1997, REV MINERAL, V35, P35; BOONE DR, 1995, INT J SYST BACTERIOL, V45, P441, DOI 10.1099/00207713-45-3-441; CAIRNSSMITH AG, 1992, ORIGINS LIFE EVOL B, V22, P161, DOI 10.1007/BF01808023; CHILDERS SE, 1992, APPL ENVIRON MICROB, V58, P3949, DOI 10.1128/AEM.58.12.3949-3953.1992; DEDUVE C, 1995, VITAL DUST, P1; DERONDE CEJ, 1994, GEOL SOC AM BULL, V106, P86, DOI 10.1130/0016-7606(1994)106<0086:EAGFOR>2.3.CO;2; GOLD T, 1992, P NATL ACAD SCI USA, V89, P6045, DOI 10.1073/pnas.89.13.6045; Greene AC, 1997, INT J SYST BACTERIOL, V47, P505, DOI 10.1099/00207713-47-2-505; HOBBIE JE, 1977, APPL ENVIRON MICROB, V33, P1225, DOI 10.1128/AEM.33.5.1225-1228.1977; HOLM NG, 1992, ORIGINS LIFE EVOL B, V22, P5, DOI 10.1007/BF01808015; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; KASTING JF, 1993, SCIENCE, V259, P920, DOI 10.1126/science.11536547; Liu SV, 1997, SCIENCE, V277, P1106, DOI 10.1126/science.277.5329.1106; Lonergan DJ, 1996, J BACTERIOL, V178, P2402, DOI 10.1128/jb.178.8.2402-2408.1996; Lovley D.R., 1997, IRON RELATED TRANSIT, P187; Lovley D. R, 1990, IRON BIOMINERALS, P151; LOVLEY DR, 1987, NATURE, V330, P252, DOI 10.1038/330252a0; LOVLEY DR, 1986, APPL ENVIRON MICROB, V51, P683, DOI 10.1128/AEM.51.4.683-689.1986; Madigan M., 1997, BROCK BIOL MICROORGA; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; PACE NR, 1991, CELL, V65, P531, DOI 10.1016/0092-8674(91)90082-A; RAVOT G, 1995, APPL ENVIRON MICROB, V61, P2053, DOI 10.1128/AEM.61.5.2053-2055.1995; Slobodkin A, 1997, INT J SYST BACTERIOL, V47, P541, DOI 10.1099/00207713-47-2-541; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; WALKER JCG, 1985, PRECAMBRIAN RES, V28, P205, DOI 10.1016/0301-9268(85)90031-2; WALKER JCG, 1987, NATURE, V329, P710, DOI 10.1038/329710a0	27	372	417	12	170	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					65	67		10.1038/25720	http://dx.doi.org/10.1038/25720			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738498				2022-12-24	WOS:000075722200046
J	Paneth, N				Paneth, N			Prenatal sonography - safe or sinister?	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIAL; PREGNANCY		Michigan State Univ, Coll Human Med, Dept Epidemiol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University College of Human Medicine	Paneth, N (corresponding author), Michigan State Univ, Coll Human Med, Dept Epidemiol, E Lansing, MI 48824 USA.							BAKKETEIG LS, 1984, LANCET, V2, P207; DUFF GB, 1993, AUST NZ J OBSTET GYN, V33, P374, DOI 10.1111/j.1479-828X.1993.tb02113.x; EIKNES SH, 1984, LANCET, V1, P1347; EWIGMAN BG, 1993, NEW ENGL J MED, V329, P821, DOI 10.1056/NEJM199309163291201; Geerts LTGM, 1996, BRIT J OBSTET GYNAEC, V103, P501, DOI 10.1111/j.1471-0528.1996.tb09796.x; Kieler H, 1997, BRIT J OBSTET GYNAEC, V104, P1267, DOI 10.1111/j.1471-0528.1997.tb10973.x; Kieler H, 1998, EARLY HUM DEV, V50, P233, DOI 10.1016/S0378-3782(97)00097-2; SAARIKEMPPAINEN A, 1990, LANCET, V336, P387, DOI 10.1016/0140-6736(90)91941-3; SALVESEN KA, 1993, BRIT MED J, V307, P1562, DOI 10.1136/bmj.307.6918.1562-a; SALVESEN KA, 1992, LANCET, V339, P85, DOI 10.1016/0140-6736(92)90998-I; SALVESEN KA, 1993, BRIT MED J, V307, P159, DOI 10.1136/bmj.307.6897.159; WALDENSTROM U, 1988, LANCET, V2, P585	12	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					5	6		10.1016/S0140-6736(05)79506-4	http://dx.doi.org/10.1016/S0140-6736(05)79506-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800735				2022-12-24	WOS:000074608600005
J	Rohrer, SP; Birzin, ET; Mosley, RT; Berk, SC; Hutchins, SM; Shen, DM; Xiong, YS; Hayes, EC; Parmar, RM; Foor, F; Mitra, SW; Degrado, SJ; Shu, M; Klopp, JM; Cai, SJ; Blake, A; Chan, WWS; Pasternak, A; Yang, LH; Patchett, AA; Smith, RG; Chapman, KT; Schaeffer, JM				Rohrer, SP; Birzin, ET; Mosley, RT; Berk, SC; Hutchins, SM; Shen, DM; Xiong, YS; Hayes, EC; Parmar, RM; Foor, F; Mitra, SW; Degrado, SJ; Shu, M; Klopp, JM; Cai, SJ; Blake, A; Chan, WWS; Pasternak, A; Yang, LH; Patchett, AA; Smith, RG; Chapman, KT; Schaeffer, JM			Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry	SCIENCE			English	Article							MOLECULAR-CLONING; TYROSINE PHOSPHATASE; GROWTH-HORMONE; RAT-BRAIN; EXPRESSION; INHIBITION; SECRETION; GLUCAGON; RELEASE; ANALOGS	Nonpeptide agonists of each of the five somatostatin receptors were identified in combinatorial Libraries constructed on the basis of molecular modeling of known peptide agonists. In vitro experiments using these selective compounds demonstrated the role of the somatostatin subtype-2 receptor in inhibition of glucagon release from mouse pancreatic alpha cells and the somatostatin subtype-5 receptor as a mediator of insulin secretion from pancreatic beta cells. Both receptors regulated growth hormone release from the rat anterior pituitary gland. The availability of high-affinity, subtype-selective agonists for each of the somatostatin receptors provides a direct approach to defining their physiological functions.	Merck Res Labs, Dept Cell Biochem & Physiol, Rahway, NJ 07065 USA; Merck Res Labs, Dept Mol Design & Divers, Rahway, NJ 07065 USA; Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA	Merck & Company; Merck & Company; Merck & Company	Rohrer, SP (corresponding author), Merck Res Labs, Dept Cell Biochem & Physiol, POB 2000, Rahway, NJ 07065 USA.	susan_rohrer@merck.com						BLOOM SR, 1974, LANCET, V2, P1106; BLOOM SR, 1975, GUT, V16, P834; BRAZEAU P, 1973, SCIENCE, V179, P77, DOI 10.1126/science.179.4068.77; BROWN M, 1977, SCIENCE, V196, P1467, DOI 10.1126/science.867045; BRUNO JF, 1992, P NATL ACAD SCI USA, V89, P11151, DOI 10.1073/pnas.89.23.11151; BUSCAIL L, 1994, P NATL ACAD SCI USA, V91, P2315, DOI 10.1073/pnas.91.6.2315; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; EPELBAUM J, 1986, PROG NEUROBIOL, V27, P63, DOI 10.1016/0301-0082(86)90012-2; Hunyady B, 1997, ENDOCRINOLOGY, V138, P2632; KLUXEN FW, 1992, P NATL ACAD SCI USA, V89, P4618, DOI 10.1073/pnas.89.10.4618; LEROMANCER M, 1994, J BIOL CHEM, V269, P17464; LIEBOW C, 1989, P NATL ACAD SCI USA, V86, P2003, DOI 10.1073/pnas.86.6.2003; MANDARINO L, 1981, NATURE, V291, P76, DOI 10.1038/291076a0; MEYERHOF W, 1992, P NATL ACAD SCI USA, V89, P10267, DOI 10.1073/pnas.89.21.10267; Mezey E, 1998, ENDOCRINOLOGY, V139, P414, DOI 10.1210/en.139.1.414; MITRA SW, IN PRESS ENDOCRINOLO; OCARROLL AM, 1992, MOL PHARMACOL, V42, P939; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; PATEL YC, 1994, BIOCHEM BIOPH RES CO, V198, P605, DOI 10.1006/bbrc.1994.1088; RAYNOR K, 1993, MOL PHARMACOL, V43, P838; REICHLIN S, 1983, NEW ENGL J MED, V309, P1495, DOI 10.1056/NEJM198312153092406; RENSDOMIANO S, 1992, MOL PHARMACOL, V42, P28; ROHRER L, 1993, P NATL ACAD SCI USA, V90, P4196, DOI 10.1073/pnas.90.9.4196; ROSSOWSKI WJ, 1994, BIOCHEM BIOPH RES CO, V205, P341, DOI 10.1006/bbrc.1994.2670; VALE W, 1974, ENDOCRINOLOGY, V95, P968, DOI 10.1210/endo-95-4-968; VANETTI M, 1992, FEBS LETT, V311, P290, DOI 10.1016/0014-5793(92)81122-3; VAYSSE N, 1981, ENDOCRINOLOGY, V108, P1843, DOI 10.1210/endo-108-5-1843; WHITE RE, 1991, NATURE, V351, P570, DOI 10.1038/351570a0; YAMADA Y, 1992, P NATL ACAD SCI USA, V89, P251, DOI 10.1073/pnas.89.1.251; Yang LH, 1998, P NATL ACAD SCI USA, V95, P10836, DOI 10.1073/pnas.95.18.10836; Yang LH, 1998, J MED CHEM, V41, P2175, DOI 10.1021/jm980194h; YASUDA K, 1992, J BIOL CHEM, V267, P20422	32	416	441	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					737	740		10.1126/science.282.5389.737	http://dx.doi.org/10.1126/science.282.5389.737			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784130				2022-12-24	WOS:000076607500049
J	Prasher, D				Prasher, D			New strategies for prevention and treatment of noise-induced hearing loss	LANCET			English	Editorial Material							AUDITORY NEURONS; PROTECTION; EXPOSURE		UCL, Inst Laryngol & Otol, London WC1X 8EE, England	University of London; University College London	Prasher, D (corresponding author), UCL, Inst Laryngol & Otol, Mortimer St, London WC1X 8EE, England.							Alberti P.W, 1998, NOISE HEALTH, V1, P3; Altschuler RA, 1996, AUDITORY SYSTEM PLASTICITY AND REGENERATION, P202; ATTIAS J, 1998, BIOL EFFECTS NOISE, P273; CANLON B, 1988, HEARING RES, V34, P197, DOI 10.1016/0378-5955(88)90107-4; Canlon Barbara, 1998, Noise Health, V1, P13; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; Jacono AA, 1998, HEARING RES, V117, P31, DOI 10.1016/S0378-5955(97)00214-1; KOMJATHY DA, 1997, ABS ASS RES OTOLARYN, V21, P748; MORATA TC, 1993, SCAND J WORK ENV HEA, V19, P245, DOI 10.5271/sjweh.1477; PUEL JL, 1994, J COMP NEUROL, V341, P241, DOI 10.1002/cne.903410209; SEIDMAN MD, 1993, OTOLARYNG HEAD NECK, V109, P1052, DOI 10.1177/019459989310900613; SHA SH, 1997, ABS ASS RES OTOLARYN, V20, P120; SHOJI F, 1998, ABS ASS RES OTOLARYN, V21, P539; YAMANE H, 1995, ACTA OTO-LARYNGOL, P87; Yamasoba T, 1998, BRAIN RES, V784, P82, DOI 10.1016/S0006-8993(97)01156-6	15	18	23	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1240	1242		10.1016/S0140-6736(05)70483-9	http://dx.doi.org/10.1016/S0140-6736(05)70483-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788450				2022-12-24	WOS:000076573800004
J	Simini, B				Simini, B			Odorous odds and ends ...	LANCET			English	Editorial Material																			0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1322	1322		10.1016/S0140-6736(05)70546-8	http://dx.doi.org/10.1016/S0140-6736(05)70546-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788494				2022-12-24	WOS:000076573800073
J	Apfeld, J; Kenyon, C				Apfeld, J; Kenyon, C			Cell nonautonomy of C-elegans daf-2 function in the regulation of diapause and life span	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CONTROLLING DAUER FORMATION; LARVAL DEVELOPMENT; CHEMOSENSORY NEURONS; INTERACTING GENES; SEX DETERMINATION; FAMILY MEMBER; LONGEVITY; EXPRESSION; PHEROMONE	The insulin/IGF receptor homolog DAF-2 regulates the aging in C. elegans. Decreasing daf-2 activity causes fertile adults to remain active much longer than normal and to live more than twice as long. A more severe decrease in daf-2 function causes young larvae to enter a state of diapause rather than progressing to adulthood. We have asked which cells require daf-2 gene activity in order for the animal to develop to adulthood and to age normally. We found that daf-a functions cell nonautonomously in both processes. Our findings imply that the life span of C. elegans is determined by a signaling cascade in which the DAF-2 receptor acts in multiple cell lineages to regulate the production or activity of a secondary signal (or signals), which, in turn, controls the growth and longevity of individual tissues in the animal.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Apfeld, J (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	japfeld@itsa.ucsf.edu; ckenyon@biochem.ucsf.edu		Apfeld, Javier/0000-0001-9897-5671	NIA NIH HHS [AG11816] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG011816, R01AG011816] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Antebi A, 1998, DEVELOPMENT, V125, P1191; Armitage P, 1987, STAT METHODS MED RES, P421; BARGMANN CI, 1991, SCIENCE, V251, P1243, DOI 10.1126/science.2006412; BRENNER S, 1974, GENETICS, V77, P71; Coburn CM, 1998, DEVELOPMENT, V125, P249; DORMAN JB, 1995, GENETICS, V141, P1399; Duret L, 1998, GENOME RES, V8, P348, DOI 10.1101/gr.8.4.348; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FRIEDMAN DB, 1988, GENETICS, V118, P75; Gems D, 1998, GENETICS, V150, P129; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GOLDEN JW, 1982, SCIENCE, V218, P578, DOI 10.1126/science.6896933; GOLDEN JW, 1984, DEV BIOL, V102, P368, DOI 10.1016/0012-1606(84)90201-X; GOTTLIEB S, 1994, GENETICS, V137, P107; HEDGECOCK EM, 1995, GENETICS, V141, P989; HORVITZ HR, 1979, MOL GEN GENET, V175, P129, DOI 10.1007/BF00425528; HUNTER CP, 1992, NATURE, V355, P551, DOI 10.1038/355551a0; KENYON C, 1986, CELL, V46, P477, DOI 10.1016/0092-8674(86)90668-9; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KLASS M, 1976, NATURE, V260, P523, DOI 10.1038/260523a0; KLASS MR, 1983, MECH AGEING DEV, V22, P279, DOI 10.1016/0047-6374(83)90082-9; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARSEN PL, 1995, GENETICS, V139, P1567; Leroith D, 1996, DIABETES MELLITUS FU; Lin K, 1997, SCIENCE, V278, P1319, DOI 10.1126/science.278.5341.1319; LIU ZC, 1989, GENE DEV, V3, P2039, DOI 10.1101/gad.3.12b.2039; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PERRY MD, 1993, GENE DEV, V7, P216, DOI 10.1101/gad.7.2.216; Ren PF, 1996, SCIENCE, V274, P1389, DOI 10.1126/science.274.5291.1389; RIDDLE DL, 1981, NATURE, V290, P668, DOI 10.1038/290668a0; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Shepherd PR, 1996, J MOL ENDOCRINOL, V17, P175, DOI 10.1677/jme.0.0170175; Sulston J, 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; THOMAS JH, 1993, GENETICS, V134, P1105; Tissenbaum HA, 1998, GENETICS, V148, P703; VOWELS JJ, 1992, GENETICS, V130, P105; WHITE JG, 1983, COLD SPRING HARB SYM, V48, P633, DOI 10.1101/SQB.1983.048.01.067; WOOLSON RF, 1987, STAT METHODS ANAL BI, P442	44	259	280	1	28	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					199	210		10.1016/S0092-8674(00)81751-1	http://dx.doi.org/10.1016/S0092-8674(00)81751-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790527	Bronze			2022-12-24	WOS:000076538300008
J	Lu, BW; Rothenberg, M; Jan, LY; Jan, YN				Lu, BW; Rothenberg, M; Jan, LY; Jan, YN			Partner of numb colocalizes with numb during mitosis and directs numb asymmetric localization in Drosophila neural and muscle progenitors	CELL			English	Article							CELL FATES; CAENORHABDITIS-ELEGANS; NERVOUS-SYSTEM; PROSPERO GENE; DAUGHTER CELL; PROTEIN; DIVISION; SEGREGATION; EMBRYOS; NOTCH	During mitosis of multiple types of precursor cells in Drosophila, Numb is asymmetrically distributed between the two daughter cells and confers distinct daughter cell fates. Here we report the identification of a novel gene product, Partner of Numb (PON), based on its physical interaction with Numb. PON is asymmetrically localized during mitosis and colocalizes with Numb. Loss of pon function disrupts Numb localization in muscle progenitors and delays Numb crescent formation in neural precursors. Moreover, ectopically expressed PON responds to the apical-basal polarity of epithelial cells and is sufficient to localize Numb basally. We propose that PON is one component of a multimolecular machinery that localizes Numb by responding to polarity cues conserved in neural precursors and epithelial cells.	Univ Calif San Francisco, Dept Physiol, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Jan, YN (corresponding author), Univ Calif San Francisco, Dept Physiol, Howard Hughes Med Inst, Box 0444, San Francisco, CA 94143 USA.	ynjan@itsa.ucsf.edu		Jan, Yuh Nung/0000-0003-1367-6299; Jan, Lily/0000-0003-3938-8498; Lu, Bingwei/0000-0002-5807-7014				ADLER PN, 1992, BIOESSAYS, V14, P735, DOI 10.1002/bies.950141103; BARTEL P, 1993, BIOTECHNIQUES, V14, P920; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRAND AH, 1993, DEVELOPMENT, V118, P401; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; BURCHARD S, 1995, J CELL SCI, V108, P1443; Carmena A, 1998, GENE DEV, V12, P304, DOI 10.1101/gad.12.3.304; Chang F, 1996, CURR BIOL, V6, P651, DOI 10.1016/S0960-9822(09)00440-0; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; Dye CA, 1998, DEVELOPMENT, V125, P1845; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gho M, 1998, NATURE, V393, P178, DOI 10.1038/30265; Gomez MR, 1997, DEVELOPMENT, V124, P4857; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Guo S, 1996, NATURE, V382, P455, DOI 10.1038/382455a0; Guo S, 1996, CURR OPIN GENET DEV, V6, P408, DOI 10.1016/S0959-437X(96)80061-X; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KAISER K, 1990, P NATL ACAD SCI USA, V87, P1686, DOI 10.1073/pnas.87.5.1686; Knirr S, 1997, MECH DEVELOP, V67, P69, DOI 10.1016/S0925-4773(97)00109-3; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, P NATL ACAD SCI USA, V94, P13005, DOI 10.1073/pnas.94.24.13005; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shapiro L, 1997, SCIENCE, V276, P712, DOI 10.1126/science.276.5313.712; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; Skeath JB, 1998, DEVELOPMENT, V125, P1857; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P942; ZHOU MM, 1995, NATURE, V378, P84	46	157	160	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					225	235		10.1016/S0092-8674(00)81753-5	http://dx.doi.org/10.1016/S0092-8674(00)81753-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790529	Bronze			2022-12-24	WOS:000076538300010
J	Pei, ZM; Ghassemian, M; Kwak, CM; McCourt, P; Schroeder, JI				Pei, ZM; Ghassemian, M; Kwak, CM; McCourt, P; Schroeder, JI			Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss	SCIENCE			English	Article							FARNESYL-PROTEIN TRANSFERASE; ACID SIGNAL-TRANSDUCTION; CULTURED TOBACCO CELLS; ABSCISIC-ACID; ARABIDOPSIS-THALIANA; PLASMA-MEMBRANE; ION CHANNELS; WILD-TYPE; ISOPRENYLATION; MUTANTS	Desiccation of plants during drought can be detrimental to agricultural production. The phytohormone abscisic acid (ABA) reduces water loss by triggering stomatal pore closure in leaves, a process requiring ion-channel modulation by cytoplasmic proteins. Deletion of the Arabidopsis farnesyltransferase gene ERA1 or application of farnesyltransferase inhibitors resulted in ABA hypersensitivity of guard cell anion-channel activation and of stomatal closing. ERA1 was expressed in guard cells, Double-mutant analyses of era1 with the ABA-insensitive mutants abi1 and abi2 showed that era1 suppresses the ABA-insensitive phenotypes. Moreover, era1 plants exhibited a reduction in transpirational water loss during drought treatment.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Toronto, Dept Bot, Toronto, ON M5S 3B2, Canada	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Toronto	Schroeder, JI (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.			Pei, Zhen-Ming/0000-0003-1473-696X; Schroeder, Julian/0000-0002-3283-5972				ARMSTRONG F, 1995, P NATL ACAD SCI USA, V92, P9520, DOI 10.1073/pnas.92.21.9520; ASSMANN SM, 1993, ANNU REV CELL BIOL, V9, P345, DOI 10.1146/annurev.cb.09.110193.002021; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEDRICH R, 1990, EMBO J, V9, P3889, DOI 10.1002/j.1460-2075.1990.tb07608.x; HETHERINGTON AM, 1991, NEW PHYTOL, V119, P9, DOI 10.1111/j.1469-8137.1991.tb01004.x; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung J, 1998, ANNU REV PLANT PHYS, V49, P199, DOI 10.1146/annurev.arplant.49.1.199; MacRobbie EAC, 1997, J EXP BOT, V48, P515, DOI 10.1093/jxb/48.Special_Issue.515; MCCOURT P, UNPUB; Moasser MM, 1998, P NATL ACAD SCI USA, V95, P1369, DOI 10.1073/pnas.95.4.1369; MOREHEAD TA, 1995, PLANT PHYSIOL, V109, P277, DOI 10.1104/pp.109.1.277; Parmryd I, 1995, EUR J BIOCHEM, V234, P723, DOI 10.1111/j.1432-1033.1995.723_a.x; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, P NATL ACAD SCI USA, V95, P6548, DOI 10.1073/pnas.95.11.6548; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; Qian DQ, 1996, PLANT CELL, V8, P2381, DOI 10.1105/tpc.8.12.2381; RANDALL SK, 1993, PLANT CELL, V5, P433, DOI 10.1105/tpc.5.4.433; Rodriguez PL, 1998, FEBS LETT, V421, P185, DOI 10.1016/S0014-5793(97)01558-5; Roelfsema MRG, 1995, PHYSIOL PLANTARUM, V95, P373, DOI 10.1111/j.1399-3054.1995.tb00851.x; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; Schmitt D, 1996, PLANT PHYSIOL, V112, P767, DOI 10.1104/pp.112.2.767; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SCHWARTZ A, 1995, PLANT PHYSIOL, V109, P651, DOI 10.1104/pp.109.2.651; VARTANIAN N, 1994, PLANT PHYSIOL, V104, P761, DOI 10.1104/pp.104.2.761; WARD JM, 1995, PLANT CELL, V7, P833, DOI 10.1105/tpc.7.7.833; Yalovsky S, 1997, MOL CELL BIOL, V17, P1986, DOI 10.1128/MCB.17.4.1986; YANG ZB, 1993, PLANT PHYSIOL, V101, P667, DOI 10.1104/pp.101.2.667; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.pp.39.060188.002255; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhou DF, 1997, PLANT J, V12, P921, DOI 10.1046/j.1365-313X.1997.12040921.x; ZHU JK, 1993, P NATL ACAD SCI USA, V90, P8557, DOI 10.1073/pnas.90.18.8557	43	300	334	3	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					287	290		10.1126/science.282.5387.287	http://dx.doi.org/10.1126/science.282.5387.287			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765153				2022-12-24	WOS:000076370200046
J	Gunn, N; White, C; Srinivasan, R				Gunn, N; White, C; Srinivasan, R			Primary care as harm reduction for injection drug users	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY; NEEDLE-EXCHANGE; INFECTIONS; PREVALENCE; PREVENTION; BEHAVIOR; AIDS; SKIN		Univ Calif Davis, Sch Med, Davis, CA 95616 USA	University of California System; University of California Davis	Gunn, N (corresponding author), Univ Calif Davis, Sch Med, Davis, CA 95616 USA.							ALTER MJ, 1995, SEMIN LIVER DIS, V15, P5, DOI 10.1055/s-2007-1007259; ASTEMBORSKI J, 1994, AM J PUBLIC HEALTH, V84, P382, DOI 10.2105/AJPH.84.3.382; BOOTH R, 1991, AM J DRUG ALCOHOL AB, V17, P337, DOI 10.3109/00952999109027557; Centers for Disease Control and Prevention, 1996, MMWR-MORBID MORTAL W, V45, P392; COTTON P, 1994, JAMA-J AM MED ASSOC, V271, P1641, DOI 10.1001/jama.271.21.1641; GABRIELLI C, 1994, J INFECTION, V29, P17, DOI 10.1016/S0163-4453(94)94952-2; Garfein RS, 1996, AM J PUBLIC HEALTH, V86, P655, DOI 10.2105/AJPH.86.5.655; HENNINGFIELD JE, 1995, NEW ENGL J MED, V333, P1196, DOI 10.1056/NEJM199511023331807; Hurley SF, 1997, LANCET, V349, P1797, DOI 10.1016/S0140-6736(96)11380-5; KIRBY D, 1991, FAM PLANN PERSPECT, V23, P6, DOI 10.2307/2135395; LAZARE A, 1987, ARCH INTERN MED, V147, P1653, DOI 10.1001/archinte.147.9.1653; LUCIDARME D, 1994, GASTROEN CLIN BIOL, V18, P964; Manoff SB, 1996, EPIDEMIOLOGY, V7, P566, DOI 10.1097/00001648-199611000-00001; Marlatt GA, 1996, ADDICT BEHAV, V21, P779, DOI 10.1016/0306-4603(96)00042-1; Morrison A, 1997, ADDICTION, V92, P1349; NEWMEYER J, 1995, MIDCITY NUMBERS MONT, V8, P4; THOMAS DL, 1995, MEDICINE, V74, P212, DOI 10.1097/00005792-199507000-00005; TRILLA A, 1995, J CHEMOTHERAPY, V7, P37; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; WATTERS JK, 1994, JAMA-J AM MED ASSOC, V271, P115, DOI 10.1001/jama.271.2.115	20	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1191	+		10.1001/jama.280.13.1191	http://dx.doi.org/10.1001/jama.280.13.1191			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	124YR	9777822				2022-12-24	WOS:000076210800036
J	Gratwohl, A; Hermans, J; Goldman, JM; Arcese, W; Carreras, E; Devergie, A; Frassoni, F; Gahrton, G; Kolb, H; Niederwieser, D; Ruutu, T; Vernant, JP; de Witte, T; Apperley, J				Gratwohl, A; Hermans, J; Goldman, JM; Arcese, W; Carreras, E; Devergie, A; Frassoni, F; Gahrton, G; Kolb, H; Niederwieser, D; Ruutu, T; Vernant, JP; de Witte, T; Apperley, J		European Grp Blood Marrow Transplantation	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation	LANCET			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC-PHASE; INTERFERON-ALPHA; CELLS	Background Transplantation of blood or bone-marrow stem cells is the treatment of choice for selected patients with chronic myeloid leukaemia (CML). Transplantation is used with increasing frequency and success, but remains associated with substantial risks of morbidity and mortality. Other treatments with satisfactory short-term outcome are available. For appropriate counselling of patients, a rapid and simple way to assess risk is needed. Methods Data from 3142 patients (1873 [60%] male, 1269 [40%] female; mean age 34 years, range <1-60 years) treated with allogeneic blood or marrow transplants for CML between 1989 and 1997, reported to the European Group for Blood and Marrow Transplantation (EBMT), were used to develop and test a simple risk score based on previously reported major pretransplant risk factors: histocompatibility, stage of disease at time of transplantation, age and sex of donor and recipient, and time from diagnosis to transplantation. We analysed probabilities of survival, leukaemia-free survival, transplant-related mortality, and relapse incidence with respect to these risk factors. Findings At the time of analysis, 1922 (61%) of the 3142 patients were alive-1567 (65%) of those with HLA-identical sibling donors and 417 (57%) of those with unrelated donors. 1682 (54%) were alive without relapse. 1220 (39%) patients had died, 1013 (83%) of transplant-related causes, 207 (17%) of relapse. 447 (14%) patients had relapsed. The final scoring system was highly predictive for leukaemia-free survival, survival and transplant-related mortality. Survival at 5 years was 72%, 70%, 62%, 48%, 40%, 18%, and 22% for patients with scores 0, 1, 2, 3, 4, 5, and 6, respectively. Risk of transplant-related mortality was 20%, 23%, 31%, 46%, 51%, 71%, and 73%. Data showed the same trends for HLA-identical sibling transplants and unrelated transplants for transplants done in 1989-93 and 1994-96. Interpretation Pretransplant risk factors are cumulative for individual patients with CML having blood or marrow transplantation. A simple system based on five main factors gives adequate risk assessment for counselling of patients and taking decisions.	Kantonsspital, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland; Leiden Univ, Dept Med Stat, NL-2300 RA Leiden, Netherlands; Hammersmith Hosp, Royal Postgrad Med Sch, Dept Haematol, London, England; Univ Hosp La Sapienza, Inst Haematol, Rome, Italy; Hosp & Clin, Bone Marrow Transplant Unit, Barcelona, Spain; Hop St Louis, Bone Marrow Transplant Unit, Paris, France; Osped San Martino Genova, Bone Marrow Transplant Unit, Genoa, Italy; Huddinge Univ Hosp, Dept Med, S-14186 Huddinge, Sweden; Univ Munich, Klinikum Grosshadern, Med Klin 3, D-8000 Munich, Germany; Univ Innsbruck, Clin Internal Med, A-6020 Innsbruck, Austria; Univ Helsinki, Cent Hosp, Dept Med, Div Haematol, FIN-00014 Helsinki, Finland; Grp Hosp Pitie Salpetriere, Serv Hematol Clin, F-75634 Paris, France; Univ Nijmegen Hosp, Div Hematol, NL-6500 HB Nijmegen, Netherlands	Kantonsspital Aarau AG (KSA); University of Basel; Leiden University; Leiden University - Excl LUMC; Imperial College London; Sapienza University Rome; University Hospital Sapienza Rome; University of Barcelona; Hospital Clinic de Barcelona; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; University of Genoa; IRCCS AOU San Martino IST; Karolinska Institutet; University of Munich; University of Innsbruck; University of Helsinki; Helsinki University Central Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Radboud University Nijmegen	Gratwohl, A (corresponding author), Kantonsspital, Dept Internal Med, Div Haematol, CH-4031 Basel, Switzerland.	hematology@ubaclu.unibas.ch	de Witte, T.J.M./L-4762-2015; Frassoni, Francesco/K-3971-2018	Frassoni, Francesco/0000-0003-1262-0648; ARCESE, WILLIAM/0000-0001-5697-366X				[Anonymous], 1993, N ENGL J MED, V329, P987; ARMITAGE JO, 1994, NEW ENGL J MED, V330, P827, DOI 10.1056/NEJM199403243301206; BEELEN DW, 1995, BLOOD, V85, P2981, DOI 10.1182/blood.V85.10.2981.bloodjournal85102981; Carella AM, 1997, HAEMATOLOGICA, V82, P478; CLIFT R, 1989, BONE MARROW TRANSPL, V4, P445; CLIFT RA, 1993, BLOOD, V82, P1954; CORTES JE, 1996, AM J MED, V100, P55; Devergie A, 1997, BONE MARROW TRANSPL, V20, P11, DOI 10.1038/sj.bmt.1700844; Dini G, 1996, BONE MARROW TRANSPL, V18, P80; FEFER A, 1979, NEW ENGL J MED, V300, P333, DOI 10.1056/NEJM197902153000702; GOLDMAN JM, 1993, BLOOD, V82, P2235; GOLDMAN JM, 1986, NEW ENGL J MED, V314, P202, DOI 10.1056/NEJM198601233140403; GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509; Gratwohl A, 1997, BONE MARROW TRANSPL, V19, P407, DOI 10.1038/sj.bmt.1700694; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; Hehlmann R, 1996, BONE MARROW TRANSPL, V17, pS21; LEE AJ, 1997, ANN INTERN MED, V127, P1080; Marubini E, 1995, ANAL SURVIVAL DATA C; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; Sierra J, 1997, BLOOD, V89, P4226, DOI 10.1182/blood.V89.11.4226; SPECK B, 1984, LANCET, V1, P665; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TURA S, 1994, NEW ENGL J MED, V330, P820; vanRhee F, 1997, BONE MARROW TRANSPL, V20, P553, DOI 10.1038/sj.bmt.1700933	25	492	518	1	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 3	1998	352	9134					1087	1092		10.1016/S0140-6736(98)03030-X	http://dx.doi.org/10.1016/S0140-6736(98)03030-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798583				2022-12-24	WOS:000076246400008
J	Lan, MS; Mason, A; Coutant, R; Chen, QY; Vargas, A; Rao, JS; Gomez, R; Chalew, S; Garry, R; Maclaren, NK				Lan, MS; Mason, A; Coutant, R; Chen, QY; Vargas, A; Rao, JS; Gomez, R; Chalew, S; Garry, R; Maclaren, NK			HERV-K10s and immune-mediated (type 1) diabetes	CELL			English	Letter							HTDV/HERV-K; MELLITUS; SUPERANTIGEN		Louisiana State Univ, Sch Med, Dept Pediat, Res Inst Children,Childrens Hosp, Harahan, LA 70123 USA; Louisiana State Univ, Sch Med, Dept Biometry & Genet, Res Inst Children,Childrens Hosp, Harahan, LA 70123 USA; Alton Ochsner Med Fdn & Ochsner Clin, Sect Gastroenterol & Hepatol, New Orleans, LA 70121 USA; Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University; Louisiana State University System; Louisiana State University; Ochsner Health System; Tulane University	Maclaren, NK (corresponding author), Louisiana State Univ, Sch Med, Dept Pediat, Res Inst Children,Childrens Hosp, Harahan, LA 70123 USA.		Co, Re/Z-5330-2019; Lan, Michael/CAF-1839-2022; Mason, Andrew/D-2938-2013	Garry, Robert/0000-0002-5683-3250; Mason, Andrew/0000-0002-0470-9522	NICHD NIH HHS [R01 HD 19469-14] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD019469] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; Maclaren NK, 1997, MOL MED TODAY, V3, P76, DOI 10.1016/S1357-4310(96)10056-3	7	32	35	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					14	16		10.1016/S0092-8674(00)81777-8	http://dx.doi.org/10.1016/S0092-8674(00)81777-8			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778243	Bronze			2022-12-24	WOS:000076242300005
J	Stenger, S; Hanson, DA; Teitelbaum, R; Dewan, P; Niazi, KR; Froelich, CJ; Ganz, T; Thoma-Uszynski, S; Melian, A; Bogdan, C; Porcelli, SA; Bloom, BR; Krensky, AM; Modlin, RL				Stenger, S; Hanson, DA; Teitelbaum, R; Dewan, P; Niazi, KR; Froelich, CJ; Ganz, T; Thoma-Uszynski, S; Melian, A; Bogdan, C; Porcelli, SA; Bloom, BR; Krensky, AM; Modlin, RL			An antimicrobial activity of cytolytic T cells mediated by granulysin	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; NATURAL-KILLER; MYCOBACTERIUM-TUBERCULOSIS; LISTERIA-MONOCYTOGENES; MURINE MACROPHAGES; LYMPHOCYTES-T; TARGET-CELLS; NK-LYSIN; PERFORIN; INFECTION	Cytolytic T Lymphocytes (CTLs) kill intracellular pathogens by a granule-dependent mechanism. Granulysin, a protein found in granules of CTLs, reduced the viability of a broad spectrum of pathogenic bacteria, fungi, and parasites in vitro. Granulysin directly killed extracellular Mycobacterium tuberculosis, altering the membrane integrity of the bacillus, and, in combination with perforin, decreased the viability of intracellular M. tuberculosis. The ability of CTLs to kill intracellular M, tuberculosis was dependent on the presence of granulysin in cytotoxic granules, defining a mechanism by which T cells directly contribute to immunity against intracellular pathogens.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Pulm Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA; Stanford Univ, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA; Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Evanston NW Healthcare Res Inst, Evanston, IL 60201 USA; Evanston Hosp Corp, Dept Med, Evanston, IL 60201 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Univ Erlangen Nurnberg, Inst Klin Mikrobiol Immunol & Hyg, D-91054 Erlangen, Germany	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Stanford University; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; NorthShore University Health System; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Erlangen Nuremberg	Modlin, RL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.	rmodlin@medicine.medsch.ucla.edu	Modlin, Robert L/M-7941-2014; Ganz, Tomas/AAN-3308-2020; Krensky, Alan/F-7956-2011; Ganz, Tomas/D-4567-2009	Modlin, Robert L/0000-0003-4720-031X; Ganz, Tomas/0000-0002-2830-5469; Bogdan, Christian/0000-0002-2300-0631				ANDERSSON M, 1995, EMBO J, V14, P1615, DOI 10.1002/j.1460-2075.1995.tb07150.x; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; Bonecini-Almeida MG, 1998, J IMMUNOL, V160, P4490; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Cooper AM, 1997, INFECT IMMUN, V65, P1317, DOI 10.1128/IAI.65.4.1317-1320.1997; DELIBERO G, 1988, EUR J IMMUNOL, V18, P59, DOI 10.1002/eji.1830180110; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DESOUZA A, COMMUNICATION; DUKE RC, 1989, J EXP MED, V170, P1451, DOI 10.1084/jem.170.4.1451; FOREMAN JC, 1977, J PHYSIOL-LONDON, V271, P215, DOI 10.1113/jphysiol.1977.sp011997; Froelich CJ, 1996, BIOCHEM BIOPH RES CO, V229, P44, DOI 10.1006/bbrc.1996.1755; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; HARTY JT, 1992, P NATL ACAD SCI USA, V89, P11612, DOI 10.1073/pnas.89.23.11612; Jackman RM, 1998, IMMUNITY, V8, P341, DOI 10.1016/S1074-7613(00)80539-7; JONGSTRA J, 1987, J EXP MED, V165, P601, DOI 10.1084/jem.165.3.601; KAPLAN G, COMMUNICATION; KAUFMANN SHE, 1986, J EXP MED, V164, P363, DOI 10.1084/jem.164.1.363; KAUFMANN SHE, 1988, IMMUNOL TODAY, V9, P168, DOI 10.1016/0167-5699(88)91292-3; Lammas DA, 1997, IMMUNITY, V7, P433, DOI 10.1016/S1074-7613(00)80364-7; Laochumroonvorapong P, 1997, INFECT IMMUN, V65, P127, DOI 10.1128/IAI.65.1.127-132.1997; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEIPPE M, 1994, MOL MICROBIOL, V14, P895, DOI 10.1111/j.1365-2958.1994.tb01325.x; LEIPPE M, 1995, CELL, V83, P17, DOI 10.1016/0092-8674(95)90229-5; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; MASSON D, 1985, J BIOL CHEM, V260, P9069; NEIGHBOUR PA, 1982, J IMMUNOL, V128, P1236; NEIGHBOUR PA, 1982, EUR J IMMUNOL, V12, P588, DOI 10.1002/eji.1830120711; Nicholson S, 1996, J EXP MED, V183, P2293, DOI 10.1084/jem.183.5.2293; ORME I, COMMUNICATION; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; Pena SV, 1997, J IMMUNOL, V158, P2680; QUAN PC, 1982, J IMMUNOL, V128, P1786; ROGERS RA, 1993, J CELL SCI, V106, P485; Stenger S, 1997, SCIENCE, V276, P1684, DOI 10.1126/science.276.5319.1684; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; YABE T, 1990, J EXP MED, V172, P1159, DOI 10.1084/jem.172.4.1159; YODOI J, 1985, J IMMUNOL, V134, P1623	37	805	875	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					121	125		10.1126/science.282.5386.121	http://dx.doi.org/10.1126/science.282.5386.121			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756476				2022-12-24	WOS:000076294900053
J	Tanabe, Y; William, C; Jessell, TM				Tanabe, Y; William, C; Jessell, TM			Specification of motor neuron identity by the MNR2 homeodomain protein	CELL			English	Article							DORSAL SPINAL-CORD; LIM HOMEOBOX GENES; SONIC HEDGEHOG; FLOOR PLATE; TRANSCRIPTION FACTOR; CELL PATTERN; FROG EMBRYOS; EXPRESSION; INDUCTION; TUBE	Sonic hedgehog signaling controls the differentiation of motor neurons in the ventral neural tube, but the intervening steps are poorly understood. A differential screen of a cDNA library derived from a single Shh-induced motor neuron has identified a novel homeobox gene, MNR2, expressed by motor neuron progenitors and transiently by postmitotic motor neurons. The ectopic expression of MNR2 in neural cells initiates a program of somatic motor neuron differentiation characterized by the expression of homeodomain proteins, by neurotransmitter phenotype, and by axonal trajectory. Our results suggest that the Shh-mediated induction of a single transcription factor, MNR2, is sufficient to direct somatic motor neuron differentiation.	Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007367] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32GM07367] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTABA ARI, 1995, MOL CELL NEUROSCI, V6, P106, DOI 10.1006/mcne.1995.1011; Anderson D, 1997, MOL CELLULAR APPROAC, P26; Bang AG, 1996, CURR OPIN NEUROBIOL, V6, P25, DOI 10.1016/S0959-4388(96)80005-5; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEGLEY CG, 1992, P NATL ACAD SCI USA, V89, P38, DOI 10.1073/pnas.89.1.38; Burke AC, 1996, DEV BIOL, V178, P192, DOI 10.1006/dbio.1996.0210; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Ding Q, 1998, DEVELOPMENT, V125, P2533; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; ERICSON J, 1992, SCIENCE, V256, P1555, DOI 10.1126/science.1350865; Fedtsova N, 1997, DEV BIOL, V190, P18, DOI 10.1006/dbio.1997.8691; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HARRISON KA, 1994, J BIOL CHEM, V269, P19968; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; Hynes M, 1997, NEURON, V19, P15, DOI 10.1016/S0896-6273(00)80344-X; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; Jurata LW, 1998, J BIOL CHEM, V273, P3152, DOI 10.1074/jbc.273.6.3152; LANGMAN J, 1966, J COMP NEUROL, V127, P399, DOI 10.1002/cne.901270308; LEBER SM, 1995, J NEUROSCI, V15, P1236; Lee J, 1997, DEVELOPMENT, V124, P2537; Liem KF, 1997, CELL, V91, P127, DOI 10.1016/S0092-8674(01)80015-5; Lo LC, 1998, DEVELOPMENT, V125, P609; Lumsden A, 1996, SCIENCE, V274, P1109, DOI 10.1126/science.274.5290.1109; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; Matise MP, 1998, DEVELOPMENT, V125, P2759; Morgan BA, 1996, METHOD CELL BIOL, V51, P185, DOI 10.1016/S0091-679X(08)60629-9; Osumi N, 1997, DEVELOPMENT, V124, P2961; Pabst O, 1998, MECH DEVELOP, V73, P85, DOI 10.1016/S0925-4773(98)00035-5; Pattyn A, 1997, DEVELOPMENT, V124, P4065; Pfaff S, 1998, CURR OPIN NEUROBIOL, V8, P27, DOI 10.1016/S0959-4388(98)80005-6; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; Roztocil T, 1997, DEVELOPMENT, V124, P3263; Saha MS, 1997, DEV BIOL, V187, P209, DOI 10.1006/dbio.1997.8625; SASAKI H, 1994, CELL, V76, P103, DOI 10.1016/0092-8674(94)90176-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; TANABE Y, 1995, CURR BIOL, V5, P651, DOI 10.1016/S0960-9822(95)00130-8; Tanabe Y, 1996, SCIENCE, V274, P1115, DOI 10.1126/science.274.5290.1115; TANAKA H, 1984, DEV BIOL, V106, P26, DOI 10.1016/0012-1606(84)90057-5; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; VarelaEchavarria A, 1996, MOL CELL NEUROSCI, V8, P242, DOI 10.1006/mcne.1996.0061; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; WESTENDORF JM, 1994, P NATL ACAD SCI USA, V91, P714, DOI 10.1073/pnas.91.2.714; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	51	287	293	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					67	80		10.1016/S0092-8674(00)81783-3	http://dx.doi.org/10.1016/S0092-8674(00)81783-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778248	hybrid			2022-12-24	WOS:000076242300011
J	Chan, WCW; Nie, SM				Chan, WCW; Nie, SM			Quantum dot bioconjugates for ultrasensitive nonisotopic detection	SCIENCE			English	Article							CADMIUM SELENIDE NANOCRYSTALS; RECEPTOR-MEDIATED ENDOCYTOSIS; CDSE NANOCRYSTALS; MOLECULES; POLYMER; ORGANIZATION; CLUSTERS; METAL; DNA	Highly luminescent semiconductor quantum dots (zinc sulfide-capped cadmium selenide) have been covalently coupled to biomolecules for use in ultrasensitive biological detection. In comparison with organic dyes such as rhodamine, this class of luminescent labels is 20 times as bright, 100 times as stable against photobleaching, and one-third as wide in spectral linewidth. These nanometer-sized conjugates are water-soluble and biocompatible, Quantum dots that were labeled with the protein transferrin underwent receptor-mediated endocytosis in cultured HeLa cells, and those dots that were labeled with immunomolecules recognized specific antibodies or antigens.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Nie, SM (corresponding author), Indiana Univ, Dept Chem, Bloomington, IN 47405 USA.		周, 伊静/I-4058-2018; Nie, Shuming/E-4843-2011					Alivisatos AP, 1996, SCIENCE, V271, P933, DOI 10.1126/science.271.5251.933; Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Andres RP, 1996, SCIENCE, V273, P1690, DOI 10.1126/science.273.5282.1690; Bangs LB, 1996, PURE APPL CHEM, V68, P1873, DOI 10.1351/pac199668101873; Blanton SA, 1996, APPL PHYS LETT, V69, P3905, DOI 10.1063/1.117565; BOWENKATARI JE, 1994, J PHYS CHEM-US, V98, P4109, DOI DOI 10.1021/J100066A034); BRUS L, 1991, APPL PHYS A-MATER, V53, P465, DOI 10.1007/BF00331535; CHAN WL, UNPUB; COLVIN VL, 1994, NATURE, V370, P354, DOI 10.1038/370354a0; DABBOUSI BO, 1995, APPL PHYS LETT, V66, P1316, DOI 10.1063/1.113227; Dabbousi BO, 1997, J PHYS CHEM B, V101, P9463, DOI 10.1021/jp971091y; DIAMANDIS EP, IMMUNOASSAY, P96; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Edwards DA, 1996, P NATL ACAD SCI USA, V93, P1786, DOI 10.1073/pnas.93.5.1786; HAUGLAND RP, 1995, HDB FLUORESCENT PROB; Heath JR, 1996, J PHYS CHEM-US, V100, P3144, DOI 10.1021/jp951903v; HENGLEIN A, 1989, CHEM REV, V89, P1861, DOI 10.1021/cr00098a010; Hermanson G. T., 1996, BIOCONJUGATE TECHNIQ; Hines MA, 1996, J PHYS CHEM-US, V100, P468, DOI 10.1021/jp9530562; ISSAC PG, 1994, PROTOCOLS NUCL ACID; Kricka L, 1995, NONISOTOPIC PROBING; Lu HP, 1997, NATURE, V385, P143, DOI 10.1038/385143a0; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; MURRAY CB, 1993, J AM CHEM SOC, V115, P8706, DOI 10.1021/ja00072a025; MURRAY CB, 1995, SCIENCE, V270, P1335, DOI 10.1126/science.270.5240.1335; Nirmal M, 1996, NATURE, V383, P802, DOI 10.1038/383802a0; PECK K, 1989, P NATL ACAD SCI USA, V86, P4087, DOI 10.1073/pnas.86.11.4087; Peng XG, 1998, J AM CHEM SOC, V120, P5343, DOI 10.1021/ja9805425; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; Speicher MR, 1996, NAT GENET, V12, P368, DOI 10.1038/ng0496-368; VandenBout DA, 1997, SCIENCE, V277, P1074, DOI 10.1126/science.277.5329.1074; WILSON WL, 1993, SCIENCE, V262, P1242, DOI 10.1126/science.262.5137.1242	32	6650	7262	39	2294	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2016	2018		10.1126/science.281.5385.2016	http://dx.doi.org/10.1126/science.281.5385.2016			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748158				2022-12-24	WOS:000076161800052
J	Solomin, L; Johansson, CB; Zetterstrom, RH; Bissonnette, RP; Heyman, RA; Olson, L; Lendahl, U; Frisen, J; Perlmann, T				Solomin, L; Johansson, CB; Zetterstrom, RH; Bissonnette, RP; Heyman, RA; Olson, L; Lendahl, U; Frisen, J; Perlmann, T			Retinoid-X receptor signalling in the developing spinal cord	NATURE			English	Article							ACID RECEPTOR; RESPONSE ELEMENT; NUCLEAR RECEPTORS; MOUSE DEVELOPMENT; FAS LIGAND; NGFI-B; EXPRESSION; GENE; RXR; DEHYDROGENASE	Retinoids regulate gene expression through the action of retinoic acid receptors (RARs) and retinoid-X receptors (RXRs), which both belong to the family of nuclear hormone receptors(1,2). Retinoids are of fundamental importance during development(2), but it has been difficult to assess the distribution of ligand-activated receptors in vivo. This is particularly the case for RXR, which is a critical unliganded auxiliary protein for several nuclear receptors, including RAR(1), but its ligand-activated role in vivo remains uncertain, Here we describe an assay in transgenic mice, based on the expression of an effector fusion protein linking the ligand-binding domain of either RXR or RAR to the yeast Gal4 DNA-binding domain, and the in situ detection of ligand-activated effector proteins by using an inducible transgenic lacZ reporter gene. We detect receptor activation in the spinal cord in a pattern that indicates that the receptor functions in the maturation of limb-innervating motor neurons. Our results reveal a specific activation pattern of Gal4-RXR which indicates that RXR is a critical bona fide receptor in the developing spinal cord.	Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Ligand Pharmaceut Inc, San Diego, CA 92121 USA	Ludwig Institute for Cancer Research; Karolinska Institutet; Karolinska Institutet; Ligand Pharmaceuticals	Perlmann, T (corresponding author), Ludwig Inst Canc Res, Stockholm Branch, POB 240, S-17177 Stockholm, Sweden.	thomas.perlmann@licr.ki.se		Lendahl, Urban/0000-0001-9543-8141; Zetterstrom, Rolf/0000-0002-3016-0019				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; BISSONNETTE RP, 1995, MOL CELL BIOL, V15, P5576; Botling J, 1997, J BIOL CHEM, V272, P9443; COLBERT MC, 1993, P NATL ACAD SCI USA, V90, P6572, DOI 10.1073/pnas.90.14.6572; Dupe V, 1997, DEVELOPMENT, V124, P399; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; HORTON C, 1995, DEV DYNAM, V202, P312, DOI 10.1002/aja.1002020310; Kastner P, 1997, DEVELOPMENT, V124, P313; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Lu HC, 1997, DEVELOPMENT, V124, P195; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MASCREZ B, IN PRESS DEVELOPMENT; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7194, DOI 10.1073/pnas.91.15.7194; MENDELSOHN C, 1991, DEVELOPMENT, V113, P723; Minucci S, 1997, MOL CELL BIOL, V17, P644, DOI 10.1128/MCB.17.2.644; Niederreither K, 1997, MECH DEVELOP, V62, P67, DOI 10.1016/S0925-4773(96)00653-3; NILSSON E, 1993, MOL REPROD DEV, V34, P149, DOI 10.1002/mrd.1080340206; PERLMANN T, 1995, GENE DEV, V9, P769, DOI 10.1101/gad.9.7.769; REYNOLDS K, 1991, MECH DEVELOP, V36, P15, DOI 10.1016/0925-4773(91)90068-H; ROSSANT J, 1991, GENE DEV, V5, P1333, DOI 10.1101/gad.5.8.1333; ROY DY, 1995, MOL CELL BIOL, V15, P6481; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WAGNER M, 1992, DEVELOPMENT, V116, P55; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YANG Y, 1995, J BIOL CHEM, V270, P18672, DOI 10.1074/jbc.270.31.18672; Zetterstrom RH, 1996, MOL ENDOCRINOL, V10, P1656, DOI 10.1210/me.10.12.1656; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	31	110	117	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					398	402		10.1038/26515	http://dx.doi.org/10.1038/26515			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759732				2022-12-24	WOS:000076083800058
J	Usrey, WM; Reppas, JB; Reid, RC				Usrey, WM; Reppas, JB; Reid, RC			Paired-spike interactions and synaptic efficacy of retinal inputs to the thalamus	NATURE			English	Article							LATERAL GENICULATE-NUCLEUS; NEOCORTICAL PYRAMIDAL NEURONS; PRIMARY VISUAL-CORTEX; GANGLION-CELLS; CAT; PLASTICITY	In many neural systems studied in vitro, the timing of afferent impulses affects the strength of postsynaptic potentials(1,2). The influence of afferent timing on postsynaptic firing in vivo has received less attention. Here we study the importance of afferent spike timing in vivo by recording simultaneously from ganglion cells in the retina and their targets in the lateral geniculate nucleus of the thalamus, When two spikes from a single ganglion-cell axon arrive within 30 milliseconds of each other, the second spike is much more likely than the first to produce a geniculate spike, an effect we call paired-spike enhancement. Furthermore, simultaneous recordings from a ganglion cell and two thalamic targets indicate that paired-spike enhancement increases the frequency of synchronous thalamic activity. We propose that information encoded in the high firing rate of an individual retinal ganglion cell becomes distributed among several geniculate neurons that fire synchronously. Because synchronous geniculate action potentials are highly effective in driving cortical neurons(3), it is likely that information encoded by this strategy is transmitted to the next level of processing.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Reid, RC (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	clay_reid@hms.harvard.edu						Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; Alonso JM, 1996, NATURE, V383, P815, DOI 10.1038/383815a0; Atluri PP, 1996, J NEUROSCI, V16, P5661; BLOOMFIELD SA, 1987, J PHYSIOL-LONDON, V383, P653; CLELAND BG, 1971, J PHYSIOL-LONDON, V217, P473, DOI 10.1113/jphysiol.1971.sp009581; CLELAND BG, 1971, NATURE-NEW BIOL, V231, P191, DOI 10.1038/newbio231191a0; CLELAND BG, 1986, VISUAL NEUROSCI, P111; DAN Y, IN PRESS NATURE NEUR; HAMOS JE, 1987, J COMP NEUROL, V259, P165, DOI 10.1002/cne.902590202; HUBEL DH, 1961, J PHYSIOL-LONDON, V155, P385, DOI 10.1113/jphysiol.1961.sp006635; KAPLAN E, 1987, J PHYSIOL-LONDON, V391, P267, DOI 10.1113/jphysiol.1987.sp016737; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KONIG P, 1996, TRENDS NEUROSCI, V22, P494; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; Markram H, 1996, NATURE, V382, P807, DOI 10.1038/382807a0; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MEISTER M, 1995, SCIENCE, V270, P1207, DOI 10.1126/science.270.5239.1207; MILLER KD, 1994, J NEUROSCI, V14, P409; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; PETERS A, 1993, CEREB CORTEX, V3, P69, DOI 10.1093/cercor/3.1.69; REID RC, 1995, NATURE, V378, P281, DOI 10.1038/378281a0; Reid RC, 1997, VISUAL NEUROSCI, V14, P1015, DOI 10.1017/S0952523800011743; Sutter E.E., 1992, NONLINEAR VISION, P171, DOI [10.1201/9781351075060-6, DOI 10.1201/9781351075060-6]; Sutter E.E., 1987, ADV METHODS PHYSIOLO, V1, P303; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; USREY WM, IN PRESS ANN REV PHY; Varela JA, 1997, J NEUROSCI, V17, P7926; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	29	169	171	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					384	387		10.1038/26487	http://dx.doi.org/10.1038/26487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759728				2022-12-24	WOS:000076083800054
J	Kaech, SM; Whitfield, CW; Kim, SK				Kaech, SM; Whitfield, CW; Kim, SK			The LIN-2/LIN-7/LIN-10 complex mediates basolateral membrane localization of the C-elegans EGF receptor LET-23 in vulval epithelial cells	CELL			English	Article							CAENORHABDITIS-ELEGANS; PDZ DOMAIN; MDCK CELLS; PROTEINS; BINDING; GENE; INDUCTION; POLARITY; ENCODES; PURIFICATION	In C. elegans, the LET-23 receptor tyrosine kinase is localized to the basolateral membranes of polarized vulval epithelial cells. lin-2, lin-7, and lin-10 are required for basolateral localization of LET-23, since LET-23 is mislocalized to the apical membrane in lin-2 lin-7, and lin-10 mutants. Yeast two-hybrid, in vitro binding, and in vivo coimmunoprecipitation experiments show that LIN-2, LIN-7, and LIN-10 form a protein complex. Furthermore, compensatory mutations in lin-7 and let-23 exhibit allele-specific suppression of apical mislocalization and signaling-defective phenotypes. These results present a mechanism for basolateral localization of LET-23 receptor tyrosine kinase by direct binding to the LIN-2/LIN-7/LIN-10 complex. Each of the binding interactions within this complex is conserved, suggesting that this complex may also mediate basolateral localization in mammals.	Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA	Stanford University	Kim, SK (corresponding author), Stanford Univ, Sch Med, Dept Dev Biol, Stanford, CA 94305 USA.				NIGMS NIH HHS [R01 GM043977] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043977] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; FERGUSON EL, 1985, GENETICS, V110, P17; Hata Y, 1996, J NEUROSCI, V16, P2488; HOBERT M, 1995, J CELL PHYSIOL, V162, P434, DOI 10.1002/jcp.1041620316; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hsueh YP, 1998, J CELL BIOL, V142, P139, DOI 10.1083/jcb.142.1.139; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; JANKNECHT R, 1991, P NATL ACAD SCI USA, V88, P8972, DOI 10.1073/pnas.88.20.8972; Jareb M, 1998, NEURON, V20, P855, DOI 10.1016/S0896-6273(00)80468-7; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; Marfatia SM, 1997, J BIOL CHEM, V272, P24191, DOI 10.1074/jbc.272.39.24191; Marfatia SM, 1996, J CELL BIOL, V135, P753, DOI 10.1083/jcb.135.3.753; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; Mellian I, 1995, COLD SPRING HARB SYM, V60, P745, DOI 10.1101/SQB.1995.060.01.080; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rongo C, 1998, CELL, V94, P751, DOI 10.1016/S0092-8674(00)81734-1; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Sheng M, 1996, NEURON, V17, P575, DOI 10.1016/S0896-6273(00)80190-7; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SIMSKE JS, 1996, CELL, V85, P2195; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Tejedor FJ, 1997, J NEUROSCI, V17, P152, DOI 10.1523/JNEUROSCI.17-01-00152.1997; Wood WB, 1988, NEMATODE CAENORHABDI; Zito K, 1997, NEURON, V19, P1007, DOI 10.1016/S0896-6273(00)80393-1	42	296	307	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					761	771		10.1016/S0092-8674(00)81735-3	http://dx.doi.org/10.1016/S0092-8674(00)81735-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753323	Green Accepted, Bronze			2022-12-24	WOS:000076021200009
J	Cohen, L; Henzel, WJ; Baeuerle, PA				Cohen, L; Henzel, WJ; Baeuerle, PA			IKAP is a scaffold protein of the I kappa B kinase complex	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; ALPHA PROTEOLYSIS; ACTIVATION; PHOSPHORYLATION; SIGNAL; FAMILY; CASCADE; STE5; BETA	The transcription factor NF-kappa B coordinates the activation of numerous genes in response to pathogens and pro-inflammatory cytokines, and is, therefore, vital in the development of acute and chronic inflammatory diseases(1-6). NF-kappa B is activated by phsophorylation of its inhibitory subunit, I kappa B-alpha (ref. 7), on serine residues 32 and 36 by cytokine-activated I kappa B kinases (IKKs); this phosphorylation precedes rapid degradation of I kappa B8-11. IKK-alpha and IKK-beta isozymes are found in large complexes of relative molecular mass 700,000-900,000 (M-r 70K-90K), but little is known about other components that organize and regulate these complexes(12-17). IKK-alpha was independently discovered as a NF-kappa B-inducing kinase(18) (NIK)-associated protein in a yeast two-hybrid screen(19), and IKK-beta was also identified by homology screening(20). It is, however, unknown whether NIK is part of the IKK complex. Here we isolate large, interleukin-1-inducible IKK complexes that contain NIK, IKK-alpha, IKK-beta, I kappa B-alpha, NF-kappa B/RelA and a protein of M-r 150K. This latter component is a new protein, termed IKK-complex-associated protein (IKAP), which can bind NIK and IKKs and assemble them into an active kinase complex. We show that IKAP is a scaffold protein and a regulator for three different kinases involved in pro-inflammatory cytokine signalling.	Tularik Inc, San Francisco, CA 94080 USA; Genentech Inc, San Francisco, CA 94080 USA	Roche Holding; Genentech	Baeuerle, PA (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.	baeuerle@tularik.com		Henzel, William/0000-0003-2940-3797				Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baeuerle PA, 1998, CURR BIOL, V8, pR19, DOI 10.1016/S0960-9822(98)70010-7; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; CHOI KY, 1994, CELL, V78, P499; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; HENZEL WJ, 1995, CURR PROT PROTEIN SC, V1; LEI L, 1998, P NATL ACAD SCI USA, V95, P3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MARCUS S, 1996, P NATL ACAD SCI USA, V271, P1128; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PRINTEN JA, 1994, GENETICS, V138, P609; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yajima H, 1997, BIOSCI BIOTECH BIOCH, V61, P704, DOI 10.1271/bbb.61.704; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	31	252	268	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					292	296		10.1038/26254	http://dx.doi.org/10.1038/26254			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751059				2022-12-24	WOS:000075974600055
J	Nelson, LS; Rosoff, ML; Li, C				Nelson, LS; Rosoff, ML; Li, C			Disruption of a neuropeptide gene, flp-1, causes multiple behavioral defects in Caenorhabditis elegans	SCIENCE			English	Article							C-ELEGANS; PRESYNAPTIC INHIBITION; FMRFAMIDE; PEPTIDES; PHE-MET-ARG-PHE-NH2; NEURONS; APLYSIA; SYSTEM; IDENTIFICATION; NOCICEPTION	Neuropeptides serve as important signaling molecules in the nervous system. The FMRFamide (Phe-Met-Arg-Phe-amide)-related neuropeptide gene family in the nematode Caenorhabditis elegans is composed of at Least 18 genes that may encode 53 distinct FMRFamide-related peptides. Disruption of one of these genes, flp-1, causes numerous behavioral defects, including uncoordination, hyperactivity, and insensitivity to high osmolarity. Conversely, overexpression of flp-1 results in the reciprocal phenotypes. On the basis of epistasis analysis, flp-1 gene products appear to signal upstream of a G protein-coupled second messenger system. These results demonstrate that varying the levels of FLP-1 neuropeptides can profoundly affect behavior and that members of this large neuropeptide gene family are not functionally redundant in C. elegans.	Boston Univ, Dept Biol, Boston, MA 02215 USA	Boston University	Li, C (corresponding author), Boston Univ, Dept Biol, 5 Cummington St, Boston, MA 02215 USA.	li@bu.edu			NIA NIH HHS [AG00708] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; BRENNER S, 1974, GENETICS, V77, P71; Brownlee DJA, 1996, PARASITOL TODAY, V12, P343, DOI 10.1016/0169-4758(96)10052-1; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; BRUNDAGE L, UNPUBAGE; BRUNDAGE L, COMMUNICATION; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHIBA O, 1992, NEUROSCI RES, V15, P255, DOI 10.1016/0168-0102(92)90046-F; CHIN GJ, 1994, BIOL BULL, V187, P185, DOI 10.2307/1542241; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; CULOTTI JG, 1978, GENETICS, V90, P243; DUSENBER.DB, 1974, J EXP ZOOL, V188, P41, DOI 10.1002/jez.1401880105; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; KAVALIERS M, 1990, NEUROSCI LETT, V115, P307, DOI 10.1016/0304-3940(90)90473-M; KAVALIERS M, 1993, NEUROSCI LETT, V157, P75, DOI 10.1016/0304-3940(93)90646-3; KUHLMAN JR, 1985, J NEUROSCI, V5, P2310; LINGUEGLIA E, 1995, NATURE, V378, P730, DOI 10.1038/378730a0; MACKEY SL, 1987, P NATL ACAD SCI USA, V84, P8730, DOI 10.1073/pnas.84.23.8730; Maule AG, 1996, PARASITOL TODAY, V12, P351, DOI 10.1016/0169-4758(96)10051-X; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; NAMBU JR, 1988, NEURON, V1, P55, DOI 10.1016/0896-6273(88)90209-7; Nelson LS, 1998, MOL BRAIN RES, V58, P103, DOI 10.1016/S0169-328X(98)00106-5; NELSON LS, UNPUB; NICHOLS R, 1988, J BIOL CHEM, V263, P12167; NICHOLS R, 1992, J MOL NEUROSCI, V3, P213, DOI 10.1007/BF03380141; PAYZA K, 1993, J NEUROCHEM, V60, P1894, DOI 10.1111/j.1471-4159.1993.tb13417.x; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RAFFA RB, 1988, PEPTIDES, V9, P915, DOI 10.1016/0196-9781(88)90141-6; ROSOFF ML, 1992, J NEUROSCI, V12, P2356; RUSHFORTH AM, 1993, MOL CELL BIOL, V13, P902, DOI 10.1128/MCB.13.2.902; SCHINKMANN K, 1992, J COMP NEUROL, V315, P1; SCHNEIDER LE, 1988, P NATL ACAD SCI USA, V85, P1993, DOI 10.1073/pnas.85.6.1993; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; SMALL SA, 1989, SCIENCE, V243, P1603, DOI 10.1126/science.2538924; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; TANG J, 1984, P NATL ACAD SCI-BIOL, V81, P5002, DOI 10.1073/pnas.81.15.5002; WARD S, 1973, P NATL ACAD SCI USA, V70, P817, DOI 10.1073/pnas.70.3.817; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; WONG TM, 1985, COMP BIOCHEM PHYS C, V81, P175, DOI 10.1016/0742-8413(85)90111-2; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431; Zwaal RR, 1996, CELL, V86, P619, DOI 10.1016/S0092-8674(00)80135-X	47	133	139	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1686	1690		10.1126/science.281.5383.1686	http://dx.doi.org/10.1126/science.281.5383.1686			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733518				2022-12-24	WOS:000075856500051
J	Xu, XHN; Yeung, ES				Xu, XHN; Yeung, ES			Long-range electrostatic trapping of single-protein molecules at a liquid-solid interface	SCIENCE			English	Article							CONFOCAL FLUORESCENCE MICROSCOPY; ZONE ELECTROPHORESIS; INDIVIDUAL MOLECULES; ENZYME; FRAGMENTS; DIFFUSION; FLOW	The motion of single, dye-labeled protein molecules was monitored at various pH and ionic strengths within the 180-nanometer-thick evanescent-field layer at a fused-silica surface. Below the isoelectric point, molecules partitioning into the excitation region increased in number but maintained a random spatial distribution, implying that surface charge can influence the charged protein at. distances beyond that of the electrical double-layer thickness. The residence times of the molecules in the interfacial layer also increased below the isoelectric point. However, immobilization on the solid surface for extended periods was not observed. Histograms of residence times exhibit nearly identical asymmetry as the corresponding elution peaks in capillary electrophoresis. These results are a direct verification of the statistical theory of chromatography at the single-molecule level, with the caveat that Long-range trapping rather than adsorption is the dominant mechanism.	Iowa State Univ, US DOE, Ames Lab, Ames, IA 50011 USA; Iowa State Univ, Dept Chem, Ames, IA 50011 USA	Iowa State University; United States Department of Energy (DOE); Ames National Laboratory; Iowa State University	Yeung, ES (corresponding author), Iowa State Univ, US DOE, Ames Lab, Ames, IA 50011 USA.							BARD AJ, 1980, ELECTROCHEMICAL METH, P488; Behrens SH, 1998, LANGMUIR, V14, P1951, DOI 10.1021/la971237k; BOCKRIS JO, 1970, MODERN ELECTROCHEMIS, V2, P826; Craig DB, 1996, J AM CHEM SOC, V118, P5245, DOI 10.1021/ja9540839; Derjaguin B. V., 1941, ACTA PHYSICOCHIM URS, V14, P633, DOI DOI 10.1016/0079-6816(93)90013-L; Dickson RM, 1996, SCIENCE, V274, P966, DOI 10.1126/science.274.5289.966; EIGEN M, 1994, P NATL ACAD SCI USA, V91, P5740, DOI 10.1073/pnas.91.13.5740; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GUTIERREZ C, 1990, SPECTROSCOPIC DIFFRA, P1; Iki N, 1996, ANAL CHEM, V68, P4321, DOI 10.1021/ac9605814; LAMBERT WJ, 1990, ANAL CHEM, V62, P1585, DOI 10.1021/ac00214a009; Larsen AE, 1997, NATURE, V385, P230, DOI 10.1038/385230a0; LIPKOWSKI J, 1993, STRUCTURE ELECTRIFIE, P201; Lyon WA, 1997, ANAL CHEM, V69, P3400, DOI 10.1021/ac9700742; MARTIN M, 1984, ANAL CHEM, V56, P614, DOI 10.1021/ac00268a006; MIKKERS FEP, 1979, J CHROMATOGR, V169, P11, DOI 10.1016/0021-9673(75)85029-1; NIE SM, 1994, SCIENCE, V266, P1018, DOI 10.1126/science.7973650; NIE SM, 1995, ANAL CHEM, V67, P2849, DOI 10.1021/ac00113a019; PETTY JT, 1995, ANAL CHEM, V67, P1755, DOI 10.1021/ac00106a017; REIJENGA JC, 1983, J CHROMATOGR, V260, P241, DOI 10.1016/0021-9673(83)80034-X; RICE CL, 1965, J PHYS CHEM-US, V69, P4017, DOI 10.1021/j100895a062; ROERAADE J, 1996, 8 INT S HIGH PERF CA; Schmidt T, 1996, P NATL ACAD SCI USA, V93, P2926, DOI 10.1073/pnas.93.7.2926; Skoog D.A, 1992, PRINCIPLES INSTRUMEN, P579; STEVENS TS, 1983, ANAL CHEM, V55, P1365, DOI 10.1021/ac00259a040; Tan WH, 1997, ANAL CHEM, V69, P4242, DOI 10.1021/ac970631k; VERVWEY EJW, 1948, THEORY STABILITY LYO; Xu XH, 1997, SCIENCE, V275, P1106, DOI 10.1126/science.275.5303.1106; XUE QF, 1995, NATURE, V373, P681, DOI 10.1038/373681a0	29	158	172	2	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1650	1653		10.1126/science.281.5383.1650	http://dx.doi.org/10.1126/science.281.5383.1650			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733506				2022-12-24	WOS:000075856500039
J	Khan, MA; Herzog, CA; St Peter, JV; Hartley, GG; Madlon-Kay, R; Dick, CD; Asinger, RW; Vessey, JT				Khan, MA; Herzog, CA; St Peter, JV; Hartley, GG; Madlon-Kay, R; Dick, CD; Asinger, RW; Vessey, JT			The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TERM WEIGHT CONTROL; FENFLURAMINE PLUS PHENTERMINE; CARCINOID HEART-DISEASE; DOPPLER-ECHOCARDIOGRAPHY; TRICUSPID REGURGITATION; BEHAVIOR-MODIFICATION; MITRAL REGURGITATION; AORTIC REGURGITATION; CALORIC RESTRICTION; OPEN-LABEL	Background. After case reports of cardiac-valve abnormalities related to the use of appetite suppressants were published, we undertook a study to determine the prevalence of the problem using transthoracic echocardiography. Methods. We examined patients who had taken dexfenfluramine alone, dexfenfluramine and phentermine, or fenfluramine and phentermine for various periods. We enrolled obese patients who had taken or were taking these agents during open-label trials from January 1994 through August 1997. We also recruited subjects who had not taken appetite suppressants and who were matched to the patients for sex, height, and pretreatment age and body-mass index. The presence of cardiac-valve abnormalities, defined by the Food and Drug Administration and Centers for Disease Control and Prevention as at least mild aortic-valve or moderate mitral-valve insufficiency, was determined independently by at least two cardiologists. Multivariate logistic-regression analysis was used to identify factors associated with cardiac-valve abnormalities. Results. Echocardiograms were available for 257 patients and 239 control subjects. The association between the use of any appetite suppressant and cardiac-valve abnormalities was analyzed in a final matched group of 233 pairs of patients and controls. A total of 1.3 percent of the controls (3 of 233) and 22.7 percent of the patients (53 of 233) met the case definition for cardiac-valve abnormalities (odds ratio, 22.6; 95 percent confidence interval, 7.1 to 114.2; P < 0.001). The odds ratio for such cardiac-valve abnormalities was 12.7 (95 percent confidence interval, 2.9 to 56.4) with the use of dexfenfluramine alone, 24.5 (5.9 to 102.2) with the use of dexfenfluramine and phentermine, and 26.3 (7.9 to 87.1) with the use of fenfluramine and phentermine. Conclusions. Obese patients who took fenfluramine and phentermine, dexfenfluramine alone, or dexfenfluramine and phentermine had a significantly higher prevalence of cardiac valvular insufficiency than a matched group of control subjects. (N Engl J Med 1998;339:713-8.) (C) 1998, Massachusetts Medical Society.	Hennepin Cty Med Ctr, Dept Med, Div Endocrinol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Med, Div Cardiol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Med, Div Internal Med, Minneapolis, MN 55415 USA; Hlth Syst Minnesota, Minneapolis, MN USA; Minnesota Heart Clin, Minneapolis, MN USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Minnesota Obes Ctr, Minneapolis, MN USA	Hennepin County Medical Center; Hennepin County Medical Center; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Khan, MA (corresponding author), Hennepin Cty Med Ctr, Dept Med, Div Endocrinol, 701 Pk Ave,865B, Minneapolis, MN 55415 USA.		StPeter, John/N-1140-2019	St. Peter, John/0000-0003-4359-7524	NIDDK NIH HHS [3P30-DK50456-03S1] Funding Source: Medline; SAMHSA HHS [MOA-5960] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK050456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); SAMHSA HHS; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKASAKA T, 1987, CIRCULATION, V76, P262, DOI 10.1161/01.CIR.76.2.262; BARGIGGIA GS, 1991, CIRCULATION, V84, P1481, DOI 10.1161/01.CIR.84.4.1481; BERGER M, 1985, J AM COLL CARDIOL, V6, P359, DOI 10.1016/S0735-1097(85)80172-8; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Connolly HM, 1997, NEW ENGL J MED, V337, P1783; CURRIE PJ, 1985, J AM COLL CARDIOL, V6, P750, DOI 10.1016/S0735-1097(85)80477-0; DOLAN MS, 1995, AM HEART J, V129, P1014, DOI 10.1016/0002-8703(95)90125-6; ENRIQUEZSARANO M, 1994, J AM COLL CARDIOL, V23, P443, DOI 10.1016/0735-1097(94)90432-4; GRAY GW, 1995, AVIAT SPACE ENVIR MD, V66, P32; HARTLEY GG, 1997, OBES RES S1, V5, pS58; KHAN MA, 1997, OBES RES S1, V5, pS22; Kushner R, 1997, ARCH INTERN MED, V157, P602, DOI 10.1001/archinte.157.6.602; PELLIKKA PA, 1993, CIRCULATION, V87, P1188, DOI 10.1161/01.CIR.87.4.1188; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; REID CL, 1994, CIRCULATION, V90, P282; ROBIOLIO PA, 1995, CIRCULATION, V92, P790, DOI 10.1161/01.CIR.92.4.790; STRYDOM AJC, 1992, CLIN CHEM, V38, P323; TRIBOUILLOY C, 1991, EUR HEART J, V12, P352, DOI 10.1093/oxfordjournals.eurheartj.a059901; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P615, DOI 10.1038/clpt.1992.73; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P581, DOI 10.1038/clpt.1992.68; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P586, DOI 10.1038/clpt.1992.69; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P642, DOI 10.1038/clpt.1992.76; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P608, DOI 10.1038/clpt.1992.72; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P634, DOI 10.1038/clpt.1992.75; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P619, DOI 10.1038/clpt.1992.74; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P595, DOI 10.1038/clpt.1992.70; WEINTRAUB M, 1992, CLIN PHARMACOL THER, V51, P602, DOI 10.1038/clpt.1992.71; YOCK PG, 1984, CIRCULATION, V70, P657, DOI 10.1161/01.CIR.70.4.657	29	189	189	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					713	718		10.1056/NEJM199809103391101	http://dx.doi.org/10.1056/NEJM199809103391101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731086				2022-12-24	WOS:000075737800001
J	Nolte, RT; Wisely, GB; Westin, S; Cobb, JE; Lambert, MH; Kurokawa, R; Rosenfeld, MG; Willson, TM; Glass, CK; Milburn, MV				Nolte, RT; Wisely, GB; Westin, S; Cobb, JE; Lambert, MH; Kurokawa, R; Rosenfeld, MG; Willson, TM; Glass, CK; Milburn, MV			Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma	NATURE			English	Article							THYROID-HORMONE RECEPTOR; NUCLEAR-RECEPTOR; TRANSACTIVATION DOMAIN; TRANSCRIPTIONAL COACTIVATOR; ESTROGEN-RECEPTOR; CRYSTAL-STRUCTURE; RETINOIC ACID; AF-2 ACTIVITY; FATTY-ACIDS; RXR-ALPHA	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a ligand-dependent transcription factor that is Important in adipocyte differentiation and glucose homeostasis and which depends on Interactions with co-activators, including steroid receptor co-activating factor-1 (SRC-1), Here we present the X-ray crystal structure of the human apo-PPAR-gamma ligand-binding domain (LBD), at 2.2 Angstrom resolution; this structure reveals a large binding pocket, which may explain the diversity of ligands for PPAR-gamma, We also describe the ternary complex containing the PPAR-gamma LED, the antidiabetic ligand rosiglitazone (BRL49653), and 88 amino acids of human SRC-1 at 2.3 Angstrom resolution. Glutamate and lysine residues that are highly conserved in LBDs of nuclear receptors form a 'charge clamp' that contacts backbone atoms of the LXXLL helices of SRC-1. These results, together with the observation that two consecutive LXXLL motifs of SRC-1 make identical contacts with both subunits of a PPAR-gamma homodimer, suggest a general mechanism for the assembly of nuclear receptors with co-activators.	Glaxo Wellcome Inc, Res & Dev, Div Chem, Dept Struct Chem, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Inc, Res & Dev, Div Chem, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	GlaxoSmithKline; GlaxoSmithKline; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Milburn, MV (corresponding author), Glaxo Wellcome Inc, Res & Dev, Div Chem, Dept Struct Chem, Res Triangle Pk, NC 27709 USA.		Glass, Christopher/AAI-3933-2021; feinstein, doug/M-9414-2019	Glass, Christopher/0000-0003-4344-3592; 				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; BRUNGER A, 1992, XPLOR VERSION 3 0 SY; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Buckle DR, 1996, BIOORG MED CHEM LETT, V6, P2127, DOI 10.1016/0960-894X(96)00382-4; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Feng X, 1997, GENE DEV, V11, P59, DOI 10.1101/gad.11.1.59; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Henttu PMA, 1997, MOL CELL BIOL, V17, P1832, DOI 10.1128/MCB.17.4.1832; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Hulin B, 1996, CURR PHARM DESIGN, V2, P85; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KEEN H, 1994, NEW ENGL J MED, V331, P1226, DOI 10.1056/NEJM199411033311812; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; TONE Y, 1994, J BIOL CHEM, V269, P31157; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; Zhu YJ, 1996, GENE EXPRESSION, V6, P185	47	1606	1661	3	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					137	143		10.1038/25931	http://dx.doi.org/10.1038/25931			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744270				2022-12-24	WOS:000075829900031
J	Tsai, TF; Popovici, F; Cernescu, C; Campbell, GL; Nedelcu, NI; Laurentia, V; Spantulescu, L; Chitu, V; Ruta, S; Tardei, G; Craciun, D; Nicolaiciuc, D; Pitigoi, D; Ceianu, C; Nicolescu, G; Ungureanu, A; Vladimirescu, LA; Deubel, V; LeGuenno, B; Han, L; Savage, H; Tengelsen, L; Tengelsen, EA; Knauert, F; Mangiafico, JA; Rossi, C				Tsai, TF; Popovici, F; Cernescu, C; Campbell, GL; Nedelcu, NI; Laurentia, V; Spantulescu, L; Chitu, V; Ruta, S; Tardei, G; Craciun, D; Nicolaiciuc, D; Pitigoi, D; Ceianu, C; Nicolescu, G; Ungureanu, A; Vladimirescu, LA; Deubel, V; LeGuenno, B; Han, L; Savage, H; Tengelsen, L; Tengelsen, EA; Knauert, F; Mangiafico, JA; Rossi, C		Investigative Team	West Nile encephalitis epidemic in southeastern Romania	LANCET			English	Article							VIRUSES	Background West Nile fever (WNF) is a mosquito-borne flavivirus infection endemic in Africa and Asia. In 1996, the first major WNF epidemic in Europe occurred in Romania, with a high rate of neurological infections. We investigated the epidemic to characterise transmission patterns in this novel setting and to determine its origin. Methods Hospital-based surveillance identified patients admitted with acute aseptic meningitis and encephalitis in 40 Romanian districts, including Bucharest. Infection was confirmed with IgM capture and indirect IgG ELISAs. In October, 1996, we surveyed outpatients in Bucharest and seven other districts to estimate seroprevalence and to detect infected patients not admitted to hospital. We also measured the rates of infection and seropositivity in mosquitoes and birds, respectively. Results Between July 15 and Oct 12, we identified 393 patients with serologically confirmed or probable WNF infection, of whom 352 had acute central-nervous-system infections. 17 patients older than 50 years died. Fatality/case ratio and disease incidence increased with age. The outbreak was confined to 14 districts In the lower Danube valley and Bucharest (attack rate 12.4/100 000 people) with a seroprevalence of 4.1%. The number of mild cases could not be estimated. WN virus was recovered from Culex pipiens mosquitoes, the most likely vector, and antibodies to WN virus were found in 41% of domestic fowl. Interpretation The epidemic in Bucharest reflected increased regional WNF transmission in 1996. Epidemics of Cx pipiens-borne WNF could occur in other European cities with conditions conducive to transmission.	Ctr Dis Control, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA; Bucharest Prevent Med Ctr, Bucharest, Romania; Inst Virol, Bucharest, Romania; Minist Hlth, Bucharest, Romania; Cantacuzino Inst, Bucharest, Romania; Ctr Natl Reference Fievres Hemorrag & Arbovirus, Paris, France; Ctr Dis Control & Prevent, Ft Collins, CO USA; US Army Med Res Inst Infect Dis, Fort Detrick, MD USA	Romanian Academy of Sciences; Stefan S. Nicolau Institute of Virology; Cantacuzino Institute Bucharest; Centers for Disease Control & Prevention - USA; United States Army Medical Research Institute of Infectious Diseases; United States Department of Defense; United States Army	Tsai, TF (corresponding author), Ctr Dis Control, Div Vector Borne Infect Dis, Ft Collins, CO 80522 USA.		Ceianu, Cornelia-Svetlana/A-7423-2018; Ruta, Simona/A-9569-2010; Institute of Virology, Stefan S Nicolau/HGE-9069-2022	Ruta, Simona/0000-0002-2492-6073; 				Berthet FX, 1997, J GEN VIROL, V78, P2293, DOI 10.1099/0022-1317-78-9-2293; Curry-Lindahl K., 1981, BIRD MIGRATION AFRIC, V1; DARWISH MA, 1987, T ROY SOC TROP MED H, V81, P1001, DOI 10.1016/0035-9203(87)90378-6; DRAGANESCU N, 1991, Revue Roumaine de Virologie, V42, P47; Draganescu N., 1993, Revue Roumaine de Virologie, V44, P207; DRAGANESCU N, 1989, REV ROUM MED VIROL, V40, P257; DUCA E, 1963, REV MED CHIR SOC MED, V67, P399; El-Harrak M., 1997, VIROLOGIE, V1, P248; ESPMARK A, 1984, AM J TROP MED HYG, V33, P1203, DOI 10.4269/ajtmh.1984.33.1203; FLATAU E, 1981, ISRAEL J MED SCI, V17, P1057; GADOTH N, 1979, ARCH NEUROL-CHICAGO, V36, P172, DOI 10.1001/archneur.1979.00500390090012; GEORGE S, 1987, INDIAN J MED RES, V86, P131; GEORGES AJ, 1987, ANN INST PASTEUR VIR, V138, P237, DOI 10.1016/S0769-2617(87)80007-2; KLINGBERG MA, 1959, P 6 INT C TROP MED, V5, P132; LeGuenno B, 1996, LANCET, V348, P1315, DOI 10.1016/S0140-6736(05)65799-6; Lundstrom J. O., 1994, Bulletin of the Society for Vector Ecology, V19, P23; MARBERG K, 1956, AM J HYG, V64, P259, DOI 10.1093/oxfordjournals.aje.a119838; MCINTOSH BM, 1976, S AFR J SCI, V72, P295; MISKOLCZY D, 1958, NEUROLOGIA PSIHIATRI, V2, P139; MITCHELL CJ, 1995, J VECTOR ECOL, V20, P44; MONATH TP, 1997, CLIN VIROLOGY, P1133; PANTHIER R, 1968, ANN I PASTEUR PARIS, V115, P435; PEIRIS JSM, 1994, HDB ZOONOSES B, P139; PERELMAN A, 1974, AM J TROP MED HYG, V23, P1150, DOI 10.4269/ajtmh.1974.23.1150; PURI B, 1994, ARCH VIROL, V134, P29, DOI 10.1007/BF01379104; TAYLOR RM, 1956, AM J TROP MED HYG, V5, P579, DOI 10.4269/ajtmh.1956.5.579; TOPCIU V, 1968, ARCH ROUM PATHOL EXP, V27, P531; Tsai Theodore F., 1995, P980; VARSANO N, 1982, ISRAEL J MED SCI, V18, P11; YUKIO S, 1991, VIROLOGY, V182, P753; 1995, LOUISIANA MORBIDITY, V5, P3	31	543	581	0	37	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					767	771		10.1016/S0140-6736(98)03538-7	http://dx.doi.org/10.1016/S0140-6736(98)03538-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737281				2022-12-24	WOS:000075762700010
J	Chawla, S; Hardingham, GE; Quinn, DR; Bading, H				Chawla, S; Hardingham, GE; Quinn, DR; Bading, H			CBP: A signal-regulated transcriptional coactivator controlled by nuclear calcium and CaM kinase IV	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; C-FOS PROMOTER; GENE-EXPRESSION; CYTOPLASMIC CALCIUM; COMPLEX-FORMATION; MAP KINASE; ACTIVATION; CREB; PHOSPHORYLATION; GROWTH	Recruitment of the coactivator, CREB binding protein (CBP), by signal-regulated transcription factors, such as CREB [adenosine 3',5'-monophosphate (cAMP) response element binding protein]. is critical for stimulation of gene expression. The mouse pituitary cell line AtT20 was used to show that the CBP recruitment step (CREB phosphorylation on serine-133) can be uncoupled from CREB/CBP-activated transcription. CBP was found to contain a signal-regulated transcriptional activation domain that is controlled by nuclear calcium and calcium/calmodulin-dependent (CaM) protein kinase IV and by cAMP, Cytoplasmic calcium signals that stimulate the Ras mitogen-activated protein kinase signaling cascade or expression of the activated form of Ras provided the CBP recruitment signal but did not increase CBP activity and failed to activate CREB- and CBP-mediated transcription. These results identify CBP as a signal-regulated transcriptional coactivator and define a regulatory role for nuclear calcium and cAMP in CBP-dependent gene expression.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bading, H (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Hardingham, Giles/0000-0002-7629-5314				Anderson KA, 1997, MOL ENDOCRINOL, V11, P725, DOI 10.1210/me.11.6.725; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bading H, 1997, BIOCHEM BIOPH RES CO, V236, P541, DOI 10.1006/bbrc.1997.7037; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHAWLA SK, UNPUB; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; Johnson CM, 1997, J NEUROSCI, V17, P6189; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kee BL, 1996, J BIOL CHEM, V271, P2373, DOI 10.1074/jbc.271.5.2373; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Parker D, 1996, MOL CELL BIOL, V16, P694; ROSEN LB, 1994, NEURON, V12, P1207, DOI 10.1016/0896-6273(94)90438-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	43	371	374	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1505	1509		10.1126/science.281.5382.1505	http://dx.doi.org/10.1126/science.281.5382.1505			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727976				2022-12-24	WOS:000075738100040
J	Shi, YG; Wang, YF; Jayaraman, L; Yang, HJ; Massague, J; Pavletich, NP				Shi, YG; Wang, YF; Jayaraman, L; Yang, HJ; Massague, J; Pavletich, NP			Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-beta signaling	CELL			English	Article							GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; TUMOR-SUPPRESSOR; RECOGNITION; DPC4; TRANSDUCTION; PATHWAYS; NUCLEUS; COMPLEX; KINASE	The Smad family of proteins, which are frequently targeted by tumorigenic mutations in cancer, mediate TGF-beta signaling from cell membrane to nucleus. The crystal structure of a Smad3 MH1 domain bound to an optimal DNA sequence determined at 2.8 Angstrom resolution reveals a novel DNA-binding motif. In the crystals, base-specific DNA recognition is provided exclusively by a conserved Ii-residue beta hairpin that is embedded in the major groove of DNA. A surface loop region, to which tumorigenic mutations map, has been identified as a functional surface important for Smad activity. This structure establishes a framework for understanding how Smad proteins may act in concert with other transcription factors in the regulation of TGF-beta-responsive genes.	Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA; Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA	Princeton University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center	Shi, YG (corresponding author), Princeton Univ, Dept Mol Biol, Lewis Thomas Lab, Princeton, NJ 08544 USA.			Massague, Joan/0000-0001-9324-8408; Shi, Yigong/0000-0003-2030-168X				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Chen Y, 1997, P NATL ACAD SCI USA, V94, P12938, DOI 10.1073/pnas.94.24.12938; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hicks GR, 1995, ANNU REV CELL DEV BI, V11, P155, DOI 10.1146/annurev.cb.11.110195.001103; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KLAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lechleider RJ, 1996, J BIOL CHEM, V271, P17617, DOI 10.1074/jbc.271.30.17617; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; MacGrogan D, 1997, ONCOGENE, V15, P1111, DOI 10.1038/sj.onc.1201232; Massague J, 1996, CANCER SURV, V27, P41; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; Saenger W., 1984, PRINCIPLES NUCL ACID; Schutte M, 1996, CANCER RES, V56, P2527; Shi YG, 1997, NATURE, V388, P87, DOI 10.1038/40431; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	41	584	614	1	73	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					585	594		10.1016/S0092-8674(00)81600-1	http://dx.doi.org/10.1016/S0092-8674(00)81600-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741623	Bronze			2022-12-24	WOS:000075851900006
J	Zhang, LI; Tao, HW; Holt, CE; Harris, WA; Poo, MM				Zhang, LI; Tao, HW; Holt, CE; Harris, WA; Poo, MM			A critical window for cooperation and competition among developing retinotectal synapses	NATURE			English	Article							LONG-TERM POTENTIATION; OCULAR DOMINANCE COLUMNS; VISUAL-CORTEX; NMDA RECEPTORS; MAP FORMATION; SEGREGATION; PROJECTION; CELLS; CONNECTIVITY; TRANSMISSION	In the developing frog visual system, topographic refinement of the retinotectal projection depends on electrical activity. In vivo whole-cell recording from developing Xenopus tectal neurons shows that convergent retinotectal synapses undergo activity-dependent cooperation and competition following correlated pre- and postsynaptic spiking within a narrow time window. Synaptic inputs activated repetitively within 20 ms before spiking of the tectal neuron become potentiated, whereas subthreshold inputs activated within 20 ms after spiking become depressed. Thus both the initial synaptic strength and the temporal order of activation are critical for heterosynaptic interactions among convergent synaptic inputs during activity-dependent refinement of developing neural networks.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	mpooe@ucsd.edu	Tao, Huizhong W/HDM-9767-2022	Holt, Christine Elizabeth/0000-0003-2829-121X				[Anonymous], [No title captured]; ARTOLA A, 1987, NATURE, V330, P649, DOI 10.1038/330649a0; BEAR MF, 1987, SCIENCE, V237, P42, DOI 10.1126/science.3037696; BEAR MF, 1992, J NEUROPHYSIOL, V67, P1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brickley SG, 1998, J NEUROSCI, V18, P1491; BROWN TH, 1990, ANNU REV NEUROSCI, V13, P475, DOI 10.1146/annurev.ne.13.030190.002355; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Debanne D, 1998, J PHYSIOL-LONDON, V507, P237, DOI 10.1111/j.1469-7793.1998.237bu.x; FREGNAC Y, 1994, J NEUROPHYSIOL, V71, P1403, DOI 10.1152/jn.1994.71.4.1403; Gerstner W, 1997, J COMPUT NEUROSCI, V4, P79, DOI 10.1023/A:1008820728122; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS WA, 1980, J COMP NEUROL, V194, P303, DOI 10.1002/cne.901940203; Hebb D.O., 1949, ORG BEHAV; HICKMOTT PW, 1993, J NEUROSCI, V13, P4339; HOLT CE, 1993, J NEUROBIOL, V24, P1400, DOI 10.1002/neu.480241011; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; LEVAY S, 1980, J COMP NEUROL, V191, P1, DOI 10.1002/cne.901910102; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; Magee JC, 1997, SCIENCE, V275, P209, DOI 10.1126/science.275.5297.209; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; Markram H, 1997, SCIENCE, V275, P213, DOI 10.1126/science.275.5297.213; Mehta MR, 1997, P NATL ACAD SCI USA, V94, P8918, DOI 10.1073/pnas.94.16.8918; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; MOONEY R, 1993, NEURON, V10, P815, DOI 10.1016/0896-6273(93)90198-Z; NAVEU D, 1996, NEURON, V16, P619; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; OROURKE NA, 1990, NEURON, V5, P159, DOI 10.1016/0896-6273(90)90306-Z; Penn AA, 1998, SCIENCE, V279, P2108, DOI 10.1126/science.279.5359.2108; RAE J, 1991, J NEUROSCI METH, V37, P15, DOI 10.1016/0165-0270(91)90017-T; REH TA, 1985, J NEUROSCI, V5, P1132; SAKAGUCHI DS, 1985, J NEUROSCI, V5, P3228; SCHMIDT JT, 1993, J NEUROBIOL, V24, P384, DOI 10.1002/neu.480240310; SCHMIDT JT, 1990, J NEUROSCI, V10, P233; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; STRYKER MP, 1986, J NEUROSCI, V6, P2117; UDIN SB, 1988, ANNU REV NEUROSCI, V11, P289, DOI 10.1146/annurev.ne.11.030188.001445; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WONG ROL, 1995, NATURE, V374, P716, DOI 10.1038/374716a0; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972	50	618	632	1	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					37	44		10.1038/25665	http://dx.doi.org/10.1038/25665			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738497				2022-12-24	WOS:000075722200038
J	Templeton, A; Morris, JK				Templeton, A; Morris, JK			Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GESTATION; IVF; PREGNANCIES; NUMBER; WOMEN	Background In vitro fertilization is associated with a high risk of multiple births, which is a direct consequence of the number of embryos transferred. However, other factors that contribute to the risk are not well defined. Methods Using the data base established by the Human Fertilisation and Embryology Authority in the United Kingdom, we studied the factors associated with an increased risk of multiple births in 44,236 cycles in 25,240 women. The factors included the woman's age, the cause and duration of infertility, previous attempts at in vitro fertilization, previous live births, number of eggs fertilized, and number of embryos transferred. Results Older age, tubal infertility, longer duration of infertility, and a higher number of previous attempts at in vitro fertilization were all associated with a significantly decreased chance of a birth and of multiple births. Previous live birth was associated with an increased chance of a birth but not of multiple births. The higher the number of eggs fertilized, the higher the likelihood of a live birth. When more than four eggs were fertilized, there was no increase in the birth rate for women receiving three transferred embryos as compared with those receiving two, but there was a considerable increase in the rate of multiple births when three were transferred (odds ratio, 1.6; 95 percent confidence interval, 1.5 to 1.8). Conclusions Among women undergoing in vitro fertilization, the chances of a live birth are related to the number of eggs fertilized, presumably because of the greater selection of embryos for transfer. When more than four eggs are fertilized and available for transfer, the woman's chance of a birth is not diminished by transferring only two embryos. Transferring more embryos increases the risk of multiple births. (N Engl J Med 1998;339:573-7.) (C) 1998, Massachusetts Medical Society.	Human Fertilisat & Embryol Author, London, England; Wolfson Inst Prevent Med, Dept Environm & Prevent Med, London, England	University of London; Queen Mary University London	Templeton, A (corresponding author), Aberdeen Matern Hosp, Dept Obstet & Gynaecol, Cornhill Rd, Aberdeen AB25 2ZD, Scotland.		Morris, Joan/AAT-9211-2020	Morris, Joan/0000-0002-7164-612X				[Anonymous], 1995, FERTIL STERIL, V64, P13; AZEM F, 1995, FERTIL STERIL, V63, P1043, DOI 10.1016/S0015-0282(16)57545-1; Baldwin VJ., 1994, PATHOLOGY MULTIPLE P; Bronson R, 1997, HUM REPROD, V12, P1605, DOI 10.1093/humrep/12.8.1605; CALLAHAN TL, 1994, NEW ENGL J MED, V331, P244, DOI 10.1056/NEJM199407283310407; COHEN J, 1991, HUM REPROD, V6, P613, DOI 10.1093/oxfordjournals.humrep.a137393; CRAFT I, 1991, BRIT MED J, V303, P185, DOI 10.1136/bmj.303.6795.185; EASTON DF, 1991, STAT MED, V10, P1025, DOI 10.1002/sim.4780100703; Faber K, 1997, HUM REPROD, V12, P1614; *HUM FERT EMBR AUT, 1997, 6 HUM FERT EMBR AUTH; JONES HW, 1995, FERTIL STERIL, V63, P701, DOI 10.1016/S0015-0282(16)57468-8; LOGEROTLEBRUN H, 1995, FERTIL STERIL, V64, P746; MCLAREN A, 1985, P 12 STUD GROUP ROYA, P13; Roest J, 1997, FERTIL STERIL, V67, P290, DOI 10.1016/S0015-0282(97)81913-9; ROYSTON P, 1994, J R STAT SOC C-APPL, V43, P429, DOI 10.2307/2986270; Senoz S, 1997, J ASSIST REPROD GEN, V14, P192, DOI 10.1007/BF02766109; STAESSEN C, 1993, HUM REPROD, V8, P1650, DOI 10.1093/oxfordjournals.humrep.a137907; TASDEMIR M, 1995, HUM REPROD, V10, P2155; Templeton A, 1996, LANCET, V348, P1402, DOI 10.1016/S0140-6736(96)05291-9; Walters DE, 1996, HUM REPROD, V11, P10; Widra EA, 1996, FERTIL STERIL, V65, P103, DOI 10.1016/S0015-0282(16)58035-2	21	291	295	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					573	577		10.1056/NEJM199808273390901	http://dx.doi.org/10.1056/NEJM199808273390901			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718375				2022-12-24	WOS:000075552900001
J	Davidson, PW; Myers, GJ; Cox, C; Axtell, C; Shamlaye, C; Sloane-Reeves, J; Cernichiari, E; Needham, L; Choi, A; Wang, YN; Berlin, M; Clarkson, TW				Davidson, PW; Myers, GJ; Cox, C; Axtell, C; Shamlaye, C; Sloane-Reeves, J; Cernichiari, E; Needham, L; Choi, A; Wang, YN; Berlin, M; Clarkson, TW			Effects of prenatal and postnatal methylmercury exposure from fish consumption on neurodevelopment - Outcomes at 66 months of age in the Seychelles Child Development Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-UTERO EXPOSURE; POLYCHLORINATED-BIPHENYLS; MERCURY; DIET; HAIR; LEAD	Context.-Human neurodevelopmental consequences of exposure to methylmercury (MeHg) from eating fish remain a question of public health concern. Objective.-To study the association between MeHg exposure and the developmental outcomes of children in the Republic of Seychelles at 66 months of age. Design.-A prospective longitudinal cohort study. Participants.-A total of 711 of 779 cohort mother-child pairs initially enrolled in the Seychelles Child Development Study in 1989. Setting.-The Republic of Seychelles, an archipelago in the Indian Ocean where 85% of the population consumes ocean fish daily. Main Outcome Measures.-Prenatal and postnatal MeHg exposure and 6 age-appropriate neurodevelopmental tests: the McCarthy Scales of Children's Abilities, the Preschool Language Scale, the Woodcock-Johnson Applied Problems and Letter and Word Recognition Tests of Achievement, the Bender Gestalt test, and the Child Behavior Checklist. Results.-The mean maternal hair total mercury level was 6.8 ppm and the mean child hair total mercury level at age 66 months was 6.5 ppm. No adverse outcomes at 66 months were associated with either prenatal or postnatal MeHg exposure. Conclusion,-In the population studied, consumption of a diet high in ocean fish appears to pose no threat to developmental outcomes through 66 months of age.	Univ Rochester, Sch Med & Dent, Strong Ctr Dev Disabil, Rochester, NY 14642 USA; Republ Seychelles Minist Hlth, Victoria, Mahe, Seychelles; Ctr Dis Control & Prevent, Atlanta, GA USA; Univ Lund, Lund, Sweden	University of Rochester; Centers for Disease Control & Prevention - USA; Lund University	Davidson, PW (corresponding author), Univ Rochester, Sch Med & Dent, Strong Ctr Dev Disabil, Box 671,601 Elmwood Ave, Rochester, NY 14642 USA.	pdavidson@cc.urmc.rochester.edu	Myers, Gary J/I-4901-2013; Needham, Larry/E-4930-2011	Myers, Gary J/0000-0003-4317-015X; Wang, Yining/0000-0003-2763-1008	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001247] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES-07271, ES-05497, ES-01247] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Achenbach T.M., 1983, MANUAL CHILD BEHAV C; *AG TOX SUBST DIS, 1997, TOX PROF POL BIOPH U; AIREY D, 1983, SCI TOTAL ENVIRON, V31, P157, DOI 10.1016/0048-9697(83)90067-0; AMLER RW, 1996, PEDIAT ENV NEUROBEHA; [Anonymous], 1958, STANDARD PROGR MATRI; BELLINGER D, 1987, NEW ENGL J MED, V316, P1037, DOI 10.1056/NEJM198704233161701; BENDERSKY M, 1994, DEV PSYCHOL, V30, P484, DOI 10.1037/0012-1649.30.4.484; BENDERSKY M, 1995, J DEV BEHAV PEDIATR, V16, P89; BLOOM NS, 1992, CAN J FISH AQUAT SCI, V49, P1010, DOI 10.1139/f92-113; BOVET P, 1997, SEYCHELLES MED DENT, V1, P8; BROCK JW, 1996, J ANAL TOXICOL, V20, P1; Caldwell BM, 1984, HOME OBSERVATION MEA; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P705; Cernichiari E, 1995, NEUROTOXICOLOGY, V16, P613; Cook RD, 1982, RESIDUALS INFLUENCE; Cox C, 1995, NEUROTOXICOLOGY, V16, P727; Cox C, 1989, ENV RES, V31, P640; Davidson PW, 1995, NEUROTOXICOLOGY, V16, P665; Davidson PW, 1995, NEUROTOXICOLOGY, V16, P677; Egeland GM, 1997, SCIENCE, V278, P1904, DOI 10.1126/science.278.5345.1904; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; GRANDJEAN P, 1995, NEUROTOXICOLOGY, V16, P32; HUISMAN M, 1995, EARLY HUM DEV, V41, P111, DOI 10.1016/0378-3782(94)01611-R; IPCS, 1990, ENV HLTH CRIT 101 ME; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Kjellstrom T, 1989, 3642 NAT SWED ENV PR; Kjellstrom T, 1986, 3080 NAT SWED ENV BO; KOPPITZ EM, 1963, BENDER GESTALT TEST; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MARSH DO, 1980, ANN NEUROL, V7, P348, DOI 10.1002/ana.410070412; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P583; MATSUMOTO H, 1965, J NEUROPATH EXP NEUR, V24, P563, DOI 10.1097/00005072-196510000-00002; McCarthy D, 1972, MANUAL MCCARTHY SCAL; MCKEOWNEYSSEN GE, 1983, AM J EPIDEMIOL, V118, P470, DOI 10.1093/oxfordjournals.aje.a113652; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P639; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P653; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; RANDJEAN P, 1997, NEUROTOXICOL TERATOL, V19, P417; Sanderson K, 1996, SCI TOTAL ENVIRON, V186, P1, DOI 10.1016/S0048-9697(96)90032-7; Shamlaye CF, 1995, NEUROTOXICOLOGY, V16, P597; Smith JC, 1997, ARCH ENVIRON HEALTH, V52, P476, DOI 10.1080/00039899709602227; Swedish Expert Group, 1971, NORD HYG TIDSKR, V4, P1; Takeuchi T., 1968, MINAMATA DISEASE, P141; Weihe P, 1996, SCI TOTAL ENVIRON, V186, P141, DOI 10.1016/0048-9697(96)05094-2; *WHO, 1972, TECHN REP SER WHO, V505; WOODCOCK R, 1989, WOODCOCKJOHNSON TEST; Zimmerman IL., 1979, PRESCHOOL LANGUAGE S	47	494	507	5	60	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					701	707		10.1001/jama.280.8.701	http://dx.doi.org/10.1001/jama.280.8.701			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728641	Bronze			2022-12-24	WOS:000075446900031
J	Price, RW				Price, RW			Neuropathy complicating diffuse infiltrative lymphocytosis	LANCET			English	Editorial Material							PATHOGENESIS; INFECTION; CELLS		Univ Calif San Francisco, San Francisco Gen Hosp, Serv Neurol, San Francisco, CA 94110 USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	Price, RW (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Serv Neurol, San Francisco, CA 94110 USA.							DWYER E, 1993, J CLIN INVEST, V92, P495, DOI 10.1172/JCI116593; Gherardi RK, 1998, NEUROLOGY, V50, P1041, DOI 10.1212/WNL.50.4.1041; GUILLON JM, 1987, AM J MED, V82, P655, DOI 10.1016/0002-9343(87)90118-5; ITESCU S, 1993, J CLIN INVEST, V91, P2216, DOI 10.1172/JCI116448; Moulignier A, 1997, ANN NEUROL, V41, P438, DOI 10.1002/ana.410410406; Simpson David M., 1997, P189; TYOR WR, 1995, J ACQ IMMUN DEF SYND, V9, P379; Yang OO, 1997, ADV IMMUNOL, V66, P273, DOI 10.1016/S0065-2776(08)60600-8	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					592	594		10.1016/S0140-6736(05)79571-4	http://dx.doi.org/10.1016/S0140-6736(05)79571-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746016				2022-12-24	WOS:000075567400004
J	Hupe, JM; James, AC; Payne, BR; Lomber, SG; Girard, P; Bullier, J				Hupe, JM; James, AC; Payne, BR; Lomber, SG; Girard, P; Bullier, J			Cortical feedback improves discrimination between figure and background by V1, V2 and V3 neurons	NATURE			English	Article							MACAQUE MONKEY; VISUAL-CORTEX; CORTICOCORTICAL CONNECTIONS; AFFERENT CONNECTIVITY; RECEPTIVE-FIELD; AREAS V1; STRIATE; CAT; ORGANIZATION; SYSTEM	A single visual stimulus activates neurons in many different cortical areas. A major challenge in cortical physiology is to understand how the neural activity in these numerous active zones leads to a unified percept of the visual sct ne. The anatomical basis for these interactions is the dense network of connections that link the visual areas. Within this network, feedforward connections transmit signals from lower-order areas such as V1 or V2 to higher-order areas. In addition, there is a dense web of feedback connections which, despite their anatomical prominence(1,4), remain functionally mysterious(5-8). Here we show, using reversible inactivation of a higher-order area (monkey area V5/MT), that feedback connections serve to amplify and focus activity of neurons in lower-order areas, and that they are important in the differentiation of figure from ground, particularly in the case of stimuli of low visibility. More specifically, we show that feedback connections facilitate responses to objects moving within the classical receptive field; enhance suppression evoked by background stimuli in the surrounding region; and have the strongest effects for stimuli of low salience.	INSERM, F-69675 Bron, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Bullier, J (corresponding author), INSERM, 18 Ave Doyen Lepine, F-69675 Bron, France.	bullier@lyon151.inserm.fr	James, Andrew C/C-9307-2009; Lomber, Stephen/B-6820-2015; Girard, Pascal/C-6427-2009	James, Andrew C/0000-0002-2447-8549; Lomber, Stephen/0000-0002-3001-7909; 				ALONSO JM, 1993, EXP BRAIN RES, V93, P363; BENITA M, 1972, BRAIN RES, V36, P133, DOI 10.1016/0006-8993(72)90771-8; Brook V, 1983, REV PHYSL BIOCH PHAR, V95, P1; BULLIER J, 1994, PRIMARY VISUAL CORTE, V10, P301; DEYOE EA, 1990, VISUAL NEUROSCI, V5, P67, DOI 10.1017/S0952523800000080; Efron Bradley., 1994, INTRO BOOTSTRAP; Felleman DJ, 1997, J COMP NEUROL, V379, P21, DOI 10.1002/(SICI)1096-9861(19970303)379:1<21::AID-CNE3>3.0.CO;2-K; GIRARD P, 1992, J NEUROPHYSIOL, V67, P1; Johnson RR, 1996, J COMP NEUROL, V368, P383, DOI 10.1002/(SICI)1096-9861(19960506)368:3<383::AID-CNE5>3.0.CO;2-1; KENNEDY H, 1985, J NEUROSCI, V5, P2815; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; Lomber SG, 1996, P NATL ACAD SCI USA, V93, P1654, DOI 10.1073/pnas.93.4.1654; MIGNARD M, 1991, SCIENCE, V251, P1249, DOI 10.1126/science.1848727; NELSON JI, 1978, BRAIN RES, V139, P359, DOI 10.1016/0006-8993(78)90937-X; NEWSOME WT, 1988, J NEUROSCI, V8, P220; NOWAK LG, 1995, VISUAL NEUROSCI, V12, P371, DOI 10.1017/S095252380000804X; PASTERNAK T, 1994, CEREB CORTEX, V4, P247, DOI 10.1093/cercor/4.3.247; PERKEL DJ, 1986, J COMP NEUROL, V253, P374, DOI 10.1002/cne.902530307; Polyak S., 1957, VERTEBRATE VISUAL SY; RODMAN HR, 1989, J NEUROSCI, V9, P2033; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SALIN PA, 1992, J COMP NEUROL, V320, P415, DOI 10.1002/cne.903200402; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; SHIPP S, 1989, EUR J NEUROSCI, V1, P333, DOI 10.1111/j.1460-9568.1989.tb00799.x; SHIPP S, 1989, EUR J NEUROSCI, V1, P308; Vanduffel W, 1997, P NATL ACAD SCI USA, V94, P7617, DOI 10.1073/pnas.94.14.7617	27	620	623	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					784	787		10.1038/29537	http://dx.doi.org/10.1038/29537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723617				2022-12-24	WOS:000075503600046
J	Rogaeva, E; Premkumar, S; Song, YQ; Sorbi, S; Brindle, N; Paterson, A; Duara, R; Levesque, G; Yu, G; Nishimura, M; Ikeda, M; O'Toole, C; Kawarai, T; Jorge, R; Vilarino, D; Bruni, AC; Farrer, LA; St George-Hyslop, PH				Rogaeva, E; Premkumar, S; Song, YQ; Sorbi, S; Brindle, N; Paterson, A; Duara, R; Levesque, G; Yu, G; Nishimura, M; Ikeda, M; O'Toole, C; Kawarai, T; Jorge, R; Vilarino, D; Bruni, AC; Farrer, LA; St George-Hyslop, PH			Evidence for an Alzheimer disease susceptibility locus on chromosome 12 and for further locus heterogeneity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMYLOID PRECURSOR PROTEIN; EARLY-ONSET ALZHEIMERS; APOLIPOPROTEIN-E; CLINICAL-DIAGNOSIS; MISSENSE MUTATIONS; TYPE-4 ALLELE; GENE; LINKAGE; PRESENILIN-1; EPSILON-4	Context. - Alzheimer disease (AD) susceptibility genes have been identified on chromosomes 1, 14, 19, and 21, and a recent study has suggested a locus on chromosome 12. Objective. - To confirm or refute the existence of a familiar AD susceptibility locus on chromosome 12 in an independent sample of familial AD cases. Design.-Retrospective cohort study. DNA data for 6 chromosome 12 genetic markers were evaluated using parametric lod score and nonparametric linkage methods and linkage heterogeneity tests. The latter include the admixture test of homogeneity in the total group of families and the predivided sample test in families stratified by the presence or absence of an apolipoprotein E (APOE) epsilon 4 allele among affected members. Parametric analyses were repeated assuming autosomal dominant inheritance of AD and either age- and sex-dependent penetrance or zero penetrance for the analysis of unaffected relatives. Setting. - Clinical populations in the continental United States, Canada, Argentina, and Italy. Patients.-Fifty-three white families composed of multiple members affected with AD, from whom DNA samples were obtained from 173 patients with AD whose conditions were diagnosed using established criteria and from 146 nondemented relatives. Main Outcome Measure. - Presence of an APOE epsilon 4 allele among affected family members. Results. - Using parametric methods, no evidence for linkage to the region spanned by the chromosome 12 markers could be detected if familial AD is assumed to arise from the same genetic locus in all 53 families. However, significant evidence for linkage was detected in the presence of locus heterogeneity using the admixture test (odds ratio, 15, 135:1). The estimated proportion of linked families within the 53 families examined varied between 0.40 and 0.65, depending on the genetic model assumed and APOE status. The precise location of the AD gene could not be determined, but includes the entire region suggested previously. Nonparametric linkage analysis confirmed linkage to chromosome 12 with the strongest evidence at D12S96 (P < .001). Conclusions. - Our data provide independent confirmation of the existence of an AD susceptibility locus on chromosome 12 and suggest the existence of AD susceptibility genes on other chromosomes. Screening a larger set of families with additional chromosome markers will be necessary for identifying the chromosome 12 AD gene.	Univ Toronto, Dept Med, Div Neurol, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Clarke Inst Psychiat, Neurogenet Lab, Toronto, ON M5S 3H2, Canada; Toronto Hosp, Dept Med, Div Neurol, Toronto, ON M5T 2S8, Canada; Boston Univ, Sch Med, Genet Program, Boston, MA 02118 USA; Mt Sinai Med Ctr, Dept Neurol, Miami Beach, FL 33140 USA; Univ Florence, Dept Neurol & Psychiat, Firenze, Italy; Univ Buenos Aires, Hosp Clin, Dept Neurol, Buenos Aires, DF, Argentina; Ctr Reg Neurogenet ASL 6, Lamezia Terme, Italy	University of Toronto; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Boston University; Mount Sinai Medical Center; University of Florence; University of Buenos Aires	St George-Hyslop, PH (corresponding author), Univ Toronto, Dept Med, Div Neurol, Ctr Res Neurodegenerat Dis, Room 118,Tanz Neurosci Bldg,6 Queens Pk Crescent, Toronto, ON M5S 3H2, Canada.		Paterson, Andrew D/A-4088-2011; Song, You-qiang/C-4401-2009; Song, You-Qiang/E-5207-2011; Farrer, Lindsay/AAS-1035-2020; Kawarai, Toshitaka/C-2822-2013; Bruni, Amalia/K-5038-2016	Paterson, Andrew D/0000-0002-9169-118X; Kawarai, Toshitaka/0000-0003-4547-8131; Farrer, Lindsay/0000-0001-5533-4225; sorbi, sandro/0000-0002-0380-6670; Bruni, Amalia/0000-0003-3471-3343; St George-Hyslop, Peter/0000-0003-0796-7209; Song, You-Qiang/0000-0001-9407-2256	NATIONAL INSTITUTE ON AGING [R01AG009029, T32AG000115] Funding Source: NIH RePORTER; CIHR [37920] Funding Source: Medline; NIA NIH HHS [AG09029, T32-AG00115] Funding Source: Medline; Telethon [E.0352] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); CIHR(Canadian Institutes of Health Research (CIHR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Telethon(Fondazione Telethon)		Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CLERGETDARPOUX F, 1986, BIOMETRICS, V42, P393, DOI 10.2307/2531059; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Fagan AM, 1996, J BIOL CHEM, V271, P30121, DOI 10.1074/jbc.271.47.30121; Farrer LA, 1997, JAMA-J AM MED ASSOC, V278, P1349, DOI 10.1001/jama.1997.03550160069041; FARRER LA, 1990, NEUROLOGY, V40, P395, DOI 10.1212/WNL.40.3_Part_1.395; FARRER LA, 1993, GENET EPIDEMIOL, V10, P425, DOI 10.1002/gepi.1370100616; GEARING M, 1995, NEUROLOGY, V45, P461, DOI 10.1212/WNL.45.3.461; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HAASS C, 1994, J BIOL CHEM, V269, P17741; HODGE SE, 1983, AM J HUM GENET, V35, P1139; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; KARLINSKY H, 1992, NEUROLOGY, V42, P1445, DOI 10.1212/WNL.42.8.1445; KATZMAN R, 1986, NEW ENGL J MED, V314, P964, DOI 10.1056/NEJM198604103141506; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; Ott J., 1991, ANAL HUMAN GENETIC L; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; RISCH N, 1991, MULTIPOINT MAPPING L, V6, P183; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Roses A. D., 1995, American Journal of Human Genetics, V57, pA202; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCOTT WK, IN PRESS NEUROGENETI; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SMITH CAB, 1963, ANN HUM GENET, V27, P175, DOI 10.1111/j.1469-1809.1963.tb00210.x; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SUSUKI N, 1994, SCIENCE, V264, P1336; TEWILLIGER JD, 1994, HDB HUMAN GENETIC LI; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2	44	140	145	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					614	618		10.1001/jama.280.7.614	http://dx.doi.org/10.1001/jama.280.7.614			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718052	Bronze			2022-12-24	WOS:000075384300029
J	Shimm, DS				Shimm, DS			Chained smoker	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	University of Arizona; University of Arizona Health Sciences	Shimm, DS (corresponding author), Univ Arizona, Hlth Sci Ctr, Dept Radiat Oncol, 1501 N Campbell Ave, Tucson, AZ 85724 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					331	332		10.7326/0003-4819-129-4-199808150-00013	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729190				2022-12-24	WOS:000075329100012
J	Rundall, P				Rundall, P			How much research in infant feeding comes from unethical marketing?	BRITISH MEDICAL JOURNAL			English	Article									Baby Milk Act, Cambridge CB2 3AX, England		Rundall, P (corresponding author), Baby Milk Act, 23 St Andrews, Cambridge CB2 3AX, England.							Mehdi T, 1998, FEEDING FIASCO PUSHI; SOKOL E, 1998, BREAKING RULES STRET; Taylor A, 1998, BMJ-BRIT MED J, V316, P1117, DOI 10.1136/bmj.316.7138.1117	3	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					338	339						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729081				2022-12-24	WOS:000075409500035
J	Dumont, DJ; Jussila, L; Taipale, J; Lymboussaki, A; Mustonen, T; Pajusola, K; Breitman, M; Alitalo, K				Dumont, DJ; Jussila, L; Taipale, J; Lymboussaki, A; Mustonen, T; Pajusola, K; Breitman, M; Alitalo, K			Cardiovascular failure in mouse embryos deficient in VEGF receptor-3	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; BLOOD-VESSEL DEVELOPMENT; TYROSINE KINASE; MICE; FLT-1; VASCULOGENESIS; APOPTOSIS; LACKING; CELLS	Vascular endothelial growth factor (VEGF) is a key regulator of blood vessel development in embryos and angiogenesis in adult tissues. Unlike VEGF, the related VEGF-C stimulates the growth of Lymphatic vessels through its specific Lymphatic endothelial receptor VEGFR-3. Here it is shown that targeted inactivation of the gene encoding VEGFR-3 resulted in defective blood vessel development in early mouse embryos. Vasculogenesis and angiogenesis occurred, but Large vessels became abnormally organized with defective lumens, Leading to fluid accumulation in the pericardial cavity and cardiovascular failure at embryonic day 9.5. Thus, VEGFR-3 has an essential role in the development of the embryonic cardiovascular system before the emergence of the Lymphatic vessels.	Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Amgen Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Helsinki; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Alitalo, K (corresponding author), Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, PL 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Mustonen, Tuija/0000-0002-2429-5064				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Eichmann A, 1998, DEVELOPMENT, V125, P743; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Joukov V, 1996, EMBO J, V15, P290; JUSSILA L, UNPUB; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Kuo CT, 1997, GENE DEV, V11, P2996, DOI 10.1101/gad.11.22.2996; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; LYMBOUSSAKI A, UNPUB; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PARK JE, 1994, J BIOL CHEM, V269, P25646; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; Sabin FR, 1912, ANAT REC, V6, P335; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SURI C, 1997, CELL, V87, P1161; VECCHI A, 1994, EUR J CELL BIOL, V63, P247; Visvader JE, 1998, GENE DEV, V12, P473, DOI 10.1101/gad.12.4.473; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293	30	629	683	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					946	949		10.1126/science.282.5390.946	http://dx.doi.org/10.1126/science.282.5390.946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794766				2022-12-24	WOS:000076727300051
J	Annas, GJ				Annas, GJ			Protecting patients from discrimination - The Americans with Disabilities Act and HIV Infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HEALTH		Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA	Boston University	Annas, GJ (corresponding author), Boston Univ, Sch Publ Hlth, Hlth Law Dept, Boston, MA 02215 USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1994, NEW ENGL J MED, V331, P1027, DOI 10.1056/NEJM199410133311521; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; FEIN E, 1998, NY TIMES        0705, pE6; Gin BR, 1997, COLUMBIA LAW REV, V97, P1406, DOI 10.2307/1123439; GLANTZ LH, 1992, MILBANK Q, V70, P43, DOI 10.2307/3350085; HOLMES S, 1991, NY TIMES        1006, P24; TOMKOWICZ SM, 1996, SYRACUSE L RERV, V46, P1051	7	22	22	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1255	1259		10.1056/NEJM199810223391723	http://dx.doi.org/10.1056/NEJM199810223391723			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	130QW	9780348	Green Published			2022-12-24	WOS:000076532400030
J	Mehlen, P; Rabizadeh, S; Snipas, SJ; Assa-Munt, N; Salvesen, GS; Bredesen, DE				Mehlen, P; Rabizadeh, S; Snipas, SJ; Assa-Munt, N; Salvesen, GS; Bredesen, DE			The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis	NATURE			English	Article							COLORECTAL-CARCINOMA; DROSOPHILA HSP27; EXPRESSION; CELLS; PHENOTYPE; GUIDANCE; SYSTEM	The development of colonic carcinoma is associated with the mutation of a specific set of genes(1). One of these, DCC (deleted in colorectal cancer)(2-5), is a candidate tumour-suppressor gene, and encodes a receptor for netrin-1, a molecule involved in axon guidance(6-8). Loss of DCC expression in tumours is not restricted to colon carcinoma(2), and, although there is no increase in the frequency of tumour formation in DCC hemizygous mice(5), reestablishment of DCC expression suppresses tumorigenicity(3,4). However, the mechanism of action of DCC is unknown. Here we show that DCC induces apoptosis in the absence of ligand binding, but blocks apoptosis when engaged by netrin-1. Furthermore, DCC is a caspase substrate, and mutation of the site at which caspase-3 cleaves DCC suppresses the pro-apoptotic effect of DCC completely. These results indicate that DCC may function as a tumour-suppressor protein by inducing apoptosis in settings in which Ligand is unavailable (for example, during metastasis or tumour growth beyond local blood supply) through functional caspase cascades by a mechanism that requires cleavage of DCC at Asp 1,290.	Burnham Inst, Program Aging, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Diego	Bredesen, DE (corresponding author), Burnham Inst, Program Aging, La Jolla, CA 92037 USA.							Bennett KL, 1997, J BIOL CHEM, V272, P26940, DOI 10.1074/jbc.272.43.26940; Bredesen DE, 1998, CELL DEATH DIFFER, V5, P365, DOI 10.1038/sj.cdd.4400378; Bredesen DE, 1997, TRENDS NEUROSCI, V20, P287, DOI 10.1016/S0166-2236(96)01049-1; BREDESEN DE, 1994, APOPTOSIS, V2, P397; CHO KR, 1995, CURR OPIN GENET DEV, V5, P72, DOI 10.1016/S0959-437X(95)90056-X; Ellerby HM, 1997, J NEUROSCI, V17, P6165; ELLERBY LM, IN PRESS J NEUROCHEM; Fazeli A, 1997, NATURE, V386, P796, DOI 10.1038/386796a0; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; Fearon ER, 1996, BBA-REV CANCER, V1288, pM17, DOI 10.1016/0304-419X(96)00023-6; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; MEHLEN P, 1995, J IMMUNOL, V154, P363; Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x; MEHLEN P, IN PRESS CELL DEATH; PFLUG BR, 1992, CANCER RES, V52, P5403; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RABIZADEH S, UNPUB CELL; REALE MA, 1994, CANCER RES, V54, P4493; Ruan YL, 1997, J NEUROSCI RES, V50, P383, DOI 10.1002/(SICI)1097-4547(19971101)50:3<383::AID-JNR4>3.0.CO;2-E; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; TANAKA K, 1991, NATURE, V349, P340, DOI 10.1038/349340a0; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Yang FS, 1998, AM J PATHOL, V152, P379	29	338	350	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					801	804		10.1038/27441	http://dx.doi.org/10.1038/27441			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796814				2022-12-24	WOS:000076607400057
J	Santocanale, C; Diffley, JFX				Santocanale, C; Diffley, JFX			A Mec1- and Rad53-dependent checkpoint controls late-firing origins of DNA replication	NATURE			English	Article							S-PHASE; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST; ARS ELEMENTS; PROTEIN; COMPLEXES; DAMAGE; TIME; PROGRESSION; ACTIVATION	DNA replication in eukaryotic cells initiates from many replication origins(1) which fire throughout the S phase of the cell cycle in a predictable pattern: some origins fire early, others late(2). Little is known about how the initiation of DNA replication and the elongation of newly synthesized DNA strands are coordinated during S phase. Here we show that, in budding yeast, hydroxyurea, which blocks the progression of replication forks from early-firing origins, also inhibits the firing of late origins. These late origins are maintained in the initiation-competent prereplicative state for extended periods. The block to late origin firing is an active process and is defective in yeast with mutations in the rad53 and mec1 checkpoint genes, indicating that regulation of late origin firing may also be an important component of the 'intra-S-phase' checkpoint(3) and may aid cell survival under adverse conditions.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Diffley, JFX (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Santocanale, Corrado/0000-0003-1337-5656; Diffley, John/0000-0001-5184-7680				ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Bousset K, 1998, GENE DEV, V12, P480, DOI 10.1101/gad.12.4.480; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, GENETICS, V145, P45; Piatti S, 1996, GENE DEV, V10, P1516, DOI 10.1101/gad.10.12.1516; Raghuraman MK, 1997, SCIENCE, V276, P806, DOI 10.1126/science.276.5313.806; REYNOLDS AE, 1989, MOL CELL BIOL, V9, P4488, DOI 10.1128/MCB.9.10.4488; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SANTOCANALE C, 1995, J MOL BIOL, V254, P595, DOI 10.1006/jmbi.1995.0641; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; Wellinger RJ, 1996, CELL, V85, P423, DOI 10.1016/S0092-8674(00)81120-4; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8	25	516	526	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					615	618		10.1038/27001	http://dx.doi.org/10.1038/27001			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783589				2022-12-24	WOS:000076362900052
J	Rojas, MR; Noueiry, AO; Lucas, WJ; Gilbertson, RL				Rojas, MR; Noueiry, AO; Lucas, WJ; Gilbertson, RL			Bean dwarf mosaic geminivirus movement proteins recognize DNA in a form- and size-specific manner	CELL			English	Article							CELL-TO-CELL; COAT PROTEIN; NICOTIANA-BENTHAMIANA; DELETION MUTANTS; VIRAL MOVEMENT; STRANDED-DNA; VIRUS; BL1; PLASMODESMATA; INFECTION	Plant viral movement proteins mediate the cell-to-cell movement of nucleic acids. This involves either a direct interaction between the viral movement protein and the nucleic acid or an indirect interaction involving host factors. The bipartite geminiviruses possess two movement proteins, BV1 and BC1, that coordinate movement of viral DNA across nuclear and plasmodesmal boundaries, respectively. Here, we demonstrate that both BV1 and BC1 interact directly with DNA and, in addition, that they have the unique property to recognize DNA on the basis of form and size rather than sequence. This is a novel feature for plant virus movement proteins and raises the possibility that BV1 and BC1 may be determinants of genome size in the bipartite geminiviruses.	Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA; Univ Calif Davis, Div Biol Sci, Plant Biol Sect, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Gilbertson, RL (corresponding author), Univ Calif Davis, Dept Plant Pathol, Davis, CA 95616 USA.							AZZAM O, 1994, VIROLOGY, V204, P289, DOI 10.1006/viro.1994.1533; BROUGH CL, 1988, J GEN VIROL, V69, P503, DOI 10.1099/0022-1317-69-3-503; BROWN KC, 1995, BIOCHEMISTRY-US, V34, P4733, DOI 10.1021/bi00014a030; Carrington JC, 1996, PLANT CELL, V8, P1669, DOI 10.1105/tpc.8.10.1669; CITOVSKY V, 1990, CELL, V60, P637, DOI 10.1016/0092-8674(90)90667-4; DEOM CM, 1992, CELL, V69, P221, DOI 10.1016/0092-8674(92)90403-Y; DING BA, 1995, VIROLOGY, V207, P345, DOI 10.1006/viro.1995.1093; ELMER S, 1990, NUCLEIC ACIDS RES, V18, P2001, DOI 10.1093/nar/18.8.2001; ETESSAMI P, 1988, NUCLEIC ACIDS RES, V16, P4811, DOI 10.1093/nar/16.11.4811; ETESSAMI P, 1989, J GEN VIROL, V70, P277, DOI 10.1099/0022-1317-70-2-277; FUJIWARA T, 1993, PLANT CELL, V5, P1783, DOI 10.1105/tpc.5.12.1783; Ghoshroy Soumitra, 1997, Annu Rev Plant Physiol Plant Mol Biol, V48, P27, DOI 10.1146/annurev.arplant.48.1.27; GIESMANCOOKMEYER D, 1993, PLANT CELL, V5, P973, DOI 10.1105/tpc.5.8.973; Gilbertson RL, 1996, TRENDS PLANT SCI, V1, P260; GILBERTSON RL, 1991, PHYTOPATHOLOGY, V81, P980, DOI 10.1094/Phyto-81-980; HIDAYAT SH, 1993, PHYTOPATHOLOGY, V83, P181, DOI 10.1094/Phyto-83-181; HOEFERT LL, 1987, PHYTOPATHOLOGY, V77, P1596, DOI 10.1094/Phyto-77-1596; Hou YM, 1998, MOL PLANT MICROBE IN, V11, P208, DOI 10.1094/MPMI.1998.11.3.208; INGHAM DJ, 1995, VIROLOGY, V207, P191, DOI 10.1006/viro.1995.1066; KLINKENBERG FA, 1989, J GEN VIROL, V70, P1837, DOI 10.1099/0022-1317-70-7-1837; Li QB, 1996, VIROLOGY, V216, P71, DOI 10.1006/viro.1996.0035; Liu HT, 1997, J GEN VIROL, V78, P1265, DOI 10.1099/0022-1317-78-6-1265; LUCAS WJ, 1994, ANNU REV PHYTOPATHOL, V32, P387, DOI 10.1146/annurev.py.32.090194.002131; Maia IG, 1996, J GEN VIROL, V77, P1335, DOI 10.1099/0022-1317-77-7-1335; McLean BG, 1997, PLANT CELL, V9, P1043, DOI 10.1105/tpc.9.7.1043; NOUEIRY AO, 1994, CELL, V76, P925, DOI 10.1016/0092-8674(94)90366-2; OSMAN TAM, 1992, J GEN VIROL, V73, P223, DOI 10.1099/0022-1317-73-2-223; PAPLOMATAS EJ, 1994, PHYTOPATHOLOGY, V84, P1215, DOI 10.1094/Phyto-84-1215; PASCAL E, 1994, PLANT CELL, V6, P995, DOI 10.1105/tpc.6.7.995; Qu F, 1997, J VIROL, V71, P1428, DOI 10.1128/JVI.71.2.1428-1435.1997; Rojas MR, 1997, VIROLOGY, V237, P283, DOI 10.1006/viro.1997.8777; ROJAS MR, 1993, PLANT DIS, V77, P340, DOI 10.1094/PD-77-0340; SANDERFOOT AA, 1995, PLANT CELL, V7, P1185, DOI 10.1105/tpc.7.8.1185; Schaffer RL, 1995, VIROLOGY, V214, P330, DOI 10.1006/viro.1995.0042; STANLEY J, 1985, NUCLEIC ACIDS RES, V13, P2189, DOI 10.1093/nar/13.7.2189; Sudarshana MR, 1998, MOL PLANT MICROBE IN, V11, P277, DOI 10.1094/MPMI.1998.11.4.277; TIMMERMANS MCP, 1994, ANNU REV PLANT PHYS, V45, P79, DOI 10.1146/annurev.pp.45.060194.000455; Wang HL, 1996, PHYTOPATHOLOGY, V86, P1204, DOI 10.1094/Phyto-86-1204; Ward BM, 1997, J VIROL, V71, P3726, DOI 10.1128/JVI.71.5.3726-3733.1997	39	91	93	1	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					105	113		10.1016/S0092-8674(00)81786-9	http://dx.doi.org/10.1016/S0092-8674(00)81786-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778251	Bronze			2022-12-24	WOS:000076242300014
J	Brandes, JA; Boctor, NZ; Cody, GD; Cooper, BA; Hazen, RM; Yoder, HS				Brandes, JA; Boctor, NZ; Cody, GD; Cooper, BA; Hazen, RM; Yoder, HS			Abiotic nitrogen reduction on the early Earth	NATURE			English	Article							AMINO-ACIDS; EVOLUTION; NITRATE; IRON; CO2	The production of organic precursors to life depends critically on the form of the reactants, In particular, an environment dominated by N-2 is far less efficient in synthesizing nitrogen-bearing organics than a reducing environment rich in ammonia (refs 1, 2). Relatively reducing lithospheric conditions on the early Earth have been presumed to favour the generation of an ammonia-rich atmosphere. but this hypothesis has not been studied experimentally. Here we demonstrate mineral-catalysed reduction of N-2, NO2- and NO3- to ammonia at temperatures between 300 and 800 degrees C and pressures of 0.1-0.4 GPa-conditions typical of crustal and oceanic hydrothermal systems. We also show that only N-2 is stable above 800 degrees C, thus precluding significant atmospheric ammonia formation during hot accretion, We conclude that mineral-catalysed N-2 reduction might have provided a significant source of ammonia to the Hadean ocean. These results also suggest that, whereas nitrogen in the Earth's early atmosphere was present predominantly as N-2, exchange with oceanic, hydrothermally derived ammonia could have provided a significant amount of the atmospheric ammonia necessary to resolve the early-faint-Sun paradox(3).	Carnegie Inst Washington, Geophys Lab, Washington, DC 20015 USA	Carnegie Institution for Science	Brandes, JA (corresponding author), Carnegie Inst Washington, Geophys Lab, 5251 Broad Branch Rd NW, Washington, DC 20015 USA.	brandes@gl.ciw.edu						BADA JL, 1968, SCIENCE, V159, P423, DOI 10.1126/science.159.3813.423; Berndt ME, 1996, GEOLOGY, V24, P351, DOI 10.1130/0091-7613(1996)024<0351:ROCDSO>2.3.CO;2; BLOCHL E, 1992, P NATL ACAD SCI USA, V89, P8117, DOI 10.1073/pnas.89.17.8117; BURESH RJ, 1976, J ENVIRON QUAL, V5, P320, DOI 10.2134/jeq1976.00472425000500030021x; FALKOWSKI PG, 1997, AQUATIC PHOTOSYNTHES, pCH10; FOURNIER RO, 1987, US GS PROF PAP, V1350, P1497; Frost B. R., 1991, REV MINERAL, V25, P469; HENDERSON-SELLERS A, 1980, NATURE, V287, P526, DOI 10.1038/287526a0; Holland H.D., 1984, CHEM EVOLUTION ATMOS; JAVOY M, 1991, EARTH PLANET SC LETT, V107, P598, DOI 10.1016/0012-821X(91)90104-P; JOHNSON MC, 1994, REV MINERAL, V30, P281; JONES MN, 1984, WATER RES, V18, P643, DOI 10.1016/0043-1354(84)90215-X; KASTING JF, 1993, J GEOL, V101, P245, DOI 10.1086/648219; KNOWLES R, 1982, MICROBIOL REV, V46, P43, DOI 10.1128/MMBR.46.1.43-70.1982; KULLERUD G, 1959, ECON GEOL, V54, P534; MANCINELI RL, 1990, ORIGINS LIFE EVOL BI, V18, P311; PIZZARELLO S, 1994, GEOCHIM COSMOCHIM AC, V58, P5579, DOI 10.1016/0016-7037(94)90251-8; Sagan C, 1997, SCIENCE, V276, P1217, DOI 10.1126/science.276.5316.1217; SCHLESINGER G, 1983, J MOL EVOL, V19, P376, DOI 10.1007/BF02101642; STEVENSON DJ, 1983, EARTHS EARLIEST BIOS, P32; STRIBLING R, 1987, ORIGINS LIFE EVOL B, V17, P261, DOI 10.1007/BF02386466; Strickland J.D.H., 1972, PRACTICAL HDB SEWATE, DOI [10.2307/1979241, DOI 10.2307/1979241]; SUMMERS DP, 1993, NATURE, V365, P630, DOI 10.1038/365630a0; Tamaru K., 1991, CATALYTIC AMMONIA SY, P1; YODER HS, 1962, J PETROL, V3, P342, DOI 10.1093/petrology/3.3.342; YODER HS, 1950, T AM GEOPHYS UNION, V31, P821; ZEIS EG, 1924, NAT GEOL SOC CONT TE, V1; ZHANG YX, 1993, EARTH PLANET SC LETT, V117, P331, DOI 10.1016/0012-821X(93)90088-Q	28	162	165	4	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					365	367		10.1038/26450	http://dx.doi.org/10.1038/26450			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759725				2022-12-24	WOS:000076083800048
J	Godt, D; Tepass, U				Godt, D; Tepass, U			Drosophila oocyte localization is mediated by differential cadherin-based adhesion	NATURE			English	Article							POLARITY GENE ARMADILLO; CELL-ADHESION; ANTERIOR-POSTERIOR; BODY AXES; OOGENESIS; PROTEIN; SPECIFICATION; REARRANGEMENT; MELANOGASTER; POLARIZATION	In a Drosophila follicle the oocyte always occupies a posterior position among a group of sixteen germline cells. Although the importance of this cell arrangement for the subsequent formation of the anterior-posterior axis of the embryo is well documented(1-4), the molecular mechanism responsible for the posterior localization of the oocyte was unknown. Here we show that the homophilic adhesion molecule DE-cadherin(5-7) mediates oocyte positioning. During follicle biogenesis, DE-cadherin is expressed in germline (including oocyte) and surrounding follicle cells, with the highest concentration of DE-cadherin being found at the interface between oocyte and posterior follicle cells. Mosaic analysis shows that DE-cadherin is required in both germline and follicle cells for correct oocyte localization, indicating that germline-soma interactions may be involved in this process. By analysing the behaviour of the oocyte in follicles with a chimaeric follicular epithelium, we find that the position of the oocyte is determined by the position of DE-cadherin-expressing follicle cells, to which the oocyte attaches itself selectively. Among the DE-cadherin positive follicle cells, the oocyte preferentially contacts those cells that express higher levels of DE-cadherin. On the basis of these data, we propose that in wild-type follicles the oocyte competes successfully with its sister germline cells for contact to the posterior follicle cells, a sorting process driven by different concentrations of DE-cadherin. This is, to our knowledge, the first in vivo example of a cell-sorting process that depends on differential adhesion mediated by a cadherin.	Univ Toronto, Dept Zool, Toronto, ON M5S 3G5, Canada	University of Toronto	Godt, D (corresponding author), Univ Toronto, Dept Zool, 25 Harbord St, Toronto, ON M5S 3G5, Canada.	dgodt@zoo.utoronto.ca; utepass@zoo.utoronto.ca						BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; FRIEDLANDER DR, 1989, P NATL ACAD SCI USA, V86, P7043, DOI 10.1073/pnas.86.18.7043; GONZALEZREYES A, 1994, SCIENCE, V266, P639, DOI 10.1126/science.7939717; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; King R. C., 1970, OVARIAN DEV DROSOPHI; Mach JM, 1997, GENE DEV, V11, P423, DOI 10.1101/gad.11.4.423; MAHOWALD AP, 1970, J CELL BIOL, V45, P306, DOI 10.1083/jcb.45.2.306; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; Oda H, 1997, GENES CELLS, V2, P29, DOI 10.1046/j.1365-2443.1997.d01-284.x; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; RAN B, 1994, DEVELOPMENT, V120, P1233; Ray RP, 1996, GENE DEV, V10, P1711, DOI 10.1101/gad.10.14.1711; ROTH S, 1995, CELL, V81, P967, DOI 10.1016/0092-8674(95)90016-0; STEINBERG MS, 1994, P NATL ACAD SCI USA, V91, P206, DOI 10.1073/pnas.91.1.206; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tepass U, 1996, GENE DEV, V10, P672, DOI 10.1101/gad.10.6.672; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; White P, 1998, J CELL BIOL, V140, P183, DOI 10.1083/jcb.140.1.183; XU T, 1994, DROSOPHILA MELANOGAS, P655	30	264	265	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					387	391		10.1038/26493	http://dx.doi.org/10.1038/26493			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759729				2022-12-24	WOS:000076083800055
J	Albota, M; Beljonne, D; Bredas, JL; Ehrlich, JE; Fu, JY; Heikal, AA; Hess, SE; Kogej, T; Levin, MD; Marder, SR; McCord-Maughon, D; Perry, JW; Rockel, H; Rumi, M; Subramaniam, C; Webb, WW; Wu, XL; Xu, C				Albota, M; Beljonne, D; Bredas, JL; Ehrlich, JE; Fu, JY; Heikal, AA; Hess, SE; Kogej, T; Levin, MD; Marder, SR; McCord-Maughon, D; Perry, JW; Rockel, H; Rumi, M; Subramaniam, C; Webb, WW; Wu, XL; Xu, C			Design of organic molecules with large two-photon absorption cross sections	SCIENCE			English	Article							2-PHOTON; MICROSCOPY; EXCITATION; SPECTROSCOPY; NM	A strategy for the design of molecules with Large two-photon absorption cross sections, delta, was developed, on the basis of the concept that symmetric charge transfer, from the ends of a conjugated system to the middle, or vice versa, upon excitation is correlated to enhanced values of delta. Synthesized bis(styryl)benzene derivatives with donor-pi-donor, donor-acceptor-donor, and acceptor-donor-acceptor structural motifs exhibit exceptionally Large values of delta, up to about 400 times that of trans-stilbene. Quantum chemical calculations performed on these molecules indicate that substantial symmetric charge redistribution occurs upon excitation and provide delta values in good agreement with experimental values. The combination of Large delta and high fluorescence quantum yield or triplet yield exhibited by molecules developed here offers potential for unprecedented brightness in two-photon fluorescent imaging or enhanced photosensitivity in two-photon sensitization, respectively.	Univ Mons, Ctr Res Mol Elect & Photon, B-7000 Mons, Belgium; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; CALTECH, Beckman Inst, Mol Mat Resource Ctr, Pasadena, CA 91125 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Penn State Univ, Dept Chem, Hazleton, PA 18201 USA	University of Mons; Cornell University; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); California Institute of Technology; University of Arizona; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University	Bredas, JL (corresponding author), Univ Mons, Ctr Res Mol Elect & Photon, Pl Parc 20, B-7000 Mons, Belgium.		Webb, Watt W./B-5905-2011; Bredas, Jean-Luc E/A-3431-2008; Rumi, Mariacristina/C-9474-2009; Marder, Seth/GRR-9990-2022; Perry, Joseph W/B-7191-2011; Xu, Chris/F-2703-2010	Bredas, Jean-Luc E/0000-0001-7278-4471; Rumi, Mariacristina/0000-0002-4597-9617; Perry, Joseph W/0000-0003-1101-7337; Xu, Chris/0000-0002-3493-6427				ANDERSON RJM, 1979, J CHEM PHYS, V70, P4310, DOI 10.1063/1.438005; BIRGE RR, 1986, ACCOUNTS CHEM RES, V19, P138, DOI 10.1021/ar00125a003; BUENKER RJ, 1974, THEOR CHIM ACTA, V35, P33, DOI 10.1007/BF02394557; CUMPSTON BH, UNPUB; DENK W, 1994, P NATL ACAD SCI USA, V91, P6629, DOI 10.1073/pnas.91.14.6629; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; Denk W, 1997, NEURON, V18, P351, DOI 10.1016/S0896-6273(00)81237-4; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; DICK B, 1987, NONLINEAR OPTICAL PR, V2, P167; Ehrlich JE, 1997, OPT LETT, V22, P1843, DOI 10.1364/OL.22.001843; KENNEDY SM, 1986, ANAL CHEM, V58, P2643, DOI 10.1021/ac00126a014; Kohler RH, 1997, SCIENCE, V276, P2039, DOI 10.1126/science.276.5321.2039; LIPSON M, UNPUB; ORR BJ, 1971, MOL PHYS, V20, P513, DOI 10.1080/00268977100100481; PARTHENOPOULOS DA, 1989, SCIENCE, V245, P843, DOI 10.1126/science.245.4920.843; RIDLEY J, 1973, THEOR CHIM ACTA, V32, P111, DOI 10.1007/BF00528484; SAID AA, 1994, CHEM PHYS LETT, V228, P646, DOI 10.1016/0009-2614(94)00999-6; WILLIAMS RM, 1994, FASEB J, V8, P804, DOI 10.1096/fasebj.8.11.8070629; Xu C, 1996, P NATL ACAD SCI USA, V93, P10763, DOI 10.1073/pnas.93.20.10763; Xu C, 1996, J OPT SOC AM B, V13, P481, DOI 10.1364/JOSAB.13.000481	20	2099	2173	17	763	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1653	1656		10.1126/science.281.5383.1653	http://dx.doi.org/10.1126/science.281.5383.1653			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	118TR	9733507				2022-12-24	WOS:000075856500040
J	Gaymard, F; Pilot, G; Lacombe, B; Bouchez, D; Bruneau, D; Boucherez, J; Michaux-Ferriere, N; Thibaud, JB; Sentenac, H				Gaymard, F; Pilot, G; Lacombe, B; Bouchez, D; Bruneau, D; Boucherez, J; Michaux-Ferriere, N; Thibaud, JB; Sentenac, H			Identification and disruption of a plant shaker-like outward channel involved in K+ release into the xylem sap	CELL			English	Article							RECTIFYING POTASSIUM CHANNEL; ARABIDOPSIS-THALIANA; ION CHANNELS; GUARD-CELLS; SACCHAROMYCES-CEREVISIAE; XENOPUS OOCYTES; EXPRESSION; GENE; ROOTS; PROTOPLASTS	SKOR, a K+ channel identified in Arabidopsis, displays the typical hydrophobic core of the Shaker channel superfamily, a cyclic nucleotide-binding domain, and an ankyrin domain. Expression in Xenopus oocytes identified SKOR as the first member of the Shaker family in plants to be endowed with outwardly rectifying properties. SKOR expression is localized in root stelar tissues. A knockout mutant shows both lower shoot K+ content and lower xylem sap K+ concentration, indicating that SKOR is involved in K+ release into the xylem sap toward the shoots. SKOR expression is strongly inhibited by the stress phytohormone abscisic acid, supporting the hypothesis that control of KC translocation toward the shoots is part of the plant response to water stress.	INRA, CNRS URA 2133, F-34060 Montpellier 1, France; INRA, F-78026 Versailles, France; BIOTROP, CIRAD, F-34032 Montpellier, France	INRAE; INRAE; UDICE-French Research Universities; Universite Paris Saclay; CIRAD	Gaymard, F (corresponding author), INRA, CNRS URA 2133, F-34060 Montpellier 1, France.		Bouchez, David/B-7463-2019; Lacombe, Benoit/B-1202-2013	Bouchez, David/0000-0003-3545-4339; THIBAUD, Jean-Baptiste/0000-0002-0824-6465; Lacombe, Benoit/0000-0001-9924-3093; Sentenac, Herve/0000-0003-3641-4822; Pilot, Guillaume/0000-0001-7520-1059				ALLEN GJ, 1995, PLANT CELL, V7, P1473; ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Blatt MR, 1997, J MEMBRANE BIOL, V158, P241, DOI 10.1007/s002329900261; BOUCHEZ D, 1993, CR ACAD SCI III-VIE, V316, P1188; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; Butt AD, 1997, J PLANT PHYSIOL, V150, P652, DOI 10.1016/S0176-1617(97)80279-9; Camilleri C, 1998, PLANT J, V14, P633, DOI 10.1046/j.1365-313X.1998.00159.x; CAO YW, 1995, PLANT PHYSIOL, V109, P1093, DOI 10.1104/pp.109.3.1093; Cherel I, 1996, BIOCHEM SOC T, V24, P964, DOI 10.1042/bst0240964; CLARKSON DT, 1993, PHILOS T R SOC B, V341, P5, DOI 10.1098/rstb.1993.0086; Daram P, 1997, EMBO J, V16, P3455, DOI 10.1093/emboj/16.12.3455; deBoer AH, 1997, J EXP BOT, V48, P441, DOI 10.1093/jxb/48.Special_Issue.441; DECOURSEY TE, 1995, J GEN PHYSIOL, V106, P745, DOI 10.1085/jgp.106.4.745; Dellaporta SL., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; Dreyer I, 1997, BIOPHYS J, V72, P2143, DOI 10.1016/S0006-3495(97)78857-X; Eisenman G., 1961, S MEMBRANE TRANSPORT, P163; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; Gaymard F, 1996, J BIOL CHEM, V271, P22863, DOI 10.1074/jbc.271.37.22863; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hirsch RE, 1998, SCIENCE, V280, P918, DOI 10.1126/science.280.5365.918; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; Ichida AM, 1997, PLANT CELL, V9, P1843, DOI 10.1105/tpc.9.10.1843; JAN LY, 1992, CELL, V69, P715, DOI 10.1016/0092-8674(92)90280-P; Jan LY, 1997, ANNU REV NEUROSCI, V20, P91, DOI 10.1146/annurev.neuro.20.1.91; Kochian LV, 1988, ADV BOT RES, V15, P136; Krysan PJ, 1996, P NATL ACAD SCI USA, V93, P8145, DOI 10.1073/pnas.93.15.8145; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; Maathuis FJM, 1997, PLANT PHYSIOL, V114, P1141, DOI 10.1104/pp.114.4.1141; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MacRobbie EAC, 1997, J EXP BOT, V48, P515, DOI 10.1093/jxb/48.Special_Issue.515; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; MINET M, 1992, PLANT J, V2, P417; NAIRN CJ, 1988, GENE, V65, P247, DOI 10.1016/0378-1119(88)90461-1; NAKAMURA RL, 1995, PLANT PHYSIOL, V109, P371, DOI 10.1104/pp.109.2.371; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; PARDO LA, 1992, P NATL ACAD SCI USA, V89, P2466, DOI 10.1073/pnas.89.6.2466; PRITCHARD J, 1991, J EXP BOT, V42, P1043, DOI 10.1093/jxb/42.8.1043; Roberts SK, 1997, J EXP BOT, V48, P839, DOI 10.1093/jxb/48.4.839; Roberts SK, 1998, PLANT PHYSIOL, V116, P145, DOI 10.1104/pp.116.1.145; Roberts SK, 1995, PLANT J, V8, P811, DOI 10.1046/j.1365-313X.1995.8060811.x; Sambrook JFE, 1989, MOL CLONING LAB MANU; SCHACHTMAN DP, 1992, SCIENCE, V258, P1654, DOI 10.1126/science.8966547; SENTENAC H, 1992, SCIENCE, V256, P663, DOI 10.1126/science.1585180; SHARP RE, 1990, PLANT PHYSIOL, V93, P1337, DOI 10.1104/pp.93.4.1337; Thiel G, 1997, TRENDS PLANT SCI, V2, P339, DOI 10.1016/S1360-1385(97)84621-3; THOMINE S, 1994, FEBS LETT, V340, P45, DOI 10.1016/0014-5793(94)80170-3; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; VERY AA, 1995, PLANT J, V7, P321, DOI 10.1046/j.1365-313X.1995.7020321.x; VOYTAS DF, 1990, GENETICS, V126, P713; WARMKE J, 1991, SCIENCE, V252, P1560, DOI 10.1126/science.1840699; WEGNER LH, 1994, PLANT PHYSIOL, V105, P799, DOI 10.1104/pp.105.3.799; Wegner LH, 1997, PLANT PHYSIOL, V115, P1707, DOI 10.1104/pp.115.4.1707; Zhang JH, 1996, PLANT CELL PHYSIOL, V37, P598, DOI 10.1093/oxfordjournals.pcp.a028987	57	531	584	5	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					647	655		10.1016/S0092-8674(00)81606-2	http://dx.doi.org/10.1016/S0092-8674(00)81606-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741629	Bronze			2022-12-24	WOS:000075851900012
J	Savage, B; Almus-Jacobs, F; Ruggeri, ZM				Savage, B; Almus-Jacobs, F; Ruggeri, ZM			Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow	CELL			English	Article							VONWILLEBRAND-FACTOR-BINDING; VON-WILLEBRAND-FACTOR; GLYCOPROTEIN-IIB-IIIA; ENDOTHELIAL-CELLS; ALPHA(2)BETA(1) INTEGRIN; MONOCLONAL-ANTIBODIES; IIB/IIIA COMPLEX; SHEAR-STRESS; VI COLLAGEN; ALPHA-CHAIN	We have used confocal videomicroscopy in real time to delineate the adhesive interactions supporting platelet thrombus formation on biologically relevant surfaces. Type I collagen fibrils exposed to flowing blood adsorb von Willebrand factor (VWF), to which platelets become initially tethered with continuous surface translocation mediated by the membrane glycoprotein Ib alpha. This step is essential at high wall shear rates to allow subsequent irreversible adhesion and thrombus growth mediated by the integrins alpha(2)beta(1) and alpha(IIb)beta(3). On subendothelial matrix, endogenous vWF and adsorbed plasma vWF synergistically initiate platelet recruitment, and alpha(2)beta(1) remains key along with alpha(IIb)beta(3) for normal thrombus development at all but low shear rates. Thus, hemodynamic forces and substrate characteristics define the platelet adhesion pathways leading to thrombogenesis.	Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, La Jolla, CA 92037 USA; Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Dept Vasc Biol, Div Expt Hemostasis & Thrombosis, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Savage, B (corresponding author), Scripps Res Inst, Roon Res Ctr Arteriosclerosis & Thrombosis, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL-42846, HL-48728, HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R37HL042846, R01HL042846, P01HL048728] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALEVRIADOU BR, 1993, BLOOD, V81, P1263; BACK LD, 1977, J BIOMECH, V10, P339, DOI 10.1016/0021-9290(77)90006-9; BAUMGARTNER HR, 1977, THROMB HAEMOSTASIS, V37, P17; Celikel R, 1998, NAT STRUCT BIOL, V5, P189, DOI 10.1038/nsb0398-189; CELIKEL R, 1997, BLOOD CELL MOL DIS, V23, P124; Chiang TM, 1997, J CLIN INVEST, V100, P514, DOI 10.1172/JCI119560; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DiazGonzalez F, 1996, MOL BIOL CELL, V7, P1939, DOI 10.1091/mbc.7.12.1939; DIAZRICART M, 1993, BLOOD, V82, P491; DISE CA, 1982, J BIOL CHEM, V257, P4701; DU XP, 1994, J BIOL CHEM, V269, P18287; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; FeldingHabermann B, 1996, J BIOL CHEM, V271, P5892, DOI 10.1074/jbc.271.10.5892; FOLIE BJ, 1988, BLOOD, V72, P1393; FRANGOS JA, 1985, SCIENCE, V227, P1477, DOI 10.1126/science.3883488; FUJIMURA Y, 1991, BLOOD, V77, P113; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GOSPODAROWICZ D, 1981, J CELL PHYSIOL, V107, P171, DOI 10.1002/jcp.1041070203; HANDA M, 1986, J BIOL CHEM, V261, P2579; Ichinohe T, 1997, J BIOL CHEM, V272, P63; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; MOHRI H, 1989, J BIOL CHEM, V264, P17361; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; NIIYA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PHILLIPS DR, 1991, CELL, V65, P359, DOI 10.1016/0092-8674(91)90451-4; PISCHEL KD, 1988, J CLIN INVEST, V81, P505, DOI 10.1172/JCI113348; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1984, J BIOL CHEM, V259, P5385; POLANOWSKAGRABOWSKA R, 1993, BIOCHEM J, V296, P543, DOI 10.1042/bj2960543; RAND JH, 1991, J CLIN INVEST, V88, P253, DOI 10.1172/JCI115285; ROSS JM, 1995, BLOOD, V85, P1826, DOI 10.1182/blood.V85.7.1826.bloodjournal8571826; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SAVAGE B, 1992, J BIOL CHEM, V267, P11300; Schneppenheim R, 1996, P NATL ACAD SCI USA, V93, P3581, DOI 10.1073/pnas.93.8.3581; SPORN LA, 1989, J CELL BIOL, V108, P1283, DOI 10.1083/jcb.108.4.1283; TANGELDER GJ, 1988, AM J PHYSIOL, V254, pH1059, DOI 10.1152/ajpheart.1988.254.6.H1059; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; USAMI S, 1993, ANN BIOMED ENG, V21, P77, DOI 10.1007/BF02368167; VICENTE V, 1988, J BIOL CHEM, V263, P18473; VICENTE V, 1990, J BIOL CHEM, V265, P274; WAGNER DD, 1984, P NATL ACAD SCI-BIOL, V81, P471, DOI 10.1073/pnas.81.2.471; WARE J, 1993, J CLIN INVEST, V92, P1213, DOI 10.1172/JCI116692; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871; YAMADA KM, 1990, CANCER RES, V50, P4485	51	638	658	1	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					657	666		10.1016/S0092-8674(00)81607-4	http://dx.doi.org/10.1016/S0092-8674(00)81607-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741630	Bronze			2022-12-24	WOS:000075851900013
J	Luo, X; Budihardjo, I; Zou, H; Slaughter, C; Wang, XD				Luo, X; Budihardjo, I; Zou, H; Slaughter, C; Wang, XD			Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors	CELL			English	Article							INDUCED APOPTOSIS; FREE SYSTEM; INTERLEUKIN-1-BETA-CONVERTING ENZYME; BCL-X(L); PROTEOLYSIS; CASPASES; PATHWAYS; MEMBRANE; COMPLEX; CPP32	We report here the purification of a cytosolic protein that induces cytochrome c release from mitochondria in response to caspase-8, the apical caspase activated by cell surface death receptors such as Fas and TNF. Peptide mass fingerprinting identified this protein as Bid, a BH3 domain-containing protein known to interact with both Bcl2 and Bar. Caspase-8 cleaves Bid, and the COOH-terminal part translocates to mitochondria where it triggers cytochrome c release. Immunodepletion of Bid from cell extracts eliminated the cytochrome c releasing activity. The cytochrome c releasing activity of Bid was antagonized by Bcl2. A mutation at the BH3 domain diminished its cytochrome c releasing activity. Bid, therefore, relays an apoptotic signal from the cell surface to mitochondria.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA.			Wang, Xiaodong/0000-0001-9885-356X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057158] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM-57158] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 1997, EMBO J, V16, P2271, DOI 10.1093/emboj/16.9.2271; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Krippner A, 1996, J BIOL CHEM, V271, P21629, DOI 10.1074/jbc.271.35.21629; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuwana T, 1998, J BIOL CHEM, V273, P16589, DOI 10.1074/jbc.273.26.16589; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1996, J BIOL CHEM, V271, P13371, DOI 10.1074/jbc.271.23.13371; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MINN AJ, 1997, NATURE, V381, P335; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Muzio M, 1997, J BIOL CHEM, V272, P2952, DOI 10.1074/jbc.272.5.2952; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; WILLIAMS KR, 1995, TECH PROT CHEM, V6, P143, DOI 10.1016/S1080-8914(06)80020-7; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	52	2953	3072	5	168	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					481	490		10.1016/S0092-8674(00)81589-5	http://dx.doi.org/10.1016/S0092-8674(00)81589-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727491	Bronze			2022-12-24	WOS:000075541100010
J	Agrawal, A; Eastman, QM; Schatz, DG				Agrawal, A; Eastman, QM; Schatz, DG			Transposition mediated by RAG1 and RAG2 and its implications for the evolution of the immune system	NATURE			English	Article							V(D)J RECOMBINATION; RETROVIRAL INTEGRATION; CATALYTIC DOMAIN; DNA; GENES; RESOLUTION; INITIATION; 12/23-RULE; MECHANISM; SEQUENCES	Immunoglobulin and T-cell-receptor genes are assembled from component gene segments in developing lymphocytes by a site-specific recombination reaction, V(D)J recombination, The proteins encoded by the recombination-activating genes, RAG1 and RAG2, are essential in this reaction, mediating sequence-specific DNA recognition of well-defined recombination signals and DNA cleavage next to these signals. Here we show that RAG1 and RAG2 together form a transposase capable of excising a piece of DNA containing recombination signals from a donor site and inserting it into a target DNA molecule. The products formed contain a short duplication of target DNA Immediately flanking the transposed fragment, a structure like that created by retroviral integration and all known transposition reactions. The results support the theory that RAG1 and RAG2 were once components of a transposable element, and that the split nature of Immunoglobulin and T-cell-receptor genes derives from germline insertion of this element into an ancestral receptor gene soon after the evolutionary divergence of jawed and jawless vertebrates.	Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Biochem & Mol Biophys, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University; Yale University	Schatz, DG (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, 333 Cedar St, New Haven, CT 06510 USA.	david.schatz@yale.edu	Schatz, David/A-6748-2013	Schatz, David/0000-0002-5669-1176				Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BROWN PO, 1989, P NATL ACAD SCI USA, V86, P2525, DOI 10.1073/pnas.86.8.2525; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; Eastman QM, 1996, NATURE, V380, P85, DOI 10.1038/380085a0; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Grawunder U, 1998, CURR OPIN IMMUNOL, V10, P172, DOI 10.1016/S0952-7915(98)80246-X; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; HSIEH CL, 1991, MOL CELL BIOL, V11, P3972, DOI 10.1128/MCB.11.8.3972; ISBERG RR, 1985, J MOL BIOL, V182, P69, DOI 10.1016/0022-2836(85)90028-2; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; LEE YMH, 1990, J VIROL, V64, P5958, DOI 10.1128/JVI.64.12.5958-5965.1990; Lewis SM, 1997, CELL, V88, P159, DOI 10.1016/S0092-8674(00)81833-4; LEWIS SM, 1991, EMBO J, V10, P3631, DOI 10.1002/j.1460-2075.1991.tb04929.x; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LITMAN GW, 1993, MOL BIOL EVOL, V10, P60; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; Rast JP, 1997, IMMUNITY, V6, P1, DOI 10.1016/S1074-7613(00)80237-X; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; Sakai J, 1997, CELL, V89, P205, DOI 10.1016/S0092-8674(00)80200-7; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Sawchuk DJ, 1997, J EXP MED, V185, P2025, DOI 10.1084/jem.185.11.2025; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SHOEMAKER C, 1981, J VIROL, V40, P164, DOI 10.1128/JVI.40.1.164-172.1981; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; vanGent DC, 1997, EMBO J, V16, P2665, DOI 10.1093/emboj/16.10.2665; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEINERT TA, 1984, COLD SPRING HARB SYM, V49, P251, DOI 10.1101/SQB.1984.049.01.029; ZWILLING S, 1995, EMBO J, V14, P1198, DOI 10.1002/j.1460-2075.1995.tb07103.x	44	568	584	2	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					744	751		10.1038/29457	http://dx.doi.org/10.1038/29457			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723614				2022-12-24	WOS:000075503600035
J	Chen, H; Fre, S; Slepnev, VI; Capua, MR; Takei, K; Butler, MH; Di Fiore, PP; De Camilli, P				Chen, H; Fre, S; Slepnev, VI; Capua, MR; Takei, K; Butler, MH; Di Fiore, PP; De Camilli, P			Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis	NATURE			English	Article							NERVE-TERMINALS; ALPHA-ADAPTIN; VESICLES; DYNAMIN; EPS15	During endocytosis, clathrin and the clathrin adaptor protein AP-2 (ref, 1), assisted by a variety of accessory factors, help to generate an invaginated bud at the cell membrane(2,3). One of these factors is Eps15, a clathrin-coat-associated protein that binds the alpha-adaptin subunit of AP-2 (refs 4-8). Here we investigate the function of Eps15 by characterizing an important binding partner for its region containing EH domains(9); this protein, epsin, is closely related to the Xenopus mitotic phosphoprotein MP90 (ref. 10) and has a ubiquitous tissue distribution. It is concentrated together with Eps15 in presynaptic nerve terminals, which are sites specialized for the clathrin-mediated endocytosis of synaptic vesicles. The central region of epsin binds AP-2 and its carboxyterminal region binds Eps15. Epsin is associated with clathrin coats in situ, can be co-precipitated with AP-2 and Eps15 from brain extracts, but does not co-purify with clathrin coat components in a clathrin-coated vesicle fraction. When epsin function is disrupted, clathrin-mediated endocytosis is blocked. We propose that epsin may participate, together with Eps15, in the molecular rearrangement of the clathrin coats that are required for coated-pit imagination and vesicle fission.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06510 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Bari, Ist Microbiol, I-70124 Bari, Italy	Howard Hughes Medical Institute; Yale University; Yale University; IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro	De Camilli, P (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 295 Congress Ave, New Haven, CT 06510 USA.		Fre, Silvia/C-7540-2017; Di Fiore, Pier Paolo/K-2130-2012	Fre, Silvia/0000-0002-7209-7636; Di Fiore, Pier Paolo/0000-0002-2252-0950; Takei, Kohji/0000-0002-6555-9425				Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; Carbone R, 1997, CANCER RES, V57, P5498; Coda L, 1998, J BIOL CHEM, V273, P3003, DOI 10.1074/jbc.273.5.3003; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Dreyling MH, 1996, P NATL ACAD SCI USA, V93, P4804, DOI 10.1073/pnas.93.10.4804; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; Iannolo G, 1997, CANCER RES, V57, P240; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1996, NATURE, V379, P353, DOI 10.1038/379353a0; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROOS J, IN PRESS J BIOL CHEM; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Srinivasan S, 1997, EUR J CELL BIOL, V74, P350; Stukenberg PT, 1997, CURR BIOL, V7, P338, DOI 10.1016/S0960-9822(06)00157-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; WANG LH, 1995, J BIOL CHEM, V270, P10079, DOI 10.1074/jbc.270.17.10079; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; ZHOU SB, 1992, J NEUROSCI, V12, P2144	30	463	476	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					793	797		10.1038/29555	http://dx.doi.org/10.1038/29555			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723620				2022-12-24	WOS:000075503600049
J	Varma, R; Mayor, S				Varma, R; Mayor, S			GPI-anchored proteins are organized in submicron domains at the cell surface	NATURE			English	Article							DETERGENT INSOLUBILITY; ALKALINE-PHOSPHATASE; CROSS-LINKING; MDCK CELLS; CHOLESTEROL; CAVEOLAE; TRANSPORT; MEMBRANES; RECEPTOR; FOLATE	Lateral heterogeneities in the classical fluid-mosaic model of cell membranes are now envisaged as domains or 'rafts' that are enriched in (glyco)sphingolipids, cholesterol, specific membrane proteins and glycosylphosphatidylinositol (GPI)-anchored proteins(1). These rafts dictate the sorting of associated proteins and/or provide sites for assembling cytoplasmic signalling molecules(2). However, there is no direct evidence that rafts exist in living cells(3,4). We have now measured the extent of energy transfer between isoforms of the folate receptor bound to a fluorescent analogue of folic acid, in terms of the dependence of fluorescence polarization on fluorophore densities in membranes(5). We find that the extent of energy transfer for the GPI-anchored folate-receptor isoform is density-independent, which is characteristic of organization in sub-pixel-sized domains at the surface of living cells; however, the extent of energy transfer for the transmembrane-anchored folate-receptor isoform was density-dependent, which is consistent with a random distribution. These domains are likely to be less than 70 nm in diameter and are disrupted by removal of cellular cholesterol. These results indicate that lipid-linked proteins are organized in cholesterol-dependent submicron-sized domains. Our methodology offers a new way of monitoring nanometre-scale association between molecules in living cells.	Natl Ctr Biol Sci, TIFR Ctr, Bangalore 560012, Karnataka, India	Tata Institute of Fundamental Research (TIFR); National Centre for Biological Sciences (NCBS)	Mayor, S (corresponding author), Natl Ctr Biol Sci, TIFR Ctr, IISc Campus,POB 1234, Bangalore 560012, Karnataka, India.		Varma, Rajat/I-1209-2012	Varma, Rajat/0000-0001-5131-0402				BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; Brown RE, 1998, J CELL SCI, V111, P1; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; Edidin M, 1997, CURR OPIN STRUC BIOL, V7, P528, DOI 10.1016/S0959-440X(97)80117-0; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; Griffiths G., 1993, FINE STRUCTURE IMMUN, P1; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; Kenworthy AK, 1998, BIOPHYS J, V74, pA8; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; Matko J, 1997, METHOD ENZYMOL, V278, P444; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; MAYOR S, IN PRESS EMBO J; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; RITTER TE, 1995, P NATL ACAD SCI USA, V92, P3824, DOI 10.1073/pnas.92.9.3824; RUNNELS LW, 1995, BIOPHYS J, V69, P1569, DOI 10.1016/S0006-3495(95)80030-5; Sheets ED, 1997, BIOCHEMISTRY-US, V36, P12449, DOI 10.1021/bi9710939; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Simson R, 1998, BIOPHYS J, V74, P297, DOI 10.1016/S0006-3495(98)77787-2; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; WEBER G, 1954, T FARADAY SOC, V50, P552, DOI 10.1039/tf9545000552; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Yancey PG, 1996, J BIOL CHEM, V271, P16026, DOI 10.1074/jbc.271.27.16026	31	976	1005	0	92	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					798	801		10.1038/29563	http://dx.doi.org/10.1038/29563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723621				2022-12-24	WOS:000075503600050
J	Ewan, PW				Ewan, PW			Prevention of peanut allergy	LANCET			English	Editorial Material							INFANTS; AGE; SENSITIZATION; AVOIDANCE		Univ Cambridge, Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England	Addenbrooke's Hospital; University of Cambridge	Ewan, PW (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England.							CANT A, 1985, BRIT MED J, V291, P932, DOI 10.1136/bmj.291.6500.932; Committee on Toxicity of Chemicals in Food, 1998, PEAN ALL; Ewan PW, 1996, BRIT MED J, V312, P1074; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; HATAHET R, 1994, REV FR ALLERGOL, V34, P377, DOI 10.1016/S0335-7457(05)80243-6; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; Hourihane JO, 1996, BRIT MED J, V313, P518, DOI 10.1136/bmj.313.7056.518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI [10.1111/j.1365-2222.1997.tb01190.x, 10.1046/j.1365-2222.1997.d01-559.x]; Lack G, 1998, J ALLERGY CLIN IMMUN, V101, pS104; Tariq SM, 1996, BRIT MED J, V313, P514, DOI 10.1136/bmj.313.7056.514; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	12	12	12	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					4	5		10.1016/S0140-6736(05)79505-2	http://dx.doi.org/10.1016/S0140-6736(05)79505-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800734				2022-12-24	WOS:000074608600004
J	Scott, K; Zuker, CS				Scott, K; Zuker, CS			Assembly of the Drosophila phototransduction cascade into a signalling complex shapes elementary responses	NATURE			English	Article							PDZ-DOMAIN PROTEIN; SIGNALING COMPLEX; CA2+ CHANNEL; IN-VIVO; TRP; PHOTORECEPTORS; MUTANTS; MORPHOGENESIS; GLYCOPROTEIN; CHAOPTIN	The subcellular compartmentalization of signalling molecules helps to ensure the selective activation of different signal-transduction cascades within a single cell(1). Although there are many examples of compartmentalized signalling molecules, there are few examples of entire signalling cascades being organized as distinct signalling complexes. In Drosophila photoreceptors, the InaD protein, which consists of five PDZ domains, functions as a multivalent adaptor that bring together several components of the phototransduction cascade into a macromolecular complex(2-5). Here we study single-photon responses in several photoreceptor mutant backgrounds, and show that the InaD macromolecular complex is the unit of signalling that underlies elementary responses. We show that the localized activity of this signalling: unit promotes reliable single-photon responses as well as rapid activation and feedback regulation. Finally, we use genetic and electrophysiological tools to illustrate how the assembly of signalling molecules into a transduction complex limits signal amplification in vivo.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Zuker, CS (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.							BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; DELAND MC, 1973, NATURE, V244, P84; FUORTES MGF, 1964, J PHYSIOL-LONDON, V172, P239, DOI 10.1113/jphysiol.1964.sp007415; HARDIE RC, 1995, CELL CALCIUM, V18, P256, DOI 10.1016/0143-4160(95)90023-3; Huber A, 1996, EMBO J, V15, P7036, DOI 10.1002/j.1460-2075.1996.tb01095.x; JOHNSON EC, 1986, J GEN PHYSIOL, V88, P651, DOI 10.1085/jgp.88.5.651; Niemeyer BA, 1996, CELL, V85, P651, DOI 10.1016/S0092-8674(00)81232-5; Pearn MT, 1996, J BIOL CHEM, V271, P4937; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; Scott K, 1997, TRENDS BIOCHEM SCI, V22, P350, DOI 10.1016/S0968-0004(97)01100-6; Scott K, 1997, CELL, V91, P375, DOI 10.1016/S0092-8674(00)80421-3; SCOTT K, 1995, NEURON, V15, P919, DOI 10.1016/0896-6273(95)90182-5; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; STIEVE H, 1986, BUMPS ELEMENTARY EXC; Tsunoda S, 1998, CURR OPIN GENET DEV, V8, P419, DOI 10.1016/S0959-437X(98)80112-3; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; YEANDLE S, 1957, THESIS J HOPKINS U; Zuker CS, 1996, P NATL ACAD SCI USA, V93, P571, DOI 10.1073/pnas.93.2.571	21	129	131	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					805	808		10.1038/27448	http://dx.doi.org/10.1038/27448			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796815				2022-12-24	WOS:000076607400058
J	Caidahl, K; Kazzam, E; Lidberg, J; Andersen, GN; Nordanstig, J; Dahlwvist, SR; Waldenstrom, A; Wikh, R				Caidahl, K; Kazzam, E; Lidberg, J; Andersen, GN; Nordanstig, J; Dahlwvist, SR; Waldenstrom, A; Wikh, R			New concept in echocardiography: harmonic imaging of tissue without use of contrast agent	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; SYSTEMIC-SCLEROSIS; INJECTION; OPACIFICATION; ULTRASOUND; RESOLUTION; EFFICACY	Background Endocardial border detection is important for echocardiographic assessment of left-ventricular function. Second harmonic imaging of contrast agents enhances this border detection. We discovered that harmonic imaging improves tissue visualisation even before contrast injection. We therefore sought objectively to demonstrate the degree of enhancement of endocardial and myocardial visualisation. Methods An ATL HDI-3000 scanner with software for contrast harmonic imaging was used to record short-axis images of the left ventricle in 27 patients with possible myocardial disease and 22 controls, in the fundamental mode and with harmonic imaging. A computer program measured the relative grey-scale values within six segments of the endocardium and myocardium. An Acuson Sequoia Scanner equipped with software for tissue harmonic imaging was used to investigate the reproducibility of ejection-fraction calculations in 22 patients with ischaemic heart disease. Findings Harmonic imaging produced brighter endocardium within each segment. Relative to the mean grey value of the total imaging sector, the values for harmonic and fundamental imaging were 171.5 vs 85.6% (p<0.0001) in end diastole and 194.1 vs 106.7% (p<0.0001) in end systole. Results for the myocardial segments were also significantly better for harmonic imaging. Structure enhancement of similar magnitude was seen among patients and healthy controls. Use of harmonic imaging reduced the proportion of unacceptable images by 14-46% in different views and improved the reproducibility of biplane ejection-fraction measurements. Interpretation In comparison with fundamental imaging, the relative endocardial and myocardial brightness is enhanced by harmonic imaging.	Sahlgrens Univ Hosp, Dept Clin Physiol, SE-41345 Gothenburg, Sweden; Univ Umea Hosp, Dept Cardiol, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Rheumatol, S-90185 Umea, Sweden	Sahlgrenska University Hospital; Umea University; Umea University	Caidahl, K (corresponding author), Sahlgrens Univ Hosp, Dept Clin Physiol, SE-41345 Gothenburg, Sweden.		Caidahl, Kenneth/AAQ-2645-2021; Silverdal, Jonas/AAY-5269-2021	Silverdal, Jonas/0000-0002-6088-7868; Waldenstrom, Anders/0000-0002-5304-0802; Nordanstig, Joakim/0000-0002-2670-2268				AVERKIOU M, 1997, IEEE ULTR S TOR ONT, P1561; Beppu S, 1997, J AM SOC ECHOCARDIOG, V10, P11, DOI 10.1016/S0894-7317(97)80028-4; BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; BONARJEE VVS, 1993, AM J CARDIOL, V72, P1004, DOI 10.1016/0002-9149(93)90853-5; CAIDAHL K, 1997, EUR HEART J SUPPL, V19, P146; Colon PJ, 1997, J AM SOC ECHOCARDIOG, V10, P602, DOI 10.1016/S0894-7317(97)70022-1; Forsberg F, 1996, J ULTRAS MED, V15, P853, DOI 10.7863/jum.1996.15.12.853; GENY B, 1993, J AM COLL CARDIOL, V22, P1193, DOI 10.1016/0735-1097(93)90437-6; GUSTAFSSON R, 1989, LANCET, V2, P475; Iliceto S, 1996, EUR HEART J, V17, P344; KAZZAM E, 1991, AM J NONINVAS CARD, V5, P343; Krishnan S, 1996, ULTRASONIC IMAGING, V18, P77, DOI 10.1006/uimg.1996.0005; Lindner JR, 1997, AM J CARDIOL, V79, P1657, DOI 10.1016/S0002-9149(97)00217-8; Mulvagh SL, 1996, J AM COLL CARDIOL, V27, P1519, DOI 10.1016/0735-1097(95)00619-2; Porter TR, 1997, J AM COLL CARDIOL, V29, P791, DOI 10.1016/S0735-1097(96)00575-X; PORTER TR, 1994, J AM COLL CARDIOL, V23, P1440, DOI 10.1016/0735-1097(94)90389-1; Schwarz KQ, 1997, J AM SOC ECHOCARDIOG, V10, P1, DOI 10.1016/S0894-7317(97)80027-2; Ward B, 1997, J ACOUST SOC AM, V101, P143, DOI 10.1121/1.417977; Zotz R J, 1996, J Am Soc Echocardiogr, V9, P1, DOI 10.1016/S0894-7317(96)90098-X	19	111	114	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 17	1998	352	9136					1264	1270		10.1016/S0140-6736(98)02361-7	http://dx.doi.org/10.1016/S0140-6736(98)02361-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131KB	9788456				2022-12-24	WOS:000076573800010
J	Liu, XH; Wang, H; Eberstadt, M; Schnuchel, A; Olejniczak, ET; Meadows, RP; Schkeryantz, JM; Janowick, DA; Harlan, JE; Harris, EAS; Staunton, DE; Fesik, SW				Liu, XH; Wang, H; Eberstadt, M; Schnuchel, A; Olejniczak, ET; Meadows, RP; Schkeryantz, JM; Janowick, DA; Harlan, JE; Harris, EAS; Staunton, DE; Fesik, SW			NMR structure and mutagenesis of the N-terminal Dbl homology domain of the nucleotide exchange factor trio	CELL			English	Article							ISOTOPICALLY ENRICHED PROTEINS; NUCLEAR-MAGNETIC-RESONANCE; BETA-GAMMA-SUBUNITS; EF-TS COMPLEX; CRYSTAL-STRUCTURE; EXPRESSION CLONING; ONCOGENE PRODUCT; BINDING; KINASE; ACTIVATION	Guanine nucleotide exchange factors for the Rho family of GTPases contain a Dbl homology (DH) domain responsible for catalysis and a pleckstrin homology (PH) domain whose function is unknown. Here we describe the solution structure of the N-terminal DH domain of Trio that catalyzes nucleotide exchange for Rac1. The all-alpha-helical protein has a very different structure compared to other exchange factors. Based on site-directed mutagenesis, functionally important residues of the DH domain were identified. They are all highly conserved and reside in close proximity on two alpha helices. In addition, we have discovered a unique capability of the PH domain to enhance nucleotide exchange in DH domain-containing proteins.	Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA; ICOS Corp, Bothell, WA 98021 USA	Abbott Laboratories; Icos Corporation	Fesik, SW (corresponding author), Abbott Labs, Div Pharmaceut Discovery, Abbott Pk, IL 60064 USA.	fesiks@pprd.abbott.com						Bellanger JM, 1998, ONCOGENE, V16, P147, DOI 10.1038/sj.onc.1201532; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; Gardner KH, 1997, J AM CHEM SOC, V119, P7599, DOI 10.1021/ja9706514; GRZESIEK S, 1993, J BIOMOL NMR, V3, P487; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEYWEGT GJ, 1995, STRUCTURE, V3, P535, DOI 10.1016/S0969-2126(01)00187-3; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rittinger K, 1997, NATURE, V388, P693, DOI 10.1038/41805; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wang DS, 1997, BIOCHEM BIOPH RES CO, V234, P183, DOI 10.1006/bbrc.1997.6589; WANG H, 1998, IN PRESS J BIOMOL NM; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	52	153	155	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					269	277		10.1016/S0092-8674(00)81757-2	http://dx.doi.org/10.1016/S0092-8674(00)81757-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790533	Bronze			2022-12-24	WOS:000076538300014
J	Sudlow, M; Thomson, R; Thwaites, B; Rodgers, H; Kenny, RA				Sudlow, M; Thomson, R; Thwaites, B; Rodgers, H; Kenny, RA			Prevalence of atrial fibrillation and eligibility for anticoagulants in the community	LANCET			English	Article							GENERAL-PRACTICE; STROKE; PREVENTION; POPULATION; WARFARIN; RECOMMENDATIONS; PERSPECTIVE	Background: Anticoagulants are effective in the prevention of stroke in atrial fibrillation and flutter (AF). We aimed to find out the prevalence of AF in the UK and to estimate the proportion of patients with AF who might benefit from anticoagulation. Methods We screened with electrocardiography a random sample of 4843 people from the community aged 65 years and older for AF. Participants with AF had further investigations to identify risk factors for stroke and contraindications to anticoagulants. We used three sets of criteria to assess risk and elibility for anticoagulation. Findings 228 (4.7%) participants had AF. According to analyses derived from risk stratifications based on the Stroke Prevention in Atrial Fibrillation (SPAF) study 61% of these patients would have benefited from anticoagulation, 49% according to pooled analysis of trial results, and 41% according to the inclusion criteria for the SPAF 3 study. Anticoagulants were used by 1114 (23%) of all patients and were least used among elderly women, who may be the most likely to benefit. Echocardiography would be useful to assess the need for anticoagulation only in patients younger than 75 years with no contraindications to treatment and no clinical risk factors for stroke. Interpretation: Anticoagulants seem to be underused and misdirected in treatment of AF, according to various criteria. Efforts to promote and support wider and more appropriate use of anticoagulants would seem to be justified, and should decrease the incidence of stroke amongst elderly patients.	Newcastle Univ, Sch Clin Med Sci, Dept Med, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England; Newcastle Univ, Sch Hlth Sci, Dept Epidemiol & Publ Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Wansbeck Gen Hosp, Ashington, England	Newcastle University - UK; Newcastle University - UK	Sudlow, M (corresponding author), Newcastle Univ, Sch Clin Med Sci, Dept Med, Newcastle Upon Tyne NE2 4AA, Tyne & Wear, England.		Rodgers, Helen/K-4358-2012	Kenny, Rose Anne/0000-0002-9336-8124				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; Blackshear JL, 1996, LANCET, V348, P633; Breeze E, 1994, HLTH SURVEY ENGLAND; COCHRAN WG, 1977, SAMPLING TECHNIQUES, P52; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GLASZIOU PP, 1995, BMJ-BRIT MED J, V311, P1356, DOI 10.1136/bmj.311.7016.1356; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; Halperin JL, 1997, CIRCULATION, V96, P1562; HILL JD, 1987, J ROY COLL GEN PRACT, V37, P172; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOUDSTAAL PJ, 1993, LANCET, V342, P1255; LAKE FR, 1989, AUST NZ J MED, V19, P321, DOI 10.1111/j.1445-5994.1989.tb00271.x; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; Lip GYH, 1997, BRIT J GEN PRACT, V47, P285; ManSonHing M, 1996, ARCH INTERN MED, V156, P1841, DOI 10.1001/archinte.156.16.1841; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; OMAHONY PG, 1995, STROKE, V26, P1334, DOI 10.1161/01.STR.26.8.1334; PETERSEN P, 1989, LANCET, V1, P175; PETRIE JC, 1986, BRIT MED J, V293, P611, DOI 10.1136/bmj.293.6547.611; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; SUDLOW CM, 1995, BRIT MED J, V311, P558, DOI 10.1136/bmj.311.7004.558; Sudlow M, 1997, BRIT MED J, V314, P1529, DOI 10.1136/bmj.314.7093.1529; Thomson R, 1998, BRIT MED J, V316, P509, DOI 10.1136/bmj.316.7130.509; Wheeldon NM, 1998, HEART, V79, P50, DOI 10.1136/hrt.79.1.50; WOLF PA, 1991, STROKE, V22, P983, DOI 10.1161/01.STR.22.8.983	29	314	320	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1167	1171		10.1016/S0140-6736(98)01401-9	http://dx.doi.org/10.1016/S0140-6736(98)01401-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777832				2022-12-24	WOS:000076415400007
J	Shirahige, K; Hori, Y; Shiraishi, K; Yamashita, M; Takahashi, K; Obuse, C; Tsurimoto, T; Yoshikawa, H				Shirahige, K; Hori, Y; Shiraishi, K; Yamashita, M; Takahashi, K; Obuse, C; Tsurimoto, T; Yoshikawa, H			Regulation of DNA-replication origins during cell-cycle progression	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; S-PHASE; YEAST ORIGIN; DAMAGE; CHECKPOINT	We have shown previously that chromosome VI of Saccharomyces cerevisiae contains nine origins of DNA replication that differ in initiation frequency and replicate sequentially during the S phase of the cell cycle(1,2). Here we show that there are links between activation of these multiple origins and regulation of S-phase progression. We study the effects of a DNA-damaging agent, methyl methane sulphonate (MMS), and of mutations in checkpoint genes such as rad53 (ref. 3) on the activity of origins, measured by two-dimensional gel analysis, and on cell-cycle progression, measured by fluorescence-activated cell sorting. We find that when MMS slows down S-phase progression it also selectively blocks initiation from late origins. A rad53 mutation enhances late and/or inefficient origins and releases the initiation block by MMS. Mutation of rad53 also results in a late origin becoming early replicating, We conclude that rad53 regulates the timing of initiation of replication from late origins during normal cell growth and blocks initiation from late origins in MMS-treated cells. rad53 is, therefore, involved in the cell's surveillance of S-phase progression(4,5). We also find that orc2, which encodes subunit 2 of the origin-recognition complex(6,7), is involved in suppression of late origins.	Nara Inst Sci & Technol, Nara 6300101, Japan; Ajinomoto Co Inc, Kawasaki, Kanagawa 2108680, Japan	Nara Institute of Science & Technology; Ajinomoto Co Inc	Yoshikawa, H (corresponding author), Nara Inst Sci & Technol, 8916-5 Takayama, Nara 6300101, Japan.		Obuse, Chikashi/F-5273-2011	Shirahige, Katsuhiko/0000-0002-7862-1144; Tsurimoto, Toshiki/0000-0001-7597-2216				BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; Friedman KL, 1997, GENES CELLS, V2, P667, DOI 10.1046/j.1365-2443.1997.1520350.x; HORIUCHI S, 1996, APPL PHYS S, V6, P7; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Lee HY, 1997, P NATL ACAD SCI USA, V94, P526, DOI 10.1073/pnas.94.2.526; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; PAULOVICH AG, 1995, CELL, V82, P841, DOI 10.1016/0092-8674(95)90481-6; Paulovich AG, 1997, GENETICS, V145, P45; Yamashita M, 1997, GENES CELLS, V2, P655, DOI 10.1046/j.1365-2443.1997.1530351.x	12	352	360	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					618	621		10.1038/27007	http://dx.doi.org/10.1038/27007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783590				2022-12-24	WOS:000076362900053
J	Nightingale, SL				Nightingale, SL			Crohn's disease treatment approved	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-24	WOS:000076210800004
J	Parente, CA; Blacklock, BJ; Froehlich, WM; Murphy, DB; Devreotes, PN				Parente, CA; Blacklock, BJ; Froehlich, WM; Murphy, DB; Devreotes, PN			G protein signaling events are activated at the leading edge of chemotactic cells	CELL			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; ADENYLYL-CYCLASE; CHEMOATTRACTANT RECEPTORS; DICTYOSTELIUM-DISCOIDEUM; MEDIATED ACTIVATION; CYTOSOLIC REGULATOR; FUSION PROTEIN; STIMULATION; DYNAMICS; KINASE	Directional sensing by eukaryotic cells does not require polarization of chemoattractant receptors. The translocation of the PH domain-containing protein CRAC in D. discoideum to binding sites on the inner face of the plasma membrane reflects activation of the G protein-linked signaling system. Increments in chemoattractant elicit a uniform response around the cell periphery. Yet when cells are exposed to a gradient, the activation occurs selectively at the stimulated edge, even in immobilized cells. We propose that such localized activation, transmitted by the recruitment of cytosolic proteins, may be a general mechanism for gradient sensing by G protein-linked chemotactic systems including those involving chemotactic cytokines in leukocytes.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Cell Biol & Anat, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Devreotes, PN (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	pnd@welchlink.welch.jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033171] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM33171, GM57874] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 1997, J CELL SCI, V110, P2333; ALEX LA, 1994, TRENDS GENET, V10, P133, DOI 10.1016/0168-9525(94)90215-1; Araki T, 1998, EMBO J, V17, P4018, DOI 10.1093/emboj/17.14.4018; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; CATERINA MJ, 1991, FASEB J, V5, P3078, DOI 10.1096/fasebj.5.15.1743439; Chen MY, 1997, GENE DEV, V11, P3218, DOI 10.1101/gad.11.23.3218; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GERISCH G, 1995, CURR BIOL, V5, P1280, DOI 10.1016/S0960-9822(95)00254-5; Gottwald U, 1996, MOL BIOL CELL, V7, P261, DOI 10.1091/mbc.7.2.261; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; HUGHES JE, 1994, MOL CELL BIOL, V14, P6117, DOI 10.1128/MCB.14.9.6117; INSALL R, 1994, J CELL BIOL, V126, P1537, DOI 10.1083/jcb.126.6.1537; JOHNSON RL, 1991, BIOCHEMISTRY-US, V30, P6982, DOI 10.1021/bi00242a025; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KOSHLAND DE, 1977, SCIENCE, V196, P1055, DOI 10.1126/science.870969; KREITMEIER M, 1995, J CELL BIOL, V129, P179, DOI 10.1083/jcb.129.1.179; Krump E, 1997, J BIOL CHEM, V272, P937, DOI 10.1074/jbc.272.2.937; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai CF, 1996, J BIOL CHEM, V271, P13968, DOI 10.1074/jbc.271.24.13968; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; LILLY PJ, 1994, J BIOL CHEM, V269, P14123; LILLY PJ, 1995, J CELL BIOL, V129, P1659, DOI 10.1083/jcb.129.6.1659; Maeda M, 1996, J BIOL CHEM, V271, P3351; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; PARENT CA, 1995, J BIOL CHEM, V270, P22693, DOI 10.1074/jbc.270.39.22693; Parent CA, 1996, J BIOL CHEM, V271, P18333, DOI 10.1074/jbc.271.31.18333; Parent CA, 1996, ANNU REV BIOCHEM, V65, P411; Peracino B, 1998, J CELL BIOL, V141, P1529, DOI 10.1083/jcb.141.7.1529; Shaw G, 1996, BIOESSAYS, V18, P35, DOI 10.1002/bies.950180109; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; THEIBERT A, 1986, J BIOL CHEM, V261, P5121; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Westphal M, 1997, CURR BIOL, V7, P176, DOI 10.1016/S0960-9822(97)70088-5; Xiao Z, 1997, J CELL BIOL, V139, P365, DOI 10.1083/jcb.139.2.365; ZIGMOND SH, 1981, J CELL BIOL, V89, P585, DOI 10.1083/jcb.89.3.585	46	489	495	2	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					81	91		10.1016/S0092-8674(00)81784-5	http://dx.doi.org/10.1016/S0092-8674(00)81784-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778249	hybrid			2022-12-24	WOS:000076242300012
J	Beecroft, N; Cochrane, GM; Milburn, HJ				Beecroft, N; Cochrane, GM; Milburn, HJ			Effect of sex of fetus on asthma during pregnancy: blind prospective study	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Guys Hosp, Dept Resp Med & Allergy, London SE1 9RT, England; United Med & Dent Sch Guys & St Thomas Hosp, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Milburn, HJ (corresponding author), Guys Hosp, Chest Clin, London SE1 9RT, England.							BEYNON HLC, 1988, LANCET, V2, P370; JUNIPER EF, 1989, AM REV RESPIR DIS, V140, P924, DOI 10.1164/ajrccm/140.4.924; SCHATZ M, 1988, Journal of Allergy and Clinical Immunology, V81, P509, DOI 10.1016/0091-6749(88)90187-X; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837, DOI 10.1001/archinte.156.16.1837; WHITE RJ, 1989, RESP MED, V83, P103, DOI 10.1016/S0954-6111(89)80222-7	5	59	59	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					856	857		10.1136/bmj.317.7162.856	http://dx.doi.org/10.1136/bmj.317.7162.856			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748178	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000076222300019
J	Meng, ID; Manning, BH; Martin, WJ; Fields, HL				Meng, ID; Manning, BH; Martin, WJ; Fields, HL			An analgesia circuit activated by cannabinoids	NATURE			English	Article							ROSTRAL VENTROMEDIAL MEDULLA; RECEPTOR; BRAIN; PAIN; NEURONS; DELTA-9-TETRAHYDROCANNABINOL; ANTINOCICEPTION; MORPHINE; AGONIST	Although many anecdotal reports indicate that marijuana and its active constituent, delta-9-tetrahydrocannabinol (delta-9-THC), may reduce pain sensation(1,2), studies of humans have produced inconsistent results(3-6). In animal studies, the apparent pain-suppressing effects of delta-9-THC and other cannabinoid drugs(7-12) are confounded by motor deficits(13,14). Here we show that a brainstem circuit that contributes to the pain-suppressing effects of morphine(15) is also required for the analgesic effects of cannabinoids. Inactivation of the rostral ventromedial medulla (RVM) prevents the analgesia but not the motor deficits produced by systemically administered cannabinoids, Furthermore, cannabinoids produce analgesia by modulating RVM neuronal activity in a manner similar to, but pharmacologically dissociable from, that of morphine. We also show that endogenous cannabinoids tonically regulate pain thresholds in part through the modulation of RVM neuronal activity. These results show that analgesia produced by cannabinoids and opioids involves similar brainstem circuitry and that cannabinoids are indeed centrally acting analgesics with a new mechanism of action.	Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Meng, ID (corresponding author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.		Manning, Barton/AAD-2340-2021; Fields, Howard/ABG-9073-2020; Martin, William J/L-9033-2017	Martin, William J/0000-0002-2749-3365				BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BUXBAUM D, 1969, FED PROC, V28, P735; Cadas H, 1997, J NEUROSCI, V17, P1226; CLARK WC, 1981, J CLIN PHARM S, V21, P299; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Dunn M, 1974, Paraplegia, V12, P175; FIELDS HL, 1983, NATURE, V306, P684, DOI 10.1038/306684a0; FIELDS HL, 1995, J NEUROPHYSIOL, V74, P1742, DOI 10.1152/jn.1995.74.4.1742; GOUGH AL, 1977, PSYCHOPHARMACOLOGY, V54, P87, DOI 10.1007/BF00426547; HEINRICHER MM, 1992, NEUROSCIENCE, V48, P533, DOI 10.1016/0306-4522(92)90400-V; Herzberg U, 1997, NEUROSCI LETT, V221, P157, DOI 10.1016/S0304-3940(96)13308-5; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; LIBMAN E, 1985, PERS INDIV DIFFER, V6, P169, DOI 10.1016/0191-8869(85)90106-0; LICHTMAN AH, 1991, BRAIN RES, V559, P309, DOI 10.1016/0006-8993(91)90017-P; Martin WJ, 1996, J NEUROSCI, V16, P6601; Martin WJ, 1998, NEUROSCI LETT, V242, P33, DOI 10.1016/S0304-3940(98)00044-5; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; Mikuriya Tod H, 1973, MARIJUANA MED PAPERS; Mitchell JM, 1998, NEUROSCIENCE, V87, P123, DOI 10.1016/S0306-4522(98)00119-5; MOSS DE, 1980, EUR J PHARMACOL, V61, P313, DOI 10.1016/0014-2999(80)90134-X; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; Pan ZZ, 1996, NEUROSCIENCE, V74, P855, DOI 10.1016/0306-4522(96)00179-0; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; RICHARDSON JD, 1998, J NEUROSCI, V518; RINALDICARMONA M, 1994, FEBS LETT, V350, P240, DOI 10.1016/0014-5793(94)00773-X; Roychowdhury SM, 1996, NEUROSCIENCE, V74, P863, DOI 10.1016/0306-4522(96)00180-7; SOFIA RD, 1973, J PHARMACOL EXP THER, V186, P646; Stella N, 1997, NATURE, V388, P773, DOI 10.1038/42015; Tsou K, 1998, NEUROSCIENCE, V83, P393, DOI 10.1016/S0306-4522(97)00436-3; UEKI S, 1980, TRENDS PHARMACOL SCI, V1, P126	31	298	305	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					381	383		10.1038/26481	http://dx.doi.org/10.1038/26481			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759727				2022-12-24	WOS:000076083800053
J	Zhu, YA; Richardson, JA; Parada, LF; Graff, JM				Zhu, YA; Richardson, JA; Parada, LF; Graff, JM			Smad3 mutant mice develop metastatic colorectal cancer	CELL			English	Article							TGF-BETA-RECEPTOR; NEURAL CREST MIGRATION; COLON-CANCER; TARGETED DISRUPTION; KNOCKOUT MICE; MAD PROTEINS; GENE; MUTATION; CELLS; IDENTIFICATION	TGF beta-related growth factors have been implicated in a variety of developmental and physiological processes in organisms ranging from nematodes to mammals. TGF beta transduces its signal to the interior of the cell via Smad2, Smad3, and Smad4. We report the cloning and targeted disruption of the mouse Smad3 gene. Smad3 mutant mice are viable and fertile. Between 4 and 6 months of age, the Smad3 mutant mice become moribund with colorectal adenocarcinomas. The neoplasms penetrate through the intestinal wall and metastasize to lymph nodes. These results directly implicate TGF beta signaling in the pathogenesis of colorectal cancer and provide a compelling animal model for the study of human colorectal cancer.	Univ Texas, SW Med Ctr, Ctr Dev Biol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Parada, LF (corresponding author), Univ Texas, SW Med Ctr, Ctr Dev Biol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Zhu, Yuan/ABF-8405-2020; Parada, luis F/B-9400-2014					Arai T, 1998, CANCER LETT, V122, P157, DOI 10.1016/S0304-3835(97)00384-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRESALIER RS, 1998, SLEISENGER FORDTRANS, P1906; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Candia AF, 1997, DEVELOPMENT, V124, P4467; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COHEN AM, 1997, CANC PRINCIPLES PRAC, V5, P1144; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Fenoglio-Preiser CM, 1989, GASTROINTESTINAL PAT; Graff JM, 1997, CELL, V89, P171, DOI 10.1016/S0092-8674(00)80196-8; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan B, 1994, MANIPULATING MOUSE E; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; JIRCINY J, 1994, TRENDS GENET, V10, P164; KAARTINEN V, 1995, NAT GENET, V11, P415, DOI 10.1038/ng1295-415; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Krull CE, 1997, CURR BIOL, V7, P571, DOI 10.1016/S0960-9822(06)00256-9; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Nakao A, 1997, J BIOL CHEM, V272, P2896, DOI 10.1074/jbc.272.5.2896; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oshima H, 1997, CANCER RES, V57, P1644; Oshima M, 1996, DEV BIOL, V179, P297, DOI 10.1006/dbio.1996.0259; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Polyak K, 1996, BBA-REV CANCER, V1242, P185, DOI 10.1016/0304-419X(95)00009-5; Riggins GJ, 1997, CANCER RES, V57, P2578; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schutte M, 1996, CANCER RES, V56, P2527; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SU L, 1992, SCIENCE, V256, P658; Suzuki A, 1997, DEV BIOL, V184, P402, DOI 10.1006/dbio.1997.8548; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Thiagalingam S, 1996, NAT GENET, V13, P343, DOI 10.1038/ng0796-343; Tomlinson I, 1997, CANCER METAST REV, V16, P67, DOI 10.1023/A:1005744323215; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Wang HU, 1997, NEURON, V18, P383, DOI 10.1016/S0896-6273(00)81240-4; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; White RL, 1998, CELL, V92, P591, DOI 10.1016/S0092-8674(00)81124-1; Wick W, 1996, ONCOGENE, V12, P973; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1; Yang X, 1998, P NATL ACAD SCI USA, V95, P3667, DOI 10.1073/pnas.95.7.3667; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	63	546	579	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					703	714		10.1016/S0092-8674(00)81730-4	http://dx.doi.org/10.1016/S0092-8674(00)81730-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753318	Bronze			2022-12-24	WOS:000076021200004
J	Canman, CE; Lim, DS; Cimprich, KA; Taya, Y; Tamai, K; Sakaguchi, K; Appella, E; Kastan, MB; Siliciano, JD				Canman, CE; Lim, DS; Cimprich, KA; Taya, Y; Tamai, K; Sakaguchi, K; Appella, E; Kastan, MB; Siliciano, JD			Activation of the ATM kinase by ionizing radiation and phosphorylation of p53	SCIENCE			English	Article							CELL-CYCLE CHECKPOINT; ATAXIA-TELANGIECTASIA CELLS; PROTEIN-KINASE; DNA-DAMAGE; PATHWAYS; RECOMBINATION; INDUCTION; PRODUCT; DEFECT; MDM2	The p53 tumor suppressor protein is activated and phosphorylated on serine-15 in response to various DNA damaging agents. The gene product mutated in ataxia telangiectasia, ATM, acts upstream of p53 in a signal transduction pathway initiated by ionizing radiation. Immunoprecipitated ATM had intrinsic protein kinase activity and phosphorylated p53 on serine-15 in a manganese-dependent manner. Ionizing radiation, but not ultraviolet radiation, rapidly enhanced this p53-directed kinase activity of endogenous ATM. These observations, along with the fact that phosphorylation of p53 on serine-15 in response to ionizing radiation is reduced in ataxia telangiectasia cells, suggest that ATM is a protein kinase that phosphorylates p53 in vivo.	Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Natl Canc Ctr, Res Inst, Chuo Ku, Tokyo 104, Japan; MBL Co Ltd, Ina Labs, Nagano 396, Japan; NIH, Cell Biol Lab, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins Medicine; Stanford University; National Cancer Center - Japan; National Institutes of Health (NIH) - USA	Kastan, MB (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St,D-1034, Memphis, TN 38105 USA.		Lim, Dae-Sik/C-1599-2011; Tamai, Katsuyuki/F-4743-2013	Lim, Dae-Sik/0000-0003-2356-7555; Tamai, Katsuyuki/0000-0003-4094-3911; Sakaguchi, Kazuyasu/0000-0002-8434-4171; , Christine/0000-0001-8892-7430	NCI NIH HHS [CA71387] Funding Source: Medline; NIEHS NIH HHS [ES05777] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES005777, R01ES005777] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Barlow C, 1997, NAT GENET, V17, P453, DOI 10.1038/ng1297-453; CANMAN CE, 1994, CANCER RES, V54, P5054; CANMAN CE, UNPUB; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; KHANNA KK, 1993, ONCOGENE, V8, P3307; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Nacht M, 1996, GENE DEV, V10, P2055, DOI 10.1101/gad.10.16.2055; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Rathmell WK, 1997, CANCER RES, V57, P68; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SHAFMAN TD, 1995, CANCER RES, V55, P3242; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	25	1662	1701	0	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1677	1679		10.1126/science.281.5383.1677	http://dx.doi.org/10.1126/science.281.5383.1677			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733515				2022-12-24	WOS:000075856500048
J	Westin, S; Kurokawa, R; Nolte, RT; Wisely, GB; McInerney, EM; Rose, DW; Milburn, MV; Rosenfeld, MG; Glass, CK				Westin, S; Kurokawa, R; Nolte, RT; Wisely, GB; McInerney, EM; Rose, DW; Milburn, MV; Rosenfeld, MG; Glass, CK			Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators	NATURE			English	Article							THYROID-HORMONE RECEPTOR; LIGAND-BINDING DOMAIN; 9-CIS RETINOIC ACID; TRANSCRIPTIONAL ACTIVATION; CRYSTAL-STRUCTURE; COACTIVATOR; SUPERFAMILY; PATHWAYS; COMPLEX; P300	Retinoic-acid receptor-alpha (RAR-alpha) and peroxisome proliferator-activated receptor-gamma (PPAR-gamma) are members of the nuclear-receptor superfamily that bind to DNA as heterodimers with retinoid-X receptors (RXRs)(1,2). PPAR-RXR heterodimers can be activated by PPAR or RXR ligands(3), whereas RAR-RXR heterodimers are selectively activated by RAR ligands only, because of allosteric inhibition of the binding of ligands to RXR by RAR(4,5). However, RXR ligands can potentiate the transcriptional effects of RAR ligands in cells(6), Transcriptional activation by nuclear receptors requires a carboxy-terminal helical region, termed activation function-2 (AF-2) (refs 7-9), that forms part of the ligand-binding pocket and undergoes a conformational change required for the recruitment of co-activator proteins, including NCoA-1/SRC-1 (refs 10-17), Here we show that allosteric inhibition of RXR results from a rotation of the RXR AF-2 helix that places it in contact with the RAR coactivator-binding site. Recruitment of an LXXLL motif of SRC-1 to RAR in response to ligand displaces the RXR AF-2 domain, allowing RXR ligands to bind and promote the binding of a second LXXLL motif from the same SRC-1 molecule, These results may partly explain the different responses of nuclear-receptor heterodimers to RXR-specific ligands.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Dept Struct Chem, Res Triangle Pk, NC 27709 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; GlaxoSmithKline	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592				BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN JY, 1996, NATURE, V382, P829; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GLASS C. K., 1994, ENDOCR REV, V15, P1503; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; NOLTE RT, IN PRESS NATURE; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	28	295	309	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					199	202		10.1038/26040	http://dx.doi.org/10.1038/26040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744281				2022-12-24	WOS:000075829900048
J	Lawrence, DJ; Feldman, WC; Barraclough, BL; Binder, AB; Elphic, RC; Maurice, S; Thomsen, DR				Lawrence, DJ; Feldman, WC; Barraclough, BL; Binder, AB; Elphic, RC; Maurice, S; Thomsen, DR			Global elemental maps of the moon: The Lunar Prospector gamma-ray spectrometer	SCIENCE			English	Article							ACTIVATION	Lunar Prospector gamma-ray spectrometer spectra along with counting rate maps of thorium, potassium, and iron delineate Large compositional variations over the lunar surface. Thorium and potassium are highly concentrated in and around the nearside western maria and Less so in the South Pole-Aitken basin. Counting rate maps of iron gamma-rays show a surface iron distribution that is in general agreement with other measurements from Clementine and the Lunar Prospector neutron detectors.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Lunar Res Inst, Gilroy, CA 95020 USA; Observ Midi Pyrenees, F-31400 Toulouse, France	United States Department of Energy (DOE); Los Alamos National Laboratory; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Lawrence, DJ (corresponding author), Univ Calif Los Alamos Natl Lab, Mail Stop D466, Los Alamos, NM 87545 USA.		Lawrence, David J/E-7463-2015	Lawrence, David J/0000-0002-7696-6667				FELDMAN WC, 1996, LUNAR PLANET SCI, V27, P355; HASKIN L, 1991, LUNAR SOURCEBOOK USE, P357; LUCEY PG, 1995, J GEOPHYS RES, V266, P1855; METZGER AE, 1993, REMOTE GEOCHEMICAL A, P341; *NAS LUN EXPL SCI, 1992, JSC25920 NASA LUN EX; Reedy R.C., 1978, P LUN PLAN SCI 9, P2961; Schultz P.H., 1979, P LUNAR PLANET SCI C, P2899; SCHULTZ PH, 1983, NATURE, V302, P233, DOI 10.1038/302233a0; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Truscott PR, 1996, IEEE T NUCL SCI, V43, P1510, DOI 10.1109/23.507094; TRUSCOTT PR, 1995, IEEE T NUCL SCI, V42, P946, DOI 10.1109/23.467766; [No title captured]	12	226	241	5	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1484	1489		10.1126/science.281.5382.1484	http://dx.doi.org/10.1126/science.281.5382.1484			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727970				2022-12-24	WOS:000075738100034
J	Sherwood, T				Sherwood, T			Ombudsman's second report, and tobacco	LANCET			English	Editorial Material							SMOKING		Lancet, London WC1B 3SL, England		Sherwood, T (corresponding author), Lancet, London WC1B 3SL, England.							ALDHOUS P, 1998, NEW SCI         0523, P16; BACON F, 1937, ESSAYS 1625; Dyer C, 1998, BRIT MED J, V316, P1555; Horton R, 1998, LANCET, V351, P1450, DOI 10.1016/S0140-6736(05)78867-X; Horton R, 1996, LANCET, V348, P6, DOI 10.1016/S0140-6736(05)64352-8; MCCORMICK J, 1988, LANCET, V1, P649; MCCORMICK J, 1994, LANCET, V344, P52, DOI 10.1016/S0140-6736(94)91071-5; SKRABANEK P, 1992, LANCET, V340, P1208, DOI 10.1016/0140-6736(92)92902-R; SKRABANEK P, 1992, LANCET, V339, P56, DOI 10.1016/0140-6736(92)90179-7; SKRABANEK P, 1989, FOLLIES FALLACIES ME	10	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					7	8		10.1016/S0140-6736(05)79508-8	http://dx.doi.org/10.1016/S0140-6736(05)79508-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800737				2022-12-24	WOS:000074608600007
J	Nussberger, J; Cugno, M; Amstutz, C; Cicardi, M; Pellacani, A; Agostoni, A				Nussberger, J; Cugno, M; Amstutz, C; Cicardi, M; Pellacani, A; Agostoni, A			Plasma bradykinin in angio-oedema	LANCET			English	Article							HEREDITARY ANGIONEUROTIC-EDEMA; CONVERTING-ENZYME-INHIBITION; KININS	Background Bradykinin is believed to be the main mediator of symptoms in hereditary (HA) and acquired (AA) angio-oedema due to C1 esterase inhibitor deficiency, as well as in angio-oedema that complicates treatment with inhibitors of angiotensin-converting enzyme (ACE). Difficulties in the measurement of kinin concentrations, however, have so far precluded the demonstration of an incontrovertible change in plasma bradykinin concentrations in these disorders. By developing a reliable assay we have been able tc follow bradykinin concentrations during attacks and during remission in HA and in AA, and also in a patient treated with an ACE-inhibitor. Methods Liquid-phase extraction, high-performance liquid chromatography, and RIA were used for specific measurement of plasma bradykinin concentrations in 22 patients with HA and in 22 healthy volunteers of similar age and sex distribution. Four patients with AA and one hypertensive patient treated with the ACE inhibitor captopril were also studied. Findings Among the healthy volunteers plasma bradykinin concentration was inversely proportional to age. The geometric mean plasma bradykinin concentration in the healthy volunteers was 2.2 fmol/mL (SD 2.2). compared with 3.9 fmol/mL (3.7) among patients with HA during remission (p=0.095). Bradykinin was also high in the patients with AA (10.4 fmol/mL [1.6]). During acute attacks of oedema, in both HA and AA, plasma bradykinin rose to two to 12 times the upper limit of normal. Infusion of C1-esterase inhibitor (the deficient factor in both HA and AA) immediately lowered bradykinin concentrations. In the patient receiving the ACE-inhibitor captopril, bradykinin concentration was very high at 47 fmol/mL during an acute attack of angio-oedema, but normal at 3.2 fmol/mL in remission after withdrawal of the drug. Interpretation A sensitive method for measurement of plasma bradykinin provided the means to show that concentrations of this peptide decrease with age in healthy people. Although the differences between patients in remission and healthy controls did not reach statistical significance, there were substantial rises in bradykinin during acute attacks of hereditary, acquired, or captopril-induced angio-oedema.	Univ Lausanne Hosp, Div Hypertens, Lausanne, Switzerland; Univ Milan, Maggiore Hosp, IRCCS, Inst Internal Med, Milan, Italy	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Nussberger, J (corresponding author), CHU Vaudois, CH-1011 Lausanne, Switzerland.		Cugno, Massimo/K-8106-2016; cicardi, marco/K-9219-2016	Cugno, Massimo/0000-0002-9918-0763; cicardi, marco/0000-0003-1251-225X				AGOSTONI A, 1992, MEDICINE, V71, P206, DOI 10.1097/00005792-199207000-00003; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39; Cicardi M, 1996, CLIN EXP IMMUNOL, V106, P475, DOI 10.1046/j.1365-2249.1996.d01-866.x; Cugno M, 1997, BLOOD, V89, P3213, DOI 10.1182/blood.V89.9.3213; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595, DOI 10.1146/annurev.iy.06.040188.003115; de la Cadena RA, 1994, HEMOSTASIS THROMBOSI, P219; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1983, NEW ENGL J MED, V308, P1094, DOI 10.1056/NEJM198305053081810; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; FRANK MM, 1976, ANN INTERN MED, V84, P580, DOI 10.7326/0003-4819-84-5-580; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; Lung CC, 1997, J ALLERGY CLIN IMMUN, V99, P134, DOI 10.1016/S0091-6749(97)81054-8; PELLACANI A, 1994, CLIN SCI, V87, P567, DOI 10.1042/cs0870567; ROSEN FS, 1971, J CLIN INVEST, V50, P2143, DOI 10.1172/JCI106708; SHAPIRA M, 1983, NEW ENGL J MED, V308, P1050; SHOEMAKER LR, 1994, CLIN EXP IMMUNOL, V95, P22; SLATER EE, 1988, JAMA-J AM MED ASSOC, V260, P967, DOI 10.1001/jama.260.7.967; TALAMO RC, 1969, J LAB CLIN MED, V74, P816; Zahedi R, 1997, J IMMUNOL, V159, P983	23	575	588	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1693	1697		10.1016/S0140-6736(97)09137-X	http://dx.doi.org/10.1016/S0140-6736(97)09137-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734886				2022-12-24	WOS:000074088900010
J	Berenguer, M; Wright, TL				Berenguer, M; Wright, TL			Are HCV-infected individuals candidates for hepatitis A vaccine?	LANCET			English	Editorial Material							FAILURE		Vet Adm, Gastrointestinal Sect, San Francisco, CA 94121 USA		Berenguer, M (corresponding author), Vet Adm, Gastrointestinal Sect, San Francisco, CA 94121 USA.		Berenguer, Marina/ABG-8602-2020	Berenguer, Marina/0000-0001-9246-4264				AKRIVADES EA, 1990, ANN INTERN MED, V110, P838; HOOFNAGLE JH, 1995, HEPATOLOGY, V21, P240, DOI 10.1002/hep.1840210137; KEEFE EB, 1995, AM J GASTROENTEROL, V90, P210; Keeffe EB, 1998, HEPATOLOGY, V27, P881, DOI 10.1002/hep.510270336; OZSOYLU S, 1989, LANCET, V1, P901; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702	7	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					924	925						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734933				2022-12-24	WOS:000072770900004
J	Lin, YJ; Seroude, L; Benzer, S				Lin, YJ; Seroude, L; Benzer, S			Extended life-span and stress resistance in the Drosophila mutant methuselah	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; POSTPONED SENESCENCE; RECEPTOR; PROTEIN; GENE; MELANOGASTER; LONGEVITY; FAMILY; MUTAGENESIS; MUTATIONS	Toward a genetic dissection of the processes involved in aging, a screen for gene mutations that extend life-span in Drosophila melanogaster was perform ed, The mutant Line methuselah (mth) displayed approximately 35 percent increase in average life-span and enhanced resistance to various forms of stress, including starvation, high temperature, and dietary paraquat, a free-radical generator. The mth gene predicted a protein with homology to several guanosine triphosphate-binding protein-coupled seven-transmembrane domain receptors. Thus, the organism may use signal transduction pathways to modulate stress response and life-span.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Benzer, S (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Seroude, Laurent/0000-0002-4785-3890	NATIONAL EYE INSTITUTE [R01EY009278] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012289] Funding Source: NIH RePORTER; NEI NIH HHS [EY09278] Funding Source: Medline; NIA NIH HHS [AG12289] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARKING R, 1991, DEV GENET, V12, P362, DOI 10.1002/dvg.1020120505; ASHTON FM, 1973, MODE ACTION INSECTIC; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; Burstein ES, 1998, BIOCHEMISTRY-US, V37, P4052, DOI 10.1021/bi972132j; COOLEY L, 1988, SCIENCE, V239, P1121, DOI 10.1126/science.2830671; FRIEDMAN DB, 1988, GENETICS, V118, P75; GRAVES JL, 1992, PHYSIOL ZOOL, V65, P268, DOI 10.1086/physzool.65.2.30158253; HAMILTON BA, 1994, METHOD CELL BIOL, V44, P81, DOI 10.1016/S0091-679X(08)60907-3; HEKIMI S, 1995, GENETICS, V141, P1351; HENIKOFF S, 1994, GENOMICS, V19, P97, DOI 10.1006/geno.1994.1018; HEYDARI AR, 1994, EXPERIENTIA, V50, P1092, DOI 10.1007/BF01923466; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Morris JZ, 1996, NATURE, V382, P536, DOI 10.1038/382536a0; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; ROSE M, 1980, NATURE, V287, P141, DOI 10.1038/287141a0; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Tatar M, 1997, NATURE, V390, P30, DOI 10.1038/36237; Tower J, 1996, BIOESSAYS, V18, P799, DOI 10.1002/bies.950181006; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605; Vassart G, 1995, ANN NY ACAD SCI, V766, P23, DOI 10.1111/j.1749-6632.1995.tb26645.x; Walker GA, 1998, ANN NY ACAD SCI, V851, P444, DOI 10.1111/j.1749-6632.1998.tb09022.x; Watson S., 1994, G PROTEIN LINKED REC; WONG SKF, 1988, J BIOL CHEM, V263, P7925	34	628	661	3	54	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					943	946		10.1126/science.282.5390.943	http://dx.doi.org/10.1126/science.282.5390.943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794765				2022-12-24	WOS:000076727300050
J	Yoon, HS; Golden, JW				Yoon, HS; Golden, JW			Heterocyst pattern formation controlled by a diffusible peptide	SCIENCE			English	Article							SP STRAIN PCC-7120; CELL-CELL COMMUNICATION; GRAM-POSITIVE BACTERIA; PCC 7120; BACILLUS-SUBTILIS; ANABAENA; DIFFERENTIATION; REARRANGEMENT; SUPPRESSION; EXPRESSION	Many filamentous cyanobacteria grow as multicellular organisms that show a developmental pattern of single nitrogen-fixing heterocysts separated by approximately 10 vegetative cells. Overexpression of a 54-base-pair gene, patS, blocked heterocyst differentiation in Anabaena sp. strain PCC 7120. A patS null mutant showed an increased frequency of heterocysts and an abnormal pattern. Expression of a patS-gfp reporter was Localized in developing proheterocysts. The addition of a synthetic peptide corresponding to the Last five amino acids of PatS inhibited heterocyst development. PatS appears to control heterocyst pattern formation through intercellular signaling mechanisms.	Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Golden, JW (corresponding author), Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA.			Golden, James/0000-0001-5463-3207	NIGMS NIH HHS [GM36890] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036890] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bauer CC, 1997, FEMS MICROBIOL LETT, V151, P23, DOI 10.1111/j.1574-6968.1997.tb10390.x; BLACK TA, 1993, MOL MICROBIOL, V9, P77, DOI 10.1111/j.1365-2958.1993.tb01670.x; BUIKEMA WJ, COMMUNICATION; Cai YP, 1997, J BACTERIOL, V179, P267, DOI 10.1128/jb.179.1.267-271.1997; CARRASCO CD, 1994, GENE DEV, V8, P74, DOI 10.1101/gad.8.1.74; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dunny GM, 1997, ANNU REV MICROBIOL, V51, P527, DOI 10.1146/annurev.micro.51.1.527; ElhaI J, 1997, J BACTERIOL, V179, P1998, DOI 10.1128/jb.179.6.1998-2005.1997; GOLDEN JW, 1991, J BACTERIOL, V173, P7098, DOI 10.1128/jb.173.22.7098-7105.1991; Kaplan HB, 1996, FEMS MICROBIOL LETT, V139, P89, DOI 10.1016/0378-1097(96)00102-4; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; Khudyakov I, 1997, J BACTERIOL, V179, P6971, DOI 10.1128/jb.179.22.6971-6978.1997; Kleerebezem M, 1997, MOL MICROBIOL, V24, P895, DOI 10.1046/j.1365-2958.1997.4251782.x; Lazazzera BA, 1997, CELL, V89, P917, DOI 10.1016/S0092-8674(00)80277-9; Nodwell JR, 1996, MOL MICROBIOL, V22, P881, DOI 10.1046/j.1365-2958.1996.01540.x; Perego M, 1996, P NATL ACAD SCI USA, V93, P1549, DOI 10.1073/pnas.93.4.1549; RAMASUBRAMANIAN TS, 1994, J BACTERIOL, V176, P1214, DOI 10.1128/jb.176.5.1214-1223.1994; Ramaswamy KS, 1997, MOL MICROBIOL, V23, P1241, DOI 10.1046/j.1365-2958.1997.3081671.x; Ramaswamy KS, 1996, J BACTERIOL, V178, P3893, DOI 10.1128/jb.178.13.3893-3898.1996; SCHAEFER MR, 1989, J BACTERIOL, V171, P3973, DOI 10.1128/jb.171.7.3973-3981.1989; SIMPSON P, 1990, DEVELOPMENT, V109, P509; WEI TF, 1994, J BACTERIOL, V176, P4473, DOI 10.1128/JB.176.15.4473-4482.1994; Wolk C. P., 1994, MOL BIOL CYANOBACTER, V1, P769; YOON H, UNPUB	24	292	307	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					935	938		10.1126/science.282.5390.935	http://dx.doi.org/10.1126/science.282.5390.935			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794762				2022-12-24	WOS:000076727300047
J	Thomson, B				Thomson, B			Time for reassessment of use of all medical information by UK insurers	LANCET			English	Editorial Material							INSURANCE		Univ Sheffield, Dept Law, Sheffield S10 1FL, S Yorkshire, England	University of Sheffield	Thomson, B (corresponding author), Univ Sheffield, Dept Law, Crookesmoor Bldg, Sheffield S10 1FL, S Yorkshire, England.							ANDREWS L, 1995, AM J HUM GENET, V56, P327; *COUNC EUR, 1961, 35 ETS COUNC EUR; *COUNC EUR, 1996, 164 ETS COUNC EUR; EMERY AEH, 1992, ELEMENTS MED GENETIC, P195; GAULDING J, 1995, CORNELL LAW REV, V80, P1645; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; Harper PS, 1997, J MED GENET, V34, P749, DOI 10.1136/jmg.34.9.749; *HC SCI TECHN COMM, 1995, HUM GEN MIN EV, V41, P38; *HOUS COMM SCI TEC, 1995, HUM GEN SCI ITS CONS, P41; *HUM GEN ADV COMM, 1997, IMPL GEN TEST INS; MacDonald AS, 1997, PHILOS T ROY SOC B, V352, P1067, DOI 10.1098/rstb.1997.0087; Nuffield Council on Bioethics, 1993, GEN SCREEN ETH ISS; ONeill O, 1997, PHILOS T ROY SOC B, V352, P1087, DOI 10.1098/rstb.1997.0089; Pokorski RJ, 1997, AM J HUM GENET, V60, P205	14	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1216	1218		10.1016/S0140-6736(97)12515-6	http://dx.doi.org/10.1016/S0140-6736(97)12515-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777856				2022-12-24	WOS:000076415400042
J	Ferre-D'Amare, AR; Zhou, KH; Doudna, JA				Ferre-D'Amare, AR; Zhou, KH; Doudna, JA			Crystal structure of a hepatitis delta virus ribozyme	NATURE			English	Article							HDV ANTIGENOMIC RIBOZYME; SELF-CLEAVAGE ACTIVITY; INTERFERENCE ANALYSIS; PSEUDOKNOT STRUCTURE; HAMMERHEAD RIBOZYME; RNA SEQUENCES; CLEAVING RNA; SITE; PAIR; CORE	The self-cleaving ribozyme of the hepatitis delta virus (HDV) is the only catalytic RNA known to be required for the viability of a human pathogen. We obtained crystals of a 72-nucleotide, self-cleaved form of the genomic HDV ribozyme that diffract X-rays to 2.3 Angstrom resolution by engineering the RNA to bind a small, basic protein without affecting ribozyme activity. The co-crystal structure shows that the compact catalytic core comprises five helical segments connected as an intricate nested double pseudoknot. The 5'-hydroxyl leaving group resulting from the self-scission reaction is buried deep within an active-site cleft produced by juxtaposition of the helices and five strand-crossovers, and is surrounded by biochemically important backbone and base functional groups in a manner reminiscent of protein enzymes.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Howard Hughes Med Inst, New Haven, CT 06520 USA	Yale University; Howard Hughes Medical Institute; Yale University	Doudna, JA (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 6666, New Haven, CT 06520 USA.	doudna@csb.yale.edu						ABRAHAMS JP, 1998, ACTA CRYSTALLOGR D, V54, P905; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Been MD, 1997, EUR J BIOCHEM, V247, P741, DOI 10.1111/j.1432-1033.1997.00741.x; BELINSKY MG, 1993, FASEB J, V7, P130, DOI 10.1096/fasebj.7.1.8422959; Bravo C, 1996, NUCLEIC ACIDS RES, V24, P1351, DOI 10.1093/nar/24.7.1351; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Duhamel J, 1996, NUCLEIC ACIDS RES, V24, P3911, DOI 10.1093/nar/24.20.3911; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ferre-D'Amare AR, 1998, J MOL BIOL, V279, P621, DOI 10.1006/jmbi.1998.1789; GLUICK TC, 1994, J MOL BIOL, V241, P246, DOI 10.1006/jmbi.1994.1493; Huang ZS, 1997, FEBS LETT, V413, P299, DOI 10.1016/S0014-5793(97)00902-2; JEOUNG YH, 1994, NUCLEIC ACIDS RES, V22, P3722, DOI 10.1093/nar/22.18.3722; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kolk MH, 1998, SCIENCE, V280, P434, DOI 10.1126/science.280.5362.434; Kolk MH, 1997, EMBO J, V16, P3685, DOI 10.1093/emboj/16.12.3685; KUMAR PKR, 1993, FASEB J, V7, P124, DOI 10.1096/fasebj.7.1.8422958; KUMAR PKR, 1994, BIOCHEMISTRY-US, V33, P583, DOI 10.1021/bi00168a025; KUMAR PKR, 1992, NUCLEIC ACIDS RES, V20, P3919, DOI 10.1093/nar/20.15.3919; KUO MYP, 1988, J VIROL, V62, P4439, DOI 10.1128/JVI.62.12.4439-4444.1988; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lynch SR, 1998, NUCLEIC ACIDS RES, V26, P980, DOI 10.1093/nar/26.4.980; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa F, 1997, NUCLEIC ACIDS RES, V25, P1605, DOI 10.1093/nar/25.8.1605; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PERROTTA AT, 1991, NATURE, V350, P434, DOI 10.1038/350434a0; PERROTTA AT, 1990, NUCLEIC ACIDS RES, V18, P6821, DOI 10.1093/nar/18.23.6821; Perrotta AT, 1996, NUCLEIC ACIDS RES, V24, P1314, DOI 10.1093/nar/24.7.1314; PLEIJ CWA, 1985, NUCLEIC ACIDS RES, V13, P1717, DOI 10.1093/nar/13.5.1717; PLEY HW, 1994, NATURE, V372, P111, DOI 10.1038/372111a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RICHARDS FM, 1971, ENZYMES, V4, P647; ROSENSTEIN SP, 1991, NUCLEIC ACIDS RES, V19, P5409, DOI 10.1093/nar/19.19.5409; Rosenstein SP, 1996, BIOCHEMISTRY-US, V35, P11403, DOI 10.1021/bi9609984; ROSENSTEIN SP, 1990, BIOCHEMISTRY-US, V29, P8011, DOI 10.1021/bi00487a002; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; SHARMEEN L, 1988, J VIROL, V62, P2674, DOI 10.1128/JVI.62.8.2674-2679.1988; STROBEL SA, 1995, SCIENCE, V267, P675, DOI 10.1126/science.7839142; SUH YA, 1993, NUCLEIC ACIDS RES, V21, P3277, DOI 10.1093/nar/21.14.3277; TANG CK, 1989, CELL, V57, P531, DOI 10.1016/0092-8674(89)90123-2; TANNER NK, 1994, CURR BIOL, V4, P488, DOI 10.1016/S0960-9822(00)00109-3; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; THILL G, 1993, BIOCHEMISTRY-US, V32, P4254, DOI 10.1021/bi00067a013; Wadkins TS, 1997, NUCLEIC ACIDS RES, V25, P4085, DOI 10.1093/nar/25.20.4085; WU HN, 1989, P NATL ACAD SCI USA, V86, P1831, DOI 10.1073/pnas.86.6.1831	49	607	627	1	58	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 8	1998	395	6702					567	574		10.1038/26912	http://dx.doi.org/10.1038/26912			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783582				2022-12-24	WOS:000076362900038
J	Mutton, D; Ide, RG; Alberman, E				Mutton, D; Ide, RG; Alberman, E			Trends in prenatal screening for and diagnosis of Down's syndrome: England and Wales, 1989-97	BRITISH MEDICAL JOURNAL			English	Article									St Bartholomews Med Coll, Dept Environm & Prevent Med, Wolfson Inst Prevent Med, Natl Down Syndrome Cytogenet Register, London EC1M 6BQ, England; Royal London Med Coll, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Mutton, D (corresponding author), St Bartholomews Med Coll, Dept Environm & Prevent Med, Wolfson Inst Prevent Med, Natl Down Syndrome Cytogenet Register, London EC1M 6BQ, England.							ALBERMAN E, 1995, BRIT J OBSTET GYNAEC, V102, P445, DOI 10.1111/j.1471-0528.1995.tb11315.x; Haddow JE, 1998, LANCET, V352, P336, DOI 10.1016/S0140-6736(98)22031-9; Morris J K, 1994, J Med Screen, V1, P233; *OFF NAT STAT, 1997, J MED SCREEN, V4, P95	4	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					922	923						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756810				2022-12-24	WOS:000076409000024
J	Kastner, S; De Weerd, P; Desimone, R; Ungerleider, LC				Kastner, S; De Weerd, P; Desimone, R; Ungerleider, LC			Mechanisms of directed attention in the human extrastriate cortex as revealed by functional MRI	SCIENCE			English	Article							VISUAL SELECTIVE ATTENTION; NEURAL MECHANISMS; AREAS; MACAQUE; V4; PERCEPTION; STIMULUS; V3; V2; MT	A typical scene contains many different objects, but the capacity of the visual system to process multiple stimuli at a given time is limited, Thus, attentional mechanisms are required to select relevant objects from among the many objects competing for visual processing. Evidence from functional magnetic resonance imaging (MRI) in humans showed that when multiple stimuli are present simultaneously in the visual field, their cortical representations within the object recognition pathway interact in a competitive, suppressive fashion. Directing attention to one of the stimuli counteracts the suppressive influence of nearby stimuli. This mechanism may serve to filter out irrelevant information in cluttered visual scenes.	NIMH, Lab Brain & Cognit, NIH, Bethesda, MD 20892 USA; NIMH, Neuropsychol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kastner, S (corresponding author), NIMH, Lab Brain & Cognit, NIH, Bldg 49,Room 1B80, Bethesda, MD 20892 USA.	sabine@ln.nimh.nih.gov	Desimone, Robert/G-1121-2018	Kastner, Sabine/0000-0002-9742-965X				BOUSSAOUD D, 1991, J COMP NEUROL, V306, P554, DOI 10.1002/cne.903060403; Conner CE, 1997, J NEUROSCI, V17, P3201; De Simone R., UNPUB; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; DRIVER J, 1989, J EXP PSYCHOL HUMAN, V15, P448, DOI 10.1037/0096-1523.15.3.448; DUNCAN J, 1989, PSYCHOL REV, V96, P433, DOI 10.1037/0033-295X.96.3.433; DUNCAN J, 1980, PSYCHOL REV, V87, P272, DOI 10.1037/0033-295X.87.3.272; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; GATTASS R, 1988, J NEUROSCI, V8, P1831; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; HADJIKHANI, 1998, NATURE NEUROSCI, V1, P235; HEINZE HJ, 1994, NATURE, V372, P543, DOI 10.1038/372543a0; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; MANGUN GR, 1995, PSYCHOPHYSIOLOGY, V32, P4, DOI 10.1111/j.1469-8986.1995.tb03400.x; McKeefry DJ, 1997, BRAIN, V120, P2229, DOI 10.1093/brain/120.12.2229; MILLER EK, 1993, BRAIN RES, V616, P25, DOI 10.1016/0006-8993(93)90187-R; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; POSNER MI, 1980, Q J EXP PSYCHOL, V32, P3, DOI 10.1080/00335558008248231; Rees G, 1997, SCIENCE, V275, P835, DOI 10.1126/science.275.5301.835; Rees G, 1997, SCIENCE, V278, P1616, DOI 10.1126/science.278.5343.1616; Reynolds J., 1995, Society for Neuroscience Abstracts, V21, P1759; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; SHIPP S, 1995, NEUROIMAGE, V2, P125, DOI 10.1006/nimg.1995.1015; Talairach I., 1988, COPLANAR STEREOTACTI; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TREISMAN A, 1985, COMPUT VISION GRAPH, V31, P156, DOI 10.1016/S0734-189X(85)80004-9; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; Vandenberghe R, 1997, J NEUROSCI, V17, P3739	30	675	689	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					108	111		10.1126/science.282.5386.108	http://dx.doi.org/10.1126/science.282.5386.108			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756472				2022-12-24	WOS:000076294900049
J	Kielkopf, CL; White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB; Rees, DC				Kielkopf, CL; White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB; Rees, DC			A structural basis for recognition of A center dot T and T center dot A base pairs in the minor groove of B-DNA	SCIENCE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; CRYSTAL-STRUCTURE; NUCLEIC-ACIDS; IMIDAZOLE; COMPLEX; BINDING; POLYAMIDES; RESOLUTION; MOLECULES; PROTEINS	Polyamide dimers containing three types of aromatic rings-pyrrole, imidazole, and hydroxypyrrole-afford a small-molecule recognition code that discriminates among all four Watson-Crick base pairs in the minor groove. The crystal structure of a specific polyamide dimer-DNA complex establishes the structural basis for distinguishing T.A from A.T base pairs. Specificity for the T.A base pair is achieved by means of distinct hydrogen bonds between pairs of substituted pyrroles on the Ligand and the O2 of thymine and N3 of adenine, In addition, shape-selective recognition of an asymmetric cleft between the thymine-O2 and the adenine-C2 was observed. Although hitherto similarities among the base pairs in the minor groove have been emphasized, the structure illustrates differences that allow specific minor groove recognition,	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Dervan, PB (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.							ADES SE, 1995, BIOCHEMISTRY-US, V34, P14601, DOI 10.1021/bi00044a040; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BAKER EN, 1984, PROG BIOPHYS MOL BIO, V44, P97, DOI 10.1016/0079-6107(84)90007-5; Brameld K, 1997, J PHYS CHEM B, V101, P4851, DOI 10.1021/jp970199a; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P83; BRUNGER TA, 1992, XPLOR VERSION 3 1 SY; CHEN X, 1994, NAT STRUCT BIOL, V1, P169, DOI 10.1038/nsb0394-169; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; GEIERSTANGER BH, 1994, SCIENCE, V266, P646, DOI 10.1126/science.7939719; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Hirsch JA, 1995, EMBO J, V14, P6280, DOI 10.1002/j.1460-2075.1995.tb00318.x; Kielkopf CL, 1998, NAT STRUCT BIOL, V5, P104, DOI 10.1038/nsb0298-104; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; Kopka ML, 1997, STRUCTURE, V5, P1033, DOI 10.1016/S0969-2126(97)00255-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS KA, 1993, BIOPHYS J, V64, pA166; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PARKINSON G, 1991, ACTA CRYSTALLOGR A, V47, P110; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P7586; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1990, Q REV BIOPHYS, V23, P203; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; TRAVERS AA, 1995, NAT STRUCT BIOL, V2, P615, DOI 10.1038/nsb0895-615; TuckerKellogg L, 1997, STRUCTURE, V5, P1047, DOI 10.1016/S0969-2126(97)00256-6; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; WAHL MC, 1997, TRENDS BIOCHEM SCI, V22, P98; White S, 1998, NATURE, V391, P468, DOI 10.1038/35106; White S, 1997, CHEM BIOL, V4, P569, DOI 10.1016/S1074-5521(97)90243-X; WHITE S, 1996, BIOCHEMISTRY-US, V35, P6147; WHITE S, 1997, J AM CHEM SOC, V119, P6953; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890	39	276	288	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					111	115		10.1126/science.282.5386.111	http://dx.doi.org/10.1126/science.282.5386.111			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756473				2022-12-24	WOS:000076294900050
J	Murphy, VJ; Harrison, LC; Rudert, WA; Luppi, P; Trucco, M; Fierabracci, A; Biro, PA; Bottazzo, GF				Murphy, VJ; Harrison, LC; Rudert, WA; Luppi, P; Trucco, M; Fierabracci, A; Biro, PA; Bottazzo, GF			Retroviral superantigens and type 1 diabetes mellitus	CELL			English	Letter							AUTOIMMUNE		Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Autoimmun & Transplantat Div, Parkville, Vic 3050, Australia; Univ Pittsburgh, Sch Med, Dept Pediat, Div Immunogenet, Pittsburgh, PA 15213 USA; Childrens Hosp, Pittsburgh, PA 15213 USA; St Bartholomews & Royal London Sch Med & Dent, Dept Immunol, London E1 2AD, England; Autoimmune Dis Charitable Trust, London NW3 4AN, England	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of London; Queen Mary University London	Bottazzo, GF (corresponding author), Osped Pediat Bambino Gesu, Inst Sci, Direz Sci, Via Piazza S Onofrio 4, I-00165 Rome, Italy.		Luppi, Pierre-Hervé/C-4333-2014; Fierabracci, Alessandra/K-5930-2016	Luppi, Pierre-Hervé/0000-0002-0503-423X; Fierabracci, Alessandra/0000-0003-3078-9754				Benoist C, 1997, NATURE, V388, P833, DOI 10.1038/42145; CONRAD B, 1994, NATURE, V371, P351, DOI 10.1038/371351a0; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; Nakagawa K, 1996, IMMUNOL REV, V152, P193, DOI 10.1111/j.1600-065X.1996.tb00917.x	4	48	48	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					9	11		10.1016/S0092-8674(00)81775-4	http://dx.doi.org/10.1016/S0092-8674(00)81775-4			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778241	Bronze			2022-12-24	WOS:000076242300003
J	Sayos, J; Wu, C; Morra, M; Wang, N; Zhang, X; Allen, D; van Schaik, S; Notarangelo, L; Geha, R; Roncarolo, MG; Oettgen, H; De Vries, JE; Aversa, G; Terhorst, C				Sayos, J; Wu, C; Morra, M; Wang, N; Zhang, X; Allen, D; van Schaik, S; Notarangelo, L; Geha, R; Roncarolo, MG; Oettgen, H; De Vries, JE; Aversa, G; Terhorst, C			The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM	NATURE			English	Article							LYMPHOCYTIC ACTIVATION MOLECULE; T-CELL ACTIVATION; CONTIG; PROLIFERATION; REGION	In addition to triggering the activation of B- or T-cell antigen receptors, the binding of a ligand to its receptor at the cell surface can sometimes determine the physiological outcome of interactions between antigen-presenting cells, Tend B lymphocytes. The protein SLAM (also known as CDw150), which is present on the surface of B and T cells, forms such a receptor-ligand pair as it is a self-ligand. We now show that a T-cell-specific, SLAM-associated protein (SAP), which contains an SH2 domain end a short tail, acts as an inhibitor by blocking recruitment of the SH2-domain-containing signal-transduction molecule SHP-2 to a docking site in the SLAM cytoplasmic region. The gene encoding SAP maps to the same area of the X chromosome as the locus for X-linked lymphoproliferative disease (XLP) and we found mutations In the SAP gene in three XLP patients. Absence of the Inhibitor SAP In XLP patients affects T/B-cell Interactions Induced by SLAM, leading to an inability to control B-cell proliferation caused by Epstein-Barr virus infections.	Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Immunol, Boston, MA 02215 USA; Univ Brescia, Dept Pediat, I-25125 Brescia, Italy; Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; Telethon Inst Gene Therapy, Cellular Therapy Lab, I-20132 Milan, Italy; Novartis Forschungsinst Geselsch Mbh, A-1235 Vienna, Austria	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Brescia; Harvard University; Boston Children's Hospital; Harvard Medical School; Fondazione Telethon	Sayos, J (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Immunol, Boston, MA 02215 USA.	jortega@bidmc.harvard.edu; terhorst@bidmc.harvard.edu	van Schaik, Sandrijn M/H-9078-2019; Notarangelo, Luigi D/F-9718-2016; Sayos, Joan/B-6119-2009	Notarangelo, Luigi D/0000-0002-8335-0262; Sayos, Joan/0000-0002-4664-3461; RONCAROLO, Maria Grazia/0000-0002-2193-9186	Telethon [TGT97000, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Aversa G, 1997, IMMUNOL CELL BIOL, V75, P202, DOI 10.1038/icb.1997.30; Aversa G, 1997, J IMMUNOL, V158, P4036; Bennett SRM, 1998, NATURE, V393, P478, DOI 10.1038/30996; Carballido JM, 1997, J IMMUNOL, V159, P4316; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; COOPER DN, 1993, HUMAN GENE MUTATIONS; deAos I, 1997, J BIOL CHEM, V272, P25310, DOI 10.1074/jbc.272.40.25310; Ferrante P, 1998, J IMMUNOL, V160, P1514; Isomaki P, 1997, J IMMUNOL, V159, P2986; Lamartine J, 1996, EUR J HUM GENET, V4, P342; Lanyi A, 1997, GENOMICS, V39, P55, DOI 10.1006/geno.1996.4466; Marengere LEM, 1996, SCIENCE, V272, P1170, DOI 10.1126/science.272.5265.1170; MartinezMartinez S, 1997, MOL CELL BIOL, V17, P6437, DOI 10.1128/MCB.17.11.6437; Porta G, 1997, GENOME RES, V7, P27, DOI 10.1101/gr.7.1.27; Punnonen J, 1997, J EXP MED, V185, P993, DOI 10.1084/jem.185.6.993; PURTILO DT, 1983, IMMUNOL TODAY, V4, P291, DOI 10.1016/0167-5699(83)90139-1; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; ROUSSET F, 1986, CLIN EXP IMMUNOL, V63, P280; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; SEEMAYER TA, 1995, PEDIATR RES, V38, P471, DOI 10.1203/00006450-199510000-00001; Sutkowski N, 1996, J EXP MED, V184, P971, DOI 10.1084/jem.184.3.971; WANG BP, 1995, INT IMMUNOL, V7, P435, DOI 10.1093/intimm/7.3.435	23	736	769	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					462	469		10.1038/26683	http://dx.doi.org/10.1038/26683			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774102				2022-12-24	WOS:000076212200046
J	Roelfsema, PR; Lamme, VAF; Spekreijse, H				Roelfsema, PR; Lamme, VAF; Spekreijse, H			Object-based attention in the primary visual cortex of the macaque monkey	NATURE			English	Article							SELECTIVE ATTENTION; STRIATE CORTEX; FOCAL ATTENTION; AREAS V1; ORGANIZATION; MODULATION; RESPONSES; ALERT; V2; V4	Typical natural visual scenes contain many objects, which need to be segregated from each other and from the background. Present theories subdivide the processes responsible for this segregation into a pre-attentive and attentive system(1,2). The pre-attentive system segregates image regions that 'pop out' rapidly and in parallel across the visual field. In the primary visual cortex, responses to pre-attentively selected image regions are enhanced(3-5). When objects do not segregate automatically from the rest of the image, the time-consuming attentive system is recruited. Here we investigate whether attentive selection is also associated with a modulation of firing rates in area V1 of the brain in monkeys trained to perform a curve-tracing task(6,7). Neuronal responses to the various segments of a target curve were simultaneously enhanced relative to responses evoked by a distracter curve, even if the two curves crossed each other. This indicates that object-based attention is associated with a response enhancement at the earliest level of the visual cortical processing hierarchy.	Grad Sch Neurosci Amsterdam, Lab Med Phys, NL-1100 AC Amsterdam, Netherlands; Netherlands Ophthalm Res Inst, Dept Visual Syst Anal, Acad Med Ctr, NL-1100 AC Amsterdam, Netherlands	University of Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical Center Amsterdam	Roelfsema, PR (corresponding author), Grad Sch Neurosci Amsterdam, Lab Med Phys, POB 12141, NL-1100 AC Amsterdam, Netherlands.	p.roelfsema@ioi.knaw.nl	Roelfsema, Pieter/J-6903-2013	Roelfsema, Pieter/0000-0002-1625-0034				Bosking WH, 1997, J NEUROSCI, V17, P2112; BOUR LJ, 1984, IEEE T BIO-MED ENG, V31, P419, DOI 10.1109/TBME.1984.325281; BUSHNELL MC, 1981, J NEUROPHYSIOL, V46, P755, DOI 10.1152/jn.1981.46.4.755; DUNCAN J, 1984, J EXP PSYCHOL GEN, V113, P501, DOI 10.1037/0096-3445.113.4.501; ERIKSEN CW, 1986, PERCEPT PSYCHOPHYS, V40, P225, DOI 10.3758/BF03211502; GATTASS R, 1981, J COMP NEUROL, V201, P519, DOI 10.1002/cne.902010405; HAENNY PE, 1988, EXP BRAIN RES, V69, P225, DOI 10.1007/BF00247569; JOLICOEUR P, 1986, MEM COGNITION, V14, P129, DOI 10.3758/BF03198373; Kanwisher N., 1992, CURR DIR PSYCHOL SCI, V1, P26; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; KRAMER AF, 1991, PERCEPT PSYCHOPHYS, V50, P267, DOI 10.3758/BF03206750; LAMME VAF, 1995, J NEUROSCI, V15, P1605; Luck SJ, 1997, J NEUROPHYSIOL, V77, P24, DOI 10.1152/jn.1997.77.1.24; MAUSELL JHR, 1995, SCIENCE, V270, P764; MORAN J, 1985, SCIENCE, V229, P782, DOI 10.1126/science.4023713; MOTTER BC, 1993, J NEUROPHYSIOL, V70, P909, DOI 10.1152/jn.1993.70.3.909; NELSON JI, 1985, EXP BRAIN RES, V61, P54; Polat U, 1998, NATURE, V391, P580, DOI 10.1038/35372; POSNER MI, 1980, J EXP PSYCHOL GEN, V109, P160, DOI 10.1037/0096-3445.109.2.160; POSNER MI, 1987, TRENDS NEUROSCI, V10, P13, DOI 10.1016/0166-2236(87)90116-0; Press W. A., 1997, Society for Neuroscience Abstracts, V23, P1026; PRINGLE R, 1988, J EXP PSYCHOL HUMAN, V14, P716, DOI 10.1037/0096-1523.14.4.716; ROCK I, 1990, SCI AM, V263, P48; Schmidt KE, 1997, EUR J NEUROSCI, V9, P1083, DOI 10.1111/j.1460-9568.1997.tb01459.x; SNODDERLY DM, 1995, J NEUROPHYSIOL, V74, P2100, DOI 10.1152/jn.1995.74.5.2100; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; Treue S, 1996, NATURE, V382, P539, DOI 10.1038/382539a0; WURTZ RH, 1976, J NEUROPHYSIOL, V39, P766, DOI 10.1152/jn.1976.39.4.766; Zipser K, 1996, J NEUROSCI, V16, P7376	30	592	596	1	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 24	1998	395	6700					376	381		10.1038/26475	http://dx.doi.org/10.1038/26475			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	122QW	9759726				2022-12-24	WOS:000076083800052
J	Parish, LC; Witkowski, JA				Parish, LC; Witkowski, JA			Melanoma and the radiograph: sanctity of human life	LANCET			English	Editorial Material									Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Ctr Int Dermatol, Philadelphia, PA 19107 USA; Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; University of Pennsylvania	Parish, LC (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.							American Joint Committee on Cancer, 1992, MAN STAG CANC, P143; BALCH CM, 1993, CANC PRINCIPLES PRAC, P163; BALCH CM, 1992, CUTANEOUS MELANOMA, P188; SACRE R, 1982, ANTICANCER RES, V2, P47; SALK D, 1988, SEMIN ONCOL, V15, P608; TAFRA L, 1995, J THORAC CARDIOV SUR, V110, P119, DOI 10.1016/S0022-5223(05)80017-0; Terhune MH, 1998, ARCH DERMATOL, V134, P569, DOI 10.1001/archderm.134.5.569	7	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					922	923		10.1016/S0140-6736(05)61508-5	http://dx.doi.org/10.1016/S0140-6736(05)61508-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752811				2022-12-24	WOS:000076002200004
J	Dean, M				Dean, M			London - UK government responds to variant-CJD news and waiting lists	LANCET			English	News Item																			0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					795	795		10.1016/S0140-6736(05)60695-2	http://dx.doi.org/10.1016/S0140-6736(05)60695-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737298				2022-12-24	WOS:000075762700032
J	Hughes, IA				Hughes, IA			Congenital adrenal hyperplasia - a continuum of disorders	LANCET			English	Editorial Material							21-HYDROXYLASE DEFICIENCY; EXPERIENCE; DIAGNOSIS; GENETICS		Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Hughes, IA (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Paediat, Cambridge CB2 2QQ, England.							BATCH JA, 1993, ARCH DIS CHILD, V68, P453, DOI 10.1136/adc.68.4.453; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Chin DS, 1998, J CLIN ENDOCR METAB, V83, P1940, DOI 10.1210/jc.83.6.1940; HUGHES IA, 1979, ARCH DIS CHILD, V59, P743; Jaaskelainen J, 1997, PEDIATR RES, V41, P30; MERCADO AB, 1995, J CLIN ENDOCR METAB, V80, P2014, DOI 10.1210/jc.80.7.2014; MILLER WL, 1989, ANNU REV GENET, V23, P371, DOI 10.1146/annurev.ge.23.120189.002103; MULAIKAL RM, 1987, NEW ENGL J MED, V316, P178, DOI 10.1056/NEJM198701223160402; PANG S, 1988, PEDIATRICS, V81, P866; Pang SY, 1997, ENDOCRIN METAB CLIN, V26, P853, DOI 10.1016/S0889-8529(05)70285-1; Premawardhana LDKE, 1997, CLIN ENDOCRINOL, V46, P327, DOI 10.1046/j.1365-2265.1997.1360962.x; Rumsby G, 1998, CLIN ENDOCRINOL, V48, P707, DOI 10.1046/j.1365-2265.1998.00402.x; Scherz R, 1994, SCREENING, V3, P77; Therrell BL, 1998, PEDIATRICS, V101, P583, DOI 10.1542/peds.101.4.583; WEDELL A, 1994, J CLIN ENDOCR METAB, V78, P1145, DOI 10.1210/jc.78.5.1145; YOUNG MC, 1998, CLIN ENDOCRINOL, P450	16	46	47	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					752	754		10.1016/S0140-6736(98)22037-X	http://dx.doi.org/10.1016/S0140-6736(98)22037-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737273				2022-12-24	WOS:000075762700002
J	Swash, M				Swash, M			Dropped-head and bent-spine syndromes; axial myopathies?	LANCET			English	Editorial Material									Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Neurol, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Swash, M (corresponding author), Royal London Hosp, St Bartholomews & Royal London Sch Med & Dent, Dept Neurol, London E1 1BB, England.			Swash, Michael/0000-0002-8717-8914				BORG K, 1989, J NEUROL SCI, V91, P53, DOI 10.1016/0022-510X(89)90075-0; Katz JS, 1996, NEUROLOGY, V46, P917, DOI 10.1212/WNL.46.4.917; Oerlemans WGH, 1998, J NEUROL NEUROSUR PS, V65, P258, DOI 10.1136/jnnp.65.2.258; SCHWARTZ MS, 1988, MUSCLE NERVE, V11, P1240, DOI 10.1002/mus.880111208; Serratrice G, 1996, J NEUROL NEUROSUR PS, V60, P51, DOI 10.1136/jnnp.60.1.51; SUAREZ GA, 1992, NEUROLOGY, V42, P1625, DOI 10.1212/WNL.42.8.1625; SWASH M, 1997, NEUROMUSCULAR DIS, P541	7	15	15	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 5	1998	352	9130					758	758		10.1016/S0140-6736(05)60677-0	http://dx.doi.org/10.1016/S0140-6736(05)60677-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737278				2022-12-24	WOS:000075762700007
J	Eastwood, R				Eastwood, R			Getting hooked on Marmite	LANCET			English	Editorial Material																			0	0	0	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					750	750		10.1016/S0140-6736(05)60877-X	http://dx.doi.org/10.1016/S0140-6736(05)60877-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9729031				2022-12-24	WOS:000075729700076
J	Zhang, Y; Feng, XH; Derynck, R				Zhang, Y; Feng, XH; Derynck, R			Smad3 and Smad4 cooperate with c-Jun/c-Fos to mediate TGF-beta-induced transcription	NATURE			English	Article							GROWTH-FACTOR-BETA; SIGNALING PATHWAYS; RECEPTOR COMPLEX; BINDING PROTEIN; DOWN-REGULATION; EXPRESSION; PROLIFERATION; ACTIVATION; CYCLIN; GENES	Smad proteins transduce signals for transforming growth factor-beta (TGF-beta)-related factors'. Smad proteins activated by receptors for TGF-beta form complexes with Smad4. These com plexes are translocated into the nucleus and regulate ligand-induced gene transcription(2-4). 12-O-tetradecanoyl-13-acetate (TPA)-responsive gene promoter elements (TREs) are involved in the transcriptional responses of several genes to TGF-beta (refs 5-8), AP-1 transcription factors, composed of c-Jun and c-Fos, bind to and direct transcription from TREs, which are therefore known as AP1-binding sites(9). Here we show that Smad3 interacts directly with the TRE and that SmadS and Smad4 can activate TGF-beta-inducible transcription from the TRE in the absence of c-Jun and c-Fos, Smad3 and Smad4 also act together with c-Jun and c-Fos to activate transcription in response to TGF-beta, through a TGF-P-inducible association of c-Jun with Smad3 and an interaction of Smad3 and c-Fos, These interactions complement interactions between c-Jun and c-Fos, and between Smad3 and Smad4, This mechanism of transcriptional activation by TGF-P, through functional and physical interactions between Smad3-Smad4 and c-Jun-c-Fos, shows that Smad signalling and MAPK/JNK signalling converge at AP1-binding promoter sites.	Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Cell Biol Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Program Dev Biol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Derynck, R (corresponding author), Univ Calif San Francisco, Dept Growth & Dev, San Francisco, CA 94143 USA.	derynck@itsa.ucsf.edu	Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; DEGROOT RP, 1990, BIOCHEM BIOPH RES CO, V168, P1074, DOI 10.1016/0006-291X(90)91139-J; FELTS SJ, 1995, BIOCHEMISTRY-US, V34, P12355, DOI 10.1021/bi00038a032; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; GRAYCAR JL, 1989, MOL ENDOCRINOL, V3, P1977, DOI 10.1210/mend-3-12-1977; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KEETON MR, 1991, J BIOL CHEM, V266, P23048; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; YANG-YEN H-F, 1990, New Biologist, V2, P351; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Yoshizumi M, 1997, J BIOL CHEM, V272, P22259, DOI 10.1074/jbc.272.35.22259; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CURR BIOL, V7, P270, DOI 10.1016/S0960-9822(06)00123-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	581	612	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					909	913		10.1038/29814	http://dx.doi.org/10.1038/29814			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732876				2022-12-24	WOS:000075611800053
J	Raoult, D; Ndihokubwayo, JB; Tissot-Dupont, H; Roux, V; Faugere, B; Abegbinni, R; Birtles, RJ				Raoult, D; Ndihokubwayo, JB; Tissot-Dupont, H; Roux, V; Faugere, B; Abegbinni, R; Birtles, RJ			Outbreak of epidemic typhus associated with trench fever in Burundi	LANCET			English	Article							SEQUENCES	Background After a 12-year absence, epidemic typhus has re-emerged among the displaced population of Burundi. Following the outbreak of civil war in 1993, over 760 000 people now inhabit refugee camps, under appalling conditions. A typhus outbreak occurred among prisoners in a jail in N'Gozi in 1995. At the time, the disease was not recognised, and was referred to as sutama. Reports of sutama among the civilian population date back to late 1995 and, in association with body-louse infestation, the disease has subsequently swept across the higher and colder regions of the country. Methods During a field study in February, 1997, 102 refugees with sutama underwent clinical examination and interview. Serum samples were collected and infesting body lice removed, Microbiological analysis included antibody estimations and specific PCRs aimed at diagnosis of Rickettsia prowezekii, Bartonella quintana, and Borrelia recurrentis. Between January and September, 1997, nationwide epidemiological data on the prevalence and distribution of sutama was obtained through liaison with local health services. A second field study in March, 1997, entailed the collection of further serum samples from suspected cases of sutama in different regions of Burundi, Findings Most of the 102 patients with sutama during initial assessment presented with manifestations similar to those previously described for typhus in Africa, though skin eruptions occurred in only 25 (25%) cases. Microbiological testing revealed evidence of R prowazeki infection in 76 (75%) patients, confirming that most cases of clinically-diagnosed sutama were epidemic typhus, and supporting the reliabilty of clinical diagnosis as a basis for the nationwide surveillance of the disease. Up to September, 1997, 45 558 typhus cases were clinically diagnosed, most of which occurred in regions at an altitude of over 1500 m. Serological testing of 232 individuals from different regions of Burundi provided microbiological evidence to support clinical diagnoses in seven provinces, confirming the widespread nature of the outbreak. Serum from 13 of the original 102 patients and 19 (8%) of the 232 suspected cases had raised antibody titres against B quintana, A fatality rate of 15% among jail inmates fell to 0.5% after administration of a single dose of 200 mg doxycycline to suspected cases. Interpretation A gigantic outbreak of R prowazekii-induced typhus and a quintana-induced trench fever is continuing in Burundi. Transmission of both diseases to such a large number of people has followed a widespread epidemic of body-louse infestation. Diagnosis of typhus could be reliably made by means of clinical criteria, and the disease could be efficiently and easily treated by antibiotics, This epidemic highlights the appalling conditions in central-African refugee camps and the failure of public-health programmes to serve their inhabitants. Louse-associated disease remains a major health threat in this and other war-torn regions of the world.	Univ Mediterranee, Fac Med, WHO Reference Ctr Rickettsial Dis, CNRS,IPRESA 6020,Unite Rickettsies, Marseille, France; CHU Bujumbura, Bujumbura, Burundi; Hop Houphouet Boigny, Parasitol Lab, Marseille, France; WHO, Bujumbura, Burundi	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; World Health Organization	Raoult, D (corresponding author), Univ Mediterranee, Fac Med, WHO Reference Ctr Rickettsial Dis, CNRS,IPRESA 6020,Unite Rickettsies, Blvd Jean Moulin, Marseille, France.	Didier.Raoult@medicine.univ-mrs.fr	TISSOT-DUPONT, Hervé/P-5808-2016; RAOULT, Didier/A-8434-2008	RAOULT, Didier/0000-0002-0633-5974; Birtles, Richard/0000-0002-4216-5044				[Anonymous], 1993, B WORLD HEALTH ORGAN, V71, P293; Birtles RJ, 1996, INT J SYST BACTERIOL, V46, P891, DOI 10.1099/00207713-46-4-891; Bise G, 1997, T ROY SOC TROP MED H, V91, P133, DOI 10.1016/S0035-9203(97)90198-X; DESALLE R, 1992, SCIENCE, V257, P1933, DOI 10.1126/science.1411508; EREMEEVA ME, 1994, CLIN DIAGN LAB IMMUN, V1, P318, DOI 10.1128/CDLI.1.3.318-324.1994; FELSENFIELD O, 1971, BORRELIA STRAINS VEC; LaScola B, 1997, J CLIN MICROBIOL, V35, P2715, DOI 10.1128/JCM.35.11.2715-2727.1997; Maurin M, 1996, CLIN MICROBIOL REV, V9, P273, DOI 10.1128/CMR.9.3.273; Maurin M, 1997, J CLIN MICROBIOL, V35, P2283, DOI 10.1128/JCM.35.9.2283-2287.1997; NIKOYAGIZE E, 1976, THESIS U CLERMONT 1; ORMSBEE R, 1977, AM J EPIDEMIOL, V105, P261, DOI 10.1093/oxfordjournals.aje.a112382; PERINE PL, 1974, LANCET, V2, P742; PERINE PL, 1992, CLIN INFECT DIS, V14, P1149, DOI 10.1093/clinids/14.5.1149; Raoult D, 1997, EMERG INFECT DIS, V3, P357, DOI 10.3201/eid0303.970313; RAOULT D, 1995, FEMS IMMUNOL MED MIC, V11, P13, DOI 10.1111/j.1574-695X.1995.tb00073.x; REGNERY RL, 1991, J BACTERIOL, V173, P1576, DOI 10.1128/jb.173.5.1576-1589.1991; ROUX V, 1995, GENE, V156, P107, DOI 10.1016/0378-1119(94)00919-J; Roux V, 1997, INT J SYST BACTERIOL, V47, P252, DOI 10.1099/00207713-47-2-252; Saah A. J., 1990, Principles and practice of infectious diseases., P1476; TAYLOR RM, 1957, AM J TROP MED HYG, V6, P863, DOI 10.4269/ajtmh.1957.6.863; 1984, WKLY EPIDEMIOL REC, V6, P45; 1986, WKLY EPIDEMIOL REC, V7, P49; 1984, WKLY EPIDEMIOL REC, V59, P29	23	163	171	1	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 1	1998	352	9125					353	358		10.1016/S0140-6736(97)12433-3	http://dx.doi.org/10.1016/S0140-6736(97)12433-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	106BU	9717922				2022-12-24	WOS:000075110500010
J	Williams, J; Tallis, G; Dalton, C; Ng, S; Beaton, S; Catton, M; Elliott, J; Carnie, J				Williams, J; Tallis, G; Dalton, C; Ng, S; Beaton, S; Catton, M; Elliott, J; Carnie, J			Community outbreak of psittacosis in a rural Australian town	LANCET			English	Article							ORNITHOSIS	Background Health authorities in Victoria, Australia were notified of three men from a rural town with atypical pneumonia, admitted to hospital over 8 days. Initial serological testing suggested Chlamydia psittaci as the cause. We did a case-control study to find risk factors for psittacosis. Methods We searched for cases of pneumonia or severe flu-like illness through family physicians and the regional hospital. We selected three controls per case from the region's electoral roll. We collected blood for serological tests and administered questionnaires to all cases and controls. Findings We found 16 cases of psittacosis and one died. Most cases were clustered within a small geographical area, with a median age of 58 years (range 23-76), 15 (94%) of whom were male. Keeping, handling, or feeding domestic or wild birds was not associated with illness. Cases spent a median of 17.5 h per week in their garden, compared with a median of 5.2 h for controls (p=0.04) and were more likely to have mowed lawns during the 3 weeks before onset of illness than controls (odds ratio 4.81 [95% CI 1.08-33.37]). Interpretation We showed that psittacosis outbreaks are not limited to direct contact with birds and pose new challenges for disease control. Modifications may be needed to work outdoors to decrease the risk psittacosis.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; Dept Human Serv, Infect Dis Unit, Fairfield, Vic, Australia; Royal Melbourne Hosp, Melbourne, Vic, Australia	Australian National University; Royal Melbourne Hospital	Williams, J (corresponding author), ACHS Care Evaluat Program, Aikkenhead Ctr, Level 9,41 Victoria Parade, Fitzroy, Vic 3065, Australia.			Williams, Joanne/0000-0002-5633-1592				ANDREWS BE, 1981, LANCET, V1, P632; [Anonymous], 1995, CONTROL COMMUNICABLE; KHATIB R, 1995, SCAND J INFECT DIS, V27, P519, DOI 10.3109/00365549509047058; Meyer KF, 1942, MEDICINE, V21, P175, DOI 10.1097/00005792-194205010-00003; NAGINGTON J, 1984, J HYG-CAMBRIDGE, V92, P9, DOI 10.1017/S0022172400063981; PALMER SR, 1981, LANCET, V2, P798; PETHER JVS, 1989, EPIDEMIOL INFECT, V103, P395, DOI 10.1017/S0950268800030752; ROBERTS JP, 1978, AVIAN DIS, V22, P698, DOI 10.2307/1589647; SCHAFFNER W, 1990, PRINCIPLES PRACTICE, P1440; SCHLOSSBERG D, 1993, ARCH INTERN MED, V153, P2594, DOI 10.1001/archinte.153.22.2594; VERBRUGGE LM, 1989, J HEALTH SOC BEHAV, V30, P282, DOI 10.2307/2136961; WATSON MW, 1991, J CLIN MICROBIOL, V29, P1188, DOI 10.1128/JCM.29.6.1188-1193.1991; 1992, MMWR MORB MORTAL WKL, V41, P794	13	51	51	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1697	1699		10.1016/S0140-6736(97)10444-5	http://dx.doi.org/10.1016/S0140-6736(97)10444-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734887				2022-12-24	WOS:000074088900011
J	Marrugat, J; Sala, J; Masia, R; Pavesi, M; Sanz, G; Valle, V; Molina, L; Seres, L; Elosua, R				Marrugat, J; Sala, J; Masia, R; Pavesi, M; Sanz, G; Valle, V; Molina, L; Seres, L; Elosua, R		RESCATE Investigators	Mortality differences between men and women following first myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; SEX-DIFFERENCES; CASE-FATALITY; MONICA PROJECT; HEART-DISEASE; OUTCOMES; REGISTER	Context.-Mortality after acute myocardial infarction is worse in women than in men, even after adjustment for comorbidity and age dissimilarities between sexes. Objective.-To assess the influence of sex on survival after acute myocardial infarction. Design.-Inception cohort obtained in a prospective registry of patients with acute myocardial infarction from 1992 through 1994. Setting.-Four teaching hospitals in northeastern Spain. Patients.-All consecutive patients aged 80 years or younger with first acute myocardial infarction. A total of 331 women and 1129 men were included. Main Outcome Measure.-Survival at 28 days and mortality or readmission at 6 months, Results.-Women were older (mean, 68.6 vs 60.1 years), presented more often with diabetes (52.9% vs 23.3%), hypertension (63.9% vs 42.3%), or previous angina (44.6% vs 37.4%), and developed more severe myocardial infarctions than men (acute pulmonary edema or cardiogenic shock occurred in 24.8% of women and 10.5% of men) tall P<.02). Men were more likely than women to receive thrombolytic therapy (41.3% vs 23.9%; P<.001), but rates of percutaneous transluminal angioplasty and coronary artery bypass graft surgery at 28 days were similar among men and women, The 28-day mortality rate was significantly higher among women (18.5% for women, 8.3% for men; P<.001). Revascularization procedures at 6 months were performed in a similar proportion of women and men. However, women had higher 6-month mortality rates (25.8% in women, 10.8% in men; P<.001) and readmission rates (23.3% for women, 12.2% for men; P<.001). After adjustment, women had greater risk of death than men at 28 days (odds ratio [OR], 1.72; 95% confidence interval [CI], 1.12-2.65) and at 6 months (OR, 1.73; 95% ci, 1.18-2.52). Conclusions.-In this study population, women experienced more lethal and severe first acute myocardial infarction than men, regardless of comorbidity, age, or previous angina.	Inst Municipal Invest Med, Unitat Lipids & Epidemiol Cardiovasc, E-08003 Barcelona, Spain; Hosp Clin Barcelona, Inst Cardiovasc Dis, Barcelona, Spain; Hosp Mar, Dept Cardiol, Barcelona, Spain; Hosp Gerona Josep Trueta, Unitat Coronaria, Gerona, Spain; Hosp Germans Trias, Dept Cardiol, Badalona, Spain	University of Barcelona; Hospital Clinic de Barcelona; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Universitat de Girona; Girona University Hospital Dr. Josep Trueta; Hospital Germans Trias i Pujol	Marrugat, J (corresponding author), Inst Municipal Invest Med, Unitat Lipids & Epidemiol Cardiovasc, Dr Aiguader 80, E-08003 Barcelona, Spain.		Alonso, Jordi/A-5514-2010	Alonso, Jordi/0000-0001-8627-9636; Marrugat, Jaume/0000-0003-3320-554X				*ACC AHA, 1990, CIRCULATION, V82, P664; BECKER RC, 1994, ANN INTERN MED, V120, P638, DOI 10.7326/0003-4819-120-8-199404150-00003; BOSCH X, 1994, REV ESP CARDIOL S, V47, P926; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Chambless L, 1997, CIRCULATION, V96, P3849; Chandra NC, 1998, ARCH INTERN MED, V158, P981, DOI 10.1001/archinte.158.9.981; DEMIROVIC J, 1995, AM J CARDIOL, V75, P1096, DOI 10.1016/S0002-9149(99)80737-1; DEVREEDE JJM, 1991, J AM COLL CARDIOL, V18, P698, DOI 10.1016/0735-1097(91)90792-8; EAKER ED, 1993, CIRCULATION, V88, P1999, DOI 10.1161/01.CIR.88.4.1999; Froufe J, 1994, Rev Esp Cardiol, V47 Suppl 1, P27; GILLUM RF, 1984, AM HEART J, V108, P150, DOI 10.1016/0002-8703(84)90558-1; GREENLAND P, 1991, CIRCULATION, V83, P484, DOI 10.1161/01.CIR.83.2.484; Herman B, 1997, EUR HEART J, V18, P963; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Hussain KMA, 1997, AM HEART J, V134, P719, DOI 10.1016/S0002-8703(97)70056-5; JAGLAL SB, 1994, CAN J CARDIOL, V10, P239; JENKINS JS, 1989, AM J CARDIOL, V130, P469; KILLIP T, 1967, AM J CARDIOL, V20, P457, DOI 10.1016/0002-9149(67)90023-9; MARRUGAT J, 1994, J CLIN EPIDEMIOL, V47, P111, DOI 10.1016/0895-4356(94)90016-7; Marrugat J, 1997, J AM COLL CARDIOL, V30, P1187, DOI 10.1016/S0735-1097(97)00312-4; MAYNARD C, 1996, CIRCULATION S, V94, P1193; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; PEREZ G, 1993, J CLIN EPIDEMIOL, V46, P1173, DOI 10.1016/0895-4356(93)90116-I; Perez G, 1998, INT J EPIDEMIOL, V27, P599, DOI 10.1093/ije/27.4.599; Schwartz LM, 1997, ARCH INTERN MED, V157, P1545, DOI 10.1001/archinte.157.14.1545; Sonke GS, 1996, BRIT MED J, V313, P853; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; VACCARINO V, 1995, CIRCULATION, V91, P1861, DOI 10.1161/01.CIR.91.6.1861	28	170	178	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 28	1998	280	16					1405	1409		10.1001/jama.280.16.1405	http://dx.doi.org/10.1001/jama.280.16.1405			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130YA	9800999	Bronze			2022-12-24	WOS:000076546900034
J	Mackie, GA				Mackie, GA			Ribonuclease E is a 5 '-end-dependent endonuclease	NATURE			English	Article							RIBOSOMAL-PROTEIN S20; ESCHERICHIA-COLI; MESSENGER-RNA; CLEAVAGE SITES; IN-VITRO; DEGRADATION; INVITRO; ENZYME; INVIVO; OVEREXPRESSION	The selective degradation of messenger RNAs enables cells to regulate the levels of particular mRNAs in response to changes in the environment. Ribonuclease (RNase) E (ref, 1), a single-strand-specific endonuclease(2-4) that is found in a multi-enzyme complex known as the 'degradosome'(5-7), initiates the degradation of many mRNAs in Escherichia coli(3,8,9). Its relative lack of sequence specificity and the presence of many potential cleavage sires in mRNA substrate(2,3) cannot explain why mRNA decay frequently proceeds in a net 5'-to-3' directian(9-11). I have prepared covalently dosed circular derivatives of natural substrates, the rpsT mRNA encoding ribosomal protein S20 (ref. 2) and the 9S precursor to 5S ribosomal RNA(1,12), and find that these derivatives are considerably more resistant to cleavage in vitro by RNase E than are linear molecules. Moreover, antisense oligo-deoxynucleotides complementary to the 5' end of linear substrates significantly reduce the latter's susceptibility to attack by RNase E. Finally, natural substrates with terminal 5'-h triphosphate groups are poorly cleaved by RNase E in vitro, whereas 5' monophosphorylated substrates are strongly preferred (compare with ref, 13). These results show that RNase E has inherent: vectorial properties, with its activity depending on the 5' end of its substrates; this can account for the direction of mRNA decay in E, coli, the phenomenon of 'all or none' mRNA decay, and the stabilization provided by 5' stem-loop structures(14-17).	Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Mackie, GA (corresponding author), Univ British Columbia, Dept Biochem & Mol Biol, 2146 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	gamackie@unixg.ubc.ca						APIRION D, 1973, MOL GEN GENET, V122, P313, DOI 10.1007/BF00269431; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; Coburn GA, 1998, J MOL BIOL, V279, P1061, DOI 10.1006/jmbi.1998.1842; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EMORY SA, 1992, GENE DEV, V6, P135, DOI 10.1101/gad.6.1.135; HANSEN MJ, 1994, MOL MICROBIOL, V12, P707, DOI 10.1111/j.1365-2958.1994.tb01058.x; Huang HJ, 1998, NATURE, V391, P99, DOI 10.1038/34219; Kennell D, 1986, MAXIMIZING GENE EXPR, P101; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; Mackie GA, 1997, J BIOL CHEM, V272, P609; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MCDOWALL KJ, 1994, J BIOL CHEM, V269, P10790; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; Nierlich DP, 1996, PROG NUCLEIC ACID RE, V52, P153, DOI 10.1016/S0079-6603(08)60967-8; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; STEVENS A, 1978, BIOCHEM BIOPH RES CO, V81, P656, DOI 10.1016/0006-291X(78)91586-3; XU E, 1995, NATURE, V374, P180; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	28	323	328	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					720	723		10.1038/27246	http://dx.doi.org/10.1038/27246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790196				2022-12-24	WOS:000076472600058
J	Moreno-Reyes, R; Suetens, C; Mathieu, F; Begaux, F; Zhu, D; Rivera, MT; Boelaert, M; Neve, J; Perlmutter, N; Vanderpas, J				Moreno-Reyes, R; Suetens, C; Mathieu, F; Begaux, F; Zhu, D; Rivera, MT; Boelaert, M; Neve, J; Perlmutter, N; Vanderpas, J			Kashin-Beck osteoarthropathy in rural Tibet in relation to selenium and iodine status	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	6th International Thyroid Symposium	MAY 08-11, 1996	GRAZ, AUSTRIA				GLUTATHIONE-PEROXIDASE; ENDEMIC CRETINISM; SERUM SELENIUM; DISEASE; SUPPLEMENTATION; HYPOTHYROIDISM; DEFICIENCY; BLOOD; AREA	Background and Methods Kashin-Beck disease is a degenerative osteoarticular disorder that is endemic to certain areas of Tibet, where selenium deficiency is also endemic; Because selenium is involved in thyroid hormone metabolism, we studied the relation among the serum selenium concentration, thyroid function, and Kashin-Beck disease in 575 subjects 5 to 15 years of age in 12 villages around Lhasa, Tibet, including 1 control village in which no subject had Kashin-Beck disease. Clinical, radiologic, and biochemical data were collected. Results Among the 575 subjects, 280 (49 percent) had Kashin-Beck disease, 267 (46 percent) had goiter, and 7 (1 percent) had cretinism. Of the 557 subjects in whom urinary iodine was measured, 66 per cent had a urinary iodine concentration of less than 2 mu g per deciliter (157 nmol per liter; normal, 5 to 25 mu g per deciliter [394 to 1968 nmol per liter]). The mean urinary iodine concentration was lower in subjects with Kashin-Beck disease than in control subjects (1.2 vs. 1.8 mu g per deciliter [94 vs. 142 nmol per liter], P<0.001) and hypothyroidism was more frequent (23 percent vs. 4 percent, P=0.01). Severe selenium deficiency was documented in all villages; 38 percent of subjects had serum concentrations of less than 5 ng per milliliter (64 nmol per liter; normal, 60 to 105 ng per milliliter [762 to 1334 nmol per liter]). When age and sex were controlled for in a multivariate analysis, low urinary iodine, high serum thyrotrophin, and low serum thyroxine-binding globulin Values were associated with an increased risk of Kashin-Beck disease, but a low serum selenium concentration was not. Conclusions In areas where severe selenium deficiency is endemic, iodine deficiency is a risk factor for Kashin-Beck disease. (N Engl J Med 1998;339: 1112-20.) (C) 1998, Massachusetts Medical Society.	Hop Erasme, Dept Nucl Med, B-1070 Brussels, Belgium; Inst Pharm, Lab Pharmaceut Chem, Brussels, Belgium; Childrens Univ Hosp, Dept Pediat Radiol, Brussels, Belgium; Free Univ Brussels, Sch Publ Hlth, Brussels, Belgium; Med Sans Frontiers, Brussels, Belgium; Ambroise Pare Hosp, Mons, Belgium	Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Moreno-Reyes, R (corresponding author), Hop Erasme, Dept Nucl Med, Route Lennik 808, B-1070 Brussels, Belgium.		Rivera, Maria/GYU-2150-2022; Boelaert, Marleen/E-2698-2012	Boelaert, Marleen/0000-0001-8051-6776; Jean, Vanderpas/0000-0003-0623-5612				Alfthan G, 1996, J TRACE ELEM MED BIO, V10, P77, DOI 10.1016/S0946-672X(96)80015-0; ALLANDER E, 1994, SCAND J RHEUMATOL S, V99, P36; [Anonymous], 1986, B WORLD HEALTH ORGAN, V64, P929; BECK MA, 1994, J MED VIROL, V43, P166, DOI 10.1002/jmv.1890430213; Calomme MR, 1995, EXPERIENTIA, V51, P1208, DOI 10.1007/BF01944738; Chasseur C, 1997, LANCET, V350, P1074, DOI 10.1016/S0140-6736(05)70453-0; CONTEMPRE B, 1991, J CLIN ENDOCR METAB, V73, P213, DOI 10.1210/jcem-73-1-213; DELANGE F, 1972, J CLIN ENDOCR METAB, V34, P1059, DOI 10.1210/jcem-34-6-1059; DIPLOCK AT, 1987, AM J CLIN NUTR, V45, P1313, DOI 10.1093/ajcn/45.5.1313; DIPLOCK AT, 1993, AM J CLIN NUTR, V57, P256, DOI 10.1093/ajcn/57.2.256S; DUNN JT, 1986, SCI PUBLICATION PAHO, V502, P373; Greulich WW, 1959, RADIOGRAPHIC ATLAS S; LOMBECK I, 1977, EUR J PEDIATR, V125, P81, DOI 10.1007/BF00470608; MA T, 1993, AM J CLIN NUTR, V57, P264; Mathieu F, 1997, INT ORTHOP, V21, P151, DOI 10.1007/s002640050139; MEINHOLD H, 1993, EXP CLIN ENDOCRINOL, V101, P87, DOI 10.1055/s-0029-1211212; Molle L., 1987, TRACE ELEM ANAL CHEM, V4, P349; NEVE J, 1995, J TRACE ELEM MED BIO, V9, P65, DOI 10.1016/S0946-672X(11)80013-1; NEVE J, 1991, J TRACE ELEM ELECT H, V5, P1; NEVE J, 1992, PURE APPL CHEM, V64, P765, DOI 10.1351/pac199264050765; PENG A, 1992, J TOXICOL ENV HEALTH, V35, P79, DOI 10.1080/15287399209531597; SOKOLOFF L, 1989, NEW YORK STATE J MED, V89, P486; SOKOLOFF L, 1989, NEW YORK STATE J MED, V89, P343; SOKOLOFF L, 1990, ANN RHEUM DIS, V49, P262, DOI 10.1136/ard.49.4.262; StGermain DL, 1997, THYROID, V7, P655; Thilly C.H., 1980, EPIDEMIOLOGIC SURVEY, P157; VANDERPAS J, 1984, CLIN ENDOCRINOL, V20, P327, DOI 10.1111/j.1365-2265.1984.tb00089.x; VANDERPAS JB, 1986, NEW ENGL J MED, V315, P791, DOI 10.1056/NEJM198609253151302; VANDERPAS JB, 1990, AM J CLIN NUTR, V52, P1087, DOI 10.1093/ajcn/52.6.1087; Wang YZ, 1996, RADIOLOGY, V201, P265, DOI 10.1148/radiology.201.1.8816556; Wu J, 1987, J Trace Elem Electrolytes Health Dis, V1, P39; Yang G Q, 1988, World Rev Nutr Diet, V55, P98; Yang Guang-Qi, 1995, Biomedical and Environmental Sciences, V8, P187	33	234	256	3	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1112	1120		10.1056/NEJM199810153391604	http://dx.doi.org/10.1056/NEJM199810153391604			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	129DP	9770558	Bronze			2022-12-24	WOS:000076448200004
J	Bonde, JPE; Ernst, E; Jensen, TK; Hjollund, NHI; Kolstad, H; Henriksen, TB; Scheike, T; Giwercman, A; Olsen, J; Skakkebaek, NE				Bonde, JPE; Ernst, E; Jensen, TK; Hjollund, NHI; Kolstad, H; Henriksen, TB; Scheike, T; Giwercman, A; Olsen, J; Skakkebaek, NE			Relation between semen quality and fertility: a population-based study of 430 first-pregnancy planners	LANCET			English	Article							INFERTILE COUPLES; SPERM COUNT; SURVIVAL; VOLUME; TIME; MEN	Background Semen analysis is part of the routine assessment of infertile couples. WHO defines a sperm concentration above 20x10(6) per mt seminal fluid as normal. We studied the association between semen quality and the probability of conception in a single menstrual cycle in Danish couples with no previous reproductive experience. Methods In 1992-94, we invited 52 255 trades-union members aged 20-35 years, who lived with a partner and had no children to take part in the study; 430 couples agreed. The couples discontinued use of contraception, and were followed up for six menstrual cycles or until a pregnancy was verified within this period. Each man was asked to provide a semen sample at enrolment (which was analysed without freezing). Women kept a daily record of vaginal bleeding and sexual activity. The association between semen quality and likelihood of pregnancy was assessed by logistic regression, adjusted for sexual activity and female factors associated with low fertility. Results There were 256 (59.5%) pregnancies among the 430 couples: 165 (65.0%) among those with a sperm concentration of 40x10(6)/mL or more and 84 (51.2%) among those with lower sperm concentrations. The probability of conception increased with increasing sperm concentration up to 40x10(6)/mL, but any higher sperm density was not associated with additional likelihood of pregnancy. The proportion of sperm with normal morphology was strongly related to likelihood of pregnancy independently of sperm concentration. Semen volume and motility were of limited value in pregnancy prediction. Interpretation Our study suggests that the current WHO guidelines for normal semen quality should be used with caution. Some men with sperm counts above the lower limit of the normal range defined by WHO may in fact be subfertile.	Aarhus Univ Hosp, Dept Occupat Med, DK-8000 Aarhus C, Denmark; Aarhus Univ Hosp, Dept Obstet & Gynaecol, Perinatal Epidemiol Res Unit, DK-8000 Aarhus, Denmark; Univ Aarhus, Inst Anat, Reprod Toxicol Unit, DK-8000 Aarhus C, Denmark; Univ Aarhus, Steno Ctr, Danish Epidemiol Sci Ctr, DK-8000 Aarhus C, Denmark; Natl Hosp, Dept Growth & Reprod, Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, DK-1168 Copenhagen, Denmark	Aarhus University; Aarhus University; Aarhus University; Aarhus University; Rigshospitalet; University of Copenhagen	Bonde, JPE (corresponding author), Aarhus Univ Hosp, Dept Occupat Med, Norrebrogade 37-39, DK-8000 Aarhus C, Denmark.			Scheike, Thomas/0000-0002-2148-4740; Jensen, Tina Kold/0000-0003-2311-5778; Hjollund, Niels Henrik I/0000-0002-6697-6597				AITKEN RJ, 1984, J ANDROL, V5, P321; Belsey MA, 1980, WHO LAB MANUAL EXAMI; BONDE JP, 1990, BRIT J IND MED, V47, P508; Bonde JPE, 1998, REPROD TOXICOL, V12, P19, DOI 10.1016/S0890-6238(97)00096-8; BOSTOFTE E, 1984, FERTIL STERIL, V41, P95; BOSTOFTE E, 1982, INT J ANDROL, V5, P267, DOI 10.1111/j.1365-2605.1982.tb00255.x; BOSTOFTE E, 1993, FERTIL STERIL, V59, P102; CHAMBERS JM, 1992, STAT MODELS S, P249; COLLINS JA, 1984, AM J OBSTET GYNECOL, V148, P527, DOI 10.1016/0002-9378(84)90741-5; COMHAIRE FH, 1993, REPROD TOXICOL, V7, P39, DOI 10.1016/0890-6238(93)90067-H; DUNPHY BC, 1989, FERTIL STERIL, V51, P324; *EUROMAC, 1992, INT J EPIDEMIOLOG S1, V21, pS1; GLAZENER CMA, 1987, HUM REPROD, V2, P665, DOI 10.1093/oxfordjournals.humrep.a136612; GWATKIN RBL, 1990, FERTIL STERIL, V53, P693; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; Jelnes J E, 1988, Reprod Toxicol, V2, P209, DOI 10.1016/0890-6238(88)90024-X; MACLEOD J, 1951, FERTIL STERIL, V2, P115; MEISTRICH ML, 1983, FERTIL STERIL, V40, P220; OLSEN J, 1994, J EPIDEMIOL COMMUN H, V48, P171, DOI 10.1136/jech.48.2.171; POLANSKY FF, 1988, FERTIL STERIL, V49, P1059; ROWE PJ, 1993, WHO MANUAL STANDARDI; Scheike TH, 1997, BIOMETRICS, V53, P318, DOI 10.2307/2533117; SCHWARTZ D, 1979, J REPROD FERTIL, V57, P391; WANG C, 1988, J ANDROL, V9, P384; WILCOX AJ, 1988, NEW ENGL J MED, V319, P189, DOI 10.1056/NEJM198807283190401; Zinaman MJ, 1996, FERTIL STERIL, V65, P503, DOI 10.1016/S0015-0282(16)58144-8	26	520	536	1	36	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1172	1177		10.1016/S0140-6736(97)10514-1	http://dx.doi.org/10.1016/S0140-6736(97)10514-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777833				2022-12-24	WOS:000076415400008
J	Lower, R; Tonjes, RR; Boller, K; Denner, J; Kaiser, B; Phelps, RC; Lower, J; Kurth, R; Badenhoop, K; Donner, H; Usadel, KH; Miethke, T; Lapatschek, M; Wagner, H				Lower, R; Tonjes, RR; Boller, K; Denner, J; Kaiser, B; Phelps, RC; Lower, J; Kurth, R; Badenhoop, K; Donner, H; Usadel, KH; Miethke, T; Lapatschek, M; Wagner, H			Development of insulin-dependent diabetes mellitus does not depend on specific expression of the human endogenous retrovirus HERV-K	CELL			English	Letter							LONG TERMINAL REPEAT; REVERSE-TRANSCRIPTASE; HTDV/HERV-K; SEQUENCES; PROTEIN; IDENTIFICATION; SUPERANTIGEN; ANTIBODIES; PARTICLES; CELLS		Paul Ehrlich Inst, D-63225 Langen, Germany; Univ Frankfurt, Dept Med 1, D-60596 Frankfurt, Germany; Tech Univ Munich, Inst Med Microbiol, D-81675 Munich, Germany	Paul Ehrlich Institute; Goethe University Frankfurt; Technical University of Munich	Lower, R (corresponding author), Paul Ehrlich Inst, Paul Ehrlich Str 51-59, D-63225 Langen, Germany.							Boller K, 1997, J VIROL, V71, P4581, DOI 10.1128/JVI.71.6.4581-4588.1997; Conrad B, 1997, CELL, V90, P303, DOI 10.1016/S0092-8674(00)80338-4; GUNZBURG WH, 1993, NATURE, V364, P154, DOI 10.1038/364154a0; Lower R, 1996, P NATL ACAD SCI USA, V93, P5177, DOI 10.1073/pnas.93.11.5177; LOWER R, 1995, J VIROL, V69, P141; LOWER R, 1993, VIROLOGY, V192, P501, DOI 10.1006/viro.1993.1066; ONO M, 1986, J VIROL, V58, P937, DOI 10.1128/JVI.58.3.937-944.1986; PYRA H, 1994, P NATL ACAD SCI USA, V91, P1544, DOI 10.1073/pnas.91.4.1544; Sauter M, 1996, CANCER RES, V56, P4362; Simpson GR, 1996, VIROLOGY, V222, P451, DOI 10.1006/viro.1996.0443; Tonjes RR, 1996, J ACQ IMMUN DEF SYND, V13, pS261; Tonjes RR, 1997, J VIROL, V71, P2747; VOGETSEDER W, 1993, AIDS RES HUM RETROV, V9, P687, DOI 10.1089/aid.1993.9.687; Weissmahr RN, 1997, J VIROL, V71, P3005, DOI 10.1128/JVI.71.4.3005-3012.1997	14	46	46	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					11	14		10.1016/S0092-8674(00)81776-6	http://dx.doi.org/10.1016/S0092-8674(00)81776-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778242	Bronze			2022-12-24	WOS:000076242300004
J	Hines, P; Culotta, E				Hines, P; Culotta, E			The evolution of sex	SCIENCE			English	Editorial Material																			0	7	8	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					1979	1979		10.1126/science.281.5385.1979	http://dx.doi.org/10.1126/science.281.5385.1979			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9767048				2022-12-24	WOS:000076161800040
J	Rosamond, WD; Chambless, LE; Folsom, AR; Cooper, LS; Conwill, DE; Clegg, L; Wang, CH; Heiss, G				Rosamond, WD; Chambless, LE; Folsom, AR; Cooper, LS; Conwill, DE; Clegg, L; Wang, CH; Heiss, G			Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMMUNITY SURVEILLANCE; ALAMEDA COUNTY; RISK-FACTORS; SURVEY MHS; MINNESOTA; DECLINE; EXPERIENCE; MORBIDITY; PROJECT; DEATH	Background and Methods To clarify the determinants of contemporary trends in mortality from coronary heart disease (CHD), we conducted surveillance of hospital admissions for myocardial infarction and of in-hospital and out-of-hospital deaths due to CHD among 35-to-74-year-old residents of four communities of varying size in the United States (a total of 352,481 persons in 1994). Between 1987 and 1994, we estimate that there were 11,869 hospitalizations for myocardial infarction (on the basis of 8572 hospitalizations sampled) and 3407 fatal coronary events (3023 sampled). Results The largest average annual decrease in mortality due to CHD occurred among white men (change in mortality, -4.7 percent; 95 percent confidence interval, -2.2 to -7.1 percent), followed by white women (-4.5 percent; 95 percent confidence interval, -0.7 to -8.2 percent), black women (-4.1 percent; 95 percent confidence interval, -10.3 to +2.5 percent), and black men (-2.5 percent; 95 percent confidence interval, -6.9 to +2.2 percent). Overall, in-hospital mortality from CHD fell by 5.1 percent per year, whereas out-of-hospital mortality declined by 3.6 percent per year. There was no evidence of a decline in the incidence of hospitalization for a first myocardial infarction among either men or women; in fact, such hospital admissions increased by 7.4 percent per year (95 percent confidence interval, 0.5 to 14.8 percent) among black women and 2.9 percent per year (95 percent confidence interval, -3.6 to +9.9 percent) among black men. Rates of recurrent myocardial infarction decreased, and survival after myocardial infarction improved. Conclusions From 1987 to 1994, we observed a stable or slightly increasing incidence of hospitalization for myocardial infarction. Nevertheless, there were significant annual decreases in mortality from CHD. The decline in mortality in the four communities we studied may be due largely to improvements in the treatment and secondary prevention of myocardial infarction. (N Engl J Med 1998;339:861-7) (C)1998, Massachusetts Medical Society.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; NHLBI, Bethesda, MD 20892 USA; Univ Mississippi, Med Ctr, Dept Prevent Med, Div Epidemiol, Jackson, MS 39216 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); University of Mississippi; University of Mississippi Medical Center	Rosamond, WD (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, CB 7400,McGavran-Greenberg Hall, Chapel Hill, NC 27599 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055018, N01HC055015, N01HC055016] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-55018, N01-HC-55016, N01-HC-55015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASSAF AR, 1993, NEW ENGL J MED, V329, P931, DOI 10.1056/NEJM199309233291307; BURKE GL, 1989, J CLIN EPIDEMIOL, V42, P17, DOI 10.1016/0895-4356(89)90021-8; COHN BA, 1988, AM J EPIDEMIOL, V127, P1143, DOI 10.1093/oxfordjournals.aje.a114908; EDLAVITCH SA, 1990, J CLIN EPIDEMIOL, V43, P93, DOI 10.1016/0895-4356(90)90061-S; ELVEBACK LR, 1986, MAYO CLIN PROC, V61, P896, DOI 10.1016/S0025-6196(12)62612-3; FORTMANN SP, 1986, AM J EPIDEMIOL, V123, P656, DOI 10.1093/oxfordjournals.aje.a114285; GILLUM RF, 1994, J AM COLL CARDIOL, V23, P1273, DOI 10.1016/0735-1097(94)90367-0; Goff DC, 1997, CIRCULATION, V95, P1433; GOLDBERG RJ, 1993, CIRCULATION, V87, P1947, DOI 10.1161/01.CIR.87.6.1947; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; HIGGINS MW, 1988, TRENDS CORONARY HEAR, P301; Hunink MGM, 1997, JAMA-J AM MED ASSOC, V277, P535, DOI 10.1001/jama.277.7.535; Ives Diane G., 1995, Annals of Epidemiology, V5, P278, DOI 10.1016/1047-2797(94)00093-9; KAPLAN GA, 1988, AM J EPIDEMIOL, V127, P1131, DOI 10.1093/oxfordjournals.aje.a114907; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; Nichaman M Z, 1993, Ann Epidemiol, V3, P42; PANKOW JS, 1994, J CLIN EPIDEMIOL, V47, P1051, DOI 10.1016/0895-4356(94)90121-X; PEDERSEN TR, 1994, LANCET, V344, P1383; Sidney S, 1996, CIRCULATION, V93, P11; Sytkowski PA, 1996, AM J EPIDEMIOL, V143, P338, DOI 10.1093/oxfordjournals.aje.a008748; White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; World Health Organization, 1980, INT CLASSIFICATION D; 1997, MMWR MORB MORTAL WKL, V46, P146	24	625	651	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					861	867		10.1056/NEJM199809243391301	http://dx.doi.org/10.1056/NEJM199809243391301			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744969				2022-12-24	WOS:000076037400001
J	Moller, H; Cortes, D; Engholm, G; Thorup, J				Moller, H; Cortes, D; Engholm, G; Thorup, J			Risk of testicular cancer with cryptorchidism and with testicular biopsy: cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BOYS; TESTIS		Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, DK-2100 Copenhagen 0, Denmark; Natl Univ Hosp, Dept Pathol, DK-2100 Copenhagen 0, Denmark; Natl Univ Hosp, Dept Paediat Surg, DK-2100 Copenhagen 0, Denmark	Danmarks Grundforskningsfond	Moller, H (corresponding author), Danish Natl Res Fdn, Ctr Res Hlth & Social Stat, Sejrogade 11, DK-2100 Copenhagen 0, Denmark.	cerefo@inet.uni2.dk		Cortes, Dina/0000-0002-6852-6530; Thorup, Jorgen/0000-0003-3550-1107				CORTES D, 1994, J UROLOGY, V151, P722, DOI 10.1016/S0022-5347(17)35071-1; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; GIWERCMAN A, 1987, J UROLOGY, V138, P1214, DOI 10.1016/S0022-5347(17)43553-1; Moller H, 1996, CANCER CAUSE CONTROL, V7, P264, DOI 10.1007/BF00051302; Swerdlow AJ, 1997, BRIT MED J, V314, P1507, DOI 10.1136/bmj.314.7093.1507	5	45	45	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 12	1998	317	7160					729	729		10.1136/bmj.317.7160.729	http://dx.doi.org/10.1136/bmj.317.7160.729			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732342	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000075995100023
J	Sierra-Honigmann, MR; Nath, AK; Murakami, C; Garcia-Cardena, G; Papapetropoulos, A; Sessa, WC; Madge, LA; Schechner, JS; Schwabb, MB; Polverini, PJ; Flores-Riveros, JR				Sierra-Honigmann, MR; Nath, AK; Murakami, C; Garcia-Cardena, G; Papapetropoulos, A; Sessa, WC; Madge, LA; Schechner, JS; Schwabb, MB; Polverini, PJ; Flores-Riveros, JR			Biological action of leptin as an angiogenic factor	SCIENCE			English	Article							MESSENGER-RNA; OB PROTEIN; OBESE GENE; CELLS; RECEPTOR; MICE; EXPRESSION; ACTIVATION; ADIPOSITY; TISSUES	Leptin is a hormone that regulates food intake, and its receptor (OB-Rb) is expressed primarily in the hypothalamus. Here, it is shown that OB-Rb is also expressed in human vasculature and in primary cultures of human endothelial coils, In vitro and in vivo assays revealed that Leptin has angiogenic activity. In vivo, Leptin induced neovascularization in corneas from normal rats but not in corneas from fa/fa Zucker rats, which Lack functional Leptin receptors. These observations indicate that the vascular endothelium is a target for Leptin and suggest a physiological mechanism whereby Leptin-induced angiogenesis may facilitate increased energy expenditure.	Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06536 USA; Univ Michigan, Sch Dent, Dept Oral Med Pathol Surg, Ann Arbor, MI 48109 USA; Bayer Corp, Inst Metab Disorders, West Haven, CT 06516 USA	Yale University; University of Michigan System; University of Michigan; Bayer AG	Sierra-Honigmann, MR (corresponding author), Yale Univ, Sch Med, Boyer Ctr Mol Med, 333 Cedar St, New Haven, CT 06536 USA.	rocio_sierra-honigmann@qm.yale.edu	Andreas, Papapetropoulos/AAJ-3089-2020; Garcia-Cardena, Guillermo/Q-6649-2019; Sessa, William C/B-6844-2011; Polverini, Peter/AAJ-8392-2020	Sessa, William C/0000-0001-5759-1938; Papapetropoulos, Andreas/0000-0002-4253-5930				AUERBACH R, 1991, PHARMACOL THERAPEUT, V51, P1, DOI 10.1016/0163-7258(91)90038-N; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Castle VP, 1997, LAB INVEST, V77, P51; Crandall DL, 1997, MICROCIRCULATION-LON, V4, P211, DOI 10.3109/10739689709146786; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Flier JS, 1997, P NATL ACAD SCI USA, V94, P4242, DOI 10.1073/pnas.94.9.4242; FREDERICH RC, 1995, J CLIN INVEST, V96, P1658, DOI 10.1172/JCI118206; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Jain RK, 1997, NAT MED, V3, P1203, DOI 10.1038/nm1197-1203; Kieffer TJ, 1997, DIABETES, V46, P1087, DOI 10.2337/diabetes.46.6.1087; Koyama K, 1997, DIABETES, V46, P1276, DOI 10.2337/diabetes.46.8.1276; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Levin N, 1996, P NATL ACAD SCI USA, V93, P1726, DOI 10.1073/pnas.93.4.1726; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Sarmiento U, 1997, LAB INVEST, V77, P243; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; SIERRAHONIGMANN MR, UNPUB; SierraHonigmann R, 1996, LAB INVEST, V74, P684; Tuominen JA, 1997, ACTA PHYSIOL SCAND, V160, P83, DOI 10.1046/j.1365-201X.1997.00102.x; WHITE DW, 1996, CTOKINE GROWTH FACTO, V7, P3003; Zachow RJ, 1997, ENDOCRINOLOGY, V138, P847, DOI 10.1210/en.138.2.847; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P6386, DOI 10.1073/pnas.94.12.6386	25	1144	1210	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	1998	281	5383					1683	1686		10.1126/science.281.5383.1683	http://dx.doi.org/10.1126/science.281.5383.1683			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733517				2022-12-24	WOS:000075856500050
J	Cohn, JA; Friedman, KJ; Noone, PG; Knowles, MR; Silverman, LM; Jowell, PS				Cohn, JA; Friedman, KJ; Noone, PG; Knowles, MR; Silverman, LM; Jowell, PS			Relation between mutations of the cystic fibrosis gene and idiopathic pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CONGENITAL BILATERAL ABSENCE; VAS-DEFERENS; PARTIAL PENETRANCE; 5T ALLELE; CFTR GENE; CHILDREN; DISEASE	Background It is unknown whether genetic factors predispose patients to idiopathic pancreatitis, In patients with cystic fibrosis, mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene typically cause pulmonary and pancreatic insufficiency while rarely causing pancreatitis. We examined whether idiopathic pancreatitis is associated with CFTR mutations in persons who do not have lung disease of cystic fibrosis. Methods We studied 27 patients (mean age at diagnosis, 36 years), 22 of whom were female, who had been referred for an evaluation of idiopathic pancreatitis. DNA was tested for 17 CFTR mutations and for the 5T allele in intron 8 of the CFTR gene. The 5T allele reduces the level of functional CFTR and is associated with an inherited form of infertility in males. Patients with two abnormal CFTR alleles were further evaluated for unrecognized cystic fibrosis-related lung disease, and bath base-line and CFTR-mediated ion transport were measured in the nasal mucosa. Results Ten patients with idiopathic chronic pancreatitis (37 percent) had at least one abnormal CFTR allele. Eight CFTR mutations were detected (prevalence ratio, 11:1; 95 percent confidence interval, 5 to 23; P<0.001). In three patients both alleles were affected (prevalence ratio, 80:1; 95 percent confidence interval, 17 to 379; P<0.001). These three patients did not have lung disease typical of cystic fibrosis on the basis of sweat testing, spirometry, or base-line nasal potential-difference measurements. Nonetheless, each had abnormal nasal cyclic AMP-mediated chloride transport. Conclusions In a group of patients referred for evaluation of idiopathic pancreatitis, there was a strong association between mutations in the CFTR gene and pancreatitis. The abnormal CFTR genotypes in these patients with pancreatitis resemble those associated with male infertility. (N Engl J Med 1998;339:653-8.) (C) 1998, Massachusetts Medical Society.	Duke Univ, Med Ctr, Durham, NC 27710 USA; Vet Affairs Med Ctr, Dept Med, Durham, NC 27705 USA; Univ N Carolina, Dept Pathol, Chapel Hill, NC USA; Univ N Carolina, Dept Lab Med, Chapel Hill, NC USA	Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Cohn, JA (corresponding author), Duke Univ, Med Ctr, Box 3378, Durham, NC 27710 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040701, R29DK040701] Funding Source: NIH RePORTER; NCRR NIH HHS [RR0006] Funding Source: Medline; NHLBI NIH HHS [HL34322] Funding Source: Medline; NIDDK NIH HHS [DK40701] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGUIANO A, 1992, JAMA-J AM MED ASSOC, V267, P1794, DOI 10.1001/jama.267.13.1794; ATLAS AB, 1992, J PEDIATR-US, V120, P756, DOI 10.1016/S0022-3476(05)80242-2; AXON ATR, 1984, GUT, V25, P1107, DOI 10.1136/gut.25.10.1107; BANK S, 1978, DIG DIS, V23, P178; BLUSTEIN PK, 1981, PEDIATRICS, V68, P387; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; COSTES B, 1995, EUR J HUM GENET, V3, P285; Davis PB, 1996, AM J RESP CRIT CARE, V154, P1229, DOI 10.1164/ajrccm.154.5.8912731; DEANGELIS C, 1992, PANCREAS, V7, P193, DOI 10.1097/00006676-199203000-00010; Diem K., 1970, SCI TABLES, VSeventh; Dumur V, 1996, HUM GENET, V97, P7; Friedman KJ, 1997, HUM MUTAT, V10, P108, DOI 10.1002/(SICI)1098-1004(1997)10:2<108::AID-HUMU3>3.3.CO;2-3; GROSS V, 1989, INT J PANCREATOL, V4, P221; HABER P, 1995, J LAB CLIN MED, V125, P305; HAMOSH A, 1996, PEDIAT PULMONOL S13, V22, P104; HANAWA M, 1978, TOHOKU J EXP MED, V125, P59, DOI 10.1620/tjem.125.59; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; Kerem E, 1997, AM J RESP CRIT CARE, V155, P1914, DOI 10.1164/ajrccm.155.6.9196095; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KNOWLES MR, 1995, HUM GENE THER, V6, P445, DOI 10.1089/hum.1995.6.4-445; LIDDLE RA, IN PRESS TXB GASTROE; MARINO CR, 1991, J CLIN INVEST, V88, P712, DOI 10.1172/JCI115358; MASARYK TJ, 1983, DIGEST DIS SCI, V28, P874, DOI 10.1007/BF01317036; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Oppenheimer E H, 1975, Perspect Pediatr Pathol, V2, P241; RaveHarel N, 1997, AM J HUM GENET, V60, P87; SHWACHMAN H, 1975, PEDIATRICS, V55, P86; STEER ML, 1995, NEW ENGL J MED, V332, P1482, DOI 10.1056/NEJM199506013322206; Stern RC, 1997, NEW ENGL J MED, V336, P487, DOI 10.1056/NEJM199702133360707; WELSH MJ, 1995, METABOLIC MOL BASES, V3, P3799; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; ZIELENSKI J, 1991, GENOMICS, V10, P229, DOI 10.1016/0888-7543(91)90504-8; Zielenski J, 1995, ANNU REV GENET, V29, P777, DOI 10.1146/annurev.ge.29.120195.004021	34	651	669	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					653	658		10.1056/NEJM199809033391002	http://dx.doi.org/10.1056/NEJM199809033391002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725922				2022-12-24	WOS:000075688100002
J	Steinbauer, JR; Cantor, SB; Holzer, CE; Volk, RJ				Steinbauer, JR; Cantor, SB; Holzer, CE; Volk, RJ			Ethnic and sex bias in primary care screening tests for alcohol use disorders	ANNALS OF INTERNAL MEDICINE			English	Article							IDENTIFICATION TEST AUDIT; UNITED-STATES; DRUG MODULES; AUDADIS-ADR; DRINKING; CAGE; QUESTIONNAIRE; RELIABILITY; PREVALENCE; HISPANICS	Background: The use of self-report screening tests for alcohol use disorders in the primary care setting has been advocated. Objective: To test for ethnic and sex bias in three self-report screening tests for alcohol use disorders in a primary care population. Design: Cross-sectional study with patients randomly selected from appointment lists. Setting: University-based family practice clinic. Patients: Probability sample of 1333 adult family practice patients stratified by sex and ethnicity. Measurements: Patients completed 1) a diagnostic interview to determine the presence of a current alcohol use disorder and 2) three screening tests: the CAGE questionnaire, the Self-Administered Alcoholism Screening Test (SAAST), and the Alcohol Use Disorders Identification Test (AUDIT). Results: The areas under the receiver-operating characteristic (ROC) curves for the CAGE questionnaire and the SAAST ranged from 0.61 to 0.88 and were particularly poor for African-American men and Mexican-American women. For the AUDIT, the area under the ROC curves was greater than 0.90 for each patient subgroup. The sensitivity of the CAGE questionnaire and the SAAST at standard cut-points was lowest for Mexican-American women (0.21 and 0.13, respectively). Positive likelihood ratios for the AUDIT were similar to or higher than those for' the other screening tests, whereas negative likelihood ratios were lowest for the AUDIT (<0.33), indicating the superiority of this test in ruling out a disorder. Conclusions: A marked inconsistency in the accuracy of common self-report screening tests for alcohol use disorders was found when these tests were used in a single clinical site with male and female family practice patients of different ethnic backgrounds. The AUDIT does not seem to be affected by ethnic and sex bias.	Univ Texas, MD Anderson Cancer Ctr, Dept Med Specialties, Gen Internal Med Sect, Houston, TX 77030 USA; Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Galveston, TX 77555 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston	Volk, RJ (corresponding author), Baylor Coll Med, Dept Family Med & Community Med, 5510 Greenbriar, Houston, TX 77005 USA.			Cantor, Scott/0000-0002-7072-6048; Volk, Robert/0000-0001-8811-5854	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA [D32PE016033] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R03AA009496] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA09496] Funding Source: Medline; BHP HRSA HHS [D32-PE16033] Funding Source: Medline	DIVISION OF MEDICINE, BUREAU HEALTH PROFESSIONS, HRSA(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); BHP HRSA HHS		Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1111/j.1530-0277.1997.tb03811.x; ALLEN JP, 1995, ARCH INTERN MED, V155, P1726, DOI 10.1001/archinte.155.16.1726; *AM AC FAM PHYS, 1994, AG CHARTS PER HLTH E; American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; Babor T., 1989, ALCOHOL HEALTH RES W, V13, P371; Babor TF., 1989, ALCOHOL USE DISORDER, V1, P45; BERESFORD TP, 1988, PREV MED, V17, P653, DOI 10.1016/0091-7435(88)90058-8; BUCHSBAUM DG, 1991, ANN INTERN MED, V115, P774, DOI 10.7326/0003-4819-115-10-774; CAETANO R, 1988, J STUD ALCOHOL, V49, P462, DOI 10.15288/jsa.1988.49.462; Caetano R, 1997, J STUD ALCOHOL, V58, P565, DOI 10.15288/jsa.1997.58.565; CAETANO R, 1983, DRUG ALCOHOL DEPEN, V12, P37, DOI 10.1016/0376-8716(83)90053-4; *CAN TASK FORC PER, 1989, CAN MED ASSOC J, V141, P4; CENTOR RM, 1992, TWOBYTWO ANAL VERSIO; CENTOR RM, 1995, ROC ANAL WINDOWS VER; Chatterji S, 1997, DRUG ALCOHOL DEPEN, V47, P171, DOI 10.1016/S0376-8716(97)00088-4; CHERPITEL CJ, 1995, ANN EMERG MED, V26, P158, DOI 10.1016/S0196-0644(95)70146-X; CHERPITEL CJ, 1995, J STUD ALCOHOL, V56, P695, DOI 10.15288/jsa.1995.56.695; CHEUNG YW, 1991, INT J ADDICT, V25, P581, DOI 10.3109/10826089109077262; Clark WB, 1991, ALCOHOL AM DRINKING; COLLIGAN RC, 1990, SELF ADM ALCOHOLISM; CONIGRAVE KM, 1995, ADDICTION, V90, P1349, DOI 10.1046/j.1360-0443.1995.901013496.x; Cottler LB, 1997, DRUG ALCOHOL DEPEN, V47, P195, DOI 10.1016/S0376-8716(97)00090-2; DAVIS LJ, 1989, ALCOHOL CLIN EXP RES, V13, P224, DOI 10.1111/j.1530-0277.1989.tb00316.x; DAVIS LJ, 1987, J CLIN PSYCHOL, V43, P423; DAVIS LJ, 1987, ALCOHOL CLIN EXP RES, V11, P269, DOI 10.1111/j.1530-0277.1987.tb01306.x; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; EWING JA, 1970, P 29 INT C ALC DRUG; GILBERT MJ, 1991, ALCOHOL HLTH RES WOR, V0015, P00234; Grant B., 1992, PSYCTESTS, DOI [10.1037/t04807-000, DOI 10.1037/T04807-000]; GRANT BF, 1995, DRUG ALCOHOL DEPEN, V39, P37, DOI 10.1016/0376-8716(95)01134-K; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HELZER JE, 1991, PSYCHIAT DISORDERS A, P81; Herd D, 1996, ADDICTION, V91, P845, DOI 10.1111/j.1360-0443.1996.tb03579.x; HURT RD, 1980, MAYO CLIN PROC, V55, P365; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; MAGRUDERHABIB K, 1991, J FAM PRACTICE, V32, P406; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MORSE RM, 1975, J STUD ALCOHOL, V36, P400, DOI 10.15288/jsa.1975.36.400; MURRAYLYON IM, 1991, LANCET, V338, P1089, DOI 10.1016/0140-6736(91)91955-T; *NAT I ALC AB ALC, 1993, 8 SPEC REP US C ALC; NIERENBERG AA, 1988, JAMA-J AM MED ASSOC, V259, P1699, DOI 10.1001/jama.259.11.1699; POKORNY AD, 1972, AM J PSYCHIAT, V129, P342, DOI 10.1176/ajp.129.3.342; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; Sox HC, 1988, MED DECISION MAKING; STEINWEG DL, 1993, AM J MED, V94, P520, DOI 10.1016/0002-9343(93)90088-7; SWENSON W, 1973, MAYO CLIN P, V50, P204; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; Ustun B, 1997, DRUG ALCOHOL DEPEN, V47, P161, DOI 10.1016/S0376-8716(97)00087-2; Volk RJ, 1997, ADDICTION, V92, P197, DOI 10.1046/j.1360-0443.1997.9221978.x; Volk RJ, 1997, J GEN INTERN MED, V12, P763, DOI 10.1046/j.1525-1497.1997.07162.x; WENRICH MD, 1995, J GEN INTERN MED, V10, P631, DOI 10.1007/BF02602748	55	106	106	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					353	362		10.7326/0003-4819-129-5-199809010-00002	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00002			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	114RL	9735062				2022-12-24	WOS:000075622600002
J	Hirschmann, JV				Hirschmann, JV			Methods for decreasing antibiotic use in otitis media	LANCET			English	Editorial Material									Vet Adm Med Ctr, Seattle, WA 98108 USA; Univ Washington, Sch Med, Seattle, WA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle	Hirschmann, JV (corresponding author), Vet Adm Med Ctr, 1660 S Columbian Way, Seattle, WA 98108 USA.							DELMAR C, 1997, BRIT MED J, V314, P126; DOZYRSKYJ AL, 1998, JAMA-J AM MED ASSOC, V279, P1736; Froom J, 1997, BRIT MED J, V315, P98, DOI 10.1136/bmj.315.7100.98; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; Roark R, 1997, PEDIATR INFECT DIS J, V16, P376, DOI 10.1097/00006454-199704000-00008; VANBUCHEM FL, 1985, BRIT MED J, V290, P1033, DOI 10.1136/bmj.290.6474.1033; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1344, DOI 10.1001/jama.270.11.1344	7	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					672	672		10.1016/S0140-6736(05)60818-5	http://dx.doi.org/10.1016/S0140-6736(05)60818-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728980				2022-12-24	WOS:000075729700008
J	Snyder, LH; Grieve, KL; Brotchie, P; Andersen, RA				Snyder, LH; Grieve, KL; Brotchie, P; Andersen, RA			Separate body- and world-referenced representations of visual space in parietal cortex	NATURE			English	Article							NEURONS; MICROSTIMULATION; INFORMATION; HIPPOCAMPUS; PERCEPTION; SACCADE; PRIMATE; MONKEYS; GAZE; RATS	In order to direct a movement towards a visual stimulus, visual spatial information must be combined with postural information(1). For example, directing gaze (eye plus head) towards a visible target requires the combination of retinal image location with eye and head position to determine the location of the target relative to the body. Similarly, world-referenced postural information is required to determine where something lies in the world. Posterior parietal neurons recorded in monkeys combine visual information with eye and head position(2-4). if population of such cells could make up a distributed representation of target location in an extraretinal frame of reference(4-7) However, pre vious studies have not. distinguished between world-referenced and body-referenced signals(4,8). Here we report that modulations of visual signals (gain fields) in two adjacent cortical fields, LIP and 7a, are referenced to the body and to the world, respectively. This segregation of spatial information is consistent with a streaming of information, with one path carrying body-referenced information for the control of gaze, and the other carrying world-referenced information for navigation and other tasks that require an absolute frame of reference.	CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology	Andersen, RA (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.	andersen@vis.caltech.edu	Snyder, Lawrence H/A-4593-2017					Aguirre GK, 1996, CEREB CORTEX, V6, P823, DOI 10.1093/cercor/6.6.823; Andersen R A, 1993, Curr Opin Neurobiol, V3, P171, DOI 10.1016/0959-4388(93)90206-E; ANDERSEN RA, 1985, SCIENCE, V230, P456, DOI 10.1126/science.4048942; ANDERSEN RA, 1983, J NEUROSCI, V3, P532; ANDERSEN RA, 1990, J COMP NEUROL, V296, P63; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BAYLIS GC, 1994, EXP BRAIN RES, V98, P110; BROTCHIE PR, 1995, NATURE, V375, P232, DOI 10.1038/375232a0; Duhamel JR, 1997, NATURE, V389, P845, DOI 10.1038/39865; Fredrickson J M, 1966, Acta Otolaryngol, V61, P168, DOI 10.3109/00016486609127054; Freedman EG, 1997, J NEUROPHYSIOL, V78, P1669, DOI 10.1152/jn.1997.78.3.1669; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JONES GM, 1965, IEEE T BIO-MED ENG, VBM12, P54, DOI 10.1109/TBME.1965.4502350; KARNATH HO, 1994, EXP BRAIN RES, V101, P140; MCNAUGHTON BL, 1983, EXP BRAIN RES, V52, P41; MERGNER T, 1983, EXP BRAIN RES, V49, P198; POUGET A, 1995, ADV NEURAL INF PROCE, V7, P137; Robinson DA, 1975, BASIC MECH OCULAR MO, P337; ROLL R, 1991, EXP BRAIN RES, V85, P423; Rolls ET, 1995, HIPPOCAMPUS, V5, P409, DOI 10.1002/hipo.450050504; SALINAS E, 1995, J NEUROSCI, V15, P6461; SHIBUTANI H, 1984, EXP BRAIN RES, V55, P1; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Thier P, 1996, P NATL ACAD SCI USA, V93, P4962, DOI 10.1073/pnas.93.10.4962; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503; ZIPSER D, 1988, NATURE, V331, P679, DOI 10.1038/331679a0	28	343	343	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					887	891		10.1038/29777	http://dx.doi.org/10.1038/29777			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732870				2022-12-24	WOS:000075611800047
J	Li, HL; Zhu, H; Xu, CJ; Yuan, JY				Li, HL; Zhu, H; Xu, CJ; Yuan, JY			Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis	CELL			English	Article							CYTOCHROME-C; CELL-DEATH; SIGNALING COMPLEX; BCL-2; PROTEASE; BCL-X(L); RELEASE; BAX; INDUCTION; DOMAIN	We report here that BID, a BH3 domain-containing proapoptotic Bcl2 family member, is a specific proximal substrate of Casp8 in the Fas apoptotic signaling pathway. While full-length BID is localized in cytosol, truncated BID (tBID) translocates to mitochondria and thus transduces apoptotic signals from cytoplasmic membrane to mitochondria, tBID induces first the clustering of mitochondria around the nuclei and release of cytochrome c independent of caspase activity, and then the loss of mitochondrial membrane potential, cell shrinkage, and nuclear condensation in a caspase-dependent fashion. Coexpression of Bclx(L) inhibits all the apoptotic changes induced by tBID. Our results indicate that BID is a mediator of mitochondrial damage induced by Casp8.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Zhu, Hong/0000-0002-2575-4031				Archambault J, 1998, J BIOL CHEM, V273, P27593, DOI 10.1074/jbc.273.42.27593; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; FernandesAlnemri T, 1996, P NATL ACAD SCI USA, V93, P7464, DOI 10.1073/pnas.93.15.7464; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Huang DCS, 1998, EMBO J, V17, P1029, DOI 10.1093/emboj/17.4.1029; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Li F, 1997, J BIOL CHEM, V272, P30299, DOI 10.1074/jbc.272.48.30299; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; Merry DE, 1997, ANNU REV NEUROSCI, V20, P245, DOI 10.1146/annurev.neuro.20.1.245; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OLTVAI ZN, 1994, CELL, V79, P189, DOI 10.1016/0092-8674(94)90188-0; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Shimizu S, 1996, ONCOGENE, V13, P21; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Srinivasan A, 1998, J BIOL CHEM, V273, P4523, DOI 10.1074/jbc.273.8.4523; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	43	3608	3776	1	195	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					491	501		10.1016/S0092-8674(00)81590-1	http://dx.doi.org/10.1016/S0092-8674(00)81590-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727492	Bronze			2022-12-24	WOS:000075541100011
J	Elders, MJ; Albert, AE				Elders, MJ; Albert, AE			Adolescent pregnancy and sexual abuse	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							FATHERS		Univ Arkansas, Sch Med, Little Rock, AR 72204 USA; Harvard Univ, Sch Med, Boston, MA USA	University of Arkansas System; University of Arkansas Fayetteville; University of Arkansas Little Rock; Harvard University; Harvard Medical School	Elders, MJ (corresponding author), Arkansas Childrens Hosp, 800 Marshall St, Little Rock, AR 72202 USA.							*A GUTTM I, 1994, SEX AM TEEN; Abma J, 1998, FAM PLANN PERSPECT, V30, P12, DOI 10.2307/2991518; *AD CHILDR FAM, 1997, CHILD AB NEGL STAT S, V1; Adams JA, 1997, PEDIATR ANN, V26, P299, DOI 10.3928/0090-4481-19970501-07; BOYER D, 1992, FAM PLANN PERSPECT, V24, P4, DOI 10.2307/2135718; BOYER D, 1992, FAMILY PLANNING PERS, V24, P19; Donovan P, 1997, FAM PLANN PERSPECT, V29, P30, DOI 10.2307/2953351; Elstein S.G., 1997, SEXUAL RELATIONSHIPS; EMANS SJ, 1990, PEDIAT ADOLESCENT GY; ERICKSON PI, 1991, J ADOLESCENT HEALTH, V12, P319, DOI 10.1016/0197-0070(91)90007-9; ESPARZA DV, 1995, J OBSTET GYNECOL NEO, V25, P321; Farber EW, 1996, GEN HOSP PSYCHIAT, V18, P56, DOI 10.1016/0163-8343(95)00098-4; GERSHENSON H, 1989, J INTERPERS VIOLENCE, V4, P204; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Kenney JW, 1997, J ADOLESCENT HEALTH, V21, P3, DOI 10.1016/S1054-139X(97)00035-9; Kerns D L, 1994, Future Child, V4, P119, DOI 10.2307/1602527; LANDRY DJ, 1995, FAM PLANN PERSPECT, V27, P159, DOI 10.2307/2136260; Lindberg LD, 1997, FAM PLANN PERSPECT, V29, P61, DOI 10.2307/2953363; Males M, 1996, AM J PUBLIC HEALTH, V86, P565, DOI 10.2105/AJPH.86.4.565; MALES MA, 1995, LANCET, V346, P64, DOI 10.1016/S0140-6736(95)92105-2; MCANARNEY ER, 1990, AM J DIS CHILD, V144, P789, DOI 10.1001/archpedi.1990.02150310057027; MOORE KA, 1989, FAM PLANN PERSPECT, V21, P110, DOI 10.2307/2135660; MOORE KA, 1997, FACTS GLANCE; NAGY S, 1995, PEDIATRICS, V96, P944; STEVENSSIMON C, 1994, ARCH PEDIAT ADOL MED, V148, P23, DOI 10.1001/archpedi.1994.02170010025005; Stock JL, 1997, FAM PLANN PERSPECT, V29, P200, DOI 10.2307/2953395; STOCK JL, 1997, FAMILY PLANNING PERS, V29, P227; VANDEVEN AM, 1992, CURR OPIN OBSTET GYN, V4, P843; Widom CS, 1996, AM J PUBLIC HEALTH, V86, P1607, DOI 10.2105/AJPH.86.11.1607	29	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					648	649		10.1001/jama.280.7.648	http://dx.doi.org/10.1001/jama.280.7.648			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	110ME	9718059				2022-12-24	WOS:000075384300036
J	Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Heiat, A; Marciniak, TA				Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Heiat, A; Marciniak, TA			National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction - National cooperative cardiovascular project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRACTICE GUIDELINES; MEDICARE; BLOCKADE; QUALITY; TRIALS; DEATH; CARE	Context. - Despite the importance of beta-blockers for secondary prevention after acute myocardial infarction (AMI), several studies have suggested that they are substantially underutilized, particularly in older patients. Objectives. - To describe the contemporary national pattern of beta-blocker prescription at hospital discharge among patients aged 65 years or older with an AMI, to identify the most important predictors of the prescribed use of beta-blockers at discharge, and to determine the independent association between beta-blockers at discharge and mortality in clinical practice. Design. - Retrospective cohort study using data created from medical charts and administrative files. Setting. - Acute care nongovernmental hospitals in the United States. Patients. - National cohort of 115015 eligible patients aged 65 years or older who survived hospitalization with a confirmed AMI in 1994 or 1995. Main Outcome Measures. - beta-Blocker as a discharge medication and mortality in the year after discharge. Results. - Among the 45308 patients without contraindications to beta-blockers, 22665 (50.0%) had a beta-blocker as a discharge medication. There was significant variation by state, ranging from 30.3% to 77.1%. Of the 36795 patients who were not receiving beta-blocker therapy on admission, 16006 (43.5%) had therapy initiated on or before discharge. Demographic and clinical variables explained relatively little of the variation in the initiation of beta-blocker therapy. The prescribed use of calcium channel blockers at discharge had a strong negative association with the use of beta-blockers (odds ratio [OR] of beta-blocker use, 0.25; 95% confidence interval [CI], 0.24-0.26). The New England region had significantly higher use of beta-blocker therapy than the rest of the country. Compared with cardiologists, internists had similar rates (OR, 0.94; 95% CI, 0.90-1.00) and general and family practice physicians had lower rates (OR, 0.78; 95% CI, 0.73-0.83), After adjusting for potential confounders, beta-blockers were associated with a 14% lower risk of mortality at 1 year after discharge. The association with lower mortality was present in subgroups stratified by age, sex, and left ventricular ejection fraction. Conclusions. - Many ideal patients for beta-blocker therapy are not prescribed these drugs at discharge following AMI. The clinical and demographic characteristics of the patients do not explain much of the variation in the treatment pattern. Geographic factors and physician specialty are independently associated with the decision to use beta-blockers, Elderly patients who are prescribed beta-blockers at discharge have a better survival rate, consistent with the findings of randomized controlled trials of younger and lower-risk populations.	Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Chron Dis Epidemiol, New Haven, CT 06520 USA; Yale New Haven Hosp, Ctr Outcomes Res & Evaluat, New Haven, CT USA; Connecticut Peer Review Org, Middletown, CT USA; Hlth Care Financing Adm, Baltimore, MD USA	Yale University; Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557				AGUSTI A, 1994, EUR J CLIN PHARMACOL, V46, P95; BRAND DA, 1995, J AM COLL CARDIOL, V26, P1432, DOI 10.1016/0735-1097(95)00362-2; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; Huff ED, 1997, J CLIN EPIDEMIOL, V50, P1395, DOI 10.1016/S0895-4356(97)00218-7; KARLSON BW, 1994, CLIN CARDIOL, V17, P311, DOI 10.1002/clc.4960170608; KESTENBAUM B, 1992, DEMOGRAPHY, V29, P565, DOI 10.2307/2061852; Marciniak TA, 1998, JAMA-J AM MED ASSOC, V279, P1351, DOI 10.1001/jama.279.17.1351; MEEHAN TP, 1995, ANN INTERN MED, V122, P928, DOI 10.7326/0003-4819-122-12-199506150-00007; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SIAL SH, 1994, J GEN INTERN MED, V9, P599, DOI 10.1007/BF02600301; SMITH SC, 1995, CIRCULATION, V92, P2; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; WHITFORD DL, 1994, BMJ-BRIT MED J, V309, P1268, DOI 10.1136/bmj.309.6964.1268; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	16	407	414	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					623	629		10.1001/jama.280.7.623	http://dx.doi.org/10.1001/jama.280.7.623			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718054	Bronze			2022-12-24	WOS:000075384300031
J	De Keyser, J				De Keyser, J			Antipyretics in acute ischaemic stroke	LANCET			English	Editorial Material							CEREBRAL-ISCHEMIA; TEMPERATURE		Acad Ziekenhuis, Dept Neurol, NL-9700 RB Groningen, Netherlands	University of Groningen	De Keyser, J (corresponding author), Acad Ziekenhuis, Dept Neurol, NL-9700 RB Groningen, Netherlands.		De Keyser, Jacques/D-3725-2013	De Keyser, Jacques/0000-0002-3394-7757				AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BEAMER NB, 1995, ANN NEUROL, V37, P800, DOI 10.1002/ana.410370614; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; CASTILLO J, 1994, CEREBROVASC DIS, V4, P56; CHOPP M, 1988, STROKE, V19, P1521, DOI 10.1161/01.STR.19.12.1521; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1250; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; TAGI T, 1994, AM J PHYSIOL, V266, pH1770; WASS CT, 1995, ANESTHESIOLOGY, V83, P325, DOI 10.1097/00000542-199508000-00013	12	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					6	7						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800736				2022-12-24	WOS:000074608600006
J	Parr, BA; McMahon, AP				Parr, BA; McMahon, AP			Sexually dimorphic development of the mammalian reproductive tract requires Wnt-7a	NATURE			English	Article							MULLERIAN-INHIBITING SUBSTANCE; ESTROGEN-RECEPTOR GENE; DUCT SYNDROME; VERTEBRATE LIMB; II RECEPTOR; EXPRESSION; HORMONE; DISRUPTION; CLONING; CELLS	An important feature of mammalian development is the generation of sexually dimorphic reproductive tracts from the Mullerian and Wolffian ducts. In females, Mullerian ducts develop into the oviduct, uterus, cervix and upper vagina, whereas Wolffian ducts regress. In males, testosterone promotes differentiation of Wolffian ducts into the epididymis, vas deferens and seminal vesicle. The Sertoli cells of the testes produce Mullerian-inhibiting substance, which stimulates Mullerian duct regression in males(1-4) The receptor for Mullerian-inhibiting substance is expressed by mesenchymal cells underlying the Mullerian duct that are thought to mediate regression of the duct(5-7). Mutations that inactivate either Mullerian-inhibiting substance or its receptor allow development of the female reproductive tract in males(8-12). These pseudohermaphrodites are frequently infertile because sperm passage is blocked by the presence of the female reproductive system(9,10,12). Here we show that male mice lacking the signalling molecule Wnt-7a fail to undergo regression of the Mullerian duct as a result of the absence of the receptor for Mullerian-inhibiting substance. Wnt7a-deficient females are infertile because of abnormal development of the oviduct and uterus, both of which are Mullerian duct derivatives. Therefore, we propose that signalling by Wnt-7a allows sexually dimorphic development of the Mullerian ducts.	Harvard Univ, Dept Mol & Cellular Biol, Biolabs, Cambridge, MA 02138 USA	Harvard University	McMahon, AP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biolabs, 16 Divin Ave, Cambridge, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					BAARENDS WM, 1994, DEVELOPMENT, V120, P189; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; Cygan JA, 1997, DEVELOPMENT, V124, P5021; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Imbeaud S, 1996, HUM MOL GENET, V5, P1269, DOI 10.1093/hmg/5.9.1269; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1953, RECENT PROG HORM RES, V8, P379; KNEBELMANN B, 1991, P NATL ACAD SCI USA, V88, P3767, DOI 10.1073/pnas.88.9.3767; Korach KS, 1996, RECENT PROG HORM RES, V51, P159; KORACH KS, 1994, SCIENCE, V266, P1524, DOI 10.1126/science.7985022; LUBAHN DB, 1993, P NATL ACAD SCI USA, V90, P11162, DOI 10.1073/pnas.90.23.11162; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Miller C, 1998, DEVELOPMENT, V125, P3201; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PARR BA, 1993, DEVELOPMENT, V119, P247; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Teixeira J, 1996, ENDOCRINOLOGY, V137, P160, DOI 10.1210/en.137.1.160; VAINIO S, UNPUB NATURE; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0	24	248	262	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					707	710		10.1038/27221	http://dx.doi.org/10.1038/27221			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790192				2022-12-24	WOS:000076472600054
J	Wang, SS; Esplin, ED; Li, JL; Huang, LY; Gazdar, A; Minna, J; Evans, GA				Wang, SS; Esplin, ED; Li, JL; Huang, LY; Gazdar, A; Minna, J; Evans, GA			Alterations of the PPP2R1B gene in human lung and colon cancer	SCIENCE			English	Article							PROTEIN PHOSPHATASE 2A; SERINE THREONINE PHOSPHATASES; MEDIATED CHROMOSOME TRANSFER; TUMORIGENIC EXPRESSION; CELLS; SUBUNIT; BREAST; SUPPRESSION; ANTIGENS; BRAIN	The PPP2R1B gene, which encodes the beta isoform of the A subunit of the serine/threonine protein phosphatase ZA (PP2A), was identified as a putative human tumor suppressor gene. Sequencing of the PPP2R1B gene, located on human chromosome 11q22-24, revealed somatic alterations in 15% (5 out of 33) of primary lung tumors, 6% (4 out of 70) of lung tumor-derived cell lines, and 15% (2 out of 13) of primary colon tumors. One deletion mutation generated a truncated PP2A-A beta protein that was unable to bind to the catalytic subunit of the PP2A holoenzyme. The PP2R1B gene product may suppress tumor development through its role in cell cycle regulation and cellular growth control.	Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Evans, GA (corresponding author), Univ Texas, SW Med Ctr, McDermott Ctr Human Growth & Dev, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.		Esplin, Ed/AAL-2226-2021	Esplin, Edward/0000-0001-9205-3756				Arai Y, 1996, GENOMICS, V35, P196, DOI 10.1006/geno.1996.0339; Evans Glen A., 1996, American Journal of Human Genetics, V59, pA66; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; HEMMINGS BA, 1990, BIOCHEMISTRY-US, V29, P3166, DOI 10.1021/bi00465a002; Heriche JK, 1997, SCIENCE, V276, P952, DOI 10.1126/science.276.5314.952; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; IOANNOU PA, 1994, NAT GENET, V6, P84, DOI 10.1038/ng0194-84; Kawai T, 1997, KOREA POLYM J, V5, P1; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; Li H, 1997, J BIOL CHEM, V272, P16729, DOI 10.1074/jbc.272.27.16729; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; McCright B, 1996, GENOMICS, V36, P168, DOI 10.1006/geno.1996.0438; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; NEGRINI M, 1994, CANCER RES, V54, P1331; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; RUEDIGER R, 1994, J VIROL, V68, P123, DOI 10.1128/JVI.68.1.123-129.1994; SATOH H, 1993, MOL CARCINOGEN, V7, P157, DOI 10.1002/mc.2940070306; SAXON PJ, 1986, EMBO J, V5, P3461, DOI 10.1002/j.1460-2075.1986.tb04670.x; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; Wang S, 1997, AM J HUM GENET, V61, pA87; WANG SG, UNPUB; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816	25	325	332	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					284	287		10.1126/science.282.5387.284	http://dx.doi.org/10.1126/science.282.5387.284			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765152				2022-12-24	WOS:000076370200045
J	Lin, HM; Kauffman, HM; McBride, MA; Davies, DB; Rosendale, JD; Smith, CM; Edwards, EB; Daily, OP; Kirklin, J; Shield, CF; Hunsicker, LG				Lin, HM; Kauffman, HM; McBride, MA; Davies, DB; Rosendale, JD; Smith, CM; Edwards, EB; Daily, OP; Kirklin, J; Shield, CF; Hunsicker, LG			Center-specific graft and patient survival rates - 1997 United Network for Organ Sharing (UNOS) Report	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; TRANSPLANT SURVIVAL; RISK ADJUSTMENT; SURGICAL RISK; MORTALITY; SURGERY; VOLUME; IMPROVE; QUALITY; CARE	Context.-Multiple comprehensive, risk-adjusted studies evaluating short-term surgical mortality have been reported previously. This report analyzes short-term and long-term outcomes, both nationally and at each individual transplant program, for all solid organ transplantations performed in the United States. Objectives.-To report graft and patient survival rates for all solid organ transplantations, both nationally and at each specific transplant program in the United States, and to compare the expected survival rate with the actual survival rate of each individual program. Design and Setting.-Multivariate regression analysis of donor and recipient factors affecting graft and patient survival of all kidney, liver, pancreas, heart, lung, and heart-lung transplants reported to the United Network for Organ Sharing from 742 separate transplant programs. Patients.-A cohort of 97 587 solid organ transplantations performed on 92 966 recipients in the United States from January 1988 through April 1994, Main Outcome Measures,-Short-term and conditional 3-year national and individual transplant program graft and patient survival rates overall and from 2 separate eras (era 1, January 1988-April 1992; era 2, May 1992-April 1994); comparison of actual center-specific performance with risk-adjusted expected performance and identification of centers with better-than-expected or worse-than-expected survival rates. Results.-One-year graft follow-up exceeded 98% and conditional 3-year followup exceeded 91% for all organs. Graft and patient survival improved significantly in era 2 compared with era 1 for all cadaver organs except heart, which remained the same. One-year cadaveric graft survival ranged from 81.5% for heart to 61.9% for heart-lung and 3-year conditional graft survival ranged from 91.3% for pancreas to 74.7% for lung. The percentage of programs whose actual 1-year graft survival was not different from or was better than their risk-adjusted expected survival ranged from 98.3% for heart-lung to 75.7% for liver. Most kidney, liver, and heart programs whose actual survival was significantly less than expected performed small numbers (less than the national average) of transplantations per year. Conclusions.-Graft and patient survival for solid organ transplantations showed improvement over time. Conditional 3-year graft and patient survival rates were approximately 90% for all organs except for lung and heart-lung. The conditional 3-year survival rates were better than 1-year survival rates, indicating the major risk after transplantation occurs in the first year. The majority of transplant programs achieved actual survival rates not significantly different from their expected survival rates. Center effects were most significant within the first year after transplantation and had much less influence on long-term survival outcomes.	United Network Organ Sharing, Richmond, VA 23220 USA; Penn State Univ, Milton S Hershey Med Ctr, Dept Hlth Evaulat Sci, Hershey, PA 17033 USA; Univ Alabama Hosp, Div Cardiac Surg, Birmingham, AL USA; Via Christi Reg Med Ctr, Dept Surg, Wichita, KS USA; Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA	United Network for Organ Sharing; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Alabama System; University of Alabama Birmingham; University of Iowa	Kauffman, HM (corresponding author), United Network Organ Sharing, 1100 Boulders Pkwy,Suite 500, Richmond, VA 23220 USA.							Burdick J, 1997, TRANSPL P, V29, P1495, DOI 10.1016/S0041-1345(96)00701-4; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; CECKA JM, 1993, TRANSPLANT P, V25, P548; CHO YW, 1993, CLIN KIDNEY TRANSPLA, P363; CHO YW, 1997, CLIN KIDNEY TRANSPLA, P427; CICCIARELLI J, 1986, CLIN KIDNEY TRANSPLA, P93; COPELAND GP, 1991, BRIT J SURG, V78, P356; EDWARDS E, 1994, 1994 CTR SPECIFIC GR; Edwards E., 1992, 1991 CTR SPECIFIC GR; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; GROVER FL, 1990, ANN THORAC SURG, V50, P12, DOI 10.1016/0003-4975(90)90073-F; HANNAN EL, 1989, JAMA-J AM MED ASSOC, V262, P503, DOI 10.1001/jama.262.4.503; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; HOSENPUD JD, 1994, JAMA-J AM MED ASSOC, V271, P1844, DOI 10.1001/jama.271.23.1844; KATZNELSON S, 1997, CLIN TRANSPLANTS 199, P361; KAUFFMAN HM, 1997, TRANSPLANT REV, V11, P165; Khuri SF, 1997, J AM COLL SURGEONS, V185, P315, DOI 10.1016/S1072-7515(01)00938-3; KHURI SF, 1995, J AM COLL SURGEONS, V180, P519; Klintmalm G., 1994, TRANSPLANT REV, V8, P53, DOI [10.1016/S0955-470X(05)80015-1, DOI 10.1016/S0955-470X(05)80015-1]; LE A, 1994, AM J KIDNEY DIS, V24, P65, DOI 10.1016/S0272-6386(12)80161-2; LIN HM, 1997, 1997 CTR SPECIFIC GR; Mickey M R, 1989, Clin Transpl, P435; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; OPELZ G, 1975, TRANSPLANTATION, V19, P226, DOI 10.1097/00007890-197503000-00005; Shield CF, 1997, TRANSPLANTATION, V63, P1257, DOI 10.1097/00007890-199705150-00011; SMITH CM, 1996, ANN REPORT US SCI RE; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	28	64	64	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1153	1160		10.1001/jama.280.13.1153	http://dx.doi.org/10.1001/jama.280.13.1153			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777815				2022-12-24	WOS:000076210800029
J	Nguyen, QE; Foster, CS				Nguyen, QE; Foster, CS			Saving the vision of children with juvenile rheumatoid arthritis-associated uveitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							THERAPY; IRIDOCYCLITIS; METHOTREXATE		Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Immunol & Uveitis Serv, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts Eye & Ear Infirmary	Foster, CS (corresponding author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Ocular Immunol & Uveitis Serv, 243 Charles St, Boston, MA 02114 USA.							Chalom EC, 1997, J RHEUMATOL, V24, P2031; CHYLACK LT, 1975, AM J OPHTHALMOL, V79, P1026, DOI 10.1016/0002-9394(75)90689-3; Dana MR, 1997, OPHTHALMOLOGY, V104, P236, DOI 10.1016/S0161-6420(97)30329-7; FOSTER CS, 1993, OPHTHALMOLOGY, V100, P809; GIANNINI EH, 1992, NEW ENGL J MED, V326, P1043, DOI 10.1056/NEJM199204163261602; HEMADY RK, 1992, INT OPHTHALMOL CLIN, V32, P241, DOI 10.1097/00004397-199203210-00018; KANSKI J J, 1988, Eye (London), V2, P641; LANE L, 1995, OPHTHALMOLOGY, V102, P1530; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; MAKELA AL, 1977, SCAND J RHEUMATOL, V6, P193; MORGAN SL, 1990, ARTHRITIS RHEUM-US, V33, P9, DOI 10.1002/art.1780330102; OBRIEN JM, 1994, PRINCIPLES PRACTICE, P2873; OLSON NY, 1988, AM J DIS CHILD, V142, P1289, DOI 10.1001/archpedi.1988.02150120043036; Peterson LS, 1996, ARTHRITIS RHEUM, V39, P1385, DOI 10.1002/art.1780390817; RAMADAN A, 1997, OPHTHALMOL CLIN N AM, V10, P377; Sibilia J, 1998, REV RHUM, V65, P267; SMITH RE, 1989, UVEITIS CLIN APPROAC, P113; Vitale AT, 1996, OPHTHALMOLOGY, V103, P365; WOLF MD, 1987, OPHTHALMOLOGY, V94, P1242; YANCEY C, 1993, PEDIATRICS, V92, P295	20	23	26	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1133	1134		10.1001/jama.280.13.1133	http://dx.doi.org/10.1001/jama.280.13.1133			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777803				2022-12-24	WOS:000076210800011
J	Hosfield, DJ; Mol, CD; Shen, BH; Tainer, JA				Hosfield, DJ; Mol, CD; Shen, BH; Tainer, JA			Structure of the DNA repair and replication endonuclease and exonuclease FEN-1: Coupling DNA and PCNA binding to FEN-1 activity	CELL			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL NUCLEAR ANTIGEN; HUMAN FLAP ENDONUCLEASE-1; MAMMALIAN 5'-EXONUCLEASE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURES; PURIFIED PROTEINS; ESCHERICHIA-COLI; POLYMERASE-I; RNASE-H	Flap endonuclease (FEN-1) removes 5' overhanging flaps in DNA repair and processes the 5' ends of Okazaki fragments in lagging strand DNA synthesis. The crystal structure of Pyrococcus furiosos FEN-1, active-site metal ions, and mutational information indicate interactions for the single- and double-stranded portions of the flap DNA substrate and identify an unusual DNA-binding motif. The enzyme's active-site structure suggests that DNA binding induces FEN-1 to clamp onto the cleavage junction to form the productive complex. The conserved FEN-1 C terminus binds proliferating cell nuclear antigen (PCNA) and positions FEN-1 to act primarily as an exonuclease in DNA replication, in contrast to its endonuclease activity in DNA repair. FEN-1 mutations altering PCNA binding should reduce activity during replication, likely causing DNA repeat expansions as seen in some cancers and genetic diseases.	Scripps Res Inst, Dept Biol Mol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Natl Med Ctr, Dept Cell & Tumor Biol, Duarte, CA 91010 USA; Beckman Res Inst, Duarte, CA 91010 USA	Scripps Research Institute; Scripps Research Institute; City of Hope; City of Hope; Beckman Research Institute of City of Hope	Tainer, JA (corresponding author), Scripps Res Inst, Dept Biol Mol, MB4,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jat@scripps.edu	Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429; Shen, Binghui/0000-0002-4408-407X	NCI NIH HHS [CA57348] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Barnes CJ, 1996, J BIOL CHEM, V271, P29624, DOI 10.1074/jbc.271.47.29624; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Bhagwat M, 1997, J BIOL CHEM, V272, P28531, DOI 10.1074/jbc.272.45.28531; BORGES KM, 1996, GENOME SCI TECHNOL, V1, P37; Brunger A. T., 1992, X PLOR SYSTEM X RAY; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Budd ME, 1997, MOL CELL BIOL, V17, P2136, DOI 10.1128/MCB.17.4.2136; Ceska TA, 1996, NATURE, V382, P90, DOI 10.1038/382090a0; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; DAVIS ME, 1991, COMPUT PHYS COMMUN, V62, P187, DOI 10.1016/0010-4655(91)90094-2; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; Gary R, 1997, J BIOL CHEM, V272, P24522, DOI 10.1074/jbc.272.39.24522; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; GOULIAN M, 1990, J BIOL CHEM, V265, P18461; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hargreaves D, 1998, NAT STRUCT BIOL, V5, P441, DOI 10.1038/nsb0698-441; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HOSFIELD DJ, 1998, IN PRESS J BIOL CHEM; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kim CY, 1998, BIOPHYS J, V74, pA63; Kim K, 1998, J BIOL CHEM, V273, P8842, DOI 10.1074/jbc.273.15.8842; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; LYAMICHEV V, 1993, SCIENCE, V260, P778, DOI 10.1126/science.7683443; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mueser TC, 1996, CELL, V85, P1101, DOI 10.1016/S0092-8674(00)81310-0; MURANTE RS, 1994, J BIOL CHEM, V269, P1191; Murante RS, 1996, J BIOL CHEM, V271, P25888, DOI 10.1074/jbc.271.42.25888; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Nolan JP, 1996, BIOCHEMISTRY-US, V35, P11668, DOI 10.1021/bi952840+; ODONOVAN A, 1994, NATURE, V371, P432, DOI 10.1038/371432a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pelletier H, 1996, BIOCHEMISTRY-US, V35, P12742, DOI 10.1021/bi952955d; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Schweitzer JK, 1998, HUM MOL GENET, V7, P69, DOI 10.1093/hmg/7.1.69; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; TURCHI JJ, 1993, J BIOL CHEM, V268, P15136; UYEMURA D, 1976, J BIOL CHEM, V251, P4078; VALLEN EA, 1995, MOL CELL BIOL, V15, P4291; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	61	216	238	23	169	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					135	146		10.1016/S0092-8674(00)81789-4	http://dx.doi.org/10.1016/S0092-8674(00)81789-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778254	Bronze			2022-12-24	WOS:000076242300017
J	Eisenberg, S; Aksentijevich, I; Deng, ZM; Kastner, DL; Matzner, Y				Eisenberg, S; Aksentijevich, I; Deng, ZM; Kastner, DL; Matzner, Y			Diagnosis of familial Mediterranean fever by a molecular genetics method	ANNALS OF INTERNAL MEDICINE			English	Article						periodic disease; mutation; molecular sequence data; polymerase chain reaction; diagnosis	COLCHICINE; FREQUENCY; ATTACKS; FLUIDS; TRIAL; ARMS	Background: Familial Mediterranean fever is a recessively inherited disorder characterized by episodes of fever with abdominal pain, pleurisy, or arthritis. The familial Mediterranean fever gene, designated MEFV, was recently cloned, and at least three missense mutations (M680I, M694V, and V726A) that account for a large percentage of patients with this disease were identified. Objective: To establish a diagnostic test for familial Mediterranean fever. Design: Cross-sectional study of a convenience sample of patients attending familial Mediterranean fever clinics. Setting: Tertiary referral hospitals. Patients: 107 patients with familiar Mediterranean fever, their family members, and controls. Measurements: Mutations in the 107 samples were assessed by amplifying genomic DNA with use of primers that selectively amplify the normal or altered DNA sequence of the 3 MEFV mutations (amplification refractory mutation system [ARMS]). Mutations were independently assessed by automated sequencing of genomic DNA amplified by polymerase chain reaction to evaluate the sensitivity and specificity of the ARMS assay. Results: The ARMS assay correctly identified M680I, M694V, and V726A mutations in 82 persons with mutations documented by DNA sequencing (21 homozygotes, 2 compound heterozygotes, and 59 simple heterozygotes). Of 7 persons known from family studies to be noncarriers and 18 unrelated persons who were negative for these mutations by sequencing, none had MEFV mutations according to ARMS. Conclusion: The ARMS assay is a rapid, cost-effective, and accurate method for detecting three common mutations in familial Mediterranean fever.	Hadassah Univ Hosp, Hematol Unit, IL-91240 Jerusalem, Israel; NIAMSD, Arthrit & Rheumatism Branch, Bethesda, MD 20892 USA	Hebrew University of Jerusalem; National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)	Matzner, Y (corresponding author), Hadassah Univ Hosp, Hematol Unit, Mt Scopus, IL-91240 Jerusalem, Israel.	matzner@cc.huji.ac.il	Aksentijevich, Ivona/AAF-1335-2019					Aksentijevich I, 1997, CELL, V90, P797; Bernot A, 1997, NAT GENET, V17, P25; Chen XG, 1998, HUM MUTAT, V11, P456, DOI 10.1002/(SICI)1098-1004(1998)11:6<456::AID-HUMU6>3.0.CO;2-G; DANIELS M, 1995, AM J MED GENET, V55, P311, DOI 10.1002/ajmg.1320550313; DINARELLO CA, 1974, NEW ENGL J MED, V291, P934, DOI 10.1056/NEJM197410312911804; DRACOPOLI NC, 1995, CURRENT PROTOCOLS HU; FERRIE RM, 1992, AM J HUM GENET, V51, P251; HELLER H, 1958, ARCH INTERN MED, V102, P50, DOI 10.1001/archinte.1958.00260190052007; Livneh A, 1997, ARTHRITIS RHEUM-US, V40, P1879, DOI 10.1002/art.1780401023; MATZNER Y, 1990, ARCH INTERN MED, V150, P1289, DOI 10.1001/archinte.150.6.1289; MATZNER Y, 1984, NEW ENGL J MED, V311, P287, DOI 10.1056/NEJM198408023110503; MATZNER Y, 1984, BLOOD, V63, P629; MATZNER Y, 1995, CRIT REV ONCOL HEMAT, V18, P197, DOI 10.1016/1040-8428(94)00130-L; NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503; REIMANN HA, 1948, JAMA-J AM MED ASSOC, V136, P239, DOI 10.1001/jama.1948.02890210023004; ROGERS DB, 1989, AM J MED GENET, V34, P168, DOI 10.1002/ajmg.1320340206; Samuels J, 1998, MEDICINE, V77, P268, DOI 10.1097/00005792-199807000-00005; SIEGAL S, 1945, ANN INTERN MED, V23, P1, DOI 10.7326/0003-4819-23-1-1; SOHAR E, 1967, AM J MED, V43, P227, DOI 10.1016/0002-9343(67)90167-2; ZEMER D, 1974, NEW ENGL J MED, V291, P932, DOI 10.1056/NEJM197410312911803; ZEMER D, 1986, NEW ENGL J MED, V314, P1001, DOI 10.1056/NEJM198604173141601	21	80	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					539	+		10.7326/0003-4819-129-7-199810010-00005	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758573				2022-12-24	WOS:000076124500004
J	Banin, S; Moyal, L; Shieh, SY; Taya, Y; Anderson, CW; Chessa, L; Smorodinsky, NI; Prives, C; Reiss, Y; Shiloh, Y; Ziv, Y				Banin, S; Moyal, L; Shieh, SY; Taya, Y; Anderson, CW; Chessa, L; Smorodinsky, NI; Prives, C; Reiss, Y; Shiloh, Y; Ziv, Y			Enhanced phosphorylation of p53 by ATN in response to DNA damage	SCIENCE			English	Article							ATAXIA-TELANGIECTASIA GENE; PHOSPHOINOSITIDE 3-KINASE; CELL-CYCLE; MAMMALIAN TARGET; PROTEIN; PRODUCT; KINASE; WORTMANNIN; INHIBITION; RAPAMYCIN	The ATM protein, encoded by the gene responsible for the human genetic disorder ataxia telangiectasia (A-T), regulates several cellular responses to DNA breaks. ATM shares a phosphoinositide 3-kinase-related domain with several proteins, some of them protein kinases. A wortmannin-sensitive protein kinase activity was associated with endogenous or recombinant ATM and was abolished by structural ATM mutations. In vitro substrates included the translation repressor PHAS-I and the p53 protein. ATM phosphorylated p53 in vitro on a single residue, serine-15, which is phosphorylated in vivo in response to DNA damage. This activity was markedly enhanced within minutes after treatment of cells with a radiomimetic drug; the total amount of ATM remained unchanged. Various damage-induced responses may be activated by enhancement of the protein kinase activity of ATM.	Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 104, Japan; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Rome La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy; Tel Aviv Univ, George S Wise Fac Life Sci, Hybridoma Unit, IL-69978 Ramat Aviv, Israel; Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Ramat Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine; Columbia University; National Cancer Center - Japan; United States Department of Energy (DOE); Brookhaven National Laboratory; Sapienza University Rome; Tel Aviv University; Tel Aviv University	Shiloh, Y (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Genet & Mol Med, IL-69978 Ramat Aviv, Israel.		Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031763] Funding Source: NIH RePORTER; NINDS NIH HHS [NS31763] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANIN S, UNPUB; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; FISCELLA M, 1993, ONCOGENE, V8, P1519; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Gilad S, 1996, HUM MOL GENET, V5, P433, DOI 10.1093/hmg/5.4.433; GOLDBERG IH, 1995, ENEDIYNE ANTIBIOTICS, P327; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HAUPT Y, 1997, NATURE, V387, P286; Hoekstra MF, 1997, CURR OPIN GENET DEV, V7, P170, DOI 10.1016/S0959-437X(97)80125-6; Keegan KS, 1996, GENE DEV, V10, P2423, DOI 10.1101/gad.10.19.2423; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIN TA, 1902, SCIENCE, V266, P94; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; MOYAL L, UNPUB; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SHILOH Y, 1998, GENETIC BASIS HUMAN, P275; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WILICIANO JD, 1997, GENE DEV, V11, P3471; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	32	1667	1715	0	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1674	1677		10.1126/science.281.5383.1674	http://dx.doi.org/10.1126/science.281.5383.1674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733514				2022-12-24	WOS:000075856500047
J	Wary, KK; Mariotti, A; Zurzolo, C; Giancotti, FG				Wary, KK; Mariotti, A; Zurzolo, C; Giancotti, FG			A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth	CELL			English	Article							ONCOGENICALLY TRANSFORMED-CELLS; MAP KINASE; ALPHA(6)BETA(4) INTEGRIN; CYCLE PROGRESSION; ADAPTER PROTEINS; C-SRC; ADHESION; ACTIVATION; RAS; VIP21-CAVEOLIN	Caveolin-l functions as a membrane adaptor to link the integrin cw subunit to the tyrosine kinase Fyn. Upon integrin ligation, Fyn is activated and binds, via its SH3 domain, to Shc. Shc is subsequently phosphorylated at tyrosine 317 and recruits Grb2. This sequence of events is necessary to couple integrins to the Ras-ERK pathway and promote cell cycle progression. These findings reveal an unexpected function of caveolin-l and Fyn in integrin signaling and anchorage-dependent cell growth.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Univ Naples, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Memorial Sloan Kettering Cancer Center; University of Naples Federico II	Giancotti, FG (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.		Zurzolo, Chiara/AAH-5225-2019	ZURZOLO, Chiara/0000-0001-6048-6602; Mariotti, Agnese/0000-0002-3704-7908; Wary, Kishore/0000-0001-8851-8565	NCI NIH HHS [P30 CA08748, CA58976] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA058976, P30CA008748, R01CA058976] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bray D, 1998, NATURE, V393, P85, DOI 10.1038/30018; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CHEN WT, 1985, J CELL BIOL, V100, P1103, DOI 10.1083/jcb.100.4.1103; Clark EA, 1997, BBA-REV CANCER, V1333, pR9, DOI 10.1016/S0304-419X(97)00028-0; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GIANCOTTI FG, 1994, BBA-REV CANCER, V1198, P47, DOI 10.1016/0304-419X(94)90005-1; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Lin TH, 1997, J BIOL CHEM, V272, P8849; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Lipardi C, 1998, J CELL BIOL, V140, P617, DOI 10.1083/jcb.140.3.617; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Murgia C, 1998, EMBO J, V17, P3940, DOI 10.1093/emboj/17.14.3940; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	37	589	599	0	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					625	634		10.1016/S0092-8674(00)81604-9	http://dx.doi.org/10.1016/S0092-8674(00)81604-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741627	Bronze			2022-12-24	WOS:000075851900010
J	Rawles, J; Sinclair, C; Jennings, K; Ritchie, L; Waugh, N				Rawles, J; Sinclair, C; Jennings, K; Ritchie, L; Waugh, N			Call to needle times after acute myocardial infarction in urban and rural areas in northeast Scotland: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article							GUIDELINES	Objective: To determine call to needle times and consider how best to provide timely thrombolytic treatment for patients with acute myocardial infarction. Design: Prospective observational study. Setting: City, suburban, and country practices referring patients to a single district general hospital in northeast Scotland. Subjects: 1046 patients with suspected acute myocardial infarction given thrombolytic treatment. Main outcome measures: Time from patients' calls for medical help until receipt of opiate or thrombolytic treatment, measured against a call to needle time of 90 minutes or less, as proposed by the British Heart Foundation. Results: General practitioners were the first medical contact in 97% (528/544) of calls by country patients and 68% (340/502) of city and suburban patients. When opiate was given by general practitioners, median call to opiate time was about 30 minutes (95% Within 90 minutes) in city, suburbs, and country; call to opiate delay was about 60 minutes in city and subul ban patients calling "999" for an ambulance. One third of country patients received thrombolytic treatment from their general practitioners with a median call to thrombolysis time of 45 minutes (93% within 90 minutes); this compares with 150 minutes (5% within 90 minutes) when this treatment was deferred until after hospital admission. In the city and suburbs, no thrombolytic treatment was given outside hospital, and only a minority of patients received it within 90 minutes of calling; median call to thrombolysis time was 95 (46% within 90 minutes) minutes. Conclusions: The first medical contact after acute myocardial infarction is most commonly with a general practitioner. This contact provides the optimum opportunity to give thrombolytic treatment within the British Heart Foundation's guideline.	Univ Aberdeen, Aberdeen Royal Infirm, Med Assessment Res Unit, Aberdeen AB25 2NZ, Scotland; Aberdeen Royal Infirm, Dept Cardiol, Aberdeen, Scotland; Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen AB25 2NZ, Scotland; Grampian Hlth Board, Aberdeen AB15 6RE, Scotland	University of Aberdeen; University of Aberdeen; University of Aberdeen	Rawles, J (corresponding author), Univ Aberdeen, Aberdeen Royal Infirm, Med Assessment Res Unit, Aberdeen AB25 2NZ, Scotland.							Banerjee S, 1998, J ROY COLL PHYS LOND, V32, P36; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CAPEWELL S, 1997, HLTH B, V55, P399; COBBE SM, 1994, BMJ-BRIT MED J, V308, P216, DOI 10.1136/bmj.308.6923.216; LIDDELL R, 1996, 67 SCOTT OFF; RAWLES J, 1995, DRUGS, V50, P615, DOI 10.2165/00003495-199550040-00004; Rawles JM, 1997, J AM COLL CARDIOL, V30, P1181, DOI 10.1016/S0735-1097(97)00299-4; WESTON CFM, 1994, BMJ-BRIT MED J, V308, P767, DOI 10.1136/bmj.308.6931.767; 1994, DRUG THERAPEUTICS B, V32, P65	9	33	33	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					576	578		10.1136/bmj.317.7158.576	http://dx.doi.org/10.1136/bmj.317.7158.576			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721115	Green Published, Bronze			2022-12-24	WOS:000075767800019
J	Tweed, D; Haslwanter, T; Fetter, M				Tweed, D; Haslwanter, T; Fetter, M			Optimizing gaze control in three dimensions	SCIENCE			English	Article							EYE-HEAD COORDINATION; 3-DIMENSIONAL EYE; MOVEMENTS; SACCADES; POSITION; VELOCITY; TORSION; SHIFTS; SYSTEM; LAW	Horizontal and vertical movements of the human eye bring new objects to the center of the visual field, but torsional movements rotate the visual world about its center. Ocular torsion stays near zero during head-fixed gaze shifts, and eye movements to Visual targets are thought to be driven by purely horizontal and vertical commands. Here, analysis of eye-head gaze shifts revealed that gaze commands were three-dimensional, with a separate neural control system for torsion. Active torsion optimized gaze control as no two-dimensional system could have, stabilizing the retinal image as quickly as possible when it would otherwise have spun around the fixation point.	Univ Western Ontario, Dept Physiol, London, ON, Canada; Univ Western Ontario, Dept Appl Math, London, ON N6A 5B9, Canada; Univ Tubingen, Dept Neurol, D-7400 Tubingen, Germany	Western University (University of Western Ontario); Western University (University of Western Ontario); Eberhard Karls University of Tubingen	Tweed, D (corresponding author), Univ Toronto, Dept Physiol, Med Sci Bldg 3207,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.							BALLIET R, 1978, INVEST OPHTH VIS SCI, V17, P303; CARPENTR RHS, 1988, MOVEMENTS EYES; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; FERMAN L, 1987, VISION RES, V27, P929, DOI 10.1016/0042-6989(87)90009-5; GUITTON D, 1987, J NEUROPHYSIOL, V58, P427, DOI 10.1152/jn.1987.58.3.427; HASLWANTER T, 1995, VISION RES, V35, P1727, DOI 10.1016/0042-6989(94)00257-M; HEPP K, 1995, VISION RES, V35, P3237, DOI 10.1016/0042-6989(95)00104-M; HEPP K, 1997, VISION RES, V37, P1939; LAURUTIS VP, 1986, J PHYSIOL-LONDON, V373, P209, DOI 10.1113/jphysiol.1986.sp016043; MERTON PA, 1956, J PHYSIOL-LONDON, V132, pP25; MILLER E F 2nd, 1962, Acta Otolaryngol, V54, P479, DOI 10.3109/00016486209126967; MINKEN AWH, 1993, EXP BRAIN RES, V93, P521, DOI 10.1007/BF00229367; PETROV AP, 1973, VISION RES, V13, P2465, DOI 10.1016/0042-6989(73)90244-7; RADAU P, 1994, J NEUROPHYSIOL, V72, P2840, DOI 10.1152/jn.1994.72.6.2840; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; ROUCOUX A, 1980, PROGR OCULOMOTOR RES, P309; STRAUMANN D, 1995, VISION RES, V35, P3321, DOI 10.1016/0042-6989(95)00091-R; TWEED D, 1994, J NEUROPHYSIOL, V72, P1425, DOI 10.1152/jn.1994.72.3.1425; TWEED D, 1995, J NEUROPHYSIOL, V73, P766, DOI 10.1152/jn.1995.73.2.766; TWEED D, 1987, J NEUROPHYSIOL, V58, P832, DOI 10.1152/jn.1987.58.4.832; TWEED D, 1990, VISION RES, V30, P111, DOI 10.1016/0042-6989(90)90131-4; TWEED D, 1990, VISION RES, V30, P97, DOI 10.1016/0042-6989(90)90130-D; Tweed D, 1997, J NEUROPHYSIOL, V77, P654, DOI 10.1152/jn.1997.77.2.654; von Helmholtz H., 1867, HDB PHYSL OPTIK, VVol. 9, DOI 10.1007/BF01708548; WESTHEIMER G, 1957, J OPT SOC AM, V47, P967, DOI 10.1364/JOSA.47.000967	25	62	62	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 28	1998	281	5381					1363	1366		10.1126/science.281.5381.1363	http://dx.doi.org/10.1126/science.281.5381.1363			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721104				2022-12-24	WOS:000075666800054
J	Zandi, E; Chen, Y; Karin, M				Zandi, E; Chen, Y; Karin, M			Direct phosphorylation of I kappa B by IKK alpha and IKK beta: Discrimination between free and NF-kappa B-bound substrate	SCIENCE			English	Article							CASEIN KINASE-II; CONSTITUTIVE PHOSPHORYLATION; TRANSCRIPTION FACTOR; ACTIVATION; DEGRADATION; SIGNAL; DISSOCIATION; PROTEOLYSIS; SUFFICIENT; EXPRESSION	A large protein complex mediates the phosphorylation of the inhibitor of kappa B (I kappa B), which results in the activation of nuclear factor kappa B (NF-kappa B). Two subunits of this complex, I kappa B kinase alpha (IKK alpha) and I kappa B kinase beta (IKK beta), are required for NF-kappa B activation. Purified recombinant IKK alpha and IKK beta expressed in insect cells were used to demonstrate that each protein can directly phosphorylate I kappa B proteins. IKK alpha and IKK beta were found to form both homodimers and heterodimers. Both IKK alpha and IKK beta phosphorylated I kappa B bound to NF-kappa B more efficiently than they phosphorylated free I kappa B. This result explains how free I kappa B can accumulate in cells in which IKK is still active and thus can contribute to the termination of NF-kappa B activation.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043477] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 43477] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Schwarz EM, 1996, MOL CELL BIOL, V16, P3554; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; ZANDI E, UNPUB	24	387	409	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1360	1363		10.1126/science.281.5381.1360	http://dx.doi.org/10.1126/science.281.5381.1360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721103				2022-12-24	WOS:000075666800053
J	West, SK; Duncan, DD; Munoz, B; Rubin, GS; Fried, LP; Bandeen-Roche, K; Schein, OD				West, SK; Duncan, DD; Munoz, B; Rubin, GS; Fried, LP; Bandeen-Roche, K; Schein, OD			Sunlight exposure and risk of lens opacities in a population-based study - The Salisbury Eye Evaluation Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ULTRAVIOLET-LIGHT EXPOSURE; CATARACT; PREVALENCE; RADIATION; BALTIMORE	Context.-Exposure to UV-B radiation in sunlight has been shown to increase the risk of cataract formation in high-risk occupational groups, but risk to the population has not been quantified. Objectives.-To determine the ocular exposure to UV-B radiation in sunlight for a population of older persons and to determine the association between UV-B and lens opacities. Design.-The Salisbury Eye Evaluation project, a population-based cohort of older adults. Setting.-Salisbury, Md. Participants.-A total of 2520 community-dwelling 65-year-old to 84-year-old adults in Salisbury, Md, from 1993 to 1995, of whom 26.4% were African Americans. Main Outcome Measure-Association of photographically documented cortical opacity 3/16 or greater in at least 1 eye with ocular UV-B exposure, reported in Maryland sun-years of exposure. Results.-The odds of cortical opacity increased with increasing ocular exposure to UV-B (odds ratio [OR], 1.10; 95% confidence interval [CI], 1.02-1.20). The relationship was similar for women (OR, 1.14; 95% CI, 1.00-1.30) and for African Americans (OR, 1.18; 95% CI, 1.04-1.33). Analyses of the ocular dose by each age group after the age of 30 years showed no vulnerable age group, suggesting damage is based on cumulative exposure. Conclusions.-Although this population of older Americans has relatively low ocular exposure to UV-B in sunlight, there is still an association between ocular exposure and increasing odds of cortical opacity. Our study found an association among African Americans, which, to our knowledge, has not been reported previously. All sex and racial groups would benefit from simple methods to avoid ocular sun exposure.	Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins Medicine	West, SK (corresponding author), Johns Hopkins Univ, Wilmer Eye Inst, Room 129,600 N Wolfe St, Baltimore, MD 21287 USA.				NATIONAL INSTITUTE ON AGING [P01AG010184] Funding Source: NIH RePORTER; NIA NIH HHS [P01-AG10184] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ARMITAGE P, 1985, STAT METHODS MED RES, P469; BAILEY IL, 1991, INVEST OPHTH VIS SCI, V32, P422; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; BRILLIANT LB, 1983, AM J EPIDEMIOL, V118, P250, DOI 10.1093/oxfordjournals.aje.a113632; COLLMAN GW, 1988, AM J PUBLIC HEALTH, V78, P1459, DOI 10.2105/AJPH.78.11.1459; CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658; DOLEZAL JM, 1989, AM J EPIDEMIOL, V129, P559, DOI 10.1093/oxfordjournals.aje.a115168; Duncan DD, 1997, INVEST OPHTH VIS SCI, V38, P1003; Duncan DD, 1997, PHOTOCHEM PHOTOBIOL, V66, P701; DUNCAN DD, 1995, PHOTOCHEM PHOTOBIOL, V62, P94, DOI 10.1111/j.1751-1097.1995.tb05244.x; Harding J., 1991, CATARACT BIOCH EPIDE; HILLER R, 1977, AM J EPIDEMIOL, V105, P450, DOI 10.1093/oxfordjournals.aje.a112404; HOLLOWS F, 1981, LANCET, V2, P1249; HOOVER RN, 1980, LANCET, V1, P837; KUPFER C, 1984, T OPHTHAL SOC UK, V104, P1; Leske MC, 1997, ARCH OPHTHALMOL-CHIC, V115, P105, DOI 10.1001/archopht.1997.01100150107018; LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051; MUNOZ B, IN PRESS ANN EPIDEMI; Peters AL, 1996, JAMA-J AM MED ASSOC, V276, P1246, DOI 10.1001/jama.276.15.1246; PITTS DG, 1976, NIOSH PUBLICATION, P1; ROSENTHAL FS, 1986, AM J PUBLIC HEALTH, V76, P1216, DOI 10.2105/AJPH.76.10.1216; ROSINI F, 1994, ANN EPIDEMIOL, V4, P266; SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032; SMITH AH, 1980, AM J EPIDEMIOL, V112, P787, DOI 10.1093/oxfordjournals.aje.a113051; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; Thylefors B, 1995, OPHTHAL EPIDEMIOL, V2, P5; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; WEST SK, 1988, INVEST OPHTH VIS SCI, V29, P73; West SK, 1997, INVEST OPHTH VIS SCI, V38, P72; WEST SK, 1993, CURR EYE RES, V12, P123, DOI 10.3109/02713689308999480; WEST SK, IN PRESS AM J EPIDEM; WONG L, 1993, J EPIDEMIOL COMMUN H, V47, P46, DOI 10.1136/jech.47.1.46	34	184	190	1	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					714	718		10.1001/jama.280.8.714	http://dx.doi.org/10.1001/jama.280.8.714			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728643	Bronze			2022-12-24	WOS:000075446900033
J	Robinson, SM; Mackenzie-Ross, S; Hewson, GLC; Egleston, C; Prevost, AT				Robinson, SM; Mackenzie-Ross, S; Hewson, GLC; Egleston, C; Prevost, AT			Psychological effect of witnessed resuscitation on bereaved relatives	LANCET			English	Article							PSYCHOMETRIC PROPERTIES; INVENTORY; ANXIETY; SCALE	Background Established practice is for the relatives of critically ill patients to be excluded from the clinical area during resuscitation. We aimed to discover whether relatives wanted to be present during the resuscitation of a family member and whether witnessing resuscitation had any adverse psychological effects on bereaved relatives. Methods In this pilot study, relatives of patients who required resuscitation were given the option to remain with the patient during resuscitation or were not given this choice and directed to the relatives' room (control group). The unit of randomisation was the patient who required resuscitation and not the relatives. One close relative was paired with each patient. All relatives were accompanied by a chaperone who gave emotional support and provided technical information on the resuscitation. Relatives were followed up 1 month after the resuscitation. We used a questionnaire to ask about the decision to be present, or absent during resuscitation, Bereaved relatives also completed five standardised psychological questionnaires to assess anxiety, depression, grief, intrusive imagery, and avoidance behaviour. Findings 25 patients underwent resuscitation (13 in witnessed resuscitation group, 12 in control group), Three patients in the witnessed group survived, all the control group patients died. Two relatives in each group were lost to follow-up. Thus, eight relatives who witnessed resuscitation and ten control-group relatives were followed up. There were no reported adverse psychological effects among the relatives who witnessed resuscitation, all of whom were satisfied with their decision to remain with the patient. The clinical team became convinced of the benefits to relatives of allowing them to witness resuscitation if they wished, so the trial was terminated. Interpretation In the context of the emergency department, routine exclusion of relatives from the resuscitation room may no longer be appropriate.	Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England; UCL, Subdept Clin Hlth Psychol, London, England; Univ Cambridge, Inst Publ Hlth, Dept Community Med, Ctr Appl Med Stat, Cambridge, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of London; University College London; University of Cambridge	Robinson, SM (corresponding author), Addenbrookes NHS Trust, Emergency Dept, Cambridge CB2 2QQ, England.			Robinson, Susan/0000-0002-1796-6739; Prevost, A. Toby/0000-0003-1723-0796				Back D, 1994, Nurs Times, V90, P34; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DOYLE CJ, 1987, ANN EMERG MED, V16, P107; Gregory C M, 1995, Accid Emerg Nurs, V3, P136, DOI 10.1016/S0965-2302(95)80006-9; Hanson C, 1992, J Emerg Nurs, V18, P104; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JUDKINS KC, 1994, BRIT MED J, V309, P406; OSUAGWN CC, 1991, J EMERG NURS, V17, P36; SCHILLING RJ, 1994, BRIT MED J, V309, P406, DOI 10.1136/bmj.309.6951.406; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZISOOK S, 1982, AM J PSYCHIAT, V139, P1590; ZOLTIE N, 1994, BRIT MED J, V309, P406	14	256	261	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					614	617		10.1016/S0140-6736(97)12179-1	http://dx.doi.org/10.1016/S0140-6736(97)12179-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	113TE	9746023				2022-12-24	WOS:000075567400011
J	White, NJ				White, NJ			Not much progress in treatment of cerebral malaria	LANCET			English	Editorial Material							FALCIPARUM-MALARIA; CONTROLLED TRIAL; IRON CHELATION; DOUBLE-BLIND; CHILDREN; ARTEMETHER; QUININE; DEXAMETHASONE; COMA		Mahidol Univ, Fac Trop Med, Bangkok 10400, Thailand	Mahidol University	White, NJ (corresponding author), Mahidol Univ, Fac Trop Med, 420-6 Rajvithi Rd, Bangkok 10400, Thailand.		White, Nick/AAC-6527-2019; White, Nicholas J/I-4629-2012	White, Nick/0000-0002-1897-1978; 				Cabantchik ZI, 1996, ACTA HAEMATOL-BASEL, V95, P70, DOI 10.1159/000203952; DIPERRI G, 1995, J INFECT DIS, V171, P1317, DOI 10.1093/infdis/171.5.1317; GORDEUK V, 1992, NEW ENGL J MED, V327, P1473, DOI 10.1056/NEJM199211193272101; GORDEUK VR, 1993, AM J TROP MED HYG, V48, P193, DOI 10.4269/ajtmh.1993.48.193; Hien TT, 1996, NEW ENGL J MED, V335, P76, DOI 10.1056/NEJM199607113350202; HOFFMAN SL, 1988, J INFECT DIS, V158, P325, DOI 10.1093/infdis/158.2.325; Karbwang J, 1995, T ROY SOC TROP MED H, V89, P668, DOI 10.1016/0035-9203(95)90437-9; Looareesuwan S, 1998, AM J TROP MED HYG, V58, P348, DOI 10.4269/ajtmh.1998.58.348; PUNYAGUPTA S, 1974, American Journal of Tropical Medicine and Hygiene, V23, P551; TAYLOR TE, 1993, LANCET, V341, P661, DOI 10.1016/0140-6736(93)90423-E; TAYLOR TE, 1992, CLIN EXP IMMUNOL, V90, P357, DOI 10.1111/j.1365-2249.1992.tb05851.x; Thuma PE, 1998, T ROY SOC TROP MED H, V92, P214, DOI 10.1016/S0035-9203(98)90753-2; van der Torn M, 1998, T ROY SOC TROP MED H, V92, P325, DOI 10.1016/S0035-9203(98)91032-X; vanHensbroek MB, 1996, J INFECT DIS, V174, P1091, DOI 10.1093/infdis/174.5.1091; vanHensbroek MB, 1996, NEW ENGL J MED, V335, P69, DOI 10.1056/NEJM199607113350201; WARRELL DA, 1982, NEW ENGL J MED, V306, P313, DOI 10.1056/NEJM198202113060601	16	32	33	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					594	595		10.1016/S0140-6736(05)79572-6	http://dx.doi.org/10.1016/S0140-6736(05)79572-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746017				2022-12-24	WOS:000075567400005
J	Cousineau, B; Smith, D; Lawrence-Cavanagh, S; Mueller, JE; Yang, J; Mills, D; Manias, D; Dunny, G; Lambowitz, AM; Belfort, M				Cousineau, B; Smith, D; Lawrence-Cavanagh, S; Mueller, JE; Yang, J; Mills, D; Manias, D; Dunny, G; Lambowitz, AM; Belfort, M			Retrohoming of a bacterial group II intron: Mobility via complete reverse splicing, independent of homologous DNA recombination	CELL			English	Article							YEAST MITOCHONDRIAL-DNA; DOUBLE-STRANDED DNA; ESCHERICHIA-COLI; LACTOCOCCUS-LACTIS; RNA; SITE; TRANSCRIPTION; TRANSPOSITION; REQUIREMENTS; INVASION	The mobile group II intron of Lactococcus lactis, LI.LtrB, provides the opportunity to analyze the homing pathway in genetically tractable bacterial systems. Here, we show that LI.LtrB mobility occurs by an RNA-based retrohoming mechanism in both Escherichia coli and L. lactis. Surprisingly, retrohoming occurs efficiently in the absence of RecA function, with a relaxed requirement for flanking exon homology and without coconversion of exon markers. These results lead to a model for bacterial retrohoming in which the intron integrates into recipient DNA by complete reverse splicing and serves as the template for cDNA synthesis. The retrohoming reaction is completed in unprecedented fashion by a DNA repair event that is independent of homologous recombination between the alleles. Thus, LI.LtrB has many features of retrotransposons, with practical and evolutionary implications.	New York State Dept Hlth, Wadsworth Ctr, Mol Genet Program, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Albany, NY 12201 USA; Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Texas, Dept Biochem & Chem, Inst Mol & Cellular Biol, Austin, TX 78712 USA; Univ Texas, Dept Microbiol, Inst Mol & Cellular Biol, Austin, TX 78712 USA	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Belfort, M (corresponding author), New York State Dept Hlth, Wadsworth Ctr, Mol Genet Program, POB 22002, Albany, NY 12201 USA.		Mills, David Andrew/G-2282-2011; Mills, David/GXF-1821-2022	Mills, David Andrew/0000-0003-1913-9865; Belfort, Marlene/0000-0002-1592-5618	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039422, R37GM039422, R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39422, GM44844, GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BELFORT M, 1990, METHOD ENZYMOL, V181, P521; BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BOEKE JD, 1985, CELL, V40, P491, DOI 10.1016/0092-8674(85)90197-7; CLYMAN J, 1992, GENE DEV, V6, P1269, DOI 10.1101/gad.6.7.1269; Curcio MJ, 1996, CELL, V84, P9, DOI 10.1016/S0092-8674(00)80987-3; Derr LK, 1998, GENETICS, V148, P937; Eskes R, 1997, CELL, V88, P865, DOI 10.1016/S0092-8674(00)81932-7; Guo HT, 1997, EMBO J, V16, P6835, DOI 10.1093/emboj/16.22.6835; Kuzminov A, 1997, J BACTERIOL, V179, P880, DOI 10.1128/jb.179.3.880-888.1997; LAZOWSKA J, 1994, EMBO J, V13, P4963, DOI 10.1002/j.1460-2075.1994.tb06823.x; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; Matsuura M, 1997, GENE DEV, V11, P2910, DOI 10.1101/gad.11.21.2910; MICHEL F, 1995, ANNU REV BIOCHEM, V64, P435, DOI 10.1146/annurev.bi.64.070195.002251; Mills DA, 1996, J BACTERIOL, V178, P3531, DOI 10.1128/jb.178.12.3531-3538.1996; Mills DA, 1997, J BACTERIOL, V179, P6107, DOI 10.1128/jb.179.19.6107-6111.1997; MORAN JV, 1995, MOL CELL BIOL, V15, P2828; Mueller JE, 1996, GENE DEV, V10, P351, DOI 10.1101/gad.10.3.351; Mueller JE, 1996, GENE DEV, V10, P2158, DOI 10.1101/gad.10.17.2158; MUELLER MW, 1993, NATURE, V366, P174, DOI 10.1038/366174a0; Parker MM, 1996, GENETICS, V143, P1057; QUIRK SM, 1989, CELL, V56, P455, DOI 10.1016/0092-8674(89)90248-1; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SELLEM CH, 1993, NATURE, V366, P176, DOI 10.1038/366176a0; SHARP PA, 1991, SCIENCE, V254, P663, DOI 10.1126/science.1948046; Shearman C, 1996, MOL MICROBIOL, V21, P45, DOI 10.1046/j.1365-2958.1996.00610.x; Stahl MM, 1997, GENETICS, V147, P961; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; THALER DS, 1987, J MOL BIOL, V195, P75, DOI 10.1016/0022-2836(87)90328-7; WALKER GC, 1984, MICROBIOL REV, V48, P60, DOI 10.1128/MMBR.48.1.60-93.1984; Yang J, 1996, NATURE, V381, P332, DOI 10.1038/381332a0; YANG J, 1998, IN PRESS J MOL BIOL; ZHANG A, 1995, RNA, V1, P783; ZIMMERLY S, 1995, CELL, V83, P529, DOI 10.1016/0092-8674(95)90092-6; ZIMMERLY S, 1995, CELL, V82, P545, DOI 10.1016/0092-8674(95)90027-6	35	167	171	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					451	462		10.1016/S0092-8674(00)81586-X	http://dx.doi.org/10.1016/S0092-8674(00)81586-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727488	Bronze			2022-12-24	WOS:000075541100007
J	Lucas, A				Lucas, A			Collaborative research with infant formula companies should not always be censored	BRITISH MEDICAL JOURNAL			English	Article							BREAST-MILK; EARLY DIET; PRETERM		Inst Child Hlth, MRC, Childhood Nutr Res Ctr, London WC1N 1EH, England	University of London; University College London	Lucas, A (corresponding author), Inst Child Hlth, MRC, Childhood Nutr Res Ctr, 30 Guilford St, London WC1N 1EH, England.							Bishop NJ, 1996, ACTA PAEDIATR, V85, P230, DOI 10.1111/j.1651-2227.1996.tb13999.x; Falkner F, 1997, INT CHILD HLTH, Vviii, P1; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FALL CHD, 1992, FETAL INFANT ORIGINS, P275; FOSTER K, 1995, INFANT FEEDING; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1994, ARCH DIS CHILD, V71, P288, DOI 10.1136/adc.71.4.288; LUCAS A, 1990, LANCET, V335, P1477, DOI 10.1016/0140-6736(90)93026-L; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MOTT GE, 1991, CIBA F SYMP, V156, P56; ROTHMAN J, 1998, MARKETING RES TODAY, P86; Wise J, 1997, BRIT MED J, V314, P167	12	6	6	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 1	1998	317	7154					337	338						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110YQ	9729080				2022-12-24	WOS:000075409500034
J	Wang, MD; Schnitzer, MJ; Yin, H; Landick, R; Gelles, J; Block, SM				Wang, MD; Schnitzer, MJ; Yin, H; Landick, R; Gelles, J; Block, SM			Force and velocity measured for single molecules of RNA polymerase	SCIENCE			English	Article							ESCHERICHIA-COLI; CHAIN ELONGATION; KINESIN MOLECULES; TERMINATION; DNA; TRANSCRIPTION; PAUSE; MECHANICS	RNA polymerase (RNAP) moves along DNA while carrying out transcription, acting as a molecular motor. Transcriptional velocities for single molecules of Escherichia coli RNAP were measured as progressively larger forces were applied by;a feedback-controlled optical trap. The shapes of RNAP force-velocity curves are distinct from those of the motor enzymes myosin or kinesin, and indicate that biochemical steps limiting transcription rates at Low loads do not generate movement. Modeling the data suggests-that high Loads may halt RNAP by promoting a structural change which moves all or part of the enzyme backwards through a comparatively Large distance, corresponding to 5 to 10 base pairs. This contrasts with previous models that assumed force acts directly upon a single-base translocation step.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Princeton Mat Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA; Brandeis Univ, Dept Biochem, Waltham, MA 02254 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Princeton University; Princeton University; Princeton University; Brandeis University; University of Wisconsin System; University of Wisconsin Madison	Block, SM (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	block@princeton.edu						ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; BERG HC, 1993, BIOPHYS J, V65, P2201, DOI 10.1016/S0006-3495(93)81278-5; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; Chan CL, 1997, J MOL BIOL, V268, P54, DOI 10.1006/jmbi.1997.0935; CHAN CL, 1994, RAV S MOL C, V3, P297; Coppin CM, 1997, P NATL ACAD SCI USA, V94, P8539, DOI 10.1073/pnas.94.16.8539; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Julicher F, 1998, BIOPHYS J, V74, P1169, DOI 10.1016/S0006-3495(98)77833-6; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; Kojima H, 1997, BIOPHYS J, V73, P2012, DOI 10.1016/S0006-3495(97)78231-6; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Landick R, 1997, CELL, V88, P741, DOI 10.1016/S0092-8674(00)81919-4; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; Mooney RA, 1998, J BACTERIOL, V180, P3265, DOI 10.1128/JB.180.13.3265-3275.1998; Palangat M, 1998, MOL CELL, V1, P1033, DOI 10.1016/S1097-2765(00)80103-3; Press W.H., 1992, NUMERICAL RECIPES, V2, P650; REISBIG RR, 1981, BIOCHEMISTRY-US, V20, P1907, DOI 10.1021/bi00510a029; Saenger W., 1988, PRINCIPLES NUCL ACID; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; Wang HY, 1998, BIOPHYS J, V74, P1186, DOI 10.1016/S0006-3495(98)77834-8; Wang M. D., 1996, Biophysical Journal, V70, pA44; Wang MD, 1997, BIOPHYS J, V72, P1335, DOI 10.1016/S0006-3495(97)78780-0; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653	29	697	735	2	110	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					902	907		10.1126/science.282.5390.902	http://dx.doi.org/10.1126/science.282.5390.902			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794753				2022-12-24	WOS:000076727300038
J	Wetterau, JR; Gregg, RE; Harrity, TW; Arbeeny, C; Cap, M; Connolly, F; Chu, CH; George, RJ; Gordon, DA; Jamil, H; Jolibois, KG; Kunselman, LK; Lan, SJ; Maccagnan, TJ; Ricci, B; Yan, MJ; Young, D; Chen, Y; Fryszman, OM; Logan, JVH; Musial, CL; Poss, MA; Robl, JA; Simpkins, LM; Slusarchyk, WA; Sulsky, R; Taunk, P; Magnin, DR; Tino, JA; Lawrence, RM; Dickson, JK; Biller, SA				Wetterau, JR; Gregg, RE; Harrity, TW; Arbeeny, C; Cap, M; Connolly, F; Chu, CH; George, RJ; Gordon, DA; Jamil, H; Jolibois, KG; Kunselman, LK; Lan, SJ; Maccagnan, TJ; Ricci, B; Yan, MJ; Young, D; Chen, Y; Fryszman, OM; Logan, JVH; Musial, CL; Poss, MA; Robl, JA; Simpkins, LM; Slusarchyk, WA; Sulsky, R; Taunk, P; Magnin, DR; Tino, JA; Lawrence, RM; Dickson, JK; Biller, SA			An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits	SCIENCE			English	Article							TRIGLYCERIDE-TRANSFER-PROTEIN; DISULFIDE-ISOMERASE; ABETALIPOPROTEINEMIA; SUBUNIT; GENE; COMPLEX; DEFECTS	Patients with abetalipoproteinemia, a disease caused by defects in the microsomal triglyceride transfer protein (MTP), do not produce apolipoprotein B-containing lipoproteins. It was hypothesized that small molecule inhibitors of MTP would prevent the assembly and secretion of these atherogenic lipoproteins. To test this hypothesis, two compounds identified in a high-throughput screen for MTP inhibitors were used to direct the synthesis of a highly potent MTP inhibitor. This molecule (compound 9) inhibited the production of Lipoprotein particles in rodent models and normalized plasma Lipoprotein Levels in Watanabe-heritable hyperlipidemic (WHHL) rabbits, which are a model for human homozygous familiar hypercholesterolemia. These results suggest that compound 9, or derivatives thereof, has potential applications for the therapeutic Lowering of atherogenic Lipoprotein levels in humans.	Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab & Pharmacokinet, Princeton, NJ 08543 USA; Bristol Myers Squibb Pharmaceut Res Inst, Div Discovery Chem, Princeton, NJ 08543 USA	Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb	Wetterau, JR (corresponding author), Bristol Myers Squibb Pharmaceut Res Inst, Dept Metab Dis, POB 4000, Princeton, NJ 08543 USA.			Musial, Christa/0000-0002-1916-596X				BORENSZTAJN J, 1976, BIOCHEM J, V156, P539, DOI 10.1042/bj1560539; CAIRNS SR, 1983, CLIN SCI, V65, P645, DOI 10.1042/cs0650645; Glueck C J, 1977, Trans Assoc Am Physicians, V90, P184; Jamil H, 1996, P NATL ACAD SCI USA, V93, P11991, DOI 10.1073/pnas.93.21.11991; KANE JP, 1995, METABOLIC MOL BASES, P1853; KITA T, 1981, P NATL ACAD SCI-BIOL, V78, P2268, DOI 10.1073/pnas.78.4.2268; Lawrence RM, 1997, SYNTHESIS-STUTTGART, P553; LINTON MF, 1993, J LIPID RES, V34, P521; NARCISI TME, 1995, AM J HUM GENET, V57, P1298; Rehberg EF, 1996, J BIOL CHEM, V271, P29945, DOI 10.1074/jbc.271.47.29945; RICCI B, 1995, J BIOL CHEM, V270, P14281, DOI 10.1074/jbc.270.24.14281; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SHOULDERS CC, 1993, HUM MOL GENET, V2, P2109, DOI 10.1093/hmg/2.12.2109; WETTERAU JR, 1990, J BIOL CHEM, V265, P9800; WETTERAU JR, 1986, BIOCHIM BIOPHYS ACTA, V875, P610, DOI 10.1016/0005-2760(86)90084-6	15	238	262	2	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					751	754		10.1126/science.282.5389.751	http://dx.doi.org/10.1126/science.282.5389.751			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784135				2022-12-24	WOS:000076607500054
J	Nakamura, TM; Cooper, JP; Cech, TR				Nakamura, TM; Cooper, JP; Cech, TR			Two modes of survival of fission yeast without telomerase	SCIENCE			English	Article							SCHIZOSACCHAROMYCES-POMBE GENOME; I RESTRICTION MAP; SACCHAROMYCES-CEREVISIAE; HOMOLOG; CHROMOSOME; PROTEIN; GENE; DNA; CLONING; REPAIR	Deletion of the telomerase catalytic subunit gene trt1(+) in Schizosaccharomyces pombe results in death for the majority of cells, but a subpopulation survives. Here it is shown that most survivors have circularized all of their chromosomes, whereas a smaller number maintain their telomeres presumably through recombination. When the telomeric DNA-binding gene taz1(+) is also deleted, trt1(-) taz1(-) survivors use the recombinational mode more frequently. Moreover, the massive elongation of telomeres in taz1(-) cells is absent in the double mutant. Thus, Taz1p appears to regulate telomeric recombination as well as telomerase activity in fission yeast.	Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cech, TR (corresponding author), Univ Colorado, Howard Hughes Med Inst, Dept Chem & Biochem, Boulder, CO 80309 USA.		Nakamura, Toru M/B-2055-2008	Nakamura, Toru M/0000-0001-5752-0814; cooper, julia promisel/0000-0003-2171-2587	NIGMS NIH HHS [GM28039] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028039, R37GM028039] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfa C., 1993, EXPT FISSION YEAST; Brun C, 1997, TRENDS CELL BIOL, V7, P317, DOI 10.1016/S0962-8924(97)01092-1; Bryan TM, 1997, EUR J CANCER, V33, P767, DOI 10.1016/S0959-8049(97)00065-8; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; Cooper JP, 1997, NATURE, V385, P744, DOI 10.1038/385744a0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; COOPER JR, UNPUB; FAN JB, 1992, NUCLEIC ACIDS RES, V20, P5943, DOI 10.1093/nar/20.22.5943; FAN JB, 1991, NUCLEIC ACIDS RES, V19, P6289, DOI 10.1093/nar/19.22.6289; FAN JB, 1989, NUCLEIC ACIDS RES, V17, P2801, DOI 10.1093/nar/17.7.2801; HOHEISEL JD, 1993, CELL, V73, P109, DOI 10.1016/0092-8674(93)90164-L; JANG YK, 1994, GENE, V142, P207, DOI 10.1016/0378-1119(94)90262-3; KLAR AJS, 1983, MOL CELL BIOL, V3, P803, DOI 10.1128/MCB.3.5.803; Lingner J, 1998, CURR OPIN GENET DEV, V8, P226, DOI 10.1016/S0959-437X(98)80145-7; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI S, 1995, MOL GEN GENET, V246, P671, DOI 10.1007/BF00290712; Muris DFR, 1996, J CELL SCI, V109, P73; MURIS DFR, 1993, NUCLEIC ACIDS RES, V21, P4586, DOI 10.1093/nar/21.19.4586; NAITOH T, IN PRESS NATURE GENE; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nimmo ER, 1998, NATURE, V392, P825, DOI 10.1038/33941; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; OSTERMANN K, 1993, NUCLEIC ACIDS RES, V21, P5940, DOI 10.1093/nar/21.25.5940; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; Sugawara N, 1989, THESIS HARVARD U CAM	28	229	231	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					493	496		10.1126/science.282.5388.493	http://dx.doi.org/10.1126/science.282.5388.493			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774280				2022-12-24	WOS:000076479600060
J	Kovtun, Y; Chiu, WL; Zeng, WK; Sheen, J				Kovtun, Y; Chiu, WL; Zeng, WK; Sheen, J			Suppression of auxin signal transduction by a MAPK cascade in higher plants	NATURE			English	Article							PROTEIN-KINASES; ARABIDOPSIS; EXPRESSION; TOBACCO; GENE; PHOSPHATASE; REPORTER; ENCODES; STRESS; CELLS	The plant hormone auxin activates many early response genes that are thought to be responsible for diverse aspects of plant growth and development(1). It has been proposed that auxin signal transduction is mediated by a conserved signalling cascade consisting of three protein kinases: the mitogen-activated protein kinase (MAPK), MAPK kinase (MAPKK) and MAPKK kinase (MAPKKK)(2), Here we show that a specific plant MAPKKK, NPK1 (ref. 3), activates a MAPK cascade that leads to the suppression of early auxin response gene transcription, A mutation in the kinase domain abolishes NPK1 activity, and the presence of the carboxy-terminal domain diminishes the kinase activity, Moreover, the effects of NPK1 on the activation of a MAPK and the repression of early auxin response gene transcription are specifically eliminated by a MAPK phosphatase(4). Transgenic tobacco plants overexpressing the NPK1 kinase domain produced seeds defective in embryo and endosperm development. These results suggest that auxin sensitivity may be balanced by antagonistic signalling pathways that use a distinct MAPK cascade in higher plants.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Sheen, J (corresponding author), Harvard Univ, Sch Med, Dept Genet, Boston, MA 02114 USA.							Abel S, 1996, PLANT PHYSIOL, V111, P9, DOI 10.1104/pp.111.1.9; BANNO H, 1993, MOL CELL BIOL, V13, P4745, DOI 10.1128/MCB.13.8.4745; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; del Pozo JC, 1998, SCIENCE, V280, P1760, DOI 10.1126/science.280.5370.1760; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; Guilfoyle TJ, 1998, TRENDS PLANT SCI, V3, P205, DOI 10.1016/S1360-1385(98)01244-8; HAGEN G, 1991, PLANT MOL BIOL, V17, P567, DOI 10.1007/BF00040658; Hirt H, 1997, TRENDS PLANT SCI, V2, P11, DOI 10.1016/S1360-1385(96)10048-0; JANG JC, 1994, PLANT CELL, V6, P1665, DOI 10.1105/tpc.6.11.1665; Jang JC, 1997, PLANT CELL, V9, P5, DOI 10.1105/tpc.9.1.5; John M, 1997, TRENDS PLANT SCI, V2, P111, DOI 10.1016/S1360-1385(97)01005-4; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KLIMCZAK LJ, 1995, PLANT PHYSIOL, V109, P687, DOI 10.1104/pp.109.2.687; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Leyser O, 1998, CURR BIOL, V8, pR305, DOI 10.1016/S0960-9822(98)70193-9; MACHIDA Y, 1998, 40 NIBB C STRESS RES; MIZOGUCHI T, 1994, PLANT J, V5, P111, DOI 10.1046/j.1365-313X.1994.5010111.x; Nakashima M, 1998, PLANT CELL PHYSIOL, V39, P690, DOI 10.1093/oxfordjournals.pcp.a029423; Nishihama R, 1997, PLANT J, V12, P39, DOI 10.1046/j.1365-313X.1997.12010039.x; SHEEN J, 1993, EMBO J, V12, P3497, DOI 10.1002/j.1460-2075.1993.tb06024.x; SHEEN J, 1990, PLANT CELL, V2, P1027, DOI 10.1105/tpc.2.10.1027; SHEEN J, 1995, PLANT J, V8, P777, DOI 10.1046/j.1365-313X.1995.08050777.x; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Zhang SQ, 1997, PLANT CELL, V9, P809, DOI 10.1105/tpc.9.5.809	29	195	224	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					716	720		10.1038/27240	http://dx.doi.org/10.1038/27240			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790195				2022-12-24	WOS:000076472600057
J	Bennett, M; Macdonald, K; Chan, SW; Luzio, JP; Simari, R; Weissberg, P				Bennett, M; Macdonald, K; Chan, SW; Luzio, JP; Simari, R; Weissberg, P			Cell surface trafficking of Fas: A rapid mechanism of p53-mediated apoptosis	SCIENCE			English	Article							TRANSCRIPTIONAL ACTIVATION; P53; GENE; INDUCTION; RECEPTOR; BINDING; LIGAND; PROLIFERATION; INHIBITION; PATHWAY	p53 acts as a tumor suppressor by inducing both growth arrest and apoptosis. p53-induced apoptosis can occur without new RNA synthesis through an unknown mechanism. In human vascular smooth muscle cells, p53 activation transiently increased surface pas (CD95) expression by transport from the Golgi complex. Golgi disruption blocked both p53-induced surface Fas expression and apoptosis. p53 also induced Fas-FADD binding and transiently sensitized cells to Fas-induced apoptosis. In contrast, lpr and gld fibroblasts were resistant to p53-induced apoptosis. Thus, p53 can mediate apoptosis through pas transport from cytoplasmic stores.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Mayo Clin & Mayo Fdn, Dept Cardiovasc Dis Biochem & Mol Biol, Rochester, MN 55905 USA	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Mayo Clinic	Bennett, M (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.			Chan, Shiu-Wan/0000-0002-4018-9309; Bennett, Martin/0000-0002-2565-1825	NHLBI NIH HHS [HL34073] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Attardi LD, 1996, EMBO J, V15, P3693, DOI 10.1002/j.1460-2075.1996.tb00739.x; Bennett MR, 1997, CIRC RES, V81, P591, DOI 10.1161/01.RES.81.4.591; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; MIYASHITA T, 1994, ONCOGENE, V9, P1799; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YonishRouach E, 1995, ONCOGENE, V11, P2197	25	622	637	3	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					290	293		10.1126/science.282.5387.290	http://dx.doi.org/10.1126/science.282.5387.290			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765154				2022-12-24	WOS:000076370200047
J	Lomeli, J; Quevedo, J; Linares, P; Rudomin, P				Lomeli, J; Quevedo, J; Linares, P; Rudomin, P			Local control of information flow in segmental and ascending collaterals of single afferents	NATURE			English	Article							CAT SPINAL-CORD; I MUSCLE AFFERENTS; PRESYNAPTIC DEPOLARIZATION; CLARKE COLUMN; FIBERS; TRANSMISSION; PATHWAYS; INTERNEURONS; MOTONEURONS; INHIBITION	In the vertebrate spinal cord, the activation of GABA (gamma-aminobutyric acid)-releasing interneurons that synapse with intraspinal terminals of sensory fibres leading into the central nervous system (afferent fibres) produces primary afferent depolarization and presynaptic inhibition(1-3). It is not known to what extent these presynaptic mechanisms allow a selective control of information transmitted through specific sets of intraspinal branches of individual afferents(4-7). Here we study the local nature of the presynaptic control by measuring primary afferent depolarization simultaneously in two intraspinal collaterals of the same muscle spindle afferent. One of these collaterals ends at the L6-L7 segmental level in the intermediate nucleus, and the other ascends to segment L3 within Clarke's column, the site of origin of spinocerebellar neurons(8). Our results indicate that there are central mechanisms that are able to affect independently the synaptic effectiveness of segmental and ascending collaterals of individual muscle spindle afferents. Focal control of presynaptic inhibition thus allows the intraspinal branches of afferent fibres to function as a dynamic assembly that can be fractionated to convey information to selected neuronal targets. This may be a mechanism by which different spinal postsynaptic targets that are coupled by sensory input from a common source could be uncoupled.	Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Physiol Biophys & Neurosci, Mexico City 07000, DF, Mexico	CINVESTAV - Centro de Investigacion y de Estudios Avanzados del Instituto Politecnico Nacional; Instituto Politecnico Nacional - Mexico	Rudomin, P (corresponding author), Inst Politecn Nacl, Ctr Invest & Estudios Avanzados, Dept Physiol Biophys & Neurosci, Apartado Postal 14-740, Mexico City 07000, DF, Mexico.	rudomin@fisio.cinvestav.mx		Lomeli, Joel/0000-0001-5318-8949				[Anonymous], [No title captured]; CHAN SHH, 1972, BRAIN RES, V45, P101, DOI 10.1016/0006-8993(72)90218-1; CURTIS DR, 1983, BRAIN RES, V258, P328, DOI 10.1016/0006-8993(83)91160-5; CURTIS DR, 1984, BRAIN RES, V295, P372, DOI 10.1016/0006-8993(84)90989-2; Eguibar JR, 1997, EXP BRAIN RES, V113, P411, DOI 10.1007/PL00005595; Enriquez M, 1996, EXP BRAIN RES, V107, P391; GEO JH, 1996, SCIENCE, V272, P545; Gossard JP, 1996, J NEUROPHYSIOL, V76, P4104, DOI 10.1152/jn.1996.76.6.4104; HARRISON PJ, 1984, BRAIN RES, V295, P203, DOI 10.1016/0006-8993(84)90968-5; HULTBORN H, 1987, J PHYSIOL-LONDON, V389, P757, DOI 10.1113/jphysiol.1987.sp016681; Iles JF, 1996, J PHYSIOL-LONDON, V491, P197, DOI 10.1113/jphysiol.1996.sp021207; JANKOWSKA E, 1981, J NEUROPHYSIOL, V46, P506, DOI 10.1152/jn.1981.46.3.506; JANKOWSKA E, 1984, BRAIN RES, V295, P195, DOI 10.1016/0006-8993(84)90967-3; JANKOWSKA E, 1992, PROG NEUROBIOL, V38, P335, DOI 10.1016/0301-0082(92)90024-9; LUSCHER HR, 1998, PRESYNAPTIC INHIBITI, P126; MADRID J, 1979, NEUROSCI LETT, V11, P253, DOI 10.1016/0304-3940(79)90003-X; MANN MD, 1973, BRAIN BEHAV EVOLUT, V7, P34, DOI 10.1159/000124397; Nelson RJ, 1996, CURR OPIN NEUROBIOL, V6, P801, DOI 10.1016/S0959-4388(96)80031-6; NUSBAUM MP, 1997, NEURONS NETWORKS MOT, P237; Quevedo J, 1997, EXP BRAIN RES, V115, P387, DOI 10.1007/PL00005709; QUEVEDO J, 1993, J NEUROPHYSIOL, V70, P1; Raymond JL, 1996, SCIENCE, V272, P1126, DOI 10.1126/science.272.5265.1126; RIDDELL JS, 1993, J PHYSIOL-LONDON, V461, P723, DOI 10.1113/jphysiol.1993.sp019538; RUDOMIN P, 1975, J NEUROPHYSIOL, V38, P267, DOI 10.1152/jn.1975.38.2.267; RUDOMIN P, 1981, J NEUROPHYSIOL, V46, P532, DOI 10.1152/jn.1981.46.3.532; RUDOMIN P, 1974, J NEUROPHYSIOL, V37, P413, DOI 10.1152/jn.1974.37.3.413; RUDOMIN P, 1987, J NEUROPHYSIOL, V57, P1288, DOI 10.1152/jn.1987.57.5.1288; RUDOMIN P, 1983, J NEUROPHYSIOL, V50, P743, DOI 10.1152/jn.1983.50.4.743; RUDOMIN P, 1990, SEGMENTAL MOTOR SYST, P349; WALL PD, 1995, TRENDS NEUROSCI, V18, P99, DOI 10.1016/0166-2236(95)93883-Y	30	76	77	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					600	604		10.1038/26975	http://dx.doi.org/10.1038/26975			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783585				2022-12-24	WOS:000076362900048
J	Makhubu, L				Makhubu, L			Bioprospecting in an African context	SCIENCE			English	Editorial Material									Univ Swaziland, Kwaluseni, Swaziland		Makhubu, L (corresponding author), Univ Swaziland, Private Bag 4, Kwaluseni, Swaziland.							Chadwick D, 1994, CIBA F B, V37, P13; Farnsworth NR, 1985, B WORLD HEALTH ORGAN, V63, P695; MAKHUBU LP, 1978, TRADIONAL HEALER; *OAU, 1997, POL ISS OWN ACC CONS; SOFOWORA A, 1992, MED PLANTS TRADITION, P9; 1985, GOOD NEWS BIBLE EDIT	6	11	12	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					41	42		10.1126/science.282.5386.41	http://dx.doi.org/10.1126/science.282.5386.41			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9786792				2022-12-24	WOS:000076294900016
J	Lundgren, E; Szabo, E; Ljunghall, S; Bergstrom, R; Holmberg, L; Rastad, J				Lundgren, E; Szabo, E; Ljunghall, S; Bergstrom, R; Holmberg, L; Rastad, J			Population based case-control study of sick leave in postmenopausal women before diagnosis of hyperparathyroidism	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM-CALCIUM; FOLLOW-UP; BONE LOSS; HYPERCALCEMIA; MAMMOGRAPHY; PREVALENCE; SURGERY; DISEASE; VALUES	Objective: To analyse sick leave in women at risk of primary hyperparathyroidism before its diagnosis. Design: Case-control study nested within a screened cohort of postmenopausal women. Cases were women with hyperparathyroidism without prior knowledge of their disease and no traditional symptoms or complications. Controls were women from the screened population without hyperparathyroidism. Setting Population based screening within a Swedish community. Subject: 48 case-control pairs of women aged 55-70 years. Main outcome measure: Sick leave during the 5 years before diagnosis. Results: Total duration of sickness benefits was longer in the cases than controls, and this discrepancy included sick leave on full time or half time and for periods of longer than a week Cases had an increased risk of sick leave more than half of the investigated time compared with controls (odds ratio 12). Doctors' certificates showed that the overrepresented sick leave in the cases related mainly to cardiovascular diseases. Conclusion: Asymptomatic mild primary hyperparathyroidism in postmenopausal women is accompanied by a previously unrecognised morbidity, which has consequences for clinical management of the disorder and its impact on the health economy.	Uppsala Univ, Dept Surg, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Internal Med, S-75185 Uppsala, Sweden; Uppsala Univ, Dept Stat, S-75185 Uppsala, Sweden	Uppsala University; Uppsala University; Uppsala University	Lundgren, E (corresponding author), Uppsala Univ, Dept Surg, S-75185 Uppsala, Sweden.	ewa.lundgren@kirurgi.uu.se						HEDBACK G, 1991, WORLD J SURG, V15, P399, DOI 10.1007/BF01658740; HORNQUIST JO, 1990, SCAND J SOC MED, V18, P91, DOI 10.1177/140349489001800202; KLEEREKOPER M, 1994, AM J MED, V96, P99, DOI 10.1016/0002-9343(94)90127-9; LJUNGDAHL LO, 1991, SCAND J SOC MED, V19, P148, DOI 10.1177/140349489101900302; LJUNGHALL S, 1991, J BONE MINER RES S2, V6, P111; LJUNGHALL S, 1989, CLIN DISORDERS BONE; Lundgren E, 1997, SURGERY, V121, P287, DOI 10.1016/S0039-6060(97)90357-3; MARTIN P, 1990, ARCH INTERN MED, V150, P1495, DOI 10.1001/archinte.150.7.1495; MEEMA HE, 1991, J BONE MINER RES, V6, P9; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PALMER M, 1988, EUR J CLIN INVEST, V18, P39, DOI 10.1111/j.1365-2362.1988.tb01163.x; PALMER M, 1987, LANCET, V1, P59; PARFITT AM, 1991, J BONE MINER RES, V6, P95; RAO DS, 1988, J CLIN ENDOCR METAB, V67, P1294, DOI 10.1210/jcem-67-6-1294; Soreide JA, 1997, SURGERY, V122, P1117, DOI 10.1016/S0039-6060(97)90216-6; *SWED INS BOARD, 1996, SICK LEAV SWED 1990; THURFJELL EL, 1994, RADIOLOGY, V193, P351, DOI 10.1148/radiology.193.2.7972742; Wermers RA, 1998, AM J MED, V104, P115, DOI 10.1016/S0002-9343(97)00270-2	18	31	31	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					848	851		10.1136/bmj.317.7162.848	http://dx.doi.org/10.1136/bmj.317.7162.848			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748176	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000076222300017
J	Zhou, YB; Gerchman, SE; Ramakrishnan, V; Travers, A; Muyldermans, S				Zhou, YB; Gerchman, SE; Ramakrishnan, V; Travers, A; Muyldermans, S			Position and orientation of the globular domain of linker histone H5 on the nucleosome	NATURE			English	Article							CRYSTAL-STRUCTURE; BINDING-SITE; DNA-SEQUENCE; CHROMATOSOMES; CHROMATIN; IDENTIFICATION; ORGANIZATION; RESOLUTION; LOCATION; PARTICLE	It is essential to identify the exact location of the linker histone within nucleosomes, the fundamental packing units of chromatin, in order to understand how condensed, transcriptionally inactive chromatin forms. Here, using a site-specific protein-DNA photocrosslinking method(1), we map the binding site and the orientation of the globular domain of linker histone H5 on mixed-sequence chicken nucleosomes. We show, in contrast to an earlier model(2), that the globular domain forms a bridge between one terminus of chromatosomal DNA and the DNA in the vicinity of the dyad axis of symmetry of the core particle. Helix III of the globular domain binds in the major groove of the first helical turn of the chromatosomal DNA, whereas the secondary DNA-binding site on the opposite face of the globular domain of histone H5 makes contact with the nucleosomal DNA dose to its midpoint. We also infer that helix I and helix II of the globular domain of histone H5 probably face, respectively, the solvent and the nucleosome. This location places the basic carboxy-terminal region of the globular domain in a position from which it could simultaneously bind the nucleosome-linking DNA strands that exit and enter the nucleosome.	Free Univ Brussels VIB, B-1640 Rhode St Genese, Belgium; Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Univ Utah, Sch Med, Dept Biochem, Salt Lake City, UT 84132 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; United States Department of Energy (DOE); Brookhaven National Laboratory; Utah System of Higher Education; University of Utah; MRC Laboratory Molecular Biology	Muyldermans, S (corresponding author), Free Univ Brussels VIB, Paardenstr 65, B-1640 Rhode St Genese, Belgium.	svmuylde@vub.ac.be	Muyldermans, Serge V/C-6418-2016; Muyldermans, Serge/AAC-7374-2019	Muyldermans, Serge V/0000-0002-3678-3575; Muyldermans, Serge/0000-0002-3678-3575; Ramakrishnan, V/0000-0002-4699-2194				ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; AN W, IN PRESS NUCL ACIDS; CERF C, 1994, BIOCHEMISTRY-US, V33, P11079, DOI 10.1021/bi00203a004; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CraneRobinson C, 1997, TRENDS BIOCHEM SCI, V22, P75, DOI 10.1016/S0968-0004(97)01013-X; DRWE HR, 1987, J MOL BIOL, V197, P485; Goytisolo FA, 1996, EMBO J, V15, P3421, DOI 10.1002/j.1460-2075.1996.tb00708.x; Hamiche A, 1996, J MOL BIOL, V257, P30, DOI 10.1006/jmbi.1996.0144; HAYES JJ, 1994, P NATL ACAD SCI USA, V91, P7817, DOI 10.1073/pnas.91.16.7817; HAYES JJ, 1993, P NATL ACAD SCI USA, V90, P6415, DOI 10.1073/pnas.90.14.6415; Hayes JJ, 1996, BIOCHEMISTRY-US, V35, P11931, DOI 10.1021/bi961590+; Howe LW, 1998, MOL CELL BIOL, V18, P1156, DOI 10.1128/MCB.18.3.1156; LAMBERT S, 1991, BIOCHEM BIOPH RES CO, V179, P810, DOI 10.1016/0006-291X(91)91889-K; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUTTER LC, 1979, NUCLEIC ACIDS RES, V6, P41, DOI 10.1093/nar/6.1.41; MIRZABEKOV AD, 1990, J MOL BIOL, V211, P479, DOI 10.1016/0022-2836(90)90366-T; MUYLDERMANS S, 1994, J MOL BIOL, V235, P855, DOI 10.1006/jmbi.1994.1044; PANNETTA G, IN PRESS J MOL BIOL; PEHRSON JR, 1989, P NATL ACAD SCI USA, V86, P9149, DOI 10.1073/pnas.86.23.9149; PENDERGRAST PS, 1992, P NATL ACAD SCI USA, V89, P10287, DOI 10.1073/pnas.89.21.10287; Pruss D, 1996, SCIENCE, V274, P614, DOI 10.1126/science.274.5287.614; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SEGERS A, 1991, J BIOL CHEM, V266, P1502; SIMPSON RT, 1978, BIOCHEMISTRY-US, V17, P5524, DOI 10.1021/bi00618a030; STAYNOV DZ, 1988, EMBO J, V7, P3685, DOI 10.1002/j.1460-2075.1988.tb03250.x; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMAS JO, 1986, EMBO J, V5, P3531, DOI 10.1002/j.1460-2075.1986.tb04679.x; THOMAS JO, 1992, NUCLEIC ACIDS RES, V20, P187, DOI 10.1093/nar/20.2.187; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178	29	167	174	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					402	405		10.1038/26521	http://dx.doi.org/10.1038/26521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759733				2022-12-24	WOS:000076083800059
J	Koepp, MJ; Richardson, MP; Brooks, DJ; Duncan, JS				Koepp, MJ; Richardson, MP; Brooks, DJ; Duncan, JS			Focal cortical release of endogenous opioids during reading-induced seizures	LANCET			English	Article							POSITRON EMISSION TOMOGRAPHY; C-11 DIPRENORPHINE; OPIATE RECEPTOR; EPILEPSY; PET; ACTIVATION; WORDS; BRAIN; TASK	Background Studies in animals implicate endogenous release of opioid peptides as a mechanism for terminating partial and generalised seizures. To localise dynamic changes in opioid neurotransmission associated with partial seizures and higher cognitive function, we investigated the release of endogenous opioids in patients with reading-induced seizures compared with healthy controls. Methods Five patients who had reading epilepsy and six controls had C-11-diprenorphine (DPN) positron-emission-tomography (PET) scans while reading a string of symbols (baseline) or a scientific paper (activation). Statistical parametric mapping was used to find areas with differences in opioid-receptor binding. Findings On activation scans mean C-11-DPN binding to opioid receptors was significantly lower (p<0.05 corrected for multiple non-independent comparisons) in the left parieto-temporo-occipital cortex (Brodmann area 37) in reading-epilepsy patients compared with controls. Interpretation These findings suggest that opioid-like substances are involved in the termination of reading-induced seizures.	Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England; Inst Neurol, London WC1N 3BG, England; Natl Soc Epilepsy, London WC1N 3BG, England	Imperial College London; University of London; University College London; University of London; University College London	Duncan, JS (corresponding author), Hammersmith Hosp, MRC, Cyclotron Unit, London W12 0HS, England.	j.duncan@ion.ucl.ac.uk	Richardson, Mark P/E-5385-2010	Richardson, Mark P/0000-0001-8925-3140; Brooks, David/0000-0003-2602-2518; Duncan, John S/0000-0002-1373-0681	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALAJOUANINE T, 1959, Rev Neurol (Paris), V101, P463; ANDERSEN RA, 1989, ANNU REV NEUROSCI, V12, P377, DOI 10.1146/annurev.neuro.12.1.377; BAILEY DL, 1992, ANN NUCL MED, V6, P121; Bajorek J G, 1986, Adv Neurol, V44, P489; BARTENSTEIN PA, 1993, J NEUROL NEUROSUR PS, V56, P1295, DOI 10.1136/jnnp.56.12.1295; BICKFORD REGINALD G., 1956, TRANS AMER NEUROL ASSOC, V81, P100; BOTTINI G, 1994, BRAIN, V117, P1241, DOI 10.1093/brain/117.6.1241; BROOKS JE, 1971, ARCH NEUROL-CHICAGO, V25, P97, DOI 10.1001/archneur.1971.00490020015001; CHENG JG, 1990, EPILEPSY RES, V6, P141; CUNNINGHAM VJ, 1993, J CEREBR BLOOD F MET, V13, P15, DOI 10.1038/jcbfm.1993.5; DEWEY SL, 1993, P NATL ACAD SCI USA, V90, P11816, DOI 10.1073/pnas.90.24.11816; DEWEY SL, 1995, J NEUROSCI, V15, P821; Friston K.J., 1994, HUMAN BRAIN MAPPING, V2, P211, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; FRISTON KJ, 1995, HUMAN BRAIN MAPPING, V2, P165; FROST JJ, 1993, J RECEPTOR RES, V13, P39, DOI 10.3109/10799899309073644; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JONES AKP, 1994, J NEUROSCI METH, V51, P123, DOI 10.1016/0165-0270(94)90002-7; KARTSOUNIS LD, 1988, J NEUROL NEUROSUR PS, V51, P128, DOI 10.1136/jnnp.51.1.128; Madar I, 1997, ANN NEUROL, V41, P358, DOI 10.1002/ana.410410311; MORRIS BJ, 1995, TRENDS NEUROSCI, V18, P350, DOI 10.1016/0166-2236(95)93927-P; Morris ED, 1995, HUM BRAIN MAPP, V3, P35, DOI 10.1002/hbm.460030105; PETERSEN SE, 1990, SCIENCE, V249, P1041, DOI 10.1126/science.2396097; PREVETT MC, 1994, EPILEPSY RES, V19, P71, DOI 10.1016/0920-1211(94)90090-6; Price CJ, 1996, CEREB CORTEX, V6, P62, DOI 10.1093/cercor/6.1.62; PRICE CJ, 1994, BRAIN, V117, P1255, DOI 10.1093/brain/117.6.1255; RADHAKRISHNAN K, 1995, BRAIN, V118, P75, DOI 10.1093/brain/118.1.75; RANABADRAN K, 1990, INT J CLIN PHARM TH, V28, P47; SEEGER TF, 1984, BRAIN RES, V305, P303, DOI 10.1016/0006-8993(84)90436-0; Theodore WH, 1996, EPILEPSIA, V37, P796, DOI 10.1111/j.1528-1157.1996.tb00654.x; TORTELLA FC, 1988, TRENDS PHARMACOL SCI, V9, P36; TORTELLA FC, 1988, NEUROBIOLOGY AMINO A, P163; Weeks RA, 1997, J CEREBR BLOOD F MET, V17, P943, DOI 10.1097/00004647-199709000-00003; Wolf Peter, 1992, P281	33	74	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					952	955		10.1016/S0140-6736(97)09077-6	http://dx.doi.org/10.1016/S0140-6736(97)09077-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752818				2022-12-24	WOS:000076002200011
J	Donchin, O; Gribova, A; Steinberg, O; Bergman, H; Vaadia, E				Donchin, O; Gribova, A; Steinberg, O; Bergman, H; Vaadia, E			Primary motor cortex is involved in bimanual coordination	NATURE			English	Article							NEURONAL-ACTIVITY; CORTICAL AREAS; RHESUS-MONKEY; MOVEMENTS; HAND; TASK; ARM; SYNCHRONIZATION; CONNECTIONS; DIRECTION	Many voluntary movements involve coordination between the limbs(1,2). However, there have been very few attempts to study the neuronal mechanisms that mediate this coordination. Here we have studied the activity of cortical neurons while monkeys performed tasks that required coordination between the two arms. We found that most neurons in the primary motor cortex (MI) show activity specific to bimanual movements (bimanual-related activity), which is strikingly different from the activity of the same neurons during unimanual movements. Moreover, units in the supplementary motor area (SMA; the area of cortex most often associated with bimanual coordination(3)) showed no more bimanual-related activity than units in MI. Our results challenge the classic view that MI controls the contralateral (opposite) side of the body and that SMA. is responsible for the coordination of the arms. Rather, our data suggest that both cortical areas share the control of bilateral coordination.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Ctr Neural Computat, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Vaadia, E (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Physiol, IL-91120 Jerusalem, Israel.	eilon@hbf.huji.ac.il	Vaadia, Eilon/E-9347-2011; Donchin, Opher/A-4389-2008	Donchin, Opher/0000-0003-0963-4467				BRINKMAN C, 1979, J NEUROPHYSIOL, V42, P681, DOI 10.1152/jn.1979.42.3.681; BRINKMAN C, 1984, J NEUROSCI, V4, P918; BRINKMAN J, 1973, BRAIN, V96, P653, DOI 10.1093/brain/96.4.653; CRAMMOND D J, 1991, Society for Neuroscience Abstracts, V17, P308; Donchin O., 1996, Society for Neuroscience Abstracts, V22, P2022; EVARTS EV, 1968, J NEUROPHYSIOL, V31, P14, DOI 10.1152/jn.1968.31.1.14; FRANZ EA, 1991, ACTA PSYCHOL, V77, P137, DOI 10.1016/0001-6918(91)90028-X; GEORGOPOULOS AP, 1992, SCIENCE, V256, P1692, DOI 10.1126/science.256.5064.1692; GEORGOPOULOS AP, 1982, J NEUROSCI, V2, P1527; JENNY AB, 1979, J COMP NEUROL, V188, P137, DOI 10.1002/cne.901880111; JONES EG, 1986, CEREB CORTEX, V5, P113; KAROL EA, 1971, BRAIN, V94, P471, DOI 10.1093/brain/94.3.471; KELSO JAS, 1979, J EXP PSYCHOL HUMAN, V5, P229, DOI 10.1037/0096-1523.5.2.229; KIM SG, 1993, SCIENCE, V261, P615, DOI 10.1126/science.8342027; LECAS JC, 1986, J NEUROPHYSIOL, V56, P1680, DOI 10.1152/jn.1986.56.6.1680; LUPPINO G, 1993, J COMP NEUROL, V338, P114, DOI 10.1002/cne.903380109; MATSUZAKA Y, 1992, J NEUROPHYSIOL, V68, P653, DOI 10.1152/jn.1992.68.3.653; MUAKKASSA KF, 1979, BRAIN RES, V177, P176, DOI 10.1016/0006-8993(79)90928-4; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; Perepelkin P. D., 1996, Society for Neuroscience Abstracts, V22, P2022; Roelfsema PR, 1997, NATURE, V385, P157, DOI 10.1038/385157a0; ROUILLER EM, 1994, EXP BRAIN RES, V102, P227; SCHWARTZ AB, 1994, SCIENCE, V265, P540, DOI 10.1126/science.8036499; Scott SH, 1997, J NEUROPHYSIOL, V77, P1016, DOI 10.1152/jn.1997.77.2.1016; Taira M, 1996, EXP BRAIN RES, V109, P367; TANJI J, 1988, J NEUROPHYSIOL, V60, P325, DOI 10.1152/jn.1988.60.1.325; TANJI J, 1987, NATURE, V327, P618, DOI 10.1038/327618a0; TOKUNO H, 1993, J COMP NEUROL, V333, P199, DOI 10.1002/cne.903330206; Wiesendanger M, 1996, ADV NEUROL, V70, P85; WIESENDANGER M, 1993, INT CONGR SER, V1024, P253	30	223	226	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					274	278		10.1038/26220	http://dx.doi.org/10.1038/26220			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751054				2022-12-24	WOS:000075974600050
J	Lessard, N; Pare, M; Lepore, F; Lassonde, W				Lessard, N; Pare, M; Lepore, F; Lassonde, W			Early-blind human subjects localize sound sources better than sighted subjects	NATURE			English	Article							CATS SUPERIOR COLLICULUS; AUDITORY SPACE; CEREBRAL-CORTEX; PLASTICITY; NEURONS; MAP; COMPENSATION; MIDBRAIN; MOTION; BRAIN	Do blind persons develop capacities of their remaining senses that exceed those of sighted individuals? Besides anecdotal suggestions, two views based on experimental studies have been advanced(1). The first proposes that blind individuals should be severely impaired, given that vision is essential to develop spatial concepts(2), The second suggests that compensation occurs through the remaining senses, allowing them to develop an accurate concept of space(3). Here we investigate how an ecologically critical function, namely three-dimensional spatial mapping, is carried out by early-blind individuals with or without residual vision. Subjects were tested under monaural and binaural listening conditions. We find that early-blind subjects can map the auditory environment with equal or better accuracy than sighted subjects. Furthermore, unlike sighted subjects, they can correctly localize sounds monaurally, Surprisingly, blind individuals with residual peripheral vision localized sounds less precisely than sighted or totally blind subjects, confirming that compensation varies according to the aetiology and extent of blindness(4). Our results resolve a long-standing controversy in that they provide behavioural evidence that totally blind individuals have better auditory ability than sighted subjects, enabling them to compensate for their loss of vision.	Univ Montreal, Dept Psychol, Grp Rech Neuropsychol Expt, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Ctr Rech Sci Neurol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Lepore, F (corresponding author), Univ Montreal, Dept Psychol, Grp Rech Neuropsychol Expt, CP 6128,Succ Ctr Ville, Montreal, PQ H3C 3J7, Canada.	leporef@ere.umontreal.ca						Axelrod S., 1959, EFFECTS EARLY BLINDN; BUTLER RA, 1987, PERCEPT PSYCHOPHYS, V41, P1, DOI 10.3758/BF03208206; CHALUPA LM, 1977, J PHYSIOL-LONDON, V270, P595, DOI 10.1113/jphysiol.1977.sp011971; Feldman DE, 1997, J NEUROSCI, V17, P6820; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; KING AJ, 1993, EXP PHYSIOL, V78, P559, DOI 10.1113/expphysiol.1993.sp003708; KUJALA T, 1992, ELECTROEN CLIN NEURO, V84, P469, DOI 10.1016/0168-5597(92)90034-9; Kujala T, 1997, PSYCHOPHYSIOLOGY, V34, P213, DOI 10.1111/j.1469-8986.1997.tb02134.x; KUJALA T, 1995, EXP BRAIN RES, V104, P519; MIDDLEBROOKS JC, 1984, J NEUROSCI, V4, P2621; POIRIER P, 1993, BRAIN, V116, P53, DOI 10.1093/brain/116.1.53; RAUSCHECKER JP, 1994, EUR J NEUROSCI, V6, P149, DOI 10.1111/j.1460-9568.1994.tb00256.x; RAUSCHECKER JP, 1983, EXP BRAIN RES, V50, P69; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; RICE C, 1970, AM F BLIND RES B, V22, P1, DOI DOI 10.3758/S13414-011-0160-4; SLATTERY WH, 1994, HEARING RES, V75, P38, DOI 10.1016/0378-5955(94)90053-1; SPITZER MW, 1991, SCIENCE, V254, P721, DOI 10.1126/science.1948053; STUMPF E, 1992, EXP BRAIN RES, V88, P158, DOI 10.1007/BF02259137; TORONCHUK JM, 1992, EXP BRAIN RES, V88, P169, DOI 10.1007/BF02259138	20	413	423	1	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					278	280		10.1038/26228	http://dx.doi.org/10.1038/26228			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751055				2022-12-24	WOS:000075974600051
J	Haissaguerre, M; Jais, P; Shah, DC; Takahashi, A; Hocini, M; Quiniou, G; Garrigue, S; Le Mouroux, A; Le Metayer, P; Clementy, J				Haissaguerre, M; Jais, P; Shah, DC; Takahashi, A; Hocini, M; Quiniou, G; Garrigue, S; Le Mouroux, A; Le Metayer, P; Clementy, J			Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIOFREQUENCY CATHETER ABLATION; MAZE PROCEDURE; HEART; OPERATION; THERAPY; DOGS	Background Atrial fibrillation, the most common sustained cardiac arrhythmia and a major cause of stroke, results from simultaneous reentrant wavelets. Its spontaneous initiation has not been studied. Methods We studied 45 patients with frequent episodes of atrial fibrillation (mean [+/-SD] duration, 344+/-326 minutes per 24 hours) refractory to drug therapy. The spontaneous initiation of atrial fibrillation was mapped with the use of multielectrode catheters designed to record the earliest electrical activity preceding the onset of atrial fibrillation and associated atrial ectopic beats. The accuracy of the mapping was confirmed by the abrupt disappearance of triggering atrial ectopic beats after ablation with local radio-frequency energy. Results A single point of origin of atrial ectopic beats was identified in 29 patients, two points of origin were identified in 9 patients, and three or four points of origin were identified in 7 patients, for a total of 69 ectopic foci. Three foci were in the right atrium, 1 in the posterior left atrium, and 65 (94 percent) in the pulmonary veins (31 in the left superior, 17 in the right superior, 11 in the left inferior, and 6 in the right inferior pulmonary vein). The earliest activation was found to have occurred 2 to 4 cm inside the veins, marked by a local depolarization preceding the atrial ectopic beats on the surface electrocardiogram by 106+/-24 msec. Atrial fibrillation was initiated by a sudden burst of rapid depolarizations (340 per minute). A local depolarization could also be recognized during sinus rhythm and abolished by radiofrequency ablation. During a follow-up period of 8+/-6 months after ablation, 28 patients (62 percent) had no recurrence of atrial fibrillation. Conclusions The pulmonary veins are an important source of ectopic beats, initiating frequent paroxysms of atrial fibrillation. These foci respond to treatment with radio-frequency ablation. (N Engl J Med 1998;339:659-66.) (C)1998, Massachusetts Medical Society.	Hop Cardiol Haut Leveque, F-33604 Bordeaux, France	CHU Bordeaux	Haissaguerre, M (corresponding author), Hop Cardiol Haut Leveque, Ave Magellan, F-33604 Bordeaux, France.							ALESSIE MA, 1990, CARDIAC ELECTROPHYSI, P548; AVITALL B, 1994, J AM COLL CARDIOL, V23, pA276; BLOUIN LT, 1991, PACE, V14, P807, DOI 10.1111/j.1540-8159.1991.tb04111.x; COSIO FG, 1993, AM J CARDIOL, V71, P705, DOI 10.1016/0002-9149(93)91014-9; COX JL, 1991, J THORAC CARDIOV SUR, V101, P406, DOI 10.1016/s0022-5223(19)36723-6; COX JL, 1993, ANN THORAC SURG, V56, P814, DOI 10.1016/0003-4975(93)90338-I; DEFAUW JJAMT, 1992, ANN THORAC SURG, V53, P564, DOI 10.1016/0003-4975(92)90312-R; ELVAN A, 1995, CIRCULATION, V91, P2235, DOI 10.1161/01.CIR.91.8.2235; FENELON G, 1997, PACING CLIN ELECTROP, V20, P1095; Garrey WE, 1914, AM J PHYSIOL, V33, P397, DOI 10.1152/ajplegacy.1914.33.3.397; Greenfield Ruth Ann, 1997, P465; HAINES DE, 1993, PACE, V16, P586, DOI 10.1111/j.1540-8159.1993.tb01630.x; HAINES DE, 1995, CIRCULATION, V92, P265; Haissaguerre M, 1996, J CARDIOVASC ELECTR, V7, P1132, DOI 10.1111/j.1540-8167.1996.tb00492.x; HAISSAGUERRE M, 1994, J CARDIOVASC ELECTR, V5, P743, DOI 10.1111/j.1540-8167.1994.tb01197.x; ITO M, 1967, JPN J PHYSIOL, V17, P174; Jais P, 1997, CIRCULATION, V95, P572, DOI 10.1161/01.CIR.95.3.572; JOSEPHSON ME, 1993, CLIN CARDIAC ELECTRO, P96; KONINGS KTS, 1994, CIRCULATION, V89, P1665, DOI 10.1161/01.CIR.89.4.1665; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOSAKAI Y, 1995, CIRCULATION, V92, P359, DOI 10.1161/01.CIR.92.9.359; MOE GK, 1964, AM HEART J, V67, P200, DOI 10.1016/0002-8703(64)90371-0; MORILLO CA, 1995, CIRCULATION, V91, P1588, DOI 10.1161/01.CIR.91.5.1588; NATHAN H, 1966, CIRCULATION, V34, P412, DOI 10.1161/01.CIR.34.3.412; Prystowsky EN, 1996, CIRCULATION, V93, P1262, DOI 10.1161/01.CIR.93.6.1262; SCHEINMAN MM, 1982, JAMA-J AM MED ASSOC, V248, P851, DOI 10.1001/jama.248.7.851; SHYU KG, 1994, J AM COLL CARDIOL, V24, P392, DOI 10.1016/0735-1097(94)90293-3; Sih HJ, 1997, J CARDIOVASC ELECTR, V8, P1046, DOI 10.1111/j.1540-8167.1997.tb00628.x; SPACH MS, 1972, AM J CARDIOL, V30, P844, DOI 10.1016/0002-9149(72)90009-4; WELLENS HJJ, 1994, NEW ENGL J MED, V331, P944, DOI 10.1056/NEJM199410063311413; WEST TC, 1962, AM J PHYSIOL, V202, P232, DOI 10.1152/ajplegacy.1962.202.2.232; WIJFFELS MCEF, 1995, CIRCULATION, V92, P1954, DOI 10.1161/01.CIR.92.7.1954; WILLIAMSON BD, 1995, NEW ENGL J MED, V332, P479; WILLIAMSON BD, 1994, NEW ENGL J MED, V331, P910, DOI 10.1056/NEJM199410063311404; ZIPES DP, 1972, AM J CARDIOL, V29, P372, DOI 10.1016/0002-9149(72)90533-4; ZIPES DP, 1994, CATHETER ABLATION AR, P1; [No title captured]	37	5348	5826	3	262	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					659	666		10.1056/NEJM199809033391003	http://dx.doi.org/10.1056/NEJM199809033391003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115WA	9725923				2022-12-24	WOS:000075688100003
J	de Beer, T; Carter, RE; Lobel-Rice, KE; Sorkin, A; Overduin, M				de Beer, T; Carter, RE; Lobel-Rice, KE; Sorkin, A; Overduin, M			Structure and Asn-Pro-Phe binding pocket of the Eps15 homology domain	SCIENCE			English	Article							TYROSINE KINASE SUBSTRATE; ANGSTROM RESOLUTION; TERMINAL DOMAIN; EH DOMAIN; PROTEIN; NMR; ASSOCIATION	Eps15 homology (EH) domains are eukaryotic signaling modules that recognize proteins containing Asn-Pro-Phe (NPF) sequences. The structure of the central EH domain of Eps15 has been solved by heteronuclear magnetic resonance spectroscopy. The fold consists of a pair of EF hand motifs, the second of Which binds tightly to calcium. The NPF peptide is bound in a hydrophobic pocket between two a helices, and binding is mediated by a critical aromatic interaction as revealed by structure-based mutagenesis. The fold is predicted to be highly conserved among 30 identified EH domains and provides a structural basis for defining EH-mediated events in protein trafficking and growth factor signaling.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Overduin, M (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, 4200 E 9th Ave, Denver, CO 80262 USA.		Overduin, Michael/AAG-3632-2020	Overduin, Michael/0000-0002-3114-6585; Sorkin, Alexander/0000-0002-4446-1920				ALTIERI AS, 1995, J AM CHEM SOC, V117, P7566, DOI 10.1021/ja00133a039; AVANTAGGIATO V, 1995, ONCOGENE, V11, P1191; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BRUNGER AT, 1992, X PLOR VERSION 3 1; Carbone R, 1997, CANCER RES, V57, P5498; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; Cupers P, 1998, J BIOL CHEM, V273, P1847, DOI 10.1074/jbc.273.4.1847; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DiFiore PP, 1997, TRENDS BIOCHEM SCI, V22, P411, DOI 10.1016/S0968-0004(97)01127-4; FALKE JJ, 1994, Q REV BIOPHYS, V27, P219, DOI 10.1017/S0033583500003012; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; Fletcher CM, 1996, J BIOMOL NMR, V8, P292, DOI 10.1007/BF00410328; Haffner C, 1997, FEBS LETT, V419, P175, DOI 10.1016/S0014-5793(97)01451-8; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Kay LE, 1997, BIOCHEM CELL BIOL, V75, P1, DOI 10.1139/o97-023; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Overduin M, 1996, J BIOMOL NMR, V7, P173; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Rogaia D, 1997, CANCER RES, V57, P799; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; Strynadka NCJ, 1997, J MOL BIOL, V273, P238, DOI 10.1006/jmbi.1997.1257; SVENSSON LA, 1992, J MOL BIOL, V223, P601, DOI 10.1016/0022-2836(92)90976-Q; Tebar F, 1997, J BIOL CHEM, V272, P15413, DOI 10.1074/jbc.272.24.15413; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WONG WT, 1995, P NATL ACAD SCI USA, V92, P9530, DOI 10.1073/pnas.92.21.9530; YAMABHAI M, UNPUB; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230	34	109	113	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1357	1360		10.1126/science.281.5381.1357	http://dx.doi.org/10.1126/science.281.5381.1357			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721102				2022-12-24	WOS:000075666800052
J	Schmedt, C; Saijo, K; Niidome, T; Kuhn, R; Aizawa, S; Tarakhovsky, A				Schmedt, C; Saijo, K; Niidome, T; Kuhn, R; Aizawa, S; Tarakhovsky, A			Csk controls antigen receptor-mediated development and selection of T-lineage cells	NATURE			English	Article							THYMOCYTE DEVELOPMENT; TYROSINE KINASES; DEFICIENT MICE; GENE; INHIBITION; LCK; DISRUPTION; EXPRESSION; MATURATION; TRANSGENE	The development and function of alpha beta T lymphocytes depend on signals derived from pre-T and alpha beta T cell receptors (preTCR and alpha beta TCR) (reviewed in refs 1, 2). The engagement of these receptors leads to the activation of Lck and Fyn(3,4), which are protein tyrosine kinases (PTKs) of the Src family. It remains unclear to what extent the activation of Src-family PTKs can direct the differentiation steps triggered by preTCR and alpha beta TCR. Here we show that the inactivation of the negative regulator of Src-family PTKs, carboxy-terminal Src kinase (Csk)(5), in immature thymocytes abrogates the requirement for preTCR, alpha beta TCR and major histocompatibility complex (MHC) class II for the development of CD4(+)8(+) double-positive and CD4(+) single-positive thymocytes as well as peripheral CD4 alpha beta T-lineage cells. These data show that Csk and its substrates are required to establish preTCR/alpha beta TCR-mediated control over the development of alpha beta T cells.	Univ Cologne, Lab Lymphocyte Signalling, D-50931 Cologne, Germany; Univ Cologne, Inst Genet, Dept Immunol, D-50931 Cologne, Germany; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Dept Morphogenesis, Kumamoto 860, Japan	University of Cologne; University of Cologne; Kumamoto University	Tarakhovsky, A (corresponding author), Univ Cologne, Lab Lymphocyte Signalling, Weyertal 121, D-50931 Cologne, Germany.	sasha@mac.genetik.uni-koeln.de	Kühn, Ralf/U-1278-2017	Kühn, Ralf/0000-0003-1694-9803				AlberolaIla J, 1997, ANNU REV IMMUNOL, V15, P125, DOI 10.1146/annurev.immunol.15.1.125; ANDERSON SJ, 1992, EMBO J, V11, P4877, DOI 10.1002/j.1460-2075.1992.tb05594.x; GOSGROVE D, 1991, CELL, V66, P1051; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; GRUSBY MJ, 1991, SCIENCE, V253, P1417, DOI 10.1126/science.1910207; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; KONTGEN F, 1993, INT IMMUNOL, V5, P957, DOI 10.1093/intimm/5.8.957; Krotkova A, 1997, J EXP MED, V186, P767, DOI 10.1084/jem.186.5.767; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; Mombaerts P, 1995, Int Rev Immunol, V13, P43, DOI 10.3109/08830189509061737; MOMBAERTS P, 1994, IMMUNITY, V1, P261, DOI 10.1016/1074-7613(94)90077-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Moore TA, 1996, J IMMUNOL, V157, P2366; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Norment AM, 1997, J EXP MED, V185, P121, DOI 10.1084/jem.185.1.121; Saijo K, 1997, J EXP MED, V185, P351, DOI 10.1084/jem.185.2.351; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; Torres RM, 1997, LAB PROTOCOLS CONDIT; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; vonBoehmer H, 1997, ANNU REV IMMUNOL, V15, P433, DOI 10.1146/annurev.immunol.15.1.433; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILSON A, 1988, CELL IMMUNOL, V117, P312, DOI 10.1016/0008-8749(88)90121-9	29	118	120	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					901	904		10.1038/29802	http://dx.doi.org/10.1038/29802			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732874				2022-12-24	WOS:000075611800051
J	Burns, MA; Johnson, BN; Brahmasandra, SN; Handique, K; Webster, JR; Krishnan, M; Sammarco, TS; Man, PM; Jones, D; Heldsinger, D; Mastrangelo, CH; Burke, DT				Burns, MA; Johnson, BN; Brahmasandra, SN; Handique, K; Webster, JR; Krishnan, M; Sammarco, TS; Man, PM; Jones, D; Heldsinger, D; Mastrangelo, CH; Burke, DT			An integrated nanoliter DNA analysis device	SCIENCE			English	Article							STRAND DISPLACEMENT AMPLIFICATION; CAPILLARY ELECTROPHORESIS; CHIPS; SEPARATIONS; PCR	A device was developed that uses microfabricated fluidic channels, heaters, temperature sensors, and fluorescence detectors to analyze nanoliter-size DNA samples. The device is capable of measuring aqueous reagent and DNA-containing solutions, mixing the solutions together, amplifying or digesting the DNA to form discrete products, and separating and defecting those products. No external Lenses, heaters, or mechanical pumps are necessary for complete sample processing and analysis. Because all of the components are made using conventional photolithographic production techniques, they operate as a single closed system. The components have the potential for assembly into complex, low-power, integrated analysis systems at Low unit cost, The availability of portable, reliable instruments may facilitate the use of DNA analysis in applications such as rapid medical diagnostics and point-of-use agricultural testing.	Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biomed Engn & Chem Engn, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Burns, MA (corresponding author), Univ Michigan, Dept Chem Engn, Ann Arbor, MI 48109 USA.		Krishnan, Madhavi/J-4217-2015	Krishnan, Madhavi/0000-0003-1274-7155; Burke, David/0000-0002-2564-7949	NHGRI NIH HHS [R01-HG01044, R01-HG01406] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001406, R01HG001044] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Arlinghaus HF, 1997, ANAL CHEM, V69, P3747, DOI 10.1021/ac970267p; Boysen C, 1997, BIOTECHNIQUES, V23, P978, DOI 10.2144/97236bm01; Burke DT, 1997, GENOME RES, V7, P189, DOI 10.1101/gr.7.3.189; Burns MA, 1996, P NATL ACAD SCI USA, V93, P5556, DOI 10.1073/pnas.93.11.5556; Chee M, 1996, SCIENCE, V274, P610, DOI 10.1126/science.274.5287.610; EFFENHAUSER CS, 1994, ANAL CHEM, V66, P2949, DOI 10.1021/ac00090a024; Effenhauser CS, 1997, ANAL CHEM, V69, P3451, DOI 10.1021/ac9703919; GIBBS RA, 1995, NAT GENET, V11, P121, DOI 10.1038/ng1095-121; Hadd AG, 1997, ANAL CHEM, V69, P3407, DOI 10.1021/ac970192p; Handique K, 1997, P SOC PHOTO-OPT INS, V3224, P185, DOI 10.1117/12.284515; HARRISON DJ, 1993, SCIENCE, V261, P895, DOI 10.1126/science.261.5123.895; JACOBSON SC, 1994, ANAL CHEM, V66, P3472, DOI 10.1021/ac00092a027; Marra MA, 1997, GENOME RES, V7, P1072, DOI 10.1101/gr.7.11.1072; McCormick RM, 1997, ANAL CHEM, V69, P2626, DOI 10.1021/ac9701997; MEASROS JM, 1993, ANAL CHEM, V65, P3313; OLSON MV, 1995, SCIENCE, V270, P394, DOI 10.1126/science.270.5235.394; Shoffner MA, 1996, NUCLEIC ACIDS RES, V24, P375, DOI 10.1093/nar/24.2.375; Simpson PC, 1998, P NATL ACAD SCI USA, V95, P2256, DOI 10.1073/pnas.95.5.2256; Sosnowski RG, 1997, P NATL ACAD SCI USA, V94, P1119, DOI 10.1073/pnas.94.4.1119; Spargo CA, 1996, MOL CELL PROBE, V10, P247, DOI 10.1006/mcpr.1996.0034; WALKER GT, 1992, NUCLEIC ACIDS RES, V20, P1691, DOI 10.1093/nar/20.7.1691; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Wilson RK, 1997, GENOME ANAL, V1, P301; Woolley AT, 1996, ANAL CHEM, V68, P4081, DOI 10.1021/ac960718q; Woolley AT, 1998, ANAL CHEM, V70, P684, DOI 10.1021/ac971135z; WOOLLEY AT, 1995, ANAL CHEM, V67, P3676, DOI 10.1021/ac00116a010; WOOLLEY AT, 1994, P NATL ACAD SCI USA, V91, P11348, DOI 10.1073/pnas.91.24.11348	27	1129	1392	2	201	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					484	487		10.1126/science.282.5388.484	http://dx.doi.org/10.1126/science.282.5388.484			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774277				2022-12-24	WOS:000076479600057
J	Hanna, Z; Kay, DG; Rebai, N; Guimond, A; Jothy, S; Jolicoeur, P				Hanna, Z; Kay, DG; Rebai, N; Guimond, A; Jothy, S; Jolicoeur, P			Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice	CELL			English	Article							DOWN-REGULATION; TAT PROTEIN; INFECTION; GENE; CD4; PROLIFERATION; MACROPHAGES; LYMPHOCYTES; EXPRESSION; APOPTOSIS	Transgenic (Tg) mice expressing the complete coding sequences of HIV-1 in CD4(+) T cells and in cells of the macrophage/dendritic lineages develop severe AIDS-like pathologies: failure to thrive/weight loss, diarrhea, wasting, premature death, thymus atrophy, loss of CD4(+) T cells, interstitial pneumonitis, and tubulo-interstitial nephritis. The generation of Tg mice expressing selected HIV-1 gene(s) revealed that nef harbors a major disease determinant. The latency and progression (fast/slow) of the disease were strongly correlated with the levels of Tg expression. Nef-expressing Tg thymocytes were activated and alpha-CD3 hyperresponsive with respect to tyrosine phosphorylation of several substrates, including LAT and MAPK. The similarity of this mouse model to human AIDS, particularly pediatric AIDS, suggests that Nef may play a critical role in human AIDS, independently of its role in virus replication.	Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Microbiol & Immunol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Dept Pathol, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Expt Med, Montreal, PQ H3G 1A4, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5G 1L5, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; McGill University; University of Toronto	Jolicoeur, P (corresponding author), Clin Res Inst Montreal, Mol Biol Lab, Montreal, PQ H2W 1R7, Canada.							BRADY HJM, 1993, EMBO J, V12, P4923, DOI 10.1002/j.1460-2075.1993.tb06186.x; CALVELLI T A, 1990, Immunodeficiency Reviews, V2, P83; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COODLEY GO, 1994, J ACQ IMMUN DEF SYND, V7, P681; DEACON NJ, 1995, SCIENCE, V270, P988, DOI 10.1126/science.270.5238.988; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P343, DOI 10.1089/aid.1994.10.343; Goudreau G, 1996, NAT MED, V2, P655, DOI 10.1038/nm0696-655; Greenway A, 1996, J VIROL, V70, P6701, DOI 10.1128/JVI.70.10.6701-6708.1996; Hanna Z, 1998, J VIROL, V72, P121, DOI 10.1128/JVI.72.1.121-132.1998; HANNA Z, 1994, MOL CELL BIOL, V14, P1084, DOI 10.1128/MCB.14.2.1084; Harris M, 1996, J GEN VIROL, V77, P2379, DOI 10.1099/0022-1317-77-10-2379; Herskowitz A, 1996, CURR OPIN CARDIOL, V11, P325, DOI 10.1097/00001573-199605000-00013; Ho DD, 1996, SCIENCE, V272, P1124, DOI 10.1126/science.272.5265.1124; HUANG M, 1991, J VIROL, V65, P6562, DOI 10.1128/JVI.65.12.6562-6571.1991; Iafrate AJ, 1997, EMBO J, V16, P673, DOI 10.1093/emboj/16.4.673; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLOTMAN PE, 1995, AIDS, V9, P313, DOI 10.1097/00002030-199509040-00001; KROEMER G, 1995, ADV IMMUNOL, V58, P211, DOI 10.1016/S0065-2776(08)60621-5; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; LINDEMANN D, 1994, J EXP MED, V179, P797, DOI 10.1084/jem.179.3.797; McSherry G D, 1996, Semin Respir Infect, V11, P173; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; SKOWRONSKI J, 1993, EMBO J, V12, P703, DOI 10.1002/j.1460-2075.1993.tb05704.x; VISCIDI RP, 1989, SCIENCE, V246, P1606, DOI 10.1126/science.2556795; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS TW, 1992, MOL BIOTHER, V4, P66; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	35	395	400	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					163	175		10.1016/S0092-8674(00)81748-1	http://dx.doi.org/10.1016/S0092-8674(00)81748-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790524	Bronze			2022-12-24	WOS:000076538300005
J	Donaldson, GC; Ermakov, SP; Komarov, YM; McDonald, CP; Keatinge, WR				Donaldson, GC; Ermakov, SP; Komarov, YM; McDonald, CP; Keatinge, WR			Cold related mortalities and protection against cold in Yakutsk, eastern Siberia: observation and interview study	BRITISH MEDICAL JOURNAL			English	Article							PLASMA-FIBRINOGEN; BODY-TEMPERATURE; DISEASE; WINTER; DEATH; INCREASES; PRESSURE; CORONARY; AIR	Objective To assess how effectively measures adopted in extreme cold in Yakutsk control winter mortality. Design interviews to assess outdoor clothing and measure indoor temperatures; regressions of these and of delayed cause-specific mortalities on temperature. Setting Yakutsk, east Siberia, Russia Subjects: AU people aged 50-59 and 65-74 years living within 400 km of Yakutsk during 1989-95 and sample of 1002 men and women who agreed to be interviewed. Main outcome measures Daily mortality from all causes and from ischaemic heart, cerebrovascular, and respiratory disease. Results Mean temperature for October-March 1989-95 was - 26.6 degrees C. At 10.2 degrees C people wore 3.30 (95% confidence interval 3.08 to 3.53) layers ofclothing outdoors, increasing to 4.39 (4.13 to 4.66; P < 0.0001) layers at - 20 degrees C. Thick coats, often of fur, replaced anoraks as temperature fell to - 48.2 degrees C, 82% of people went out each day when temperatures were 10.2 degrees C to - 20 degrees C, but below - 20 degrees C the proportion fell steadily to 44% (35% to 53%) at -48.2 degrees C (P < 0.001), and overall shivering outdoors did not increase. Living room temperature was 17.9 (17.2 to 18.5)degrees C at 10.2 degrees C outdoors, 19.6 (18.8 to 20.4)degrees C at - 20 degrees C, and 19.1 (18.6 to 19.6)degrees C at -48.2 degrees C. Mortality from all causes and from ischaemic heart and respiratory disease was unaffected by the fall in temperature. Mortality from respiratory disease (daily deaths per million) rose from 4.7 (4.3 to 5.1) to 5.1 (4.4 to 5.7) (P = 0.03), but this was offset by a fall in deaths from injury Conclusions People in Yakutsk wore very warm clothing, and in extremely cold weather stayed indoors in warm housing preventing the increases in mortality seen in winter in milder regions of the world. Only respiratory mortality rose, perhaps because of breathing cold air.	Univ London Queen Mary & Westfield Coll, Dept Physiol, London E1 4NS, England; Minist Publ Hlth Russia, Publ Hlth Res Inst, Moscow 127254, Russia; Peckwater, Res, Surrey GU15 2LY, England	University of London; Queen Mary University London	Keatinge, WR (corresponding author), Univ London Queen Mary & Westfield Coll, Dept Physiol, Mile End Rd, London E1 4NS, England.	wr.keatinge@qmw.ac.uk	Ermakov, Sergey/G-1709-2016; Donaldson, Gavin/M-7992-2017	Ermakov, Sergey/0000-0003-1072-1162; Donaldson, Gavin/0000-0002-5538-4190	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BULL G M, 1978, Age and Ageing, V7, P210, DOI 10.1093/ageing/7.4.210; COLLINS KJ, 1985, CLIN SCI, V69, P465, DOI 10.1042/cs0690465; Donaldson GC, 1997, J EPIDEMIOL COMMUN H, V51, P643, DOI 10.1136/jech.51.6.643; Donaldson GC, 1998, BRIT MED J, V316, P514, DOI 10.1136/bmj.316.7130.514; ESCHENBACHER WL, 1992, LUNG, V170, P51, DOI 10.1007/BF00164755; FARB A, 1995, CIRCULATION, V92, P1701, DOI 10.1161/01.CIR.92.7.1701; FROST DB, 1992, INT J BIOMETEOROL, V36, P14, DOI 10.1007/BF01208729; GIESBRECHT GG, 1995, AVIAT SPACE ENVIR MD, V66, P890; GRAY PG, 1950, J ROY STAT SOC A STA, V113, P150, DOI 10.2307/2981039; HAYWARD MG, 1981, J PHYSIOL-LONDON, V320, P229, DOI 10.1113/jphysiol.1981.sp013946; HEUNIS JC, 1995, S AFR MED J, V85, P1016; HILL L, 1928, LANCET, V1, P802; Keatinge WR, 1997, LANCET, V349, P1341, DOI 10.1016/S0140-6736(96)12338-2; KEATINGE WR, 1984, BMJ-BRIT MED J, V289, P1405, DOI 10.1136/bmj.289.6456.1405; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; LEWIS C, 1970, OXFORD ATLAS, P11; LOVETT AA, 1986, SOC SCI MED, V23, P935, DOI 10.1016/0277-9536(86)90251-0; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564, DOI 10.1152/jappl.1985.58.2.564; NEILD PJ, 1994, CLIN SCI, V86, P43, DOI 10.1042/cs0860043; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; YOSHIHARA S, 1995, AM J RESP CRIT CARE, V151, P1011	21	65	67	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 10	1998	317	7164					978	982		10.1136/bmj.317.7164.978	http://dx.doi.org/10.1136/bmj.317.7164.978			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129EA	9765165	Green Submitted, Green Published, Bronze			2022-12-24	WOS:000076449300022
J	Hoekstra, EJ; LeBaron, CW; Megaloeconomou, Y; Guerrero, H; Byers, C; Johnson-Partlow, T; Lyons, B; Mihalek, E; Devier, J; Mize, J				Hoekstra, EJ; LeBaron, CW; Megaloeconomou, Y; Guerrero, H; Byers, C; Johnson-Partlow, T; Lyons, B; Mihalek, E; Devier, J; Mize, J			Impact of a large-scale immunization initiative in the special supplemental nutrition program for women, infants, and children (WIC)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRESCHOOL-CHILDREN; UNITED-STATES; MEASLES; EPIDEMIC; RATES	Context.-Inner-city immunization rates have lagged behind those in other areas of the country. Objective.-To evaluate the impact of an initiative linking immunization with distribution of food vouchers in the inner city, Design.-Retrospective analysis of immunization data gathered in 1996 and 1997, Setting.-Nineteen Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) sites serving 30% of the Chicago, III, birth cohort, Participants.-A total of 16581 children 24 months old or younger. Interventions.-voucher incentives (varying frequency of food voucher issuance based on immunization status) and assessment of immunization status and referral to immunization provider. Main Outcome Measures.-Age-appropriate immunization rates and WIC enrollment rates. Results.-During the 15-month period of evaluation, immunization rates increased from 56% to 89% at sites performing voucher incentives. The proportion of children needing voucher incentives declined from 51% to 12%, Sites performing assessment and referral, but not providing voucher incentives, showed no evidence of improvement in immunization coverage. No difference was observed in enrollment rates between sites performing voucher incentives and those that did not, Conclusion.-Applied in a large-scale, programmatic fashion, voucher incentives in WIC can rapidly increase and sustain high childhood immunization rates in an inner-city population.	Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA 30333 USA; Catholic Charities, Chicago, IL USA; Chicago Dept Publ Hlth, Chicago Immunizat Program, Chicago, IL USA; Special Supplemental Nutr Program Women Infants &, Chicago, IL USA	Centers for Disease Control & Prevention - USA; Chicago Department of Public Health	LeBaron, CW (corresponding author), Ctr Dis Control & Prevent, Natl Immunizat Program, MS E-61, Atlanta, GA 30333 USA.			Lyons, Bridget/0000-0003-1152-9439				BIRKHEAD GS, 1995, JAMA-J AM MED ASSOC, V274, P312, DOI 10.1001/jama.274.4.312; *CDC, 1990, MMWR-MORBID MORTAL W, V40, P317; *CDC, 1991, MMWR-MORBID MORTAL W, V40, P369; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P176; *CDCP, 1995, MMWR-MORBID MORTAL W, V44, P613; Centers for Disease Control and Prevention (CDC), 1996, MMWR Morb Mortal Wkly Rep, V45, P217; Flatt K, 1996, 124 ANN M EXP AM PUB; GINDLER JS, 1992, PEDIATR INFECT DIS J, V11, P841, DOI 10.1097/00006454-199210000-00007; Goldstein KP, 1996, JAMA-J AM MED ASSOC, V276, P56, DOI 10.1001/jama.276.1.56; Hutchins S, 1996, PEDIATR INFECT DIS J, V15, P31, DOI 10.1097/00006454-199601000-00007; HUTCHINS SS, 1993, AM J PUBLIC HEALTH, V83, P862, DOI 10.2105/AJPH.83.6.862; HUTCHINS SS, 1995, P 28 NAT IMM C ATL G, P1; Kenyon TA, 1998, PEDIATRICS, V101, P612, DOI 10.1542/peds.101.4.612; LeBaron CW, 1997, JAMA-J AM MED ASSOC, V277, P631, DOI 10.1001/jama.277.8.631; LeBaron CW, 1996, AM J PUBLIC HEALTH, V86, P1551, DOI 10.2105/AJPH.86.11.1551; SCHLENKER TL, 1992, JAMA-J AM MED ASSOC, V267, P823, DOI 10.1001/jama.267.6.823; Shefer A, 1996, J Public Health Manag Pract, V2, P34; Shefer A, 1998, ARCH PEDIAT ADOL MED, V152, P65; WOOD DL, 1997, 37 ANN AM AMB PED AS	19	45	45	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1143	1147		10.1001/jama.280.13.1143	http://dx.doi.org/10.1001/jama.280.13.1143			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777813	Bronze			2022-12-24	WOS:000076210800027
J	Hurt, RD; Robertson, CR				Hurt, RD; Robertson, CR			Prying open the door to the tobacco industry's secrets about nicotine - The Minnesota Tobacco Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							WILLIAMSON DOCUMENTS; LAWYER CONTROL; ADDICTION	In 1994 the state of Minnesota filed suit against the tobacco industry, This trial is now history, but its legacy will carry on into the 21st century because of the revelations contained in the millions of pages of previously secret internal tobacco industry documents made public in the trial. In this article, we review representative documents relating to nicotine addiction, low-tar, low-nicotine cigarettes, and cigarette design and nicotine manipulation in cigarette manufacture. These documents reveal that for decades, the industry knew and internally acknowledged that nicotine is an addictive drug and cigarettes are the ultimate nicotine delivery device; that nicotine addiction can be perpetuated and even enhanced through cigarette design alterations and manipulations; and that "health-conscious" smokers could be captured by low-tar, low-nicotine products, all the while ensuring the marketplace viability of their products. Appreciation of tobacco industry strategies over the past decades is essential to formulate an appropriate legislative and public policy response. We propose key elements for such legislation and urge no legal or financial immunity for the tobacco industry.	Mayo Clin & Mayo Fdn, Nicotine Dependence Ctr, Rochester, MN 55905 USA; Stanford Univ, Sch Engn, Dept Chem Engn, Stanford, CA 94305 USA	Mayo Clinic; Stanford University	Hurt, RD (corresponding author), Mayo Clin & Mayo Fdn, Nicotine Dependence Ctr, 200 1st St SW, Rochester, MN 55905 USA.							[Anonymous], 1971, COMMUNICATION; AYRES CI, 1984, P SMOK BEH MARK C 3; BARNES DE, 1995, JAMA-J AM MED ASSOC, V274, P248, DOI 10.1001/jama.274.3.248; BENOWITZ NL, 1994, NEW ENGL J MED, V331, P123, DOI 10.1056/NEJM199407143310212; BENOWITZ NL, 1983, NEW ENGL J MED, V309, P139, DOI 10.1056/NEJM198307213090303; BENTLEY HR, 1958, BAT             0417; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P241, DOI 10.1001/jama.274.3.241; BLACKHURST JD, 1966, WORK EXTRACTABLE NIC; BROOKS GO, 1982, COMMUNICATION   0407; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1043; CHEN L, 1976, PH SMOKE REV; COLBY FG, 1981, COMMUNICATION   1209; COLBY FG, 1973, COMMUNICATION   1204; CREIGHTON DE, 1988, SIGNIFICANCE PH TOBA; CREIGHTON DE, 1978, COMPENSATION CHANGED; CRELLIN RA, 1980, BRAINSTORMING, V2; *DEP HLTH UK, 1998, REP SCI COMM TOB HLT, P9; DOLL R, 1950, BRIT MED J, V2, P739, DOI 10.1136/bmj.2.4682.739; DUKES CA, 1974, COMMUNICATION   0930; Dunn W.L., 1972, MOTIVES INCENTIVES C; DUNN WL, 1980, COMMUNICATION   0324; DUNN WL, 1980, COMMUNICATION   0321; DUNN WL, 1969, COMMUNICATION   0219; ELLIS C, 1962, BAT             0213; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V274, P219, DOI 10.1001/jama.274.3.219; Goodman B., 1975, MARLBORO MARLBORO LI; GREEN SJ, 1976, PRODUCT EARLY 1980S; GREGORY CF, 1980, OBSERVATIONS FREE NI; GREIG CC, STRUCTURED CREATIVIT; GRIFFITH RB, 1963, COMMUNICATION   0918; GUESS HE, 1980, COMMUNICATION   0205; HANAUER P, 1995, JAMA-J AM MED ASSOC, V274, P234; HANNERS D, 1998, ST PAUL PIONEER 0215, pA12; HANNERS D, 1998, ST PAUL PIONEER 0215, pA1; HENNINGFIELD JE, 1993, J CONSULT CLIN PSYCH, V61, P743, DOI 10.1037/0022-006X.61.5.743; HIND JF, 1975, COMMUNICATION   0123; HIRJI T, 1987, COMMUNICATION   0723; IHRIG AM, 1973, COMMUNICATION   0208; JOHNSON RL, 1973, COMMUNICATION   0221; JOHNSON RR, 1989, AMM TECHN C MIN LOUI; KNOPICK P, 1980, COMMUNICATION   0909; Koop CE, 1998, JAMA-J AM MED ASSOC, V279, P550, DOI 10.1001/jama.279.7.550; Kozlowski L T, 1996, Tob Control, V5, P265, DOI 10.1136/tc.5.4.265; LAURENE AH, 1971, COMMUNICATION   0524; LONG GH, 1980, COMMUNICATION   0722; MACKENZIE JL, 1976, COMMUNICATION   0921; MCCORMICK AD, 1974, SMOKNG HLTH; MELLMAN AJ, 1983, COMMUNICATION   0325; *NOWL ORG INC, 1976, SHF CIG MARK OPP SEA; OLDMAN M, 1991, PRODUCTS CONSUMER IN; OLDMAN M, 1979, CIGARETTE SMOKING HL; OSDENE TS, 1980, COMMUNICATION   0812; OSDENE TS, 1978, COMMUNICATION   0110; *P MORR, 1994, EFF CIG SMOK PH NIC; PANZER F, 1972, COMMUNICATION   0501; PEPLES E, 1977, COMMUNICATION; RIEHL T, 1984, PROJECT SHIP REV PRO; *RJR, 1992, RJR BIOS GEN JOINT R; ROBERTS DL, 1983, COMMUNICATION   1013; ROBINSON JH, 1992, PSYCHOPHARMACOLOGY, V108, P411, DOI 10.1007/BF02247414; ROBINSON JH, 1983, COMMUNICATION   0725; RODGMAN A, 1980, COMMUNICATION   0908; Schori TR, 1979, FREE NICOTINE ITS IM; SCHUMACHER S, 1977, NICOTINE SMOKER SATI; SENKUS M, 1969, COMMUNICATION; SHAFFER D, 1998, EXTOBACCO RES TAKES; SHORT A, 1971, NEW PRODUCT; SHORT PL, 1977, COMMUNICATION   0414; SHORT PL, 1977, COMMUNICATION   0428; SLADE J, 1995, JAMA-J AM MED ASSOC, V274, P225, DOI 10.1001/jama.274.3.225; SLAVEN RW, 1982, PROGR REPORT NICOTIN; SMITH RE, 1980, COMMUNICATION   0213; STANFORD JE, 1993, COMMUNICATION   1202; STEELE HD, 1978, COMMUNICATION   0824; TEAGUE CE, 1972, COMMUNICATION   0414; TEAGUE CE, 1973, IMPLICATIONS ACTIVIT; *TOB IND RES COMM, 1954, TOC IND RES COMM M J; TODD JS, 1995, JAMA-J AM MED ASSOC, V274, P256, DOI 10.1001/jama.274.3.256; *US DEP HHS, 1988, PUBL CDC; *US DHHS, 1996, NIH PUBL US DEP HLTH; WILLIAMS RK, 1971, DEV CIGARETTE INCREA; WOOD DJ, 1977, SMOKING PRODUCTS RES; Woods J.D., 1973, HIST REV SMOKE PH DA; WOODS JD, 1975, 4 RDM; WYNDER EL, 1950, JAMA-J AM MED ASSOC, V143, P329, DOI 10.1001/jama.1950.02910390001001; WYNDER EL, 1953, CANCER RES, V13, P855; 1984, P SMOK BEH MARK C JU	87	156	185	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1173	1181		10.1001/jama.280.13.1173	http://dx.doi.org/10.1001/jama.280.13.1173			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777818				2022-12-24	WOS:000076210800032
J	Klement, IA; Skinner, PJ; Kaytor, MD; Yi, H; Hersch, SM; Clark, HB; Zoghbi, HY; Orr, HT				Klement, IA; Skinner, PJ; Kaytor, MD; Yi, H; Hersch, SM; Clark, HB; Zoghbi, HY; Orr, HT			Ataxin-1 nuclear localization and aggregation: Role in polyglutamine-induced disease in SCA1 transgenic mice	CELL			English	Article							NEURONAL INTRANUCLEAR INCLUSIONS; PALLIDOLUYSIAN ATROPHY DRPLA; MACHADO-JOSEPH DISEASE; CAG REPEAT; EXPANDED POLYGLUTAMINE; NEUROLOGICAL PHENOTYPE; TRINUCLEOTIDE REPEAT; PROTEIN; GENE; EXPANSION	Transgenic mice carrying the spinocerebellar ataxia type 1 (SCA1) gene, a polyglutamine neurodegenerative disorder, develop ataxia with ataxin-l localized to aggregates within cerebellar Purkinje cells nuclei. To examine the importance of nuclear localization and aggregation in pathogenesis, mice expressing ataxin-1[82] with a mutated NLS were established. These mice did not develop disease, demonstrating that nuclear localization is critical for pathogenesis. In a second series of transgenic mice, ataxin-1[77] containing a deletion within the self-association region was expressed within Purkinje cells nuclei. These mice developed ataxia and Purkinje cell pathology similar to the original SCA1 mice. However, no evidence of nuclear ataxin-l aggregates was found. Thus, although nuclear localization of ataxin-1 is necessary, nuclear aggregation of ataxin-l is not required to initiate pathogenesis in transgenic mice.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Dept Mol & Human Genet, Houston, TX 77030 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Emory University; Baylor College of Medicine; Howard Hughes Medical Institute; Baylor College of Medicine; Howard Hughes Medical Institute	Orr, HT (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.	harry@lenti.med.umn.edu		Skinner, Pamela/0000-0003-3388-1687; Zoghbi, Huda/0000-0002-0700-3349; Orr, Harry/0000-0001-6118-741X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035255, R01NS022920, R37NS022920, R01NS027699] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35255, NS27699, NS22920] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Becher MW, 1997, MOVEMENT DISORD, V12, P519, DOI 10.1002/mds.870120408; BISOTTO S, 1995, J CELL SCI, V108, P1873; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Burright EN, 1997, HUM MOL GENET, V6, P513, DOI 10.1093/hmg/6.4.513; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark HB, 1997, J NEUROSCI, V17, P7385; Colomer V, 1997, HUM MOL GENET, V6, P1519, DOI 10.1093/hmg/6.9.1519; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; FRANGIONI JV, 1993, J CELL SCI, V105, P481; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; Koob MD, 1998, NAT GENET, V18, P72, DOI 10.1038/ng0198-72; Koshy B, 1996, HUM MOL GENET, V5, P1311, DOI 10.1093/hmg/5.9.1311; LA SA, 1991, NATURE, V352, P77; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; MATILLA A, 1998, IN PRESS J NEUROSCI; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; Ordway JM, 1997, CELL, V91, P753, DOI 10.1016/S0092-8674(00)80464-X; Orr HT, 1996, COLD SPRING HARB SYM, V61, P649; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; QUINLAN MP, 1984, CELL, V36, P857, DOI 10.1016/0092-8674(84)90035-7; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SERVADIO A, 1995, NAT GENET, V10, P94, DOI 10.1038/ng0595-94; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wellington CL, 1998, J BIOL CHEM, V273, P9158, DOI 10.1074/jbc.273.15.9158; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404; YI H, 1997, RECEPTOR LOCALIZATIO, P107	49	820	849	2	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					41	53		10.1016/S0092-8674(00)81781-X	http://dx.doi.org/10.1016/S0092-8674(00)81781-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778246	Bronze			2022-12-24	WOS:000076242300009
J	Yamashita, A; Watanabe, Y; Nukina, N; Yamamoto, M				Yamashita, A; Watanabe, Y; Nukina, N; Yamamoto, M			RNA-assisted nuclear transport of the meiotic regulator Mei2p in fission yeast	CELL			English	Article							PREMEIOTIC DNA-SYNTHESIS; SCHIZOSACCHAROMYCES-POMBE; MEIOSIS; PROTEIN; GENE; TELOMERES; PROPHASE; IDENTIFICATION; TRANSCRIPTION; CENTROMERES	Fission yeast Mei2p is an RNA-binding protein required for both premeiotic DNA synthesis and meiosis I. Mei2p binds to a polyadenylated RNA molecule, meiRNA, loss of which blocks meiosis I. Mei2p forms a dot in meiotic prophase nuclei. Here, we show that meiRNA is required for the nuclear localization of Mei2p and is detectable in the dot. However, Mei2p carrying a nuclear localization signal can produce a nuclear dot and promote meiosis I in the absence of meiRNA. Mei2p expressed in cultured mammalian cells stays in the cytoplasm, but it accumulates in the nucleolus if meiRNA is coexpressed. These results indicate that meiRNA contributes to the promotion of meiosis I exclusively as a cofactor that assists nuclear transport of Mei2p.	Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan; RIKEN, Inst Phys & Chem Res, Brain Sci Inst, Wako, Saitama 3510198, Japan	University of Tokyo; RIKEN	Yamamoto, M (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biochem & Biophys, Tokyo 1130033, Japan.	myamamot@ims.u-tokyo.ac.jp	Nukina, Nobuyuki/GPP-6265-2022; Yamashita, Akira/A-5278-2015	Yamashita, Akira/0000-0002-1805-1434; Watanabe, Yoshinori/0000-0002-5488-4812				ARIS JP, 1988, J CELL BIOL, V107, P17, DOI 10.1083/jcb.107.1.17; BAHLER J, 1993, J CELL BIOL, V121, P241, DOI 10.1083/jcb.121.2.241; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bass HW, 1997, J CELL BIOL, V137, P5, DOI 10.1083/jcb.137.1.5; CHIKASHIGE Y, 1994, SCIENCE, V264, P270, DOI 10.1126/science.8146661; Chikashige Y, 1997, EMBO J, V16, P193, DOI 10.1093/emboj/16.1.193; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; FISCHER U, 1990, SCIENCE, V249, P786, DOI 10.1126/science.2143847; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; FUSSELL C P, 1987, P275; Gebauer F, 1997, BIOESSAYS, V19, P23, DOI 10.1002/bies.950190106; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gutz H., 1974, HDB GENETICS, V1, P395; HAGAN I, 1995, J CELL BIOL, V129, P1033, DOI 10.1083/jcb.129.4.1033; HAGAN IM, 1988, J CELL SCI, V89, P343; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HELM R, 1995, NATURE, V373, P663; IINO Y, 1995, GENETICS, V140, P1235; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KOHLI J, 1994, EXPERIENTIA, V50, P295, DOI 10.1007/BF01924013; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Kupiec M., 1997, MOL CELLULAR BIOL YE, P889; Li P, 1996, CELL, V87, P869, DOI 10.1016/S0092-8674(00)81994-7; LIN Y, 1992, GENETICS, V132, P75; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; MOLNAR M, 1995, GENETICS, V141, P61; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; ROBINOW CF, 1977, GENETICS, V87, P491; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; Sagata N, 1997, BIOESSAYS, V19, P13, DOI 10.1002/bies.950190105; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Sherman F., 1986, METHODS YEAST GENETI; SHIMODA C, 1987, J BACTERIOL, V169, P93, DOI 10.1128/jb.169.1.93-96.1987; Stutz F, 1997, GENE DEV, V11, P2857, DOI 10.1101/gad.11.21.2857; SVOBODA A, 1995, CHROMOSOMA, V104, P203, DOI 10.1007/s004120050109; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; UZAWA S, 1992, J CELL SCI, V101, P267; WATANABE Y, 1994, CELL, V78, P487, DOI 10.1016/0092-8674(94)90426-X; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x; Watanabe Y, 1997, NATURE, V386, P187, DOI 10.1038/386187a0; Yamamoto M., 1997, MATING SPORULATION S, P1037; Yamashita A, 1997, GENES CELLS, V2, P155, DOI 10.1046/j.1365-2443.1997.1100307.x	44	95	98	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					115	123		10.1016/S0092-8674(00)81787-0	http://dx.doi.org/10.1016/S0092-8674(00)81787-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778252	Bronze			2022-12-24	WOS:000076242300015
J	Zeng, Y; Forbes, KC; Wu, ZQ; Moreno, S; Piwnica-Worms, H; Enoch, T				Zeng, Y; Forbes, KC; Wu, ZQ; Moreno, S; Piwnica-Worms, H; Enoch, T			Replication checkpoint requires phosphorylation of the phosphatase Cdc25 by Cds1 or Chk1	NATURE			English	Article							DNA-DAMAGE CHECKPOINT; FISSION YEAST; MITOTIC INDUCER; PROTEIN-KINASE; S-PHASE; MITOSIS; SERINE-216; THIAMINE; PATHWAY; GENE	Checkpoints maintain the order and fidelity of events of the cell cycle by blocking mitosis in response to unreplicated or damaged DNA(1). In most species this is accomplished by preventing activation of the cell-division kinase Cdc2, which regulates entry into mitosis(2-5). The Chk1 kinase, an effector of the DNA-damage checkpoint, phosphorylates Cdc25, an activator of Cdc2 (refs 6-11), Phosphorylation of Cdc25 promotes its binding, to 14-3-3 proteins, preventing it from activating: Cdc2 (ref. 8). Here we propose that a similar pathway is required for mitotic arrest in the presence of unreplicated DNA (that is, in the replication checkpoint) in fission yeast. We show by mutagenesis that Chk1 functions redundantly with the kinase Cds1 at the replication checkpoint and that both kinases phosphorylate Cdc25 on the same sites, which include serine residues at positions 99, 192 and 359, Mutation of these residues reduces binding of 14-3-3 proteins to Cdc25 in vitro and disrupts the replication checkpoint in vivo. We conclude that both Cds1 and Chk1 regulate the binding of Cdc25 to 14-3-3 proteins as part of the checkpoint response to unreplicated DNA.	Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca, Spain	Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Harvard University; Harvard Medical School; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca	Piwnica-Worms, H (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Box 8228,660 S Euclid Ave, St Louis, MO 63110 USA.	hpiwnica@cellbio.wustl.edu	Moreno, Sergio/K-3671-2014; Piwnica-Worms, Helen/C-5214-2012	Moreno, Sergio/0000-0002-8039-1413; 				ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FORBES KC, IN PRESS GENETICS; Francesconi S, 1997, EMBO J, V16, P1332, DOI 10.1093/emboj/16.6.1332; Furnari B, 1997, SCIENCE, V277, P1495, DOI 10.1126/science.277.5331.1495; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; LEE MS, 1994, J BIOL CHEM, V269, P30530; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1990, NATURE, V344, P549, DOI 10.1038/344549a0; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; OGG S, 1994, J BIOL CHEM, V269, P30461; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rhind N, 1997, GENE DEV, V11, P504, DOI 10.1101/gad.11.4.504; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sibon OCM, 1997, NATURE, V388, P93, DOI 10.1038/40439; Uchiyama M, 1997, MOL CELL BIOL, V17, P3103, DOI 10.1128/MCB.17.6.3103; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Walworth NC, 1996, SCIENCE, V271, P353, DOI 10.1126/science.271.5247.353; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0	30	304	313	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					507	510		10.1038/26766	http://dx.doi.org/10.1038/26766			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774107				2022-12-24	WOS:000076212200058
J	Lowe, M; Rabouille, C; Nakamura, N; Watson, R; Jackman, M; Jamsa, E; Rahman, D; Pappin, DJC; Warren, G				Lowe, M; Rabouille, C; Nakamura, N; Watson, R; Jackman, M; Jamsa, E; Rahman, D; Pappin, DJC; Warren, G			Cdc2 kinase directly phosphorylates the cis-Golgi matrix protein GM130 and is required for Golgi fragmentation in mitosis	CELL			English	Article							CELL-FREE SYSTEM; VESICLE DOCKING; MITOTIC FRAGMENTATION; HELA-CELLS; IN-VIVO; TRANSPORT; INHIBITOR; APPARATUS; P115; MEMBRANES	Mitotic fragmentation of the Golgi apparatus can be largely explained by disruption of the interaction between GM130 and the vesicle-docking protein p115. Here we identify a single serine (Ser-25) in GM130 as the key phosphorylated target and Cdc2 as the responsible kinase. MEK1, a component of the MAP kinase signaling pathway recently implicated in mitotic Golgi fragmentation, was not required for GM130 phosphorylation or mitotic fragmentation either in vitro or in vivo. We propose that Cdc2 is directly involved in mitotic Golgi fragmentation and that signaling via MEK1 is not required for this process.	Imperial Canc Res Fund, Cell Biol Lab, London WC2A 3PX, England; Imperial Canc Res Fund, Prot Sequencing Lab, London WC2A 3PX, England; Wellcome CRC Inst, Cambridge CB2 1QR, England	Cancer Research UK; Cancer Research UK	Warren, G (corresponding author), Imperial Canc Res Fund, Cell Biol Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.		Nakamura, Nobuhiro/F-7811-2011; Jokitalo, Eija/C-8375-2009	Nakamura, Nobuhiro/0000-0002-8836-6714; Jokitalo, Eija/0000-0002-4159-6934; Pappin, Darryl/0000-0002-8981-8401	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Acharya U, 1998, CELL, V92, P183, DOI 10.1016/S0092-8674(00)80913-7; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; BARROSO M, 1995, P NATL ACAD SCI USA, V92, P527, DOI 10.1073/pnas.92.2.527; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; Edelmann HML, 1996, J BIOL CHEM, V271, P963, DOI 10.1074/jbc.271.2.963; Guadagno TM, 1996, CELL, V84, P73, DOI 10.1016/S0092-8674(00)80994-0; HEIDER H, 1994, EUR J BIOCHEM, V219, P513, DOI 10.1111/j.1432-1033.1994.tb19966.x; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Krude T, 1997, CELL, V88, P109, DOI 10.1016/S0092-8674(00)81863-2; Levine TP, 1996, J BIOL CHEM, V271, P17304, DOI 10.1074/jbc.271.29.17304; MACKAY D, 1993, FEBS LETT, V336, P549, DOI 10.1016/0014-5793(93)80874-T; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; PAPPIN DJC, 1993, CURR BIOL, V3, P327, DOI 10.1016/0960-9822(93)90195-T; Pfeffer SR, 1996, ANNU REV CELL DEV BI, V12, P441, DOI 10.1146/annurev.cellbio.12.1.441; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sapperstein SK, 1996, J CELL BIOL, V132, P755, DOI 10.1083/jcb.132.5.755; SAPPERSTEIN SK, 1995, P NATL ACAD SCI USA, V92, P522, DOI 10.1073/pnas.92.2.522; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Sohda M, 1998, J BIOL CHEM, V273, P5385, DOI 10.1074/jbc.273.9.5385; Sonnichsen B, 1998, J CELL BIOL, V140, P1013, DOI 10.1083/jcb.140.5.1013; STUART RA, 1993, J BIOL CHEM, V268, P4050; Takenaka K, 1998, SCIENCE, V280, P599, DOI 10.1126/science.280.5363.599; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	35	255	260	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1998	94	6					783	793		10.1016/S0092-8674(00)81737-7	http://dx.doi.org/10.1016/S0092-8674(00)81737-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753325	Bronze			2022-12-24	WOS:000076021200011
J	Peter, BJ; Ullsperger, C; Hiasa, H; Marians, KJ; Cozzarelli, NR				Peter, BJ; Ullsperger, C; Hiasa, H; Marians, KJ; Cozzarelli, NR			The structure of supercoiled intermediates in DNA replication	CELL			English	Article							ESCHERICHIA-COLI; TOPOISOMERASE-IV; ELECTRON-MICROSCOPY; STRAND; DECATENATION; MOLECULES; PROTEIN; GYRASE; YEAST	We studied the structure of replication intermediates accumulated by Tus-induced arrest of plasmid DNA replication at termination sites. For intermediates generated both in vitro with purified components and in vivo, superhelical stress is distributed throughout the entire partially replicated molecule; daughter DNA segments are wound around each other, and the unreplicated region is supercoiled. Thus, unlinking of parental DNA strands by topoisomerases can be carried out both behind and in front of the replication fork. We explain why previous studies with prokaryotic and eukaryotic replication intermediates discerned only supercoiling in the unreplicated portion.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	University of California System; University of California Berkeley; Memorial Sloan Kettering Cancer Center	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B., 1980, MECH STUDIES DNA REP, P809, DOI DOI 10.1016/B978-0-12-048850-6.50072-7; Ausubel F, 1989, MOL REPROD DEV, V1, P146; BASTIA D, 1981, P NATL ACAD SCI-BIOL, V78, P2095, DOI 10.1073/pnas.78.4.2095; BATES AD, 1993, DNA TOPOLOGY; Benjamin KR, 1996, J MOL BIOL, V256, P50, DOI 10.1006/jmbi.1996.0067; BOLES TC, 1990, J MOL BIOL, V213, P931, DOI 10.1016/S0022-2836(05)80272-4; BOURGAUX P, 1972, J MOL BIOL, V70, P399, DOI 10.1016/0022-2836(72)90548-7; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; Eckstein F., 1995, NUCLEIC ACIDS MOL BI, P115; FUKE M, 1972, P NATL ACAD SCI USA, V69, P89, DOI 10.1073/pnas.69.1.89; HIASA H, 1994, J BIOL CHEM, V269, P6058; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1994, J BIOL CHEM, V269, P32655; Hiasa H, 1996, J BIOL CHEM, V271, P21529, DOI 10.1074/jbc.271.35.21529; ISHIMI Y, 1992, J BIOL CHEM, V267, P462; KHATRI GS, 1989, CELL, V59, P667, DOI 10.1016/0092-8674(89)90012-3; KHODURSKY AB, 1995, P NATL ACAD SCI USA, V92, P11801, DOI 10.1073/pnas.92.25.11801; KHODURSKY AB, 1997, THESIS U CALIFORNIA; KIM RA, 1989, J MOL BIOL, V208, P257, DOI 10.1016/0022-2836(89)90387-2; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; Kleinschmidt A.K.=, 1968, METHODS ENZYMOL, V12, P361; Kornberg A., 1992, DNA REPLICATION; LANG D, 1970, BIOPOLYMERS, V9, P373, DOI 10.1002/bip.1970.360090310; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOHMAN TM, 1996, ANNU REV BIOCHEM, V65, P168; MAXWELL A, 1984, J BIOL CHEM, V259, P4472; PENG H, 1993, P NATL ACAD SCI USA, V90, P8571, DOI 10.1073/pnas.90.18.8571; Roca J, 1996, GENES CELLS, V1, P17, DOI 10.1046/j.1365-2443.1996.01001.x; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SEBRING ED, 1971, J VIROL, V8, P478, DOI 10.1128/JVI.8.4.478-490.1971; SEBRING ED, 1974, J MOL BIOL, V90, P371, DOI 10.1016/0022-2836(74)90380-5; SUNDIN O, 1981, CELL, V25, P659, DOI 10.1016/0092-8674(81)90173-2; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; Ullsperger C, 1996, J BIOL CHEM, V271, P31549, DOI 10.1074/jbc.271.49.31549; Wang J. C., 1990, DNA TOPOLOGY ITS BIO, P321; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WILLIAMS RC, 1977, P NATL ACAD SCI USA, V74, P2311, DOI 10.1073/pnas.74.6.2311; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	38	120	124	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					819	827		10.1016/S0092-8674(00)81740-7	http://dx.doi.org/10.1016/S0092-8674(00)81740-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753328	Bronze			2022-12-24	WOS:000076021200014
J	Chen, RZ; Pettersson, U; Beard, C; Jackson-Grusby, L; Jaenisch, R				Chen, RZ; Pettersson, U; Beard, C; Jackson-Grusby, L; Jaenisch, R			DNA hypomethylation leads to elevated mutation rates	NATURE			English	Article							HOMOLOGOUS RECOMBINATION; V(D)J RECOMBINATION; METHYLATION; CELLS; MOUSE; METHYLTRANSFERASE; EXPRESSION; GENE	Genome-wide demethylation has been suggested to be a step in carcinogenesis(1). Evidence for this notion comes from the frequently observed global DNA hypomethylation in tumour cells(2), and from a recent study suggesting that defects in DNA methylation might contribute to the genomic instability of some colorecal tumour cell lines(3). DNA hypomethylation has also been associated with abnormal chromosomal structures, as observed in cells from patients with ICF (Immunodeficiency, Centromeric instability and Facial abnormalities) syndrome(4,5) and in cells treated with the demethylating agent 5-azadeoxycytidine(6). Here we report that murine embryonic stem cells nullizygous for the major DNA methyltransferase (Dnmt1) gene exhibited significantly elevated mutation rates at both the endogenous hypoxanthine phosphoribosyltransferase (Hprt) gene and an integrated viral thymidine kinase (tk) transgene. Gene deletions were the predominant mutations at both loci. The major cause of the observed tk deletions was either mitotic recombination or chromosomal loss accompanied by duplication of the remaining chromosome. Our results imply an important role for mammalian DNA methylation in maintaining genome stability.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Jaenisch, R (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; HSIEH CL, 1992, EMBO J, V11, P315, DOI 10.1002/j.1460-2075.1992.tb05054.x; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; JEANPIERRE M, 1993, HUM MOL GENET, V2, P731, DOI 10.1093/hmg/2.6.731; Ji WZ, 1997, MUTAT RES-FUND MOL M, V379, P33, DOI 10.1016/S0027-5107(97)00088-2; KENDAL WS, 1988, CANCER RES, V48, P1060; LAIRD PW, 1995, CELL, V81, P197, DOI 10.1016/0092-8674(95)90329-1; Lei H, 1996, DEVELOPMENT, V122, P3195; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LOEB LA, 1991, CANCER RES, V51, P3075; Maloisel L, 1998, GENE DEV, V12, P1381, DOI 10.1101/gad.12.9.1381; MELTON DW, 1984, P NATL ACAD SCI-BIOL, V81, P2147, DOI 10.1073/pnas.81.7.2147; MONK M, 1987, DEVELOPMENT, V99, P371; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PROFFITT JH, 1984, MOL CELL BIOL, V4, P985, DOI 10.1128/MCB.4.5.985; SANFORD JP, 1987, GENE DEV, V1, P1039, DOI 10.1101/gad.1.10.1039; SHIROISHI T, 1995, ADV BIOPHYS, V31, P119, DOI 10.1016/0065-227X(95)99387-5; SHULMAN MJ, 1995, EMBO J, V14, P4102, DOI 10.1002/j.1460-2075.1995.tb00082.x; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; WAHLS WP, 1990, CELL, V60, P95, DOI 10.1016/0092-8674(90)90719-U; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	27	715	757	0	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					89	93		10.1038/25779	http://dx.doi.org/10.1038/25779			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738504				2022-12-24	WOS:000075722200053
J	Boring, L; Gosling, J; Cleary, M; Charo, IF				Boring, L; Gosling, J; Cleary, M; Charo, IF			Decreased lesion formation in CCR2(-/-) mice reveals a role for chemokines in the initiation of atherosclerosis	NATURE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; SMOOTH-MUSCLE CELLS; APOLIPOPROTEIN-E; DENSITY-LIPOPROTEIN; HYPERCHOLESTEROLEMIA; SUSCEPTIBILITY; EXPRESSION; RECEPTORS; INFECTION	Chemokines are proinflammatory cytokines that function in leukocyte chemoattraction and activation and have recently been shown to block the HIV-1 infection of target cells through interactions with chemokine receptors(1,2). In addition to their function in viral disease, chemokines have been implicated in the pathogenesis of atherosclerosis. Expression of the CC chemokine monocyte chemoattractant protein-1 (MCP-1) is upregulated in human atherosclerotic plaques(3,4), in arteries of primates on a hypercholesteralaemic diet(5) and in vascular endothelial and smooth muscle cells exposed to minimally modified lipids(5,6). ab determine whether MCP-1 is causally related to the development of atherosclerosis, we generated mice that lack CCR2, the receptor for MCP-1 (ref. 7), and crossed them with apolipoprotein (apo) E-null mice(8-10) which develop severe atherosclerosis. Here we show that the selective absence of CCR2 decreases lesion formation markedly in apoE(-/-) mice but has no effect on plasma lipid or lipoprotein concentrations. These data reveal a role for MCP-1 in the development of early atherosclerotic lesions and suggest that upregulation of this chemokine by minimally oxidized lipids is an important link between hyperlipidaemia and fatty streak formation.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94110 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; Univ Calif San Francisco, Daiichi Res Ctr, San Francisco, CA 94141 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Charo, IF (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.							Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; KRAAL G, 1987, SCAND J IMMUNOL, V26, P653, DOI 10.1111/j.1365-3083.1987.tb02301.x; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Veniant MM, 1997, J CLIN INVEST, V100, P180, DOI 10.1172/JCI119511; Yia-Herttuala S., 1991, P NATL ACAD SCI USA, V88, P5252; YU XH, 1992, P NATL ACAD SCI USA, V89, P6953, DOI 10.1073/pnas.89.15.6953; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	17	1577	1672	1	70	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					894	897		10.1038/29788	http://dx.doi.org/10.1038/29788			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732872				2022-12-24	WOS:000075611800049
J	Xu, Y; Shen, ZZ; Wiper, DW; Wu, MZ; Morton, RE; Elson, P; Kennedy, AW; Belinson, J; Markman, M; Casey, G				Xu, Y; Shen, ZZ; Wiper, DW; Wu, MZ; Morton, RE; Elson, P; Kennedy, AW; Belinson, J; Markman, M; Casey, G			Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							XENOPUS OOCYTES; TUMOR-MARKERS; ASCITIC FLUID; SERUM-ALBUMIN; CELLS; IDENTIFICATION; PLATELETS; MESSENGER; CURRENTS; GROWTH	Context.-Lysophosphatidic acid (LPA) has been shown to stimulate proliferation of ovarian cancer cells and is present in the ascitic fluid of patients with ovarian cancer. Objectives.-To determine whether elevated levels of LPA are present in plasma from patients with ovarian cancer and other gynecologic malignancies compared with healthy controls and to evaluate whether an elevated LPA plasma level may be a biomarker for these diseases. Design.-A research assay was used to measure total LPA levels in plasma from healthy women and women with different diseases. All LPA assays and comparison of LPA levels and CA125 tan ovarian cancer biomarker) levels were performed by observers blinded to patient status or group. Setting.-The Cleveland Clinic Foundation. Participants.-A convenience sample of 48 healthy control women, 48 women with ovarian cancer, 36 women with other gynecologic cancers, 17 women with benign gynecologic diseases, 11 women with breast cancer, and 5 women with leukemias. Main Outcome Measures.-Total LPA levels in plasma Samples from patients and controls. Results.-Patients in the ovarian cancer group had significantly higher plasma LPA levels (mean, 8.6 mu mol/L; range, 1.0-43.1 mu mol/L) compared with the healthy control group (mean, 0.6 mu mol/L; range, <0.1-6.3 mu mol/L) (P<.001). Elevated plasma LPA levels were detected in 9 of 10 patients with stage I ovarian cancer, 24 of 24 patients with stage 11, III, and IV ovarian cancer, and 14 of 14 patients with recurrent ovarian cancer. Of 36 patients with other gynecologic cancers, 33 also showed higher LPA levels (mean, 14.9 mu mol/L; range, <0.1-63.2 mu mol/L), compared with healthy controls (P<.001). Elevated plasma LPA levels were detected in 5 of 48 controls and 4 of 17 patients with benign gynecologic diseases and in no women with breast cancer or leukemia. In comparison, among a subset of patients with ovarian cancer, 28 of 47 had elevated CA125 levels, including 2 of 9 patients with stage I disease. Conclusions.-Plasma LPA levels may represent a potential biomarker for ovarian cancer and other gynecologic cancers. However, these findings are preliminary and require confirmation in larger studies.	Cleveland Clin Fdn, Dept Gynecol & Obstet, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Biostat, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Canc, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Dept Canc Biol, NN10,9500 Euclid Ave, Cleveland, OH 44195 USA.							American Cancer Society, 1998, CANC FACTS FIG 1998; BAST RC, 1983, NEW ENGL J MED, V309, P883, DOI 10.1056/NEJM198310133091503; BEREK JS, 1995, CANCER-AM CANCER SOC, V76, P2092, DOI 10.1002/1097-0142(19951115)76:10+<2092::AID-CNCR2820761331>3.0.CO;2-T; Boente M P, 1996, Curr Probl Cancer, V20, P83; DURIEUX ME, 1993, TRENDS PHARMACOL SCI, V14, P249, DOI 10.1016/0165-6147(93)90021-B; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FARGHALY SA, 1992, GYNECOL OBSTET INVES, V34, P65, DOI 10.1159/000292728; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Lehman EL, 1975, NONPARAMETRICS STAT; MILLS GB, 1990, J CLIN INVEST, V86, P851, DOI 10.1172/JCI114784; MILLS GB, 1988, CANCER RES, V48, P1066; MOOLENAAR WH, 1995, J BIOL CHEM, V270, P12949, DOI 10.1074/jbc.270.22.12949; Moolenaar Wouter H., 1994, Trends in Cell Biology, V4, P213, DOI 10.1016/0962-8924(94)90144-9; RUSTIN GJS, 1993, ANN ONCOL, V4, P71; SHEN Z, IN PRESS GYNECOL ONC; TAYLOR KJW, 1994, RADIOLOGY, V192, P1; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TIGYI G, 1991, J BIOL CHEM, V266, P20602; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; WATSON SP, 1985, BIOCHEM J, V232, P61, DOI 10.1042/bj2320061; WHO, 1979, WHO HDB REP RES CANC; WOOLAS RP, 1993, JNCI-J NATL CANCER I, V85, P1748, DOI 10.1093/jnci/85.21.1748; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Xu Y, 1995, CLIN CANCER RES, V1, P1223; XU Y, 1996, OVARIAN CANC, V3, P121; ZWEIG MH, 1993, CLIN CHEM, V39, P561	27	516	571	0	27	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					719	723		10.1001/jama.280.8.719	http://dx.doi.org/10.1001/jama.280.8.719			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728644	Bronze			2022-12-24	WOS:000075446900034
J	Friedrichson, T; Kurzchalia, TV				Friedrichson, T; Kurzchalia, TV			Microdomains of GPI-anchored proteins in living cells revealed by crosslinking	NATURE			English	Article							EPITHELIAL-CELLS; DETERGENT INSOLUBILITY; MDCK CELLS; ALKALINE-PHOSPHATASE; CHOLESTEROL CONTENT; TYROSINE KINASE; CROSS-LINKING; MA104 CELLS; SURFACE; TRANSPORT	There is some discussion as to whether glycosyl-phosphatidylinositol(GPI)-anchored proteins occur in microdomains in the cell membrane(.1,2) These putative microdomains have been implicated in processes such as sorting in polarized cells(3-5) and signal transduction(6-8), Complexes enriched in GPI-anchored proteins, cholesterol and glycosphingolipids have been isolated from cell membranes by using non-ionic detergents: these complexes were thought to represent a clustered arrangement of GPI-anchored proteins(9,10). However, results obtained when clustering of GPI-anchored proteins induced by antibodies or by detergents was prevented support the idea of a dispersed surface distribution of GPI-anchored proteins at steady state(11-13). Here we use chemical crosslinking to show that membrane microdomains of a GPI-anchored protein exist at the surface in living cells. This clustering is specific for the GPI-anchored form, as two transmembrane forms bearing the same ectodomain do not form oligomers. Depletion of membrane cholesterol causes the clustering of GPI-anchored proteins to break up, whereas treatment of cells with detergent substantially increases the size of the complexes. We find that in living cells these GPI-anchored proteins reside in microdomains consisting of at least 15 molecules, which are much smaller than those seen after detergent extraction.	Max Delbruck Ctr Mol Med, Dept Cell Biol, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kurzchalia, TV (corresponding author), Max Delbruck Ctr Mol Med, Dept Cell Biol, Robert Rossle Str 10, D-13125 Berlin, Germany.							BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CERNEUS DP, 1993, J BIOL CHEM, V268, P3150; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Fujimoto T, 1996, J HISTOCHEM CYTOCHEM, V44, P929, DOI 10.1177/44.8.8756764; HANADA K, 1995, J BIOL CHEM, V270, P6254, DOI 10.1074/jbc.270.11.6254; HANNAN LA, 1993, J CELL BIOL, V120, P353, DOI 10.1083/jcb.120.2.353; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; KURZCHALIA T, 1995, TRENDS CELL BIOL, V5, P187, DOI 10.1016/S0962-8924(00)88990-4; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; MAYOR S, 1995, MOL BIOL CELL, V6, P929, DOI 10.1091/mbc.6.7.929; RODGERS W, 1994, MOL CELL BIOL, V14, P5384, DOI 10.1128/MCB.14.8.5384; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Smart EJ, 1996, J CELL BIOL, V134, P1169, DOI 10.1083/jcb.134.5.1169; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Weimbs T, 1997, TRENDS CELL BIOL, V7, P393, DOI 10.1016/S0962-8924(97)01130-6; Wu M, 1997, J MEMBRANE BIOL, V159, P137, DOI 10.1007/s002329900277	31	470	475	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					802	805		10.1038/29570	http://dx.doi.org/10.1038/29570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723622	Green Accepted			2022-12-24	WOS:000075503600051
J	Fairhurst, K; Huby, G				Fairhurst, K; Huby, G			From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR	Objectives To explore how general practitioners have accessed and evaluated evidence from trials on the use of statin lipid lowering drugs and incorporated this evidence into their practice. To draw out the practical implications of this study for strategies to integrate clinical evidence into general medical practice. Design Qualitative analysis of semistructured interviews. Setting General practices in Lothian, Subjects 24 general practitioners selected to obtain a heterogeneous sample. Results Respondents were generally aware of the evidence relating to the use of statins in secondary prevention of coronary heart disease, but they were less clear about the evidence in primary prevention, The benefits of statins in secondary prevention were clearer to them and the social and economic issues less complex than was the case for use in primary prevention, Respondents rarely said they appraised the methods and content of trials, rather they judged the trustworthiness of the source of trial evidence and interpreted it within the context of the economic and social factors which impinge on their practice Moreover, trial data become relevant for routine practice only when underpinned by a consensus an these issues. Conclusion Strategies to promote incorporation of evidence from clinical trials into everyday practice are likely to be effective if they tap into and build on the process of local consensus building. Strategies such as teaching critical appraisal skills and guideline development may have little effect if they are separated from this process.	Univ Edinburgh, Dept Community Hlth Sci Gen Practice, Edinburgh EH8 9DX, Midlothian, Scotland	University of Edinburgh	Fairhurst, K (corresponding author), Univ Edinburgh, Dept Community Hlth Sci Gen Practice, Levinson House, Edinburgh EH8 9DX, Midlothian, Scotland.	Karen.Fairhurst@ed.ac.uk						Allery LA, 1997, BMJ-BRIT MED J, V314, P870; [Anonymous], 1979, STRUCTURE SCI REVOLU; Armstrong D, 1996, BRIT MED J, V312, P949; Caro J, 1997, BRIT MED J, V315, P1577, DOI 10.1136/bmj.315.7122.1577; *DEP HLTH, 1997, CMND3807; Freemantle N, 1997, BMJ-BRIT MED J, V315, P826, DOI 10.1136/bmj.315.7112.826; Gill P, 1996, BRIT MED J, V312, P819; HORDER J, 1986, J ROY COLL GEN PRACT, V36, P517; Maxwell M, 1998, BRIT J GEN PRACT, V48, P1467; McColl A, 1998, BRIT MED J, V316, P361, DOI 10.1136/bmj.316.7128.361; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; PEDERSEN TR, 1994, LANCET, V344, P1383; ROSENBERG W, 1995, BMJ-BRIT MED J, V310, P1122, DOI 10.1136/bmj.310.6987.1122; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SECR STAT SCOTL S, 1997, DIS CAR NAT HLTH SER; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STAND MED ADV COM, 1997, US STAT; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W	19	104	106	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1130	1134						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784451				2022-12-24	WOS:000076755100033
J	Sablin, EP; Case, RB; Dai, SC; Hart, CL; Ruby, A; Vale, RD; Fletterick, RJ				Sablin, EP; Case, RB; Dai, SC; Hart, CL; Ruby, A; Vale, RD; Fletterick, RJ			Direction determination in the minus-end-directed kinesin motor ncd	NATURE			English	Article							CRYOELECTRON MICROSCOPY; PROTEIN; DROSOPHILA; MICROTUBULES; SEGREGATION; DOMAIN	Motor proteins of the kinesin superfamily transport intracellular cargo along microtubules. Although different kinesin proteins share 30-50% amino-acid identity in their motor catalytic cores, some move to the plus end of microtubules whereas others travel in the opposite direction(1,2). Crystal structures of the Catalytic cores of conventional kinesin (a plus-end-directed motor involved in organelle transport) and ncd (a minus-end-directed motor involved in chromosome segregation) are nearly identical(3,4); therefore, the structural basis for their opposite directions of movement is unknown. Here we show that the ncd 'neck', made up of 13 class-specific residues next to the superfamily-conserved catalytic core, is essential for minus-end-directed motility, as mutagenesis of these neck residues reverses the direction of ncd motion. By solving the 2.5 Angstrom structure of a functional ncd dimer,we show that the ncd neck(a coiled-coil) differs from the corresponding region in the kinesin neck tan interrupted beta-strand)(5,6), although both necks interact with similar elements in the catalytic cores. The distinct neck architectures also confer different symmetries to the ncd and kinesin dimers and position these motors with appropriate directional bias on the microtubule.	Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Vale, RD (corresponding author), Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA.	vale@phy.ucsf.edu						Amos LA, 1997, CURR OPIN CELL BIOL, V9, P4, DOI 10.1016/S0955-0674(97)80145-7; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; ENDOW SA, 1990, NATURE, V345, P81, DOI 10.1038/345081a0; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; Hirokawa N, 1998, SCIENCE, V279, P519, DOI 10.1126/science.279.5350.519; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HYMAN AA, 1991, J CELL SCI, P125; KODAMA T, 1986, J BIOCHEM-TOKYO, V99, P1465, DOI 10.1093/oxfordjournals.jbchem.a135616; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; Rost B, 1996, METHOD ENZYMOL, V266, P525; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sosa H, 1997, CELL, V90, P217, DOI 10.1016/S0092-8674(00)80330-X; Vale RD, 1997, ANNU REV CELL DEV BI, V13, P745, DOI 10.1146/annurev.cellbio.13.1.745; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	20	178	180	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 22	1998	395	6704					813	816		10.1038/27463	http://dx.doi.org/10.1038/27463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796817				2022-12-24	WOS:000076607400060
J	Flahault, A; Dias-Ferrao, V; Chaberty, P; Esteves, K; Valleron, AJ; Lavanchy, D				Flahault, A; Dias-Ferrao, V; Chaberty, P; Esteves, K; Valleron, AJ; Lavanchy, D			FluNet as a tool for global monitoring of influenza on the web	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In collaboration with the Institut National de la Sante et de la Recherche Medicale, the World Health Organization (WHO) has developed an Internet application linking the global WHO network of influenza centers (FluNet; http:// oms.b3e.jussieu.fr/flunet/). During 1997, 22 pilot centers entered data on influenza activity and viral laboratory results directly into FluNet via secured access. In addition, 54 centers sent data to WHO for entry. Four countries (the Russian Federation, Romania, Sweden, and the United Kingdom) reported widespread outbreaks of at least 4 weeks' duration. The FluNet server ran 24 hours a day without interruption. To improve management and enhance standardization of reporting, this early-alert system for the global monitoring of influenza provides international and national authorities, the public, and the media with full access to real-time epidemiological and virological information.	INSERM, U444, Unite Epidemiol & Sci Informat, F-75571 Paris 12, France; WHO, Div Emerging & Other Communicable Dis Surveillanc, CH-1211 Geneva, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); World Health Organization	Flahault, A (corresponding author), INSERM, U444, Unite Epidemiol & Sci Informat, 27 Rue Challigny, F-75571 Paris 12, France.							COSTAGLIOLA D, 1991, AM J PUBLIC HEALTH, V81, P97, DOI 10.2105/AJPH.81.1.97; Glezen WP, 1996, EPIDEMIOL REV, V18, P64, DOI 10.1093/oxfordjournals.epirev.a017917; Hampson Alan W., 1997, Journal of Infectious Diseases, V176, pS8, DOI 10.1086/514184; LeDuc JW, 1996, JAMA-J AM MED ASSOC, V275, P318, DOI 10.1001/jama.275.4.318; PENNISI E, 1995, SCIENCE, V270, P1916, DOI 10.1126/science.270.5244.1916; 1997, J INFECT DIS S1, V176, pS73	6	46	47	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1330	1332		10.1001/jama.280.15.1330	http://dx.doi.org/10.1001/jama.280.15.1330			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794312				2022-12-24	WOS:000076472500025
J	Kramer, RH; Karpen, JW				Kramer, RH; Karpen, JW			Spanning binding sites on allosteric proteins with polymer-linked ligand dimers	NATURE			English	Article							NUCLEOTIDE-GATED CHANNELS; CYCLIC-GMP; ROD PHOTORECEPTOR; FUNCTIONAL EXPRESSION; DIVERSE FUNCTIONS; CATION CHANNEL; CGMP ANALOGS; SUBUNIT; KINASE; CAMP	One approach to drug design involves determination of the structure of binding sites on target proteins to provide templates for ligand construction. Alternatively, random combinations of chemical groups can be used to generate diverse molecules for screening in the search for effective compounds'. Here we report a strategy for developing potent ligands for proteins with multiple binding sites, which combines elements of both approaches: 'polymer-linked ligand dimers: in which two ligands are joined by a polymer chain of variable length. We find that polymer-linked ligand dimers containing two cyclic GMP moieties are up to a thousand times more potent than cyclic GMP in activating cyclic-nucleotide-gated channels and cGMP-dependent protein kinase. Each target protein responds optimally to a polymer-linked ligand dimer with a different average polymer length, even though their cyclic-nucleotide-binding sites are conserved. The tuning of polymer-linked ligand dimers indicates that each protein has a unique spacing of binding sites and provides an estimate of the distance between these sires. As optimal ligands are selected empirically, the: polymer-linked Ligand dimer strategy enables potent and selective agents to be identified without requiring previous structural information about the target proteins.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ Colorado, Sch Med, Dept Physiol & Biophys, Denver, CO 80262 USA	University of Miami; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Kramer, RH (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA.							BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; BROWN RL, 1993, BIOCHEMISTRY-US, V32, P10089, DOI 10.1021/bi00089a026; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; BUTTS NK, 1994, J STRENGTH COND RES, V8, P265; CARTETTA A, 1985, EUR J BIOCHEM, V153, P49; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; FLOREY PJ, 1953, PRINCIPLES POLYM CHE; Francis S H, 1994, Adv Pharmacol, V26, P115, DOI 10.1016/S1054-3589(08)60053-8; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KNOLL D, 1983, J BIOL CHEM, V258, P5710; KOCH KW, 1985, J BIOL CHEM, V260, P6788; KORSCHEN HG, 1995, NEURON, V15, P627, DOI 10.1016/0896-6273(95)90151-5; Kramer RH, 1996, J NEUROSCI, V16, P1285; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; Liu DT, 1996, NEURON, V16, P983, DOI 10.1016/S0896-6273(00)80121-X; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; SHABB JB, 1992, J BIOL CHEM, V267, P5723; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; TANAKA JC, 1989, BIOCHEMISTRY-US, V28, P2776, DOI 10.1021/bi00433a006; TAYLOR SS, 1990, ANNU REV BIOCHEM, V59, P971, DOI 10.1146/annurev.biochem.59.1.971; Wei JY, 1996, BIOCHEMISTRY-US, V35, P16815, DOI 10.1021/bi961763v; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	28	226	240	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					710	713		10.1038/27227	http://dx.doi.org/10.1038/27227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790193				2022-12-24	WOS:000076472600055
J	Katlama, C; Valantin, MA; Matheron, S; Coutellier, A; Calvez, V; Descamps, D; Longuet, C; Bonmarchand, M; Tubiana, R; De Sa, M; Lancar, R; Agut, H; Brun-Vezinet, F; Costagliola, D				Katlama, C; Valantin, MA; Matheron, S; Coutellier, A; Calvez, V; Descamps, D; Longuet, C; Bonmarchand, M; Tubiana, R; De Sa, M; Lancar, R; Agut, H; Brun-Vezinet, F; Costagliola, D			Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection	ANNALS OF INTERNAL MEDICINE			English	Article						human immunodeficiency virus infections; stavudine; lamivudine; anti-HIV agents; antiviral agents	IMMUNODEFICIENCY-VIRUS INFECTION; ZIDOVUDINE COMBINATION THERAPY; CUBIC MILLIMETER; PHASE I/II; CD4 CELLS; MONOTHERAPY; SAFETY; ZALCITABINE; ADULTS; TRIAL	Background: A combination of two nucleoside analogues is currently the core of any antiretroviral regimen for HIV-1 infection. Stavudine plus lamivudine has shown an additive effect in vitro, as well as an absence of overlapping toxicity and cross-resistance. Objective: To evaluate the antiviral efficacy of stavudine plus lamivudine in treatment-naive patients and in patients previously treated with other nucleoside reverse transcriptase inhibitors. Design: Prospective, open-label pilot study. Setting: Three urban clinical centers in Paris. Patients: 83 patients with CD4(+) cell counts between 50 and 400 cells/mm(3) (42 treatment-naive and 41 treatment-experienced patients). Interventions: Stavudine, 40 mg twice daily (30 mg twice daily in patients with a body weight less than or equal to 60 kg), and lamivudine, 150 mg twice daily. Measurements: Primary end points for efficacy included changes in plasma viral load and CD4(+) cell count at 24 weeks compared with baseline. Results: Therapy with stavudine plus lamivudine resulted in a median decrease of 1.66 log(10) (10(1.66)) (range, -3.04 to -0.79 log(10)) in plasma HIV-1 RNA; the median increase in CD4(+) cell count was 108 cells/mm(3) (range, -58 to 406 cells/mm(3)) at week 24 in treatment-naive patients. In treatment-experienced patients, the median reduction in plasma HIV-1 RNA was 0.55 log(10) (range, -2.86 to 0.52 log(10)), and the median increase in CD4(+) cell count was 46 cells/mm(3) (range, -188 to 311 cells/mm(3)). The percentages of patients with less than 3000 HIV-1 RNA copies/mL and less than 400 copies/mL at 24 weeks were, respectively, 57% (95% CI, 41% to 72%) and 26% (CI, 12% to 40%) among treatment-naive patients and 22% (CI, 10% to 38%) and 5% (CI, 1% to 17%) among treatment-experienced patients. Of 82 patients, 14 (17%) experienced grade 3 or 4 toxicity and 2 discontinued therapy because of intolerance toward treatment. Conclusion: Stavudine plus lamivudine seems to have a potent antiviral effect in treatment-naive and treatment-experienced patients. No major drug-limiting toxicity was found. This two-nucleoside combination should be considered in multidrug therapy for HIV.	Hop La Pitie Salpetriere, Dept Infect Dis, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Med, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Virol, F-75013 Paris, France; Hop Bichat Claude Bernard, Dept Infect Dis, F-75018 Paris, France; Inst St Antoine Rech Sante, INSERM, SC4, F-75012 Paris, France; Hop Bichat Claude Bernard, Dept Virol, F-75018 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite	Katlama, C (corresponding author), Hop La Pitie Salpetriere, Dept Infect Dis, 47 Blvd Hop, F-75013 Paris, France.		Matheron, Sophie/D-7420-2017; Costagliola, Dominique/H-5849-2011	Matheron, Sophie/0000-0001-7879-6553; Costagliola, Dominique/0000-0003-0765-0869				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Bartlett JA, 1996, ANN INTERN MED, V125, P161, DOI 10.7326/0003-4819-125-3-199608010-00001; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; DAQUILA RT, 1995, ANN INTERN MED, V122, P401, DOI 10.7326/0003-4819-122-6-199503150-00001; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; GILLINGS D, 1991, DRUG INF J, V25, P411, DOI DOI 10.1177/009286159102500311; Griffith BP, 1996, J INFECT DIS, V173, P1252, DOI 10.1093/infdis/173.5.1252; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; KATIAMA C, 1996, 3 C RETR OPP INF WAS, P196; Katlama C, 1996, JAMA-J AM MED ASSOC, V276, P118, DOI 10.1001/jama.276.2.118; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; LARDER BA, 1995, SCIENCE, V269, P696, DOI 10.1126/science.7542804; LIN PF, 1994, J INFECT DIS, V170, P1157, DOI 10.1093/infdis/170.5.1157; Merrill DP, 1996, J INFECT DIS, V173, P355, DOI 10.1093/infdis/173.2.355; MURRAY HW, 1995, J INFECT DIS, V171, pS123, DOI 10.1093/infdis/171.Supplement_2.S123; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; PETERSEN EA, 1995, J INFECT DIS, V171, pS131, DOI 10.1093/infdis/171.Supplement_2.S131; PLUDA JM, 1995, J INFECT DIS, V171, P1438, DOI 10.1093/infdis/171.6.1438; POLLARD R, 1996, 3 C RETR OPP INF WAS; Saravolatz LD, 1996, NEW ENGL J MED, V335, P1099, DOI 10.1056/NEJM199610103351503; SCHUURMAN R, 1995, J INFECT DIS, V171, P1411, DOI 10.1093/infdis/171.6.1411; SOMMADOSSI JP, 1998, 5 C RETR OPP INF CHI, P362; Spruance SL, 1997, ANN INTERN MED, V126, P355, DOI 10.7326/0003-4819-126-5-199703010-00003; Staszewski S, 1996, JAMA-J AM MED ASSOC, V276, P111, DOI 10.1001/jama.276.2.111; VANLEEUWEN R, 1995, J INFECT DIS, V171, P1166, DOI 10.1093/infdis/171.5.1166; Wainberg MA, 1996, SCIENCE, V271, P1282, DOI 10.1126/science.271.5253.1282	26	43	43	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					525	+		10.7326/0003-4819-129-7-199810010-00003	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758571				2022-12-24	WOS:000076124500002
J	Sereno, AB; Maunsell, JHR				Sereno, AB; Maunsell, JHR			Shape selectivity in primate lateral intraparietal cortex	NATURE			English	Article							POSTERIOR PARIETAL CORTEX; PREFRONTAL CORTEX; VISUAL GUIDANCE; MONKEY; MECHANISMS; NEURONS; CONNECTIONS; PERCEPTION; PREHENSION; PATHWAYS	The extrastriate visual cortex can be divided into functionally distinct temporal and parietal regions, which have been implicated in feature-related ('what') and spatial ('where') vision, respectively(1). Neuropsychological studies of patients with damage to either the temporal or the parietal regions provide support for this functional distinction(2-4). Given the prevailing modular theoretical framework and the fact that prefrontal cortex receives inputs from both temporal and parietal streams(5,6), recent studies have focused on the role of prefrontal cortex in understanding where and how information about object identity is integrated with (or remains segregated from) information about object location(7-10). Here we show that many neurons in primate posterior parietal cortex (the 'where' pathway) show sensory shape selectivities to simple, two-dimensional geometric shapes while the animal performs a simple fixation task. In a delayed match-to-sample paradigm, many neuronal units also show significant differences in delay-period activity, and these differences depend on the shape of the sample. These results indicate that units in posterior parietal cortex contribute to attending to and remembering shape features in a way that is independent of eye movements, reaching, or object manipulation. These units show shape selectivity equivalent to any shown in the ventral pathway.	Baylor Coll Med, Div Neurosci S603, Houston, TX 77030 USA; Baylor Coll Med, Howard Hughes Med Inst, Houston, TX 77030 USA; Rutgers State Univ, Ctr Mol & Behav Neurosci, Newark, NJ 07102 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Rutgers State University Newark; Rutgers State University New Brunswick	Sereno, AB (corresponding author), Baylor Coll Med, Div Neurosci S603, Houston, TX 77030 USA.	sereno@cmbn.rutgers.edu	Maunsell, John/G-5702-2010	Maunsell, John/0000-0003-0018-4439	NEI NIH HHS [R01 EY005911] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANDERSEN RA, 1990, J COMP NEUROL, V296, P65, DOI 10.1002/cne.902960106; BARASH S, 1991, J NEUROPHYSIOL, V66, P1109, DOI 10.1152/jn.1991.66.3.1109; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Colby CL, 1998, NEURON, V20, P15, DOI 10.1016/S0896-6273(00)80429-8; Courtney SM, 1998, SCIENCE, V279, P1347, DOI 10.1126/science.279.5355.1347; FARAH MJ, 1990, VISUAL AGNOSIA; GALLESE V, 1994, NEUROREPORT, V5, P1525, DOI 10.1097/00001756-199407000-00029; Goldberg M. E., 1997, Society for Neuroscience Abstracts, V23, P17; GOODALE MA, 1994, CURR BIOL, V4, P604, DOI 10.1016/S0960-9822(00)00132-9; GOODALE MA, 1992, TRENDS NEUROSCI, V15, P20, DOI 10.1016/0166-2236(92)90344-8; JEANNEROD M, 1986, BEHAV BRAIN RES, V19, P99, DOI 10.1016/0166-4328(86)90008-2; JEANNEROD M, 1995, TRENDS NEUROSCI, V18, P314, DOI 10.1016/0166-2236(95)93921-J; Murata A, 1996, J NEUROPHYSIOL, V75, P2180, DOI 10.1152/jn.1996.75.5.2180; OScalaidhe SP, 1997, SCIENCE, V278, P1135, DOI 10.1126/science.278.5340.1135; PERENIN MT, 1988, BRAIN, V111, P643, DOI 10.1093/brain/111.3.643; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; RIZZOLATTI G, 1994, ATTENTION PERFORM, V15, P231; SAKATA H, 1995, CEREB CORTEX, V5, P429, DOI 10.1093/cercor/5.5.429; Shadlen M, 1997, NATURE, V386, P122, DOI 10.1038/386122a0; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; TAIRA M, 1990, EXP BRAIN RES, V83, P29; Troscianko T, 1996, CURR BIOL, V6, P200, DOI 10.1016/S0960-9822(02)00453-0; Ungerleider LG., 1982, ANAL VISUAL BEHAV, P549; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	26	310	312	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					500	503		10.1038/26752	http://dx.doi.org/10.1038/26752			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774105				2022-12-24	WOS:000076212200056
J	Marzo, I; Brenner, C; Zamzami, N; Jurgensmeier, JM; Susin, SA; Vieira, HLA; Prevost, MC; Xie, ZH; Matsuyama, S; Reed, JC; Kroemer, G				Marzo, I; Brenner, C; Zamzami, N; Jurgensmeier, JM; Susin, SA; Vieira, HLA; Prevost, MC; Xie, ZH; Matsuyama, S; Reed, JC; Kroemer, G			Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis	SCIENCE			English	Article							PERMEABILITY TRANSITION PORE; PROAPOPTOTIC PROTEIN BAX; CELL-DEATH; NUCLEAR APOPTOSIS; MAMMALIAN-CELLS; INNER MEMBRANE; CYTOCHROME-C; BCL-2; CHANNEL; YEAST	The proapoptotic Bax protein induces cell death by acting on mitochondria. Bax binds to the permeability transition pore complex (PTPC), a composite proteaceous channel that is involved in the regulation of mitochondrial membrane permeability. Immunodepletion of Bax from PTPC or purification of PTPC from Bax-deficient mice yielded a PTPC that could not permeabilize membranes in response to atractyloside, a proapoptotic Ligand of the adenine nucleotide translocator (ANT). Bax and ANT coimmunoprecipitated and interacted in the yeast two-hybrid system: Ectopic expression of Bax Induced cell death in wild-type but not in ANT-deficient yeast. Recombinant Bax and purified ANT, but neither of them alone, efficiently formed atractyloside-responsive channels in artificial membranes. Hence, the proapoptotic molecule Bax and the constitutive mitochondrial protein ANT cooperate within the PTPC to increase mitochondrial membrane permeability and to trigger cell death.	CNRS, UPR 420, F-94801 Villejuif, France; Univ Technol Compiegne, CNRS, UPRES A6022, F-60200 Compiegne, France; Burnham Inst, La Jolla, CA 92037 USA; Inst Pasteur, Unite Oncol Virale, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Picardie Universites; Universite de Technologie de Compiegne; Sanford Burnham Prebys Medical Discovery Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Kroemer, G (corresponding author), CNRS, UPR 420, 19 Rue Guy Moquet, F-94801 Villejuif, France.	kroemer@infobiogen.fr	Susin, Santos A/Q-6754-2017; Vieira, Helena/AAZ-9562-2021; Juergensmeier, Juliane/I-4117-2013; Marzo, Isabel/E-6918-2016; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Susin, Santos A/0000-0002-3366-1628; Marzo, Isabel/0000-0002-2315-9079; KROEMER, Guido/0000-0002-9334-4405; Vieira, Helena/0000-0001-9415-3742				Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Bargou RC, 1996, J CLIN INVEST, V97, P2651, DOI 10.1172/JCI118715; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; Bisaccia F, 1996, BBA-PROTEIN STRUCT M, V1292, P281, DOI 10.1016/0167-4838(95)00215-4; Brustovetsky N, 1996, BIOCHEMISTRY-US, V35, P8483, DOI 10.1021/bi960833v; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; GironCalle J, 1996, BIOCHEMISTRY-US, V35, P15440, DOI 10.1021/bi960840j; GonzalezBarroso MM, 1997, BIOCHEMISTRY-US, V36, P10930, DOI 10.1021/bi971104y; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Halestrap AP, 1997, J BIOL CHEM, V272, P3346, DOI 10.1074/jbc.272.6.3346; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; KLINGENBERG M, 1980, J MEMBRANE BIOL, V56, P97, DOI 10.1007/BF01875961; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; MARZO I, UNPUB; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Petit PX, 1998, FEBS LETT, V426, P111, DOI 10.1016/S0014-5793(98)00318-4; REINHART PH, 1982, BIOCHEM J, V204, P731, DOI 10.1042/bj2040731; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruck A, 1998, FEBS LETT, V426, P97, DOI 10.1016/S0014-5793(98)00317-2; SALVAYRE AN, 1997, FASEB J, V11, P809; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Shimizu S, 1998, P NATL ACAD SCI USA, V95, P1455, DOI 10.1073/pnas.95.4.1455; Susin SA, 1997, EXP CELL RES, V236, P397, DOI 10.1006/excr.1997.3733; SUSIN SA, IN PRESS METHODS ENZ; TRGON T, 1991, FEBS LETT, V289, P159; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Xie ZH, 1998, BIOCHEMISTRY-US, V37, P6410, DOI 10.1021/bi973052i; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zamzami N, 1996, J EXP MED, V183, P1533, DOI 10.1084/jem.183.4.1533; Zamzami N, 1998, ONCOGENE, V16, P1055, DOI 10.1038/sj.onc.1201864; Zha HB, 1997, J BIOL CHEM, V272, P31482, DOI 10.1074/jbc.272.50.31482; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	48	1038	1097	2	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2027	2031		10.1126/science.281.5385.2027	http://dx.doi.org/10.1126/science.281.5385.2027			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748162				2022-12-24	WOS:000076161800056
J	Kleyn, PW; Vesell, ES				Kleyn, PW; Vesell, ES			Genetic variation as a guide to drug development	SCIENCE			English	Article							ALZHEIMERS-DISEASE; POLYMORPHISM; PREDICTOR; ALLELE; CDNA		Millennium Predict Med Inc, Cambridge, MA 02139 USA; Penn State Univ, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Kleyn, PW (corresponding author), Millennium Predict Med Inc, 640 Mem Dr, Cambridge, MA 02139 USA.	kleyn@mpi.com						Arranz MJ, 1996, NEUROSCI LETT, V217, P177, DOI 10.1016/S0304-3940(96)13094-9; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; de Maat MPM, 1998, ARTERIOSCL THROM VAS, V18, P265, DOI 10.1161/01.ATV.18.2.265; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Drews J, 1996, NAT BIOTECHNOL, V14, P1516, DOI 10.1038/nbt1196-1516; EmmertBuck MR, 1996, SCIENCE, V274, P998, DOI 10.1126/science.274.5289.998; IDLE JR, 1979, DRUG METAB REV, V9, P301, DOI 10.3109/03602537908993896; Jukema JW, 1996, CIRCULATION, V94, P1913, DOI 10.1161/01.CIR.94.8.1913; Kornmann M, 1997, CANCER LETT, V118, P29, DOI 10.1016/S0304-3835(97)00220-6; Kuivenhoven JA, 1998, NEW ENGL J MED, V338, P86, DOI 10.1056/NEJM199801083380203; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Persidis A, 1998, NAT BIOTECHNOL, V16, P393, DOI 10.1038/nbt0498-393; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; Poirier J, 1995, P NATL ACAD SCI USA, V92, P12260, DOI 10.1073/pnas.92.26.12260; TRENT JM, 1984, J CLIN ONCOL, V2, P8, DOI 10.1200/JCO.1984.2.1.8; VANGELDER RN, 1990, P NATL ACAD SCI USA, V87, P1663, DOI 10.1073/pnas.87.5.1663; VATSIS KP, 1991, P NATL ACAD SCI USA, V88, P6333, DOI 10.1073/pnas.88.14.6333; Wilkins M. R., 1997, PROTEOME RES NEW FRO; Zubenko GS, 1998, GENOMICS, V50, P121, DOI 10.1006/geno.1998.5306	20	92	99	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	1998	281	5384					1820	1821		10.1126/science.281.5384.1820	http://dx.doi.org/10.1126/science.281.5384.1820			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776686				2022-12-24	WOS:000076007100040
J	Xu, L; Lavinsky, RM; Dasen, JS; Flynn, SE; McInerney, EM; Mullen, TM; Heinzel, T; Szeto, D; Korzus, E; Kurokawa, R; Aggarwal, AK; Rose, DW; Glass, CK; Rosenfeld, MG				Xu, L; Lavinsky, RM; Dasen, JS; Flynn, SE; McInerney, EM; Mullen, TM; Heinzel, T; Szeto, D; Korzus, E; Kurokawa, R; Aggarwal, AK; Rose, DW; Glass, CK; Rosenfeld, MG			Signal-specific co-activator domain requirements for Pit-1 activation	NATURE			English	Article							MEDIATE TRANSCRIPTIONAL RESPONSES; PROLACTIN GENE; HISTONE DEACETYLASE; N-COR; REPRESSION; CBP; HORMONE; COACTIVATOR; RECEPTORS; DNA	POU-domain proteins, such as the pituitary-specific factor Pit-1, are members of the homeodomain family of proteins which are important in development and homeostasis, acting constitutively or in response to signal-transduction pathways to either repress or activate the expression of specific genes(1). Here we show that whereas homeodomain-containing repressors such as Rpx(2) seem to recruit only a co-repressor complex, the activity of Pit-1 (ref. 3) is determined by a regulated balance between a co-repressor complex that contains N-CoR/SMRT4,5, mSin3A/B6-8 and histone deacetylases(6-8), and a co-activator complex that includes the CREB-binding protein (CBP)(9) and p/CAF(10). Activation of Pit-1 by cyclic AMP or growth factors depends on distinct amino- and carboxy-terminal domains of CBP, respectively. Furthermore, the histone acetyltransferase functions of CBP11,12 or p/CAF(10) are required for Pit-1 function that is stimulated by cyclic AMP or growth factors, respectively. These data show that there is a switch in specific requirements for histone acetyltransferases and CBP domains in mediating the effects of different signal-transduction pathways on specific DNA-bound transcription factors.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Biol, Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Whittier Diabet Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept & Sch Med, La Jolla, CA 92093 USA; CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Heinzel, Thorsten/B-1013-2015; Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; MULLEN, Tina-Marie/0000-0001-6150-8084				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ELSHOLTZ HP, 1991, J BIOL CHEM, V266, P22919; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; Gray S, 1996, CURR OPIN CELL BIOL, V8, P358; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hermesz E, 1996, DEVELOPMENT, V122, P41; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HOWARD PW, 1995, J BIOL CHEM, V270, P20930, DOI 10.1074/jbc.270.36.20930; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jacobson EM, 1997, GENE DEV, V11, P198, DOI 10.1101/gad.11.2.198; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MURDOCH GH, 1985, J BIOL CHEM, V260, P1852; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OKIMURA Y, 1994, MOL ENDOCRINOL, V8, P1559, DOI 10.1210/me.8.11.1559; ONATE SA, 1995, SCIENCE, V270, P1354; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0	28	241	242	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					301	306		10.1038/26270	http://dx.doi.org/10.1038/26270			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751061				2022-12-24	WOS:000075974600057
J	Mochizuki, T; Saijoh, Y; Tsuchiya, K; Shirayoshi, Y; Takai, S; Taya, C; Yonekawa, H; Yamada, K; Nihei, H; Nakatsuji, N; Overbeek, PA; Hamada, H; Yokoyama, T				Mochizuki, T; Saijoh, Y; Tsuchiya, K; Shirayoshi, Y; Takai, S; Taya, C; Yonekawa, H; Yamada, K; Nihei, H; Nakatsuji, N; Overbeek, PA; Hamada, H; Yokoyama, T			Cloning of inv, a gene that controls left/right asymmetry and kidney development	NATURE			English	Article							NODAL EXPRESSION; YEAST; MOUSE; SIMILARITY; DROSOPHILA; PROTEINS; INVERSUS; MUTATION; EMBRYOS; NOTCH	Most vertebrate internal organs show a distinctive left/right asymmetry. The inv (inversion of embryonic turning) mutation in mice was created previously by random insertional mutagenesis(1); it produces both a constant reversal of left/right polarity (situs inversus) and cyst formation in the kidneys(2). Asymmetric expression patterns of the genes nodal and lefty are reversed in the inv mutant(3-6), indicating that inv may act early in left/right determination. Here we identify a new gene located at the inv locus. The encoded protein contains 15 consecutive repeats of an Ank/Swi6 motif(7,8) at its amino terminus. Expression of the gene is the highest in the kidneys and liver among adult tissues, and is seen in presomite-stage embryos. Analysis of the transgenic genome and the structure of the candidate gene indicate that the candidate gene is the only gene that is disrupted in inv mutants. Transgenic introduction of a minigene encoding the candidate protein restores normal left/right asymmetry and kidney development in the inv mutant, confirming the identity of the candidate gene.	Japan Sci & Technol Corp, Crest, Tokyo 1700013, Japan; Tokyo Womens Med Univ, Sch Med, Dept Med, Kidney Ctr,Shinjuku Ku, Tokyo 1628600, Japan; Tokyo Womens Med Univ, Sch Med, Dept Anat & Dev Biol, Shinjuku Ku, Tokyo 1628600, Japan; Osaka Univ, Inst Mol & Cellular Biol, Suita, Osaka 565, Japan; Natl Inst Genet, Mammalian Dev Lab, Mishima, Shizuoka 411, Japan; Inst Med Ctr Japan, Res Inst, Dept Genet, Shinjuku Ku, Tokyo 162, Japan; Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 113, Japan	Japan Science & Technology Agency (JST); Tokyo Women's Medical University; Tokyo Women's Medical University; Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Tokyo Metropolitan Institute of Medical Science	Yokoyama, T (corresponding author), Japan Sci & Technol Corp, Crest, Tokyo 1700013, Japan.	tyoko@research.twmc.ac.jp	Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948; Overbeek, Paul/0000-0001-9784-2084; Saijoh, Yukio/0000-0002-7548-4789				ANDREWS BJ, 1989, NATURE, V342, P830, DOI 10.1038/342830a0; AVES SJ, 1985, EMBO J, V4, P457, DOI 10.1002/j.1460-2075.1985.tb03651.x; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; HOGAN B, 1986, MANIPULATING MOUSE E, P153; Hummel K. P., 1959, Journal of Heredity, V50, P9; Hyatt BA, 1996, NATURE, V384, P62, DOI 10.1038/384062a0; Hyatt BA, 1998, CELL, V93, P37, DOI 10.1016/S0092-8674(00)81144-7; Isaac A, 1997, SCIENCE, V275, P1301, DOI 10.1126/science.275.5304.1301; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LARIN Z, 1991, P NATL ACAD SCI USA, V88, P4123, DOI 10.1073/pnas.88.10.4123; LAWRENCE JB, 1988, CELL, V52, P51; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Lowe LA, 1996, NATURE, V381, P158, DOI 10.1038/381158a0; LUX SE, 1990, NATURE, V344, P36, DOI 10.1038/344036a0; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1996, NATURE, V381, P151, DOI 10.1038/381151a0; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PETERS LL, 1993, SEMIN HEMATOL, V30, P85; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; YOCHEM J, 1989, CELL, V58, P887; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOKOYAMA T, 1995, DEVELOPMENTAL MECHANISMS OF HEART DISEASE, P513; YOKOYAMA T, 1990, NUCLEIC ACIDS RES, V18, P7293, DOI 10.1093/nar/18.24.7293; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0	29	208	213	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 10	1998	395	6698					177	181		10.1038/26006	http://dx.doi.org/10.1038/26006			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744276				2022-12-24	WOS:000075829900043
J	Dustin, ML; Olszowy, MW; Holdorf, AD; Li, J; Bromley, S; Desai, N; Widder, P; Rosenberger, F; van der Merwe, PA; Allen, PM; Shaw, AS				Dustin, ML; Olszowy, MW; Holdorf, AD; Li, J; Bromley, S; Desai, N; Widder, P; Rosenberger, F; van der Merwe, PA; Allen, PM; Shaw, AS			A novel adaptor protein orchestrates receptor patterning and cytoskeletal polarity in T-cell contacts	CELL			English	Article							ADHESION MOLECULE-1 ICAM-1; PRESENTING B-CELLS; ANTIGEN RECEPTOR; CYTOPLASMIC DOMAIN; BINDING-PROTEIN; CD2; RECOGNITION; ACTIVATION; COMPLEX; LFA-1	Recognition of antigen by T cells requires the formation of a specialized junction between the T cell and the antigen-presenting cell. This junction is generated by the recruitment and the exclusion of specific proteins from the contact area. The mechanisms that regulate these events are unknown. Here we demonstrate that ligand engagement of the adhesion molecule, CD2, initiates a process of protein segregation, CD2 clustering, and cytoskeletal polarization. Although protein segregation was not dependent on the cytoplasmic domain of CD2, CD2 clustering and cytoskeletal polarization required an interaction of the CD2 cytoplasmic domain with a novel SH3-containing protein. This novel protein, called CD2AP, is likely to facilitate receptor patterning in the contact area by linking specific adhesion receptors to the cytoskeleton.	Washington Univ, Inst Biomed Comp, Dept Pathol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Inst Biomed Comp, Ctr Immunol, Sch Med, St Louis, MO 63110 USA; Univ Oxford, Sir William Dunn Sch Pathol, MRC, Cellular Immunol Unit, Oxford OX1 3RE, England	Washington University (WUSTL); Washington University (WUSTL); University of Oxford	Shaw, AS (corresponding author), Washington Univ, Inst Biomed Comp, Dept Pathol, Sch Med, St Louis, MO 63110 USA.		Dustin, Michael/AAM-4611-2020; van der Merwe, P. Anton/F-8539-2011	Dustin, Michael/0000-0003-4983-6389; Holdorf, Amy/0000-0001-5699-4081				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOCKENSTEDT LK, 1988, J IMMUNOL, V141, P1904; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CLAYTON LK, 1987, EUR J IMMUNOL, V17, P1367, DOI 10.1002/eji.1830170922; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; Davis SJ, 1996, IMMUNOL TODAY, V17, P177, DOI 10.1016/0167-5699(96)80617-7; Dustin ML, 1997, J BIOL CHEM, V272, P30889, DOI 10.1074/jbc.272.49.30889; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Dustin ML, 1997, P NATL ACAD SCI USA, V94, P3909, DOI 10.1073/pnas.94.8.3909; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; EVAN GI, 1985, MOL CELL BIOL, V4, P2843; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HAHN WC, 1992, P NATL ACAD SCI USA, V89, P7179, DOI 10.1073/pnas.89.15.7179; HE Q, 1988, CELL, V54, P979, DOI 10.1016/0092-8674(88)90112-2; JEFFERIES WA, 1985, J EXP MED, V162, P117, DOI 10.1084/jem.162.1.117; KATO K, 1992, J EXP MED, V176, P1241, DOI 10.1084/jem.176.5.1241; KILEEN N, 1992, EMBO J, V11, P4329; KUPFER A, 1986, P NATL ACAD SCI USA, V83, P6080, DOI 10.1073/pnas.83.16.6080; KUPFER A, 1989, J EXP MED, V170, P1697, DOI 10.1084/jem.170.5.1697; Lowin-Kropf B, 1998, J CELL BIOL, V140, P861, DOI 10.1083/jcb.140.4.861; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12861; MCCONNELL HM, 1986, BIOCHIM BIOPHYS ACTA, V864, P95, DOI 10.1016/0304-4157(86)90016-X; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; MONKS CRF, 1998, IN PRESS NATURE, V395; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; OLIVE D, 1986, EUR J IMMUNOL, V16, P1063, DOI 10.1002/eji.1830160906; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PREZA C, 1992, J OPT SOC AM A, V9, P219, DOI 10.1364/JOSAA.9.000219; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; RICKLES RJ, 1995, P NATL ACAD SCI USA, V92, P10909, DOI 10.1073/pnas.92.24.10909; Sambrook J., 1989, MOL CLONING; Shaw AS, 1997, IMMUNITY, V6, P361, DOI 10.1016/S1074-7613(00)80279-4; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; STAUNTON DE, 1990, CELL, V61, P243, DOI 10.1016/0092-8674(90)90805-O; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; TAKEI F, 1985, J IMMUNOL, V134, P1403; TEMPONI M, 1988, SEMIN ONCOL, V15, P595; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VANDERMERWE PA, 1995, CURR BIOL, V5, P74; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; XU P, 1995, J BIOL CHEM, V270, P25316, DOI 10.1074/jbc.270.43.25316	48	571	592	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					667	677		10.1016/S0092-8674(00)81608-6	http://dx.doi.org/10.1016/S0092-8674(00)81608-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741631	Green Published, Bronze			2022-12-24	WOS:000075851900014
J	Hallam, SJ; Jin, Y				Hallam, SJ; Jin, Y			lin-14 regulates the timing of synaptic remodelling in Caenorhabditis elegans	NATURE			English	Article							HETEROCHRONIC GENE LIN-14; NERVOUS-SYSTEM; C-ELEGANS; NEUROMUSCULAR-JUNCTIONS; NEMATODE; CONNECTIVITY; EXPRESSION; MUTANTS; PROTEIN; ENCODES	In the nematode Caenorhabditis elegans six GABAergic motor neurons, known as DDs(1,2), remodel their patterns of synaptic connectivity during larval development(3). DD remodelling involves a complete reversal of the direction of information now within nerve processes without marked changes in process morphology. We used a marker localized in vivo to DD presynaptic zones to analyse how the timing of DD remodelling is controlled. In wild-type animals, DDs remodel their synaptic outputs within a 3-5-hour period at the end of the first larval stage. We show that the heterochronic gene lin-14, which controls the timing of stage-specific cell lineages(4,5), regulates the timing of DD synaptic output remodelling. In lin-14 loss-of-function mutants, DDs remodel precociously. The degree of precocious remodelling is correlated with the level of lin-14 activity. Expression of lin-14(+) in the DDs of lin-14-null mutants rescues the precocious remodelling, indicating that lin-14 can act cell-autonomously. Consistent with this hypothesis, LIN-14 protein levels decrease in the DDs before remodelling. Our observations reveal a role of heterochronic genes in non-dividing cells, and provide an example of cell-autonomous respecification of neuronal connectivity.	Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Jin, Y (corresponding author), Univ Calif Santa Cruz, Dept Biol, Sinsheimer Labs, Santa Cruz, CA 95064 USA.	jin@biology.ucsc.edu		Jin, Yishi/0000-0002-9371-9860				ALLEY KE, 1990, J NEUROBIOL, V21, P1092, DOI 10.1002/neu.480210713; AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AMBROS V, 1994, TRENDS GENET, V10, P123, DOI 10.1016/0168-9525(94)90213-5; AMBROS V, 1987, GENE DEV, V1, P398, DOI 10.1101/gad.1.4.398; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN LL, 1991, J NEUROSCI, V11, P2920; CLARK SG, 1994, GENETICS, V137, P987; DOTTI CG, 1987, NATURE, V330, P254, DOI 10.1038/330254a0; Euling S, 1996, CELL, V84, P667, DOI 10.1016/S0092-8674(00)81045-4; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; HARRIS WA, 1990, J NEUROBIOL, V21, P953, DOI 10.1002/neu.480210702; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; JORGENSEN EM, 1995, NATURE, V378, P196, DOI 10.1038/378196a0; Levine Richard B., 1995, Current Opinion in Neurobiology, V5, P28, DOI 10.1016/0959-4388(95)80083-2; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; NAITO M, 1992, NUCLEIC ACIDS RES, V20, P2967, DOI 10.1093/nar/20.12.2967; Nonet ML, 1998, J NEUROSCI, V18, P70; PURVES D, 1985, NATURE, V315, P404, DOI 10.1038/315404a0; PURVES D, 1980, SCIENCE, V210, P153, DOI 10.1126/science.7414326; RUVKUN G, 1989, NATURE, V338, P313, DOI 10.1038/338313a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TRUMAN JW, 1990, J NEUROBIOL, V21, P1072, DOI 10.1002/neu.480210711; WHITE JG, 1978, NATURE, V271, P764, DOI 10.1038/271764a0; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4; WIGHTMAN B, 1991, GENE DEV, V5, P1813, DOI 10.1101/gad.5.10.1813; WIGSTON DJ, 1990, J NEUROSCI, V10, P1753	29	131	134	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 3	1998	395	6697					78	82		10.1038/25757	http://dx.doi.org/10.1038/25757			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738501				2022-12-24	WOS:000075722200050
J	Schneider, BL; Patton, EE; Lanker, S; Mendenhall, MD; Wittenberg, C; Futcher, B; Tyers, M				Schneider, BL; Patton, EE; Lanker, S; Mendenhall, MD; Wittenberg, C; Futcher, B; Tyers, M			Yeast G1 cyclins are unstable in G1 phase	NATURE			English	Article							CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; MATING PHEROMONE; PROTEASOME PATHWAY; RAPID DEGRADATION; G2 CYCLINS; PHOSPHORYLATION; PROTEIN; KINASE; TURNOVER	In most eukaryotes, commitment to cell division occurs in late G1 phase at an event called Start in the yeast Saccharomyces cerevisiae(1), and called the restriction point in mammalian cells(2). Start is triggered by the cyclin-dependent kinase Cdc28 and three rate-limiting activators, the G1 cyclins Cln1, Cln2 and Cln3 (ref. 3). Cyclin accumulation in G1 is driven in part by the cell-cycle-regulated transcription of CLN1 and CLN2, which peaks at Start(3). CLN transcription is modulated by physiological signals that regulate G1 progression(4,5), but it is unclear whether Cln protein stability is cell-cycle-regulated It has been suggested that once cells pass Start, Cln proteolysis is triggered by the mitotic cyclins Clb1, 2, 3 and 4 (ref. 6), But here we show that G1 cyclins are unstable in G1 phase, and that Clb-Cdc28 activity is not needed for G1 cyclin turnover. Cln instability thus provides a means to couple Cln-Cdc28 activity to transcriptional regulation and protein synthetic rate in pre-Start G1 cells.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Toronto, Grad Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Kentucky, Dept Biochem, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA	Cold Spring Harbor Laboratory; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Scripps Research Institute; University of Kentucky	Futcher, B (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	futcher@cshl.org; tyers@mshri.on.ca	Tyers, Michael/ABE-3194-2021					AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; BARONI MD, 1994, NATURE, V371, P339, DOI 10.1038/371339a0; BARRAL Y, 1995, GENE DEV, V9, P399, DOI 10.1101/gad.9.4.399; Blondel M, 1996, NATURE, V384, P279, DOI 10.1038/384279a0; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1993, MOL CELL BIOL, V13, P3266, DOI 10.1128/MCB.13.6.3266; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; KO HA, 1990, J BIOL CHEM, V265, P21652; Lanker S, 1996, SCIENCE, V271, P1597, DOI 10.1126/science.271.5255.1597; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; ROSSOW PW, 1979, P NATL ACAD SCI USA, V76, P4446, DOI 10.1073/pnas.76.9.4446; SALAMA SR, 1994, MOL CELL BIOL, V14, P7953, DOI 10.1128/MCB.14.12.7953; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; TOKIWA G, 1994, NATURE, V371, P342, DOI 10.1038/371342a0; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; VALDIVIESO MH, 1993, MOL CELL BIOL, V13, P1013, DOI 10.1128/MCB.13.2.1013; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731; ZETTERBERG A, 1991, COLD SH Q B, V56, P137	30	58	59	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					86	89		10.1038/25774	http://dx.doi.org/10.1038/25774			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738503				2022-12-24	WOS:000075722200052
J	Rolla, G; Brussino, L; Colagrande, P; Scappaticci, E; Morello, M; Bergerone, S; Ottobrelli, A; Cerutti, E; Polizzi, S; Bucca, C				Rolla, G; Brussino, L; Colagrande, P; Scappaticci, E; Morello, M; Bergerone, S; Ottobrelli, A; Cerutti, E; Polizzi, S; Bucca, C			Exhaled nitric oxide and impaired oxygenation in cirrhotic patients before and after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							HEPATOPULMONARY SYNDROME; DISEASE; ABNORMALITIES	Background: Nitric oxide may be involved in the impaired oxygenation of cirrhotic patients, a condition that improves in most patients after liver transplantation. Objective: To compare oxygenation and nitric oxide concentrations before and after liver transplantation. Design: Before-and-after observational study. Setting: Academic medical center. Patients: 18 patients with cirrhosis and no obvious cardiopulmonary disease who underwent successful orthotopic liver transplantation. Intervention: Orthotopic liver transplantation. Measurements: Blood gas analysis, measurement of exhaled nitric oxide, contrast-enhanced echocardiography, and pulmonary function tests. Results: Before transplantation, the mean (+/- SD) exhaled nitric oxide concentration was higher in patients than in normal controls (13 +/- 4.9 parts per billion [ppb] compared with 5.75 +/- 1.9 ppb; P < 0.001). After transplantation, the alveolar-arterial oxygen gradient significantly decreased (from 17.3 +/- 7.1 mm Hg to 9 +/- 5.2 mm Hg; P < 0.001), as did the exhaled nitric oxide concentration (from 13 +/- 4.9 ppb to 6.2 +/- 2.8 ppb; P < 0.001). The decrease in the exhaled nitric oxide concentration was significantly correlated with the decrease in the alveolar-arterial oxygen gradient (r = 0.56; P = 0.014). Five patients met the criteria for the diagnosis of the hepatopulmonary syndrome before transplantation; the syndrome was cured by transplantation. Conclusions: The correlation between the decrease in exhaled nitric oxide concentration after liver transplantation and the improvement in oxygenation reinforces the hypothesis that nitric oxide is an important mediator of impaired oxygenation in patients with cirrhosis.	Univ Turin, Dipartimento Sci Biomed & Oncol Umana, I-10126 Turin, Italy; Osped Molinette, Ctr Trapianto Epat, I-10126 Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; AOU San Giovanni Battista-Molinette	Rolla, G (corresponding author), Univ Turin, Dipartimento Sci Biomed & Oncol Umana, Via Genova 3, I-10126 Turin, Italy.		Bucca, Caterina/C-9886-2009; Rolla, Giovanni/C-9901-2009; brussino, luisa/J-2486-2012	Bucca, Caterina/0000-0002-9941-9236; Rolla, Giovanni/0000-0001-5997-7172; brussino, luisa/0000-0001-7249-7616				[Anonymous], 1995, AM J RESP CRIT CARE, V152, P2185; BARZILAI B, 1991, AM J CARDIOL, V68, P1507, DOI 10.1016/0002-9149(91)90287-U; Battaglia SE, 1997, HEPATOLOGY, V25, P1228, DOI 10.1002/hep.510250527; CREMONA G, 1995, EUR RESPIR J, V8, P1883, DOI 10.1183/09031936.95.08111883; Fallon MB, 1997, GASTROENTEROLOGY, V113, P606, DOI 10.1053/gast.1997.v113.pm9247483; HOURANI JM, 1991, AM J MED, V90, P693; ISAWA T, 1978, AM REV RESPIR DIS, V118, P55; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KROWKA MJ, 1985, MAYO CLIN PROC, V60, P407, DOI 10.1016/S0025-6196(12)60852-0; KROWKA MJ, 1994, CHEST, V105, P1528, DOI 10.1378/chest.105.5.1528; MATSUMOTO A, 1995, ANN INTERN MED, V123, P110, DOI 10.7326/0003-4819-123-2-199507150-00005; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RodriguezRoisin R, 1997, GASTROENTEROLOGY, V113, P682, DOI 10.1053/gast.1997.v113.agast971130682; RODRIGUEZROISIN R, 1994, EUR RESPIR J, V7, P839; Rolla G, 1997, HEPATOLOGY, V26, P842, DOI 10.1002/hep.510260406; SCHRADER PC, 1983, B EUR PHYSIOPATH RES, V19, P43; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260, DOI 10.1164/ajrccm.155.1.9001322; SOGNI P, 1995, J HEPATOL, V23, P218, DOI 10.1016/0168-8278(95)80339-4	18	132	140	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					375	378		10.7326/0003-4819-129-5-199809010-00005	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735065				2022-12-24	WOS:000075622600005
J	de Quervain, DJF; Roozendaal, B; McGaugh, JL				de Quervain, DJF; Roozendaal, B; McGaugh, JL			Stress and glucocorticoids impair retrieval of long-term spatial memory	NATURE			English	Article							DECLARATIVE MEMORY; CORTICOSTERONE; PERFORMANCE; RAT	Extensive evidence from animal and human studies indicates that stress and glucocorticoids influence cognitive function(1-11). Previous studies have focused exclusively on glucocorticoid effects on acquisition and long-term storage of newly acquired information. Here we report that stress and glucocorticoids also affect memory retrieval. We show that rats have impaired performance in a water-maze spatial task after being given footshock 30 min before retention testing but are not impaired when footshock is given 2 min or 4 h before testing. These time-dependent effects on retention performance correspond to the circulating corticosterone levels at the time of testing, which suggests that the retention impairment is directly related to increased adrenocortical function. In support of this idea, we find that suppression of corticosterone synthesis with metyrapone blocks the stress-induced retention impairment. In addition, systemic corticosterone administered to non-stressed rats 30 min before retention testing induces dose-dependent retention impairment. The impairing effects of stress and glucocorticoids on retention are not due to disruption of spatial navigation per se. Our results indicate that besides the well described effects of stress and glucocorticoids on acquisition and consolidation processes, glucocorticoids also affect memory retrieval mechanisms.	Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Psychobiol, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Roozendaal, B (corresponding author), Univ Calif Irvine, Ctr Neurobiol Learning & Memory, Irvine, CA 92697 USA.		Roozendaal, Benno/B-8403-2013	de Quervain, Dominique/0000-0001-7131-2464				Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; DEBOER SF, 1990, PHYSIOL BEHAV, V47, P1117, DOI 10.1016/0031-9384(90)90361-7; DEKLOET ER, 1991, FRONT NEUROENDOCRIN, V12, P955; JOELS M, 1994, ANN NY ACAD SCI, V746, P166; Kirschbaum C, 1996, LIFE SCI, V58, P1475, DOI 10.1016/0024-3205(96)00118-X; LUINE V, 1994, BRAIN RES, V639, P167, DOI 10.1016/0006-8993(94)91778-7; Luine Victoria, 1996, Physiology and Behavior, V59, P27, DOI 10.1016/0031-9384(95)02016-0; LUINE VN, 1993, BRAIN RES, V616, P65, DOI 10.1016/0006-8993(93)90193-Q; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; Lupien SJ, 1997, J CLIN ENDOCR METAB, V82, P2070, DOI 10.1210/jc.82.7.2070; MCEWEN BS, 1994, HORM BEHAV, V28, P396, DOI 10.1006/hbeh.1994.1036; Monk TH, 1997, J SLEEP RES, V6, P9, DOI 10.1046/j.1365-2869.1997.00023.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; NEWCOMER JW, 1994, J NEUROSCI, V14, P2047; OITZL MS, 1992, BEHAV NEUROSCI, V106, P62, DOI 10.1037/0735-7044.106.1.62; ORCHINIK M, 1994, ANN NY ACAD SCI, V746, P101; Roozendaal B, 1996, NEUROBIOL LEARN MEM, V65, P1, DOI 10.1006/nlme.1996.0001; Roozendaal B, 1996, PSYCHONEUROENDOCRINO, V21, P681, DOI 10.1016/S0306-4530(96)00028-5; Sandi C, 1997, EUR J NEUROSCI, V9, P637, DOI 10.1111/j.1460-9568.1997.tb01412.x; SHORS TJ, 1992, SCIENCE, V257, P537, DOI 10.1126/science.1636089; THOMAS DN, 1994, ANN NY ACAD SCI, V746, P467	21	867	908	1	79	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					787	790		10.1038/29542	http://dx.doi.org/10.1038/29542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723618				2022-12-24	WOS:000075503600047
J	Saito, N; Ebara, S; Ohotsuka, K; Kumeta, H; Takaoka, K				Saito, N; Ebara, S; Ohotsuka, K; Kumeta, H; Takaoka, K			Natural history of scoliosis in spastic cerebral palsy	LANCET			English	Article							SEGMENTAL SPINAL INSTRUMENTATION; FUSION; DEFORMITY; ROD	Background Although the frequent occurrence of scoliosis in patients who have spastic cerebral palsy is well known and surgical treatment has often been recommended for these patients, little is known about the natural history of scoliosis in this population. We aimed to clarify the natural history of scoliosis from childhood through to adulthood and provide objective data on proper surgical indications for such patients. Methods The participants were 37 institutionalised patients with severe spastic cerebral palsy and scoliosis. All the participants had a series of radiographs taken, starting at a mean age of 7.8 years; they were followed up for an average of 17.3 years. We retrospectively reviewed radiographs and assessed the effect of five factors on progression of scoliosis: sex, degree of spasticity, initial physical capability, pattern of spinal curve, and location of curve. Findings Scoliosis usually started before the age of 10 years and progressed rapidly during the growth period. In many cases, even after growth had ended, continuous progression was seen. The mean magnitude of the curves at final examination was 55 degrees (Cobb angle). In 11 (85%) of 13 patients who had a spinal curve of more than 40 degrees before age 15 years, the scoliosis progressed to more than 60 degrees by the time of the final examination. Meanwhile, in only three (13%) of 24 patients who had a curve of less than 40 degrees at age 15 years, did the scoliosis progress to more than 60 degrees. Severe scoliosis (greater than or equal to 60 degrees) developed predominantly in those who had total body involvement (67%), were bedridden (100%), or had throacolumbar curves (57%). Interpretation The risk factors for progression of scoliosis in spastic cerebral palsy are: having a spinal curve of 40 degrees before age 15 years; having total body involvement; being bedridden; and having a thoracolumbar curve. Patients with these risk factors might benefit from early surgical intervention to prevent progression to severe scoliosis.	Shinshu Univ, Sch Med, Dept Orthopaed Surg, Matsumoto, Nagano, Japan; Nagano Rehabil Ctr, Dept Orthopaed Surg, Nagano, Japan; E Nagano Hosp, Dept Orthopaed Surg, Nagano, Japan	Shinshu University	Saito, N (corresponding author), Shinshu Univ, Sch Med, Dept Orthopaed Surg, Asahi 3-1-1, Matsumoto, Nagano, Japan.							Balmer G A, 1970, J Bone Joint Surg Br, V52, P134; BOACHIEADJEI O, 1989, J BONE JOINT SURG AM, V71A, P548, DOI 10.2106/00004623-198971040-00011; BONNETT C, 1976, J BONE JOINT SURG AM, V58, P328, DOI 10.2106/00004623-197658030-00006; BROWN JC, 1982, SPINE, V7, P570, DOI 10.1097/00007632-198211000-00010; Bulman WA, 1996, J PEDIATR ORTHOPED, V16, P314, DOI 10.1097/01241398-199605000-00005; CASSIDY C, 1994, J PEDIATR ORTHOPED, V14, P731, DOI 10.1097/01241398-199414060-00008; GERSOFF WK, 1988, J BONE JOINT SURG AM, V70A, P41, DOI 10.2106/00004623-198870010-00007; KALEN V, 1992, J PEDIATR ORTHOPED, V12, P337, DOI 10.1097/01241398-199205000-00010; LONSTEIN JE, 1983, J BONE JOINT SURG AM, V65, P43, DOI 10.2106/00004623-198365010-00007; LONSTEIN JE, 1994, TXB SCOLIOSIS OTHER, P45; MADIGAN RR, 1981, SPINE, V6, P583, DOI 10.1097/00007632-198111000-00009; Majd ME, 1997, SPINE, V22, P1461, DOI 10.1097/00007632-199707010-00007; Miller A, 1996, J PEDIATR ORTHOPED, V16, P332, DOI 10.1097/01241398-199605000-00007; NASH CL, 1969, J BONE JOINT SURG AM, VA 51, P223, DOI 10.2106/00004623-196951020-00002; RENSHAW TS, 1995, J BONE JOINT SURG AM, V77, P1590, DOI 10.2106/00004623-199510000-00016; RINSKY LA, 1990, CLIN ORTHOP RELAT R, V253, P100; ROBSON P, 1968, DEV MED CHILD NEUROL, V10, P447; ROSENTHAL RK, 1974, DEV MED CHILD NEUROL, V16, P664; SPONSELLER PD, 1986, J PEDIATR ORTHOPED, V6, P559, DOI 10.1097/01241398-198609000-00006; STANITSKI CL, 1982, SPINE, V7, P563, DOI 10.1097/00007632-198211000-00009; SUZUKI S, 1993, SPINE, V18, P2290, DOI 10.1097/00007632-199311000-00026; SWANK SM, 1989, SPINE, V14, P750, DOI 10.1097/00007632-198907000-00018; THOMETZ JG, 1988, J BONE JOINT SURG AM, V70A, P1290, DOI 10.2106/00004623-198870090-00002	23	158	167	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 6	1998	351	9117					1687	1692		10.1016/S0140-6736(98)01302-6	http://dx.doi.org/10.1016/S0140-6736(98)01302-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734885				2022-12-24	WOS:000074088900009
J	Schnuelle, P; van der Woude, FJ				Schnuelle, P; van der Woude, FJ			Should A(2) kidneys be transplanted into B or O recipients?	LANCET			English	Editorial Material							ACCELERATED ACUTE REJECTION; RENAL-TRANSPLANTATION; GRAFT-SURVIVAL; A2; EXPERIENCE; ALLOGRAFTS; DONORS		Univ Heidelberg, Univ Hosp Mannheim, Fac Med, Med Clin 5, D-68135 Mannheim, Germany	Ruprecht Karls University Heidelberg	Schnuelle, P (corresponding author), Univ Heidelberg, Univ Hosp Mannheim, Fac Med, Med Clin 5, D-68135 Mannheim, Germany.							ALEXANDRE GPJ, 1987, TRANSPLANT P, V19, P4538; BARIETY J, 1980, KIDNEY INT, V17, P820, DOI 10.1038/ki.1980.94; BRYNGER H, 1984, TRANSPLANT P, V16, P1175; COOK DJ, 1987, TRANSPLANT P, V19, P4549; HANTO DW, 1993, TRANSPLANTATION, V56, P743; JAKOBSEN A, 1987, TRANSPLANT P, V19, P4561; MENDEZ R, 1991, TRANSPLANT P, V23, P1738; Nelson PW, 1998, TRANSPLANTATION, V65, P256; NELSON PW, 1992, AM J SURG, V164, P541, DOI 10.1016/S0002-9610(05)81197-3; PORT FK, 1991, AM J KIDNEY DIS, V17, P519, DOI 10.1016/S0272-6386(12)80492-6; RYDBERG L, 1987, TRANSPLANT P, V19, P4528; SHAPIRA Z, 1987, TRANSPLANT P, V19, P4562; WELSH KI, 1987, TRANSPLANT P, V19, P4565	13	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1675	1676		10.1016/S0140-6736(05)77737-0	http://dx.doi.org/10.1016/S0140-6736(05)77737-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734881				2022-12-24	WOS:000074088900005
J	Gemke, RJBJ; Tasker, RC				Gemke, RJBJ; Tasker, RC			Clinical assessment of acute coma in children	LANCET			English	Editorial Material							SCALE		Wilhelmina Childrens Hosp, Dept Paediat Cardiol, NL-3501 CA Utrecht, Netherlands; Great Ormond St Hosp Children, London WC1N 3JH, England	Wilhelmina Kinderziekenhuis; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Gemke, RJBJ (corresponding author), Wilhelmina Childrens Hosp, Dept Paediat Cardiol, NL-3501 CA Utrecht, Netherlands.		Tasker, Robert C/R-5837-2019	Tasker, Robert/0000-0003-3647-8113				GORDON NS, 1983, NEUROPEDIATRICS, V14, P3, DOI 10.1055/s-2008-1059545; Kirkpatrick PJ, 1997, J NEUROL NEUROSUR PS, V62, P109, DOI 10.1136/jnnp.62.2.109; LOVEJOY FH, 1974, AM J DIS CHILD, V128, P36, DOI 10.1001/archpedi.1974.02110260038007; MORRAY JP, 1984, CRIT CARE MED, V12, P1018, DOI 10.1097/00003246-198412000-00002; PLUM F, 1966, DIAGNOSIS COMA STUPO; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; ROWLEY G, 1991, LANCET, V337, P535, DOI 10.1016/0140-6736(91)91309-I; SIMPSON DA, 1991, CHILD NERV SYST, V7, P183; Tatman A, 1997, ARCH DIS CHILD, V77, P519, DOI 10.1136/adc.77.6.519; TEASDALE G, 1974, LANCET, V2, P81; YAGER JY, 1990, AM J DIS CHILD, V144, P1088, DOI 10.1001/archpedi.1990.02150340032019	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					926	927						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734935				2022-12-24	WOS:000072770900006
J	Rosen, CJ				Rosen, CJ			Pre-emptive bone strikes in prevention of osteoporosis	LANCET			English	Editorial Material							WOMEN; FRACTURES		Univ Maine, St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA	University of Maine System; University of Maine Orono	Rosen, CJ (corresponding author), Univ Maine, St Joseph Hosp, Maine Ctr Osteoporosis Res & Educ, Bangor, ME 04401 USA.							Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; DawsonHughes B, 1997, NEW ENGL J MED, V337, P670, DOI 10.1056/NEJM199709043371003; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Hosking D, 1998, NEW ENGL J MED, V338, P485, DOI 10.1056/NEJM199802193380801; KIEL DP, 1987, NEW ENGL J MED, V317, P1169, DOI 10.1056/NEJM198711053171901; McClung M, 1998, ANN INTERN MED, V128, P253, DOI 10.7326/0003-4819-128-4-199802150-00001	7	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					927	928						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734936				2022-12-24	WOS:000072770900007
J	Brannon, EM; Terrace, HS				Brannon, EM; Terrace, HS			Ordering of the numerosities 1 to 9 by monkeys	SCIENCE			English	Article							SQUIRREL-MONKEYS; RHESUS-MONKEYS; SERIAL; CHIMPANZEE; DISCRIMINATION; JUDGMENTS; STIMULI; PIGEONS; SYMBOLS; RATS	A fundamental question in cognitive science is whether animals can represent numerosity (a property of a stimulus that is defined by the number of discriminable elements it contains) and use numerical representations computationally. Here, it was shown that rhesus monkeys represent the numerosity of visual stimuli and detect their ordinal disparity. Two monkeys were first trained to respond to exemplars of the numerosities 1 to 4 in an ascending numerical order (1 --> 2 --> 3 --> 4). As a control for non-numerical cues, exemplars were varied with respect to size, shape, and color, The monkeys were later tested, without reward, on their ability to order stimulus pairs composed of the novel numerosities 5 to 9. Both monkeys responded in an ascending order to the novel numerosities, These results show that rhesus monkeys represent the numerosities 1 to 9 on an ordinal scale.	Columbia Univ, Dept Psychol, New York, NY 10027 USA; Columbia Univ, Dept Psychiat, New York, NY 10027 USA	Columbia University; Columbia University	Brannon, EM (corresponding author), Columbia Univ, Dept Psychol, New York, NY 10027 USA.				NIMH NIH HHS [MH406462] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BOYSEN ST, 1989, J COMP PSYCHOL, V103, P23, DOI 10.1037/0735-7036.103.1.23; Breukelaar JWC, 1998, J EXP PSYCHOL ANIM B, V24, P84, DOI 10.1037/0097-7403.24.1.84; BUCKLEY PB, 1974, J EXP PSYCHOL, V103, P1131, DOI 10.1037/h0037361; CAPALDI EJ, 1988, J EXP PSYCHOL ANIM B, V14, P3, DOI 10.1037/0097-7403.14.1.3; Chen SF, 1997, PSYCHOL SCI, V8, P80, DOI 10.1111/j.1467-9280.1997.tb00687.x; Dantzig T., 1930, NUMBER LANGUAGE SCI; DAVIS H, 1988, BEHAV BRAIN SCI, V11, P602, DOI 10.1017/S0140525X00053693; DAVIS H, 1986, ANIM LEARN BEHAV, V14, P57, DOI 10.3758/BF03200037; Dehaene S, 1998, TRENDS NEUROSCI, V21, P355, DOI 10.1016/S0166-2236(98)01263-6; Emmerton J, 1997, ANIM LEARN BEHAV, V25, P234, DOI 10.3758/BF03199062; GALLISTEL CR, 1992, COGNITION, V44, P43, DOI 10.1016/0010-0277(92)90050-R; Gelman R., 1978, CHILDS UNDERSTANDING; HARLOW HF, 1949, PSYCHOL REV, V56, P51, DOI 10.1037/h0062474; Hauser MD, 1996, P NATL ACAD SCI USA, V93, P1514, DOI 10.1073/pnas.93.4.1514; Hiestand L, 1996, MATH COGNIT, V2, P171; HONIG WK, 1989, ANIM LEARN BEHAV, V17, P134, DOI 10.3758/BF03207628; HULSE SH, 1977, LEARN MOTIV, V8, P488, DOI 10.1016/0023-9690(77)90047-9; MATSUZAWA T, 1985, NATURE, V315, P57, DOI 10.1038/315057a0; MCGONIGLE BO, 1977, NATURE, V267, P694, DOI 10.1038/267694a0; MCGONIGLE BO, 1986, REASONING DISCOURSE, P141; MECK WH, 1983, J EXP PSYCHOL ANIM B, V9, P320, DOI 10.1037/0097-7403.9.3.320; MITCHELL RW, 1985, J COMP PSYCHOL, V99, P218, DOI 10.1037/0735-7036.99.2.218; MOYER RS, 1967, NATURE, V215, P1519, DOI 10.1038/2151519a0; Ohshiba N, 1997, JPN PSYCHOL RES, V39, P236, DOI 10.1111/1468-5884.00057; Olthof A, 1997, J EXP PSYCHOL ANIM B, V23, P325, DOI 10.1037/0097-7403.23.3.325; PEPPERBREG I, 1987, ETHLOGY, V75, P137; SWARTZ KB, 1991, J EXP PSYCHOL ANIM B, V17, P396, DOI 10.1037/0097-7403.17.4.396; TERRACE HS, 1984, QUANTITATIVE ANAL BE, P115; THOMAS RK, 1980, AM J PSYCHOL, V93, P247, DOI 10.2307/1422230; THOMAS RK, 1993, DEV NUMERICAL COMPET, P127; WASHBURN DA, 1991, PSYCHOL SCI, V2, P190, DOI 10.1111/j.1467-9280.1991.tb00130.x	31	381	390	2	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					746	749		10.1126/science.282.5389.746	http://dx.doi.org/10.1126/science.282.5389.746			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	132AM	9784133				2022-12-24	WOS:000076607500052
J	Armstrong, JA; Bieker, JJ; Emerson, BM				Armstrong, JA; Bieker, JJ; Emerson, BM			A SWI/SNF-related chromatin remodeling complex, E-RC1, is required for tissue-specific transcriptional regulation by EKLF in vitro	CELL			English	Article							KRUPPEL-LIKE FACTOR; HUMAN GAMMA-GLOBIN; SWI-SNF COMPLEX; BETA-THALASSEMIA; DNA INTERACTIONS; NUCLEOSOMAL DNA; BINDING PROTEIN; IN-VITRO; GENE; ACTIVATION	Erythroid Kruppel-like factor (EKLF) is necessary for stage-specific expression of the human beta-globin gene. We show that EKLF requires a SWI/SNF-related chromatin remodeling complex, EKLF coactivator-remodeling complex 1 (E-RC1), to generate a DNase I hypersensitive, transcriptionally active beta-globin promoter on chromatin templates in vitro. E-RC1 contains BRG1, BAF170, BAF155, and INI1 (BAF47) homologs of yeast SWI/SNF subunits, as well as a subunit unique to higher eukaryotes, BAF57, which is critical for chromatin remodeling and transcription with EKLF. E-RC1 displays functional selectivity toward transcription factors, since it cannot activate expression of chromatin-assembled HIV-1 templates with the E box-binding protein TFE-3. Thus, a member of the SWI/SNF family acts directly in transcriptional activation and may regulate subsets of genes by selectively interacting with specific DNA-binding proteins.	Salk Inst Biol Studies, Regulatory Biol Lab, La Jolla, CA 92037 USA; CUNY Mt Sinai Sch Med, Brookdale Ctr Mol Biol, New York, NY 10029 USA	Salk Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Emerson, BM (corresponding author), Salk Inst Biol Studies, Regulatory Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM 38760] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038760] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KP, 1995, MOL CELL BIOL, V15, P5957; Armstrong JA, 1996, MOL CELL BIOL, V16, P5634; Armstrong JA, 1998, CURR OPIN GENET DEV, V8, P165, DOI 10.1016/S0959-437X(98)80137-8; Baron MH, 1997, BBA-GENE STRUCT EXPR, V1351, P51, DOI 10.1016/S0167-4781(96)00195-9; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Bulger M., 1994, METH MOL G, V5, P241; Burns LG, 1997, MOL CELL BIOL, V17, P4811, DOI 10.1128/MCB.17.8.4811; Cairns BR, 1998, TRENDS BIOCHEM SCI, V23, P20, DOI 10.1016/S0968-0004(97)01160-2; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; Crossley M, 1996, MOL CELL BIOL, V16, P1695; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; FENG WC, 1994, J BIOL CHEM, V269, P1493; GROUDINE M, 1983, P NATL ACAD SCI-BIOL, V80, P7551, DOI 10.1073/pnas.80.24.7551; IMBALZANO AN, 1994, NATURE, V370, P481, DOI 10.1038/370481a0; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; KIM TK, 1994, P NATL ACAD SCI USA, V91, P4170, DOI 10.1073/pnas.91.10.4170; KULOZIK AE, 1991, BLOOD, V77, P2054; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; Mizuguchi G, 1997, MOL CELL, V1, P141, DOI 10.1016/S1097-2765(00)80015-5; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1982, NATURE, V296, P627, DOI 10.1038/296627a0; OwenHughes T, 1996, SCIENCE, V273, P513, DOI 10.1126/science.273.5274.513; PAPOULAS O, 1998, IN PRESS DEVELOPMENT; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; PERKINS AC, 1995, NATURE, V375, P318; SHERIDAN PL, 1995, GENE DEV, V9, P2090, DOI 10.1101/gad.9.17.2090; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Utley RT, 1997, J BIOL CHEM, V272, P12642, DOI 10.1074/jbc.272.19.12642; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; WEINTRAUB H, 1976, SCIENCE, V193, P848, DOI 10.1126/science.948749; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; WORKMAN JL, 1992, SCIENCE, V258, P1780, DOI 10.1126/science.1465613; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	48	268	277	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					93	104		10.1016/S0092-8674(00)81785-7	http://dx.doi.org/10.1016/S0092-8674(00)81785-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778250	Bronze			2022-12-24	WOS:000076242300013
J	Jarvis, P; Chen, LJ; Li, HM; Pete, CA; Fankhauser, C; Chory, J				Jarvis, P; Chen, LJ; Li, HM; Pete, CA; Fankhauser, C; Chory, J			An Arabidopsis mutant defective in the plastid general protein import apparatus	SCIENCE			English	Article							DEVELOPMENTAL REGULATION; CHLOROPLAST ENVELOPE; CHLOROPHYLL-A; EXPRESSION; TRANSPORT; COMPONENTS; LEAF; DNA	Elaborate mechanisms have evolved for the translocation of nucleus-encoded proteins across the plastid envelope membrane. Although putative components of the import apparatus have been identified biochemically, their role in import remains to be proven in vivo. An Arabidopsis mutant lacking a new component of the import machinery [translocon at the outer envelope membrane of chloroplasts (Toc33), a 33-kilodalton protein] has been isolated. The functional similarity of Toc33 to another translocon component (Toc34) implies that multiple different translocon complexes are present in plastids. Processes that are mediated by Toc33 operate during the early stages of plastid and Leaf development. The data demonstrate the in vivo role of a translocon component in plastid protein import.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan; Salk Inst Biol Studies, Neuronal Struct & Funct Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Academia Sinica - Taiwan; Salk Institute; Howard Hughes Medical Institute; Salk Institute	Chory, J (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chory@salk.edu	Fankhauser, Christian/ABE-8757-2021; Li, Hsou-min/AAZ-8011-2021; Fankhauser, Christian/C-4291-2018	Fankhauser, Christian/0000-0003-4719-5901; Li, Hsou-min/0000-0002-0211-7339; Fankhauser, Christian/0000-0003-4719-5901				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; DAHLIN C, 1991, PLANT CELL, V3, P1131, DOI 10.1105/tpc.3.10.1131; DEAN C, 1982, PLANT PHYSIOL, V69, P904, DOI 10.1104/pp.69.4.904; FANKHAUSER C, UNPUB; Fuks B, 1997, PLANT PHYSIOL, V114, P405, DOI 10.1104/pp.114.2.405; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; LAMPPA GK, 1985, MOL CELL BIOL, V5, P1370, DOI 10.1128/MCB.5.6.1370; Li HM, 1997, J BIOL CHEM, V272, P10968; LI HM, 1995, PLANT CELL, V7, P1599, DOI 10.1105/tpc.7.10.1599; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; LOPEZJUEZ E, IN PRESS PLANT PHYSL; MULLET JE, 1988, ANNU REV PLANT PHYS, V39, P475, DOI 10.1146/annurev.arplant.39.1.475; PERRY SE, 1991, METHOD CELL BIOL, V34, P327; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; REINBOTHE C, 1995, MOL CELL BIOL, V15, P6206; Reinbothe S, 1996, PLANT CELL, V8, P763, DOI 10.1105/tpc.8.5.763; Schnell DJ, 1997, TRENDS CELL BIOL, V7, P303, DOI 10.1016/S0962-8924(97)01111-2; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SEEDORF M, 1995, FEBS LETT, V367, P19, DOI 10.1016/0014-5793(95)00529-I; VIRO M, 1980, PLANTA, V150, P41, DOI 10.1007/BF00385613; Wan JX, 1996, J BIOL CHEM, V271, P31227, DOI 10.1074/jbc.271.49.31227	24	273	313	2	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					100	103		10.1126/science.282.5386.100	http://dx.doi.org/10.1126/science.282.5386.100			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756470				2022-12-24	WOS:000076294900047
J	Norman, PE; Semmens, JB; Lawrence-Brown, MMD; Holman, CDJ				Norman, PE; Semmens, JB; Lawrence-Brown, MMD; Holman, CDJ			Long term relative survival after surgery for abdominal aortic aneurysm in Western Australia: population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective: To determine the long term relative survival of all patients who had surgery for abdominal aortic aneurysm in Western Australia during 1985-94. Design: Population based study. Setting: Western Australia Subjects: All patients who had had surgery for abdominal aortic aneurysm in Western, Australia during 1985-94. Main outcome measures: Morbidity and mortality data of patients admitted and surgically treated for abdominal aortic aneurysm in Western Australia during 1985-94. Elective, ruptured, and acute non-ruptured cases were analysed separately. Independent analyses for sex and patients aged 80 years or more were also undertaken. Postoperative (>30 days) relative survival was assessed against age and sex matched controls. Results: Overall, 1475 (1257 men, 218 women) cases were identified The crude five year survival after elective surgery, including deaths within 30 days of surgery was 79% for both men and women. When compared with a matched population the five year relative survival after elective surgery was 94.9% (95% confidence interval 89.9% to 99.9%) for men but only 88.0% (76.3% to 99.7%) for women. The five year relative survival of those aged 80 years and over was good: 116.6% (89.1% to 144.0%) compared with 92.4% (87.7% to 97.0%) for those under 80 years of age (men and women combined). Cardiovascular disease caused 57.8% of the 341 deaths after 30 days. Conclusion: In a condition such as abdominal aortic aneurysm, which occurs in elderly patients, relative survival is more clinically meaningful than crude survival. The five year relative survival in cases of elective and ruptured abdominal aortic aneurysm was better in men than in women This is probably because of greater comorbidity in women with abdominal aortic aneurysm and this deserves more attention in the future. The long term survival outcome in octogenarians supports surgery in selected cases.	Univ Western Australia, Fremantle Hosp, Dept Surg, Fremantle, WA 6959, Australia; Univ Western Australia, Dept Publ Hlth, Ctr Hlth Serv Res, Nedlands, WA 6009, Australia; Royal Perth Hosp, Dept Vasc Surg, Perth, WA 6000, Australia	University of Western Australia; University of Western Australia; Royal Perth Hospital; University of Western Australia	Norman, PE (corresponding author), Univ Western Australia, Fremantle Hosp, Dept Surg, POB 480, Fremantle, WA 6959, Australia.	pnorman@cyllene.uwa.edu.au	Holman, Cashel DJ/B-6173-2009; Norman, Paul E/C-5485-2013	Norman, Paul E/0000-0003-3406-0506				Campbell W B, 1991, Eur J Vasc Surg, V5, P111; EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101; ESTEVE J, 1990, STAT MED, V9, P529, DOI 10.1002/sim.4780090506; HAKULINEN T, 1982, BIOMETRICS, V38, P933, DOI 10.2307/2529873; JOHNSTON KW, 1994, J VASC SURG, V20, P163, DOI 10.1016/0741-5214(94)90002-7; MULUK SC, 1994, J VASC SURG, V20, P880, DOI 10.1016/0741-5214(94)90224-0; *OFF NAT COD CTR A, 1995, TAB LIST DIS; *OFF NCC AUSTR VER, 1995, TAB LIST ANN IND PRO; OLSEN PS, 1991, J CARDIOVASC SURG, V32, P636; Semmens JB, 1998, BRIT J SURG, V85, P648; Semmens JB, 1998, AUST NZ J SURG, V68, P397, DOI 10.1111/j.1445-2197.1998.tb04786.x; SOREIDE O, 1982, SURGERY, V91, P188; STONEBRIDGE PA, 1993, BRIT J SURG, V80, P585, DOI 10.1002/bjs.1800800511; THERNEAU T, 1994, 52 MAYO CLIN; THOMAS PRS, 1988, BRIT J SURG, V75, P733, DOI 10.1002/bjs.1800750804; World Health Organization, 1978, INT CLASS PROC MED; World Health Organization, 1977, INT CLASS DIS MAN IN	17	94	96	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					852	856		10.1136/bmj.317.7162.852	http://dx.doi.org/10.1136/bmj.317.7162.852			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748177	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000076222300018
J	Cecconi, F; Alvarez-Bolado, G; Meyer, BI; Roth, KA; Gruss, P				Cecconi, F; Alvarez-Bolado, G; Meyer, BI; Roth, KA; Gruss, P			Apaf1 (CED-4 homolog) regulates programmed cell death in mammalian development	CELL			English	Article							EMBRYONIC STEM-CELLS; C-ELEGANS CED-4; CAENORHABDITIS-ELEGANS; INSITU HYBRIDIZATION; RETINITIS-PIGMENTOSA; NOONAN-SYNDROME; DEFICIENT MICE; BCL-2 FAMILY; CYTOCHROME-C; GENE	The cytosolic protein APAF1, human homolog of C. elegans CED-4 participates in the CASPASE 9 (CASP9)-dependent activation of CASP3 in the general apoptotic pathway. We have generated by gene trap a null allele of the murine Apaf1. Homozygous mutants die at embryonic day 16.5. Their phenotype includes severe craniofacial malformations, brain overgrowth, persistence of the interdigital webs, and dramatic alterations of the lens and retina. Homozygous embryonic fibroblasts exhibit reduced response to various apoptotic stimuli. In situ immunodetection shows that the absence of Apaf1 protein prevents the activation of Casp3 in vivo. In agreement with the reported function of CED-4 in C. elegans, this phenotype can be correlated with a defect of apoptosis. Our findings suggest that Apaf1 is essential for Casp3 activation in embryonic brain and is a key regulator of developmental programmed cell death in mammals.	Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA	Max Planck Society; Washington University (WUSTL)	Gruss, P (corresponding author), Max Planck Inst Biophys Chem, Dept Mol Cell Biol, D-37077 Gottingen, Germany.		Cecconi, Francesco/K-3969-2016	Cecconi, Francesco/0000-0002-5614-4359; Alvarez-Bolado, Gonzalo/0000-0002-3044-1603; Roth, Kevin/0000-0002-0643-995X	NINDS NIH HHS [NS35107, NS35484] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035484, R01NS035107] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUNT SM, 1981, BRAIN RES, V211, P399, DOI 10.1016/0006-8993(81)90712-5; CAPECCHI MR, 1974, P NATL ACAD SCI USA, V71, P4732, DOI 10.1073/pnas.71.12.4732; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Chowdhury K, 1997, NUCLEIC ACIDS RES, V25, P1531, DOI 10.1093/nar/25.8.1531; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; COULOMBRE JL, 1963, SCIENCE, V142, P1489, DOI 10.1126/science.142.3598.1489; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Deckwerth TL, 1996, NEURON, V17, P401, DOI 10.1016/S0896-6273(00)80173-7; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Farrow SN, 1996, CURR OPIN GENET DEV, V6, P45, DOI 10.1016/S0959-437X(96)90009-X; FERGUSON MWJ, 1988, DEVELOPMENT, V103, P41; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; Harris BS, 1997, TERATOLOGY, V55, P231, DOI 10.1002/(SICI)1096-9926(199704)55:4<231::AID-TERA3>3.3.CO;2-U; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; Hoeppner DJ, 1996, BBA-REV CANCER, V1242, P217, DOI 10.1016/0304-419X(95)00017-A; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; JACOBSON M, 1981, DEV NEUROBIOLOGY; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KNUDSON CM, 1995, SCIENCE, V270, P96, DOI 10.1126/science.270.5233.96; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Lang RA, 1997, CELL DEATH DIFFER, V4, P12, DOI 10.1038/sj.cdd.4400211; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lorenzetti ME, 1996, AM J MED GENET, V65, P97, DOI 10.1002/(SICI)1096-8628(19961016)65:2<97::AID-AJMG1>3.0.CO;2-R; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Newton K, 1998, CURR OPIN GENET DEV, V8, P68, DOI 10.1016/S0959-437X(98)80064-6; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; RECHSTEINER M, 1987, ANNU REV CELL BIOL, V3, P1, DOI 10.1146/annurev.cb.03.110187.000245; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Rehen SK, 1996, DEVELOPMENT, V122, P1439; Richman J, 1996, CURR BIOL, V6, P364, DOI 10.1016/S0960-9822(02)00496-7; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; SILVER J, 1973, J MORPHOL, V140, P159, DOI 10.1002/jmor.1051400204; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; SRINIVASAN A, 1998, IN PRESS CELL DEATH; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WELL M, 1996, J CELL BIOL, V133, P1053; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	61	770	790	0	23	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					727	737		10.1016/S0092-8674(00)81732-8	http://dx.doi.org/10.1016/S0092-8674(00)81732-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753320	hybrid			2022-12-24	WOS:000076021200006
J	Feldman, B; Gates, MA; Egan, ES; Dougan, ST; Rennebeck, G; Sirotkin, HI; Schier, AF; Talbot, WS				Feldman, B; Gates, MA; Egan, ES; Dougan, ST; Rennebeck, G; Sirotkin, HI; Schier, AF; Talbot, WS			Zebrafish organizer development and germ-layer formation require nodal-related signals	NATURE			English	Article							GOOSECOID EXPRESSION; SPEMANN ORGANIZER; MUTANT EMBRYOS; NO TAIL; GENE; MESODERM; MOUSE; SPECIFICATION; GASTRULATION; NUCLEI	The vertebrate body plan is established during gastrulation, when cells move inwards to form the mesodermal and endodermal germ layers. Signals from a region of dorsal mesoderm, which is termed the organizer, pattern the body axis by specifying the fates of neighbouring cells(1,2). The organizer is itself induced by earlier signals(1). Although members of the transforming growth factor-beta (TGF-beta) and Wnt families have been implicated in the formation of the organizer, no endogenous signalling molecule is known to be required for this process(1). Here we report that the zebrafish squint (sqt)(3) and cyclops (cyc)(4) genes have essential, although partly redundant, functions in organizer development and also in the formation of mesoderm and endoderm. We show that the sqt gene encodes a member of the TGF-beta superfamily that is related to mouse nodal. cyc encodes another nodal-related protein(5,6), which is consistent with our genetic evidence that sqt and cyc have overlapping functions. The sqt gene is expressed in a dorsal region of the blastula that includes the extraembryonic yolk syncytial layer (YSL). The YSL has been implicated as a source of signals that induce organizer development and mesendoderm formation(2,7). Misexpression of sqt RNA within the embryo or specifically in the YSL induces expanded or ectopic dorsal mesoderm, These results establish an essential role for nodal-related signals in organizer development and mesendoderm formation.	NYU Med Ctr, Skirball Inst Biomol Med, Dev Genet Program, New York, NY 10016 USA; NYU Med Ctr, Dept Cell Biol, New York, NY 10016 USA	New York University; New York University	Talbot, WS (corresponding author), NYU Med Ctr, Skirball Inst Biomol Med, Dev Genet Program, 540 1st Ave, New York, NY 10016 USA.		Dougan, Scott/B-8416-2008	Dougan, Scott/0000-0003-0214-4772; Feldman, Benjamin/0000-0003-4838-8641; , William/0000-0002-2048-7472; Schier, Alexander Franz/0000-0001-7645-5325				CONLON FL, 1994, DEVELOPMENT, V120, P1919; Harland R, 1997, ANNU REV CELL DEV BI, V13, P611, DOI 10.1146/annurev.cellbio.13.1.611; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; Heisenberg CP, 1997, DEV BIOL, V184, P85, DOI 10.1006/dbio.1997.8511; JONES CM, 1995, DEVELOPMENT, V121, P3651; Joseph EM, 1997, DEV BIOL, V184, P367, DOI 10.1006/dbio.1997.8510; Kanki JP, 1997, DEVELOPMENT, V124, P881; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Knapik EW, 1998, NAT GENET, V18, P338, DOI 10.1038/ng0498-338; KRAUSS S, 1991, DEVELOPMENT, V113, P1193; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; Mizuno T, 1996, NATURE, V383, P131, DOI 10.1038/383131a0; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Rebagliati MR, 1998, P NATL ACAD SCI USA, V95, P9932, DOI 10.1073/pnas.95.17.9932; Rebagliati MR, 1998, DEV BIOL, V199, P261, DOI 10.1006/dbio.1998.8935; SAMPATH K, IN PRESS NATUR; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1998, CURR OPIN GENET DEV, V8, P464, DOI 10.1016/S0959-437X(98)80119-6; Schneider S, 1996, MECH DEVELOP, V57, P191, DOI 10.1016/0925-4773(96)00546-1; SCHULTEMERKER S, 1992, DEVELOPMENT, V116, P1021; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; STACHEL SE, 1993, DEVELOPMENT, V117, P1261; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; Talbot WS, 1998, GENETICS, V148, P373; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; THISSE C, 1993, DEVELOPMENT, V119, P1203; TOYAMA R, 1995, DEVELOPMENT, V121, P383; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	553	578	2	41	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					181	185		10.1038/26013	http://dx.doi.org/10.1038/26013			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744277				2022-12-24	WOS:000075829900044
J	Butler, CC; Rollnick, S; Pill, R; Maggs-Rapport, F; Stott, N				Butler, CC; Rollnick, S; Pill, R; Maggs-Rapport, F; Stott, N			Understanding the culture of prescribing: qualitative study of general practitioners' and patients' perceptions of antibiotics for sore throats	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY-INFECTIONS; PRESCHOOL-CHILDREN; RANDOMIZED TRIAL; EXPECTATIONS; PENICILLIN; CARE; POPULATION; PHYSICIANS; STRATEGIES; RESISTANCE	Objectives: To better understand reasons for antibiotics being prescribed for sore throats despite well known evidence that they are generally of little help. Design: Qualitative study with semi-structured interviews. Setting: General practices in South Wales. Subjects: 21 general practitioners and 17 of their patients who had recently consulted for a sore throat or upper respiratory tract infection. Main outcome measures: Subjects' experience of management of the illness, patients' expectations, beliefs about antibiotic treatment for sore throats, and ideas for reducing prescribing. Results: Doctors knew of the evidence for marginal effectiveness yet often prescribed for good relationships with patients Possible patient benefit outweighed theoretical community risk from resistant bacteria. Most doctors found prescribing "against the evidence" uncomfortable and realised this probably increased workload, Explanations of the distinction between virus and bacterium often led to perceived confusion. Clinicians were divided on the value of leaflets and national campaigns, but several favoured patient empowerment for self care by other members of the primary care team. Patient expectations were seldom made explicit, and many were not met A third of patients had a clear expectation for antibiotics, and mothers were more likely to accept non-antibiotic treatment for their children than for themselves. Satisfaction was not necessarily related to receiving antibiotics, with many seeking reassurance, further information, and pain relief. Conclusions: This prescribing decision is greatly influenced by considerations of the doctor-patient relationship. Consulting strategies that make patient expectations explicit without damaging relationships might reduce unwanted antibiotics. Repeating evidence for lack or effectiveness is unlikely to change doctors' prescribing, but information about risk to individual patients might. Emphasising positive aspects of non-antibiotic treatment and lack of efficacy in general might be helpful.	Univ Wales Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales; Univ Wales Coll Med, Dept Dent Publ Hlth, Lansdowne Hosp, Cardiff CF4 4XN, S Glam, Wales	Cardiff University; Cardiff University	Rollnick, S (corresponding author), Univ Wales Coll Med, Llanedeyrn Hlth Ctr, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales.	genpract@cf.ac.uk	Butler, Christopher C/B-5048-2009	Rapport, Frances/0000-0002-4428-2826; Butler, Christopher/0000-0002-0102-3453				BRADLEY CP, 1992, BRIT MED J, V304, P294, DOI 10.1136/bmj.304.6822.294; BRITTEN N, 1994, BRIT J GEN PRACT, V44, P465; BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; CAMPION PD, 1984, BRIT MED J, V288, P1426, DOI 10.1136/bmj.288.6428.1426; Cartwright A., 1981, GEN PRACTICE REVISIT; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; COMAROFF J, 1976, SOCIOL REV, V24, P79, DOI 10.1111/j.1467-954X.1976.tb00574.x; Dagnelie CF, 1996, BRIT J GEN PRACT, V46, P589; Davey PG, 1996, BRIT MED J, V312, P613, DOI 10.1136/bmj.312.7031.613; DELMAR CB, 1997, ACUTE RESP INFECT MO; DEMELKER RA, 1991, BRIT J GEN PRACT, V41, P504; Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647; Glaser B. G., 1978, AWARENESS DYING; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Hamm RM, 1996, J FAM PRACTICE, V43, P56; Hart CA, 1998, BMJ-BRIT MED J, V316, P1255, DOI 10.1136/bmj.316.7140.1255; HAWKLEY PM, 1998, LANCET, V351, P1208; Herold BC, 1998, JAMA-J AM MED ASSOC, V279, P593, DOI 10.1001/jama.279.8.593; HERZ MJ, 1988, FAM PRACT, V5, P196, DOI 10.1093/fampra/5.3.196; Hickner JM, 1998, J FAM PRACTICE, V46, P119; Howe RW, 1997, BRIT J GEN PRACT, V47, P280; Kai J, 1996, BRIT MED J, V313, P987; Kai J, 1996, BRIT MED J, V313, P983; KUYVENHOVEN MM, 1993, FAM PRACT, V10, P266; Little P, 1996, FAM PRACT, V13, P317, DOI 10.1093/fampra/13.3.317; Little P, 1997, BRIT MED J, V315, P350; Little P, 1997, BMJ-BRIT MED J, V314, P722, DOI 10.1136/bmj.314.7082.722; Mainous AG, 1998, J FAM PRACTICE, V46, P142; Mainous AG, 1997, J FAM PRACTICE, V45, P75; Mainous AG, 1996, J FAM PRACTICE, V42, P357; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; NAVA JM, 1994, CLIN INFECT DIS, V19, P884, DOI 10.1093/clinids/19.5.884; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; *SHOUS LORDS SEL C, 1998, RES ANT OTH ANT AG; STOTT NCH, 1979, BRIT MED J, V1, P29, DOI 10.1136/bmj.1.6155.29; Swartz MN, 1997, NEW ENGL J MED, V337, P491, DOI 10.1056/NEJM199708143370709; TAN TQ, 1993, PEDIATRICS, V92, P761; VINSON DC, 1993, J FAM PRACTICE, V37, P23; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; WHITFIELD MJ, 1981, PRACTITIONER, V225, P234	44	471	479	0	45	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					637	642		10.1136/bmj.317.7159.637	http://dx.doi.org/10.1136/bmj.317.7159.637			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727992	Green Accepted, Bronze, Green Submitted, Green Published			2022-12-24	WOS:000075830200022
J	Yang, XL; Chang, HY; Baltimore, D				Yang, XL; Chang, HY; Baltimore, D			Essential role of CED-4 oligomerization in CED-3 activation and apoptosis	SCIENCE			English	Article							DEATH REGULATORS CED-9; CELL-DEATH; CYTOCHROME-C; ELEGANS; PROTEIN; ENCODES; DATP	Control,of the activation of apoptosis is important both in development and in protection against cancer. In the classic genetic model Caenorhabditis elegans,;the pro-apoptotic protein CED-4 activates the CED-3 caspase and is inhibited by the Bcl-2-like protein CED-9, Both processes are mediated by protein-protein interaction. Facilitating the proximity of CED-3 zymogen molecules was found to induce caspase activation and cell death. CED-4 protein oligomerized in cells and in vitro. This oligomerization induced CED-3 proximity and competed with CED-4:CED-9 interaction. Mutations that abolished CED-4 oligomerization inactivated its ability to activate CED-3, Thus, the mechanism of control is that CED-3 in CED-3:CED-4 complexes is activated by CED-4 oligomerization, which is inhibited by binding of CED-9 to CED-4.	MIT, Dept Biol, Cambridge, MA 02139 USA; CALTECH, Pasadena, CA 91125 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.				NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Chinnaiyan AM, 1997, NATURE, V388, P728, DOI 10.1038/41913; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; Hengartner MO, 1997, NATURE, V388, P714, DOI 10.1038/41873; HORVITZ HR, 1994, COLD SPRING HARB SYM, V59, P377, DOI 10.1101/SQB.1994.059.01.042; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Ottilie S, 1997, CELL DEATH DIFFER, V4, P526, DOI 10.1038/sj.cdd.4400288; Shaham S, 1996, CELL, V86, P201, DOI 10.1016/S0092-8674(00)80092-6; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Steller H, 1998, P NATL ACAD SCI USA, V95, P5421, DOI 10.1073/pnas.95.10.5421; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHOU H, 1997, CELL, V90, P405	23	224	240	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1355	1357		10.1126/science.281.5381.1355	http://dx.doi.org/10.1126/science.281.5381.1355			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721101				2022-12-24	WOS:000075666800051
J	Hatch, EE; Palmer, JR; Titus-Ernstoff, L; Noller, KL; Kaufman, RH; Mittendorf, R; Robboy, SJ; Hyer, M; Cowan, CM; Adam, E; Colton, T; Hartge, P; Hoover, RN				Hatch, EE; Palmer, JR; Titus-Ernstoff, L; Noller, KL; Kaufman, RH; Mittendorf, R; Robboy, SJ; Hyer, M; Cowan, CM; Adam, E; Colton, T; Hartge, P; Hoover, RN			Cancer risk in women exposed to diethylstilbestrol in utero	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; FOLLOW-UP; STILBESTROL THERAPY; YOUNG-WOMEN; PREGNANCY; MOTHERS; ADENOCARCINOMA; ESTROGENS; VAGINA	Context. - The association between in utero exposure to diethylstilbestrol (DES) and clear cell adenocarcinoma (CCA) of the vagina and cervix is well known, yet there has been no systematic study of DES-exposed daughters to determine whether they have an increased risk of other cancers, As many as 3 million women in the United States may have been exposed to DES in utero. Objective. - To determine whether women exposed to DES in utero have a higher risk of cancer after an average of 16 years of follow-up. Design. - A cohort study with mailed questionnaires and medical record review of reported cancer outcomes. Participants. - A cohort of 4536 DES-exposed daughters (of whom 81% responded) and 1544 unexposed daughters (of whom 79% responded) who were first identified in the mid-1970s. Main Outcome Measures. - Cancer incidence in DES-exposed daughters compared with population-based rates and compared with cancer incidence in unexposed daughters. Results. - To date, DES-exposed daughters have not experienced an increased risk for all cancers (rate ratio, 0.96; 95% confidence interval [CI], 0.58-1.56) or for individual cancer sites, except for CCA. Three cases of vaginal CCA occurred among the exposed daughters, resulting in a standardized incidence ratio of 40.7 (95% CI, 13.1-126.2) in comparison with population-based incidence rates. The rate ratio for breast cancer was 1.18 (95% CI, 0.56-2.49); adjustment for known risk factors did not alter this result. Conclusions. - Thus far, DES-exposed daughters show no increased cancer risk, except for CCA. Nevertheless, because exposed daughters included in our study were, on average, only 38 years old at last follow-up, continued surveillance is warranted to determine whether any increases in cancer risk occur during the menopausal years.	NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; Boston Univ, Sch Publ Hlth, Stone Epidemiol Unit, Boston, MA USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA; Univ Massachusetts, Med Ctr, Dept Obstet & Gynecol, Worcester, MA USA; Baylor Coll Med, Dept Obstet & Gynecol, Houston, TX 77030 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; Informat Management Serv, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Boston University; Dartmouth College; Norris Cotton Cancer Center; University of Massachusetts System; University of Massachusetts Worcester; Baylor College of Medicine; University of Chicago; Duke University; Duke University	Hatch, EE (corresponding author), NCI, Div Canc Epidemiol & Genet, 6130 Execut Blvd,MSC7362, Bethesda, MD 20892 USA.			Hatch, Elizabeth/0000-0001-7901-3928; Palmer, Julie/0000-0002-6534-335X				BIBBO M, 1977, OBSTET GYNECOL, V49, P1; BIBBO M, 1978, NEW ENGL J MED, V298, P763, DOI 10.1056/NEJM197804062981403; BRAUN MM, 1995, CANCER CAUSE CONTROL, V6, P519, DOI 10.1007/BF00054160; BRESLOW NE, 1987, IARC SCI PUBLICATION, V88; Calle EE, 1996, AM J EPIDEMIOL, V144, P645, DOI 10.1093/oxfordjournals.aje.a008976; COLTON T, 1993, JAMA-J AM MED ASSOC, V269, P2096, DOI 10.1001/jama.269.16.2096; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; Dodds EC, 1938, NATURE, V141, P247, DOI 10.1038/141247b0; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; GREENBERG ER, 1984, NEW ENGL J MED, V311, P1393, DOI 10.1056/NEJM198411293112201; GREENWALD P, 1971, NEW ENGL J MED, V285, P390, DOI 10.1056/NEJM197108122850707; Guisti RM, 1995, ANN INTERN MED, V122, P778; HADJIMICHAEL OC, 1984, J NATL CANCER I, V73, P831; HERBST AL, 1981, AM J OBSTET GYNECOL, V141, P1019; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HORNSBY PP, 1994, AM J OBSTET GYNECOL, V170, P709, DOI 10.1016/S0002-9378(94)70268-3; HUBBY MM, 1981, DEV EFFECTS DES PREG; Huckell C, 1996, LANCET, V348, P331, DOI 10.1016/S0140-6736(96)24031-0; LABARTHE D, 1978, OBSTET GYNECOL, V51, P453, DOI 10.1097/00006250-197804000-00014; MARSELOS M, 1993, EUR J CANCER, V29A, P149, DOI 10.1016/0959-8049(93)90597-9; MELNICK S, 1987, NEW ENGL J MED, V316, P514, DOI 10.1056/NEJM198702263160905; NOLLER KL, 1974, MED CLIN N AM, V58, P739; Ries L, 1994, NIH PUBLICATION, V94-2789; ROBBOY SJ, 1981, AM J OBSTET GYNECOL, V140, P579, DOI 10.1016/0002-9378(81)90236-2; ROBBOY SJ, 1984, JAMA-J AM MED ASSOC, V252, P2979, DOI 10.1001/jama.252.21.2979; SMITH OW, 1949, NEW ENGL J MED, V241, P562, DOI 10.1056/NEJM194910132411503; Thompson W D, 1990, Epidemiology, V1, P101, DOI 10.1097/00001648-199003000-00004; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x	29	138	141	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					630	634		10.1001/jama.280.7.630	http://dx.doi.org/10.1001/jama.280.7.630			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718055	Bronze			2022-12-24	WOS:000075384300032
J	Aversa, F; Tabilio, A; Velardi, A; Cunningham, I; Terenzi, A; Falzetti, F; Ruggeri, L; Barbabietola, G; Aristei, C; Latini, P; Reisner, Y; Martelli, MF				Aversa, F; Tabilio, A; Velardi, A; Cunningham, I; Terenzi, A; Falzetti, F; Ruggeri, L; Barbabietola, G; Aristei, C; Latini, P; Reisner, Y; Martelli, MF			Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; SEVERE COMBINED IMMUNODEFICIENCY; VERSUS-HOST DISEASE; ALLOGENEIC MARROW; UNRELATED DONORS; GRAFT-REJECTION; ENGRAFTMENT; IRRADIATION; ENHANCEMENT; RECIPIENTS	Background In this study we tried to achieve successful transplantation in patients with acute leukemia with the use of hematopoietic stem cells from donors who shared only one HLA haplotype with the recipient (a "full-haplotype mismatch"). To prevent graft failure, large doses of T-cell-depleted hematopoietic stem cells were transplanted after a conditioning regimen of enhanced myeloablation and immunosuppression was administered to the recipient. Methods Forty-three patients with high-risk acute leukemia who were scheduled for transplantation received total-body irradiation, thiotepa, fludarabine, and antithymocyte globulin. The graft consisted of peripheral-blood progenitor cells that had been mobilized in the donor with recombinant granulocyte colony-stimulating factor and also, in 28 cases, bone marrow. Bone marrow from the donor was depleted of T lymphocytes by processing with soybean agglutinin and E-rosetting. T-cell depletion of peripheral-blood mononuclear cells was achieved by E-rosetting followed by positive selection of CD34+ cells. No post-transplantation prophylaxis against graft-versus-host disease (GVHD) was administered, Results In all the patients, full donor-type engraftment was achieved. In none of the patients who could be evaluated did acute or chronic GVHD develop. Regimen-related toxicity was minimal. Eleven of the 23 patients with acute lymphoblastic leukemia had a relapse, as did 2 of the 20 patients with acute myeloid leukemia. Transplantation-related mortality was 40 percent. After a median follow-up of 18 months (range, 8 to 30), 12 of the 43 patients were alive and free of disease. All surviving patients had a good quality of life. Conclusions The main limitations of transplantation of bone marrow from donors who are matched with the recipient for only one HLA haplotype GVHD and graft failure - can be overcome. Since most patients have a relative with one haplotype mismatch, advances in this method will increase the availability of hematopoietic-cell transplantation as curative therapy for acute leukemia. (N Engl J Med 1998;339:1186-93.) (C) 1998, Massachusetts Medical Society.	Univ Perugia, Dept Internal & Expt Med, Hematopoiet Stem Cell Transplant Program, I-06100 Perugia, Italy; Univ Perugia, Dept Radiotherapy, I-06100 Perugia, Italy; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	University of Perugia; University of Perugia; Weizmann Institute of Science	Aversa, F (corresponding author), Univ Perugia, Monteluce Policlin, Ist Ematol, Via Brunamonti, I-06100 Perugia, Italy.		Reisner, Yair/AAA-4772-2019	Aversa, Franco/0000-0002-8871-6817; Reisner, Yair/0000-0002-3354-6945				ANASETTI C, 1989, NEW ENGL J MED, V320, P197, DOI 10.1056/NEJM198901263200401; ANASETTI C, 1995, ANNU REV MED, V46, P169; AVERSA F, 1994, BLOOD, V84, P3948, DOI 10.1182/blood.V84.11.3948.bloodjournal84113948; BACHARLUSTIG E, 1995, NAT MED, V1, P1268, DOI 10.1038/nm1295-1268; BEATTY PG, 1985, NEW ENGL J MED, V313, P765, DOI 10.1056/NEJM198509263131301; BEATTY PG, 1995, TRANSPLANTATION, V60, P778, DOI 10.1097/00007890-199510270-00003; BERENSON RJ, 1990, PROG CLIN BIOL RES, V333, P403; CHAMPLIN R, 1993, BONE MARROW TRANSPL, V11, P74; Ciccone E, 1996, IMMUNOL TODAY, V17, P450, DOI 10.1016/0167-5699(96)30054-V; CLIFT RA, 1990, BLOOD, V76, P1867; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; COTTLERFOX M, 1995, EXP HEMATOL, V23, P320; FISCHER A, 1990, LANCET, V336, P850, DOI 10.1016/0140-6736(90)92348-L; GALE RP, 1986, LANCET, V1, P1468; Gerritsen EJA, 1996, BONE MARROW TRANSPL, V18, P377; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; KAUFMAN CL, 1994, BLOOD, V84, P2436; KERNAN NA, 1987, TRANSPLANTATION, V43, P842, DOI 10.1097/00007890-198743060-00014; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Lamparelli T, 1997, BONE MARROW TRANSPL, V20, P1057, DOI 10.1038/sj.bmt.1701031; LAPIDOT T, 1990, P NATL ACAD SCI USA, V87, P4595, DOI 10.1073/pnas.87.12.4595; LAPIDOT T, 1992, BLOOD, V80, P2406; LUBIN I, 1995, TRANSPLANTATION, V60, P740, DOI 10.1097/00007890-199510150-00022; MARMONT AM, 1991, BLOOD, V78, P2120, DOI 10.1182/blood.V78.8.2120.bloodjournal7882120; MARTIN PJ, 1990, BONE MARROW TRANSPL, V6, P283; O'Reilly R J, 1996, Important Adv Oncol, P149; PETERSEN FB, 1994, BONE MARROW TRANSPL, P79; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; Rachamim N, 1998, TRANSPLANTATION, V65, P1386, DOI 10.1097/00007890-199805270-00017; REISNER Y, 1983, BLOOD, V61, P341; REISNER Y, 1986, P NATL ACAD SCI USA, V83, P4012, DOI 10.1073/pnas.83.11.4012; REISNER Y, 1995, IMMUNOL TODAY, V16, P437, DOI 10.1016/0167-5699(95)80021-2; REISNER Y, 1986, TRANSPLANTATION, V42, P312; Reisner Y., 1997, Blood, V90, p563A; REISNER Y, 1988, SERONO S REV, V13, P37; Rothberg PG, 1997, CLIN LAB MED, V17, P109, DOI 10.1016/S0272-2712(18)30235-X; SCHMIDT J, 1994, IMMUNOPHARMACOLOGY, V27, P173, DOI 10.1016/0162-3109(94)90013-2; SIENA S, 1991, BLOOD, V77, P400; Sierra J, 1997, BLOOD, V89, P4226, DOI 10.1182/blood.V89.11.4226; SOIFFER RJ, 1991, BONE MARROW TRANSPL, V7, P23; STROBER S, 1987, J IMMUNOL, V138, P699; Tabilio A, 1997, J HEMATOTHER, V6, P227, DOI 10.1089/scd.1.1997.6.227; TERENZI A, 1990, TRANSPLANTATION, V50, P717; TERENZI A, 1996, BONE MARROW TRANS S1, V17, pS11; THOMAS ED, 1983, J CLIN ONCOL, V1, P517, DOI 10.1200/JCO.1983.1.9.517; THOMAS JM, 1995, TRANSPLANTATION, V59, P245, DOI 10.1097/00007890-199501270-00017; Uchida N, 1998, J CLIN INVEST, V101, P961, DOI 10.1172/JCI1681; UrbanoIspizua A, 1997, BLOOD, V89, P3967, DOI 10.1182/blood.V89.11.3967; VELARDI A, 1990, BLOOD, V75, P1364; Velardi A., 1996, Blood, V88, p267A; WOODS WG, 1990, BONE MARROW TRANSPL, V6, P9	53	917	980	0	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1186	1193		10.1056/NEJM199810223391702	http://dx.doi.org/10.1056/NEJM199810223391702			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780338				2022-12-24	WOS:000076532400002
J	Lau, AY; Scharer, OD; Samson, L; Verdine, GL; Ellenberger, E				Lau, AY; Scharer, OD; Samson, L; Verdine, GL; Ellenberger, E			Crystal structure of a human alkylbase-DNA repair enzyme complexed to DNA: Mechanisms for nucleotide flipping and base excision	CELL			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; 3-METHYLADENINE-DNA GLYCOSYLASE; ENDONUCLEASE-III; ALKA GENE; OGG1 GENE; PROTEIN; CLONING; 1,N-6-ETHENOADENINE; SEQUENCE	DNA N-glycosylases are base excision-repair proteins that locate and cleave damaged bases from DNA as the first step in restoring the genetic blueprint. The human enzyme 3-methyladenine DNA glycosylase removes a diverse group of damaged bases from DNA, including cytotoxic and mutagenic alkylation adducts of purines. We report the crystal structure of human 3-methyladenine DNA glycosylase complexed to a mechanism-based pyrrolidine inhibitor. The enzyme has intercalated into the minor groove of DNA, causing the abasic pyrrolidine nucleotide to flip into the enzyme active site, where a bound water is poised for nucleophilic attack. The structure shows an elegant means of exposing a nucleotide for base excision as well as a network of residues that could catalyze the in-line displacement of a damaged base from the phosphodeoxyribose backbone.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Harvard Univ, Grad Program Biophys, Cambridge, MA 02138 USA	Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Erasmus University Rotterdam; Harvard University	Ellenberger, E (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	tome@jeckle.med.harvard.edu	Schärer, Orlando D./AAF-8613-2021; Scharer, Orlando/B-8908-2008	Scharer, Orlando/0000-0003-2425-2715; Lau, Albert/0000-0002-0967-7558				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Adams PD, 1997, P NATL ACAD SCI USA, V94, P5018, DOI 10.1073/pnas.94.10.5018; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barnes DE, 1993, CURR OPIN CELL BIOL, V5, P424, DOI 10.1016/0955-0674(93)90007-D; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BENNETT SE, 1995, BIOCHEMISTRY-US, V34, P6109, DOI 10.1021/bi00018a014; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Bjoras M, 1997, EMBO J, V16, P6314, DOI 10.1093/emboj/16.20.6314; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1998, IN PRESS ACTA CRYST; CHAKRAVARTI D, 1991, J BIOL CHEM, V266, P15710; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; CLARKE ND, 1984, MOL GEN GENET, V197, P368, DOI 10.1007/BF00329931; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; David SS, 1998, CHEM REV, V98, P1221, DOI 10.1021/cr980321h; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Doherty AJ, 1996, NUCLEIC ACIDS RES, V24, P2488, DOI 10.1093/nar/24.13.2488; DOSANJH MK, 1994, BIOCHEMISTRY-US, V33, P1624, DOI 10.1021/bi00173a002; DOSANJH MK, 1994, P NATL ACAD SCI USA, V91, P1024, DOI 10.1073/pnas.91.3.1024; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Ezaz-Nikpay K, 1994, Chem Biol, V1, P235, DOI 10.1016/1074-5521(94)90016-7; Fraser CM, 1997, NATURE, V390, P580, DOI 10.1038/37551; FRIEDBERG EC, 1995, DNA REPAIR MUTAGNESI; Girard PM, 1997, NUCLEIC ACIDS RES, V25, P3204, DOI 10.1093/nar/25.16.3204; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Hang B, 1996, CARCINOGENESIS, V17, P155, DOI 10.1093/carcin/17.1.155; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hodel AE, 1996, CELL, V85, P247, DOI 10.1016/S0092-8674(00)81101-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ISHIDA T, 1988, J AM CHEM SOC, V110, P2286, DOI 10.1021/ja00215a046; Jones T. A., 1992, MANUAL; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; Krokan HE, 1997, BIOCHEM J, V325, P1; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; LARSON K, 1985, MUTAT RES, V150, P77, DOI 10.1016/0027-5107(85)90103-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LEONARD GA, 1994, BIOCHEMISTRY-US, V33, P4755, DOI 10.1021/bi00182a002; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; Ma JC, 1997, CHEM REV, V97, P1303, DOI 10.1021/cr9603744; MACKAY WJ, 1994, J BACTERIOL, V176, P3224, DOI 10.1128/jb.176.11.3224-3230.1994; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; Mattes WB, 1996, CARCINOGENESIS, V17, P643, DOI 10.1093/carcin/17.4.643; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; Memisoglu A, 1996, GENE, V177, P229, DOI 10.1016/0378-1119(96)00308-3; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MOROHOSHI F, 1993, J BACTERIOL, V175, P6010, DOI 10.1128/JB.175.18.6010-6017.1993; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OCONNOR TR, 1991, BIOCHEM BIOPH RES CO, V176, P1170, DOI 10.1016/0006-291X(91)90408-Y; OCONNOR TR, 1993, NUCLEIC ACIDS RES, V21, P5561; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEGG AE, 1995, PROG NUCLEIC ACID RE, V51, P167, DOI 10.1016/S0079-6603(08)60879-X; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; Roy R, 1998, BIOCHEMISTRY-US, V37, P580, DOI 10.1021/bi972313l; RYDBERG B, 1982, EMBO J, V1, P211, DOI 10.1002/j.1460-2075.1982.tb01149.x; SAMSON L, 1991, P NATL ACAD SCI USA, V88, P9127, DOI 10.1073/pnas.88.20.9127; SANTERRE A, 1994, P NATL ACAD SCI USA, V91, P2240, DOI 10.1073/pnas.91.6.2240; SAPARBAEV M, 1995, NUCLEIC ACIDS RES, V23, P3750, DOI 10.1093/nar/23.18.3750; SAPARBAEV M, 1994, P NATL ACAD SCI USA, V91, P5873, DOI 10.1073/pnas.91.13.5873; SCHARER OD, 1995, J AM CHEM SOC, V117, P6623, DOI 10.1021/ja00129a039; Scharer OD, 1998, J BIOL CHEM, V273, P8592, DOI 10.1074/jbc.273.15.8592; SCHRAMM VL, 1994, J BIOL CHEM, V269, P18259; Singer B., 1983, MOL BIOL MUTAGENS CA; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Taverna P, 1996, J BACTERIOL, V178, P5105, DOI 10.1128/jb.178.17.5105-5111.1996; TERWILLIGER TC, 1997, SOLVE; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Verdine GL, 1997, CHEM BIOL, V4, P329, DOI 10.1016/S1074-5521(97)90123-X; WEIBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842; XUAN JC, 1992, NUCLEIC ACIDS RES, V20, P5457, DOI 10.1093/nar/20.20.5457; Yamagata Y, 1996, CELL, V86, P311, DOI 10.1016/S0092-8674(00)80102-6	86	262	268	0	21	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					249	258		10.1016/S0092-8674(00)81755-9	http://dx.doi.org/10.1016/S0092-8674(00)81755-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790531	Bronze			2022-12-24	WOS:000076538300012
J	Daviglus, ML; Liu, KA; Greenland, P; Dyer, AR; Garside, DB; Manheim, L; Lowe, LP; Rodin, M; Lubitz, J; Stamler, J				Daviglus, ML; Liu, KA; Greenland, P; Dyer, AR; Garside, DB; Manheim, L; Lowe, LP; Rodin, M; Lubitz, J; Stamler, J			Benefit of a favorable cardiovascular risk-factor profile in middle age with respect to Medicare costs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; BLOOD-PRESSURE; CARE; MORTALITY; PATTERNS; ACCURACY; WOMEN; DEATH; MEN	Background People without major risk factors for cardiovascular disease in middle age live longer than those with unfavorable risk-factor profiles. it is not known whether such low-risk status also results in lower expenditures for medical care at older ages. We used data from the Chicago Heart Association Detection Project in Industry to assess the relation of a low risk of cardiovascular disease in middle age to Medicare expenditures later in life. Methods We studied 7039 men and 6757 women who were 40 to 64 years of age when surveyed between 1967 and 1973 and who survived to have at least two years of Medicare coverage in 1984 through 1994. Men and women classified as being at low risk for cardiovascular disease were those who had the following characteristics at the time they were initially surveyed: serum cholesterol level, <200 mg per deciliter (5.2 mmol per liter); blood pressure, less than or equal to 120/80 mm Hg; no current smoking; an absence of electrocardiographic abnormalities; no history of diabetes; and no history of myocardial infarction. We compared Medicare costs for the 279 men (4.0 percent) and 298 women (4.4 percent) who had this low-risk profile with those for the rest of the study group, who were not at low risk. Health Care Financing Administration charges for services to Medicare beneficiaries were used to estimate average annual health care costs (total costs, those for cardiovascular diseases, and those for cancer). Results Average annual health care charges were much lower for persons at low risk - the total charges for the men at low risk were less than two thirds of the charges for the men not at low risk($1,615 less); for the women at low risk, the charges were less than one half of those far the women not at low risk ($1,885 less). Charges related to cardiovascular disease were lower for the low-risk groups of men and women than for those nor at low risk (by $979 and $556, respectively), and charges related to cancer were also lower (by $134 and $189). Conclusions People with favorable cardiovascular risk profiles in middle age had lower average annual Medicare charges in older age. Having optimal status with respect to major cardiovascular risk factors may result nor only in greater longevity but also in lower health care costs. (N Engl J Med 1998;339: 1122-9.) (C) 1998, Massachusetts Medical Society.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Div Geriatr, Chicago, IL 60611 USA; Northwestern Univ, Inst Hlth Serv Res & Policy Studies, Evanston, IL USA; Hlth Care Financing Adm, Off Res & Demonstrat, Baltimore, MD USA	Northwestern University; Northwestern University; Northwestern University	Daviglus, ML (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1102, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NHLBI NIH HHS [HL03387, HL21010] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K14HL003387, R01HL021010] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BERTERA RL, 1991, J OCCUP ENVIRON MED, V33, P1119, DOI 10.1097/00043764-199111000-00006; BLAUM CS, 1994, J AM GERIATR SOC, V42, P1087, DOI 10.1111/j.1532-5415.1994.tb06214.x; *BUR CENS, 1996, STAT ABSTR US 1996, P486; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; COX DR, 1972, J R STAT SOC B, V34, P187; *DEPT HLTH HUM SER, 1980, DHHS PUBL; Dyer A R, 1992, Ann Epidemiol, V2, P51, DOI 10.1016/1047-2797(92)90037-Q; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; GREENE VL, 1990, J GERONTOL, V45, P250; HLATKY MA, 1990, CIRCULATION, V82, P208; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; HULKA BS, 1985, MED CARE, V23, P438, DOI 10.1097/00005650-198505000-00009; Inter-Society Commission for Heart Disease Resources Atherosclerosis Study Group and Epidemiology Study Group, 1970, CIRCULATION, V42, pA55; KEIL JE, 1993, NEW ENGL J MED, V329, P73, DOI 10.1056/NEJM199307083290201; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2538, DOI 10.1001/jama.258.18.2538; LEIGH JP, 1992, INQUIRY-J HEALTH CAR, V29, P44; LEVINE JB, 1964, CLIN CHIM ACTA, V10, P381, DOI 10.1016/0009-8981(64)90073-7; Levit KR, 1996, HEALTH CARE FINANC R, V18, P175; LIU K, 1978, J CHRON DIS, V31, P399, DOI 10.1016/0021-9681(78)90004-8; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; *MILL ROB, 1987, HLTH RISKS BEH IMP M; *NAT HEART LUNG BL, 1994, TASK FORC RES EP PRE; NATHANSON CA, 1977, SOC SCI MED, V11, P13, DOI 10.1016/0037-7856(77)90141-X; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; PRINEAS RJ, 1983, HYPERTENSION, V5, P160; SCHAUFFLER HH, 1993, AM J PREV MED, V9, P146, DOI 10.1016/S0749-3797(18)30730-X; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; STAMLER J, 1991, CARDIOLOGY ILLUSTRAT, V2; Stamler J, 1992, CORONARY HEART DIS E, P35; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WOLINSKY FD, 1992, J GERONTOL, V47, pS173, DOI 10.1093/geronj/47.4.S173; Yen L T, 1991, Am J Health Promot, V6, P46; [No title captured]	37	135	138	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1122	1129		10.1056/NEJM199810153391606	http://dx.doi.org/10.1056/NEJM199810153391606			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129DP	9770560	Bronze			2022-12-24	WOS:000076448200006
J	Werstuck, G; Green, MR				Werstuck, G; Green, MR			Controlling gene expression in living cells through small molecule-RNA interactions	SCIENCE			English	Article							MAMMALIAN-CELLS; TRANSLATION; LIGANDS	Short RNA aptamers that specifically bind to a wide variety of Ligands in vitro can be isolated from randomized pools of RNA. Here it is shown that small molecule aptamers also bound their ligand in vivo, enabling development of a method for controlling gene expression in living cells. Insertion of a small molecule aptamer into the 5' untranslated region of a messenger RNA allowed its translation to be repressible by ligand addition in vitro as well as in mammalian cells. The ability of small molecules to control expression of specific genes could facilitate studies in many areas of biology and medicine.	Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, Worcester, MA 01605 USA	Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Green, MR (corresponding author), Univ Massachusetts, Med Ctr, Howard Hughes Med Inst, Program Mol Med, 373 Plantat St,Suite 309, Worcester, MA 01605 USA.							ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; KOZAK M, 1992, ANNU REV CELL BIOL, V8, P197, DOI 10.1146/annurev.cb.08.110192.001213; Liu C, 1996, P NATL ACAD SCI USA, V93, P940, DOI 10.1073/pnas.93.2.940; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Paraskeva E, 1998, P NATL ACAD SCI USA, V95, P951, DOI 10.1073/pnas.95.3.951; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SINGH R, 1995, SCIENCE, V268, P173; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; STRIPECKE R, 1994, MOL CELL BIOL, V14, P5898, DOI 10.1128/MCB.14.9.5898; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Uphoff KW, 1996, CURR OPIN STRUC BIOL, V6, P281, DOI 10.1016/S0959-440X(96)80045-5	14	328	379	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					296	298		10.1126/science.282.5387.296	http://dx.doi.org/10.1126/science.282.5387.296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765156				2022-12-24	WOS:000076370200049
J	Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL				Anderson, JD; Schubert, G; Jacobson, RA; Lau, EL; Moore, WB; Sjogren, WL			Europa's differentiated internal structure: Inferences from four Galileo encounters	SCIENCE			English	Article							SATELLITES; MOMENTS; MODELS	Radio Doppler data from four encounters of the Galileo spacecraft with the jovian moon Europa have been used to refine models of Europa's interior. Europa is most Likely differentiated into a metallic core surrounded by a rock mantle and a water ice-liquid outer shell, but the data cannot eliminate the possibility of a uniform mixture of dense silicate and metal beneath the water ice-liquid shell. The size of a metallic core is uncertain because of its unknown composition, but it could be as targe as about 50 percent of Europa's radius. The thickness of Europa's outer shell of water ice-liquid must lie in the range of about 80 to 170 kilometers.	CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of California System; University of California Los Angeles	Anderson, JD (corresponding author), CALTECH, Jet Prop Lab, 4800 Oak Grove Dr, Pasadena, CA 91109 USA.							Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Anderson JD, 1996, SCIENCE, V272, P709, DOI 10.1126/science.272.5262.709; ANDERSON JD, 1974, EXPT GRAVITATION, P163; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; COHEN ER, 1997, PHYS TODAY, V50, pBG7; Davies ME, 1992, CELEST MECH DYN ASTR, V53, P377, DOI 10.1007/BF00051818; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; HUBBARD WB, 1978, ICARUS, V33, P336, DOI 10.1016/0019-1035(78)90153-7; Kaula W.M., 1966, THEORY SATELLITE GEO; KHURANA KK, IN PRESS NATURE; Kivelson MG, 1997, SCIENCE, V276, P1239, DOI 10.1126/science.276.5316.1239; Kliore AJ, 1997, SCIENCE, V277, P355, DOI 10.1126/science.277.5324.355; LIESKE JH, 1977, ASTRON ASTROPHYS, V56, P333; Moyer T., 1971, JPLTR321527 CALTECH; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; Rappaport N, 1997, ICARUS, V126, P313, DOI 10.1006/icar.1996.5661; SCHUBERT G, 1977, PHILOS T R SOC A, V285, P523, DOI 10.1098/rsta.1977.0096; SCHUBERT G, 1994, ICARUS, V111, P433, DOI 10.1006/icar.1994.1154; SCHUBERT G, 1986, SATELLITES, P629; Seidelmann P. K., 1992, EXPLANATORY SUPPLEME; Sullivan R, 1998, NATURE, V391, P371, DOI 10.1038/34874; TAPLEY BD, 1973, RECENT ADV DYNAMICAL, P396; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; WOO R, 1979, J GEOPHYS RES-SPACE, V84, P7288, DOI 10.1029/JA084iA12p07288; ZHARKOV VN, 1985, ICARUS, V61, P92, DOI 10.1016/0019-1035(85)90157-5	27	280	286	2	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2019	2022		10.1126/science.281.5385.2019	http://dx.doi.org/10.1126/science.281.5385.2019			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748159				2022-12-24	WOS:000076161800053
J	Feldman, WC; Maurice, S; Binder, AB; Barraclough, BL; Elphic, RC; Lawrence, DJ				Feldman, WC; Maurice, S; Binder, AB; Barraclough, BL; Elphic, RC; Lawrence, DJ			Fluxes of fast and epithermal neutrons from lunar prospector: Evidence for water ice at the lunar poles	SCIENCE			English	Article							MERCURY RADAR; MOON; CLEMENTINE; STABILITY; DEPOSITS; IMAGES; MARS	Maps of epithermal- and fast-neutron fluxes measured by Lunar Prospector were used to search for deposits enriched in hydrogen at both lunar poles. Depressions in epithermal fluxes were observed close to permanently shaded areas at both poles. The peak depression at the North Pole is 4.6 percent below the average epithermal flux intensity at Lower latitudes, and that at the South Pole is 3.0 percent below the Low-Latitude average. No measurable depression in fast neutrons is seen at either pole. These data are consistent with deposits of hydrogen in the form of water ice that are covered by as much as 40 centimeters of desiccated regolith within permanently shaded craters near both poles.	Univ Calif Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Observ Midi Pyrenees, F-31400 Toulouse, France; Lunar Res Inst, Gilroy, CA 95020 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Feldman, WC (corresponding author), Univ Calif Los Alamos Natl Lab, MS D-466, Los Alamos, NM 87545 USA.		Lawrence, David J/E-7463-2015	Lawrence, David J/0000-0002-7696-6667				ALCOUFFE RE, 1995, LA7369M LANL; ARNOLD JR, 1979, J GEOPHYS RES, V84, P5659, DOI 10.1029/JB084iB10p05659; Butler BJ, 1997, J GEOPHYS RES-PLANET, V102, P19283, DOI 10.1029/97JE01347; BUTLER BJ, 1993, J GEOPHYS RES-PLANET, V98, P15003, DOI 10.1029/93JE01581; BUTLER BJ, 1994, THESIS CALTECH PASAD; BYRD RC, 1994, LA12833MS LANL; FEDLMAN WC, IN PRESS NUCL INST A; FELDMAN WC, 1991, NUCL INSTRUM METH A, V306, P350, DOI 10.1016/0168-9002(91)90342-N; Feldman WC, 1998, SCIENCE, V281, P1489, DOI 10.1126/science.281.5382.1489; Feldman WC, 1997, J GEOPHYS RES-PLANET, V102, P25565, DOI 10.1029/97JE02353; FELDMAN WC, 1993, J GEOPHYS RES-PLANET, V98, P20855, DOI 10.1029/93JE02325; FELDMAN WC, 1991, GEOPHYS RES LETT, V18, P2157, DOI 10.1029/91GL02618; HARMON JK, 1992, SCIENCE, V258, P640, DOI 10.1126/science.258.5082.640; Harmon JK, 1997, ADV SPACE RES-SERIES, V19, P1487, DOI 10.1016/S0273-1177(97)00347-5; INGERSOLL AP, 1992, ICARUS, V100, P40, DOI 10.1016/0019-1035(92)90016-Z; JEANLOZ R, 1995, SCIENCE, V268, P1455, DOI 10.1126/science.7770770; LANZEROTTI LJ, 1981, J GEOPHYS RES, V86, P3949, DOI 10.1029/JB086iB05p03949; MORGAN TH, 1991, J GEOPHYS RES-SPACE, V96, P1351, DOI 10.1029/90JA02127; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; SHOEMAKER EM, 1994, SCIENCE, V266, P1851, DOI 10.1126/science.266.5192.1851; Simpson RV, UNPUB; SLADE MA, 1992, SCIENCE, V258, P635, DOI 10.1126/science.258.5082.635; Stacy NJS, 1997, SCIENCE, V276, P1527, DOI 10.1126/science.276.5318.1527; *US GEOL SURV, 1981, SURF REL MAPS LUN PO; Vaniman D., 1991, LUNAR SOURCEBOOK, P5; WATSON K, 1961, J GEOPHYS RES, V66, P3033, DOI 10.1029/JZ066i009p03033; [No title captured]	27	398	418	2	73	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1496	1500		10.1126/science.281.5382.1496	http://dx.doi.org/10.1126/science.281.5382.1496			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727973				2022-12-24	WOS:000075738100037
J	Weinstein, DC; Marden, J; Carnevali, F; Hemmati-Brivanlou, A				Weinstein, DC; Marden, J; Carnevali, F; Hemmati-Brivanlou, A			FGF-mediated mesoderm induction involves the Src-family kinase Laloo	NATURE			English	Article							EARLY XENOPUS DEVELOPMENT; MAP KINASE; REQUIRES FGF; SIGNALING PATHWAYS; NEURAL INDUCTION; EARLY RESPONSE; EXPRESSION; EMBRYOS; PROTEIN; RNA	During embryogenesis, inductive interactions underlie the development of much of the body plan. In Xenopus laevis factors secreted from the vegetal pole induce mesoderm in the adjacent marginal zone; members of both the transforming growth factor-beta (TGF-beta) and fibroblast growth factor (FGF) ligand families seem to have critical roles in this process(1). Here we report the identification and characterization of laloo a novel participant in the signal transduction cascade linking extracellular, mesoderm-inducing signals to the nucleus, where alteration of cell fate is driven by changes in gene expression. Overexpression of laloo, a member of the Src-related gene family, in Xenopus embryos gives rise to ectopic posterior structures that frequently contain axial tissue. Laloo induces mesoderm in Xenopus ectodermal explants; this induction is blocked by reagents that disrupt the FGF signalling pathway. Conversely, expression of a dominant-inhibitory Laloo mutant blocks mesoderm induction by FGF and causes severe posterior truncations in vivo. This work provides the first evidence that a Src-related kinase is involved in vertebrate mesoderm induction.	Rockefeller Univ, Dept Mol Vertebrate Embryol, New York, NY 10021 USA	Rockefeller University	Hemmati-Brivanlou, A (corresponding author), Rockefeller Univ, Dept Mol Vertebrate Embryol, 1230 York Ave, New York, NY 10021 USA.	brvnlou@rockvax.rockefeller.edu		Weinstein, Daniel/0000-0001-7832-9285	NICHD NIH HHS [HD 32105-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R55HD032105, R01HD032105] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BASSEZ T, 1990, DEVELOPMENT, V110, P955; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; CORNELL RA, 1994, DEVELOPMENT, V120, P453; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; ISAACS HV, 1994, EMBO J, V13, P4469, DOI 10.1002/j.1460-2075.1994.tb06769.x; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; Kroll KL, 1996, DEVELOPMENT, V122, P3173; LABONNE C, 1994, DEVELOPMENT, V120, P463; LABONNE C, 1995, DEVELOPMENT, V121, P1475; LaBonne C, 1997, DEV BIOL, V183, P9, DOI 10.1006/dbio.1996.8497; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lustig KD, 1996, DEVELOPMENT, V122, P4001; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NORTHROP J, 1995, DEV BIOL, V172, P242, DOI 10.1006/dbio.1995.0019; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SCHULTEMERKER S, 1995, CURR BIOL, V5, P62, DOI 10.1016/S0960-9822(95)00017-0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WRIGHT CVE, 1990, DEVELOPMENT, V109, P225	30	75	76	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					904	908		10.1038/29808	http://dx.doi.org/10.1038/29808			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732875				2022-12-24	WOS:000075611800052
J	Harris, CM; Wolpert, DM				Harris, CM; Wolpert, DM			Signal-dependent noise determines motor planning	NATURE			English	Article							SACCADIC EYE-MOVEMENTS; DRAWING MOVEMENTS; ARM MOVEMENTS; MODEL; COORDINATION	When we make saccadic eye movements or goal-directed arm movements, there is an infinite number of possible trajectories that the eye or arm could take to reach the target(1,2). However, humans show highly stereotyped trajectories in which velocity profiles of both the eye and hand are smooth and symmetric for brief movements(3,4). Here we present a unifying theory of eye and arm movements based on the single physiological assumption that the neural control signals are corrupted by noise whose variance increases with the size of the control signal. We propose that in the presence of such signal-dependent noise, the shape of a trajectory is selected to minimize the variance of the final eye or arm position. This minimum-variance theory accurately predicts the trajectories of both saccades and arm movements and the speed-accuracy trade-off described by Fitt's law(5). These profiles are robust to changes in the dynamics of the eye or arm, as found empirically(6,7) 7. Moreover, the relation between path curvature and hand velocity during drawing movements reproduces the empirical 'two-thirds power law'(8,9). This theory provides a simple and powerful unifying perspective for both eye and arm movement control.	Great Ormond St Hosp Sick Children, Dept Ophthalmol, London WC1N 3JH, England; Great Ormond St Hosp Sick Children, Visual Sci Unit, London WC1N 3JH, England; UCL, Inst Child Hlth, London WC1N 3JH, England; UCL, Inst Neurol, Sobell Dept Neurophysiol, London WC1N 3BG, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London; University of London; University College London	Harris, CM (corresponding author), Great Ormond St Hosp Sick Children, Dept Ophthalmol, Great Ormond St, London WC1N 3JH, England.			Wolpert, Daniel/0000-0003-2011-2790; Harris, Chris/0000-0003-0452-8518	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bernstein N.A., 1967, COORDINATION REGULAT; BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; CLAMANN HP, 1969, BIOPHYS J, V9, P1233, DOI 10.1016/S0006-3495(69)86448-9; COLLEWIJN H, 1988, J PHYSIOL-LONDON, V404, P157, DOI 10.1113/jphysiol.1988.sp017284; ENDERLE JD, 1987, IEEE T BIO-MED ENG, V34, P43, DOI 10.1109/TBME.1987.326014; FITTS PM, 1954, J EXP PSYCHOL, V47, P381, DOI 10.1037/h0055392; FLASH T, 1985, J NEUROSCI, V5, P1688, DOI 10.1523/jneurosci.05-07-01688.1985; Goodbody SJ, 1998, J NEUROPHYSIOL, V79, P1825, DOI 10.1152/jn.1998.79.4.1825; Gurevich T, 1997, SELF ORG COMPUTATION, P423, DOI 10.1016/S0166-4115(97)80015-5; HARRIS CM, 1990, J NEUROPHYSIOL, V63, P877, DOI 10.1152/jn.1990.63.4.877; Harris CM, 1998, J NEUROSCI METH, V83, P73, DOI 10.1016/S0165-0270(98)00063-6; HARRIS CM, 1995, VISION RES, V35, P691, DOI 10.1016/0042-6989(94)00163-G; HOGAN N, 1984, J NEUROSCI, V4, P2745; JEANNEROD M, 1988, OUP PSYCHOL SER, V5; Kawato M, 1996, ATTENTION PERFORM, VXVI, P335; KELSO JAS, 1979, SCIENCE, V203, P1029, DOI 10.1126/science.424729; LACKNER JR, 1994, J NEUROPHYSIOL, V72, P299, DOI 10.1152/jn.1994.72.1.299; LACQUANITI F, 1983, ACTA PSYCHOL, V54, P115, DOI 10.1016/0001-6918(83)90027-6; Matthews PBC, 1996, J PHYSIOL-LONDON, V492, P597, DOI 10.1113/jphysiol.1996.sp021332; MEYER DE, 1988, PSYCHOL REV, V95, P340, DOI 10.1037/0033-295X.95.3.340; MORASSO P, 1981, EXP BRAIN RES, V42, P223; ROBINSON DA, 1986, BIOL CYBERN, V55, P43, DOI 10.1007/BF00363977; Sainburg R. L., 1995, Society for Neuroscience Abstracts, V21, P686; SHADMEHR R, 1994, J NEUROSCI, V14, P3208; UNO Y, 1989, BIOL CYBERN, V61, P89, DOI 10.1007/BF00204593; VANDERHLEM FCT, IN PRESS BIOMECHANIC; VANGISBERGEN JAM, 1981, J NEUROPHYSIOL, V45, P417, DOI 10.1152/jn.1981.45.3.417; VIVIANI P, 1991, J EXP PSYCHOL HUMAN, V17, P198, DOI 10.1037/0096-1523.17.1.198; Wolpert DM, 1997, TRENDS COGN SCI, V1, P209, DOI 10.1016/S1364-6613(97)01070-X; WOLPERT DM, 1995, SCIENCE, V269, P1880, DOI 10.1126/science.7569931	30	1655	1667	5	143	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					780	784		10.1038/29528	http://dx.doi.org/10.1038/29528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	112PR	9723616				2022-12-24	WOS:000075503600045
J	Goldberg, J				Goldberg, J			Structural basis for activation of ARF GTPase: Mechanisms of guanine nucleotide exchange and GTP-myristoyl switching	CELL			English	Article							ADP-RIBOSYLATION FACTOR-1; AMINO-ACID-RESIDUES; EF-TS COMPLEX; MEMBRANE PHOSPHOLIPIDS; CRYSTAL-STRUCTURE; RAS; GDP; TU; PROTEINS; PROGRAM	Ras-related GTPases are positively regulated by guanine nucleotide exchange factors (GEFs) that promote the exchange of GDP for GTP. The crystal structure of the Sec7 domain GEF bound to nucleotide-free ARF1 GTPase has been determined at 2.8 Angstrom resolution and the structure of ARF1 in the GTP-analog form determined at 1.6 Angstrom resolution. The Sec7 domain binds to the switch regions of ARF1 and inserts residues directly into the GTPase active site. The interaction leaves the purine-binding site intact but perturbs the Mg2+ and phosphate groups to promote the dissociation of guanine nucleotides. The structure of ARF1 in the GTP-analog form closely resembles Pas, revealing a substantial rearrangement from the GDP conformation. The transition controls the exposure of the myristoylated N terminus, explaining how ARF GTPases couple the GDP-GTP conformational switch to membrane binding.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	jonathan@ximpact4.ski.mskcc.org						Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; Antonny B, 1997, BIOCHEMISTRY-US, V36, P4675, DOI 10.1021/bi962252b; Beraud-Dufour S, 1998, EMBO J, V17, P3651, DOI 10.1093/emboj/17.13.3651; Betz SF, 1998, P NATL ACAD SCI USA, V95, P7909, DOI 10.1073/pnas.95.14.7909; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOUME HR, 1991, NATURE, V349, P117; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; GREASLEY SE, 1995, NAT STRUCT BIOL, V2, P797, DOI 10.1038/nsb0995-797; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P12543, DOI 10.1021/bi00039a008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI SHY, 1993, COMPUT IND ENG, V25, P13, DOI 10.1016/0360-8352(93)90209-G; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; PARK WM, 1994, MOL CELL BIOL, V14, P8117, DOI 10.1128/MCB.14.12.8117; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zhao LY, 1997, P NATL ACAD SCI USA, V94, P4418, DOI 10.1073/pnas.94.9.4418	35	425	428	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					237	248		10.1016/S0092-8674(00)81754-7	http://dx.doi.org/10.1016/S0092-8674(00)81754-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790530	Bronze			2022-12-24	WOS:000076538300011
J	Ding, JX; Yang, L; Yan, YT; Chen, A; Desai, N; Wynshaw-Boris, A; Shen, MM				Ding, JX; Yang, L; Yan, YT; Chen, A; Desai, N; Wynshaw-Boris, A; Shen, MM			Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo	NATURE			English	Article							NEURAL PLATE; PRIMITIVE ENDODERM; GENE; EXPRESSION; MESODERM; GASTRULATION; FAMILY; GROWTH; BRAIN; CELLS	The anterior-posterior axis of the mouse embryo is established by two distinct organizing centres in the anterior visceral endoderm and the distal primitive streak(1-7). These organizers induce and pattern the head and trunk respectively, and have been proposed to be localized through coordinate cell movements that rotate a pre-existing pre-existing proximal-distal axis(6,8). Here we show that correct localization of both head- and trunk-organizing centres requires Cripto(9,10), a putative signalling molecule that is a member of the EGF-CFC gene family(11,12), Before gastrulation, Cripto is asymmetrically expressed in a proximal-distal gradient in the epiblast, and subsequently is expressed in the primitive streak and newly formed embryonic mesoderm. A Cripto null mutation generated by targeted gene disruption results in homozygous Cripto(-/-) embryos that mostly consist of anterior neuroectoderm and lack posterior structures, thus resembling a head without a trunk, Notably, markers of the head organizer are located at the distal end of the embryo, whereas markers of the primitive streak are absent or localized to the proximal side. Our results indicate that Cripto signalling is essential for the conversion of a pro;proximal-distal asymmetry into an orthogonal anterior-posterior axis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, Piscataway, NJ 08854 USA; Natl Human Genome Res Inst, Lab Genet Dis Res, Bethesda, MD 20892 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Shen, MM (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Adv Biotechnol & Med, 679 Hoes Lane, Piscataway, NJ 08854 USA.	mshen@cabm.rutgers.edu	Shen, Michael M/C-7546-2009; Yan, Yu-Ting/Q-3065-2018	Shen, Michael M/0000-0002-4042-1657; Yan, Yu-Ting/0000-0002-9559-706X				ANG SL, 1994, DEVELOPMENT, V120, P2979; Ang SL, 1996, DEVELOPMENT, V122, P243; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; Biben C, 1998, DEV BIOL, V194, P135, DOI 10.1006/dbio.1997.8812; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Deng CX, 1996, CELL, V84, P911, DOI 10.1016/S0092-8674(00)81069-7; DONO R, 1993, DEVELOPMENT, V118, P1157; DOWNS KM, 1993, DEVELOPMENT, V118, P1255; Hermesz E, 1996, DEVELOPMENT, V122, P41; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Liguori G, 1996, MAMM GENOME, V7, P344, DOI 10.1007/s003359900100; Muhr J, 1997, NEURON, V19, P487, DOI 10.1016/S0896-6273(00)80366-9; Rhinn M, 1998, DEVELOPMENT, V125, P845; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Shen MM, 1997, DEVELOPMENT, V124, P429; Tam PPL, 1997, MECH DEVELOP, V68, P3, DOI 10.1016/S0925-4773(97)00123-8; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas PQ, 1998, DEVELOPMENT, V125, P85; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Xu CH, 1998, DEV BIOL, V196, P237, DOI 10.1006/dbio.1998.8862; Zhang JJ, 1998, CELL, V92, P241, DOI 10.1016/S0092-8674(00)80918-6	30	383	389	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					702	707		10.1038/27215	http://dx.doi.org/10.1038/27215			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790191				2022-12-24	WOS:000076472600053
J	Durso, SC				Durso, SC			The season's end	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA	Johns Hopkins University	Durso, SC (corresponding author), 8800 Walther Blvd, Parkville, MD 21234 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					658	660		10.7326/0003-4819-129-8-199810150-00017	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00017			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786816				2022-12-24	WOS:000076431800011
J	Limousin, P; Krack, P; Pollak, P; Benazzouz, A; Ardouin, C; Hoffmann, D; Benabid, AL				Limousin, P; Krack, P; Pollak, P; Benazzouz, A; Ardouin, C; Hoffmann, D; Benabid, AL			Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-FREQUENCY STIMULATION; GLOBUS-PALLIDUS; NEURONAL-ACTIVITY; GPI PALLIDOTOMY; MPTP MODEL; PRIMATE; REVERSAL; SYMPTOMS; MONKEYS	Background In many patients with idiopathic Parkinson's disease, treatment with levodopa is complicated by fluctuations between an "off" period (also referred to as "off medication"), when the medication is not working and the motor symptoms of parkinsonism are present, and an "on" period, when the medication is causing improved mobility (also referred to as "on medication"), often accompanied by debilitating dyskinesias. In animal models of Parkinson's disease, there is overactivity in the subthalamic nucleus, and electrical stimulation of the subthalamic nucleus improves parkinsonism. We therefore sought to determine the efficacy and safety of electrical stimulation of the subthalamic nucleus in patients with Parkinson's disease. Methods We studied 24 patients with idiopathic Parkinson's disease in whom electrodes were implanted bilaterally in the subthalamic nucleus under stereotactic guidance with imaging and electrophysiologic testing of the location. Twenty were followed for at least 12 months. Clinical evaluations included the Unified Parkinson's Disease Rating Scale, a dyskinesia scale, and timed tests conducted before and after surgery, when patients were off and on medications. Results After one year of electrical stimulation of the subthalamic nucleus, the patients' scores for activities of daily living and motor examination scores (Unified Parkinson's Disease Rating Scale parts II and III, respectively) off medication improved by 60 percent (P<0.001). The subscores improved for limb akinesia, rigidity, tremor, and gait. In the testing done on medication, the scores on part III improved by 10 percent (P<0.005). The mean dose of dopaminergic drugs was reduced by half. The cognitive-performance scores remained unchanged, but one patient had paralysis and aphasia after an intracerebral hematoma during the implantation procedure. Conclusions Electrical stimulation of the subthalamic nucleus is an effective treatment for advanced Parkinson's disease. The severity of symptoms off medication decreases, and the dose of levodopa can be reduced, with a consequent reduction in dyskinesias. (N Engl J Med 1998;339:1105-11.) (C) 1998, Massachusetts Medical Society.	Univ Grenoble 1, Dept Clin & Biol Neurosci, F-38043 Grenoble 9, France; MRC, Human Movement & Balance Unit, London, England; Univ Kiel, Dept Neurol, D-2300 Kiel, Germany	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); University of Kiel	Pollak, P (corresponding author), Univ Grenoble 1, Dept Clin & Biol Neurosci, BP 217, F-38043 Grenoble 9, France.		Benazzouz, Abdelhamid/E-5050-2016; Benabid, Alim L/Q-3506-2017	Krack, Paul/0000-0002-3508-7295				AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; Benabid AL, 1996, J NEUROSURG, V84, P203, DOI 10.3171/jns.1996.84.2.0203; BENABID AL, 1991, LANCET, V337, P401; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BROWN RG, 1990, TRENDS NEUROSCI, V13, P21, DOI 10.1016/0166-2236(90)90058-I; COOPER IS, 1958, PATHOGENESIS TREATME, P325; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GALVEZJIMENEZ N, 1996, MOVEMENT DISORD, V11, P242; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Golbe LI, 1998, LANCET, V351, P998, DOI 10.1016/S0140-6736(98)22014-9; Gross C, 1997, J NEUROSURG, V87, P491, DOI 10.3171/jns.1997.87.4.0491; GUIOT G, 1953, REV NEUROL, V89, P578; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hassler R, 1954, NERVENARZT, V25, P441; Karusu T.B., 1976, GERIATRIC PSYCHIAT, P77; Krack P, 1997, LANCET, V350, P1675, DOI 10.1016/S0140-6736(97)24049-3; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; LANGSTON JW, 1984, BRAIN RES, V292, P390; LEPORE FE, 1985, NEUROLOGY, V35, P423, DOI 10.1212/WNL.35.3.423; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; Limousin P, 1996, MOVEMENT DISORD, V11, P231, DOI 10.1002/mds.870110303; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; LOZANO AM, 1996, LANCET, V348, P1108; Meyers R, 1942, N ST J MED, V42, P317; MILLER WC, 1987, ADV BEHAV BIOL, V32, P415; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Obeso JA, 1997, J NEUROL NEUROSUR PS, V62, P2, DOI 10.1136/jnnp.62.1.2; Pahwa R, 1997, NEUROLOGY, V49, P249, DOI 10.1212/WNL.49.1.249; Penney JB, 1996, ANN NEUROL, V39, P37; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; SIEGFRIED J, 1994, NEUROSURGERY, V35, P1126, DOI 10.1227/00006123-199412000-00016; SVENNILSON E, 1960, ACTA PSYCH NEUROL, V35, P358, DOI 10.1111/j.1600-0447.1960.tb07606.x; Tronnier VM, 1997, J NEUROSURG, V87, P700, DOI 10.3171/jns.1997.87.5.0700; WICHMANN T, 1994, J NEUROPHYSIOL, V72, P521, DOI 10.1152/jn.1994.72.2.521	43	1361	1430	1	219	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 15	1998	339	16					1105	1111		10.1056/NEJM199810153391603	http://dx.doi.org/10.1056/NEJM199810153391603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129DP	9770557				2022-12-24	WOS:000076448200003
J	Shwayder, TA				Shwayder, TA			Call of the loon	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1221	1222		10.1001/jama.280.14.1221	http://dx.doi.org/10.1001/jama.280.14.1221			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786364				2022-12-24	WOS:000076357900012
J	Forman, BM; Tzameli, I; Choi, HS; Chen, L; Simha, D; Seol, W; Evans, RM; Moore, DD				Forman, BM; Tzameli, I; Choi, HS; Chen, L; Simha, D; Seol, W; Evans, RM; Moore, DD			Androstane metabolites bind to and deactivate the nuclear receptor CAR-beta	NATURE			English	Article							THYROID-HORMONE RECEPTOR; FATTY-ACIDS; INVERSE AGONISTS; RETINOIC ACID; LXR-ALPHA; EICOSANOIDS; ACTIVATION; IDENTIFICATION; 16-ANDROSTENES; COACTIVATOR	The orphan receptor CAR-beta (ref. 1) binds DNA as a heterodimer with the retinoid-X receptor and activates gene transcription in a constitutive manner. Here we show that, in contrast to the classical nuclear receptors, the constitutive activity of CAR-beta results from a ligand-independent recruitment of transcriptional co-activators. While searching for potential ligands of CAR-beta, we found that the steroids androstanol and androstenol inhibit the constitutive activity of CAR-beta. This effect is stereospecific: only 3 alpha-hydroxy, 5 alpha-reduced androstanes are active. These androstanes do not interfere with heterodimerization or DNA binding of CAR-beta; instead, they promote co-activator release from the ligand-binding domain. These androstane ligands are examples of naturally occurring inverse agonists(2,3) that reverse transcriptional activation by nuclear receptors. CAR-beta (constitutive androstane receptor-beta), therefore, defines an unanticipated steroidal signalling pathway that functions in a manner opposite to that of the conventional nuclear receptor pathways.	City Hope Natl Med Ctr, Duarte, CA 91010 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77401 USA; Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Dana Farber Canc Inst, Div Neoplast Dis Mechanisms, Boston, MA 02115 USA	City of Hope; Howard Hughes Medical Institute; Salk Institute; Baylor College of Medicine; Chonnam National University; Harvard University; Massachusetts General Hospital; Harvard University; Dana-Farber Cancer Institute	Forman, BM (corresponding author), City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965				BICKNELL DC, 1976, J STEROID BIOCHEM, V7, P451, DOI 10.1016/0022-4731(76)90111-4; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1997, P NATL ACAD SCI USA, V94, P10588, DOI 10.1073/pnas.94.20.10588; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GOWER DB, 1994, J STEROID BIOCHEM, V48, P409, DOI 10.1016/0960-0760(94)90082-5; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Klein ES, 1996, J BIOL CHEM, V271, P22692, DOI 10.1074/jbc.271.37.22692; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LOUVEAU I, 1991, ACTA ENDOCRINOL-COP, V125, P526, DOI 10.1530/acta.0.1250526; ONATE SA, 1995, SCIENCE, V270, P1354; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; SEOL W, 1996, SCIENCE, V272, P1136; SINGER AG, 1991, J STEROID BIOCHEM, V39, P627, DOI 10.1016/0960-0760(91)90261-3; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; WEUSTEN JJAM, 1989, J STEROID BIOCHEM, V32, P689, DOI 10.1016/0022-4731(89)90513-X	26	412	432	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					612	615		10.1038/26996	http://dx.doi.org/10.1038/26996			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783588				2022-12-24	WOS:000076362900051
J	Grubb, RL; Derdeyn, CP; Fritsch, SM; Carpenter, DA; Yundt, KD; Videen, TO; Spitznagel, EL; Powers, WJ				Grubb, RL; Derdeyn, CP; Fritsch, SM; Carpenter, DA; Yundt, KD; Videen, TO; Spitznagel, EL; Powers, WJ			Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON EMISSION TOMOGRAPHY; INTRACRANIAL ARTERIAL BYPASS; CEREBRAL BLOOD-FLOW; CEREBROVASCULAR-DISEASE; O-15 RADIOTRACERS; MISERY-PERFUSION; PERFORMANCE; ISCHEMIA; SURGERY; HUMANS	Context.-The relative importance of hemodynamic factors in the pathogenesis and treatment of stroke in patients with carotid artery occlusion remains controversial. Objective.-To test the hypothesis that stage II cerebral hemodynamic failure (increased oxygen extraction measured by positron emission tomography [PET]) distal to symptomatic carotid artery occlusion is an independent risk factor for subsequent stroke in medically treated patients. Design and Setting.-Prospective, blinded, longitudinal cohort study of patients referred from a group of regional hospitals between 1992 and 1996, Patients.-From 419 subjects referred, 81 with previous stroke or transient ischemic attack in the territory of an occluded carotid artery were enrolled. All were followed up to completion of the study, with average follow-up of 31.5 months. Main Outcome Measures.-Telephone contact every 6 months recorded the subsequent occurrence of all stroke, ipsilateral ischemic stroke, and death. Results.-Stroke occurred in 12 of 39 patients with stage II hemodynamic failure and in 3 of 42 patients without (P=.005); stroke was ipsilateral in 11 of 39 patients with stage II hemodynamic failure and in 2 of 42 patients without (P=.004). Six deaths occurred in each group (P=.94). The age-adjusted relative risk conferred by stage II hemodynamic failure was 6.0 (95% confidence interval [CI], 1.7-21.6) for all stroke and 7.3 (95% CI, 1.6-33.4) for ipsilateral stroke. Conclusions.-Stage II hemodynamic failure defines a subgroup of patients with symptomatic carotid occlusion who are at high risk for subsequent stroke when treated medically, A randomized trial evaluating surgical revascularization in this high-risk subgroup is warranted.	Washington Univ, Med Ctr, E Bldg Imaging Ctr, Dept Neurol & Neurol Surg, St Louis, MO 63110 USA; Washington Univ, Edward Mallinckrodt Inst Radiol, St Louis, MO 63110 USA; Washington Univ, Dept Math, St Louis, MO 63110 USA; Jewish Hosp St Louis, Lillian Strauss Inst Neurosci, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Barnes-Jewish Hospital	Powers, WJ (corresponding author), Washington Univ, Med Ctr, E Bldg Imaging Ctr, Dept Neurol & Neurol Surg, 4525 Scott Ave,Box 8225, St Louis, MO 63110 USA.	wjp@npg.wustl.edu			NIA NIH HHS [AG05681, AG03991] Funding Source: Medline; NINDS NIH HHS [NS28947] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG003991, P50AG005681] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALOW J, 1966, NEUROLOGY, V16, P559, DOI 10.1212/WNL.16.6.559; BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; Barnett HJM, 1997, STROKE, V28, P1857; BARON JC, 1981, STROKE, V12, P454, DOI 10.1161/01.STR.12.4.454; BOZZAO L, 1989, STROKE, V20, P735, DOI 10.1161/01.STR.20.6.735; Derdeyn CP, 1998, STROKE, V29, P754, DOI 10.1161/01.STR.29.4.754; GIBBS JM, 1984, LANCET, V1, P310; GIBBS JM, 1987, J NEUROL NEUROSUR PS, V50, P140, DOI 10.1136/jnnp.50.2.140; HANKEY GJ, 1991, CEREBROVASC DIS, V1, P245, DOI 10.1159/000108851; Klijn CJM, 1997, STROKE, V28, P2084, DOI 10.1161/01.STR.28.10.2084; MINTUN MA, 1984, J NUCL MED, V25, P177; PESSIN MS, 1977, NEW ENGL J MED, V296, P358, DOI 10.1056/NEJM197702172960703; POWERS WJ, 1989, ANN NEUROL, V25, P325, DOI 10.1002/ana.410250403; POWERS WJ, 1984, NEUROLOGY, V34, P1168, DOI 10.1212/WNL.34.9.1168; POWERS WJ, 1991, ANN NEUROL, V29, P231, DOI 10.1002/ana.410290302; POWERS WJ, 1987, ANN INTERN MED, V106, P27, DOI 10.7326/0003-4819-106-1-27; POWERS WJ, 1985, J CEREBR BLOOD F MET, V5, P600, DOI 10.1038/jcbfm.1985.89; SAMSON Y, 1985, STROKE, V16, P609, DOI 10.1161/01.STR.16.4.609; SPINKS TJ, 1992, PHYS MED BIOL, V37, P1637, DOI 10.1088/0031-9155/37/8/002; STREIFLER JY, 1995, ARCH NEUROL-CHICAGO, V52, P246, DOI 10.1001/archneur.1995.00540270034016; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; THIELE BL, 1980, NEUROLOGY, V30, P1041, DOI 10.1212/WNL.30.10.1041; VIDEEN TO, 1987, J CEREBR BLOOD F MET, V7, P513, DOI 10.1038/jcbfm.1987.97; WIENHARD K, 1994, J COMPUT ASSIST TOMO, V18, P110, DOI 10.1097/00004728-199401000-00023; Yamauchi H, 1996, J NEUROL NEUROSUR PS, V61, P18, DOI 10.1136/jnnp.61.1.18; Yokota C, 1998, STROKE, V29, P640, DOI 10.1161/01.STR.29.3.640	26	556	584	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 30	1998	280	12					1055	1060		10.1001/jama.280.12.1055	http://dx.doi.org/10.1001/jama.280.12.1055			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FJ	9757852	Bronze			2022-12-24	WOS:000076002400033
J	van Leyen, K; Duvoisin, RM; Engelhardt, H; Wiedmann, M				van Leyen, K; Duvoisin, RM; Engelhardt, H; Wiedmann, M			A function for lipoxygenase in programmed organelle degradation	NATURE			English	Article							RETICULOCYTE LIPOXYGENASE; MESSENGER-RNA; 15-LIPOXYGENASE; PROTEINS; TRANSLATION; MEMBRANES; CELLS; LENS	Membrane-enclosed organelles, a defining characteristic of eukaryotic cells, are lost during differentiation of specific cell types such as reticulocytes (an intermediate in differentiation of erythrocytes), central fibre cells of the eye lens, and keratinocytes(1). The degradation of these organelles must be tightly regulated with respect to both the time of activation and the specificity of membrane degradation. The expression of 15-lipoxygenase (15-LOX) peaks in reticulocytes immediately before organelle degradation(2). Here we show that 15-LOX integrates into the membranes of various organelles, allowing release of proteins from the organelle lumen and access of proteases to both lumenal and integral membrane proteins. In addition, by sparing the plasma membrane, 15-LOX shows the required specificity for organellar membranes. Thus, the action of 15-LOX provides a mechanism by which the natural degradation process can be explained. This conclusion is supported by our finding that lipoxygenase expression in the eye lens is restricted to the region at which organelle degradation occurs.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Dyson Vis Res Inst, Coll Med, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA; Max Planck Inst Biochem, Abt Mol Strukturbiol, D-82152 Martinsried, Germany	Memorial Sloan Kettering Cancer Center; Cornell University; Dyson; Cornell University; Max Planck Society	Wiedmann, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.							ALBERTS B, 1994, MOL BIOL CELL, P1158; Arora JK, 1996, INVEST OPHTH VIS SCI, V37, P1411; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; BORDIER C, 1981, J BIOL CHEM, V256, P1604; Brinckmann R, 1998, BLOOD, V91, P64, DOI 10.1182/blood.V91.1.64.64_64_74; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Gouaux E, 1997, CURR OPIN STRUC BIOL, V7, P566, DOI 10.1016/S0959-440X(97)80123-6; HUNT T, 1989, TRENDS BIOCHEM SCI, V14, P393, DOI 10.1016/0968-0004(89)90280-6; Ishizaki Y, 1998, J CELL BIOL, V140, P153, DOI 10.1083/jcb.140.1.153; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JAIN MK, 1980, INTRO BIOL MEMBRANES; KUHN H, 1990, J BIOL CHEM, V265, P18351; Kuhn H, 1997, CURR OPIN LIPIDOL, V8, P111; MAYER A, 1989, SCIENCE, V244, P1480, DOI 10.1126/science.2544030; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NEW RRC, 1990, LIPOSOMES PRACTICAL, P37; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PAUL A, 1992, BIOPHYS J, V61, P172, DOI 10.1016/S0006-3495(92)81825-8; RAPOPORT SM, 1979, EUR J BIOCHEM, V96, P545, DOI 10.1111/j.1432-1033.1979.tb13068.x; SAMUELSSON B, 1991, ANN NY ACAD SCI, V629, P89; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SCHEWE T, 1986, ADV ENZYMOL RAMB, V58, P191; Steck T L, 1974, Methods Enzymol, V31, P172; WALTER P, 1983, METHOD ENZYMOL, V96, P84; WATSON A, 1994, BIOCHEM J, V298, P377, DOI 10.1042/bj2980377	26	246	247	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 24	1998	395	6700					392	395		10.1038/26500	http://dx.doi.org/10.1038/26500			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	122QW	9759730				2022-12-24	WOS:000076083800056
J	McCreadie, R; Macdonald, E; Blacklock, C; Tilak-Singh, D; Wiles, D; Halliday, J; Paterson, J				McCreadie, R; Macdonald, E; Blacklock, C; Tilak-Singh, D; Wiles, D; Halliday, J; Paterson, J			Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland; Dumfries & Galloway Royal Infirm, Dept Biochem, Dumfries DG1 4AP, Scotland; Greencroft Med Ctr N, Annan DG12 6BG, Scotland		McCreadie, R (corresponding author), Crichton Royal Hosp, Dept Clin Res, Dumfries DG1 4TG, Scotland.							CATIGNANI GL, 1983, CLIN CHEM, V29, P708; *DEP HLTH, 1991, DICT REF VAL FOND EN; HEIMENDINGER J, 1995, AM J CLIN NUTR, V61, p1397S, DOI 10.1093/ajcn/61.6.1397S; *SCOTT OFF HOM HLT, 1993, SCHOTT DIET; YARNELL JWG, 1983, HUM NUTR-APPL NUTR, V37, P103	5	130	131	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					784	785		10.1136/bmj.317.7161.784	http://dx.doi.org/10.1136/bmj.317.7161.784			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740565	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000076084200025
J	Bracy, JL; Sachs, DH; Iacomini, J				Bracy, JL; Sachs, DH; Iacomini, J			Inhibition of xenoreactive natural antibody production by retroviral gene therapy	SCIENCE			English	Article							XENOTRANSPLANTATION; PIG; REJECTION; BARRIERS; SAFE; LINE	The major barrier to transplantation across discordant species, such as from pig to human, is rejection mediated by xenoreactive natural antibodies (XNA) that bind the carbohydrate epitope Gal alpha 1-3Gal beta 1-4GlcNAc-R (alpha Gal) on donor tissues. This epitope is synthesized by the enzyme glucosyltransferase uridine 5'-diphosphate galactose:beta-D-galactosyl-1.4-N-acetyl-D-glucosaminide alpha(1-3)galactosyltransferase (E.C. 2.4.1.151), pr simply alpha GT. When a functional alpha GT gene was introduced by retroviral gene transfer into bone marrow cells, alpha GaL XNA production in a murine model ceased. Thus, genetic engineering of bone marrow may overcome humoral rejection of discordant xenografts and may be useful for inducing B cell tolerance.	Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Allegheny Univ Hlth Sci, Mol & Cellular Biol Program, Philadelphia, PA 19129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Drexel University	Iacomini, J (corresponding author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bldg 149-5210,13th St, Boston, MA 02129 USA.							ARMENTANO D, 1987, J VIROL, V61, P1647, DOI 10.1128/JVI.61.5.1647-1650.1987; Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; Bagley J, 1998, TRANSPLANTATION, V65, P1233, DOI 10.1097/00007890-199805150-00015; BRACY JL, UNPUB; Cooper DKC, 1997, WORLD J SURG, V21, P901, DOI 10.1007/s002689900324; GALILI U, 1988, INFECT IMMUN, V56, P1730, DOI 10.1128/IAI.56.7.1730-1737.1988; GOOD AH, 1992, TRANSPL P, V24, P559; HANTZOPOULOS PA, 1989, P NATL ACAD SCI USA, V86, P3519, DOI 10.1073/pnas.86.10.3519; KOREN E, 1994, TRANSPLANT P, V26, P1166; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; ORIOL R, 1993, TRANSPLANTATION, V56, P1433, DOI 10.1097/00007890-199312000-00031; Platt JL, 1996, CRIT REV IMMUNOL, V16, P331; Platt JL, 1998, NATURE, V392, P11; Platt JL, 1997, XENOTRANSPLANTATION, P8; Sachs David H., 1995, Xenotransplantation, V2, P234, DOI 10.1111/j.1399-3089.1995.tb00101.x; SACHS DH, 1994, PATHOL BIOL, V42, P217; STRAHAN KM, 1995, IMMUNOGENETICS, V41, P101, DOI 10.1007/BF00182319; THALL A, 1996, TRANSPLANT P, V28, P561; THALL AD, 1995, J BIOL CHEM, V270, P21437, DOI 10.1074/jbc.270.37.21437; Tumbleson M. E., 1986, SWINE BIOMEDICAL RES; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; Yang YG, 1998, J EXP MED, V187, P1335, DOI 10.1084/jem.187.8.1335	25	107	115	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1845	1847		10.1126/science.281.5384.1845	http://dx.doi.org/10.1126/science.281.5384.1845			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743496				2022-12-24	WOS:000076007100051
J	Brotherton, DH; Dhanaraj, V; Wick, S; Brizuela, L; Domaille, PJ; Volyanik, E; Xu, X; Parisini, E; Smith, BO; Archer, SJ; Serrano, M; Brenner, SL; Blundell, TL; Laue, ED				Brotherton, DH; Dhanaraj, V; Wick, S; Brizuela, L; Domaille, PJ; Volyanik, E; Xu, X; Parisini, E; Smith, BO; Archer, SJ; Serrano, M; Brenner, SL; Blundell, TL; Laue, ED			Crystal structure of the complex of the cyclin D dependent kinase Cdk6 bound to the cell-cycle inhibitor p19(INK4d)	NATURE			English	Article							TGF-BETA; PROTEIN; IDENTIFICATION; PHOSPHORYLATION; P15(INK4B); ACTIVATION; P16(INK4); P27(KIP1); MELANOMA; ANKYRIN	The crystal structure of the cyclin D-dependent kinase Cdk6 bound to the p19(INK4d) protein has been determined at 1.9 Angstrom resolution. The results provide the first structural Information for a cyclin D-dependent protein kinase and show how the INK4 family of CDK inhibitors bind. The structure indicates that the conformational changes Induced by p19(INK4d) Inhibit both productive binding of ATP and the cyclin-induced rearrangement of the kinase from an Inactive to an active conformation. The structure also shows how binding of an INK4 inhibitor would prevent binding of p27(Kip1), resulting In Its redistribution to other CDKs. identification of the critical residues involved in the Interaction explains how mutations in Cdk4 and p16(INK4a) result in loss of kinase inhibition and cancer.	Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, Cambridge CB2 1GA, England; Mitotix Inc, Cambridge, MA 02139 USA; Dupont Merck Pharmaceut Co, Wilmington, DE 19880 USA; Ctr Nacl Biotecnol, Dept Immunol & Oncol, E-28049 Madrid, Spain	University of Cambridge; DuPont; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Laue, ED (corresponding author), Univ Cambridge, Dept Biochem, Cambridge Ctr Mol Recognit, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	e.d.laue@bioc.cam.ac.uk	Serrano, Manuel/H-2634-2015; Smith, Brian O/J-1899-2015	Serrano, Manuel/0000-0001-7177-9312; Smith, Brian O/0000-0003-3363-4168; Laue, Ernest/0000-0002-7476-4148; Wick, Scott/0000-0002-6906-4980; PARISINI, Emilio/0000-0002-5529-0039	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; BORK P, 1993, PROTEINS, V17, P363, DOI 10.1002/prot.340170405; BRUNGER AT, 1992, XPLOR VERSION 3 U SY; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DellaRagione F, 1996, J BIOL CHEM, V271, P15942, DOI 10.1074/jbc.271.27.15942; Foulkes WD, 1997, MOL MED, V3, P5, DOI 10.1007/BF03401664; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harper JW, 1997, CANCER SURV, V29, P91; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hubbard SJ, 1993, NACCESS COMPUTER PRO; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; PARKER LL, 1995, P NATL ACAD SCI USA, V92, P9638, DOI 10.1073/pnas.92.21.9638; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Sandhu C, 1997, MOL CELL BIOL, V17, P2458, DOI 10.1128/MCB.17.5.2458; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Soufir N, 1998, HUM MOL GENET, V7, P209, DOI 10.1093/hmg/7.2.209; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; Tsao H, 1998, CANCER RES, V58, P109; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; YANG R, 1995, CANCER RES, V55, P2503; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	49	173	174	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					244	250		10.1038/26164	http://dx.doi.org/10.1038/26164			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751051				2022-12-24	WOS:000075974600041
J	Rothwarf, DM; Zandi, E; Natoli, G; Karin, M				Rothwarf, DM; Zandi, E; Natoli, G; Karin, M			IKK-gamma is an essential regulatory subunit of the I kappa B kinase complex	NATURE			English	Article							TRANSCRIPTION FACTOR; ACTIVATION; ALPHA; PHOSPHORYLATION; DISSOCIATION; BETA	Pro-inflammatory cytokines activate the transcription factor NF-kappa B by stimulating the activity of a protein kinase that phosphorylates I kappa B, an inhibitor of NF-kappa B1-5, af sites that trigger its ubiquitination and degradation. This results in the nuclear translocation of freed NF-kappa B dimers and the activation of transcription of target genes(6,7). Many of these target genes code for immunoregulatory proteins(8,9). A large, cytokine-responsive I kappa B kinase (IKK) complex has been purified and the genes encoding two of its subunits have been cloned(1,2,5). These subunits, IKK-alpha and IKK-beta, are protein kinases whose function is needed for NF-kappa B activation by pro-inflammatory stimuli. Here, by using a monoclonal antibody against IKK-alpha, we purify the IKK complex to homogeneity from human cell lines. We find that IKK is composed of similar amounts of IKK-alpha, IKK-beta and two other polypeptides, for which we obtained partial sequences. These polypeptides are differentially processed forms of a third subunit, IKK-gamma. Molecular cloning and sequencing indicate that IKK-gamma is composed of several potential coiled-coil moths. IKK-gamma interacts preferentially with IKK-beta and is required for the activation of the IKK complex. An IKK-gamma carboxy-terminal truncation mutant that still binds IKK-beta blocks the activation of IKK and NF-kappa B.	Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Karin, M (corresponding author), Univ Calif San Diego, Dept Pharmacol, Lab Gene Regulat & Signal Transduct, 9500 Gilman Dr, La Jolla, CA 92093 USA.	karinoffice@ucsd.edu	Natoli, gioacchino/ABB-8679-2020; Natoli, gioacchino/J-2100-2018	Natoli, Gioacchino/0000-0003-0711-2411				Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; Frishman D, 1996, PROTEIN ENG, V9, P133, DOI 10.1093/protein/9.2.133; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rost B, 1996, METHOD ENZYMOL, V266, P525; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	18	810	871	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					297	300		10.1038/26261	http://dx.doi.org/10.1038/26261			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751060				2022-12-24	WOS:000075974600056
J	Sechi, LA; Zingaro, L; De Carli, S; Sechi, G; Catena, C; Falleti, E; Dell'Anna, E; Bartoli, E				Sechi, LA; Zingaro, L; De Carli, S; Sechi, G; Catena, C; Falleti, E; Dell'Anna, E; Bartoli, E			Increased serum lipoprotein(a) levels in patients with early renal failure	ANNALS OF INTERNAL MEDICINE			English	Article							APOLIPOPROTEIN(A) PHENOTYPES; SIZE POLYMORPHISM; DISEASE; PLASMA; ABNORMALITIES; HEMODIALYSIS; DIALYSIS; RISK	Background: Elevated serum lipoprotein(a) levels have been found in patients with end-stage renal disease and in patients undergoing dialysis, suggesting that this lipoprotein contributes to the increased cardiovascular risk seen in these patients. It is not known whether lipoprotein(a) levels are elevated in the early phases of renal disease. Objective: To evaluate levels of lipoprotein(a) and other lipids and the prevalence of atherosclerotic disease in patients with early renal failure. Design: Cross-sectional study. Setting: Hypertension clinic of a university medical center. Patients: 257 patients with normal renal function and 160 patients with early impairment of renal function (creatinine clearance, 30 to 89 mL/min per 1.73 m(2) of body surface area). Measurements: Renal function was assessed by 24-hour creatinine clearance, proteinuria, and microalbuminuria. Cardiovascular disease status was also assessed. Serum lipoprotein(a), lipids, apolipoproteins, and apolipoprotein(a) isoforms were measured. Results: Age, blood pressure, and serum lipoprotein(a) levels were greater in patients with early renal failure than in those with normal renal function and were independently associated with the presence of decreased creatinine clearance. Serum lipoprotein(a) and creatinine clearance were inversely correlated. The prevalence of coronary artery, cerebrovascular, and peripheral vascular disease was greater in patients with early renal failure than in those with normal renal function. The frequency distribution of apolipoprotein(a) isoforms was similar in patients with normal and those with impaired renal function. Conclusions: Serum lipoprotein(a) levels are elevated in patients with early impairment of renal function and are associated with greater prevalence of cardiovascular disease. An inverse correlation between serum lipoprotein(a) level and creatinine clearance and a frequency distribution of apolipoprotein(a) isoforms similar to that of normal patients point to decreased renal catabolism as a probable mechanism of lipoprotein(a) elevation in patients with early renal failure.	Univ Udine, Sch Med, Osped Civile, Dept Internal Med,Hypertens Unit,Padigl Med, I-33100 Udine, Italy	University of Udine	Sechi, LA (corresponding author), Univ Udine, Sch Med, Osped Civile, Dept Internal Med,Hypertens Unit,Padigl Med, I-33100 Udine, Italy.	sechi@uniud.it	Sechi, Leonardo Antonio/Y-3109-2018; dell'anna, m. elisabetta/AAO-1673-2020	dell'anna, m. elisabetta/0000-0002-5376-670X; Catena, Cristiana/0000-0001-5039-435X				Arnadottir M, 1996, NEPHRON, V72, P712, DOI 10.1159/000188970; BOERWINKLE E, 1992, J CLIN INVEST, V90, P52, DOI 10.1172/JCI115855; Bostom AG, 1997, ANN INTERN MED, V127, P1089, DOI 10.7326/0003-4819-127-12-199712150-00006; CHAN MK, 1981, KIDNEY INT, V19, P625, DOI 10.1038/ki.1981.62; DIEPLINGER H, 1993, J CLIN INVEST, V91, P397, DOI 10.1172/JCI116213; HAFFNER SM, 1992, J AM SOC NEPHROL, V3, P1156; HIRATA K, 1993, KIDNEY INT, V44, P1062, DOI 10.1038/ki.1993.349; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; KIM KE, 1988, DISEASES KIDNEY, P3093; Kronenberg F, 1996, CRIT REV CL LAB SCI, V33, P495, DOI 10.3109/10408369609080056; Kronenberg F, 1996, AM J KIDNEY DIS, V27, P1, DOI 10.1016/S0272-6386(96)90026-8; KRONENBERG F, 1995, J AM SOC NEPHROL, V6, P110; RADER DJ, 1994, ANN INTERN MED, V120, P1012, DOI 10.7326/0003-4819-120-12-199406150-00008; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; SECHI LA, 1992, METABOLISM, V41, P1261, DOI 10.1016/0026-0495(92)90019-7; Sechi LA, 1997, JAMA-J AM MED ASSOC, V277, P1689, DOI 10.1001/jama.277.21.1689; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; ZANCHETTI A, 1993, HYPERTENSION, V22, P392	20	70	70	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					457	461		10.7326/0003-4819-129-6-199809150-00006	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735083				2022-12-24	WOS:000075892100004
J	Whitmarsh, AJ; Cavanagh, L; Tournier, C; Yasuda, L; Davis, RJ				Whitmarsh, AJ; Cavanagh, L; Tournier, C; Yasuda, L; Davis, RJ			Mammalian scaffold complex that selectively mediates MAP kinase activation	SCIENCE			English	Article							SIGNAL-TRANSDUCTION PATHWAY; N-TERMINAL KINASE; PROTEIN-KINASE; JUN KINASE; PHOSPHORYLATES; SAPK/JNK; CLONING; CASCADE; MEMBER; FAMILY	The c-Jun NH2-terminal kinase (JNK) group of mitogen-activated protein (MAP) kinases is activated by the exposure of cells to multiple forms of stress. A putative scaffold protein was identified that interacts with multiple components of the JNK signaling pathway, including the mixed-lineage group of MAP kinase kinase kinases (MLK), the MAP kinase kinase MKK7, and the MAP kinase JNK. This scaffold protein selectively enhanced JNK activation by the MLK signaling pathway. These data establish that a mammalian scaffold protein can mediate activation of a MAP kinase signaling pathway.	Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Davis, RJ (corresponding author), Univ Massachusetts, Sch Med, Dept Biochem & Mol Biol, Program Mol Med, Worcester, MA 01605 USA.			Yasuda, Jun/0000-0002-3887-6871; Tournier, Cathy/0000-0002-4618-2570; Whitmarsh, Alan/0000-0003-1184-6610				BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; CHOI KY, 1994, CELL, V78, P499; Deacon K, 1997, J BIOL CHEM, V272, P14489, DOI 10.1074/jbc.272.22.14489; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; EllingerZiegelbauer H, 1997, J BIOL CHEM, V272, P2668, DOI 10.1074/jbc.272.5.2668; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; HIRAI S, 1996, ONCOGENE, V12, P341; Hu MCT, 1996, GENE DEV, V10, P2251, DOI 10.1101/gad.10.18.2251; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kiefer F, 1996, EMBO J, V15, P7013, DOI 10.1002/j.1460-2075.1996.tb01093.x; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Posas F, 1997, SCIENCE, V276, P1702, DOI 10.1126/science.276.5319.1702; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; TOUMIER C, 1997, P NATL ACAD SCI USA, V94, P7337; Tung RM, 1997, ONCOGENE, V14, P653, DOI 10.1038/sj.onc.1200877; WANG W, 1997, J BIOL CHEM, V272, P2271; WARTMANN M, 1994, J BIOL CHEM, V269, P6695; WHITMARSH AJ, UNPUB	29	580	605	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1671	1674		10.1126/science.281.5383.1671	http://dx.doi.org/10.1126/science.281.5383.1671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733513				2022-12-24	WOS:000075856500046
J	Leclercq, R; Courvalin, P				Leclercq, R; Courvalin, P			Streptogramins: an answer to antibiotic resistance in gram-positive bacteria	LANCET			English	Editorial Material							RP-59500 QUINUPRISTIN-DALFOPRISTIN; IN-VITRO; STAPHYLOCOCCUS-AUREUS; QUINUPRISTIN/DALFOPRISTIN; ERYTHROMYCIN		Hop Cote de Nacre, Microbiol Serv, F-14033 Caen, France; Inst Pasteur, Unite Agents Antibacteriens, F-75015 Paris, France	CHU de Caen NORMANDIE; Universite de Caen Normandie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Leclercq, R (corresponding author), Hop Cote de Nacre, Microbiol Serv, F-14033 Caen, France.							Allignet J, 1996, ANTIMICROB AGENTS CH, V40, P2523, DOI 10.1128/AAC.40.11.2523; Bouanchaud DH, 1997, J ANTIMICROB CHEMOTH, V39, P15, DOI 10.1093/jac/39.suppl_1.15; Cocito C, 1997, J ANTIMICROB CHEMOTH, V39, P7, DOI 10.1093/jac/39.suppl_1.7; DUVAL J, 1985, J ANTIMICROB CHEMOTH, V16, P137, DOI 10.1093/jac/16.suppl_A.137; Eliopoulos GM, 1998, ANTIMICROB AGENTS CH, V42, P1088, DOI 10.1128/AAC.42.5.1088; FANTIN B, 1995, ANTIMICROB AGENTS CH, V39, P400, DOI 10.1128/AAC.39.2.400; Gold HS, 1996, NEW ENGL J MED, V335, P1445, DOI 10.1056/NEJM199611073351907; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; HoogkampKorstanje JAA, 1997, J ANTIMICROB CHEMOTH, V40, P427, DOI 10.1093/jac/40.3.427; Leclercq R, 1997, CLIN INFECT DIS, V24, P545, DOI 10.1093/clind/24.4.545; LECLERCQ R, 1991, ANTIMICROB AGENTS CH, V35, P1273, DOI 10.1128/AAC.35.7.1273; LONCLE V, 1993, ANTIMICROB AGENTS CH, V37, P2159, DOI 10.1128/AAC.37.10.2159; Low DE, 1995, MICROB DRUG RESIST, V1, P223, DOI 10.1089/mdr.1995.1.223; OBRIEN TF, 1982, REV INFECT DIS, V4, P351; Pankuch GA, 1996, ANTIMICROB AGENTS CH, V40, P2071, DOI 10.1128/AAC.40.9.2071; WEISBLUM B, 1995, ANTIMICROB AGENTS CH, V39, P577, DOI 10.1128/AAC.39.3.577; Welton LA, 1998, ANTIMICROB AGENTS CH, V42, P705, DOI 10.1128/AAC.42.3.705; Williams JD, 1997, J ANTIMICROB CHEMOTH, V39, P41, DOI 10.1093/jac/39.suppl_1.41	18	29	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					591	592		10.1016/S0140-6736(05)79570-2	http://dx.doi.org/10.1016/S0140-6736(05)79570-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746015				2022-12-24	WOS:000075567400003
J	Valegard, K; van Scheltinga, ACT; Lloyd, MD; Hara, T; Ramaswamy, S; Perrakis, A; Thompson, A; Lee, HJ; Baldwin, JE; Schofield, CJ; Hajdu, J; Andersson, I				Valegard, K; van Scheltinga, ACT; Lloyd, MD; Hara, T; Ramaswamy, S; Perrakis, A; Thompson, A; Lee, HJ; Baldwin, JE; Schofield, CJ; Hajdu, J; Andersson, I			Structure of a cephalosporin synthase	NATURE			English	Article							DEACETOXYCEPHALOSPORIN-C SYNTHASE; STREPTOMYCES-CLAVULIGERUS; ESCHERICHIA-COLI; REFINEMENT	Penicillins and cephalosporins are among the most widely used therapeutic agents. These antibiotics are produced from fermentation-derived materials as their chemical synthesis is not commercially viable. Unconventional steps in their biosynthesis are catalysed by Fe(II)-dependent oxidases/oxygenases; isopenicillin N synthase (IPNS)(1,2) creates in one step the bicyclic nucleus of penicillins, and deacetoxycephalosporin C synthase (DAOCS) catalyses the expansion of the penicillin nucleus into the nucleus of cephalosporins. Both enzymes use dioxygen-derived ferryl intermediates in catalysis but, in contrast to IPNS, the ferryl form of DAOCS is produced by the oxidative splitting of a cosubstrate, 2-oxoglutarate (alpha-ketoglutarate). This route of controlled ferryl formation and reaction is common to many mononuclear ferrous enzymes(3), which participate in a broader range of reactions than their well-characterized counterparts, the haem enzymes, Here we report the first crystal structure of a 2-oxoacid-dependent oxygenase, High-resolution structures for apo-DAOCS, the enzyme complexed with Fe(II), and with Fe(II) and 2-oxoglutarate, were obtained from merohedrally twinned crystals. Using a model based on these structures, we propose a mechanism for ferryl formation.	Swedish Univ Agr Sci, Dept Mol Biol, S-75124 Uppsala, Sweden; Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden; Univ Oxford, Dyson Perrins Lab, Oxford Ctr Mol Sci, Oxford OX1 3QY, England; European Mol Biol Lab, ILL, F-38042 Grenoble 9, France	Swedish University of Agricultural Sciences; Uppsala University; University of Oxford; European Molecular Biology Laboratory (EMBL); Institut Laue-Langevin (ILL)	Andersson, I (corresponding author), Swedish Univ Agr Sci, Dept Mol Biol, Box 590, S-75124 Uppsala, Sweden.	christopher.schofield@chemistry.oxford.ac.uk; inger@xray.bmc.uu.se	Subramanian, Ramaswamy/Q-8671-2019; Perrakis, Anastassis/E-8704-2013; Lloyd, Matthew/AAX-6048-2021	Subramanian, Ramaswamy/0000-0002-6709-190X; Perrakis, Anastassis/0000-0002-1151-6227; Lloyd, Matthew/0000-0002-4821-4361; Schofield, Christopher/0000-0002-0290-6565				ABRAHAM EP, 1961, BIOCHEM J, V79, P377, DOI 10.1042/bj0790377; ABRAHAM EP, 1956, BIOCHEM J, V63, P628, DOI 10.1042/bj0630628; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin J. E., 1992, CHEM BETA LACTAMS, P1; BROTZU G, 1948, LAVORI I IGIENE CAGL, P1; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; DOTZLAF JE, 1989, J BIOL CHEM, V264, P10219; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FISHER RG, 1980, ACTA CRYSTALLOGR A, V36, P755, DOI 10.1107/S0567739480001520; Hegg EL, 1997, EUR J BIOCHEM, V250, P625, DOI 10.1111/j.1432-1033.1997.t01-1-00625.x; HODGKIN DC, 1961, BIOCHEM J, V79, P393, DOI 10.1042/bj0790393; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KOVACEVIC S, 1989, J BACTERIOL, V171, P754, DOI 10.1128/jb.171.2.754-760.1989; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Landman O, 1997, FEBS LETT, V405, P172, DOI 10.1016/S0014-5793(97)00180-4; Lester DR, 1997, PLANT CELL, V9, P1435, DOI 10.1105/tpc.9.8.1435; MORGAN N, 1994, BIOORG MED CHEM LETT, V4, P1595, DOI 10.1016/S0960-894X(01)80573-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; NEWTON GGF, 1955, NATURE, V175, P548, DOI 10.1038/175548a0; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PRESCOTT AG, 1993, J EXP BOT, V44, P849, DOI 10.1093/jxb/44.5.849; ROACH PL, 1995, NATURE, V375, P700, DOI 10.1038/375700a0; Roach PL, 1997, NATURE, V387, P827, DOI 10.1038/42990; Schofield CJ, 1997, CURR OPIN STRUC BIOL, V7, P857, DOI 10.1016/S0959-440X(97)80158-3; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; YOSHIDA M, 1978, P NATL ACAD SCI USA, V75, P6253, DOI 10.1073/pnas.75.12.6253; Zhang ZH, 1997, BIOCHEMISTRY-US, V36, P15999, DOI 10.1021/bi971823c	30	301	307	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 20	1998	394	6695					805	809		10.1038/29575	http://dx.doi.org/10.1038/29575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723623				2022-12-24	WOS:000075503600052
J	Andreone, P; Zignego, AL; Cursaro, C; Gramenzi, A; Gherlinzoni, F; Fiorino, S; Giannini, C; Boni, P; Sabattini, E; Pileri, S; Tura, S; Bernardi, M				Andreone, P; Zignego, AL; Cursaro, C; Gramenzi, A; Gherlinzoni, F; Fiorino, S; Giannini, C; Boni, P; Sabattini, E; Pileri, S; Tura, S; Bernardi, M			Prevalence of monoclonal gammopathies in patients with hepatitis C virus infection	ANNALS OF INTERNAL MEDICINE			English	Article							MULTIPLE-MYELOMA; CRYOGLOBULINEMIA; CLASSIFICATION; LYMPHOMA	Background: An association between monoclonal gammopathies and chronic liver diseases has been reported. Objective: To determine the prevalence of monoclonal gammopathies in patients with chronic hepatitis C virus (HCV) infection and the possible association of monoclonal gammopathies with HCV genotypes. Design: Prospective study. Setting: Departments of internal medicine and hematology at two university hospitals in Italy. Patients: 239 HCV-positive and 98 HCV-negative patients with chronic liver diseases were recruited consecutively. Measurements: Clinical data were gathered, liver histologic examination was done, serum immunoglobulin and cryoglobulin levels were measured, and immunoelectrophoresis was done for monoclonal component detection. Patients with monoclonal gammopathy had serum HCV RNA measured and HCV genotype determined by polymerase chain reaction and had histologic examination of bone marrow. Results: Monoclonal band was detected in 11% of HCV-positive patients and in 1% of HCV-negative patients (P = 0.004). The prevalence of HCV genotype 2a/c was higher in patients with monoclonal gammopathies than in those without (50% compared with 18%; P = 0.009). Conclusion: The prevalence of monoclonal gammopathies in patients with HCV-related chronic liver disease is striking and is often associated with genotype 2a/c infection.	Univ Bologna, Dipartimento Med Interna Cardioangiol & Epatol, Serv Semeiot Med, I-40138 Bologna, Italy; Univ Bologna, Ist Ematol & Oncol Med, Serv Anat Patol, I-40138 Bologna, Italy; Policlin S Orsola, Lab Centralizzato, I-40138 Bologna, Italy; Univ Florence, Ist Med Interna, I-50134 Florence, Italy	University of Bologna; University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Florence	Andreone, P (corresponding author), Univ Bologna, Dipartimento Med Interna Cardioangiol & Epatol, Serv Semeiot Med, Via Massarenti 9, I-40138 Bologna, Italy.	andreone@med.unibo.it	Sabattini, Elena/K-6720-2016; Andreone, Pietro/K-8050-2016; Pileri, Stefano/AAP-6337-2020; Zignego, Anna Linda/AAL-8205-2021	Sabattini, Elena/0000-0002-4136-3591; Andreone, Pietro/0000-0002-4794-9809; Cursaro, Carmela/0000-0002-5644-2508				AXELSSON U, 1966, ACTA MED SCAND, V179, P235; BARTL R, 1987, AM J CLIN PATHOL, V87, P342, DOI 10.1093/ajcp/87.3.342; BROUET JC, 1974, AM J MED, V57, P775, DOI 10.1016/0002-9343(74)90852-3; ELLMAN LL, 1969, GASTROENTEROLOGY, V57, P138; ENGLISOVA M, 1968, SCAND J GASTROENTERO, V3, P413, DOI 10.3109/00365526809180138; FERRI C, 1995, LANCET, V346, P1426, DOI 10.1016/S0140-6736(95)92442-6; GRAMENZI A, 1991, BRIT J CANCER, V63, P769, DOI 10.1038/bjc.1991.172; HARRIS NL, 1994, BLOOD, V84, P1361; HEER M, 1984, LIVER, V4, P255; MALACRIDA V, 1987, J CLIN PATHOL, V40, P793, DOI 10.1136/jcp.40.7.793; Mangia A, 1996, LEUKEMIA, V10, P1209; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; Mussini C, 1995, CLIN EXP RHEUMATOL, V13, pS45; PAWLOTSKY JM, 1995, ANN INTERN MED, V122, P169, DOI 10.7326/0003-4819-122-3-199502010-00002; Pileri SA, 1997, J CLIN PATHOL, V50, P2, DOI 10.1136/jcp.50.1.2; PONTISSO P, 1995, J VIRAL HEPATITIS, V2, P33, DOI 10.1111/j.1365-2893.1995.tb00069.x; RIEDEL DA, 1992, HEMATOL ONCOL CLIN N, V6, P225, DOI 10.1016/S0889-8588(18)30341-1; SALMON SE, 1989, CANC PRINCIPLES PRAC, P1884; TANAKA H, 1989, BLOOD, V74, P1718; Zignego AL, 1996, ANN INTERN MED, V124, P31, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00006	20	89	90	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					294	298		10.7326/0003-4819-129-4-199808150-00005	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729182				2022-12-24	WOS:000075329100005
J	Presgraves, DC; Orr, HA				Presgraves, DC; Orr, HA			Haldane's rule in taxa lacking a hemizygous X	SCIENCE			English	Article							DROSOPHILA-SIMULANS; REPRODUCTIVE ISOLATION; LINKAGE MAP; CHROMOSOME	Haldane's rule states that species hybrids of the XY sex are preferentially sterile or inviable. In all taxa known to obey this rule, the Y is inert and X-Linked genes show full expression in XY individuals. Until recently, all theories of Haldane's rule depended on this hemizygosity. A test of Haldane's rule in animals Lacking a hemizygous sex-mosquitoes having two functional sex chromosomes in both sexes-reveals that these species show Haldane's rule for sterility but not inviability, A related group having a "normal" hemizygous X obeys Haldane's rule for both sterility and inviability. These results support the faster male and dominance theories of Haldane's rule.	Univ Rochester, Dept Biol, Rochester, NY 14627 USA	University of Rochester	Presgraves, DC (corresponding author), Univ Rochester, Dept Biol, Rochester, NY 14627 USA.							[Anonymous], 1967, GENETICS INSECT VECT; BHALLA SC, 1970, CAN J GENET CYTOL, V12, P425, DOI 10.1139/g70-061; COULTHART MB, 1988, MOL BIOL EVOL, V5, P182; Coyne J.A., 1989, P180; Eberhard W. G., 1985, SEXUAL SELECTION ANI; Haldane JBS, 1922, J GENET, V12, P101, DOI 10.1007/BF02983075; Hollocher H, 1996, GENETICS, V143, P1243; KITZMILLER JB, 1976, ADV GENET, V18, P315, DOI 10.1016/S0065-2660(08)60441-1; KUITZMILLER JB, 1967, GENETICS INSECT VECT, P151; Laurie CC, 1997, GENETICS, V147, P937; Muller H., 1942, BIOL S, V6, P71; MUNSTERMANN LE, 1990, GENETIC MAPS LOCUS M, P179; ORR HA, 1993, EVOLUTION, V47, P1606, DOI [10.2307/2410171, 10.1111/j.1558-5646.1993.tb02179.x]; ORR HA, 1992, GENET RES, V59, P73, DOI 10.1017/S0016672300030275; ORR HA, 1993, NATURE, V361, P532, DOI 10.1038/361532a0; Orr HA, 1997, ANNU REV ECOL SYST, V28, P195, DOI 10.1146/annurev.ecolsys.28.1.195; QUINN TC, 1971, J HERED, V62, P2, DOI 10.1093/oxfordjournals.jhered.a108114; SEVERSON DW, 1993, J HERED, V84, P241, DOI 10.1093/oxfordjournals.jhered.a111333; TADANO T, 1984, JPN J GENET, V59, P165, DOI 10.1266/jjg.59.165; True JR, 1996, GENETICS, V142, P819; Turelli M, 1997, GENETICS, V147, P1799; WU CI, 1993, AM NAT, V142, P187, DOI 10.1086/285534; WU CI, 1996, TRENDS ECOL EVOL, V11, P411; ZHENG LB, 1993, SCIENCE, V261, P605, DOI 10.1126/science.8342025	24	109	109	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 30	1998	282	5390					952	954		10.1126/science.282.5390.952	http://dx.doi.org/10.1126/science.282.5390.952			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794768				2022-12-24	WOS:000076727300053
J	Takayama, T; Katsuki, S; Takahashi, Y; Ohi, M; Nojiri, S; Sakamaki, S; Kato, J; Kogawa, K; Miyake, H; Niitsu, Y				Takayama, T; Katsuki, S; Takahashi, Y; Ohi, M; Nojiri, S; Sakamaki, S; Kato, J; Kogawa, K; Miyake, H; Niitsu, Y			Aberrant crypt foci of the colon as precursors of adenoma and cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							K-RAS MUTATIONS; PUTATIVE PRENEOPLASTIC LESIONS; CARCINOGENESIS; AZOXYMETHANE; SULINDAC; ASPIRIN; POLYPS; RISK; QUANTIFICATION; MICROADENOMAS	Background Aberrant crypt foci of the colon are possible precursors of adenoma and cancer, but these lesions have been studied mainly in surgical specimens from patients who already had colon cancer. Methods Using magnifying endoscopy, we studied the prevalence, number, size, and dysplastic features of aberrant crypt foci and their distribution according to age in 171 normal subjects, 131 patients with adenoma, and 48 patients with colorectal cancer. We also prospectively examined the prevalence of aberrant crypt foci in 11 subjects (4 normal subjects, 6 with adenoma, and 1 with cancer) before and after the administration of 100 mg of sulindac three times a day for 8 to 12 months and compared the results with those in 9 untreated subjects (4 normal subjects and 5 with adenoma). All 20 subjects had aberrant crypt foci at base line. Results We identified 3155 aberrant crypt foci, 161 of which were dysplastic; the prevalence and number increased with age. There were significant (P<0.001) correlations between the number of aberrant crypt foci, the presence of dysplastic foci, the size of the foci, and the number of adenomas. After sulindac therapy, the number of foci decreased, disappearing in 7 of 11 subjects. In the untreated control group, the number of foci was unchanged in eight subjects and slightly increased in one (P<0.001 for the difference between the groups). Conclusions Aberrant crypt foci, particularly those that are large and have dysplastic features, may be precursors of adenoma and cancer. (N Engl J Med 1998;339:1277-84.) (C)1998, Massachusetts Medical Society.	Sapporo Med Univ, Dept Internal Med 4, Chuo Ku, Sapporo, Hokkaido, Japan; Sapporo Med Univ, Dept Publ Hlth, Chuo Ku, Sapporo, Hokkaido, Japan; Muroran Shinnittetsu Hosp, Muroran, Hokkaido, Japan	Sapporo Medical University; Sapporo Medical University	Niitsu, Y (corresponding author), Sapporo Med Univ, Dept Internal Med 4, Chuo Ku, South-1,West-16, Sapporo, Hokkaido, Japan.							Altman D., 1991, PRACTICAL STAT MED R; BERNSTEIN MA, 1985, RADIOLOGY, V155, P35, DOI 10.1148/radiology.155.1.3975415; BIRD RP, 1987, CANCER LETT, V37, P147, DOI 10.1016/0304-3835(87)90157-1; Cox DR., 1970, ANAL BINARY DATA; DiGregori C, 1997, HISTOPATHOLOGY, V30, P328, DOI 10.1046/j.1365-2559.1997.d01-626.x; DiGregorio C, 1997, HISTOPATHOLOGY, V31, P491; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; HEATH CW, 1993, JNCI-J NATL CANCER I, V85, P258, DOI 10.1093/jnci/85.4.258; HELWIG EB, 1943, SURG GYNECOL OBSTET, V76, P419; JEN J, 1994, CANCER RES, V54, P5523; KIM HG, 1994, AM J PATHOL, V145, P148; Kune GA, 2007, INT J EPIDEMIOL, V36, P951, DOI 10.1093/ije/dym193; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; LADENHEIM J, 1995, GASTROENTEROLOGY, V108, P1083, DOI 10.1016/0016-5085(95)90206-6; LEVI S, 1991, CANCER RES, V51, P3497; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; MCLELLAN EA, 1991, CANCER RES, V51, P5270; MERETO E, 1994, CANCER LETT, V76, P5, DOI 10.1016/0304-3835(94)90127-9; PRETLOW TP, 1991, CANCER RES, V51, P1564; PRETLOW TP, 1993, J NATL CANCER I, V85, P2004, DOI 10.1093/jnci/85.24.2004; PRETLOW TP, 1995, GASTROENTEROLOGY, V108, P600, DOI 10.1016/0016-5085(95)90092-6; PRETLOW TP, 1992, J CELL BIOCHEM, P55; RONCUCCI L, 1991, HUM PATHOL, V22, P287, DOI 10.1016/0046-8177(91)90163-J; RONCUCCI L, 1991, CANCER EPIDEM BIOMAR, V1, P57; RONCUCCI L, 1992, ITAL J GASTROENTEROL, V24, P498; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SHIVAPURKAR N, 1994, CARCINOGENESIS, V15, P775, DOI 10.1093/carcin/15.4.775; STOPERA SA, 1992, CARCINOGENESIS, V13, P573, DOI 10.1093/carcin/13.4.573; SUTHERLAND LAM, 1994, CANCER LETT, V76, P101, DOI 10.1016/0304-3835(94)90384-0; TACHINO N, 1995, MOL CARCINOGEN, V12, P187, DOI 10.1002/mc.2940120402; TAKAHASHI M, 1994, CANCER LETT, V83, P177, DOI 10.1016/0304-3835(94)90316-6; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; VIVONA AA, 1993, CARCINOGENESIS, V14, P1777, DOI 10.1093/carcin/14.9.1777; YAMASHITA N, 1995, CANCER, V75, P1527, DOI 10.1002/1097-0142(19950315)75:6+<1527::AID-CNCR2820751524>3.0.CO;2-Y; YAMASHITA N, 1995, GASTROENTEROLOGY, V108, P434, DOI 10.1016/0016-5085(95)90071-3	35	472	490	2	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 29	1998	339	18					1277	1284		10.1056/NEJM199810293391803	http://dx.doi.org/10.1056/NEJM199810293391803			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	132XC	9791143				2022-12-24	WOS:000076655300003
J	Mathew, MO; Ramamohan, N; Bennet, GC				Mathew, MO; Ramamohan, N; Bennet, GC			Importance of bruising associated with paediatric fractures: prospective observational study	BRITISH MEDICAL JOURNAL			English	Article									Royal Hosp Sick Children, Dept Orthopaed, Glasgow G3 8SJ, Lanark, Scotland	University of Glasgow	Bennet, GC (corresponding author), Royal Hosp Sick Children, Dept Orthopaed, Glasgow G3 8SJ, Lanark, Scotland.							PATERSON CR, 1987, BRIT MED J, V295, P213, DOI 10.1136/bmj.295.6591.213-a; TAITZ LS, 1991, BRIT MED J, V302, P1244, DOI 10.1136/bmj.302.6787.1244; TAITZ LS, 1991, HOSPITAL UPDATE  MAY, P400	3	34	34	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 24	1998	317	7166					1117	1118						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784447				2022-12-24	WOS:000076755100028
J	Yetman, AT; McCrindle, BW; MacDonald, C; Freedom, RM; Gow, R				Yetman, AT; McCrindle, BW; MacDonald, C; Freedom, RM; Gow, R			Myocardial bridging in children with hypertrophic cardiomyopathy - A risk factor for sudden death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DESCENDING CORONARY-ARTERY; BLOOD-PRESSURE RESPONSE; QT DISPERSION; CARDIAC-ARREST; EXERCISE CAPACITY; ISCHEMIA; SCINTIGRAPHY; INTERVAL; OBSTRUCTION; ARRHYTHMIA	Background Myocardial bridging may cause compression of a coronary artery, and it has been suggested that myocardial ischemia may result. The clinical significance and prognostic value of myocardial bridging of the left anterior descending coronary artery in children with hypertrophic cardiomyopathy are unknown. We sought to determine the prevalence and clinical effects of myocardial bridging in children with hypertrophic cardiomyopathy who underwent cardiac catheterization. Methods Angiograms from 36 children with hypertrophic cardiomyopathy were reviewed to determine whether myocardial bridging was present and, if so, to assess the characteristics of systolic narrowing of the left anterior descending coronary artery caused by myocardial bridging and the duration of residual diastolic compression. We also reviewed clinical data on these patients. Results Myocardial bridging was present in 10 (28 percent) of the patients. Compression of the left anterior descending coronary artery persisted for a mean (+/-SD) of 50+/-17 percent of diastole. As compared with patients without bridging, patients with bridging had a greater incidence of chest pain (60 percent vs. 19 percent, P=0.04), cardiac arrest with subsequent resuscitation (50 percent vs. 4 percent, P=0.004), and ventricular tachycardia (80 percent vs. 8 percent, P<0.001). On average, the patients with bridging had a reduction in systolic blood pressure with exercise of 17+/-27 mm Hg, as compared with an elevation of 43+/-31 mm Hg in those without bridging (P<0.001). The patients with bridging also had greater ST-segment depression with exercise (median, 5 vs. 0 mm, P=0.004) and a shorter duration of exercise (mean, 6.6+/-2.4 vs. 9.1+/-1.4 minutes, P=0.008). The degree of dispersion of the OT interval corrected for heart rate on the electrocardiogram was greater in patients with bridging than in those without bridging (104+/-46 vs. 48+/-31 msec, P=0.002). Kaplan-Meier estimates of the proportions of patients who had not died or had cardiac arrest with subsequent resuscitation five years after the diagnosis of hypertrophic cardiomyopathy were 67 percent among patients with bridging and 94 percent among those without bridging (P=0.004). Conclusions Myocardial bridging is associated with a poor outcome in children with hypertrophic cardiomyopathy. Our observations suggest that bridging is associated with myocardial ischemia. (N Engl J Med 1998;339:1201-9.) (C) 1998, Massachusetts Medical Society.	Univ Toronto, Hosp Sick Children, Fac Med, Dept Pediat,Div Cardiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Gow, R (corresponding author), Childrens Hosp Eastern Ontario, 401 Smythe Rd, Ottawa, ON K1H 8L1, Canada.							ACHRAFI H, 1992, INT J CARDIOL, V37, P111, DOI 10.1016/0167-5273(92)90138-S; ANGELINI P, 1983, PROG CARDIOVASC DIS, V26, P75, DOI 10.1016/0033-0620(83)90019-1; BORVINICK EH, 1993, J AM COLL CARDIOL, V22, P805; BRAUNWALD E, 1997, HEART DIS TXB CARDIO, P1169; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; CANNON RO, 1985, CIRCULATION, V71, P234, DOI 10.1161/01.CIR.71.2.234; Colleran JA, 1996, AM HEART J, V131, P196, DOI 10.1016/S0002-8703(96)90071-X; COUNIHAN PJ, 1991, CIRCULATION, V84, P686, DOI 10.1161/01.CIR.84.2.686; COWAN JC, 1988, AM J CARDIOL, V61, P83, DOI 10.1016/0002-9149(88)91309-4; CUMMING GR, 1978, AM J CARDIOL, V41, P69, DOI 10.1016/0002-9149(78)90134-0; DAY CP, 1990, BRIT HEART J, V63, P342; DAY CP, 1992, BRIT HEART J, V67, P39; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; EDWARDS JC, 1956, CIRCULATION, V13, P235, DOI 10.1161/01.CIR.13.2.235; FANANAPAZIR L, 1991, AM J CARDIOL, V67, P280, DOI 10.1016/0002-9149(91)90560-8; FELD H, 1991, CHEST, V99, P1295, DOI 10.1378/chest.99.5.1295; FRENNEAUX MP, 1990, CIRCULATION, V82, P1995, DOI 10.1161/01.CIR.82.6.1995; GARDIN LL, 1994, CAN J CARDIOL, V10, P548; GE JB, 1994, CIRCULATION, V89, P1725, DOI 10.1161/01.CIR.89.4.1725; GEIRINGER E, 1951, AM HEART J, V41, P359, DOI 10.1016/0002-8703(51)90036-1; GREENSPAN M, 1980, CATHETER CARDIO DIAG, V6, P173, DOI 10.1002/ccd.1810060207; ILLERA JP, 1985, INT J CARDIOL, V8, P327, DOI 10.1016/0167-5273(85)90224-4; IRVIN RG, 1982, CHEST, V81, P198, DOI 10.1378/chest.81.2.198; ISHIMORI T, 1977, CATHETER CARDIO DIAG, V3, P59, DOI 10.1002/ccd.1810030107; IVERSEN S, 1992, SCAND J THORAC CARD, V26, P107, DOI 10.3109/14017439209099063; JUILLIERE Y, 1995, AM HEART J, V129, P663, DOI 10.1016/0002-8703(95)90312-7; KITAZUME H, 1983, AM HEART J, V106, P131, DOI 10.1016/0002-8703(83)90450-7; KRAMER JR, 1982, AM HEART J, V103, P283, DOI 10.1016/0002-8703(82)90500-2; Lazzeroni E, 1997, CIRCULATION, V96, P4268; LELE SS, 1995, CIRCULATION, V92, P2886, DOI 10.1161/01.CIR.92.10.2886; MARON BJ, 1979, AM J CARDIOL, V43, P1086, DOI 10.1016/0002-9149(79)90139-5; MCKENNA WJ, 1988, J AM COLL CARDIOL, V11, P147, DOI 10.1016/0735-1097(88)90181-7; MCKENNA WJ, 1984, ARCH DIS CHILD, V59, P971, DOI 10.1136/adc.59.10.971; MIORELLI M, 1994, INT J CARDIOL, V45, P121, DOI 10.1016/0167-5273(94)90267-4; MORALES AR, 1980, CIRCULATION, V62, P230, DOI 10.1161/01.CIR.62.2.230; NAIR C K, 1986, Canadian Journal of Cardiology, V2, P218; NAVARROLOPEZ F, 1986, INT J CARDIOL, V12, P309, DOI 10.1016/0167-5273(86)90267-6; Nezuo S, 1996, J Cardiol, V27, P65; NIHOYANNOPOULOS P, 1992, J AM COLL CARDIOL, V19, P536, DOI 10.1016/S0735-1097(10)80268-2; NOBLE J, 1976, AM J CARDIOL, V37, P993, DOI 10.1016/0002-9149(76)90414-8; NOBLE J, 1977, AM J CARDIOL, V39, P267; PERKIOMAKI JS, 1995, J AM COLL CARDIOL, V26, P174, DOI 10.1016/0735-1097(95)00122-G; Portsmann W., 1960, ROFO FORTSCHR RONTG, V92, P129, DOI 10.1055/s-0029-1226492; REIG J, 1990, PEDIATR CARDIOL, V11, P186, DOI 10.1007/BF02238364; Sadoul N, 1997, CIRCULATION, V96, P2987, DOI 10.1161/01.CIR.96.9.2987; Schwarz ER, 1996, J AM COLL CARDIOL, V27, P1637, DOI 10.1016/0735-1097(96)00062-9; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; Stoletniy LN, 1997, CIRCULATION, V96, P904; VISSCHER DW, 1983, CATHETER CARDIO DIAG, V9, P493, DOI 10.1002/ccd.1810090508; VOELKER W, 1989, INT J CARDIOL, V23, P258, DOI 10.1016/0167-5273(89)90257-X; Vogt PR, 1996, CIRCULATION, V93, P614, DOI 10.1161/01.CIR.93.3.614; VONDOHLEN TW, 1989, AM J CARDIOL, V64, P498, DOI 10.1016/0002-9149(89)90428-1; Vongpatanasin W, 1997, AM HEART J, V133, P463, DOI 10.1016/S0002-8703(97)70190-X; WIGLE ED, 1995, CIRCULATION, V92, P1680, DOI 10.1161/01.CIR.92.7.1680	54	183	201	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1201	1209		10.1056/NEJM199810223391704	http://dx.doi.org/10.1056/NEJM199810223391704			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780340				2022-12-24	WOS:000076532400004
J	Suri, C; McClain, J; Thurston, G; McDonald, DM; Zhou, H; Oldmixon, EH; Sato, TN; Yancopoulos, GD				Suri, C; McClain, J; Thurston, G; McDonald, DM; Zhou, H; Oldmixon, EH; Sato, TN; Yancopoulos, GD			Increased vascularization in mice overexpressing angiopoietin-1	SCIENCE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSGENIC MICE; TIE2 RECEPTOR; EXPRESSION; ANGIOGENESIS; NEOVASCULARIZATION; VASCULOGENESIS; LETHALITY; VESSELS; LIGAND	The angiopoietins and members of the vascular endothelial growth factor (VEGF) family are the only growth factors thought to be largely specific for vascular endothelial cells. Targeted gene inactivation studies in mice have shown that VEGF is necessary for the early stages of vascular development and that angiopoietin-1 is required for the later stages of vascular remodeling. Here it is shown that transgenic overexpression of angiopoietin-1 in the skin of mice produces larger, more numerous, and more highly branched vessels. These results raise the possibility that angiopoietins can be used, alone or in combination with VEGF, to promote therapeutic angiogenesis.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Rogers Imaging, Needham, MA 02192 USA; Univ Texas, SW Med Ctr, Dallas, TX 75235 USA	Regeneron; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yancopoulos, GD (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.			Thurston, Gavin/0000-0002-4105-5919	NHLBI NIH HHS [HL-59157, HL-24136] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DRAKE CJ, 1995, P NATL ACAD SCI USA, V92, P7657, DOI 10.1073/pnas.92.17.7657; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Koblizek TI, 1998, CURR BIOL, V8, P529, DOI 10.1016/S0960-9822(98)70205-2; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGY JA, 1995, CANCER RES, V55, P360; Okamoto N, 1997, AM J PATHOL, V151, P281; OLDMIXON E, 1994, FASEB J, V8, pA691; OLDMIXON EH, 1989, J APPL PHYSIOL, V67, P1930, DOI 10.1152/jappl.1989.67.5.1930; RISAU W, 1997, NATURE, V386, P631; Robinson GS, 1998, INT OPHTHALMOL CLIN, V38, P89, DOI 10.1097/00004397-199838020-00007; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TAKAHASHI K, 1994, J CLIN INVEST, V93, P2357, DOI 10.1172/JCI117241; Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965; Thurston G, 1996, AM J PHYSIOL-HEART C, V271, pH2547, DOI 10.1152/ajpheart.1996.271.6.H2547; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; Viac J, 1997, ARCH DERMATOL RES, V289, P158, DOI 10.1007/s004030050172; WEIBEL E, 1979, STEREOLOGICAL METHOD, V1, P143	28	643	714	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					468	471		10.1126/science.282.5388.468	http://dx.doi.org/10.1126/science.282.5388.468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774272				2022-12-24	WOS:000076479600052
J	Burton, EC; Troxclair, DA; Newman, WP				Burton, EC; Troxclair, DA; Newman, WP			Autopsy diagnoses of malignant neoplasms - How often are clinical diagnoses incorrect?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; ACCURACY	Context.-Autopsy often reveals new diagnoses of malignant neoplasms, but as technological advances to improve diagnosis during life have improved, autopsy rates have declined dramatically. Objective.-To determine if there is still a high discordance rate between clinical and autopsy diagnoses of malignant neoplasms despite increasing technological advances in diagnostic methods. Design and Setting.-A 10-year retrospective study (1986-1995) of all autopsies performed at the Medical Center of Louisiana at New Orleans. Participants.-All patients autopsied, excluding preterm fetuses, at the Medical Center of Louisiana at New Orleans, by both Tulane and Louisiana State University Schools of Medicine in which consent was obtained or authorization given from the Orleans Parish Coroner's Office. Main Outcome Measures.-Discordance between clinical and autopsy diagnoses of malignant neoplasms. Results.-A total of 1625 cases were reviewed of which 520 preterm fetuses were excluded. Of the remaining 1105 cases, 654 were male and 451 were female. The mean age was 48.3 years (range, 1-98 years). A total of 433 neoplasms were diagnosed, 250 of which were malignant. One hundred eleven malignant neoplasms in 100 patients had been either undiagnosed or misdiagnosed, and in 57 patients, the immediate cause of death could be attributed to the malignant neoplasm. The discordance between clinical and autopsy diagnoses of malignant neoplasms in this study is 44%, which is similar to previously reported studies. Conclusion.-The discordance rate between clinical and autopsy diagnoses of malignant neoplasms is large and confirms the importance of the postmortem examination.	Louisiana State Univ, Med Ctr, Dept Pathol, New Orleans, LA 70112 USA	Louisiana State University System	Burton, EC (corresponding author), Louisiana State Univ, Med Ctr, Dept Pathol, P5-1,1901 Perdido St, New Orleans, LA 70112 USA.							BAUER FW, 1972, J AMER MED ASSOC, V221, P1471, DOI 10.1001/jama.221.13.1471; BRITTON M, 1974, ACTA MED SCAND, V196, P211; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; GOBBATO F, 1982, HUM PATHOL, V13, P1036, DOI 10.1016/S0046-8177(82)80096-8; KAJIWARA JK, 1993, J INTERN MED, V234, P181, DOI 10.1111/j.1365-2796.1993.tb00728.x; MANZINI VD, 1995, HUM PATHOL, V26, P280, DOI 10.1016/0046-8177(95)90058-6; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P1889, DOI 10.1001/jama.273.24.1889; ROTHWELL DJ, 1993, SNOMED INT MICROGLOS; SARODE VR, 1993, HUM PATHOL, V24, P194, DOI 10.1016/0046-8177(93)90300-6; *SAS I INC, 1990, SAS US GUID STAT VER; STEVANOVIC G, 1986, HUM PATHOL, V17, P1225, DOI 10.1016/S0046-8177(86)80564-0; SUEN KC, 1974, CANCER-AM CANCER SOC, V33, P1164, DOI 10.1002/1097-0142(197404)33:4<1164::AID-CNCR2820330440>3.0.CO;2-O; Wells HG, 1923, J AMER MED ASSOC, V80, P0737, DOI 10.1001/jama.1923.02640380001001	14	115	122	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1245	1248		10.1001/jama.280.14.1245	http://dx.doi.org/10.1001/jama.280.14.1245			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786374	Bronze			2022-12-24	WOS:000076357900030
J	Lees, KR				Lees, KR			Multifactorial approach to stroke investigation and prevention	LANCET			English	Editorial Material									Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Lees, KR (corresponding author), Univ Glasgow, Western Infirm, Acute Stroke Unit, Glasgow G11 6NT, Lanark, Scotland.							Bath P, 1997, BRIT MED J, V315, P1167; Caplan LR, 1998, J NEUROL NEUROSUR PS, V64, P716, DOI 10.1136/jnnp.64.6.716; Curb JD, 1996, ARTERIOSCL THROM VAS, V16, P1495, DOI 10.1161/01.ATV.16.12.1495; Diener HC, 1996, J NEUROL SCI, V143, P1, DOI 10.1016/S0022-510X(96)00308-5; Sandercock P, 1997, LANCET, V349, P1569; WEIR CJ, 1994, LANCET, V344, P999, DOI 10.1016/S0140-6736(94)91648-9; Yamamoto H, 1998, J NEUROL NEUROSUR PS, V64, P771, DOI 10.1136/jnnp.64.6.771	7	6	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					923	924		10.1016/S0140-6736(05)61509-7	http://dx.doi.org/10.1016/S0140-6736(05)61509-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752812				2022-12-24	WOS:000076002200005
J	Rao, VD; Misra, S; Boronenkov, IV; Anderson, RA; Hurley, JH				Rao, VD; Misra, S; Boronenkov, IV; Anderson, RA; Hurley, JH			Structure of type II beta phosphatidylinositol phosphate kinase: A protein kinase fold flattened for interfacial phosphorylation	CELL			English	Article							MULTIPLE ISOMORPHOUS REPLACEMENT; CATALYTIC SUBUNIT; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; INOSITOL TRISPHOSPHATE; DIFFRACTION DATA; 5-KINASE; FAMILY; 3-KINASE; DOMAIN	Phosphoinositide kinases play central roles in signal transduction by phosphorylating the inositol ring at specific positions. The structure of one such enzyme, type I1 beta phosphatidylinositol phosphate kinase, reveals a protein kinase ATP-binding core and demonstrates that all phosphoinositide kinases belong to one superfamily. The enzyme is a disc-shaped homodimer with a 33 x 48 Angstrom basic flat face that suggests an electrostatic mechanism for plasma membrane targeting. Conserved basic residues form a putative phosphatidylinositol phosphate specificity site. The substrate-binding site is open on one side, consistent with dual specificity for phosphatidylinositol 3- and 5-phosphates. A modeled complex with membrane-bound substrate and ATP shows how a phosphoinositide kinase can phosphorylate its substrate in situ at the membrane interface.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA; Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Wisconsin System; University of Wisconsin Madison	Hurley, JH (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.			Anderson, Richard/0000-0001-6265-8359; Misra, Saurav/0000-0002-1385-8554	NIGMS NIH HHS [GM51968, GM57549] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051968] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1996, XPLOR VERSION 3 8; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; *COLL COMP PROJ, 1994, ACTA CRYSTALLOGR D, V50, P670; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Essen LO, 1996, NATURE, V380, P595, DOI 10.1038/380595a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Gibrat JF, 1996, CURR OPIN STRUC BIOL, V6, P377, DOI 10.1016/S0959-440X(96)80058-3; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hinchliffe K, 1997, NATURE, V390, P123, DOI 10.1038/36458; Homma K, 1998, J BIOL CHEM, V273, P15779, DOI 10.1074/jbc.273.25.15779; Hon WC, 1997, CELL, V89, P887, DOI 10.1016/S0092-8674(00)80274-3; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Hurley JH, 1997, CURR OPIN STRUC BIOL, V7, P557, DOI 10.1016/S0959-440X(97)80122-4; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V24, P946; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MALDONADO F, 1988, NUCLEIC ACIDS RES, V16, P8189, DOI 10.1093/nar/16.16.8189; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PEARSON RH, 1979, NATURE, V281, P499, DOI 10.1038/281499a0; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; Terwilliger TC, 1996, ACTA CRYSTALLOGR D, V52, P749, DOI 10.1107/S0907444996000832; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; WONG K, 1994, J BIOL CHEM, V269, P2881; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; YAMAMOTO A, 1995, MOL BIOL CELL, V6, P525, DOI 10.1091/mbc.6.5.525; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416; Zhang XL, 1997, J BIOL CHEM, V272, P17756, DOI 10.1074/jbc.272.28.17756	57	182	188	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					829	839		10.1016/S0092-8674(00)81741-9	http://dx.doi.org/10.1016/S0092-8674(00)81741-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753329	Bronze			2022-12-24	WOS:000076021200015
J	Boyle, P; Horton, R; Radda, G; Sharp, D; Veronesi, U; Walker, AM				Boyle, P; Horton, R; Radda, G; Sharp, D; Veronesi, U; Walker, AM			Open debate on hormone-replacement therapy	LANCET			English	Editorial Material							METAANALYSIS		European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; The Lancet, London, England; MRC, London, England; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	IRCCS European Institute of Oncology (IEO); Harvard University; Harvard T.H. Chan School of Public Health	Boyle, P (corresponding author), European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy.		Boyle, Peter/A-4380-2014	Boyle, Peter/0000-0001-6251-0610				[Anonymous], 1997, LANCET, V350, P675; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Naylor CD, 1997, BMJ-BRIT MED J, V315, P617, DOI 10.1136/bmj.315.7109.617; *NIH CONS DEV PAN, 1995, NIH CONS DEV C STAT	4	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					836	836		10.1016/S0140-6736(05)60003-7	http://dx.doi.org/10.1016/S0140-6736(05)60003-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742975				2022-12-24	WOS:000075857300005
J	Lanphear, BP				Lanphear, BP			Environmental health - The paradox of lead poisoning prevention	SCIENCE			English	Article							PAINT HAZARD REMEDIATION; CONTAMINATED HOUSE-DUST; COGNITIVE FUNCTION; EXPOSURE; CHILDREN; CHILDHOOD; ABATEMENT; INTELLIGENCE; IMPACT		Univ Cincinnati, Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Lanphear, BP (corresponding author), Univ Cincinnati, Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA.	bruce.lanphear@chmcc.org						AMITAI Y, 1991, PEDIATRICS, V88, P893; Aschengrau A, 1997, AM J PUBLIC HEALTH, V87, P1698, DOI 10.2105/AJPH.87.10.1698; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BELLINGER D, 1994, PEDIATR ANN, V23, P600, DOI 10.3928/0090-4481-19941101-08; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER DC, 1992, PEDIATRICS, V90, P855; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P141; *CDC, 1997, SCREEN YOUNG CHILDRE; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; CHARNEY E, 1983, NEW ENGL J MED, V309, P1089, DOI 10.1056/NEJM198311033091804; CHISOLM JJ, 1986, AM J PUBLIC HEALTH, V26, P236; CLARK CS, 1985, ENVIRON RES, V38, P46, DOI 10.1016/0013-9351(85)90071-4; DIETRICH KN, 1993, PEDIATRICS, V91, P301; FARFEL MR, 1994, ENVIRON RES, V66, P217, DOI 10.1006/enrs.1994.1057; FARFEL MR, 1990, AM J PUBLIC HEALTH, V80, P1240, DOI 10.2105/AJPH.80.10.1240; HARVEY B, 1994, PEDIATRICS, V93, P201; HAYES EB, 1994, PEDIATRICS, V93, P195; Lanphear BP, 1998, PEDIATRICS, V101, P264, DOI 10.1542/peds.101.2.264; LANPHEAR BP, 1995, ENVIRON RES, V68, P114, DOI 10.1006/enrs.1995.1015; Lanphear BP, 1997, ENVIRON RES, V74, P67, DOI 10.1006/enrs.1997.3726; Lanphear BP, 1996, AM J PUBLIC HEALTH, V86, P1460, DOI 10.2105/AJPH.86.10.1460; Lanphear BP, 1996, AM J PUBLIC HEALTH, V86, P1416, DOI 10.2105/AJPH.86.10.1416; LANPHEAR BP, IN PRESS ENV RES; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; RABINOWITZ M, 1985, ENVIRON RES, V38, P96, DOI 10.1016/0013-9351(85)90075-1; REYALVAREZ S, 1987, PEDIATRICS, V79, P214; ROSNER D, 1985, AM J PUBLIC HEALTH, V75, P344, DOI 10.2105/AJPH.75.4.344; SARGENT JD, 1995, AM J PUBLIC HEALTH, V85, P528, DOI 10.2105/AJPH.85.4.528; SHANNON MW, 1992, PEDIATRICS, V89, P87; STAES C, 1994, AM J EPIDEMIOL, V139, P1016, DOI 10.1093/oxfordjournals.aje.a116941; SWINDELL SL, 1994, CLIN PEDIATR, V33, P536, DOI 10.1177/000992289403300905; THACKER SB, 1992, ARCH ENVIRON HEALTH, V47, P336, DOI 10.1080/00039896.1992.9938372; *US DEP HOUS URB D, 1995, GUID CONTR LEAD BAS; *US EPA, 1996, 747R95009 US EPA	36	83	84	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1617	1618		10.1126/science.281.5383.1617	http://dx.doi.org/10.1126/science.281.5383.1617			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	118TR	9767027				2022-12-24	WOS:000075856500029
J	Andersen, RE; Franckowiak, SC; Snyder, J; Bartlett, SJ; Fontaine, KR				Andersen, RE; Franckowiak, SC; Snyder, J; Bartlett, SJ; Fontaine, KR			Can inexpensive signs encourage the use of stairs? Results from a community intervention	ANNALS OF INTERNAL MEDICINE			English	Article							PHYSICAL-ACTIVITY; HEALTH; EXERCISE	Background: The U.S. Surgeon General advocates the accumulation of moderate-intensity activity throughout the day to improve health. Objective: To test the effectiveness of signs to encourage use of stairs instead of escalators. Design: Community intervention. Setting: Shopping center. Participants: 17 901 shoppers. Intervention: Signs promoting the hearth and weight-control benefits of stair use were placed beside escalators with adjacent stairs. Measurements: The sex, age, race,weight classification, and use of stairs were observed. Results: Overall, stair use increased from 4.8% to 6.9% and 7.2% with the health and weight-control signs, respectively. Younger persons increased their stair use from 4.6% to 6.0% with the health sign and 6.1% with the weight-control sign. Older persons almost doubled their stair use from 5.1% to 8.1% with the health sign and increased use to 8.7% with the weight-control sign. Differential use of stairs was observed between ethnic groups. Among white persons, stair use increased from 5.1% to 7.5% and 7.8% with the health and weight-control signs, respectively. Among black persons, stair use decreased from 4.1% to 3.4% with the health sign and increased to 5.0% with the weight-control sign. At baseline, lean persons used the stairs more often than overweight persons (5.4% and 3.8%, respectively). The health sign increased stair use to 7.2% among normal-weight persons and 6.3% among overweight persons; the weight-control sign prompted stair use to increase to 6.9% among persons of normal weight and to 7.8% among overweight persons. Conclusions: Simple, inexpensive interventions can increase physical activity. Research is needed to identify effective motivators to promote activity among black persons.	Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Div Gastroenterol, Baltimore, MD 21224 USA; Johns Hopkins Weight Management Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Andersen, RE (corresponding author), Johns Hopkins Univ, Sch Med, Div Geriatr Med & Gerontol, 5501 Hopkins Bayview Circle JHAAC SB-81, Baltimore, MD 21224 USA.	andersen@welchlink.welchjhu.edu	Bartlett, Susan J./J-9864-2012; Bartlett, Susan Joan/AAD-4103-2020	Bartlett, Susan Joan/0000-0001-9755-2490				Andersen RE, 1997, ANN INTERN MED, V127, P395, DOI 10.7326/0003-4819-127-5-199709010-00010; Andersen RE, 1998, JAMA-J AM MED ASSOC, V279, P938, DOI 10.1001/jama.279.12.938; ANDERSEN RE, 1995, MED EXERC NUTR HLTH, V4, P57; ANDERSEN RE, 1996, LIFESTYLE WEIGHT MAN, P95; BLACKBURN GL, 1995, EATING DISORDERS OBE, P406; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BLAIR SN, 1992, MED EXERCISE NUTRITI, V1, P54; BLAMEY A, 1995, BRIT MED J, V311, P289, DOI 10.1136/bmj.311.7000.289; BROWNELL KD, 1980, AM J PSYCHIAT, V137, P1540; BROWNELL KD, 1992, J CONSULT CLIN PSYCH, V60, P505, DOI 10.1037/0022-006X.60.4.505; *CDCP, 1994, BRFSS SUMM PREV REP; DUNN AL, IN PRESS AM J PREV M; Fletcher GF, 1996, CIRCULATION, V94, P857, DOI 10.1161/01.CIR.94.4.857; Gordon NF, 1993, J CARDIOPULM REHABIL, V13, P161, DOI DOI 10.1097/00008483-199305000-00001; HASKELL WL, 1994, MED SCI SPORT EXER, V26, P649, DOI 10.1249/00005768-199406000-00001; *INT COUNC SHOPP C, 1997, SCOP SHOPP CENT 1997, P3; KELLY RB, 1987, J FAM PRACTICE, V24, P630; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUTYLA D, 1994, ICSC RES Q, V1, P8; LOGSDON DN, 1989, AM J PREV MED, V5, P249, DOI 10.1016/S0749-3797(18)31065-1; MUTRIE N, 1997, AM COLL SPORTS MED P, P37; NORUSIS MJ, 1992, SPSS PC PLUS ADV STA; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; STAMFORD BA, 1988, EXERCISE SPORT SCI R, P341; STRAKOSCH GR, 1996, ELEVATOR WORLD, V44, P68; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, pR25; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P597; *US PUBL HLTH SERV, 1996, OFF SURG GEN PHYS AC	29	123	126	0	17	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1998	129	5					363	369		10.7326/0003-4819-129-5-199809010-00003	http://dx.doi.org/10.7326/0003-4819-129-5-199809010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114RL	9735063				2022-12-24	WOS:000075622600003
J	Bix, M; Locksley, RM				Bix, M; Locksley, RM			Independent and epigenetic regulation of the interleukin-4 alleles in CD4(+) T cells	SCIENCE			English	Article							GENE-EXPRESSION; DEFICIENT MICE; COEXPRESSION; LYMPHOCYTES; INTERFERON; GENERATION; RECEPTOR; CLONES; GAMMA	How an individual effector T cell acquires a particular cytokine expression pattern from many possible patterns remains unclear. CD4(+) T cells from F-1 mice, which allowed assignment of the parental origin of interleukin-4 (IL-4) transcripts, were divided into clones that expressed IL-4 biallelically or monoallelically from either allele. The allelic pattern was transmitted as a stable epigenetic trait. Regulation of cytokine expression by a mechanism that treats each allele independently suggests a probabilistic process by which a diverse repertoire of combinatorially assorted cytokine gene expression patterns could be generated among the clonally related daughters of a single precursor cell.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol Microbiol, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Locksley, RM (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Box 0654,C-443,521 Parnassus Ave, San Francisco, CA 94143 USA.			Bix, Mark/0000-0003-4617-0497	NHLBI NIH HHS [HL56385] Funding Source: Medline; NIAID NIH HHS [AI26918] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056385, P01HL056385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI026918, R01AI026918] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BIX M, UNPUB; BUCY RP, 1994, J EXP MED, V180, P1251, DOI 10.1084/jem.180.4.1251; BUCY RP, 1995, P NATL ACAD SCI USA, V92, P7565, DOI 10.1073/pnas.92.16.7565; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Cross MA, 1997, CURR OPIN GENET DEV, V7, P609, DOI 10.1016/S0959-437X(97)80007-X; Held W, 1997, EUR J IMMUNOL, V27, P2876, DOI 10.1002/eji.1830271120; HELD W, 1995, NATURE, V376, P355, DOI 10.1038/376355a0; Hollander GA, 1998, SCIENCE, V279, P2118, DOI 10.1126/science.279.5359.2118; KELSO A, 1988, P NATL ACAD SCI USA, V85, P9189, DOI 10.1073/pnas.85.23.9189; KELSO A, 1995, EUR J IMMUNOL, V25, P1168, DOI 10.1002/eji.1830250506; KIOUSSIS D, 1998, MOL BIOL B CELL T CE, P31; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Melo JV, 1996, LEUKEMIA, V10, P1217; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	18	204	205	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1352	1354		10.1126/science.281.5381.1352	http://dx.doi.org/10.1126/science.281.5381.1352			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721100				2022-12-24	WOS:000075666800050
J	Bartus, RT; Tracy, MA; Emerich, DF; Zale, SE				Bartus, RT; Tracy, MA; Emerich, DF; Zale, SE			Sustained delivery of proteins for novel therapeutic products	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; RELEASE; MODEL		Alkermes Inc, Cambridge, MA 02139 USA	Alkermes	Bartus, RT (corresponding author), Alkermes Inc, 64 Sidney St, Cambridge, MA 02139 USA.							Bawa R., 1985, J CONTR RELEASE, V1, P259, DOI [10.1016/0168-3659(85)90002-1, DOI 10.1016/0168-3659(85)90002-1]; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Johnson OL, 1997, PHARM RES-DORDR, V14, P730, DOI 10.1023/A:1012142204132; Khan A, 1998, Patent No. [US 5 711 968, 5711968]; LANGER R, 1990, SCIENCE, V249, P1527, DOI 10.1126/science.2218494; LANGER R, 1976, NATURE, V263, P797, DOI 10.1038/263797a0; Lee HJ, 1997, J PHARMACOL EXP THER, V281, P1431; LEE VHL, 1991, ADV PARENTERAL SCI, V4, P691; NAFFAKH N, 1995, P NATL ACAD SCI USA, V92, P3194, DOI 10.1073/pnas.92.8.3194; Nieforth KA, 1996, CLIN PHARMACOL THER, V59, P636, DOI 10.1016/S0009-9236(96)90003-X; SALTZMAN WM, 1989, BIOPHYS J, V55, P163, DOI 10.1016/S0006-3495(89)82788-2; Tracy MA, 1998, BIOTECHNOL PROGR, V14, P108, DOI 10.1021/bp9701271; Wall D.A., 1995, DRUG DELIV, V2, P1, DOI DOI 10.3109/10717549509031346; WRIGHT JC, 1997, P INT S CONTR REL BI, V24, P59; Zale S. E., 1997, US Patent, Patent No. [5,674,534, 5674534]; Zhang Y, 1997, J BIOMED MATER RES, V34, P531, DOI 10.1002/(SICI)1097-4636(19970315)34:4<531::AID-JBM13>3.0.CO;2-F; [No title captured]	17	94	108	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1161	1162		10.1126/science.281.5380.1161	http://dx.doi.org/10.1126/science.281.5380.1161			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735031				2022-12-24	WOS:000075531200040
J	He, QS; Viljanen, MK; Arvilommi, H; Aittanen, B; Mertsola, J				He, QS; Viljanen, MK; Arvilommi, H; Aittanen, B; Mertsola, J			Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; INFECTION; TOXIN	Context. - The prevalence of Bordetella pertussis and Bordetella parapertussis infections among outpatients in an immunized population is not known. Objective. - To study the prevalence of these infections in outpatients with paroxysmal cough in Finland, where the pertussis vaccine coverage of 4 doses is 98%. Design. - Prospective cohort study. Setting. - Thirty-two health centers in southwestern Finland. Patients. - A total of 584 patients with paroxysmal cough seen at local health centers from October 1994 through March 1997 from whom nasopharyngeal swabs were collected. Main Outcome Measures.-Prevalence of positive cultures for a pertussis or B parapertussis and/or positive polymerase chain reaction (PCR) results and frequency of symptoms in those with pertussis and parapertussis. Results. - A total of 153 subjects (26.2%) had Bordetella infection by culture or PCR: 93 (60.8%) had B pertussis infection, 49 (32.0%) had B parapertussis infection, and 11 (7.2%) had both. Of these cases, 39 (25.5%) had positive cultures and 95 (62.1%) had positive PCR results for B pertussis, and 19 (12.4%) had positive cultures and 55 (35.9%) had positive PCR results for B parapertussis. At the time of diagnosis, no difference was found in the frequency of symptoms between patients with B parapertussis infection and those with B pertussis infection. Bordetella parapertussis infection was as common as a pertussis infection in children before school entry, whereas in schoolchildren and adults, B pertussis infection was more common than B parapertussis infection (P < .001). Conclusion. - Bordetella infections are common in an immunized population, and B parapertussis infections apparently are more prevalent than previously documented.	Natl Publ Hlth Inst, Dept Turku, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, Turku, Finland	Finland National Institute for Health & Welfare; University of Turku	He, QS (corresponding author), Natl Publ Hlth Inst, Dept Turku, Kiinamyllynkatu 13, FIN-20520 Turku, Finland.		Mertsola, Jussi/AAE-3460-2021					ARICO B, 1987, J BACTERIOL, V169, P2847, DOI 10.1128/jb.169.6.2847-2853.1987; BORSKA K, 1972, J HYG EPID MICROB IM, V16, P159; ELDERING G, 1952, AM J PUBLIC HEALTH, V42, P27, DOI 10.2105/AJPH.42.1.27; He Q, 1996, EUR J CLIN MICROBIOL, V15, P793, DOI 10.1007/BF01701521; He QS, 1996, J INFECT DIS, V174, P1288, DOI 10.1093/infdis/174.6.1288; HE QS, 1993, J CLIN MICROBIOL, V31, P642, DOI 10.1128/JCM.31.3.642-645.1993; HEININGER U, 1994, PEDIATR INFECT DIS J, V13, P306, DOI 10.1097/00006454-199404000-00011; KHALEF N, 1993, INFECT IMMUN, V61, P486; LAUTROP H, 1971, LANCET, V1, P1195; LINNEMANN CC, 1977, AM J DIS CHILD, V131, P560, DOI 10.1001/archpedi.1977.02120180074014; Mastrantonio P, 1997, DEV BIOL STAND, V89, P255; MERTSOLA J, 1985, EUR J CLIN MICROBIOL, V4, P123, DOI 10.1007/BF02013576; Miller JJ, 1941, J PEDIATR-US, V19, P229, DOI 10.1016/S0022-3476(41)80066-3; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; Stehr K, 1998, PEDIATRICS, V101, P1, DOI 10.1542/peds.101.1.1; VANDERZEE A, 1993, J CLIN MICROBIOL, V31, P2134, DOI 10.1128/JCM.31.8.2134-2140.1993; VONKONIG CHW, 1994, EUR J CLIN MICROBIOL, V13, P455, DOI 10.1007/BF01974634; VYSOKA-BURIANOVA B., 1963, J HYG EPIDEMIOL MICROBIOL IMMUNOL, V7, P472; Willems RJL, 1998, VACCINE, V16, P410, DOI 10.1016/S0264-410X(97)80919-X	19	86	95	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					635	637		10.1001/jama.280.7.635	http://dx.doi.org/10.1001/jama.280.7.635			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718056				2022-12-24	WOS:000075384300033
J	Krumholz, HM				Krumholz, HM			Time to focus on the more typical heart-failure patients	LANCET			English	Editorial Material									Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, Dept Med, 333 Cedar St, New Haven, CT 06520 USA.		, Harlan/AAI-2875-2020					HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; LUCHI RJ, 1991, J AM GERIATR SOC, V39, P810, DOI 10.1111/j.1532-5415.1991.tb02705.x; Pitt B, 1997, LANCET, V349, P747, DOI 10.1016/S0140-6736(97)01187-2; *US DEPT HHS, 1994, MORB MORT CHARTB CAR; WEI JY, 1992, NEW ENGL J MED, V327, P1735, DOI 10.1056/NEJM199212103272408; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	6	9	9	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					3	4		10.1016/S0140-6736(05)79504-0	http://dx.doi.org/10.1016/S0140-6736(05)79504-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800733				2022-12-24	WOS:000074608600003
J	McKenna, WJ; Coccolo, F; Elliott, PM				McKenna, WJ; Coccolo, F; Elliott, PM			Genes and disease expression in hypertrophic cardiomyopathy	LANCET			English	Editorial Material							CARDIAC TROPONIN-T; ALPHA-TROPOMYOSIN; MUTATIONS; MYOSIN; SITE		St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	McKenna, WJ (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.		McKenna, William J/C-3243-2008; Elliott, Perry/AAR-3430-2020	McKenna, William J/0000-0001-7994-2460; Elliott, Perry/0000-0003-3383-3984				BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; Charron P, 1998, CIRCULATION, V97, P2230, DOI 10.1161/01.CIR.97.22.2230; DUFOUR C, 1994, J MOL CELL CARDIOL, V26, P1241, DOI 10.1006/jmcc.1994.1142; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; KARAM R, 1989, J AM COLL CARDIOL, V13, P580, DOI 10.1016/0735-1097(89)90596-2; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LECHIN M, 1995, CIRCULATION, V92, P1808, DOI 10.1161/01.CIR.92.7.1808; LEWIS JF, 1994, AM J CARDIOL, V73, P1105, DOI 10.1016/0002-9149(94)90291-7; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; Spirito P, 1997, NEW ENGL J MED, V336, P775, DOI 10.1056/NEJM199703133361107; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603	16	17	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1162	1163		10.1016/S0140-6736(98)00033-6	http://dx.doi.org/10.1016/S0140-6736(98)00033-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777827				2022-12-24	WOS:000076415400002
J	Waltzer, L; Bienz, M				Waltzer, L; Bienz, M			Drosophila CBP represses the transcription factor TCF to antagonize Wingless signalling	NATURE			English	Article							BETA-CATENIN; HISTONE ACETYLTRANSFERASES; ENDODERM INDUCTION; GENE-EXPRESSION; TARGET GENE; ACTIVATION; ARMADILLO; COACTIVATOR; ACETYLATION; COMPLEX	T-cell factor (TCF), a high-mobility-group domain protein, is the transcription factor activated by Wnt/Wingless signalling(1-4). When signalling occurs, TCF binds to its coactivator, beta-catenin/Armadillo, and stimulates the transcription of the target genes of Wnt/Wingless by binding to TCF-responsive enhancers(1,5). Inappropriate activation of TCF in the colon epithelium and other cells leads to cancer(6-8). It is therefore desirable for unstimulated cells to have a negative control mechanism to keep TCF inactive. Here we report that Drosophila CREB-binding protein (dCBP)(9,10) binds to dTCF. dCBP mutants show mild Wingless overactivation phenotypes in various tissues. Consistent with this, dCBP loss-of-function suppresses the effects of armadillo mutation. Moreover, our data show that dCBP acetylates a conserved lysine in the Armadillo-binding domain of dTCF, and that this acetylation lowers the affinity of Armadillo binding to dTCF. Although CBP is a coactivator of other transcription factors(11,12), our data show that CBP represses TCF.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Bienz, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.			Waltzer, Lucas/0000-0002-5361-727X				Akimaru H, 1997, NATURE, V386, P735, DOI 10.1038/386735a0; Akimaru H, 1997, NAT GENET, V17, P211, DOI 10.1038/ng1097-211; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; CHIVRIA JC, 1993, NATURE, V365, P855; Eresh S, 1997, EMBO J, V16, P2014, DOI 10.1093/emboj/16.8.2014; Goldman PS, 1997, RECENT PROG HORM RES, V52, P103; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HOPPLER S, 1995, EMBO J, V14, P5016, DOI 10.1002/j.1460-2075.1995.tb00184.x; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; IMMERGLUCK K, 1990, CELL, V62, P261, DOI 10.1016/0092-8674(90)90364-K; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Muraoka M, 1996, ONCOGENE, V12, P1565; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PEIFER M, 1994, DEVELOPMENT, V120, P369; PERRIMON N, 1994, CELL, V76, P781, DOI 10.1016/0092-8674(94)90351-4; Riese J, 1997, DEVELOPMENT, V124, P3353; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sanson B, 1996, NATURE, V383, P627, DOI 10.1038/383627a0; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; Szuts D, 1997, DEVELOPMENT, V124, P3209; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Yu X, 1996, DEVELOPMENT, V122, P849	29	314	318	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					521	525		10.1038/26785	http://dx.doi.org/10.1038/26785			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774110				2022-12-24	WOS:000076212200061
J	Berger, A				Berger, A			Action on clinical audit: progress report 2	BMJ-BRITISH MEDICAL JOURNAL			English	Article									BMJ, London WC1H 9JR, England		Berger, A (corresponding author), BMJ, London WC1H 9JR, England.							Berger A, 1998, BMJ-BRIT MED J, V316, P1893; Miller E, 1998, BRIT MED J, V316, P875, DOI 10.1136/bmj.316.7135.875	2	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 26	1998	317	7162					880	881		10.1136/bmj.317.7162.880	http://dx.doi.org/10.1136/bmj.317.7162.880			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748193	Green Published			2022-12-24	WOS:000076222300029
J	Kirschenbaum, LA; Astiz, ME; Rackow, EC				Kirschenbaum, LA; Astiz, ME; Rackow, EC			Interpretation of blood lactate concentrations in patients with sepsis	LANCET			English	Editorial Material							SEPTIC SHOCK; OXYGEN DELIVERY; CONSUMPTION; PYRUVATE		New York Med Coll, St Vincent Hosp & Med Ctr, Dept Med, New York, NY 10011 USA	New York Medical College; Saint Vincents Hospital Manhattan	Kirschenbaum, LA (corresponding author), New York Med Coll, St Vincent Hosp & Med Ctr, Dept Med, New York, NY 10011 USA.							ASTIZ M, 1988, CIRC SHOCK, V26, P311; Astiz ME, 1998, LANCET, V351, P1501, DOI 10.1016/S0140-6736(98)01134-9; ASTIZ ME, 1987, CRIT CARE MED, V15, P26, DOI 10.1097/00003246-198701000-00005; BAKKER J, 1991, CHEST, V99, P956, DOI 10.1378/chest.99.4.956; Bakker J, 1996, AM J SURG, V171, P221, DOI 10.1016/S0002-9610(97)89552-9; BRODER G, 1964, SCIENCE, V143, P1457, DOI 10.1126/science.143.3613.1457; FRIEDMAN G, 1995, CRIT CARE MED, V23, P1184, DOI 10.1097/00003246-199507000-00006; Levraut J, 1998, AM J RESP CRIT CARE, V157, P1021, DOI 10.1164/ajrccm.157.4.9705037; RONCO JJ, 1993, AM REV RESPIR DIS, V147, P25, DOI 10.1164/ajrccm/147.1.25; SCHAEFER CF, 1991, J SURG RES, V51, P382, DOI 10.1016/0022-4804(91)90138-C; SIEGEL JH, 1979, SURGERY, V86, P163; VARY TC, 1986, AM J PHYSIOL, V250, pE634, DOI 10.1152/ajpendo.1986.250.6.E634; VINCENT JL, 1983, CRIT CARE MED, V11, P449, DOI 10.1097/00003246-198306000-00012; VITEK V, 1971, ANN SURG, V173, P308, DOI 10.1097/00000658-197102000-00021; WEIL MH, 1970, CIRCULATION, V41, P989, DOI 10.1161/01.CIR.41.6.989	15	17	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					921	922		10.1016/S0140-6736(05)61507-3	http://dx.doi.org/10.1016/S0140-6736(05)61507-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752810				2022-12-24	WOS:000076002200003
J	Bruijn, LI; Houseweart, MK; Kato, S; Anderson, KL; Anderson, SD; Ohama, E; Reaume, AG; Scott, RW; Cleveland, DW				Bruijn, LI; Houseweart, MK; Kato, S; Anderson, KL; Anderson, SD; Ohama, E; Reaume, AG; Scott, RW; Cleveland, DW			Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1	SCIENCE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; CU,ZN SUPEROXIDE-DISMUTASE; OXIDATIVE DAMAGE; MICE; INCLUSIONS; MUTATION; DISEASE; GENE; DEGENERATION; PROPERTY	Analysis of transgenic mice expressing familiar amyotrophic Lateral sclerosis (ALS)-linked mutations in the enzyme superoxide dismutase (SOD1) have shown that motor neuron death arises from a mutant-mediated toxic property or properties. In testing the disease mechanism, both elimination and elevation of wild-type SOD1 were found to have no effect on mutant-mediated disease, which demonstrates that the use of SOD mimetics is unlikely to be an effective therapy and raises the question of whether toxicity arises from superoxide-mediated oxidative stress. Aggregates containing SOD1 were common to disease caused by different mutants, implying that coaggregation of an unidentified essential component or components or aberrant catalysis by misfolded mutants underlies a portion of mutant-mediated toxicity.	Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Tottori Univ, Fac Med, Dept Neuropathol, Inst Neurol Sci, Yonago, Tottori 683, Japan; Cephalon, W Chester, PA 19380 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Tottori University; Teva Pharmaceutical Industries; Cephalon Inc.	Cleveland, DW (corresponding author), Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.		Cleveland, Don/AAN-9783-2021	Cleveland, Don/0000-0002-1934-3682	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027036, R37NS027036] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27036] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAL MF, 1997, ANN NEUROL, V42, P646; BECHER M, COMMUNICATION; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruijn LI, 1997, P NATL ACAD SCI USA, V94, P7606, DOI 10.1073/pnas.94.14.7606; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Chou SM, 1996, J CHEM NEUROANAT, V10, P249, DOI 10.1016/0891-0618(96)00137-8; Chou SM, 1996, J NEUROL SCI, V139, P16, DOI 10.1016/0022-510X(96)00090-1; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; DalCanto MC, 1997, ACTA NEUROPATHOL, V93, P537; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DURHAM HD, 1997, J NEUROPATHOL EXP NE, V56, P52; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 1997, AM J PATHOL, V151, P611; Liochev SI, 1997, ARCH BIOCHEM BIOPHYS, V346, P263, DOI 10.1006/abbi.1997.0298; OREELL R, 1995, NATURE, V274, P504; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SHIBATA N, 1994, NEUROSCI LETT, V179, P149, DOI 10.1016/0304-3940(94)90956-3; Shibata N, 1996, DEV NEUROSCI-BASEL, V18, P492, DOI 10.1159/000111445; Shibata N, 1996, J NEUROPATH EXP NEUR, V55, P481, DOI 10.1097/00005072-199604000-00011; Singh RJ, 1998, P NATL ACAD SCI USA, V95, P6675, DOI 10.1073/pnas.95.12.6675; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Williamson TL, 1998, P NATL ACAD SCI USA, V95, P9631, DOI 10.1073/pnas.95.16.9631; WILLIAMSON TL, UNPUB; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yim HS, 1997, J BIOL CHEM, V272, P8861	31	948	986	1	76	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1851	1854		10.1126/science.281.5384.1851	http://dx.doi.org/10.1126/science.281.5384.1851			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743498				2022-12-24	WOS:000076007100053
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Metastasis in eggs	SCIENCE			English	Article																		KIM J, 1998, CELL, V353	1	1	1	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1823	1823		10.1126/science.281.5384.1823	http://dx.doi.org/10.1126/science.281.5384.1823			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776688				2022-12-24	WOS:000076007100043
J	Yoshida, H; Kong, YY; Yoshida, R; Elia, AJ; Hakem, A; Hakem, R; Penninger, JM; Mak, TW				Yoshida, H; Kong, YY; Yoshida, R; Elia, AJ; Hakem, A; Hakem, R; Penninger, JM; Mak, TW			Apaf1 is required for mitochondrial pathways of apoptosis and brain development	CELL			English	Article							PROGRAMMED CELL-DEATH; C-ELEGANS; CAENORHABDITIS-ELEGANS; CYTOCHROME-C; PROTEASE ACTIVATION; NEGATIVE SELECTION; SIGNALING COMPLEX; GENE CED-3; BCL-2; SURVIVAL	Apoptosis is essential for the precise regulation of cellular homeostasis and development. The role in vivo of Apaf1, a mammalian homolog of C. elegans CED-4, was investigated in gene-targeted Apaf1(-/-) mice. Apaf1-deficient mice exhibited reduced apoptosis in the brain and striking craniofacial abnormalities with hyperproliferation of neuronal cells. Apaf1-deficient cells were resistant to a variety of apoptotic stimuli, and the processing of Caspases 2, 3, and 8 was impaired. However, both Apaf1(-/-) thymocytes and activated T lymphocytes were sensitive to Fas-induced killing, showing that Fas-mediated apoptosis in these cells is independent of Apaf1. These data indicate that Apaf1 plays a central role in the common events of mitochondria-dependent apoptosis in most death pathways and that this role is critical for normal development.	Amgen Inst, Toronto, ON, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2C1, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5G 2C1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Mak, TW (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON, Canada.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Hakem, Razqallah/0000-0001-5948-7931				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; Boise LH, 1997, P NATL ACAD SCI USA, V94, P3759, DOI 10.1073/pnas.94.8.3759; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Clarke PGH, 1996, ANAT EMBRYOL, V193, P81; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; FADOK VA, 1992, J IMMUNOL, V148, P2207; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Golstein P, 1997, SCIENCE, V275, P1081, DOI 10.1126/science.275.5303.1081; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; HORVITZ HR, 1983, COLD SPRING HARB SYM, V48, P453, DOI 10.1101/SQB.1983.048.01.050; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1992, IMMUNOL TODAY, V13, P285, DOI 10.1016/0167-5699(92)90037-8; KROEMER G, 1995, FASEB J, V9, P1277, DOI 10.1096/fasebj.9.13.7557017; Kroemer G, 1997, IMMUNOL TODAY, V18, P44, DOI 10.1016/S0167-5699(97)80014-X; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; OPPENHEIM RW, 1991, SCIENCE, V251, P1616, DOI 10.1126/science.2011743; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Shaham S, 1996, GENE DEV, V10, P578, DOI 10.1101/gad.10.5.578; Shimizu S, 1996, ONCOGENE, V13, P21; Shortman K, 1990, Semin Immunol, V2, P3; Spector MS, 1997, NATURE, V385, P653, DOI 10.1038/385653a0; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; TAKAHASHI T, 1995, J NEUROSCI, V15, P6046; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weller M, 1997, J NEURAL TRANSM-SUPP, P115; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Wu DY, 1997, J BIOL CHEM, V272, P21449, DOI 10.1074/jbc.272.34.21449; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	64	958	995	1	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 18	1998	94	6					739	750		10.1016/S0092-8674(00)81733-X	http://dx.doi.org/10.1016/S0092-8674(00)81733-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753321	Bronze			2022-12-24	WOS:000076021200007
J	Cook, DJ; Walter, SD; Cook, RJ; Griffith, LE; Guyatt, GH; Leasa, D; Jaeschke, RZ; Brun-Buisson, C				Cook, DJ; Walter, SD; Cook, RJ; Griffith, LE; Guyatt, GH; Leasa, D; Jaeschke, RZ; Brun-Buisson, C		Canadian Critical Care Trials Grp	Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients	ANNALS OF INTERNAL MEDICINE			English	Article						ventilators, mechanical; pneumonia; cross-infection; time factors	NOSOCOMIAL MAXILLARY SINUSITIS; INTENSIVE-CARE UNITS; RECEIVING MECHANICAL VENTILATION; PREVIOUS ANTIMICROBIAL THERAPY; INTUBATED PATIENTS; PSEUDOMONAS-AERUGINOSA; MULTIVARIATE-ANALYSIS; ENTERAL NUTRITION; MORTALITY; INFECTION	Background: Understanding the risk factors for ventilator-associated pneumonia can help to assess prognosis and devise and test preventive strategies. Objective: To examine the baseline and time-dependent risk factors for ventilator-associated pneumonia and to determine the conditional probability and cumulative risk over the duration of stay in the intensive care unit. Design: Prospective cohort study. Setting: 16 intensive care units in Canada. Patients: 1014 mechanically ventilated patients. Measurements: Demographic and time-dependent variables reflecting illness severity, ventilation, nutrition, and drug exposure. Pneumonia was classified by using five methods: adjudication committee, bedside clinician's diagnosis, Centers for Disease Control and Prevention definition, Clinical Pulmonary Infection score, and positive culture from bronchoalveolar lavage or protected specimen brush. Results: 177 of 1014 patients (17.5%) developed ventilator-associated pneumonia 9.0 +/- 5.9 days (median, 7 days [interquartile range, 5 to 10 days]) after admission to the intensive care unit. Although the cumulative risk increased over time, the daily hazard rate decreased after day 5 (3.3% at day 5, 2.3% at day 10, and 1.3% at day 15). independent predictors of ventilator-associated pneumonia in multivariable analysis were a primary admitting diagnosis of burns (risk ratio, 5.09 [95% CI, 1.52 to 17.03]), trauma (risk ratio, 5.00 [CI, 1.91 to 13.11]), central nervous system disease (risk ratio, 3.40 [CI, 1.31 to 8.81]), respiratory disease (risk ratio, 2.79 [CI, 1.04 to 7.51]), cardiac disease (risk ratio, 2.72 [CI, 1.05 to 7.01]), mechanical ventilation in the previous 24 hours (risk ratio, 2.28 [CI, 1.11 to 4.68]), witnessed aspiration (risk ratio, 3.25 [CI, 1.62 to 6.50]), and paralytic agents (risk ratio, 1.57 [CI, 1.03 to 2.39]). Exposure to antibiotics conferred protection (risk ratio, 0.37 [CI, 0.27 to 0.51]). Independent risk factors were the same regardless of the pneumonia definition used. Conclusions: The daily risk for pneumonia decreases with increasing duration of stay in the intensive care unit. Witnessed aspiration and exposure to paralytic agents are potentially modifiable independent risk factors. Exposure to antibiotics was associated with low rates of early ventilator-associated pneumonia, but this effect attenuates over time.	McMaster Univ, Med Ctr, Dept Clin Epidemiol, Hamilton, ON L8N 3Z5, Canada; Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada; Univ Paris 12, Hop Henri Mondor, Dept Med Intens Care, F-94010 Creteil, France; Univ Paris 12, Hop Henri Mondor, Infect Control Unit, F-94010 Creteil, France; Univ Western Ontario, London, ON, Canada	McMaster University; University of Waterloo; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Western University (University of Western Ontario)	Cook, DJ (corresponding author), St Josephs Hosp, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	debcook@fhs.csu.mcmaster.ca	Walter, Stephen/AAB-5548-2022	Walter, Stephen/0000-0003-4157-8928; Cook, Richard/0000-0002-1414-4908				Alvarez-lerma F, 1997, CLIN INTENSIVE CARE, V8, P164; [Anonymous], 1989, AM REV RESPIR DIS, V139, P1058; ATHERTON ST, 1978, LANCET, V2, P968; Baraibar J, 1997, CHEST, V112, P1050, DOI 10.1378/chest.112.4.1050; Bonten MJM, 1997, CLIN INFECT DIS, V24, P309, DOI 10.1093/clinids/24.3.309; BRAUN SR, 1986, CRIT CARE MED, V14, P198, DOI 10.1097/00003246-198603000-00006; Brewer C, 1996, CHEST, V109, P1019; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHASTRE J, 1994, AM J RESP CRIT CARE, V150, P570, DOI 10.1164/ajrccm.150.2.8049850; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; Cook, 1997, Crit Care, V1, P3, DOI 10.1186/cc1; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; Cook D, 1998, JAMA-J AM MED ASSOC, V279, P781, DOI 10.1001/jama.279.10.781; Cook DJ, 1998, JAMA-J AM MED ASSOC, V279, P1605, DOI 10.1001/jama.279.20.1605; COOK DJ, 1994, AM J RESP CRIT CARE, V149, pA640; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; Cunnion KM, 1996, AM J RESP CRIT CARE, V153, P158, DOI 10.1164/ajrccm.153.1.8542110; Elatrous S, 1996, CLIN INTENSIVE CARE, V7, P276, DOI DOI 10.3109/TCIC.7.6.276.281; Fagon JY, 1996, JAMA-J AM MED ASSOC, V275, P866, DOI 10.1001/jama.275.11.866; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; HANSON LC, 1992, AM J MED, V92, P161, DOI 10.1016/0002-9343(92)90107-M; HEYLAND D, 1992, CHEST, V101, P187, DOI 10.1378/chest.101.1.187; HOLZAPFEL L, 1993, CRIT CARE MED, V21, P1132, DOI 10.1097/00003246-199308000-00010; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JOSHI N, 1992, AM J MED, V93, P135, DOI 10.1016/0002-9343(92)90042-A; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; Kollef MH, 1997, CHEST, V112, P765, DOI 10.1378/chest.112.3.765; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; Kropec A, 1996, INTENS CARE MED, V22, P1155, DOI 10.1007/BF01709329; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LIBERATI A, 1997, ACUTE RESP INFECT MO, V3, P1; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MICHELSON A, 1991, ANAESTHESIST, V40, P100; MONTECALVO MA, 1992, CRIT CARE MED, V20, P1377, DOI 10.1097/00003246-199210000-00004; MOSCONI P, 1991, EUR J EPIDEMIOL, V7, P320, DOI 10.1007/BF00144995; NIEDERMAN MS, 1994, AM J RESP CRIT CARE, V150, P565, DOI 10.1164/ajrccm.150.2.8049849; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; Papazian L, 1996, AM J RESP CRIT CARE, V154, P91, DOI 10.1164/ajrccm.154.1.8680705; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PUGIN J, 1991, AM REV RESPIR DIS, V143, P1121, DOI 10.1164/ajrccm/143.5_Pt_1.1121; RELLO J, 1992, CHEST, V102, P1562, DOI 10.1378/chest.102.5.1562; RELLO J, 1994, INTENS CARE MED, V20, P193, DOI 10.1007/BF01704699; RELLO J, 1993, CHEST, V104, P1230, DOI 10.1378/chest.104.4.1230; Rello J, 1996, AM J RESP CRIT CARE, V154, P111, DOI 10.1164/ajrccm.154.1.8680665; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SALORD F, 1990, INTENS CARE MED, V16, P390, DOI 10.1007/BF01735177; Sirvent JM, 1997, AM J RESP CRIT CARE, V155, P1729, DOI 10.1164/ajrccm.155.5.9154884; Timsit JF, 1996, AM J RESP CRIT CARE, V154, P116, DOI 10.1164/ajrccm.154.1.8680666; TIMSIT JF, 1995, CHEST, V108, P1036, DOI 10.1378/chest.108.4.1036; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	55	588	623	0	27	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1998	129	6					433	440		10.7326/0003-4819-129-6-199809150-00002	http://dx.doi.org/10.7326/0003-4819-129-6-199809150-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JJ	9735080				2022-12-24	WOS:000075892100001
J	Laramore, GE; Stelzer, KJ				Laramore, GE; Stelzer, KJ			Radiation therapy for benign disease: an old area revisited	LANCET			English	Editorial Material							IRRADIATION; RESTENOSIS; PREVENTION; PARADIGM		Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Laramore, GE (corresponding author), Univ Washington, Med Ctr, Dept Radiat Oncol, Seattle, WA 98195 USA.							Brady LW, 1997, INT J RADIAT ONCOL, V39, P945, DOI 10.1016/S0360-3016(97)00708-6; Brenner DJ, 1996, INT J RADIAT ONCOL, V36, P805, DOI 10.1016/S0360-3016(96)00414-2; BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5; Carter AJ, 1996, INT J RADIAT ONCOL, V36, P797, DOI 10.1016/S0360-3016(96)00410-5; CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265; Fajardo LF, 1998, INT J RADIAT ONCOL, V40, P761; Gregoritch SJ, 1996, INT J RADIAT ONCOL, V36, P981, DOI 10.1016/S0360-3016(96)00442-7; Koh WJ, 1996, INT J RADIAT ONCOL, V36, P829, DOI 10.1016/S0360-3016(96)00408-7; Mazur W, 1996, INT J RADIAT ONCOL, V36, P777, DOI 10.1016/S0360-3016(96)00298-2; OGILVY CS, 1990, NEUROSURGERY, V26, P725, DOI 10.1227/00006123-199005000-00001; ORDER SE, 1990, RAD THERAPY BENIGN D; Popowski Y, 1996, INT J RADIAT ONCOL, V36, P923, DOI 10.1016/S0360-3016(96)00409-9; Rubin P, 1998, INT J RADIAT ONCOL, V40, P929, DOI 10.1016/S0360-3016(97)00937-1; SCHWARTZ RS, 1992, J AM COLL CARDIOL, V20, P1284, DOI 10.1016/0735-1097(92)90389-5; STALMAN SP, 1997, RETINA, V17, P481; WAKSMAN R, 1995, CIRCULATION, V91, P1533, DOI 10.1161/01.CIR.91.5.1533	16	4	4	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	1998	352	9131					834	835		10.1016/S0140-6736(05)60001-3	http://dx.doi.org/10.1016/S0140-6736(05)60001-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742973				2022-12-24	WOS:000075857300003
J	Gaydos, CA; Howell, MR; Pare, B; Clark, KL; Ellis, DA; Hendrix, RM; Gaydos, JC; McKee, KT; Quinn, TC				Gaydos, CA; Howell, MR; Pare, B; Clark, KL; Ellis, DA; Hendrix, RM; Gaydos, JC; McKee, KT; Quinn, TC			Chlamydia trachomatis infections in female military recruits	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIGASE CHAIN-REACTION; PELVIC INFLAMMATORY DISEASE; FIRST-VOID URINE; REACTION ASSAY; UNITED-STATES; WOMEN; DIAGNOSIS; PREVALENCE; ADOLESCENTS; RISK	Background. Asymptomaticgenital Chlamydia trachomatis infections in women can lead to pelvic inflammatory disease, infertility, and ectopic pregnancy. To design a chlamydia-control program, we conducted a large survey of women in the U.S. military. Methods From January 1996 through December 1997, urine samples from 13,204 new female U.S. Army recruits from 50 states were screened by ligase chain reaction for C. trachomatis infection. Information on potential risk factors was obtained by questionnaire. With multivariate analysis, we identified criteria for a screening program. Results The overall prevalence of chlamydial infection was 9.2 percent, with a peak of 12.2 percent among the 17-year-old recruits. The prevalence was 15 percent or more among the recruits from five southern states. The following risk factors were independently associated with chlamydial infection: having ever had vaginal sex (odds ratio for infection, 5.9), being 25 years of age or less (odds ratio, 3.0), being black (odds ratio, 3.4), having had more than one sex partner in the previous 90 days (odds ratio, 1.4), having had a new partner in the previous 90 days (odds ratio, 1.3), having had a partner in the previous 90 days who did not always use condoms (odds ratio, 1.4), and having ever had a sexually transmitted disease (odds ratio, 1.2). A screening program for subjects 25 years of age or less (87.9 per cent of our sample) would have identified 95.3 percent of the infected women. Conclusions. Among female military recruits, the prevalence of chlamydial infection is high. A control program that screens female recruits who are 25 years old or younger with urine DNA-amplification assays has the potential to reduce infection, transmission, and the sequelae of chlamydial infection. (N Engl J Med 1998;339:739-44.) (C) 1998, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Washington, DC 20307 USA; USA, Med Dept Act, Ft Jackson, SC USA; Henry M Jackson Fdn, Rockville, MD USA; Womack Army Med Ctr, Ft Bragg, NC USA; NIAID, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Walter Reed National Military Medical Center; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc; United States Department of Defense; United States Army; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gaydos, CA (corresponding author), Johns Hopkins Univ, Sch Med, Div Infect Dis, 720 Rutland Ave,1159 Ross Res Bldg, Baltimore, MD 21205 USA.		Gaydos, Charlotte A./E-9937-2010; Quinn, Thomas/A-2494-2010					ADDISS DG, 1993, SEX TRANSM DIS, V20, P28, DOI 10.1097/00007435-199301000-00006; BOYD RS, 1991, MIL MED, V156, P420, DOI 10.1093/milmed/156.8.420; CATES W, 1991, AM J OBSTET GYNECOL, V164, P1771, DOI 10.1016/0002-9378(91)90559-A; CATTERSON ML, 1993, MIL MED, V158, P618, DOI 10.1093/milmed/158.9.618; CHERNESKY MA, 1994, J CLIN MICROBIOL, V32, P2682, DOI 10.1128/JCM.32.11.2682-2685.1994; Emerson LAC, 1997, MIL MED, V162, P87, DOI 10.1093/milmed/162.2.87; Eng TR, 1997, HIDDEN EPIDEMIC CONF, P28; Gaydos CA, 1998, J CLIN MICROBIOL, V36, P1300, DOI 10.1128/JCM.36.5.1300-1304.1998; Gaydos CA, 1998, J INFECT DIS, V177, P417, DOI 10.1086/514207; Hillis SD, 1996, NEW ENGL J MED, V334, P1399, DOI 10.1056/NEJM199605233342111; Howell MR, 1998, SEX TRANSM DIS, V25, P108, DOI 10.1097/00007435-199802000-00008; Howell MR, 1998, ANN INTERN MED, V128, P277, DOI 10.7326/0003-4819-128-4-199802150-00005; Jensen IP, 1997, LANCET, V349, P329, DOI 10.1016/S0140-6736(05)62829-2; Katz BP, 1996, SEX TRANSM DIS, V23, P226, DOI 10.1097/00007435-199605000-00011; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MALONE JD, 1993, SEX TRANSM DIS, V20, P294, DOI 10.1097/00007435-199309000-00011; Marrazzo JM, 1997, ANN INTERN MED, V127, P796, DOI 10.7326/0003-4819-127-9-199711010-00004; Marrazzo JM, 1997, SEX TRANSM DIS, V24, P131, DOI 10.1097/00007435-199703000-00003; Mosure DJ, 1996, AM J EPIDEMIOL, V144, P997, DOI 10.1093/oxfordjournals.aje.a008870; Mosure DJ, 1997, J ADOLESCENT HEALTH, V20, P6, DOI 10.1016/S1054-139X(96)00157-7; Oh MK, 1996, J ADOLESCENT HEALTH, V18, P270, DOI 10.1016/1054-139X(95)00232-H; PFAFF JA, 1991, MIL MED, V156, P362, DOI 10.1093/milmed/156.7.362; Quinn TC, 1996, JAMA-J AM MED ASSOC, V276, P1737, DOI 10.1001/jama.276.21.1737; QUINN TC, 1992, ADV HOST DEFENSE MEC, V8, P1; SCHACHTER J, 1995, J INFECT DIS, V172, P1411, DOI 10.1093/infdis/172.5.1411; STAMM WE, 1988, ANN INTERN MED, V108, P710, DOI 10.7326/0003-4819-108-5-710; Stamm WE, 1990, SEXUALLY TRANSMITTED, P181; Stary A, 1996, SEX TRANSM DIS, V23, P97, DOI 10.1097/00007435-199603000-00002; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; VANDOORNUM GJJ, 1995, J CLIN MICROBIOL, V33, P2042, DOI 10.1128/JCM.33.8.2042-2047.1995; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2565, DOI 10.1001/jama.266.18.2565; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070; WEINSTOCK HS, 1992, AM J EPIDEMIOL, V135, P41, DOI 10.1093/oxfordjournals.aje.a116200; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003; 1997, MMWR MORB MORTAL WKL, V46, P928; 1997, MMWR MORB MORTAL WKL, V46, P193; 1993, MMWR MORB MORTAL WKL, V42, P1; 1997, MMWR MORB MORTAL WKL, V46, P819	38	194	200	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					739	744		10.1056/NEJM199809103391105	http://dx.doi.org/10.1056/NEJM199809103391105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731090	Bronze			2022-12-24	WOS:000075737800005
J	Schwoebel, V; Decludt, B; de Benoist, AC; Haeghebaert, S; Torrea, G; Vincent, V; Grosset, J				Schwoebel, V; Decludt, B; de Benoist, AC; Haeghebaert, S; Torrea, G; Vincent, V; Grosset, J			Multidrug resistant tuberculosis in France 1992-4: two case-control studies	BRITISH MEDICAL JOURNAL			English	Article; Proceedings Paper	XIth International Conference on AIDS	JUL 07-13, 1996	VANCOUVER, CANADA				MYCOBACTERIUM-TUBERCULOSIS		Fac Med Pitie Salpetriere, Ctr Natl Reference Surveillance TB, Serv Bacteriol, F-75634 Paris 13, France; Inst Pasteur, Ctr Natl Reference Mycobacteries, F-75724 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Schwoebel, V (corresponding author), European Ctr Epidemiol Monitoring AIDS, F-94415 St Maurice, France.							Bifani PJ, 1996, JAMA-J AM MED ASSOC, V275, P452, DOI 10.1001/jama.275.6.452; SCHWOEBEL V, 1994, TUBERCLE LUNG DIS, V75, P44, DOI 10.1016/0962-8479(94)90101-5; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; 1996, MMWR, V45, P330; 1995, COMMUN DIS REP CDR W, V5, P161	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					630	631		10.1136/bmj.317.7159.630	http://dx.doi.org/10.1136/bmj.317.7159.630			4	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727990	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000075830200018
J	Prandoni, P; Bagatella, P; Bernardi, E; Girolami, B; Rossi, L; Scarano, L; Marchiori, A; Piccioli, A; Girolami, A				Prandoni, P; Bagatella, P; Bernardi, E; Girolami, B; Rossi, L; Scarano, L; Marchiori, A; Piccioli, A; Girolami, A			Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article							PROXIMAL-VEIN THROMBOSIS; INITIAL TREATMENT; NOMOGRAM; THERAPY; TRIAL; HOME	Background: Despite the widespread use of subcutaneous heparin in the initial treatment of deep venous thrombosis, there are no guidelines for achieving adequate anticoagulation with this drug. Objective: To implement a weight-based algorithm for the administration of subcutaneous unfractionated heparin after an intravenous loading dose. Design: Prospective cohort study. Setting: University hospital. Participants: 70 outpatients with proximal venous thrombosis. Intervention: An intravenous bolus of heparin followed by a subcutaneous injection of heparin in doses adjusted for body weight. Subsequent adjustments of the subcutaneous heparin dose were scheduled twice daily according to the algorithm; the activated partial thromboplastin time (aPTT) was measured in the mid-interval (target range, 50 to 90 seconds). Results: The therapeutic threshold aPTT (greater than or equal to 50 seconds) was achieved in 61 patients (87%) within 24 hours and in 69 patients (99%) within 48 hours. In 7 patients (10%), a supratherapeutic aPTT lasted more than 12 hours. No major bleeding episodes or cases of heparin-induced thrombocytopenia were seen. Three patients (4.3% [95% CI, 0.9 % to 12.0 %]) had recurrent thromboembolism during 3 months of follow-up. Conclusion: The administration of subcutaneous heparin according to a weight-based algorithm allows the rapid achievement of effective and safe anticoagulation in patients with deep venous thrombosis.	Univ Padua, Sch Med, Inst Med Semeiot, I-35128 Padua, Italy	University of Padua	Prandoni, P (corresponding author), Univ Padua, Sch Med, Inst Med Semeiot, Via Osped Civile 105, I-35128 Padua, Italy.							CIPOLLE RJ, 1981, CLIN PHARMACOL THER, V29, P387, DOI 10.1038/clpt.1981.53; CRUICKSHANK MK, 1991, ARCH INTERN MED, V151, P333, DOI 10.1001/archinte.151.2.333; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; HIRSH J, 1995, CHEST, V108, pS258, DOI 10.1378/chest.108.4_Supplement.258S; HOMMES DW, 1992, ANN INTERN MED, V116, P279, DOI 10.7326/0003-4819-116-4-279; Hull RD, 1997, ARCH INTERN MED, V157, P2317, DOI 10.1001/archinte.157.20.2317; Hull RD, 1997, ARCH INTERN MED, V157, P2562, DOI 10.1001/archinte.157.22.2562; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1992, ARCH INTERN MED, V152, P1589, DOI 10.1001/archinte.152.8.1589; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; LEVINE MN, 1994, ARCH INTERN MED, V154, P49, DOI 10.1001/archinte.154.1.49; PRANDONI P, 1993, CIRCULATION, V88, P1730, DOI 10.1161/01.CIR.88.4.1730; Raschke RA, 1996, ARCH INTERN MED, V156, P1645, DOI 10.1001/archinte.156.15.1645; RASCHKE RA, 1993, ANN INTERN MED, V119, P874, DOI 10.7326/0003-4819-119-9-199311010-00002; tenCate JW, 1997, NEW ENGL J MED, V337, P657; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Weitz JI, 1997, NEW ENGL J MED, V337, P688, DOI 10.1056/NEJM199709043371007; White RH, 1997, ARCH INTERN MED, V157, P2468, DOI 10.1001/archinte.157.21.2468	19	19	20	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					299	302		10.7326/0003-4819-129-4-199808150-00006	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729183				2022-12-24	WOS:000075329100006
J	John, TJ; Samuel, R; Balraj, V; John, R				John, TJ; Samuel, R; Balraj, V; John, R			Disease surveillance at district level: a model for developing countries	LANCET			English	Article								For over a decade we have maintained within a district of 5 million people, a system of prompt reporting of cases of childhood vaccine-preventable diseases, encephalitis, meningitis, hepatitis, and rabies; together with a sentinel laboratory surveillance of cholera, typhoid fever, malaria, HIV infection and antimicrobial-resistance patterns of selected pathogens. The system combined government and private sectors, with every hospital enrolled and participating. Reports were scanned daily on a computer for any clustering of cases. Interventions included investigations, immunisation, antimicrobial treatment, health education, and physical rehabilitation of children with paralysis. All vaccine-preventable diseases have declined markedly, whilst malaria and HIV infections have increased steadily. Annual expense was less than one US cent per head. The reasons for the success and sustainability of this model include simplicity or reporting procedure, low budget, private-sector participation, personal rapport with people in the network, regular feedback of information through a monthly bulletin, and the visible interventions consequent upon reporting. This district-level disease surveillance model is replicable in developing countries for evaluating polio eradication efforts, monitoring immunisation programmes, detecting outbreaks of old or new diseases, and for evaluating control measures.	Christian Med Coll & Hosp, Dept Clin Virol, Vellore 632004, Tamil Nadu, India	Christian Medical College & Hospital (CMCH) Vellore	John, TJ (corresponding author), Christian Med Coll & Hosp, Dept Clin Virol, Vellore 632004, Tamil Nadu, India.			John, Rohan/0000-0001-7946-3013				JOHN TJ, 1993, REV MED VIROL, V3, P149, DOI 10.1002/rmv.1980030305; KUMAR S, 1994, LANCET, V344, P941, DOI 10.1016/S0140-6736(94)92280-2; SANCHEZ A, 1995, EMERG INFECT DIS, V1, P96, DOI 10.3201/eid0103.950307	3	50	51	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					58	61						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800768				2022-12-24	WOS:000074608600051
J	Delange, F				Delange, F			Risks and benefits of iodine supplementation	LANCET			English	Editorial Material							THYROTOXICOSIS		Int Council Control Iodine Deficiency Disorders, B-1170 Brussels, Belgium		Delange, F (corresponding author), Int Council Control Iodine Deficiency Disorders, B-1170 Brussels, Belgium.							BALTISBERGER BL, 1995, EUR J ENDOCRINOL, V132, P546, DOI 10.1530/eje.0.1320546; Bourdoux PP, 1996, LANCET, V347, P552, DOI 10.1016/S0140-6736(96)91188-5; CONNOLLY RJ, 1970, LANCET, V1, P500; Delange F, 1996, B WORLD HEALTH ORGAN, V74, P101; Dremier S, 1996, J CLIN ENDOCR METAB, V81, P4187, DOI 10.1210/jc.81.12.4187; Elimination of Iodine Deficiency Disorders in Southeast Asia WHO, 1997, SEANUT138 WHO, P1; HERZEL BS, 1983, LANCET, V2, P1126; Kahaly G, 1997, J CLIN ENDOCR METAB, V82, P4049, DOI 10.1210/jc.82.12.4049; Stanbury JB, 1998, THYROID, V8, P83, DOI 10.1089/thy.1998.8.83; Stanbury JB, 1994, DAMAGED BRAIN IODINE, P1; TODD CH, 1995, LANCET, V346, P1563, DOI 10.1016/S0140-6736(95)92095-1; [WHO UNICEF ICCIDD], 1996, WHONUT9613 UNICEF IC; *WHO UNICEF ICCIDD, 1994, WHONUT946 UNICEF ICC; *WHO UNICEF ICCIDD, 1998, AFRONUT972 WHO UNICE; [No title captured]	15	47	52	3	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					923	924		10.1016/S0140-6736(05)60596-X	http://dx.doi.org/10.1016/S0140-6736(05)60596-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734932				2022-12-24	WOS:000072770900003
J	van Dissel, JT; van Langevelde, P; Westendorp, RGJ; Kwappenberg, K; Frolich, M				van Dissel, JT; van Langevelde, P; Westendorp, RGJ; Kwappenberg, K; Frolich, M			Anti-inflammatory cytokine profile and mortality in febrile patients	LANCET			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; SEPTIC SHOCK; TNF-ALPHA; IN-VITRO; SEPSIS; ANTIBODIES; ENDOTOXIN; SERUM; INTERLEUKIN-6	Background An anti-inflammatory cytokine profile on whole-blood stimulation in vitro is associated with fatal outcome of meningococcal disease. We investigated whether an antiinflammatory cytokine profile in the circulation is associated with adverse outcome in other infectious diseases. Methods We enrolled 464 consecutive patients (272 men, 192 women) who presented to hospital with fever (greater than or equal to 38.2 degrees C). On admission we measured plasma interleukin 10 (IL-10) and tumour necrosis factor alpha (TNF alpha), and collected clinical and microbiological data on the febrile illness, then followed up all patients for clinical outcome. Findings In at least 399 of the 464 patients fever was caused by infection. 33 patients died after a median hospital stay of 11 days (interquartile range 3-20). Concentrations of IL-10 were significantly higher in non-survivors (median 169 pg/mL [IQR 83-530]) than in survivors (median 88 pg/mL [42-235], p=0.042). When dichotomised around the median, the mortality risk was two times higher in patients who had high concentrations of IL-10 than in those with low concentrations (relative risk 2.39 [95% CI 1.07-5.33]), in patients with low and high concentrations of TNF alpha. In the 406 patients without haemodynamic deterioration in the first 24 h, IL-10 was higher and TNF alpha lower in patients who died than in those who survived. The ratio of IL-10 to TNF alpha was higher in non-survivors (median 6.9 [3.0-21.0]) than in survivors (median 3.9 [2.0-7.0], p=0.040). This ratio was highest in patients who died without underlying disease (median 21.5 [5.0-25.0]). Age, sex, and duration of fever before admission did not explain the differences in IL-10 and TNF alpha. Interpretation An anti-inflammatory cytokine profile of a high ratio of IL-10 to TNF alpha is associated with fatal outcome in febrile patients with community-acquired infection. Our findings caution against a widespread use of proinflammatory cytokine inhibition in patients with sepsis.	Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Epidemiol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Clin Chem, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	van Dissel, JT (corresponding author), Leiden Univ, Med Ctr, Dept Infect Dis, POB 9600, NL-2300 RC Leiden, Netherlands.							ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; [Anonymous], J ENDOTOXIN RES; BAGBY GJ, 1991, J INFECT DIS, V163, P83, DOI 10.1093/infdis/163.1.83; Bone RC, 1996, ANN INTERN MED, V125, P680, DOI 10.7326/0003-4819-125-8-199610150-00009; BOTHE J, 1993, NATURE, V364, P782; COHEN J, 1997, CLIN MICROBIOL INFEC, V13, P2; COOPER JF, 1971, J LAB CLIN MED, V78, P138; Docke WD, 1997, NAT MED, V3, P678, DOI 10.1038/nm0697-678; ECHTENACHER B, 1990, J IMMUNOL, V163, P83; Fisher CJ, 1996, NEW ENGL J MED, V334, P1697, DOI 10.1056/NEJM199606273342603; GIRARDIN E, 1988, NEW ENGL J MED, V319, P397, DOI 10.1056/NEJM198808183190703; GOLDIE AS, 1995, JAMA-J AM MED ASSOC, V274, P172, DOI 10.1001/jama.274.2.172; GrossWeege W, 1997, INTENS CARE MED, V23, P16, DOI 10.1007/s001340050285; GUICE KS, 1991, J SURG RES, V51, P494; HAMILTON G, 1992, SCAND J INFECT DIS, V24, P361, DOI 10.3109/00365549209061344; HAVELL EA, 1992, J IMMUNOL, V148, P1486; HEATH DI, 1993, GUT, V34, P41, DOI 10.1136/gut.34.1.41; HESSE DG, 1988, SURG GYNECOL OBSTET, V166, P147; LEIBOVICI L, 1991, ARCH INTERN MED, V151, P1801; MALO D, 1994, TRENDS GENET, V10, P365, DOI 10.1016/0168-9525(94)90133-3; MARCHANT A, 1994, LANCET, V343, P707, DOI 10.1016/S0140-6736(94)91584-9; MASTROENI P, 1991, MICROB PATHOGENESIS, V11, P33, DOI 10.1016/0882-4010(91)90091-N; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; Nelson S, 1996, CLIN CHEST MED, V17, P319, DOI 10.1016/S0272-5231(05)70317-8; Newport MJ, 1997, CURR OPIN INFECT DIS, V10, P233, DOI 10.1097/00001432-199706000-00013; PINSKY MR, 1993, CHEST, V103, P565, DOI 10.1378/chest.103.2.565; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; vanderPoll T, 1997, AM J RESP CRIT CARE, V155, P603, DOI 10.1164/ajrccm.155.2.9032201; VANFURTH R, 1994, J INFECT DIS, V170, P234, DOI 10.1093/infdis/170.1.234; WESTENDORP RGJ, 1995, J INFECT DIS, V171, P1057, DOI 10.1093/infdis/171.4.1057; Westendorp RGJ, 1997, LANCET, V349, P170, DOI 10.1016/S0140-6736(96)06413-6	32	337	345	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					950	953		10.1016/S0140-6736(05)60606-X	http://dx.doi.org/10.1016/S0140-6736(05)60606-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734942				2022-12-24	WOS:000072770900013
J	Troger, U; Meyer, FP				Troger, U; Meyer, FP			Personal paper - Validity of advertising claims for multivitamin preparation Vitacor 20/90 on the internet	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; VITAMIN-E CONSUMPTION; BETA-CAROTENE; CARDIOVASCULAR-DISEASE; PLASMA-CONCENTRATIONS; ALPHA-TOCOPHEROL; RISK; DEATH; MEN; ANTIOXIDANT		Univ Magdeburg, Univ Hosp, Inst Clin Pharmacol, D-39120 Magdeburg, Germany	Otto von Guericke University; University Hospital Magdeburg	Troger, U (corresponding author), Univ Magdeburg, Univ Hosp, Inst Clin Pharmacol, Leipziger Str 44, D-39120 Magdeburg, Germany.	uwe.troeger@medizin.uni-magdeburg.de						Bower H, 1996, BRIT MED J, V313, P381; Decsi T, 1997, J PEDIATR-US, V130, P653, DOI 10.1016/S0022-3476(97)70253-1; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; GALE CR, 1995, BRIT MED J, V310, P1563, DOI 10.1136/bmj.310.6994.1563; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; Pandey DK, 1995, AM J EPIDEMIOL, V142, P1269, DOI 10.1093/oxfordjournals.aje.a117594; Rapola JM, 1997, LANCET, V349, P1715, DOI 10.1016/S0140-6736(97)01234-8; Rath Matthias, 1996, Journal of Applied Nutrition, V48, P67; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Tardif JC, 1997, NEW ENGL J MED, V337, P365, DOI 10.1056/NEJM199708073370601	16	5	5	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1069	1071						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774300	Green Published			2022-12-24	WOS:000076577200034
J	Griffith, CA; Owen, T; Miller, GA; Geballe, T				Griffith, CA; Owen, T; Miller, GA; Geballe, T			Transient clouds in Titan's lower atmosphere	NATURE			English	Article							VOYAGER-1 RADIO-OCCULTATION; MU-M; SURFACE; METHANE; TROPOSPHERE; REANALYSIS; SPECTRUM; AEROSOLS; IMAGES; ALBEDO	The 1980 encounter by the Voyager I spacecraft with Titan, Saturn's largest moon, revealed(1,2) the presence of a thick atmosphere containing nitrogen and methane (1.4 and similar to 0.05 bar, respectively). Methane was found to be nearly saturated at Titan's tropopause, which, with other considerations, led to the hypothesis that Titan might experience a methane analogue of Earth's vigorous hydrological cycle, with clouds, rain and seas(3-7). Yet recent analyses of Voyager data indicate large areas of supersaturated methane, more indicative of dry and stagnant conditions(8,9), A resolution to this apparent contradiction requires observations of Titan's lower atmosphere, which was hidden from the Voyager cameras by the photochemical haze (or smog) in Titan's stratosphere. Here we report near-infrared spectroscopic observations of Titan within four narrow spectral windows where the moon's atmosphere is ostensibly transparent. We detect pronounced flux enhancements that indicate the presence of reflective methane condensation clouds in the troposphere, These clouds occur at a relatively low altitude (15 +/- 10 km), at low latitudes, and appear to cover similar to 9 per cent of Titan's disk.	No Arizona Univ, Dept Phys & Astron, Flagstaff, AZ 86001 USA; Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Joint Astron Ctr, Hilo, HI 96720 USA	Northern Arizona University; University of Hawaii System	Griffith, CA (corresponding author), No Arizona Univ, Dept Phys & Astron, POB 6010, Flagstaff, AZ 86001 USA.							CALVIN WM, 1991, ICARUS, V89, P305, DOI 10.1016/0019-1035(91)90180-2; Combes M, 1997, ICARUS, V129, P482, DOI 10.1006/icar.1997.5772; COURTIN R, 1995, ICARUS, V114, P144, DOI 10.1006/icar.1995.1050; COUSTENIS A, 1995, ICARUS, V118, P87, DOI 10.1006/icar.1995.1179; ESHLEMAN VR, 1983, SCIENCE, V221, P55; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; GRIFFITH CA, 1993, NATURE, V364, P511, DOI 10.1038/364511a0; GRIFFITH CA, 1991, ICARUS, V93, P362, DOI 10.1016/0019-1035(91)90219-J; Hunten D.M, 1984, SATURN, P671; HUSSON N, 1991, 163 LMD; KHARE BN, 1984, ICARUS, V60, P127, DOI 10.1016/0019-1035(84)90142-8; LELLOUCH E, 1989, ICARUS, V79, P328, DOI 10.1016/0019-1035(89)90081-X; LEMMON MT, 1995, ICARUS, V113, P27, DOI 10.1006/icar.1995.1003; LEMMON MT, 1993, ICARUS, V103, P329, DOI 10.1006/icar.1993.1074; LINDAL GF, 1983, ICARUS, V53, P348, DOI 10.1016/0019-1035(83)90155-0; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; Noll KS, 1996, ICARUS, V124, P625, DOI 10.1006/icar.1996.0236; RAGES K, 1983, J GEOPHYS RES-SPACE, V88, P8721, DOI 10.1029/JA088iA11p08721; Samuelson RE, 1997, PLANET SPACE SCI, V45, P959, DOI 10.1016/S0032-0633(97)00090-1; Smith PH, 1996, ICARUS, V119, P336, DOI 10.1006/icar.1996.0023; STRONG K, 1993, J QUANT SPECTROSC RA, V50, P363, DOI 10.1016/0022-4073(93)90072-P; TOON OB, 1988, ICARUS, V75, P255, DOI 10.1016/0019-1035(88)90005-X; TOON OB, 1992, ICARUS, V95, P24, DOI 10.1016/0019-1035(92)90188-D	25	168	168	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					575	578		10.1038/26920	http://dx.doi.org/10.1038/26920			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783583				2022-12-24	WOS:000076362900039
J	Ristow, M; Muller-Wieland, D; Pfeiffer, A; Krone, W; Kahn, CR				Ristow, M; Muller-Wieland, D; Pfeiffer, A; Krone, W; Kahn, CR			Obesity associated with a mutation in a genetic regulator of adipocyte differentiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN-RESISTANCE; RECEPTOR; ADIPOGENESIS; PHOSPHORYLATION; CLONING; GAMMA	Background There is increasing evidence of genetic factors leading to obesity, but the exact genes involved have not been defined. Peroxisome-proliferator-activated receptor gamma 2 (PPAR gamma 2) is a transcription factor that has a key role in adipocyte differentiation, and therefore mutations of the gene for this factor might predispose people to obesity. Methods We studied 358 unrelated German subjects, including 121 obese subjects (defined as those with a body-mass index [the weight in kilograms divided by the square of the height in meters] of more than 29). We evaluated these subjects for mutations in the gene for PPAR gamma 2 at or near a site of serine phosphorylation at position 114 that negatively regulates the transcriptional activity of the protein, using a polymerase-chain-reaction-based assay coupled with specific endonuclease digestion. The activity of the mutation identified was analyzed by retroviral transfection and overexpression in murine fibroblasts. Results Four of the 121 obese subjects had a missense mutation in the gene for PPAR gamma 2 that resulted in the conversion of proline to glutamine at position 115, as compared with none of the 237 subjects of normal weight (P=0.01). All the subjects with the mutant allele were markedly obese, with body-mass-index values ranging from 37.9 to 47.3, as compared with a mean of 33.6 in the other obese subjects. Overexpression of the mutant gene in murine fibroblasts led to the production of a protein in which the phosphorylation of serine at position 114 was defective, as well as to accelerated differentiation of the cells into adipocytes and greater cellular accumulation of triglyceride than with the wild-type PPAR gamma 2. These effects were similar to those of an in vitro mutation created directly at the Ser114 phosphorylation site. Conclusions A Pro115Gln mutation in PPAR gamma 2 accelerates the differentiation of adipocytes and may cause obesity. (N Engl J Med 1998;339:953-9.) (C)1998, Massachusetts Medical Society.	Joslin Diabet Ctr, Div Res, Sect Cellular & Mol Physiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Univ Cologne, Klin & Poliklin Innere Med 2, Cologne, Germany; Ruhr Univ Bochum, Bergmannsheil, Med Klin & Poliklin, D-4630 Bochum, Germany	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; University of Cologne; Ruhr University Bochum	Kahn, CR (corresponding author), Joslin Diabet Ctr, Div Res, Sect Cellular & Mol Physiol, 1 Joslin Pl, Boston, MA 02215 USA.		Ristow, Michael/O-9858-2014; Kahn, Ronald/AAY-2435-2021; Pfeiffer, Andreas F.H./AAJ-2311-2020	Ristow, Michael/0000-0003-2109-2453; Kahn, Ronald/0000-0002-7583-9228; Pfeiffer, Andreas F.H./0000-0002-6887-0016	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836, R01DK045935] Funding Source: NIH RePORTER; NIDDK NIH HHS [2 P30 DK 36836, DK 45935] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Bouchard C, 1994, GENETICS OBESITY; Bruning JC, 1997, MOL CELL BIOL, V17, P1513; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; KAHN CR, 1994, DIABETES, V43, P1066, DOI 10.2337/diab.43.8.1066; Knebel B, 1997, BIOCHEM BIOPH RES CO, V234, P626, DOI 10.1006/bbrc.1997.6696; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Latruffe N, 1997, BIOCHIMIE, V79, P81, DOI 10.1016/S0300-9084(97)81496-4; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; *NAT DIAB DAT GROU, 1905, NIH PUBL; Okuno A, 1998, J CLIN INVEST, V101, P1354, DOI 10.1172/JCI1235; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Ristow M, 1998, DIABETES, V47, P851, DOI 10.2337/diabetes.47.5.851; RISTOW M, 1995, LANCET, V346, P502, DOI 10.1016/S0140-6736(95)91351-3; Ristow M, 1997, J CLIN INVEST, V100, P2833, DOI 10.1172/JCI119831; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TONTONOZ P, 1995, CELL, V80, P957; Whitaker RC, 1997, NEW ENGL J MED, V337, P869, DOI 10.1056/NEJM199709253371301; Yen CJ, 1997, BIOCHEM BIOPH RES CO, V241, P270, DOI 10.1006/bbrc.1997.7798; ZHANG YY, 1995, NATURE, V374, P479, DOI 10.1038/374479a0; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	31	434	459	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					953	959		10.1056/NEJM199810013391403	http://dx.doi.org/10.1056/NEJM199810013391403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753710				2022-12-24	WOS:000076186900003
J	Syed, RS; Reid, SW; Li, CW; Cheetham, JC; Aoki, KH; Liu, BS; Zhan, HJ; Osslund, TD; Chirino, AJ; Zhang, JD; Finer-Moore, J; Elliott, S; Sitney, K; Katz, BA; Matthews, DJ; Wendoloski, JJ; Egrie, J; Stroud, RM				Syed, RS; Reid, SW; Li, CW; Cheetham, JC; Aoki, KH; Liu, BS; Zhan, HJ; Osslund, TD; Chirino, AJ; Zhang, JD; Finer-Moore, J; Elliott, S; Sitney, K; Katz, BA; Matthews, DJ; Wendoloski, JJ; Egrie, J; Stroud, RM			Efficiency of signalling through cytokine receptors depends critically on receptor orientation	NATURE			English	Article							HUMAN ERYTHROPOIETIN RECEPTOR; EXTRACELLULAR DOMAIN; DIFFRACTION DATA; PROTEIN HORMONE; GROWTH-HORMONE; LIGAND-BINDING; EPO RECEPTOR; MUTAGENESIS; ACTIVATION; MOTIF	Human erythropoietin is a haematopoietic cytokine required for the differentiation and proliferation of precursor cells into red blood cells(1). It activates cells by binding and orientating two cell-surface erythropoietin receptors (EPORs) which trigger an intracellular phosphorylation cascade(2). The half-maximal response in a cellular proliferation assay is evoked at an erythropoietin concentration of 10 pM (ref. 3), 10(-2) of its K-d value for erythropoietin-EPOR binding site 1 (K-d approximate to 1 nM), and 10(-5) of the K-d for erythropoietin-EPOR binding site 2 (K-d approximate to 1 mu M)(4). Overall half-maximal binding (IC50) of cell-surface receptors is produced with similar to 0.18 nM erythropoietin, indicating that only similar to 6% of the receptors would be bound in the presence of 10 pM erythropoietin. Other effective erythropoietin-mimetic ligands that dimerize receptors can evoke the same cellular responses(5,6) but much less efficiently, requiring concentrations close to their K-d values (similar to 0.1 mu M). The crystal structure of erythropoietin complexed to the extracellular ligand-binding domains of the erythropoietin receptor, determined at 1.9 Angstrom from two crystal forms, shows that erythropoietin imposes a unique 120 degrees angular relationship and orientation that is responsible for optimal signalling through intracellular kinase pathways.	Amgen Inc, Thousand Oaks, CA 91320 USA; Axys Pharmaceut Inc, San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	Amgen; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Syed, RS (corresponding author), Amgen Inc, 1 Amgen Ctr Dr, Thousand Oaks, CA 91320 USA.	rsyed@amgen.com; stroud@msg.ucsf.edu	Stroud, Rhonda M./C-5503-2008	Stroud, Rhonda M./0000-0001-5242-8015				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barbone FP, 1997, J BIOL CHEM, V272, P4985, DOI 10.1074/jbc.272.8.4985; BAUMGARTNER JW, 1994, J BIOL CHEM, V269, P29094; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHEETHAM JC, IN PRESS NATURE STRU; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; Damen JE, 1996, EXP HEMATOL, V24, P1455; DERBY P, 1996, TECHNIQUES PROTEIN C, V7, P109; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Elliott S, 1997, BLOOD, V89, P493, DOI 10.1182/blood.V89.2.493; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; GRABER SE, 1978, ANNU REV MED, V29, P51, DOI 10.1146/annurev.me.29.020178.000411; GRODBERG J, 1993, EUR J BIOCHEM, V218, P597, DOI 10.1111/j.1432-1033.1993.tb18413.x; Hilton DJ, 1996, J BIOL CHEM, V271, P4699; Johnson DL, 1998, BIOCHEMISTRY-US, V37, P3699, DOI 10.1021/bi971956y; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; Livnah O, 1996, SCIENCE, V273, P464, DOI 10.1126/science.273.5274.464; Matthews DJ, 1996, P NATL ACAD SCI USA, V93, P9471, DOI 10.1073/pnas.93.18.9471; Middleton SA, 1996, J BIOL CHEM, V271, P14045, DOI 10.1074/jbc.271.24.14045; NARHI LO, 1991, J BIOL CHEM, V266, P23022; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Philo JS, 1996, BIOCHEMISTRY-US, V35, P1681, DOI 10.1021/bi9524272; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WEN DY, 1994, J BIOL CHEM, V269, P22839; Wrighton NC, 1996, SCIENCE, V273, P458, DOI 10.1126/science.273.5274.458; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619	29	440	483	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					511	516		10.1038/26773	http://dx.doi.org/10.1038/26773			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774108				2022-12-24	WOS:000076212200059
J	Chart, H				Chart, H			Are all infections with Escherichia coli O157 associated with cattle?	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME; HEMORRHAGIC COLITIS; OUTBREAK; DIARRHEA; DEATH		Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England	Public Health England	Chart, H (corresponding author), Cent Publ Hlth Lab, Lab Enter Pathogens, London NW9 5HT, England.							Ackers ML, 1998, J INFECT DIS, V177, P1588, DOI 10.1086/515323; Ackman D, 1997, EPIDEMIOL INFECT, V119, P1, DOI 10.1017/S095026889700770X; Chalmers RM, 1997, LANCET, V349, P1816, DOI 10.1016/S0140-6736(05)61697-2; Chapman PA, 1996, VET REC, V138, P23; Clark A, 1997, Commun Dis Rep CDR Rev, V7, pR206; From the centers for disease control and prevention, 1996, JAMA-J AM MED ASSOC, V276, P1865, DOI [10.1001/jama.1996.03540230015010, DOI 10.1001/JAMA.1996.03540230015010]; Germani Y, 1997, LANCET, V349, P1670, DOI 10.1016/S0140-6736(05)62636-0; Itoh Y, 1998, APPL ENVIRON MICROB, V64, P1532; KARMALI MA, 1985, J INFECT DIS, V151, P775, DOI 10.1093/infdis/151.5.775; Keene WE, 1997, JAMA-J AM MED ASSOC, V277, P1229, DOI 10.1001/jama.277.15.1229; MORGAN GM, 1988, EPIDEMIOL INFECT, V101, P83, DOI 10.1017/S0950268800029241; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RYAN CA, 1986, J INFECT DIS, V154, P631, DOI 10.1093/infdis/154.4.631; Shefer AM, 1996, WESTERN J MED, V165, P15; SWERDLOW DL, 1992, ANN INTERN MED, V117, P812, DOI 10.7326/0003-4819-117-10-812; TAYLOR CM, 1986, BRIT MED J, V292, P1513, DOI 10.1136/bmj.292.6534.1513; Wallace JS, 1997, J APPL MICROBIOL, V82, P399, DOI 10.1046/j.1365-2672.1997.00378.x; WILLSHAW GA, 1994, LETT APPL MICROBIOL, V19, P304, DOI 10.1111/j.1472-765X.1994.tb00461.x	18	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1005	1005		10.1016/S0140-6736(05)60072-4	http://dx.doi.org/10.1016/S0140-6736(05)60072-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759740				2022-12-24	WOS:000076121800006
J	Binder, AB				Binder, AB			Lunar prospector: Overview	SCIENCE			English	Article							SINGLE-IMPACT HYPOTHESIS; MOON; ORIGIN	Lunar Prospector is providing a global map of the composition of the moon and analyzing the moon's gravity and magnetic fields. It has been in a polar orbit around the moon since 16 January 1998. Neutron flux data show that there is abundant H, and hence probably abundant water ice, in the Lunar polar regions. Gamma-ray and neutron data reveal the distribution of Fe, Ti, and other major and trace elements on the moon. The data delineate the global distributions of a key trace element-rich component of lunar materials called KREEP and of the major rock types. Magnetic mapping shows that the Lunar magnetic fields are strong antipodal to Mare Imbrium and Mare Serenitatis and has discovered the smallest known magnetosphere, magnetosheath, and bow shock complex in the solar system. Gravity mapping has delineated seven new gravity anomalies and shown that the moon has a small Fe-rich core of about 300 km radius.	Lunar Res Inst, Gilroy, CA 95020 USA		Binder, AB (corresponding author), Lunar Res Inst, 1800 Sunrise Dr, Gilroy, CA 95020 USA.	abinder@mail.arc.nasa.gov						BENZ W, 1986, ICARUS, V66, P515, DOI 10.1016/0019-1035(86)90088-6; Blewett DT, 1997, J GEOPHYS RES-PLANET, V102, P16319, DOI 10.1029/97JE01505; Cameron AGW, 1997, ICARUS, V126, P126, DOI 10.1006/icar.1996.5642; Canup RM, 1996, ICARUS, V119, P427, DOI 10.1006/icar.1996.0028; Elphic RC, 1998, SCIENCE, V281, P1493, DOI 10.1126/science.281.5382.1493; Feldman WC, 1998, SCIENCE, V281, P1489, DOI 10.1126/science.281.5382.1489; Konopliv AS, 1998, SCIENCE, V281, P1476, DOI 10.1126/science.281.5382.1476; Lawrence DJ, 1998, SCIENCE, V281, P1484, DOI 10.1126/science.281.5382.1484; Lin RP, 1998, SCIENCE, V281, P1480, DOI 10.1126/science.281.5382.1480; Lucey PG, 1998, J GEOPHYS RES-PLANET, V103, P3679, DOI 10.1029/97JE03019; LUCEY PG, 1995, SCIENCE, V268, P1150, DOI 10.1126/science.268.5214.1150; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495	12	138	153	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1998	281	5382					1475	1476		10.1126/science.281.5382.1475	http://dx.doi.org/10.1126/science.281.5382.1475			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727967				2022-12-24	WOS:000075738100031
J	Sharer, N; Schwarz, M; Malone, G; Howarth, A; Painter, J; Super, M; Braganza, J				Sharer, N; Schwarz, M; Malone, G; Howarth, A; Painter, J; Super, M; Braganza, J			Mutations of the cystic fibrosis gene in patients with chronic pancreatitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	British-Society-of-Gastroenterology Autumn Meeting	SEP 18-20, 1996	MANCHESTER, ENGLAND	British Soc Gastroenterol			RISK FACTOR; CFTR GENE	Background The pancreatic lesions of cystic fibrosis develop in utero and closely resemble those of chronic pancreatitis. Therefore, we hypothesized that mutations of the cystic fibrosis transmembrane conductance regulator (CFTR) gene may be more common than expected among patients with chronic pancreatitis. Methods We studied 134 consecutive patients with chronic pancreatitis (alcohol-related disease in 71, hyperparathyroidism in 2, hypertriglyceridemia in 1, and idiopathic disease in 60). We examined DNA for 22 mutations of the CFTR gene that together account for 95 percent of all mutations in patients with cystic fibrosis in the northwest of England. We also determined the length of the noncoding sequence of thymidines in intron 8, since the shorter the sequence, the lower the proportion of normal CFTR messenger RNA. Results The 94 male and 40 female patients ranged in age from 16 to 86 years. None had a mutation on both copies of the CFTR gene. Eighteen patients (13.4 percent), including 12 without alcoholism, had a CFTR mutation on one chromosome, as compared with a frequency of 5.3 percent among 600 local unrelated partners of persons with a family history of cystic fibrosis (P<0.001). A total of 10.4 percent of the patients had the 5T allele in intron 8 (14 of 134), which is twice the expected frequency (P=0.008). Four patients were heterozygous for both a CFTR mutation and the 5T allele. Patients with a CFTR mutation were younger than those with no mutations (P=0.03). None had the combination of sinopulmonary disease, high sweat electrolyte concentrations, and low nasal potential-difference values that are diagnostic of cystic fibrosis. Conclusions Mutations of the CFTR gene and the 5T genotype are associated with chronic pancreatitis. (N Engl J Med 1998;339:645-52.) (C) 1998, Massachusetts Medical Society.	Manchester Royal Infirm, Pancreatobiliary Unit, Manchester M13 9WL, Lancs, England; Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Royal Manchester Childrens Hosp, Reg Genet Serv, Manchester M27 1HA, Lancs, England	University of Manchester; University of Manchester; Royal Manchester Children's Hospital	Braganza, J (corresponding author), Manchester Royal Infirm, Pancreatobiliary Unit, Oxford Rd, Manchester M13 9WL, Lancs, England.							ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Armitage P., 2001, STAT METHODS MED RES; AYGALENQ P, 1994, GASTROEN CLIN BIOL, V18, P907; BANK S, 1978, DIG DIS, V23, P178; BILTON D, 1994, DRUG INVEST, V8, P10, DOI 10.1007/BF03257422; BRAGANZA JM, 1986, MED HYPOTHESES, V20, P233, DOI 10.1016/0306-9877(86)90129-5; BRAGANZA JM, 1983, CLIN CHIM ACTA, V130, P339, DOI 10.1016/0009-8981(83)90308-X; Braganza JM, 1996, QJM-INT J MED, V89, P243; BRAGANZA JM, 1991, PATHOGENESIS OF PANCREATITIS, P178; BRAGANZA JM, 1982, GASTROENTEROLOGY, V82, P1341; BURGER J, 1991, LANCET, V337, P974, DOI 10.1016/0140-6736(91)91603-R; CHILLON M, 1995, NEW ENGL J MED, V332, P1475, DOI 10.1056/NEJM199506013322204; CHU CS, 1993, NAT GENET, V3, P151, DOI 10.1038/ng0293-151; Cohn JA, 1997, GASTROENTEROLOGY, V112, pA434; DELISLE RC, 1995, AM J PHYSIOL-GASTR L, V268, pG717, DOI 10.1152/ajpgi.1995.268.4.G717; FERRIE RM, 1992, AM J HUM GENET, V51, P251; GIBSON LE, 1959, PEDIATRICS, V23, P545; HANAWA M, 1978, TOHOKU J EXP MED, V125, P59, DOI 10.1620/tjem.125.59; KIESEWETTER S, 1993, NAT GENET, V5, P274, DOI 10.1038/ng1193-274; KRISTIDIS P, 1992, AM J HUM GENET, V50, P1178; Lebenthal Emanuel, 1993, P1041; LENCH N, 1988, LANCET, V1, P1356; LONGNECKER DS, 1991, PATHOGENESIS OF PANCREATITIS, P3; MCNAMEE R, 1994, OCCUP ENVIRON MED, V51, P631, DOI 10.1136/oem.51.9.631; MIDDLETON PG, 1994, EUR RESPIR J, V7, P2050; Miller PW, 1996, AM J HUM GENET, V59, P45; MORRIS AP, 1994, ANNU REV PHYSIOL, V56, P371; NORTON ID, 1995, GASTROENTEROLOGY, V108, pA380; PARIS J, 1969, LILLE MED, V14, P588; PEMBERTON PW, 1991, CLIN CHIM ACTA, V199, P253, DOI 10.1016/0009-8981(91)90119-W; PORTA EA, 1964, AM J CLIN PATHOL, V42, P451, DOI 10.1093/ajcp/42.5.451; Quesnel LB, 1998, J ANTIMICROB CHEMOTH, V41, P215, DOI 10.1093/jac/41.2.215; Ravnik-Glavac Metka, 1996, Pfluegers Archiv European Journal of Physiology, V431, pR191, DOI 10.1007/BF02346333; RIORDAN JR, 1989, SCIENCE, V245, P1437; SANDILANDS D, 1990, GASTROENTEROLOGY, V98, P766, DOI 10.1016/0016-5085(90)90300-P; Scheele GA, 1996, PANCREAS, V12, P1, DOI 10.1097/00006676-199601000-00001; Stern RC, 1997, NEW ENGL J MED, V336, P487, DOI 10.1056/NEJM199702133360707; SUPER M, 1992, EUR J PEDIATR, V151, P108, DOI 10.1007/BF01958953; SUPER M, 1994, BRIT MED J, V308, P1462, DOI 10.1136/bmj.308.6942.1462; Talamini G, 1996, PANCREAS, V12, P131, DOI 10.1097/00006676-199603000-00004; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141; Whiteley G, 1994, PANCREAS, V9, pA807; Worning H, 1989, Int J Pancreatol, V5 Suppl, P1	43	678	691	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	1998	339	10					645	652		10.1056/NEJM199809033391001	http://dx.doi.org/10.1056/NEJM199809033391001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	115WA	9725921				2022-12-24	WOS:000075688100001
J	McCarron, DA				McCarron, DA			Biomedicine - Diet and blood pressure the paradigm shift	SCIENCE			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; METAANALYSIS; CALCIUM; SODIUM; SALT		Oregon Hlth Sci Univ, Portland, OR 97201 USA	Oregon Health & Science University	McCarron, DA (corresponding author), Oregon Hlth Sci Univ, Portland, OR 97201 USA.	mccarron@ohsu.edu						ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; BILEZIKIAN JP, 1994, JAMA-J AM MED ASSOC, V272, P1942, DOI 10.1001/jama.1994.03520240070044; Black HR, 1997, ARCH INTERN MED, V157, P2413; Bucher HC, 1996, JAMA-J AM MED ASSOC, V275, P1016, DOI 10.1001/jama.275.13.1016; ELLIOTT P, 1988, BRIT MED J, V297, P319; Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383; KOLATA G, 1982, SCIENCE, V216, P38, DOI 10.1126/science.7063868; MCCARRON DA, 1984, SCIENCE, V224, P1392, DOI 10.1126/science.6729459; MCCARRON DA, 1982, SCIENCE, V217, P267, DOI 10.1126/science.7089566; Midgley JP, 1996, JAMA-J AM MED ASSOC, V275, P1590, DOI 10.1001/jama.275.20.1590; MUNTZEL M, 1992, AM J HYPERTENS, V5, pS1, DOI 10.1093/ajh/5.4S.1S; *NAT RES COUNC COM, 1989, DIET HLTH IMPL RED C, P665; Pickering TG, 1997, ARCH INTERN MED, V157, P596, DOI 10.1001/archinte.157.6.596; SWALES JD, 1988, BRIT MED J, V297, P307, DOI 10.1136/bmj.297.6644.307; Whelton PK, 1997, ARCH INTERN MED, V157, P657, DOI 10.1001/archinte.157.6.657	17	51	52	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 14	1998	281	5379					933	934		10.1126/science.281.5379.933	http://dx.doi.org/10.1126/science.281.5379.933			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	110ZK	9722467				2022-12-24	WOS:000075412700030
J	Verma, L; Macdonald, F; Leedham, P; McConachie, M; Dhanjal, S; Hulten, M				Verma, L; Macdonald, F; Leedham, P; McConachie, M; Dhanjal, S; Hulten, M			Rapid and simple prenatal DNA diagnosis of Down's syndrome	LANCET			English	Article							POLYMERASE CHAIN-REACTION; ANEUPLOIDIES; PCR; MARKERS	Background Prenatal diagnosis of chromosomal abnormality requires cytogenetic analysis of amniotic fetal cells. The necessary culture time delays diagnosis, is expensive, and requires substantial scientific expertise. In a masked prospective study, we investigated the feasibility of PCR amplification of chromosome 21 markers for the prenatal diagnosis of Down's syndrome. Methods The study population consisted of 2167 pregnant women, undergoing amniocentesis for prenatal diagnosis. In this cohort at least 1.5 mL amniotic fluid was available surplus to the requirements for traditional diagnostic methods. DNA was extracted from the surplus amniotic fluid and amplified in fluorescence-based PCR reactions, with three small-tandem-repeat markers located on chromosome 21. The products of the reactions were analysed on a DNA sequencer to identify the presence of two or three copies of chromosome 21. Findings In 2083 (97.4%) of 2139 samples of amniotic fluid that were not macroscopically blood-stained, two DNA markers gave an informative and correct result, identifying 2053 fetuses as normal and 30 as having trisomy 21 Down's syndrome (as confirmed by cytogenetic analysis). An extra marker was informative in 32 of 41 other clear samples. Thus a total of 99.6% informative results was achieved with these three markers. Macroscopically bloodstained samples (28 [1.3%]) were unsuitable for DNA testing. They gave a typical but non-informative result. There were no false-positive or false-negative results. Interpretation The PCR-based DNA diagnostic test has great potential for improved prenatal diagnosis of Down's syndrome, with the advantage that results may be available within a day.	Birmingham Heartlands Hosp, Reg Genet Serv, LSF Res Unit, Birmingham B9 5ST, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham	Hulten, M (corresponding author), Univ Warwick, Dept Biol Sci, Mol Med Res Ctr, Coventry CV4 7AL, W Midlands, England.	ceht@dna.bio.warwick.ac.uk						ADINOLFI M, 1995, BIOESSAYS, V17, P661, DOI 10.1002/bies.950170712; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Bosch A, 1996, EUR J HUM GENET, V4, P135; Falconer C, 1997, J MED GENET, V34, pSP67; Gardner RJM, 1996, CHROMOSOME ABNORMALI, V2nd; Goldberg JD, 1997, AM J HUM GENET, V61, P806, DOI 10.1086/514889; Leschot NJ, 1997, EUR J HUM GENET, V5, P1; LUBIN MB, 1991, MOL CELL PROBE, V5, P307, DOI 10.1016/0890-8508(91)90054-N; MANSFIELD ES, 1993, HUM MOL GENET, V2, P43, DOI 10.1093/hmg/2.1.43; MCINNIS MG, 1993, GENOMICS, V16, P562, DOI 10.1006/geno.1993.1231; Nakamura A, 1997, J BIOCHEM-TOKYO, V122, P872; Pertl B, 1996, HUM GENET, V98, P55, DOI 10.1007/s004390050159; PERTL B, 1994, LANCET, V343, P1197, DOI 10.1016/S0140-6736(94)92404-X; SHARMA V, 1992, HUM MOL GENET, V1, P67, DOI 10.1093/hmg/1.1.67-a; SPATHAS DH, 1994, PRENATAL DIAG, V14, P1049, DOI 10.1002/pd.1970141107; *UK NAT EXT QUAL A, 1996, CLIN CYTOGENET; WARBURTON D, 1991, AM J HUM GENET, V49, P995; WARD BE, 1993, AM J HUM GENET, V52, P854; Winsor EJT, 1996, PRENATAL DIAG, V16, P49, DOI 10.1002/(SICI)1097-0223(199601)16:1<49::AID-PD808>3.3.CO;2-L	19	95	134	0	8	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1998	352	9121					9	12		10.1016/S0140-6736(97)11090-X	http://dx.doi.org/10.1016/S0140-6736(97)11090-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800738				2022-12-24	WOS:000074608600009
J	Volta, U; De Franceschi, L; Lari, F; Molinaro, N; Zoli, M; Bianchi, FB				Volta, U; De Franceschi, L; Lari, F; Molinaro, N; Zoli, M; Bianchi, FB			Coeliac disease hidden by cryptogenic hypertransaminasaemia	LANCET			English	Article							ADULT CELIAC-DISEASE; GLUTEN-FREE DIET; ANTIBODIES; GLIADIN; ENTEROPATHY; LIVER	Background Hypertransaminasaemia of unknown, cryptogenic, origin occasionally has been found to be the only sign of coeliac disease. Raised concentrations of transaminases, or aminotransferases, have been retrospectively observed in about a half of patients with coeliac disease who are on a gluten-containing diet. We aimed to establish the overall prevalence of coeliac disease among patients with cryptogenic hypertransaminasaemia. Methods Of the 600 consecutive patients referred to our outpatient clinic for liver disease due to raised serum transaminases from September, 1995, to June, 1997, 55 were classified as having cryptogenic hypertransaminasaemia after the exclusion of every known cause of liver disease. These patients were tested by indirect immunofluorescence for IgA to endomysium and for IgA and IgG to gliadin. Findings Five patients were positive for both IgA to endomysium and IgG to gliadin, whereas IgA to gliadin was only found in four patients. IgG to gliadin was also present in another patient who was not positive for antibodies to endomysium. The six antibody-positive patients had duodenal biopsy that showed a subtotal villous atrophy consistent with coeliac disease in the five patients with antibodies to endomysium. The patient with only IgG to gliadin had a normal small-intestine mucosa. None of the five patients with coeliac disease had gastrointestinal symptoms. Liver biopsy samples were taken from three of the five patients with flat mucosa and showed a histological picture of nonspecific reactive hepatitis. Transaminase concentrations reverted to normal within 6 months in four patients with coeliac disease who followed a strict gluten-free diet. Interpretation Our results show that about 9% of patients with cryptogenic hypertransaminasaemia are affected by symptom-free coeliac disease. Gluten-sensitive enteropathy and antibody screening for coeliac disease by means of antibodies to endomysium and gliadin should be considered in these patients.	Univ Bologna, SOrsola Malpighi Policlin, Dept Internal Med Cardioangiol Hepatol, I-40138 Bologna, Italy	University of Bologna	Volta, U (corresponding author), Univ Bologna, SOrsola Malpighi Policlin, Dept Internal Med Cardioangiol Hepatol, Via Massarenti 9, I-40138 Bologna, Italy.			De Franceschi, Lucia/0000-0003-1257-8101; Volta, Umberto/0000-0003-3405-3808				BARDELLA MT, 1995, HEPATOLOGY, V22, P833, DOI 10.1002/hep.1840220322; Bode S, 1996, SCAND J GASTROENTERO, V31, P54, DOI 10.3109/00365529609031627; Bonamico M, 1986, Minerva Pediatr, V38, P959; BRAZIER F, 1994, EUR J GASTROEN HEPAT, V6, P183, DOI 10.1097/00042737-199402000-00016; CACCIARI E, 1985, LANCET, V1, P1469; CORAZZA G, 1992, GASTROENTEROLOGY, V103, P1517, DOI 10.1016/0016-5085(92)91172-Z; CORAZZA GR, 1995, SCAND J GASTROENTERO, V30, P153, DOI 10.3109/00365529509093254; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1002/hep.1840190629; Hadjivassiliou M, 1996, LANCET, V347, P369, DOI 10.1016/S0140-6736(96)90540-1; HAGANDER B, 1977, LANCET, V2, P270; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; JACOBSEN MB, 1990, SCAND J GASTROENTERO, V25, P656, DOI 10.3109/00365529008997589; LEONARDI S, 1990, J PEDIATR GASTR NUTR, V11, P404, DOI 10.1097/00005176-199010000-00021; LINDGREN S, 1994, SCAND J GASTROENTERO, V29, P661, DOI 10.3109/00365529409092489; MCFARLANE XA, 1995, GUT, V36, P710, DOI 10.1136/gut.36.5.710; MEYERS S, 1981, GUT, V22, P61, DOI 10.1136/gut.22.1.61; POLLOCK DJ, 1977, HISTOPATHOLOGY, V1, P421, DOI 10.1111/j.1365-2559.1977.tb01681.x; ROY-CHOUDHURY D, 1966, Scandinavian Journal of Gastroenterology, V1, P57; SHER KS, 1994, DIGESTION, V55, P243, DOI 10.1159/000201155; TRIER JS, 1991, NEW ENGL J MED, V325, P1709, DOI 10.1056/NEJM199112123252406; VAJRO P, 1993, J PEDIATR-US, V122, P416, DOI 10.1016/S0022-3476(05)83430-4; VOLTA U, 1985, GUT, V26, P667, DOI 10.1136/gut.26.7.667; VOLTA U, 1995, DIGEST DIS SCI, V40, P1902, DOI 10.1007/BF02208653; VOLTA U, 1992, LANCET, V339, P242, DOI 10.1016/0140-6736(92)90040-A	24	166	171	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	1998	352	9121					26	29		10.1016/S0140-6736(97)11222-3	http://dx.doi.org/10.1016/S0140-6736(97)11222-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800742				2022-12-24	WOS:000074608600013
J	Deloukas, P; Schuler, GD; Gyapay, G; Beasley, EM; Soderlund, C; Rodriguez-Tome, P; Hui, L; Matise, TC; McKusick, KB; Beckmann, JS; Bentolila, S; Bihoreau, MT; Birren, BB; Browne, J; Butler, A; Castle, AB; Chiannilkulchai, N; Clee, C; Day, PJR; Dehejia, A; Dibling, T; Drouot, N; Duprat, S; Fizames, C; Fox, S; Gelling, S; Green, L; Harrison, P; Hocking, R; Holloway, E; Hunt, S; Keil, S; Lijnzaad, P; Louis-Dit-Sully, C; Ma, J; Mendis, A; Miller, J; Morissette, J; Muselet, D; Nusbaum, HC; Peck, A; Rozen, S; Simon, D; Slonim, DK; Staples, R; Stein, LD; Stewart, EA; Suchard, MA; Thangarajah, T; Vega-Czarny, N; Webber, C; Wu, X; Hudson, J; Auffray, C; Nomura, N; Sikela, JM; Polymeropoulos, MH; James, MR; Lander, ES; Hudson, TJ; Myers, RM; Cox, DR; Weissenbach, J; Boguski, MS; Bentley, DR				Deloukas, P; Schuler, GD; Gyapay, G; Beasley, EM; Soderlund, C; Rodriguez-Tome, P; Hui, L; Matise, TC; McKusick, KB; Beckmann, JS; Bentolila, S; Bihoreau, MT; Birren, BB; Browne, J; Butler, A; Castle, AB; Chiannilkulchai, N; Clee, C; Day, PJR; Dehejia, A; Dibling, T; Drouot, N; Duprat, S; Fizames, C; Fox, S; Gelling, S; Green, L; Harrison, P; Hocking, R; Holloway, E; Hunt, S; Keil, S; Lijnzaad, P; Louis-Dit-Sully, C; Ma, J; Mendis, A; Miller, J; Morissette, J; Muselet, D; Nusbaum, HC; Peck, A; Rozen, S; Simon, D; Slonim, DK; Staples, R; Stein, LD; Stewart, EA; Suchard, MA; Thangarajah, T; Vega-Czarny, N; Webber, C; Wu, X; Hudson, J; Auffray, C; Nomura, N; Sikela, JM; Polymeropoulos, MH; James, MR; Lander, ES; Hudson, TJ; Myers, RM; Cox, DR; Weissenbach, J; Boguski, MS; Bentley, DR			A physical map of 30,000 human genes	SCIENCE			English	Article							EXPRESSED SEQUENCE TAGS; RADIATION HYBRID MAP; OPEN-ANGLE GLAUCOMA; HOLT-ORAM SYNDROME; HUMAN GENOME; POSITIONAL CLONING; MUTATIONS; HOMOLOGY; IDENTIFICATION; PROTEIN	A map of 30,181 human gene-based markers was assembled and integrated with the current genetic map by radiation hybrid mapping. The new gene map contains nearly twice as many genes as the previous release, includes most genes that encode proteins of known function, and is twofold to threefold more accurate than the previous version. A redesigned, more informative and functional World Wide Web site (www.ncbi.nlm.nih.gov/genemap) provides the mapping information and associated data and annotations. This resource constitutes an important infrastructure and tool for the study of complex genetic traits, the positional cloning of disease genes, the cross-referencing of mammalian genomes, and validated human transcribed sequences for Large-scale studies of gene expression.	Sanger Ctr, Cambridge CB10 1SA, England; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA; CNRS, URA 1922, F-91000 Evry, France; Stanford Univ, Sch Med, Stanford Human Genome Ctr, Dept Genet, Stanford, CA 94305 USA; European Bioinformat Inst, European Mol Biol Lab Outstn, Cambridge CB10 1SD, England; MIT, Whitehead Inst Biomed Res, Ctr Genome Res, Cambridge Ctr 9, Cambridge, MA 02142 USA; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Genethon, CNRS, URA 1922, F-91000 Evry, France; Univ Oxford, Nuffield Dept Clin Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; NIH, Lab Genet Dis Res, Natl Ctr Human Genome Res, Bethesda, MD 20892 USA; CHU Laval, Ctr Rech, Quebec City, PQ G1V 4G2, Canada; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Univ Calif Los Angeles, Sch Med, Dept Biomath, Los Angeles, CA 90095 USA; Res Genet, Huntsville, AL 35801 USA; CNRS, UPR 420, F-94801 Villejuif, France; Kazusa DNA Res Inst, Chiba 292, Japan; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; McGill Univ, Montreal Gen Hosp, Res Inst, Montreal, PQ H3G 1A4, Canada	Wellcome Trust Sanger Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Centre National de la Recherche Scientifique (CNRS); Stanford University; European Molecular Biology Laboratory (EMBL); Massachusetts Institute of Technology (MIT); Whitehead Institute; Rockefeller University; Centre National de la Recherche Scientifique (CNRS); University of Oxford; Wellcome Centre for Human Genetics; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Laval University; Cold Spring Harbor Laboratory; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Centre National de la Recherche Scientifique (CNRS); Kazusa DNA Research Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Massachusetts Institute of Technology (MIT); McGill University	Deloukas, P (corresponding author), Sanger Ctr, Hixton Hall, Cambridge CB10 1SA, England.		Beckmann, Jacques S/A-9772-2008; Lijnzaad, Philip/ABE-4205-2021; Deloukas, Panos/B-2922-2013; Suchard, Marc A/A-9703-2008; Rozen, Steven G./J-5939-2013	Beckmann, Jacques S/0000-0002-9741-1900; Lijnzaad, Philip/0000-0002-7535-583X; Deloukas, Panos/0000-0001-9251-070X; Rozen, Steven G./0000-0002-4288-0056; Slonim, Donna/0000-0003-3357-437X; Hunt, Sarah/0000-0002-8350-1235; Fizames, Cecile/0000-0002-0551-8250; Hudson, Thomas/0000-0002-1376-4849; Webber, Caleb/0000-0001-8063-7674	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADAMS MD, 1995, NATURE, V377, P3; Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Basson CT, 1997, NAT GENET, V15, P30, DOI 10.1038/ng0197-30; BOGUSKI MS, 1995, NAT GENET, V10, P369, DOI 10.1038/ng0895-369; Camper SA, 1997, MAMM GENOME, V8, P461, DOI 10.1007/s003359900476; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; DAHL C, 1998, COMPREHENSIVE TRANSC; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Eckman BA, 1998, BIOINFORMATICS, V14, P2, DOI 10.1093/bioinformatics/14.1.2; Everett LA, 1997, NAT GENET, V17, P411, DOI 10.1038/ng1297-411; EVERETT LA, 1997, NAT GENET, V17, P399; EVERETT LA, 1997, CELL, V90, P797; FIELDS C, 1994, NAT GENET, V7, P345, DOI 10.1038/ng0794-345; Gebbia M, 1997, NAT GENET, V17, P305, DOI 10.1038/ng1197-305; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOULGATTE R, 1995, GENOME RES, V5, P272, DOI 10.1101/gr.5.3.272; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; James MR, 1997, TRENDS GENET, V13, P171, DOI 10.1016/S0168-9525(97)01130-X; Kenmochi N, 1998, GENOME RES, V8, P509, DOI 10.1101/gr.8.5.509; Kishino T, 1997, NAT GENET, V15, P70, DOI 10.1038/ng0197-70; Li QY, 1997, NAT GENET, V15, P21; LYNCH ED, 1997, SCIENCE, V278, P115; Makalowski W, 1998, P NATL ACAD SCI USA, V95, P9407, DOI 10.1073/pnas.95.16.9407; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Nagamine K, 1997, NAT GENET, V17, P393, DOI 10.1038/ng1297-393; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Ortego J, 1997, FEBS LETT, V413, P349, DOI 10.1016/S0014-5793(97)00934-4; Ouellette BFF, 1997, GENOME RES, V7, P952, DOI 10.1101/gr.7.10.952; Ozelius LJ, 1997, NAT GENET, V17, P40, DOI 10.1038/ng0997-40; PICKERAL O, UNPUB; Pruitt KD, 1997, GENOME RES, V7, P1038, DOI 10.1101/gr.7.11.1038; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; Schuler GD, 1997, GENOME RES, V7, P541, DOI 10.1101/gr.7.5.541; Schuler GD, 1997, J MOL MED, V75, P694, DOI 10.1007/s001090050155; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Stewart EA, 1997, GENOME RES, V7, P422, DOI 10.1101/gr.7.5.422; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Venter JC, 1998, SCIENCE, V280, P1540, DOI 10.1126/science.280.5369.1540; WILLIAMSON AR, 1995, J NIH RES, V7, P63	45	565	584	3	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					744	746		10.1126/science.282.5389.744	http://dx.doi.org/10.1126/science.282.5389.744			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784132				2022-12-24	WOS:000076607500051
J	Stanley, SL				Stanley, SL			Malaria vaccines: are seven antigens better than one?	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM MALARIA		Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Stanley, SL (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.							BARUCH DI, 1995, CELL, V82, P77, DOI 10.1016/0092-8674(95)90054-3; Bull PC, 1998, NAT MED, V4, P358, DOI 10.1038/nm0398-358; Conway DJ, 1997, PARASITOL TODAY, V13, P26, DOI 10.1016/S0169-4758(96)10077-6; MILLER LH, 1994, SCIENCE, V264, P1878, DOI 10.1126/science.8009217; Ockenhouse CF, 1998, J INFECT DIS, V177, P1664, DOI 10.1086/515331; Stoute JA, 1997, NEW ENGL J MED, V336, P86, DOI 10.1056/NEJM199701093360202; Tine JA, 1996, INFECT IMMUN, V64, P3833, DOI 10.1128/IAI.64.9.3833-3844.1996	7	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	1998	352	9135					1163	1164		10.1016/S0140-6736(05)60525-9	http://dx.doi.org/10.1016/S0140-6736(05)60525-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777828				2022-12-24	WOS:000076415400003
J	Johnston, CM; Nesterova, TB; Formstone, EJ; Newall, AET; Duthie, SM; Sheardown, SA; Brockdorff, N				Johnston, CM; Nesterova, TB; Formstone, EJ; Newall, AET; Duthie, SM; Sheardown, SA; Brockdorff, N		X Inactivation Grp	Developmentally regulated Xist promoter switch mediates initiation of X inactivation	CELL			English	Article							CHROMOSOME INACTIVATION; GENE-EXPRESSION; MOUSE; RNA; METHYLATION; STABILIZATION; CONSERVATION; AUTOSOME; NUCLEUS; EMBRYOS	Developmental regulation of the mouse Xist gene at the onset of X chromosome inactivation is mediated by RNA stabilization. Here, we show that alternate promoter usage gives rise to distinct stable and unstable RNA isoforms. Unstable Xist transcript initiates at a novel upstream promoter, whereas stable Xist RNA is transcribed from the previously identified promoter and from a novel downstream promoter. Analysis of cells undergoing X inactivation indicates that a developmentally regulated promoter switch mediates stabilization and accumulation of Xist RNA on the inactive X chromosome.	Hammersmith Hosp, Imperial Coll Sch Med, MRC,Clin Sci Ctr, Inactivat Grp X, London W12 0NN, England; Russian Acad Sci, Inst Cytol & Genet, Siberian Dept, Novosibirsk 630090, Russia	Imperial College London; Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Brockdorff, N (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, MRC,Clin Sci Ctr, Inactivat Grp X, DuCane Rd, London W12 0NN, England.			Brockdorff, Neil/0000-0003-4838-2653; Nesterova, Tatyana/0000-0001-7740-4386				ARIEL M, 1995, NAT GENET, V9, P312, DOI 10.1038/ng0395-312; ATWATER JA, 1990, ANNU REV GENET, V24, P519; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; CIANETTI L, 1990, NUCLEIC ACIDS RES, V18, P4361, DOI 10.1093/nar/18.15.4361; Clemson CM, 1996, J CELL BIOL, V132, P259, DOI 10.1083/jcb.132.3.259; Clerc P, 1998, NAT GENET, V19, P249, DOI 10.1038/924; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; HENDRICH BD, 1993, HUM MOL GENET, V2, P663, DOI 10.1093/hmg/2.6.663; Hendrich BD, 1997, NUCLEIC ACIDS RES, V25, P2661, DOI 10.1093/nar/25.13.2661; Herzing LBK, 1997, NATURE, V386, P272, DOI 10.1038/386272a0; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; Lee JT, 1997, NATURE, V386, P275, DOI 10.1038/386275a0; Lee JT, 1996, CELL, V86, P83, DOI 10.1016/S0092-8674(00)80079-3; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Marahrens Y, 1998, CELL, V92, P657, DOI 10.1016/S0092-8674(00)81133-2; Marahrens Y, 1997, GENE DEV, V11, P156, DOI 10.1101/gad.11.2.156; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCMAHON A, 1983, J EMBRYOL EXP MORPH, V46, P53; MONK M, 1979, NATURE, V281, P311, DOI 10.1038/281311a0; NORRIS DP, 1994, CELL, V77, P41, DOI 10.1016/0092-8674(94)90233-X; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Panning B, 1997, CELL, V90, P907, DOI 10.1016/S0092-8674(00)80355-4; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; RASTAN S, 1983, J EMBRYOL EXP MORPH, V78, P1; RASTAN S, 1985, J EMBRYOL EXP MORPH, V90, P379; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; Sheardown SA, 1997, GENE, V203, P159, DOI 10.1016/S0378-1119(97)00507-6; Sheardown SA, 1997, CELL, V91, P99, DOI 10.1016/S0092-8674(01)80012-X; TAKAGI N, 1975, NATURE, V256, P640, DOI 10.1038/256640a0; ZUCCOTTI M, 1995, NAT GENET, V9, P316, DOI 10.1038/ng0395-316	38	69	69	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					809	817		10.1016/S0092-8674(00)81739-0	http://dx.doi.org/10.1016/S0092-8674(00)81739-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753327	Bronze			2022-12-24	WOS:000076021200013
J	Nikolic, M; Chou, MM; Lu, WG; Mayer, BJ; Tsai, LH				Nikolic, M; Chou, MM; Lu, WG; Mayer, BJ; Tsai, LH			The p35/Cdk5 kinase is a neuron-specific Rac effector that inhibits Pak1 activity	NATURE			English	Article							CYCLIN-DEPENDENT KINASE-5; REGULATORY SUBUNIT; ACTIN ORGANIZATION; FAMILY; RHO; EXPRESSION; ACTIVATOR; GTPASES; CDC42; BRAIN	Cyclin-dependent kinase 5 (Cdk5) and its neuron-specific regulator p35 (refs 1-4) are essential for neuronal migration and for the laminar configuration of the cerebral cortex(5-7). In addition, p35/ Cdk5 kinase concentrates at the leading edges of axonal growth cones and regulates neurite outgrowth in cortical neurons in cultures. The Rho family of small GTPases is implicated in a range of cellular functions, including cell migration and neurite outgrowth(9-13). Here we show that the p35/Cdk5 kinase co-localizes with Raf in neuronal growth cones, Furthermore, p35 associates;: directly with Rac in a GTP-dependent manner. Another Rac effector, Pak1 kinase(14,15), is also present in the Rac-p35/Cdk5 complexes and co-localizes with p35/Cdk5 and Rac at neuronal peripheries. The active p35/Cdk5 kinase causes Pak1 hyperphosphorylation in a Rac-dependent manner, which results in downregulation of Pak1 kinase activity. Because the Rho family of GTPases and the Pak kinases are implicated in actin polymerization(16-18), the modification of Pak1, imposed by the p35/Cdk5 kinase, is likely to have an impact on the dynamics of the reorganization of the actin cytoskeleton in neurons, thus promoting neuronal migration and neurite outgrowth.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Harvard Medical School	Tsai, LH (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, 200 Longwood Ave, Boston, MA 02115 USA.	lhtsai@warren.med.harvard.edu	Chou, Mitch Ming Chi/AAP-7037-2021	Chou, Mitch Ming Chi/0000-0002-6786-6867				Chae T, 1997, NEURON, V18, P29, DOI 10.1016/S0896-6273(01)80044-1; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Delalle I, 1997, J NEUROCYTOL, V26, P283, DOI 10.1023/A:1018500617374; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Dynlacht BD, 1997, MOL CELL BIOL, V17, P3867, DOI 10.1128/MCB.17.7.3867; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kwon YT, 1998, J COMP NEUROL, V395, P510, DOI 10.1002/(SICI)1096-9861(19980615)395:4<510::AID-CNE7>3.0.CO;2-4; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Luo LQ, 1996, NATURE, V379, P837, DOI 10.1038/379837a0; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohshima T, 1996, P NATL ACAD SCI USA, V93, P11173, DOI 10.1073/pnas.93.20.11173; PATRICK GN, IN PRESS J BIOL CHEM; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; Tomizawa K, 1996, NEUROSCIENCE, V74, P519, DOI 10.1016/0306-4522(96)00136-4; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Zipkin ID, 1997, CELL, V90, P883, DOI 10.1016/S0092-8674(00)80353-0	30	330	346	0	8	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	SEP 10	1998	395	6698					194	198		10.1038/26034	http://dx.doi.org/10.1038/26034			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744280				2022-12-24	WOS:000075829900047
J	de Bono, M; Bargmann, CI				de Bono, M; Bargmann, CI			Natural variation in a neuropeptide Y receptor homolog modifies social behavior and food response in C-elegans	CELL			English	Article							PROTEIN-COUPLED RECEPTORS; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; MICE LACKING; AMINO-ACID; GENE; IDENTIFICATION; EVOLUTION; NEMATODE; MULTIPLE	Natural isolates of C. elegans exhibit either solitary or social feeding behavior. Solitary foragers move slowly on a bacterial lawn and disperse across it,while social foragers move rapidly on bacteria and aggregate together. A loss-of-function mutation in the npr-1 gene, which encodes a predicted G protein-coupled receptor similar to neuropeptide Y receptors, causes a solitary strain to take on social behavior. Two isoforms of NPR-1 that differ at a single residue occur in the wild. One isoform, NPR-1 215F, is found exclusively in social strains, while the other isoform, NPR-1 215V, is found exclusively in solitary strains. An NPR-1 215V transgene can induce solitary feeding behavior in a wild social strain. Thus, isoforms of a putative neuropeptide receptor generate natural variation in C. elegans feeding behavior.	Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, Howard Hughes Med Inst, Program Neurosci & Genet, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	de Bono, M (corresponding author), Univ Calif San Francisco, Dept Anat, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA.			de Bono, Mario/0000-0001-8347-0443; Bargmann, Cornelia/0000-0002-8484-0618				ANDREW PA, 1976, NEMATOLOGICA, V22, P451, DOI 10.1163/187529276X00454; Baraban SC, 1997, J NEUROSCI, V17, P8927, DOI 10.1523/jneurosci.17-23-08927.1997; Bargmann CI, 1998, ANNU REV NEUROSCI, V21, P279, DOI 10.1146/annurev.neuro.21.1.279; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; BLUML K, 1994, J BIOL CHEM, V269, P402; BLUML K, 1994, J BIOL CHEM, V269, P11537; BRENNER S, 1974, GENETICS, V77, P71; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; BROWNLEE DJA, 1994, PARASITOLOGY, V108, P587, DOI 10.1017/S0031182000077453; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; Burstein ES, 1996, J BIOL CHEM, V271, P2882, DOI 10.1074/jbc.271.6.2882; CLARK SG, 1994, GENETICS, V137, P987; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; CROLL NA, 1970, BEHAV NEMATODES, P18; DAINTY RH, 1985, J APPL BACTERIOL, V59, P303, DOI 10.1111/j.1365-2672.1985.tb03324.x; EGILMEZ NK, 1995, J MOL EVOL, V40, P372, DOI 10.1007/BF00164023; Finley KD, 1997, P NATL ACAD SCI USA, V94, P913, DOI 10.1073/pnas.94.3.913; GREWAL P S, 1992, Fundamental and Applied Nematology, V15, P159; Gu T, 1998, MOL CELL BIOL, V18, P4556, DOI 10.1128/MCB.18.8.4556; Gudermann T, 1997, ANNU REV NEUROSCI, V20, P399, DOI 10.1146/annurev.neuro.20.1.399; HEILIG M, 1995, CRIT REV NEUROBIOL, V9, P115; Hodgkin J, 1997, GENETICS, V146, P149; HOLLIS JP, 1962, NATURE, V193, P798, DOI 10.1038/193798b0; HOLLIS JP, 1960, PHYTOPATHOLOGY, V50, P639; Karayiorgou M, 1997, P NATL ACAD SCI USA, V94, P4572, DOI 10.1073/pnas.94.9.4572; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; LORENZ KZ, 1950, SYM SOC EXP BIOL, V4, P221; Maule AG, 1996, INT J PARASITOL, V26, P927, DOI 10.1016/S0020-7519(96)80066-X; MCBRIDE JM, 1966, NATURE, V211, P545, DOI 10.1038/211545b0; McGue M, 1998, ANNU REV NEUROSCI, V21, P1, DOI 10.1146/annurev.neuro.21.1.1; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Melo JA, 1996, NAT GENET, V13, P147, DOI 10.1038/ng0696-147; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Monaghan AP, 1997, NATURE, V390, P515, DOI 10.1038/37364; Osborne KA, 1997, SCIENCE, V277, P834, DOI 10.1126/science.277.5327.834; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; ROSOFF ML, 1993, PEPTIDES, V14, P331, DOI 10.1016/0196-9781(93)90049-M; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Sawyer LA, 1997, SCIENCE, V278, P2117, DOI 10.1126/science.278.5346.2117; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Sokolowski MB, 1997, P NATL ACAD SCI USA, V94, P7373, DOI 10.1073/pnas.94.14.7373; SOKOLOWSKI MB, 1980, BEHAV GENET, V10, P291, DOI 10.1007/BF01067774; Soll DR, 1995, INT REV CYTOL, V163, P43; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; Sulston J, 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1993, GENETICS, V134, P1105; WAHLESTEDT C, 1993, ANNU REV PHARMACOL, V33, P309, DOI 10.1146/annurev.pa.33.040193.001521; Wehner JM, 1997, NAT GENET, V17, P331, DOI 10.1038/ng1197-331; WILSON EO, SOCIOBIOLOGY; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; ZECHMAN JM, 1985, CAN J MICROBIOL, V31, P232, DOI 10.1139/m85-045	52	558	572	2	41	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					679	689		10.1016/S0092-8674(00)81609-8	http://dx.doi.org/10.1016/S0092-8674(00)81609-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741632	Bronze			2022-12-24	WOS:000075851900015
J	Hirose, Y; Manley, JL				Hirose, Y; Manley, JL			RNA polymerase II is an essential mRNA polyadenylation factor	NATURE			English	Article							C-TERMINAL DOMAIN; PRE-MESSENGER-RNAS; POLY(A) POLYMERASE; SPLICING FACTORS; 3'-END CLEAVAGE; SR PROTEINS; IN-VITRO; PHOSPHORYLATION; TRANSCRIPTION; SUBUNIT	Production of messenger RNA in eukaryotic cells is a complex, multistep process. mRNA polyadenylation, or 3' processing, requires several protein factors, including cleavage/polyadenylation-specificity factor (CPSF), cleavage-stimulation factor, two cleavage factors and poly(A) polymerase (reviewed in refs 1, 2). These proteins seem to be unnecessary for other steps in mRNA synthesis such as transcription and splicing, and factors required for these processes were not considered to be essential for polyadenylation. Nonetheless, these reactions may be linked so that they are effectively coordinated in vivo(3-9). For example, the CTD carboxy-terminal domain of the largest subunit of RNA polymerase II (RNAP II) is required for efficient splicing and polyadenylation in vivo(8), and CPSF is brought to a promoter by the transcription factor TFIID and transferred to RNAP II at the time of transcription initiation(9). These findings suggest that polyadenylation factors can be recruited to an RNA 3'-processing signal by RNAP II, where they dissociate from the polymerase and initiate polyadenylation. Here we present results that extend this model by showing that RNAP II is actually required, in the absence of transcription, for 3' processing in vitro.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA	Columbia University	Manley, JL (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.			Manley, James/0000-0002-8341-1459				Besse Sylvie, 1995, Gene Expression, V4, P143; CANTONEL JC, 1997, NATURE, V389, P399; CHRISTOFORI G, 1988, CELL, V54, P875, DOI 10.1016/S0092-8674(88)91263-9; Colgan DF, 1996, NATURE, V384, P282, DOI 10.1038/384282a0; Colgan DF, 1998, EMBO J, V17, P1053, DOI 10.1093/emboj/17.4.1053; Colgan DF, 1997, GENE DEV, V11, P2755, DOI 10.1101/gad.11.21.2755; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Flaherty SM, 1997, P NATL ACAD SCI USA, V94, P11893, DOI 10.1073/pnas.94.22.11893; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; Harlow E, 1988, ANTIBODIES LAB MANUA; Hirose Y, 1997, J BIOL CHEM, V272, P29636, DOI 10.1074/jbc.272.47.29636; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; Lutz CS, 1996, GENE DEV, V10, P325, DOI 10.1101/gad.10.3.325; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MATTHEWS HR, 1995, PHARMACOL THERAPEUT, V67, P323, DOI 10.1016/0163-7258(95)00020-8; McCracken S, 1997, NATURE, V385, P357, DOI 10.1038/385357a0; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; PETERSON SR, 1992, GENE DEV, V6, P426, DOI 10.1101/gad.6.3.426; REINBERG D, 1987, J BIOL CHEM, V262, P3310; TAKAGAKI Y, 1990, GENE DEV, V4, P2112, DOI 10.1101/gad.4.12a.2112; TAKAGAKI Y, 1988, CELL, V52, P731, DOI 10.1016/0092-8674(88)90411-4; TAKAGAKI Y, 1989, GENE DEV, V3, P1711, DOI 10.1101/gad.3.11.1711; Wahle E, 1996, TRENDS BIOCHEM SCI, V21, P247, DOI 10.1016/S0968-0004(96)10030-X; Yuryev A, 1996, P NATL ACAD SCI USA, V93, P6975, DOI 10.1073/pnas.93.14.6975; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837	28	295	299	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					93	96		10.1038/25786	http://dx.doi.org/10.1038/25786			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738505				2022-12-24	WOS:000075722200054
J	McGregor, AM				McGregor, AM			Has the target autoantigen for Graves' ophthalmopathy been found?	LANCET			English	Editorial Material							THYROID-ASSOCIATED OPHTHALMOPATHY; AUTOANTIBODIES; TISSUE; MUSCLE		Kings Coll London, Sch Med & Dent, Dept Med, London SE5 9PJ, England	University of London; King's College London	McGregor, AM (corresponding author), Kings Coll London, Sch Med & Dent, Dept Med, London SE5 9PJ, England.							Bahn RS, 1998, J CLIN ENDOCR METAB, V83, P998, DOI 10.1210/jc.83.3.998; Bartalena L, 1998, NEW ENGL J MED, V338, P73, DOI 10.1056/NEJM199801083380201; BURCH HB, 1993, ENDOCR REV, V14, P747, DOI 10.1210/er.14.6.747; Crisp MS, 1997, J CLIN ENDOCR METAB, V82, P2003; ELSHEIKH M, 1994, CURRENT THERAPY ENDO, P90; Gunji K, 1998, THYROID, V8, P553, DOI 10.1089/thy.1998.8.553; Heufelder AE, 1997, BAILLIERE CLIN ENDOC, V11, P499, DOI 10.1016/S0950-351X(97)80723-9; Kubota S, 1998, THYROID, V8, P175, DOI 10.1089/thy.1998.8.175; Kubota S, 1998, J CLIN ENDOCR METAB, V83, P443, DOI 10.1210/jc.83.2.443; Perros P, 1998, THYROID, V8, P423, DOI 10.1089/thy.1998.8.423; PRUMMEL MF, 1993, JAMA-J AM MED ASSOC, V269, P479, DOI 10.1001/jama.269.4.479; Sorisky A, 1996, J CLIN ENDOCR METAB, V81, P3428, DOI 10.1210/jc.81.9.3428; WALL JR, 1995, J CLIN ENDOCR METAB, V80, P1226, DOI 10.1210/jc.80.4.1226; ZHANG ZG, 1992, CLIN IMMUNOL IMMUNOP, V62, P183, DOI 10.1016/0090-1229(92)90071-U	14	26	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	1998	352	9128					595	596		10.1016/S0140-6736(05)79573-8	http://dx.doi.org/10.1016/S0140-6736(05)79573-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746018				2022-12-24	WOS:000075567400006
J	Pouria, S; de Andrade, A; Barbosa, J; Cavalcanti, RL; Barreto, VTS; Ward, CJ; Preiser, W; Poon, GK; Neild, GH; Codd, GA				Pouria, S; de Andrade, A; Barbosa, J; Cavalcanti, RL; Barreto, VTS; Ward, CJ; Preiser, W; Poon, GK; Neild, GH; Codd, GA			Fatal microcystin intoxication in haemodialysis unit in Caruaru, Brazil	LANCET			English	Article							CYANOBACTERIAL TOXINS	Background After a drought in February, 1996, all 126 patients in a haemodialysis unit in Caruaru, north-east Brazil, developed signs and symptoms of acute neurotoxicity and subacute hepatotoxicity following the use of water from a lake with massive growth of cyanobacteria (blue-green algae). 60 patients died. Methods Besides recording clinical details and outcome at follow-up, we arranged laboratory, radiological, and histological investigations on the patients and toxicological studies of serum and haemodialysis water filters. Findings The acute presentation was with malaise, myalgia and weakness, nausea and vomiting, and tender hepatomegaly, with a range of neurological symptoms from tinnitus, vertigo, headaches, and deafness to blindness and convulsions. Liver injury ranged from abnormal liver-function test results to rapidly progressive and fatal hepatic failure, Biochemical investigations revealed gross hyperbilirubinaemia, abnormal liver enzyme activities, and hypertriglyceridaemia, but there was no evidence of haemolysis or microangiopathy. Histology revealed a novel acute toxic hepatitis with diffuse panlobular hepatocyte necrosis, neutrophil infiltration, canalicular cholestasis, and regenerative multinucleate hepatocytes. Samples of serum, dialysis filters, and water-treatment columns contained microcystins, the highly toxic low-molecular-weight hepatotoxins produced by cyanobacteria. Interpretation Cyanobacteria present water-borne hazards to health via drinking water and recreational water. Haemodialysis presents an additional high-risk exposure route: when they enter directly into the circulation, microcystins can lead to fatal clinical syndromes ranging from acute neurotoxic illness to subacute liver failure.	UCL, Sch Med, Inst Urol & Nephrol, London W1N 8AA, England; Univ Fed Pernambuco, Hosp Clin, Recife, PE, Brazil; Hosp Barao Lucena, Recife, PE, Brazil; Univ Dundee, Dept Biol Sci, Dundee DD1 4HN, Scotland; UCL, Sch Med, Dept Virol, London W1N 8AA, England; Adv Bioanalyt Serv Inc, Ithaca, NY USA	University of London; University College London; UCL Medical School; Universidade Federal de Pernambuco; University of Dundee; University of London; University College London; UCL Medical School	Neild, GH (corresponding author), Middlesex Hosp, Inst Urol & Nephrol, London W1N 8AA, England.	g.neild@ucl.ac.uk	Neild, Guy/K-2513-2013; Preiser, Wolfgang/J-4875-2016	Preiser, Wolfgang/0000-0002-0254-7910; ward, clive/0000-0001-7093-5109				AZEVEDO SMF, 1996, P 4 S BRAZ SOC TOX, P83; BARRETO V, 1996, HEPATOLOGY S, V24, P2; CARMICHAEL WW, 1985, CRIT REV ENV CONTR, V15, P275, DOI 10.1080/10643388509381734; Carmichael WW, 1996, HARMFUL ALGAE NEWS, V15, P11; CARMICHAEL WW, 1996, P 4 S BRAZ SOC TOX, P83; Codd GA, 1995, WATER SCI TECHNOL, V32, P149, DOI 10.1016/0273-1223(95)00692-3; CODD GA, 1996, PROGR RES 4 S SOC BR, P87; Codd GA., 1994, REV MED MICROBIOL, V5, P256, DOI [DOI 10.1097/00013542-199410000-00005, 10.1097/00013542-199410000-00005]; ELDER GH, 1993, LANCET, V341, P1519, DOI 10.1016/0140-6736(93)90643-U; FALCONER IR, 1983, MED J AUSTRALIA, V1, P511, DOI 10.5694/j.1326-5377.1983.tb136192.x; JACKSON ARB, 1984, VET PATHOL, V21, P102, DOI 10.1177/030098588402100117; Jochimsen EM, 1998, NEW ENGL J MED, V338, P873, DOI 10.1056/NEJM199803263381304; Lawton Linda A., 1995, Natural Toxins, V3, P50, DOI 10.1002/nt.2620030110; POON GK, 1993, J CHROMATOGR, V628, P215, DOI 10.1016/0021-9673(93)80005-S; Sivonen Kaarina, 1996, Phycologia, V35, P12, DOI 10.2216/i0031-8884-35-6S-12.1; TURNER PC, 1990, BRIT MED J, V300, P1440, DOI 10.1136/bmj.300.6737.1440; Ueno Y, 1996, CARCINOGENESIS, V17, P1317, DOI 10.1093/carcin/17.6.1317; Ward CJ, 1997, FEMS MICROBIOL LETT, V153, P465, DOI 10.1016/S0378-1097(97)00290-5; *WHO, 1997, WORK M CHEM SUBST DR; YU SZ, 1997, PRIMARY LIVER CANC, P30	20	572	641	6	130	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 4	1998	352	9121					21	26		10.1016/S0140-6736(97)12285-1	http://dx.doi.org/10.1016/S0140-6736(97)12285-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZY322	9800741				2022-12-24	WOS:000074608600012
J	Haller, H; Hempel, A; Homuth, V; Mandelkow, A; Busjahn, A; Maasch, C; Drab, M; Lindschau, C; Jupner, A; Vetter, K; Dudenhausen, J; Luft, FC				Haller, H; Hempel, A; Homuth, V; Mandelkow, A; Busjahn, A; Maasch, C; Drab, M; Lindschau, C; Jupner, A; Vetter, K; Dudenhausen, J; Luft, FC			Endothelial-cell permeability and protein kinase C in pre-eclampsia	LANCET			English	Article							ALBUMIN PERMEABILITY; BIOCHEMICAL-EVIDENCE; PREECLAMPSIA; FIBRONECTIN; PREGNANCY; HYPERTENSION; DYSFUNCTION; EXPRESSION; ACTIVATION	Background Oedema and vascular leakage play a part in the pathogenesis of pre-eclampsia. We tested the hypothesis that serum from pre-eclamptic increases endothelial-cell permeability and possible signal-transduction pathways. Methods We studied eight patients with pre-eclampsia, eight normotensive pregnant women, eight non-pregnant women, five pregnant patients with pre-existing hypertension, and four hypertensive non-pregnant women, Cultured human umbilical-vein endothelial-cell monolayers were used and permeability was measured by albumin flux, The part played by protein kinase C (PKC) signalling was examined by down-regulation with phorbol ester and with the inhibitors Goe 6976 and staurosporine, PKC isoforms were assessed by western blot and confocal microscopy, Antisense oligodesoxynucleotides (ODN) were used to test for specific PKC isoforms. Findings Serum from pre-eclamptic women increased endothelial permeability significantly (by 100%, p < 0.01). The change in permeability decreased rapidly after delivery, Serum from normotensive pregnant women and non-pregnant women had no effect, Permeability was not influenced by serum from pateints with essential hypertension or pregnant patients with pre-existing hypertension. Serum from pre-eclamptic patients induced a translocation of PKC isoforms alpha and epsilon within the cells, Goe 6976 and staurosporine (10(-8) mol/L) inhibited the increase in permeability induced by serum from preeclamptic patients. Down-regulation of PKC alpha and, to a lesser extent, PKC epsilon by antisense ODN also inhibited the pre-eclampsia-induced permeability increase. Interpretation Serum from pre-eclamptic patients contains a factor or factors that increase endothelial-cell permeability. The effect of pre-eclamptic serum may be mediated by PKC alpha and epsilon.	Franz Volhard Clin, D-13122 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Klinikum Buch, Berlin, Germany; Krankenhaus Neukolln, Dept Obstet & Gynaecol, Berlin, Germany; Humboldt Univ, Virchow Klinikum Charite, Dept Obstet, D-1086 Berlin, Germany	Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haller, H (corresponding author), Franz Volhard Clin, Wiltberg Str 50, D-13122 Berlin, Germany.		Lindschau, Carsten/AAE-6721-2020; Drab, Marek/J-5196-2013; Busjahn, Andreas/F-9936-2011; Busjahn, Andreas/P-5023-2019; Lindschau, Carsten/G-1798-2011; Drab, Marek/AAQ-1892-2020	Drab, Marek/0000-0002-2771-1692; Busjahn, Andreas/0000-0001-9650-6919; Lindschau, Carsten/0000-0003-1960-099X; Luft, Friedrich/0000-0002-8635-1199				BROWN MA, 1984, CLIN OBSTET GYNAECOL, V8, P287; DAVISON JM, 1997, KIDNEY INT S, V59, pS90; DEAN NM, 1994, J BIOL CHEM, V269, P16416; DEJAGER CA, 1995, J LAB CLIN MED, V125, P522; EDEN TW, 1922, J OBSTET GYN BR COMM, V29, P386; FRIEDMAN SA, 1994, AM J OBSTET GYNECOL, V170, P838, DOI 10.1016/S0002-9378(94)70295-0; FRIEDMAN SA, 1991, CLIN PERINATOL, V18, P661, DOI 10.1016/S0095-5108(18)30490-1; Haller H, 1997, HYPERTENSION, V29, P291, DOI 10.1161/01.HYP.29.1.291; HALLER H, 1994, ANN NY ACAD SCI, V733, P313, DOI 10.1111/j.1749-6632.1994.tb17281.x; Haller H, 1996, J AM SOC NEPHROL, V7, P40; HEMPEL A, IN PRESS CIRC RES; LINDHEIMER MD, 1989, ANNU REV MED, V40, P233; LYNCH JJ, 1990, J CLIN INVEST, V85, P1991, DOI 10.1172/JCI114663; NORTHOVER AM, 1994, INFLAMMATION, V18, P481, DOI 10.1007/BF01560695; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; PERRY KG, 1992, CLIN OBSTET GYNECOL, V35, P338; ROBERTS JM, 1991, AM J HYPERTENS, V4, P700, DOI 10.1093/ajh/4.8.700; ROBERTS JM, 1991, SEMIN PERINATOL, V15, P86; ROBERTS JM, 1993, LANCET, V341, P1447, DOI 10.1016/0140-6736(93)90889-O; ROBERTS JM, 1992, AM J REPROD IMMUNOL, V27, P101, DOI 10.1111/j.1600-0897.1992.tb00735.x; SCHRIER RW, 1991, OBSTET GYNECOL, V77, P632; STASEK JE, 1992, J CELL PHYSIOL, V153, P62, DOI 10.1002/jcp.1041530110; TAYLOR RN, 1991, AM J OBSTET GYNECOL, V165, P895, DOI 10.1016/0002-9378(91)90435-T	23	56	58	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					945	949						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734941				2022-12-24	WOS:000072770900012
J	Johnson, GJ				Johnson, GJ			Limitations of epidemiology in understanding pathogenesis of cataracts	LANCET			English	Editorial Material									UCL, Inst Ophthalmol, London EC1V 9EL, England	University of London; University College London	Johnson, GJ (corresponding author), UCL, Inst Ophthalmol, London EC1V 9EL, England.							Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Harding J., 1991, CATARACT BIOCH EPIDE; Jacques PF, 1997, AM J CLIN NUTR, V66, P911, DOI 10.1093/ajcn/66.4.911; Rauf A., 1996, Investigative Ophthalmology and Visual Science, V37, pS237; THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115	5	5	5	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 28	1998	351	9107					925	926						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734934				2022-12-24	WOS:000072770900005
J	Berthet, FX; Lagranderie, M; Gounon, P; Laurent-Winter, C; Ensergueix, D; Chavarot, P; Thouron, F; Maranghi, E; Pelicic, V; Portnoi, D; Marchal, G; Gicquel, B				Berthet, FX; Lagranderie, M; Gounon, P; Laurent-Winter, C; Ensergueix, D; Chavarot, P; Thouron, F; Maranghi, E; Pelicic, V; Portnoi, D; Marchal, G; Gicquel, B			Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene	SCIENCE			English	Article							CULTURED MACROPHAGES; EARLY ENDOSOMES; PHAGOSOME; MATURATION; PROTEIN; FUSION; AVIUM	The virulence of the mycobacteria that cause tuberculosis depends on their ability to multiply in mammalian hosts. Disruption of the bacterial erp gene, which encodes the exported repetitive protein, impaired multiplication of M. tuberculosis and M, bovis Bacille Calmette-Guerin in cultured macrophages and mice. Reintroduction of erp into the mutants restored their ability to multiply. These results indicate that erp contributes to the virulence of M. tuberculosis.	Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; Inst Pasteur, Lab BCG, F-75724 Paris, France; Inst Pasteur, Stn Cent Microscopie Elect, F-75724 Paris 15, France; Inst Pasteur, Lab Electrophorese Bidimens, F-75724 Paris 15, France; Inst Pasteur, Unite Physiopathol Infect, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Gicquel, B (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 25 Rue Dr Roux, F-75724 Paris 15, France.	bgicquel@pasteur.fr	Pelicic, Vladimir/N-3755-2017; Pelicic, Vladimir/ABD-3102-2021	Pelicic, Vladimir/0000-0002-9456-4995; Pelicic, Vladimir/0000-0002-9456-4995	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035207] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 35207] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARMSTRONG JA, 1975, J EXP MED, V142, P1, DOI 10.1084/jem.142.1.1; ARMSTRONG JA, 1971, J EXP MED, V134, P713, DOI 10.1084/jem.134.3.713; BERTHET FX, 1995, MICROBIOL-UK, V141, P2123, DOI 10.1099/13500872-141-9-2123; BIGI F, 1995, INFECT IMMUN, V63, P2581, DOI 10.1128/IAI.63.7.2581-2586.1995; CHERAYIL BJ, 1988, J IMMUNOL, V141, P4370; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; Clemens DL, 1996, TRENDS MICROBIOL, V4, P113, DOI 10.1016/0966-842X(96)81528-9; Clemens DL, 1996, J EXP MED, V184, P1349, DOI 10.1084/jem.184.4.1349; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DECHASTELLIER C, 1995, EUR J CELL BIOL, V68, P167; DUBOS RJ, 1956, AM REV TUBERC PULM, V74, P699; DUBOS RJ, 1956, AM REV TUBERC PULM, V74, P655; Lagranderie MRR, 1996, INFECT IMMUN, V64, P1; LIM EM, 1995, J BACTERIOL, V177, P59, DOI 10.1128/jb.177.1.59-65.1995; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; PELICIC V, 1996, FEMS MICROBIOL LETT, V144, P61; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P667; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P683; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; SturgillKoszycki S, 1996, EMBO J, V15, P6960, DOI 10.1002/j.1460-2075.1996.tb01088.x; Via LE, 1997, J BIOL CHEM, V272, P13326, DOI 10.1074/jbc.272.20.13326; *WHO, 1997, GLOB TUB CONTR	22	170	193	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					759	762		10.1126/science.282.5389.759	http://dx.doi.org/10.1126/science.282.5389.759			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784137				2022-12-24	WOS:000076607500056
J	Reid, I				Reid, I			Patients' preference for male or female breast surgeons: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article							PHYSICIAN; SEX		Univ Glasgow, Glasgow G42 9TY, Lanark, Scotland; Victoria Infirm, Glasgow G42 9TY, Lanark, Scotland	University of Glasgow	Reid, I (corresponding author), Univ Glasgow, Glasgow G42 9TY, Lanark, Scotland.							FENNEMA K, 1990, J FAM PRACTICE, V30, P441; HAAR E, 1975, MED CARE, V13, P782, DOI 10.1097/00005650-197509000-00008; Kerssens JJ, 1997, SOC SCI MED, V44, P1531, DOI 10.1016/S0277-9536(96)00272-9; WEYRAUCH KF, 1990, J FAM PRACTICE, V30, P559	4	30	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 17	1998	317	7165					1051	1051						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774289				2022-12-24	WOS:000076577200025
J	Best, PJ; Tajik, AJ; Gibbons, RJ; Pellikka, PA				Best, PJ; Tajik, AJ; Gibbons, RJ; Pellikka, PA			The safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms	ANNALS OF INTERNAL MEDICINE			English	Article							CORONARY-ARTERY DISEASE; CARDIAC RISK; VASCULAR-SURGERY; ECHOCARDIOGRAPHY; DOBUTAMINE; COMPLICATIONS	Background: Exercise stress testing in patients with abdominal aortic aneurysms may cause enlargement or rupture of aneurysms. Objective: To evaluate the safety of treadmill exercise stress testing in patients with abdominal aortic aneurysms. Design: Retrospective descriptive study. Setting: Tertiary care center. Patients: 262 patients who had abdominal aortic aneurysms more than 4 cm in diameter and underwent treadmill exercise stress testing. Measurements: Pain after stress testing, rupture of the aneurysm or death, aneurysm size, and exercise stress test results. Results: The average aneurysm diameter was 5.5 +/- 1.1 cm. One patient with a 6.1-cm aneurysm was found to have a contained rupture 12 hours after stress testing. The event rate for aneurysm rupture was 0.4% (95% CI, 0.0% to 2.1%). No deaths or other negative outcomes were documented. Conclusion: Despite theoretical concerns, exercise stress testing of patients with abdominal aortic aneurysms seems to be safe and is associated with a low incidence of acute adverse events.	Mayo Clin & Mayo Fdn, Div Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA	Mayo Clinic	Pellikka, PA (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, W16A,200 1st St SW, Rochester, MN 55905 USA.		Pellikka, Patricia A/N-5387-2014	Pellikka, Patricia A/0000-0001-6800-3521				BELESLIN BD, 1994, CIRCULATION, V90, P1168, DOI 10.1161/01.CIR.90.3.1168; BELLER GA, 1989, J AM COLL CARDIOL, V14, P1642, DOI 10.1016/0735-1097(89)90009-0; Daida H, 1996, MAYO CLIN PROC, V71, P445, DOI 10.4065/71.5.445; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; ELMORE JR, 1993, MAYO CLIN PROC, V68, P637, DOI 10.1016/S0025-6196(12)60598-9; FELDMAN AY, 1994, J CARDIOVASC SURG, V35, P541; Fleisher L A, 1993, J Cardiothorac Vasc Anesth, V7, P650, DOI 10.1016/1053-0770(93)90047-O; FLEMING RM, 1995, ANGIOLOGY, V46, P547, DOI 10.1177/000331979504600701; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; LEPPO J, 1987, J AM COLL CARDIOL, V9, P269, DOI 10.1016/S0735-1097(87)80374-1; MCPHAIL N, 1988, J VASC SURG, V7, P60, DOI 10.1067/mva.1988.avs0070060; Pellikka PA, 1996, AM J CARDIOL, V77, P413, DOI 10.1016/S0002-9149(97)89374-5; POLDERMANS D, 1993, CIRCULATION, V87, P1506, DOI 10.1161/01.CIR.87.5.1506; Pollock ML, 1990, EXERCISE HLTH DIS EV; PREVITALI M, 1993, AM J CARDIOL, V72, P865, DOI 10.1016/0002-9149(93)91097-2; Roger VL, 1997, CIRCULATION, V95, P405; ROGER VL, 1989, J AM COLL CARDIOL, V14, P1245, DOI 10.1016/0735-1097(89)90423-3	20	15	15	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					628	631		10.7326/0003-4819-129-8-199810150-00008	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786810				2022-12-24	WOS:000076431800005
J	Gronbaek, M; Becker, U; Johansen, D; Tonnesen, H; Jensen, G; Sorensen, TIA				Gronbaek, M; Becker, U; Johansen, D; Tonnesen, H; Jensen, G; Sorensen, TIA			Population based cohort study of the association between alcohol intake and cancer of the upper digestive tract	BRITISH MEDICAL JOURNAL			English	Article							UPPER AERODIGESTIVE TRACT; ESOPHAGEAL CANCER; RISK-FACTORS; ORAL-CANCER; CONSUMPTION; MORTALITY; DRINKING; BEVERAGE; ETIOLOGY; SMOKING	Objective: To examine the relation between different types of alcoholic drinks and upper digestive tract cancers (oropharyngeal and oesophageal). Design: Population based study with baseline assessment or intake or beer, wine, and spirits, smoking habits, educational level, and 2-19 years' follow up on risk of upper digestive tract cancer. Setting: Denmark. Subjects: 15 117 men and 13 063 women aged 20 to 98 years. Main outcome measure: Number and time of identification of incident upper digestibe tract cancer during follow up. Results: During a mean follow up of 13.5 years, 156 subjects developed upper digestive tract cancer. Compared with non-drinkers (drinkers of <1 drink/week), subjects who drank 7-21 beers or spirits a week but no wine were at a risk of 3.0 (95% confidence interval 1.5 to 6.1), whereas those who had the same total alcohol intake but with wine as greater than or equal to 30% Of their intake had a risk of 0.5 (0.2 to 1.4). Drinkers of >21 beers and spirits but no wine had a relative risk of 5.2 (2.7 to 10.2) compared with non-drinkers, whereas those who drank the same amount, but included wine in their alcohol intake, had a relative risk of 1.7 (0.6 to 4.4). Conclusion: A moderate intake of wine probably does not increase the risk of upper digestive tract cancer, whereas a moderate intake of beer or spirits increases the risk considerably.	Kommunehosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, DK-1399 Copenhagen K, Denmark; Hvidovre Univ Hosp, Dept Med Gastroenterol, Alcohol Unit, DK-2650 Hvidovre, Denmark; Hvidovre Univ Hosp, Dept Surg Gastroenterol, DK-2650 Hvidovre, Denmark; Bispebjerg Univ Hosp, Epidemiol Res Unit, Copenhagen City Heart City, DK-2400 Copenhagen NV, Denmark	Aarhus University; University of Copenhagen; University of Copenhagen; University of Copenhagen; Bispebjerg Hospital	Gronbaek, M (corresponding author), Kommunehosp, Inst Prevent Med, Danish Epidemiol Sci Ctr, Copenhagen Ctr Prospect Populat Studies, DK-1399 Copenhagen K, Denmark.		Becker, Ulrik/D-2657-2012	Becker, Ulrik/0000-0002-1678-7771; Tonnesen, Hanne/0000-0002-7161-3416; Gronbaek, Morten Klocker/0000-0002-8473-6474				Andersen P. K., 2012, STAT MODELS BASED CO; Appleyard M., 1989, SCAND J SOC MED, V41, P1; BLOT WJ, 1988, CANCER RES, V48, P3282; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; DECARLI A, 1987, Nutrition and Cancer, V10, P29; GAO YT, 1994, INT J CANCER, V58, P192, DOI 10.1002/ijc.2910580208; Gronbaek M, 1996, EUR J CLIN NUTR, V50, P487; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; HEIN HO, 1993, LANCET, V341, P392, DOI 10.1016/0140-6736(93)92987-5; HEITMANN BL, 1993, INT J OBESITY, V17, P329; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; KABAT GC, 1989, INT J CANCER, V43, P190, DOI 10.1002/ijc.2910430203; KATO I, 1992, CANCER CAUSE CONTROL, V3, P145, DOI 10.1007/BF00051654; Lieber C. S., 1992, MED NUTR COMPLICATIO; Macfarlane GJ, 1996, J EPIDEMIOL COMMUN H, V50, P636, DOI 10.1136/jech.50.6.636; MERLETTI F, 1989, CANCER RES, V49, P4919; OLSEN J, 1985, J EPIDEMIOL COMMUN H, V39, P304, DOI 10.1136/jech.39.4.304; Storm HH, 1989, CANC INCIDENCE DENMA; TAVANI A, 1993, CANCER-AM CANCER SOC, V72, P2531, DOI 10.1002/1097-0142(19931101)72:9<2531::AID-CNCR2820720903>3.0.CO;2-T; TUYNS AJ, 1979, INT J CANCER, V23, P443, DOI 10.1002/ijc.2910230402; Uenobe F, 1997, MUTAT RES-FUND MOL M, V373, P197, DOI 10.1016/S0027-5107(96)00191-1; WINN DM, 1995, AM J CLIN NUTR, V61, p437S, DOI 10.1093/ajcn/61.2.437S	22	140	147	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 26	1998	317	7162					844	847		10.1136/bmj.317.7162.844	http://dx.doi.org/10.1136/bmj.317.7162.844			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125DN	9748175	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000076222300015
J	Galimand, M; Gerbaud, G; Guibourdenche, M; Riou, JY; Courvalin, P				Galimand, M; Gerbaud, G; Guibourdenche, M; Riou, JY; Courvalin, P			High-level chloramphenicol resistance in Neisseria meningitidis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLOSTRIDIUM-PERFRINGENS; SULFONAMIDE RESISTANCE; TRANSPOSON TN4451; MUTAGENESIS; SEROGROUP; GENETICS; EXCISES; CLONING; STRAINS	Background Neisseria meningitidis is nearly always susceptible to the penicillins, the cephalosporins, and chloramphenicol. Between 1987 and 1996, however, chloramphenicol-resistant strains were isolated from 11 patients in Vietnam and 1 in France. Methods The minimal inhibitory concentration of chloramphenicol was determined for the 12 isolates. The isolates were analyzed by monoclonal-antibody-based serotyping and subtyping, pulsed-field gel electrophoresis, and multilocus enzyme electrophoresis. Bacterial DNA was analyzed by hybridization, the polymerase chain reaction, and sequencing to identify the resistance gene and determine the origin of the resistance. Results The isolates were resistant to chloramphenicol (minimal inhibitory concentration, greater than or equal to 64 mg per liter) and produced an active chloramphenicol acetyltransferase. All 12 strains belonged to serogroup B but had a high degree of diversity, and 10 could not be typed with the use of monoclonal antibodies. The nucleotide sequence of the resistance gene and the flanking regions was identical to that of an internal portion of transposon Tn4451 that carries the catP gene in Clostridium perfringens. Moreover, this gene was located in the same genomic site in the chloramphenicol-resistant isolates. Conclusions The high-level chloramphenicol resistance that we describe in N. meningitidis isolates is of great concern, since in developing countries, chloramphenicol given intramuscularly is the standard therapy for meningococcal meningitis. The resistance to chloramphenicol is due to the presence of the catP gene on a truncated transposon that has lost mobility because of internal deletions, and the transformation of genetic material between strains of N. meningitidis probably played an important part in the dissemination of the gene. (N Engl J Med 1998;339:868-74.) (C)1998, Massachusetts Medical Society.	Inst Pasteur, Unite Agents Antibacteriens, Natl Reference Ctr Meningococci, F-75724 Paris 15, France; Inst Pasteur, Natl Reference Ctr Antibiotics, F-75724 Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Galimand, M (corresponding author), Inst Pasteur, Unite Agents Antibacteriens, Natl Reference Ctr Meningococci, 28 Rue Dr Roux, F-75724 Paris 15, France.							Abadi FJR, 1996, ANTIMICROB AGENTS CH, V40, P646, DOI 10.1128/AAC.40.3.646; ABDILLAHI H, 1987, FEMS MICROBIOL LETT, V48, P367, DOI 10.1016/0378-1097(87)90077-2; ABRAHAM LJ, 1988, PLASMID, V19, P164, DOI 10.1016/0147-619X(88)90055-8; Achtman M, 1995, MENINGOCOCCAL DIS, P159; BANNAM TL, 1995, MOL MICROBIOL, V16, P535, DOI 10.1111/j.1365-2958.1995.tb02417.x; BOWLER LD, 1994, J BACTERIOL, V176, P333, DOI 10.1128/JB.176.2.333-337.1994; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; CAUGANT DA, 1986, P NATL ACAD SCI USA, V83, P4927, DOI 10.1073/pnas.83.13.4927; FERMER C, 1995, J BACTERIOL, V177, P4669, DOI 10.1128/jb.177.16.4669-4675.1995; FUNATSU G, 1972, J MOL BIOL, V68, P547, DOI 10.1016/0022-2836(72)90108-8; GASCOYNEBINZI DM, 1994, J ANTIMICROB CHEMOTH, V34, P1015, DOI 10.1093/jac/34.6.1015; Haas M J, 1975, Methods Enzymol, V43, P611; HOKE C, 1982, INT J SYST BACTERIOL, V32, P57, DOI 10.1099/00207713-32-1-57; KELLOGG DS, 1963, J BACTERIOL, V85, P1274, DOI 10.1128/JB.85.6.1274-1279.1963; Knapp Joan S., 1995, P324; KRISTIANSEN BE, 1990, ANTIMICROB AGENTS CH, V34, P2277, DOI 10.1128/AAC.34.11.2277; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; NASSIF X, 1991, J BACTERIOL, V173, P2147, DOI 10.1128/JB.173.7.2147-2154.1991; Nolte O, 1997, J ANTIMICROB CHEMOTH, V39, P747, DOI 10.1093/jac/39.6.747; Oppenheim BA, 1997, CLIN INFECT DIS, V24, pS98, DOI 10.1093/clinids/24.Supplement_1.S98; RADSTROM P, 1992, J BACTERIOL, V174, P6386; ROBERTS MC, 1990, ANTIMICROB AGENTS CH, V34, P476, DOI 10.1128/AAC.34.3.476; Sambrok J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shaw W V, 1975, Methods Enzymol, V43, P737; STEFFEN C, 1989, GENE, V75, P349, DOI 10.1016/0378-1119(89)90282-5; SWARTLEY JS, 1993, MOL MICROBIOL, V10, P299, DOI 10.1111/j.1365-2958.1993.tb01956.x; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; VEDROS NA, 1978, METHOD MICROBIOL, V10, P293; WINTERSCHEID KK, 1994, ANTIMICROB AGENTS CH, V38, P1661, DOI 10.1128/AAC.38.7.1661; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	31	81	85	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 24	1998	339	13					868	874		10.1056/NEJM199809243391302	http://dx.doi.org/10.1056/NEJM199809243391302			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121VY	9744970				2022-12-24	WOS:000076037400002
J	Kahn, HS; Tatham, LM; Patel, AV; Thun, MJ; Heath, CW				Kahn, HS; Tatham, LM; Patel, AV; Thun, MJ; Heath, CW			Increased cancer mortality following a history of nonmelanoma skin cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NON-HODGKINS-LYMPHOMA; BASAL-CELL CARCINOMA; RENAL-TRANSPLANT RECIPIENTS; ULTRAVIOLET-RADIATION; MALIGNANCIES; SUNLIGHT; ASSOCIATION; EXPOSURE; RISK; DNA	Context.-Cancer registries have reported an increased incidence of melanoma and certain noncutaneous cancers following nonmelanoma skin cancer (NMSC). Whether these findings were attributable to intensified surveillance, shared risk factors, or increased cancer susceptibility remains unclear. Objective.-To determine whether a history of NMSC predicts cancer mortality. Design.-Prospective cohort with Ie-year mortality follow-up adjusted for multiple risk factors. Setting.-Cancer Prevention Study II, United States and Puerto Rico. Participants.-Nearly 1.1 million adult volunteers who completed a baseline questionnaire in 1982. Main Outcome Measure.-Deaths due to all cancers and common cancers. Results.-After adjusting for age, race, education, smoking, obesity, alcohol use, and other conventional risk factors, a baseline history of NMSC was associated with increased total cancer mortality (men's relative risk [RR], 1.30; 95% confidence interval [CI], 1.23-1.36; women's RR, 1.26; 95% CI, 1.17-1.35). Exclusion of deaths due to melanoma reduced these RRs only slightly. Mortality was increased for the following cancers: melanoma (RR, 3.36 in men, 3.52 in women); pharynx (RR, 2.77 in men, 2.81 in women); lung (RR, 1.37 in men, 1.46 in women); non-Hodgkin lymphoma (RR, 1.32 in men, 1.50 in women); in men only, salivary glands (RR, 2.96), prostate (RR, 1.28), testis (RR, 12.7), urinary bladder (RR, 1.41), and leukemia (RR, 1.37); and in women only, breast (RR, 1.34). All-cause mortality was slightly increased (adjusted men's RR, 1.03 [95% CI, 1.00-1.06]; women's RR, 1.04 [95% CI, 1.00-1.09]). Conclusions.-Persons with a history of NMSC are at increased risk of cancer mortality. Although the biological mechanisms are unknown, a history of NMSC should increase the clinician's alertness for certain noncutaneous cancers as well as melanoma.	Amer Canc Soc, Dept Epidemiol & Surveillance Res, Atlanta, GA 30329 USA; Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA USA	American Cancer Society; Emory University	Thun, MJ (corresponding author), Amer Canc Soc, Dept Epidemiol & Surveillance Res, 1599 Clifton Rd NE, Atlanta, GA 30329 USA.		Kahn, Henry S/A-6946-2009	Kahn, Henry S/0000-0003-2533-1562				ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; Au WW, 1996, ENVIRON HEALTH PERSP, V104, P579, DOI 10.2307/3432826; Black Homer S., 1993, Cancer Bulletin (Houston), V45, P232; Boxman ILA, 1997, J INVEST DERMATOL, V108, P712, DOI 10.1111/1523-1747.ep12292090; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235, DOI 10.1093/oxfordjournals.aje.a116664; CARTWRIGHT R, 1994, LEUKEMIA LYMPHOMA, V14, P387, DOI 10.3109/10428199409049694; COX DR, 1972, J R STAT SOC B, V34, P187; English DR, 1997, CANCER CAUSE CONTROL, V8, P271, DOI 10.1023/A:1018440801577; EUVRARD S, 1993, CANCER, V72, P2198, DOI 10.1002/1097-0142(19931001)72:7<2198::AID-CNCR2820720722>3.0.CO;2-Q; Frankel S, 1998, BMJ-BRIT MED J, V316, P499, DOI 10.1136/bmj.316.7130.499; Freedman DM, 1997, BRIT MED J, V314, P1451, DOI 10.1136/bmj.314.7092.1451; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; GARFINKEL L, 1992, STAT B METROP INSUR, V73, P21; Goldberg LH, 1997, LANCET, V349, P664, DOI 10.1016/S0140-6736(05)60130-4; HALL P, 1995, INT J CANCER, V62, P519, DOI 10.1002/ijc.2910620505; KRIPKE ML, 1994, CANCER RES, V54, P6102; Leigh IM, 1996, CANCER SURV, V26, P1; Levi F, 1998, AM J EPIDEMIOL, V147, P722; Levi F, 1997, AM J EPIDEMIOL, V146, P734; LINDELOF B, 1991, J AM ACAD DERMATOL, V25, P245, DOI 10.1016/0190-9622(91)70189-9; McMichael AJ, 1996, BRIT J CANCER, V73, P945, DOI 10.1038/bjc.1996.169; Newton R, 1997, BRIT MED J, V314, P1483, DOI 10.1136/bmj.314.7092.1483b; Payne DA, 1995, ANTICANCER RES, V15, P2213; Schottenfeld D, 1996, ANN INTERN MED, V125, P852, DOI 10.7326/0003-4819-125-10-199611150-00011; SCOTTO J, 1996, CANC EPIDEMIOLOGY PR, P1313; Shisler JL, 1998, SCIENCE, V279, P102, DOI 10.1126/science.279.5347.102; SPITZ MR, 1984, CANCER, V54, P1854, DOI 10.1002/1097-0142(19841101)54:9<1854::AID-CNCR2820540915>3.0.CO;2-1; TEPPO L, 1985, J NATL CANCER I, V75, P207; Tyring Stephen K., 1993, Cancer Bulletin (Houston), V45, P212	30	89	90	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					910	912		10.1001/jama.280.10.910	http://dx.doi.org/10.1001/jama.280.10.910			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739976	Bronze			2022-12-24	WOS:000075666600038
J	Pacini, F; Vorontsova, T; Molinaro, E; Kuchinskaya, E; Agate, L; Shavrova, E; Astachova, L; Chiovato, L; Pinchera, A				Pacini, F; Vorontsova, T; Molinaro, E; Kuchinskaya, E; Agate, L; Shavrova, E; Astachova, L; Chiovato, L; Pinchera, A			Prevalence of thyroid autoantibodies in children and adolescents from Belarus exposed to the Chernobyl radioactive fallout	LANCET			English	Article							ATOMIC-BOMB SURVIVORS; RADIATION; DISORDERS; DISEASES; CANCER	Background The long-term effects of ionising radiation, including radioiodine, on thyroid function are not well known. We compared thyroid immunity and function in two groups of children from Belarus, one of whom was exposed to the radioactive fallout of Chernobyl. Methods We measured serum free thyroxine 4 (free T4), free T3, and thyrotropin hormone (TSH) and the prevalence of thyroid autoantibodies (antithyroglobulin and antithyroperoxidase), in 287 children or adolescents living in Hoiniki (average caesium contamination of 5.4 Ci/km(2)). We also studied 208 children and adolescents living in Braslav (average contamination <0.1 Ci/km(2)), who were age 12 years or less at the time of the Chernobyl accident. Findings The prevalence of antithyroglobulin or antithyroperoxidase, or both, was significantly higher (p=0.0001) in individuals living in Hoiniki (56 [19.5%] of 287) than in those living in Braslav (eight [3.8%] of 208). In both villages, no sex differences were found in the antibody prevalence before age 13 years. Thereafter, a significantly higher prevalence of thyroid autoantibodies was found in girls from Hoiniki. The increase in the prevalence of circulating antibodies in the contaminated group was already apparent in individuals who, at the time of the accident, were in utero or newborn (15.7%), and was even more pronounced in children of 9 years or more (35.1%). No major alterations of serum FT-4, FT-3, or TSH were found. Interpretation 6-8 years after the Chernobyl accident, a significant increase in thyroid autoimmunity was found in children exposed to radioactive fallout. Pubertal age in girls is a risk factor for increased prevalence of thyroid autoimmunity. The autoimmune phenomena are limited to an increased prevalence of circulating thyroid autoantibodies without evidence of significant thyroid dysfunction, The future development of clinically relevant thyroid autoimmune diseases, especially hypothyroidism, is a possibility.	Univ Pisa, Inst Endocrinol, I-56124 Pisa, Italy; Ctr Thyroid Pathol, Minsk, BELARUS; Inst Radiat Med & Endocrinol, Minsk, BELARUS	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Pisa	Pacini, F (corresponding author), Univ Pisa, Inst Endocrinol, Via Paradisa 2, I-56124 Pisa, Italy.	fpacini@endoc.med.unipi.it	chiovato, luca/AAC-9003-2019; Chiovato, Luca/K-6617-2016	Chiovato, Luca/0000-0001-7457-7353				AKIYAMA M, 1995, INT J RADIAT BIOL, V68, P497, DOI 10.1080/09553009514551491; ASANO M, 1978, Journal of Radiation Research, V19, P306, DOI 10.1269/jrr.19.306; BAVERSTOCK K, 1992, NATURE, V359, P21, DOI 10.1038/359021b0; CHIOVATO L, 1993, J ENDOCRINOL INVEST, V16, P384, DOI 10.1007/BF03348863; *COMM EUR COMM, 1993, OFF OFF PUBL EUR COM, P1; CONARD RA, 1980, 51261 BNL, P1; DEGROOT LJ, 1983, AM J MED, V74, P852, DOI 10.1016/0002-9343(83)91077-X; DEMIDCHIK E, 1994, CHERNOBYL UPDATE FUT, P21; Goulko GM, 1998, RADIAT ENVIRON BIOPH, V36, P261, DOI 10.1007/s004110050081; HANCOCK SL, 1991, NEW ENGL J MED, V325, P599, DOI 10.1056/NEJM199108293250902; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; MARIOTTI S, 1992, LANCET, V339, P1506, DOI 10.1016/0140-6736(92)91265-A; MARIOTTI S, 1997, J ENDOCRINOL INVE S5, V20, P38; MASAHIRO I, 1995, THYROID, V5, P365; MORIMOTO I, 1987, J NUCL MED, V28, P1115; NAGATAKI S, 1994, JAMA-J AM MED ASSOC, V272, P364, DOI 10.1001/jama.272.5.364; NIKIFOROV YE, 1995, CANCER-AM CANCER SOC, V76, P900, DOI 10.1002/1097-0142(19950901)76:5<900::AID-CNCR2820760527>3.0.CO;2-X; Pacini F, 1997, J CLIN ENDOCR METAB, V82, P3563, DOI 10.1210/jc.82.11.3563; Sobolev B., 1996, Radiological Consequences of the Chernobyl Accident. Proceedings of the First International Conference (EUR 16544 EN), P741; SPITALNIK PF, 1978, CANCER, V41, P1098, DOI 10.1002/1097-0142(197803)41:3<1098::AID-CNCR2820410344>3.0.CO;2-#; Tronko N., 1996, Radiological Consequences of the Chernobyl Accident. Proceedings of the First International Conference (EUR 16544 EN), P683; Tsyb A. F., 1996, Radiological Consequences of the Chernobyl Accident. Proceedings of the First International Conference (EUR 16544 EN), P691; Vykhovanets EV, 1997, CLIN IMMUNOL IMMUNOP, V84, P251, DOI 10.1006/clin.1997.4379	24	69	74	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					763	766		10.1016/S0140-6736(97)11397-6	http://dx.doi.org/10.1016/S0140-6736(97)11397-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737280				2022-12-24	WOS:000075762700009
J	Kawasaki, I; Shim, YH; Kirchner, J; Kaminker, J; Wood, WB; Strome, S				Kawasaki, I; Shim, YH; Kirchner, J; Kaminker, J; Wood, WB; Strome, S			PGL-1, a predicted RNA-binding component of germ granules, is essential for fertility in C-elegans	CELL			English	Article							CAENORHABDITIS-ELEGANS; CELL-FORMATION; P-GRANULE; GENE; PROTEIN; EMBRYOS; DROSOPHILA; LINE; LOCALIZATION; SEGREGATION	Germ cells are distinct from somatic cells in their immortality, totipotency, and ability to undergo meiosis. Candidates for components that guide the unique germline program are the distinctive granules observed in germ cells of many species. We show that a component of germ granules is essential for fertility in C. elegans and that its primary function is in germline proliferation. This role has been revealed by molecular and genetic analyses of pgl-1. PGL-1 is a predicted RNA-binding protein that is present on germ granules at all stages of development. Elimination of PGL-1 results in defective germ granules and sterility. Interestingly, PGL-1 function is required for fertility only at elevated temperatures, suggesting that germline development is inherently sensitive to temperature.	Indiana Univ, Dept Biol, Bloomington, IN 47405 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Indiana University System; Indiana University Bloomington; University of Colorado System; University of Colorado Boulder	Strome, S (corresponding author), Indiana Univ, Dept Biol, Bloomington, IN 47405 USA.		Kawasaki, Ichiro/D-6864-2011	Kawasaki, Ichiro/0000-0003-1722-0993	NIGMS NIH HHS [GM34059, R01 GM034059] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034059] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARDSLEY A, 1993, DEVELOPMENT, V119, P207; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; BARTON MK, 1987, GENETICS, V115, P107; BEANAN MJ, 1992, DEVELOPMENT, V116, P755; BOURBON HM, 1988, J MOL BIOL, V200, P627, DOI 10.1016/0022-2836(88)90476-7; BRENNER S, 1974, GENETICS, V77, P71; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CZOLOWSKA R, 1972, ROUX ARCH DEV BIOL, V169, P335, DOI 10.1007/BF00580253; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; EDDY EM, 1975, INT REV CYTOL, V43, P229; Edgar LG, 1995, METHOD CELL BIOL, V48, P303; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Evans D, 1997, P NATL ACAD SCI USA, V94, P9751, DOI 10.1073/pnas.94.18.9751; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forbes A, 1998, DEVELOPMENT, V125, P679; FRANCIS R, 1995, GENETICS, V139, P579; GHISOLFI L, 1992, EUR J BIOCHEM, V209, P541, DOI 10.1111/j.1432-1033.1992.tb17318.x; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; GIRARD JP, 1993, NUCLEIC ACIDS RES, V21, P2149, DOI 10.1093/nar/21.9.2149; Gruidl ME, 1996, P NATL ACAD SCI USA, V93, P13837, DOI 10.1073/pnas.93.24.13837; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; HAY B, 1988, CELL, V55, P577, DOI 10.1016/0092-8674(88)90216-4; Hird SN, 1996, DEVELOPMENT, V122, P1303; Holdeman R, 1998, DEVELOPMENT, V125, P2457; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; KEMPHUES KJ, 1988, GENETICS, V120, P977; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KIMBLE J, 1984, DEV BIOL, V105, P234, DOI 10.1016/0012-1606(84)90279-3; Kobayashi S, 1996, NATURE, V380, P708, DOI 10.1038/380708a0; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LASKO PF, 1990, GENE DEV, V4, P905, DOI 10.1101/gad.4.6.905; LASKO PF, 1988, NATURE, V335, P611, DOI 10.1038/335611a0; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MAHOWALD AP, 1977, AM ZOOL, V17, P551; MARSH J, 1994, CIBA FDN S, V182; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; OLMSTED JB, 1986, METHOD ENZYMOL, P467; PAULSEN JE, 1995, GENETICS, V141, P1383; PLOUGASTEL B, 1993, GENOMICS, V18, P609, DOI 10.1016/S0888-7543(05)80363-5; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; RUSSELL ID, 1992, J CELL BIOL, V119, P737, DOI 10.1083/jcb.119.4.737; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPIETH J, 1993, CELL, V73, P521, DOI 10.1016/0092-8674(93)90139-H; STROME S, 1995, DEVELOPMENT, V121, P2961; STROME S, 1982, P NATL ACAD SCI-BIOL, V79, P1558, DOI 10.1073/pnas.79.5.1558; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; STROME S, 1986, GAMETOGENESIS EARLY, P77; Styhler S, 1998, DEVELOPMENT, V125, P1569; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WOLF N, 1983, J EMBRYOL EXP MORPH, V73, P297; Wood W. B., 1984, Molecular biology of development. Proceedings of a CETUS-UCLA Symposium held 1-7 April, 1984, in Steamboat Springs, Colorado. (UCLS Symposia on Molecular and Cellular Biology, New Series, Volume 19.), P37; YAMAGUCHI Y, 1983, DEV GROWTH DIFFER, V25, P121	58	280	286	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	SEP 4	1998	94	5					635	645		10.1016/S0092-8674(00)81605-0	http://dx.doi.org/10.1016/S0092-8674(00)81605-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741628	Bronze			2022-12-24	WOS:000075851900011
J	Moghaddam, B; Adams, BW				Moghaddam, B; Adams, BW			Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats	SCIENCE			English	Article							NONCOMPETITIVE NMDA ANTAGONIST; EXCITATORY AMINO-ACIDS; SCHIZOPHRENIA; DYSFUNCTION; KETAMINE; CORTEX; MGLUR3; DIZOCILPINE; HYPOTHESIS; LY354740	Glutamatergic abnormalities have been associated with several psychiatric disorders, including schizophrenia and addiction. Group II metabotropic glutamate receptors were targeted to normalize glutamatergic disruptions associated with an animal model of schizophrenia, the phencyclidine model. An agonist of this group of receptors, at a dose that was without effects on spontaneous activity and corticolimbic dopamine neurotransmission, attenuated the disruptive effects of phencyclidine on working memory, stereotypy, Locomotion, and cortical glutamate efflux. This behavioral reversal occurred in spite of sustained dopamine hyperactivity. Thus, targeting this group of receptors may present a nondopaminergic: therapeutic strategy for treatment of psychiatric disorders.	Yale Univ, Sch Med, Dept Psychiat, Vet Adm Med Ctr, West Haven, CT 06516 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Moghaddam, B (corresponding author), Yale Univ, Sch Med, Dept Psychiat, Vet Adm Med Ctr, 116A-2, West Haven, CT 06516 USA.	bita.moghaddam@yale.edu						Adams B, 1998, J NEUROSCI, V18, P5545, DOI 10.1523/JNEUROSCI.18-14-05545.1998; ANAND A, 1997, SOC NEUR ABSTR, V23; Battaglia G, 1997, NEUROSCI LETT, V229, P161, DOI 10.1016/S0304-3940(97)00442-4; BENES FM, 1992, CEREB CORTEX, V2, P503, DOI 10.1093/cercor/2.6.503; Bleuler E., 1950, DEMENTIA PRAECOX GRO; BUBSER M, 1995, J NEURAL TRANSM-GEN, V101, P115, DOI 10.1007/BF01271550; Bunney Blynn Garland, 1995, P1205; BURNS RS, 1976, CLIN TOXICOL, V9, P477; CARLSSON A, 1993, NEW GENERATION ANTIP, V4, P118; CARLSSON M, 1989, J NEURAL TRANSM, V75, P221, DOI 10.1007/BF01258633; Conn PJ, 1997, ANNU REV PHARMACOL, V37, P205, DOI 10.1146/annurev.pharmtox.37.1.205; Coyle JT, 1996, HARVARD REV PSYCHIAT, V3, P241, DOI 10.3109/10673229609017192; DEAKIN JFW, 1989, J NEUROCHEM, V52, P1781, DOI 10.1111/j.1471-4159.1989.tb07257.x; DEAKIN JFW, 1990, BRIT J PSYCHIAT, V157, P459, DOI 10.1192/bjp.157.3.459; EAST SJ, 1995, EUR J PHARMACOL, V277, P117, DOI 10.1016/0014-2999(95)00119-6; GOLDMANRAKIC PS, 1991, AM PSYCHOP, P1; Helton DR, 1998, J PHARMACOL EXP THER, V284, P651; IVERSEN SD, 1995, BEHAV PHARMACOL, V6, P478; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; KIM JS, 1980, NEUROSCI LETT, V20, P379, DOI 10.1016/0304-3940(80)90178-0; KRYSTAL JH, 1994, ARCH GEN PSYCHIAT, V51, P199, DOI 10.1001/archpsyc.1994.03950030035004; LAHTI AC, 1995, NEUROPSYCHOPHARMACOL, V13, P9, DOI 10.1016/0893-133X(94)00131-I; LOVINGER DM, 1995, J NEUROPHYSIOL, V73, P1076, DOI 10.1152/jn.1995.73.3.1076; LUBY ED, 1959, ARCH NEURO PSYCHIATR, V81, P363, DOI 10.1001/archneurpsyc.1959.02340150095011; LYON N, 1986, J PSYCHIAT RES, V20, P137, DOI 10.1016/0022-3956(86)90013-0; Malhotra AK, 1996, NEUROPSYCHOPHARMACOL, V14, P301, DOI 10.1016/0893-133X(95)00137-3; Moghaddam B, 1997, J NEUROSCI, V17, P2921; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; OGREN SO, 1994, NEUROPSYCHOPHARMACOL, V11, P167, DOI 10.1038/sj.npp.1380103; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; ROBBINS TW, 1990, SCHIZOPHRENIA BULL, V16, P391, DOI 10.1093/schbul/16.3.391; SCHMIDT WJ, 1994, J NEURAL TRANSM-SUPP, P63; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; Schoepp DD, 1997, NEUROPHARMACOLOGY, V36, P1, DOI 10.1016/S0028-3908(96)00160-8; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; TSAI GC, 1995, ARCH GEN PSYCHIAT, V52, P829; WILLINS DL, 1993, PHARMACOL BIOCHEM BE, V46, P881, DOI 10.1016/0091-3057(93)90217-H; Wroblewska B, 1997, J NEUROCHEM, V69, P174	39	848	889	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 28	1998	281	5381					1349	1352		10.1126/science.281.5381.1349	http://dx.doi.org/10.1126/science.281.5381.1349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	115LQ	9721099				2022-12-24	WOS:000075666800049
J	Maiti, A; Maki, G; Johnson, P				Maiti, A; Maki, G; Johnson, P			TNF-alpha induction of CD44-mediated leukocyte adhesion by sulfation	SCIENCE			English	Article							CD44; SELECTIN; EXTRAVASATION; LYMPHOCYTES; REQUIREMENT; HYALURONATE; LIGAND; MATRIX; CELLS	Regulation of cell adhesion is important for immune system function. CD44 is a tightly regulated cell adhesion molecule present on Leukocytes and implicated in their attachment to endothelium during an inflammatory immune response. The proinflammatory cytokine tumor necrosis factor-alpha, but not interferon-gamma, was found to convert CD44 from its inactive, nonbinding form to its active form by inducing the sulfation of CD44. This posttranslational modification was required for CD44-mediated binding to the extracellular matrix component hyaluronan and to vascular endothelial cells. Sulfation is thus a potential means of regulating CD44-mediated Leukocyte adhesion at inflammatory sites.	Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of British Columbia	Johnson, P (corresponding author), Univ British Columbia, Dept Microbiol & Immunol, 6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.		Johnson, Pauline/G-9659-2019	Johnson, Pauline/0000-0001-7367-4653				BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BROWN TA, 1991, J CELL BIOL, V113, P207, DOI 10.1083/jcb.113.1.207; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; Clark RA, 1996, J CELL BIOL, V134, P1075, DOI 10.1083/jcb.134.4.1075; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; DeGrendele HC, 1996, J EXP MED, V183, P1119, DOI 10.1084/jem.183.3.1119; Esford LE, 1998, J CELL SCI, V111, P1021; IMAI Y, 1993, NATURE, V361, P555; JALKANEN S, 1988, J IMMUNOL, V141, P1615; Kincade PW, 1997, CURR OPIN CELL BIOL, V9, P635, DOI 10.1016/S0955-0674(97)80116-0; KLINGEMANN HG, 1994, LEUKEMIA LYMPHOMA, V12, P463, DOI 10.3109/10428199409073789; Lesley J, 1997, GLYCOCONJUGATE J, V14, P611, DOI 10.1023/A:1018540610858; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Levesque MC, 1997, J IMMUNOL, V159, P6184; MAITI A, UNPUB; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; OCONNELL KA, 1990, J IMMUNOL, V144, P521; Rosen SD, 1996, CURR BIOL, V6, P261, DOI 10.1016/S0960-9822(02)00473-6; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1995, CELL, V83, P333; Sleeman JP, 1998, EUR J BIOCHEM, V255, P74, DOI 10.1046/j.1432-1327.1998.2550074.x; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; TROWBRIDGE IS, 1982, IMMUNOGENETICS, V15, P299, DOI 10.1007/BF00364338; VARKI A, 1994, P NATL ACAD SCI USA, V91, P7390, DOI 10.1073/pnas.91.16.7390	26	117	125	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					941	943		10.1126/science.282.5390.941	http://dx.doi.org/10.1126/science.282.5390.941			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794764				2022-12-24	WOS:000076727300049
J	Pileri, P; Uematsu, Y; Campagnoli, S; Galli, G; Falugi, F; Petracca, R; Weiner, AJ; Houghton, M; Rosa, D; Grandi, G; Abrignani, S				Pileri, P; Uematsu, Y; Campagnoli, S; Galli, G; Falugi, F; Petracca, R; Weiner, AJ; Houghton, M; Rosa, D; Grandi, G; Abrignani, S			Binding of hepatitis C virus to CD81	SCIENCE			English	Article							INFECTION; CELLS; CRYOGLOBULINEMIA; ANTIBODIES; PROTEINS; TAPA-1; TARGET; GENE	Chronic hepatitis C virus (HCV) infection occurs in about 3 percent of the world's population and is a major cause of liver disease. HCV infection is also associated with cryoglobulinemia, a B Lymphocyte proliferative disorder. Virus tropism is controversial, and the mechanisms of cell entry remain unknown. The HCV envelope protein E2 binds human CD81,a tetraspanin expressed on various cell types including hepatocytes and B Lymphocytes. Binding of E2 was mapped to the major extracellular Loop of CD81. Recombinant molecules containing this loop bound HCV and antibodies that neutralize HCV infection in vivo inhibited virus binding to CD81 in vitro.	Chiron Corp, IRIS, I-53100 Siena, Italy; Chiron Corp, Emeryville, CA 94608 USA	Novartis; Novartis	Abrignani, S (corresponding author), Chiron Corp, IRIS, I-53100 Siena, Italy.	abrignani@iris02.biocine.it	Cheng, Yushao/E-6256-2011; Pileri, Piero/N-6227-2016	Pileri, Piero/0000-0002-2888-8748; Abrignani, Sergio/0000-0002-0794-3285; Grandi, Guido/0000-0001-9724-2185; Houghton, Michael/0000-0003-3762-6771				ABRIGNANI S, UNPUB; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ANDRIA ML, 1991, J IMMUNOL, V147, P1030; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BLIGHT K, 1994, HEPATOLOGY, V20, P553, DOI 10.1016/0270-9139(94)90087-6; BOUFFARD P, 1992, J INFECT DIS, V166, P1276, DOI 10.1093/infdis/166.6.1276; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; CAMPBELL IG, 1991, CANCER RES, V51, P5329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CHOO QL, 1994, P NATL ACAD SCI USA, V91, P1294, DOI 10.1073/pnas.91.4.1294; COOPER NR, 1988, ANNU REV IMMUNOL, V6, P85; DAILEY L, 1985, J VIROL, V54, P739, DOI 10.1128/JVI.54.3.739-749.1985; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; FERRI C, 1991, CLIN EXP RHEUMATOL, V9, P95; Geisert EE, 1996, J NEUROSCI, V16, P5478; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hoofnagle JH, 1997, HEPATOLOGY, V26, pS15, DOI 10.1002/hep.510260703; HOUGHTON M, 1996, VIROLOGY, P1035; Ivanovski M, 1998, BLOOD, V91, P2433, DOI 10.1182/blood.V91.7.2433.2433_2433_2442; LEYV S, 1998, ANNU REV IMMUNOL, V16, P89; Mannion BA, 1996, J IMMUNOL, V157, P2039; PILERI P, UNPUB; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P65; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X	27	1622	1727	1	90	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 30	1998	282	5390					938	941		10.1126/science.282.5390.938	http://dx.doi.org/10.1126/science.282.5390.938			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	134DH	9794763				2022-12-24	WOS:000076727300048
J	Sohl, JL; Jaswal, SS; Agard, DA				Sohl, JL; Jaswal, SS; Agard, DA			Unfolded conformations of alpha-lytic protease are more stable than its native state	NATURE			English	Article							PRO-REGION; FOLDING REACTION; DOMAIN	alpha-Lytic protease (alpha LP), an extracellular bacterial protease, is synthesized with a large amino-terminal pro-region that is essential for its folding in vivo and in vitro(1,2). In the absence of the proregion, the protease folds to an inactive, partially folded state, designated 'I'. The pro-region catalyses protease folding by directly stabilizing the folding transition state (>26 kcal mol(-1)) which separates the native state 'N' from I-1,I-3. Although a basic tenet of protein folding is that the native state of a protein is at the minimum free energy(4), we show here that both the I and fully unfolded states of alpha LP we lower in free energy than the native state. Native alpha LP is thus metastable: its apparent stability derives from a large barrier to unfolding. Consequently the evolution of alpha LP has been distinct from most other proteins: it has not been constrained by the free-energy difference between the native and unfolded states, but instead by the size of its unfolding barrier.	Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Agard, DA (corresponding author), Univ Calif San Francisco, Grad Grp Biophys, San Francisco, CA 94143 USA.							BAKER D, 1992, PROTEINS, V12, P339, DOI 10.1002/prot.340120406; BAKER D, 1992, NATURE, V356, P263, DOI 10.1038/356263a0; Baker D, 1993, CURR OPIN CELL BIOL, V5, P966, DOI 10.1016/0955-0674(93)90078-5; BRYAN P, 1995, BIOCHEMISTRY-US, V34, P10310, DOI 10.1021/bi00032a026; Chen J, 1995, P NATL ACAD SCI USA, V92, P12205, DOI 10.1073/pnas.92.26.12205; Clark AC, 1997, BIOCHEMISTRY-US, V36, P1891, DOI 10.1021/bi962477m; DAquino JA, 1996, PROTEINS, V25, P143, DOI 10.1002/(SICI)1097-0134(199606)25:2<143::AID-PROT1>3.0.CO;2-J; EDER J, 1995, MOL MICROBIOL, V16, P609, DOI 10.1111/j.1365-2958.1995.tb02423.x; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; Harrison PM, 1997, CURR OPIN STRUC BIOL, V7, P53, DOI 10.1016/S0959-440X(97)80007-3; MACE JE, 1995, J MOL BIOL, V254, P720, DOI 10.1006/jmbi.1995.0650; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; Peters RJ, 1998, BIOCHEMISTRY-US, V37, P12058, DOI 10.1021/bi980883v; SILEN JL, 1989, NATURE, V341, P462, DOI 10.1038/341462a0; Sohl JL, 1997, BIOCHEMISTRY-US, V36, P3894, DOI 10.1021/bi962341o; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p	17	181	183	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 22	1998	395	6704					817	819		10.1038/27470	http://dx.doi.org/10.1038/27470			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AL	9796818				2022-12-24	WOS:000076607400061
J	Sadiq, ST; Copas, AJ; Johnson, AM				Sadiq, ST; Copas, AJ; Johnson, AM			Factors associated with gonorrhoea in men aware of being positive for HIV infection: case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED DISEASES; TRANSMISSION; ENGLAND; WALES; SEMEN		Camden & Islington Community NHS Trust, Mortimer Market Ctr, London WC1E 6AU, England; UCL, Sch Med, Dept Sexually Transmitted Dis, Div Pathol & Infect Dis, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Sadiq, ST (corresponding author), Camden & Islington Community NHS Trust, Mortimer Market Ctr, London WC1E 6AU, England.	tsadi@msn.com		Copas, Andrew/0000-0001-8968-5963; Johnson, Anne/0000-0003-1330-7100; Sadiq, S Tariq/0000-0002-0608-3818				Catchpole MA, 1996, BRIT MED J, V312, P539, DOI 10.1136/bmj.312.7030.539; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; EVANS BG, 1993, BRIT MED J, V306, P426, DOI 10.1136/bmj.306.6875.426; *EXP GROUP, 1996, COMMUNICAB DIS REP, V6, P1; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006	5	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 17	1998	317	7165					1052	1053						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	131LH	9774290				2022-12-24	WOS:000076577200026
J	Barreto, ML				Barreto, ML			Questionnaire approach to diagnosis in developing countries	LANCET			English	Editorial Material							SCHISTOSOMIASIS; EPIDEMIOLOGY; MANSONI; RISK		Univ Fed Bahia, Inst Saude Colet, BR-40110170 Salvador, BA, Brazil	Universidade Federal da Bahia	Barreto, ML (corresponding author), Univ Fed Bahia, Inst Saude Colet, BR-40110170 Salvador, BA, Brazil.		Barreto, Mauricio L/B-1752-2008	Barreto, Mauricio L/0000-0002-0215-4930				BARRETO ML, 1993, AM J TROP MED HYG, V48, P742, DOI 10.4269/ajtmh.1993.48.742; BIBEAU G, 1981, SOC SCI MED-MED SOC, V15, P357, DOI 10.1016/0271-7123(81)90066-3; CHANDRAMOHAN D, 1994, INT J EPIDEMIOL, V23, P213, DOI 10.1093/ije/23.2.213; GRAY HR, 1990, 10 J HOPK U SCH HYG; Hammad TA, 1996, T ROY SOC TROP MED H, V90, P372, DOI 10.1016/S0035-9203(96)90509-X; KROEGER A, 1983, INT J EPIDEMIOL, V12, P465, DOI 10.1093/ije/12.4.465; LENGELER C, 1991, INT J EPIDEMIOL, V20, P796, DOI 10.1093/ije/20.3.796; MEZZICH JE, 1994, ACTA PSYCHIAT SCAND, V90, P61, DOI 10.1111/j.1600-0447.1994.tb05915.x; Reeves BC, 1997, INT J EPIDEMIOL, V26, P1080, DOI 10.1093/ije/26.5.1080; STREINER DL, 1989, HLTH MEASUREMENTS SC; Zhou H, 1998, T ROY SOC TROP MED H, V92, P245, DOI 10.1016/S0035-9203(98)90997-X	11	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1164	1165		10.1016/S0140-6736(05)60526-0	http://dx.doi.org/10.1016/S0140-6736(05)60526-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	128PQ	9777829				2022-12-24	WOS:000076415400004
J	Fairbank, J				Fairbank, J			Trials and tribulations in cervical spondylosis	LANCET			English	Editorial Material									Nuffield Orthopaed Ctr, Oxford OX3 7LD, England	Nuffield Orthopaedic Centre	Fairbank, J (corresponding author), Nuffield Orthopaed Ctr, Oxford OX3 7LD, England.		Fairbank, Jeremy/AAA-3411-2019					Farrell B, 1998, LANCET, V351, P1379, DOI 10.1016/s0140-6736(97)09292-1; FROST H, 1997, PHYSIOTHERAPY, V83, P645; ROWLAND LP, 1992, NEUROLOGY, V42, P5, DOI 10.1212/WNL.42.1.5; Savolainen S, 1998, NEUROSURGERY, V43, P51, DOI 10.1097/00006123-199807000-00032; STIRRAT GM, 1992, ANN ROY COLL SURG, V74, P80	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 10	1998	352	9135					1165	1166		10.1016/S0140-6736(05)60527-2	http://dx.doi.org/10.1016/S0140-6736(05)60527-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128PQ	9777830				2022-12-24	WOS:000076415400005
J	Watanabe, D; Inokawa, H; Hashimoto, K; Suzuki, N; Kano, M; Shigemoto, R; Hirano, T; Toyama, K; Kaneko, S; Yokoi, M; Moriyoshi, K; Suzuki, M; Kobayashi, K; Nagatsu, T; Kreitman, RJ; Pastan, I; Nakanishi, S				Watanabe, D; Inokawa, H; Hashimoto, K; Suzuki, N; Kano, M; Shigemoto, R; Hirano, T; Toyama, K; Kaneko, S; Yokoi, M; Moriyoshi, K; Suzuki, M; Kobayashi, K; Nagatsu, T; Kreitman, RJ; Pastan, I; Nakanishi, S			Ablation of cerebellar Golgi cells disrupts synaptic integration involving GABA inhibition and NMDA receptor activation in motor coordination	CELL			English	Article							METABOTROPIC GLUTAMATE RECEPTORS; GRANULE CELLS; TRANSGENIC MICE; NERVOUS-SYSTEM; MUTANT MICE; TOXIN GENE; RAT; MGLUR2; EXPRESSION; CURRENTS	The role of inhibitory Golgi cells in cerebellar function was investigated by selectively ablating Golgi cells expressing human interleukin-2 receptor alpha subunit in transgenic mice, using the immunotoxin-mediated cell targeting technique. Golgi cell disruption caused severe acute motor disorders. These mice showed gradual recovery but retained a continuing inability to perform compound movements. Optical and electrical recordings combined with immunocytological analysis indicated that elimination of Golgi cells not only reduces GABA-mediated inhibition but also attenuates functional NMDA receptors in granule cells. These results demonstrate that synaptic integration involving both GABA inhibition and NMDA receptor activation is essential for compound motor coordination. Furthermore, this integration can adapt after Golgi cell elimination so as not to evoke overexcitation by the reduction of NMDA receptors.	Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan; Kyoto Prefectural Univ Med, Dept Physiol, Kyoto 6020841, Japan; Kanazawa Univ, Sch Med, Dept Physiol, Kanazawa, Ishikawa 9208640, Japan; Kyoto Univ, Grad Sch Sci, Dept Biophys, Kyoto 6068502, Japan; Kumamoto Univ, Sch Med, Lab Transgen Technol, Inst Mol Embryol & Genet, Kumamoto 8600976, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Ikoma 6300101, Japan; Fujita Hlth Univ, Sch Med, Inst Comprehens Med Sci, Toyoake, Aichi 4701192, Japan; NCI, Mol Biol Lab, Div Basic Sci, Bethesda, MD 20892 USA	Kyoto University; Kyoto Prefectural University of Medicine; Kanazawa University; Kyoto University; Kumamoto University; Nara Institute of Science & Technology; Fujita Health University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Nakanishi, S (corresponding author), Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan.		Shigemoto, Ryuichi/E-3628-2013; pastan, ira/P-9319-2019	Shigemoto, Ryuichi/0000-0001-8761-9444; pastan, ira/0000-0002-9223-0270; Hashimoto, Kouichi/0000-0002-3884-8213; Kobayashi, Kazuto/0000-0002-7617-2939; Kano, Masanobu/0000-0002-0725-3292				AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALBUS J S, 1971, Mathematical Biosciences, V10, P25, DOI 10.1016/0025-5564(71)90051-4; ANDERSEN P, 1964, J NEUROPHYSIOL, V27, P1138, DOI 10.1152/jn.1964.27.6.1138; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; Brickley SG, 1996, J PHYSIOL-LONDON, V497, P753, DOI 10.1113/jphysiol.1996.sp021806; BUONOMANO DV, 1994, NEURAL COMPUT, V6, P38, DOI 10.1162/neco.1994.6.1.38; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; DANGELO E, 1994, EUR J NEUROSCI, V6, P640, DOI 10.1111/j.1460-9568.1994.tb00309.x; DANGELO E, 1995, J PHYSIOL-LONDON, V484, P397, DOI 10.1113/jphysiol.1995.sp020673; ECCLES J, 1964, NATURE, V204, P1265, DOI 10.1038/2041265a0; Eccles JC, 1967, CEREBELLUM NEURONAL; Flourens P, 1824, RECHERCHES EXPT PROP; FUJITA M, 1982, BIOL CYBERN, V45, P195, DOI 10.1007/BF00336192; GABBIANI F, 1994, J NEUROPHYSIOL, V72, P999, DOI 10.1152/jn.1994.72.2.999; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; Ito M, 1984, CEREBELLUM NEURAL CO; Kadotani H, 1996, J NEUROSCI, V16, P7859; Kano M, 1995, CELL, V83, P1223, DOI 10.1016/0092-8674(95)90147-7; KASE M, 1980, J PHYSIOL-LONDON, V300, P539, DOI 10.1113/jphysiol.1980.sp013178; KOBAYASHI K, 1995, P NATL ACAD SCI USA, V92, P1132, DOI 10.1073/pnas.92.4.1132; KONNERTH A, 1987, J PHYSIOL-LONDON, V393, P681, DOI 10.1113/jphysiol.1987.sp016848; Lujan R, 1997, J CHEM NEUROANAT, V13, P219, DOI 10.1016/S0891-0618(97)00051-3; MARR D, 1969, J PHYSIOL-LONDON, V202, P437, DOI 10.1113/jphysiol.1969.sp008820; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAPPER RMA, 1988, J COMP NEUROL, V274, P168, DOI 10.1002/cne.902740204; Neki A, 1996, NEUROSCIENCE, V75, P815, DOI 10.1016/0306-4522(96)00316-8; NIRENBERG S, 1993, J NEUROSCI, V13, P3238, DOI 10.1523/jneurosci.13-08-03238.1993; Nirenberg S, 1997, NEURON, V18, P637, DOI 10.1016/S0896-6273(00)80304-9; NUSSER Z, 1995, J NEUROSCI, V15, P2948; OHISHI H, 1994, NEURON, V13, P55, DOI 10.1016/0896-6273(94)90459-6; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; PUIA G, 1994, NEURON, V12, P117, DOI 10.1016/0896-6273(94)90157-0; Ramon y Cajal S, 1995, HIST NERVOUS SYSTEM; SILVER RA, 1992, NATURE, V355, P163, DOI 10.1038/355163a0; Singer W, 1996, CURR BIOL, V6, P395, DOI 10.1016/S0960-9822(02)00505-5; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANIFUJI M, 1994, SCIENCE, V266, P1057, DOI 10.1126/science.7973662; Ueda Y, 1997, J NEUROSCI, V17, P3014; Yokoi M, 1996, SCIENCE, V273, P645, DOI 10.1126/science.273.5275.645	44	172	176	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					17	27		10.1016/S0092-8674(00)81779-1	http://dx.doi.org/10.1016/S0092-8674(00)81779-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778244	Green Submitted, Bronze			2022-12-24	WOS:000076242300007
J	Laine, L; Estrada, R; Trujillo, M; Knigge, K; Fennerty, MB				Laine, L; Estrada, R; Trujillo, M; Knigge, K; Fennerty, MB			Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori	ANNALS OF INTERNAL MEDICINE			English	Article							UREA BREATH TEST; OMEPRAZOLE; LANSOPRAZOLE; ERADICATION; GASTRITIS; ACCURACY	Background: Proton-pump inhibitor therapy may cause false-negative results on Helicobacter pylori diagnostic testing. Objective: To determine the frequency and duration of conversion of urea breath test results from positive to negative in patients given a proton-pump inhibitor. Setting: Two urban university gastroenterology clinics. Patients: Patients infected with H. pylori who had positive results on urea breath tests. Intervention: Lansoprazole, 30 mg/d for 28 days. Measurements: The urea breath test was repeated at 28 days. If the results were negative, testing was repeated 3, 7, 14, and 28 days after completion of therapy until the results reverted to positive. Results: 31 (33%) of 93 patients in whom H. pylori was not eradicated had a negative breath test result while receiving lansoprazole. The proportions of patients whose breath test results were positive after completion of lansoprazole therapy were 91% (95% CI, 83% to 96%) at 3 days, 97% (CI, 90% to 99%) at 7 days, and 100% (CI, 96% to 100%) at 14 days. Conclusion: Patients should not receive proton-pump inhibitors for 2 weeks before receiving the urea breath test for H. pylori infection.	Univ So Calif, Sch Med, Dept Med, Gastrointestinal Div, Los Angeles, CA 90033 USA	University of Southern California	Laine, L (corresponding author), Univ So Calif, Sch Med, Dept Med, Gastrointestinal Div, 2025 Zonal Ave, Los Angeles, CA 90033 USA.							Atherton JC, 1997, ALIMENT PHARM THER, V11, P11, DOI 10.1046/j.1365-2036.11.s1.3.x; BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; BIASCO G, 1989, LANCET, V2, P1403; Chey WD, 1997, AM J GASTROENTEROL, V92, P446; Chey WD, 1996, AM J GASTROENTEROL, V91, P89; Cutler AF, 1996, AM J GASTROENTEROL, V91, P85; DAW MA, 1991, ALIMENT PHARM THERAP, V5, P435; HUI WM, 1991, DIGEST DIS SCI, V36, P577, DOI 10.1007/BF01297022; IWAHI T, 1991, ANTIMICROB AGENTS CH, V35, P490, DOI 10.1128/AAC.35.3.490; Kolt SD, 1997, GASTROENTEROLOGY, V112, pA180; LAINE LA, 1996, AM J MED, V100, P525; Malfertheiner P, 1997, GUT, V41, P8; SHARP J, 1991, GUT, V32, pA565; UNGE P, 1989, SCAND J GASTROENTERO, V24, P49, DOI 10.3109/00365528909091311; WEIL J, 1991, ALIMENT PHARM THERAP, V5, P309	15	153	160	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					547	550		10.7326/0003-4819-129-7-199810010-00007	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758575				2022-12-24	WOS:000076124500006
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Two-hybridzyme	SCIENCE			English	Article																		Kamada S, 1998, P NATL ACAD SCI USA, V95, P8532, DOI 10.1073/pnas.95.15.8532	1	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1822	1823						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9776687				2022-12-24	WOS:000076007100042
J	Single, S; Borst, A				Single, S; Borst, A			Dendritic integration and its role in computing image velocity	SCIENCE			English	Article							INTRINSIC ELECTROPHYSIOLOGICAL CHARACTERISTICS; BLOWFLY CALLIPHORA-ERYTHROCEPHALA; VISUAL-MOTION DETECTION; PLATE TANGENTIAL CELLS; LOBULA PLATE; CALCIUM ACCUMULATION; MEMBRANE-PROPERTIES; HORIZONTAL CELLS; FLY; INTERNEURONS	The mechanisms underlying visual motion detection can be studied simultaneously in different cell compartments in vivo by using calcium as a reporter of the spatiotemporal activity distribution in single motion-sensitive cells of the fly. As predicted by the Reichardt model, Local dendritic calcium signals are found to indicate the direction and velocity of pattern motion but are corrupted by spatial pattern properties. The latter are canceled out by spatial integration, thus Leading to a purely directional selective output signal in the axon. These;findings attribute a specific computational task to the dendrites of visual interneurons and imply a functional interpretation of dendritic morphology.	Max Planck Soc, Friedrich Miescher Lab, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen; Max Planck Society	Borst, A (corresponding author), Max Planck Soc, Friedrich Miescher Lab, Spemannstr 37-39, D-72076 Tubingen, Germany.	alexander.borst@tuebingen.mpg.de						BORST A, 1992, P NATL ACAD SCI USA, V89, P4139, DOI 10.1073/pnas.89.9.4139; Borst A, 1996, J COMPUT NEUROSCI, V3, P313, DOI 10.1007/BF00161091; BREER H, 1988, INT CONGR SER, V832, P301; Brotz TM, 1996, J NEUROPHYSIOL, V76, P1786, DOI 10.1152/jn.1996.76.3.1786; BUCHNER E, 1984, J COMP PHYSIOL, V155, P471, DOI 10.1007/BF00611912; DOUGLASS JK, 1995, J NEUROSCI, V15, P5596; ECKERT H, 1983, J INSECT PHYSIOL, V29, P547, DOI 10.1016/0022-1910(83)90020-3; EECKMAN FH, 1994, NEURAL NETWORK SIMUL, P114; EGELHAAF M, 1995, J NEUROPHYSIOL, V73, P2540, DOI 10.1152/jn.1995.73.6.2540; EGELHAAF M, 1989, J OPT SOC AM A, V6, P1070, DOI 10.1364/JOSAA.6.001070; EGELHAAF M, 1992, VISUAL NEUROSCI, V8, P151, DOI 10.1017/S0952523800009317; Haag J, 1997, J NEUROSCI, V17, P4809; Haag J, 1997, J COMPUT NEUROSCI, V4, P349, DOI 10.1023/A:1008804117334; HAUSEN K, 1982, BIOL CYBERN, V46, P67, DOI 10.1007/BF00335352; HAUSEN K, 1982, BIOL CYBERN, V45, P143, DOI 10.1007/BF00335241; HAUSEN K, 1976, Z NATURFORSCH C, V31, P629; Hausen K., 1984, PHOTORECEPTION VISIO, P523, DOI [10.1007/978-1-4613-2743-1_15, DOI 10.1007/978-1-4613-2743-1_15]; HENGSTENBERG R, 1977, NATURE, V270, P338, DOI 10.1038/270338a0; HENGSTENBERG R, 1982, J COMP PHYSIOL, V149, P163, DOI 10.1007/BF00619211; OCarroll DC, 1996, NATURE, V382, P63, DOI 10.1038/382063a0; REICHARDT W, 1987, J COMP PHYSIOL A, V161, P533, DOI 10.1007/BF00603660; Reichardt W, 1961, SENS COMMUN, P303; Single S, 1997, J NEUROSCI, V17, P6023; VERNINO S, 1994, J NEUROSCI, V14, P5514; ZAAGMAN WH, 1978, BIOL CYBERN, V31, P163, DOI 10.1007/BF00337002	25	152	153	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1848	1850		10.1126/science.281.5384.1848	http://dx.doi.org/10.1126/science.281.5384.1848			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743497				2022-12-24	WOS:000076007100052
J	Unrau, PJ; Bartel, DP				Unrau, PJ; Bartel, DP			RNA-catalysed nucleotide synthesis	NATURE			English	Article							PREBIOTIC SYNTHESIS; BINDING-SITE; OROTATE PHOSPHORIBOSYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; PURINE NUCLEOSIDES; RIBOZYME; LIGASE	The 'RNA world' hypothesis proposes that early life developed by making use of RNA molecules, rather than proteins, to catalyse the synthesis of important biological molecules'. It is thought, however, that the nucleotides constituting RNA were scarce on early Earth(1-4), RNA-based life must therefore have acquired the ability to synthesize RNA nucleotides from simpler and more readily available precursors, such as sugars and bases. Plausible prebiotic synthesis routes have been proposed for sugars', sugar phosphates(6) and the four RNA bases(7-11), but the coupling of these molecules into nucleotides, specifically pyrimidine nucleotides, poses a challenge to the RNA world hypothesis(1-3). Here we report the application of in vitro selection to isolate RNA molecules that catalyse the synthesis of a pyrimidine nucleotide at their 3' terminus. The finding that RNA can catalyse this type of reaction, which is modelled after pyrimidine synthesis in contemporary metabolism, supports the idea of an RNA world that included nucleotide synthesis and other metabolic pathways mediated by ribozymes.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Bartel, DP (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BEEN MD, 1991, SCIENCE, V252, P434, DOI 10.1126/science.2017681; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; BHATIA MB, 1990, BIOCHEMISTRY-US, V29, P10480, DOI 10.1021/bi00498a009; EKLAND EH, 1995, NUCLEIC ACIDS RES, V23, P3231, DOI 10.1093/nar/23.16.3231; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; ENGLAND TE, 1977, P NATL ACAD SCI USA, V74, P4839, DOI 10.1073/pnas.74.11.4839; FERRIS JP, 1968, J MOL BIOL, V33, P693, DOI 10.1016/0022-2836(68)90314-8; FULLER WD, 1972, J MOL EVOL, V1, P249, DOI 10.1007/BF01660244; FULLER WD, 1972, J MOL BIOL, V67, P25, DOI 10.1016/0022-2836(72)90383-X; GOLD L, 1995, ANNU REV BIOCHEM, V64, P763, DOI 10.1146/annurev.bi.64.070195.003555; GRAY MW, 1974, BIOCHEMISTRY-US, V13, P5453, DOI 10.1021/bi00724a001; IGLOI GL, 1988, BIOCHEMISTRY-US, V27, P3842, DOI 10.1021/bi00410a048; JAFFE EK, 1979, J BIOL CHEM, V254, P839; Joyce GF., 1993, COLD SPRING HARB MON, V24, P1; LARRALDE R, 1995, P NATL ACAD SCI USA, V92, P8158, DOI 10.1073/pnas.92.18.8158; LOHRMANN R, 1978, TETRAHEDRON, V34, P853, DOI 10.1016/0040-4020(78)88129-0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; Mizuno T., 1974, Advances in Carbohydrate Chemistry and Biochemistry, V29, P173; MIZUNO Y, 1962, CHEM PHARM BULL, V10, P647; ORO J, 1961, NATURE, V191, P1193, DOI 10.1038/1911193a0; PITSCH S, 1995, ORIGINS LIFE EVOL B, V25, P297, DOI 10.1007/BF01581773; PSODA A, 1974, J AM CHEM SOC, V96, P6832, DOI 10.1021/ja00829a003; ROBERTSON MP, 1995, NATURE, V375, P772, DOI 10.1038/375772a0; SANCHEZ RA, 1967, J MOL BIOL, V30, P223; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; STOKS PG, 1979, NATURE, V282, P709, DOI 10.1038/282709a0; Tao W, 1996, BIOCHEMISTRY-US, V35, P14, DOI 10.1021/bi951898l; Wecker M, 1996, RNA, V2, P982; WIERZCHOWSKI KL, 1965, J AM CHEM SOC, V87, P4621, DOI 10.1021/ja00948a039	30	195	205	2	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					260	263		10.1038/26193	http://dx.doi.org/10.1038/26193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751052				2022-12-24	WOS:000075974600045
J	Tashima, KT				Tashima, KT			Cerebrospinal fluid levels of antiretroviral medications - Abstract and commentary	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ZIDOVUDINE		Brown Univ, Providence, RI 02912 USA	Brown University	Tashima, KT (corresponding author), Brown Univ, Providence, RI 02912 USA.							ARENDT G, 1998, 12 WORLD AIDS C JUN; BUTLER KM, 1991, NEW ENGL J MED, V324, P137, DOI 10.1056/NEJM199101173240301; COLLIER AC, 1997, 35 ANN M INF DIS SOC; FARTHING C, 1997, 37 INT C ANT AG CHEM; Foudraine NA, 1998, LANCET, V351, P1547, DOI 10.1016/S0140-6736(98)07333-4; GISOLF GH, 1998, 12 WORLD AIDS C JUN; Gisslen M, 1997, J INFECT DIS, V175, P434, DOI 10.1093/infdis/175.2.434; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V279, P419, DOI 10.1001/jama.279.6.419; Stahle L, 1997, LANCET, V350, P1823, DOI 10.1016/S0140-6736(05)63640-9; TASHIMA KT, 1998, 12 WORLD AIDS C JUN; YAZDANIAN M, 1997, 4 C RETR OPP INF JAN	12	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					879	880		10.1001/jama.280.10.879	http://dx.doi.org/10.1001/jama.280.10.879			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739960				2022-12-24	WOS:000075666600016
J	Heneine, W; Tibell, A; Switzer, WM; Sandstrom, P; Rosales, GV; Mathews, A; Korsgren, O; Chapman, LE; Folks, TM; Groth, CG				Heneine, W; Tibell, A; Switzer, WM; Sandstrom, P; Rosales, GV; Mathews, A; Korsgren, O; Chapman, LE; Folks, TM; Groth, CG			No evidence of infection with porcine endogenous retrovirus in recipients of porcine islet-cell xenografts	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; REVERSE-TRANSCRIPTASE; DIABETIC-PATIENTS; TRANSPLANTATION; ASSAY; XENOTRANSPLANTATION; SURVIVAL; PLASMA	Background The study of whether porcine xenografts can lead to porcine endogenous retrovirus (PERV) infection of recipients is critical for evaluating the safety of pig-to-man xenotransplantation. PERV is carried in the pig germline, and all recipients of porcine tissues or organs will be exposed to the virus. Methods We studied 10 diabetic patients who had received porcine fetal islets between 1990 and 1993, looking for evidence of PERV infection by using PCR serology, PCR, and reverse transcriptase assays. Prolonged xenograft survival (up to a year) was confirmed in five patients by porcine C-peptide excretion and detection of pig mitochondrial DNA (mtDNA) in serum. Findings Despite the evidence for extended exposure to pig cells and despite concomitant immunosuppressive therapy, we were unable to detect markers of PERV infection in any patient, Screening for two PERV sequences in peripheral blood lymphocytes collected 4-7 years after the xenotransplantation was negative. Markers of PERV expression, including viral RNA and reverse transcriptase, were undetectable in sera from both early (day 3 to day 180) and late (4-7 years) time points. Western blot analysis for antibodies was consistently negative, Interpretation These results suggested the absence of PERV infection in these patients. Also this study establishes a minimum standard for post-transplant surveillance of patients given porcine xenografts.	Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Karolinska Inst, Huddinge Hosp, Dept Transplantat Surg, S-10401 Stockholm, Sweden; Univ Uppsala, Acad Hosp, Dept Clin Immunol, S-75105 Uppsala, Sweden	Centers for Disease Control & Prevention - USA; Karolinska Institutet; Uppsala University	Heneine, W (corresponding author), Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Natl Ctr Infect Dis, 1600 Clifton Rd NE,Mail Stop G-19, Atlanta, GA 30333 USA.	WMH2@cdc.gov		Korsgren, Olle/0000-0002-8524-9547				Akiyoshi DE, 1998, J VIROL, V72, P4503, DOI 10.1128/JVI.72.5.4503-4507.1998; Bjoersdorff A., 1995, Xenotransplantation, V2, P26, DOI 10.1111/j.1399-3089.1995.tb00062.x; Busch Michael P., 1997, American Journal of Medicine, V102, P117, DOI 10.1016/S0002-9343(97)00077-6; CHAPMAN LE, 1995, NEW ENGL J MED, V333, P1498, DOI 10.1056/NEJM199511303332211; CHARI RS, 1994, NEW ENGL J MED, V331, P234, DOI 10.1056/NEJM199407283310404; COFFIN J M, 1990, P1437; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; DUNNING JJ, 1994, PATHOL BIOL, V42, P231; GALILI U, 1995, TRANSPLANTATION, V59, P1549, DOI 10.1097/00007890-199506150-00008; GROTH CG, 1994, LANCET, V344, P1402, DOI 10.1016/S0140-6736(94)90570-3; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; KAPLAN JE, 1993, REV MED VIROL, V3, P137, DOI 10.1002/rmv.1980030304; Lerma JGG, 1998, J INFECT DIS, V177, P1221, DOI 10.1086/515272; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; LIEBER MM, 1975, VIROLOGY, V66, P616, DOI 10.1016/0042-6822(75)90234-2; LUTZ H, 1983, AM J VET RES, V44, P2054; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Satake Masahiro, 1994, Xenotransplantation, V1, P24, DOI 10.1111/j.1399-3089.1994.tb00047.x; SHERR CJ, 1975, J VIROL, V15, P1440, DOI 10.1128/JVI.15.6.1440-1448.1975; SUZUKA I, 1986, FEBS LETT, V198, P339, DOI 10.1016/0014-5793(86)80432-X; TIBELL A, 1994, TRANSPLANT P, V26, P1121; Watson A, 1997, J VIROL, V71, P284, DOI 10.1128/JVI.71.1.284-290.1997; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; Yamamoto S, 1996, J VIROL METHODS, V61, P135, DOI 10.1016/0166-0934(96)02078-2	26	287	306	1	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					695	699		10.1016/S0140-6736(98)07145-1	http://dx.doi.org/10.1016/S0140-6736(98)07145-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728986				2022-12-24	WOS:000075729700014
J	Martin, U; Kiessig, V; Blusch, JH; Haverich, A; von der Helm, K; Herden, T; Steinhoff, G				Martin, U; Kiessig, V; Blusch, JH; Haverich, A; von der Helm, K; Herden, T; Steinhoff, G			Expression of pig endogenous retrovirus by primary porcine endothelial cells and infection of human cells	LANCET			English	Article								Background The risk of interspecies transmission of retroviruses during xenotransplantation is suggested by reports of pig endogenous retrovirus (PERV) released from porcine cell lines productively infecting human cell lines in vitro and of infectious PERV being released from pig peripheral blood mononuclear cells after mitogenic stimulation. Endothelial cells are the main interface between a xenograft and the recipient's leucocytes and tissues. Methods We have analysed pig primary aortic endothelial cells (PAEC) together with other transplantation-relevant porcine cells and tissues for expression of PERV mRNA. Release of virus particles by PAEC was monitored by reverse transcriptase (RT) activity in the medium of cultured PAEC. Infectivity for human cells was tested by co-cultivation of irradiated PAEC with the human embryonal kidney cell line HEK293 and looking for virus release from the human cells. Findings PAECs, hepatocytes, lung, and skin from a variety of pig strains and breeds expressed PERV mRNA, PAEC released infectious particles. Go-cultivation of PAEC and HEK293 led to productive infection of the human cells and expression of PERV types A and B. Interpretation Release of infectious virus from PAEC occurred without mitogenic stimulation, suggesting a serious risk of retrovirus transfer after xenotransplantation.	Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, D-30659 Hannover, Germany; Hannover Med Sch, Dept Thorac & Cardiovasc Surg, D-30659 Hannover, Germany; Pettenkofer Inst, Munich, Germany	Hannover Medical School; Hannover Medical School	Martin, U (corresponding author), Hannover Med Sch, Leibniz Res Labs Biotechnol & Artificial Organs, Podbielskistr 380, D-30659 Hannover, Germany.		Martin, Ulrich/F-4888-2017; Haverich, Axel/AAC-7552-2022	Martin, Ulrich/0000-0003-1058-4540; 				Bach FH, 1998, NATURE, V391, P326, DOI 10.1038/34766; Heneine W, 1996, TRANSPLANTATION, V62, P1360, DOI 10.1097/00007890-199611150-00033; Hoopes CW, 1997, TRANSPLANTATION, V64, P347, DOI 10.1097/00007890-199707270-00029; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; SILVER J, 1993, NUCLEIC ACIDS RES, V21, P3593, DOI 10.1093/nar/21.15.3593; Vogel G, 1998, SCIENCE, V279, P648, DOI 10.1126/science.279.5351.648; Weiss RA, 1998, NATURE, V391, P327, DOI 10.1038/34772; Wilson CA, 1998, J VIROL, V72, P3082, DOI 10.1128/JVI.72.4.3082-3087.1998; 1998, NAT MED, V4, P131; 1998, NATURE, V391, P309	12	270	280	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 29	1998	352	9129					692	694		10.1016/S0140-6736(98)07144-X	http://dx.doi.org/10.1016/S0140-6736(98)07144-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728985				2022-12-24	WOS:000075729700013
J	Xu, L; Anwyl, R; Rowan, MJ				Xu, L; Anwyl, R; Rowan, MJ			Spatial exploration induces a persistent reversal of long-term potentiation in rat hippocampus	NATURE			English	Article							SYNAPTIC PLASTICITY; IN-VIVO; BRAIN TEMPERATURE; MOTOR-ACTIVITY; 1-5 HZ; DEPRESSION; DEPOTENTIATION; STIMULATION; MEMORY; ASSOCIATION	Experience-dependent long-lasting increases in excitatory synaptic transmission in the hippocampus are believed to underlie certain types of memory(1-3). Whereas stimulation of hippocampal pathways in freely moving rats can readily elicit a long-term potentiation (LTP) of transmission that may last for weeks, previous studies have failed to detect persistent increases in synaptic efficacy after hippocampus-mediated learning(4-6). As changes in synaptic efficacy are contingent on the history of plasticity at the synapses(7), we have examined the effect of experience-dependent hippocampal activation on transmission after the induction of LTP, We show that exploration of a new, non-stressful environment rapidly induces a complete and persistent reversal of the expression of high-frequency stimulation-induced early-phase LTP in the CA1 area of the hippocampus, without affecting baseline transmission in a control pathway. LTP expression is not affected by exploration of familiar environments. We found that spatial exploration affected LTP within a defined time window because neither the induction of LTP nor the maintenance of long-established LTP was blocked. The discovery of a novelty-induced reversal of LTP expression provides strong evidence that extensive long-lasting decreases in synaptic efficacy may act in tandem with enhancements at selected synapses to allow the detection and storage of new information by the hippocampus.	Trinity Coll, Dept Pharmacol & Therapeut, Dublin 2, Ireland; Trinity Coll, Dept Physiol, Dublin 2, Ireland; Chinese Acad Sci, Kunming Inst Zool, Kunming, Peoples R China	Trinity College Dublin; Trinity College Dublin; Chinese Academy of Sciences; Kunming Institute of Zoology	Rowan, MJ (corresponding author), Trinity Coll, Dept Pharmacol & Therapeut, Dublin 2, Ireland.		Xu, Lin/T-5531-2017	Xu, Lin/0000-0002-2710-3507; Rowan, Michael Joseph/0000-0002-3867-9536	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abraham WC, 1996, TRENDS NEUROSCI, V19, P126, DOI 10.1016/S0166-2236(96)80018-X; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BUZSAKI G, 1989, NEUROSCIENCE, V31, P551, DOI 10.1016/0306-4522(89)90423-5; Doyle C, 1996, J NEUROSCI, V16, P418; Doyle CA, 1997, NEUROSCIENCE, V77, P75, DOI 10.1016/S0306-4522(96)00427-7; Dudai Y, 1996, NEURON, V17, P367, DOI 10.1016/S0896-6273(00)80168-3; Eichenbaum H, 1996, CURR OPIN NEUROBIOL, V6, P187, DOI 10.1016/S0959-4388(96)80072-9; ERICKSONLAMY K, 1993, BASIC ASPECTS GLAUCO, V3, P275; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; Gluck MA, 1997, ANNU REV PSYCHOL, V48, P481, DOI 10.1146/annurev.psych.48.1.481; GREEN JD, 1954, J NEUROPHYSIOL, V17, P553; Grunwald T, 1998, P NATL ACAD SCI USA, V95, P3193, DOI 10.1073/pnas.95.6.3193; HARGREAVES EL, 1990, J NEUROSCI, V10, P1472; Honey RC, 1998, J NEUROSCI, V18, P2226; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUERTA PT, 1995, NEURON, V15, P1053, DOI 10.1016/0896-6273(95)90094-2; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; LEUNG LS, 1980, BRAIN RES, V198, P95; ManahanVaughan D, 1997, J NEUROSCI, V17, P3303; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; Miller KD, 1996, NEURON, V17, P371, DOI 10.1016/S0896-6273(00)80169-5; Morris RGM, 1997, PHILOS T ROY SOC B, V352, P1489, DOI 10.1098/rstb.1997.0136; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; MOSER EI, 1994, LEARN MEMORY, V1, P55; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; Parkin AJ, 1997, CURR BIOL, V7, pR768, DOI 10.1016/S0960-9822(06)00400-3; STAUBLI U, 1990, BRAIN RES, V513, P113, DOI 10.1016/0006-8993(90)91096-Y; Staubli U, 1996, J NEUROSCI, V16, P853; Xu L, 1997, NATURE, V387, P497, DOI 10.1038/387497a0	29	222	237	3	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					891	894		10.1038/29783	http://dx.doi.org/10.1038/29783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732871				2022-12-24	WOS:000075611800048
J	Hiom, K; Melek, M; Gellert, M				Hiom, K; Melek, M; Gellert, M			DNA transposition by the RAG1 and RAG2 proteins: A possible source of oncogenic translocations	CELL			English	Article							POLYNUCLEOTIDYL TRANSFER-REACTIONS; V(D)J RECOMBINATION; CHROMOSOMAL TRANSLOCATION; STRAND TRANSFER; SIGNAL ENDS; TARGET SITE; MECHANISM; CLEAVAGE; INTEGRATION; GENES	The RAG1 and RAG2 proteins are known to initiate V(D)J recombination by making a double-strand break between the recombination signal sequence (RSS) and the neighboring coding DNA. We show that these proteins can also drive the coupled insertion of cleaved recombination signals into new DNA sites in a transpositional reaction. This RAG-mediated DNA transfer provides strong evidence for the evolution of the V(D)J recombination system from an ancient mobile DNA element and suggests that repeated transposition may have promoted the expansion of the antigen receptor loci. The inappropriate diversion of V(D)J rearrangement to a transpositional pathway may also help to explain certain types of DNA translocation associated with lymphatic tumors.	NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Gellert, M (corresponding author), NIDDKD, Mol Biol Lab, NIH, Bethesda, MD 20892 USA.		Hiom, Kevin/B-4374-2009					Agrawal A, 1997, CELL, V89, P43, DOI 10.1016/S0092-8674(00)80181-6; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; ATKINSON PW, 1993, P NATL ACAD SCI USA, V90, P9693, DOI 10.1073/pnas.90.20.9693; BAKHSHI A, 1987, P NATL ACAD SCI USA, V84, P2396, DOI 10.1073/pnas.84.8.2396; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; Bogue M, 1996, CURR OPIN IMMUNOL, V8, P175, DOI 10.1016/S0952-7915(96)80055-0; Bogue MA, 1997, IMMUNITY, V7, P37, DOI 10.1016/S1074-7613(00)80508-7; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; COEN ES, 1989, AM SOC MICROBIOLOGY, P413; Colot V, 1998, MOL CELL BIOL, V18, P4337, DOI 10.1128/MCB.18.7.4337; Craig NL, 1997, ANNU REV BIOCHEM, V66, P437, DOI 10.1146/annurev.biochem.66.1.437; Craig NL, 1996, SCIENCE, V271, P1512, DOI 10.1126/science.271.5255.1512; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Gellert M, 1997, ADV IMMUNOL, V64, P39, DOI 10.1016/S0065-2776(08)60886-X; Goossens T, 1998, P NATL ACAD SCI USA, V95, P2463, DOI 10.1073/pnas.95.5.2463; Han JO, 1997, MOL CELL BIOL, V17, P2226, DOI 10.1128/MCB.17.4.2226; Hiom K, 1997, CELL, V88, P65, DOI 10.1016/S0092-8674(00)81859-0; Hiom K, 1998, MOL CELL, V1, P1011, DOI 10.1016/S1097-2765(00)80101-X; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; RABBITTS TH, 1991, ADV IMMUNOL, V50, P119; Ramsden DA, 1997, NATURE, V388, P488, DOI 10.1038/41351; RAMSDEN DA, 1995, GENE DEV, V9, P2409, DOI 10.1101/gad.9.19.2409; SADOFSKY MJ, 1995, GENE DEV, V9, P2193, DOI 10.1101/gad.9.17.2193; SAKANO H, 1979, NATURE, V280, P288, DOI 10.1038/280288a0; Savilahti H, 1996, CELL, V85, P271, DOI 10.1016/S0092-8674(00)81103-4; Steen SB, 1996, GENES CELLS, V1, P543; THOMPSON CB, 1995, IMMUNITY, V3, P531, DOI 10.1016/1074-7613(95)90124-8; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; TYCKO B, 1990, CANCER CELL-MON REV, V2, P1; vanGent DC, 1996, CELL, V85, P107, DOI 10.1016/S0092-8674(00)81086-7; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592	40	407	413	1	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					463	470		10.1016/S0092-8674(00)81587-1	http://dx.doi.org/10.1016/S0092-8674(00)81587-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727489	Bronze			2022-12-24	WOS:000075541100008
J	Jegalian, K; Page, DC				Jegalian, K; Page, DC			A proposed path by which genes common to mammalian X and Y chromosomes evolve to become X inactivated	NATURE			English	Article							CPG ISLANDS; ZFY; PROTEIN; METHYLATION; EXPRESSION; EVOLUTION; SELECTION; REGION; ESCAPE; RPS4	Mammalian X and Y chromosomes evolved from an autosomal pair; the X retained and the Y gradually lost most ancestral genes(1,2), In females, one X chromosome is silenced by X inactivation, a process that is often assumed to have evolved on a broadly regional or chromosomal basis(3). Here we propose that genes or clusters common to both the X and Y chromosomes (X-Y genes) evolved independently along a multistep path, eventually acquiring dosage compensation on the X chromosome. Three genes studied here, and other extant genes, appear to be intermediates. ZFX, RPS4X and SMCX were monitored for X inactivation in diverse species by assaying CpG-island methylation, which mirrors X inactivation in many eutherians. ZFX evidently escaped X inactivation in proto-eutherians, which also possessed a very similar Y-linked gene; both characteristics were retained in most extant orders, but not in myomorph rodents. For RPS4X, escape from X inactivation seems unique to primates. SMCX escapes inactivation in primates and myomorphs but not in several other lineages. Thus, X inactivation can evolve independently for each of these genes. We propose that it is an adaptation to the decay of a homologous, Y-linked gene.	MIT, Howard Hughes Med Inst, Whitehead Inst, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	Page, DC (corresponding author), MIT, Howard Hughes Med Inst, Whitehead Inst, 9 Cambridge Ctr, Cambridge, MA 02142 USA.							ADLER DA, 1991, P NATL ACAD SCI USA, V88, P4592, DOI 10.1073/pnas.88.11.4592; Adler DA, 1997, P NATL ACAD SCI USA, V94, P9244, DOI 10.1073/pnas.94.17.9244; AGUINIK AI, 1994, HUM MOL GENET, V3, P873; AGUINIK AI, 1994, HUM MOL GENET, V3, P879; ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; Brown CJ, 1997, AM J HUM GENET, V60, P1333, DOI 10.1086/515488; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; DEsposito M, 1996, NAT GENET, V13, P227, DOI 10.1038/ng0696-227; Disteche CM, 1997, AM J HUM GENET, V60, P1312, DOI 10.1086/515484; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; Graves JAM, 1992, CURR OPIN GENET DEV, V2, P890, DOI 10.1016/S0959-437X(05)80112-1; LOVETT M, 1991, P NATL ACAD SCI USA, V88, P9628, DOI 10.1073/pnas.88.21.9628; LUOH SW, 1995, GENOMICS, V29, P353, DOI 10.1006/geno.1995.9994; LYON MF, 1974, NATURE, V250, P651, DOI 10.1038/250651a0; Mahaffey CL, 1997, GENOMICS, V41, P123, DOI 10.1006/geno.1997.4611; MIGEON BR, 1981, P NATL ACAD SCI-BIOL, V78, P5066, DOI 10.1073/pnas.78.8.5066; Muller H.J., 1950, HARVEY LECT, V43, P165; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Ohno S., 1967, SEX CHROMOSOMES SEX; Omoe K, 1996, GENOMICS, V31, P44, DOI 10.1006/geno.1996.0007; PAGE DC, 1987, CELL, V51, P1091, DOI 10.1016/0092-8674(87)90595-2; Rice WR, 1996, BIOSCIENCE, V46, P331, DOI 10.2307/1312947; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINCLAIR AH, 1988, NATURE, V336, P780, DOI 10.1038/336780a0; TRIBIOLI C, 1992, NUCLEIC ACIDS RES, V20, P727, DOI 10.1093/nar/20.4.727; WU JS, 1994, NAT GENET, V7, P491, DOI 10.1038/ng0894-491; WU JS, 1994, HUM MOL GENET, V3, P153, DOI 10.1093/hmg/3.1.153; ZINN AR, 1991, GENOMICS, V11, P1097, DOI 10.1016/0888-7543(91)90037-F	30	165	171	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 20	1998	394	6695					776	780		10.1038/29522	http://dx.doi.org/10.1038/29522			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	112PR	9723615				2022-12-24	WOS:000075503600044
J	Myers, J; Gullestad, L; Vagelos, R; Do, D; Bellin, D; Ross, H; Fowler, MB				Myers, J; Gullestad, L; Vagelos, R; Do, D; Bellin, D; Ross, H; Fowler, MB			Clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients referred for evaluation of heart failure	ANNALS OF INTERNAL MEDICINE			English	Article						heart failure, congestive; exercise test; hemodynamics; peak Vo(2); outcome and process assessment (health care)	OXYGEN-CONSUMPTION; DILATED CARDIOMYOPATHY; TRANSPLANTATION; CAPACITY; CANDIDATES	Background: Accurate prognosis in chronic heart failure has become increasingly important in assessing the efficacy of treatment and in appropriately allocating scarce resources for transplantation. Previous studies of severe heart failure have been limited by short follow-up periods and few deaths. Objective: To establish clinical, hemodynamic, and cardiopulmonary exercise test determinants of survival in patients with heart failure. Design: Retrospective study. Setting: Hospital-based outpatient heart failure clinic. Participants: 644 patients referred for evaluation of heart failure over 10 years. Measurements: Age, cause of heart failure, body surface area, cardiac index, ejection fraction, pulmonary capillary wedge pressure, left ventricular dimensions, watts achieved during exercise, heart rate, maximum systolic blood pressure, a nd oxygen uptake ((V) over dot O-2) at the ventilatory threshold and at peak exercise were measured at baseline. Univariate and multivariate analyses were done for clinical, hemodynamic, and exercise test predictors of death. A Cox hazards model was developed for time of death. Results: During a mean follow-up period of 4 years, 187 patients (29%) died and 101 underwent transplantation. Actuarial 1-year and 5-year survival rates were 90.5% and 73.4%, respectively. Resting systolic blood pressure, watts achieved, peak (V) over dot O-2, (V) over dot O-2 at the ventilatory threshold, and peak heart rate were greater among survivors than among nonsurvivors. Cause of heart failure (coronary artery disease or cardiomyopathy) was a strong determinant of death (relative risk for coronary artery disease, 1.73; P < 0.01). By multivariate analysis, only peak (V) over dot O-2 was a significant predictor of death. Stratification of peak (V) over dot O-2 above and below 12, 14, and 16 mL/kg per minute demonstrated significant differences in risk for death, but each cut-point predicted risk to a similar degree. Conclusions: Peak (V) over dot O-2 outperforms clinical variables, right-heart catheterization data, exercise time, and other exercise test variables in predicting outcome in severe chronic heart failure. Direct measurement of (V) over dot O-2 should be included when clinical or surgical decisions are being made in patients referred for evaluation of heart failure or those considered for transplantation.	Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Med Ctr, Stanford, CA 96305 USA; Palo Vet Affairs Hlth Care Syst, Palo Alto, CA USA	Stanford University	Fowler, MB (corresponding author), Stanford Univ, Sch Med, Falk Cardiovasc Res Ctr, Med Ctr, Stanford, CA 96305 USA.			Vagelos, Randall/0000-0001-6562-7216				AARONSON KD, 1995, J HEART LUNG TRANSPL, V14, P981; Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; Bart BA, 1997, J AM COLL CARDIOL, V30, P1002, DOI 10.1016/S0735-1097(97)00235-0; CHANG JA, 1994, CURR PROB CARDIOLOGY, V19, P537; Chomsky DB, 1996, CIRCULATION, V94, P3176, DOI 10.1161/01.CIR.94.12.3176; COHN JN, 1991, NEW ENGL J MED, V325, P303, DOI 10.1056/NEJM199108013250502; COHN JN, 1993, CIRCULATION, V87, P5; Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; FOLLNSBEE WP, 1993, EXERCISE HEART, P252; MANCINI DM, 1991, CIRCULATION, V83, P778, DOI 10.1161/01.CIR.83.3.778; MINOTTI JR, 1993, J APPL PHYSIOL, V75, P373, DOI 10.1152/jappl.1993.75.1.373; MUDGE GH, 1993, J AM COLL CARDIOL, V22, P21, DOI 10.1016/0735-1097(93)90812-F; Myers J, 1997, CHEST, V111, P787, DOI 10.1378/chest.111.3.787; MYERS J, 1991, ANN INTERN MED, V115, P377, DOI 10.7326/0003-4819-115-5-377; Myers J, 1996, ESSENTIALS CARDIOPUL; Packer M, 1996, NEW ENGL J MED, V334, P1349, DOI 10.1056/NEJM199605233342101; Rickenbacher PR, 1996, J AM COLL CARDIOL, V27, P1192, DOI 10.1016/0735-1097(95)00587-0; ROUL G, 1994, EUR HEART J, V15, P495, DOI 10.1093/oxfordjournals.eurheartj.a060533; SAXON LA, 1993, AM J CARDIOL, V72, P62, DOI 10.1016/0002-9149(93)90220-7; Stelken AM, 1996, J AM COLL CARDIOL, V27, P345, DOI 10.1016/0735-1097(95)00464-5; STEVENSON LW, 1987, AM J MED, V83, P871, DOI 10.1016/0002-9343(87)90644-9; STEVENSON LW, 1995, CIRCULATION, V92, P174, DOI 10.1161/01.CIR.92.9.174; STEVENSON LW, 1995, J AM COLL CARDIOL, V25, P163, DOI 10.1016/0735-1097(94)00357-V; SULLIVAN M, 1984, CHEST, V86, P375, DOI 10.1378/chest.86.3.375; SZLACHCIC J, 1985, AM J CARDIOL, V55, P1037, DOI 10.1016/0002-9149(85)90742-8; Wasserman K., 1994, PRINCIPLES EXERCISE, V2nd edn; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	27	200	204	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					286	+		10.7326/0003-4819-129-4-199808150-00004	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729181				2022-12-24	WOS:000075329100004
J	Gelbart, WM				Gelbart, WM			Databases in genomic research	SCIENCE			English	Editorial Material								Genome-related databases have already become an invaluable part of the scientific Landscape. The role played by these databases will only increase as the volume and complexity of relevant biology data rapidly expand. We are far enough into the genome project and into the development of these databases to assess their attributes and to reexamine some of the conceptual organizations and approaches they are taking. It is clear that there are needs for both highly detailed and simplified database views, the Latter being especially needed to make expert domain data more accessible to nonspecialists.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Gelbart, WM (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.								0	54	65	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 23	1998	282	5389					659	661		10.1126/science.282.5389.659	http://dx.doi.org/10.1126/science.282.5389.659			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784119				2022-12-24	WOS:000076607500038
J	Lange, P; Parner, J; Vestbo, J; Schnohr, P; Jensen, G				Lange, P; Parner, J; Vestbo, J; Schnohr, P; Jensen, G			A 15-year follow-up study of ventilatory function in adults with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; PULMONARY-FUNCTION; BRONCHIAL-ASTHMA; MUCUS HYPERSECRETION; AIRWAYS OBSTRUCTION; DECLINE; MORTALITY; HYPERRESPONSIVENESS; BUDESONIDE	Background Although the prevalence of asthma and morbidity related to asthma are increasing, little is known about the natural history of lung function in adults with this disease. Methods We used data from a longitudinal epidemiologic study of the general population in a Danish city, the Copenhagen City Heart Study, to analyze changes over time in the forced expiratory volume in one second (FEV1) in adults with self-reported asthma and adults without asthma. The study was conducted between 1976 and 1994; for each patient, three measurements of lung function were obtained over a 15-year period. The final data set consisted of measurements from 17,506 subjects (8136 men and 9370 women), of whom 1095 had asthma. Results Among subjects who participated in all three evaluations, the unadjusted decline in FEV1 among subjects with asthma was 38 mi per year, as compared with 22 mi per year in those without asthma. The decline in FEV1 normalized for height (FEV1 divided by the square of the height in meters) was greater among the subjects with asthma than among those without the disease (P<0.001). Among both men and women, and among both smokers and nonsmokers, subjects with asthma had greater declines in FEV1 over time than those without asthma (P<0.001). At the age of 60 years, a 175-cm-tall nonsmoking man without asthma had an average FEV1 of 3.05 liters, as compared with 1.99 liters for a man of similar age and height who smoked and had asthma. Conclusions In a sample of the general population, people who identified themselves as having asthma had substantially greater declines in FEV1 over time than those who did not, (N Engl J Med 1998;339:1194-200.) (C) 1998, Massachusetts Medical Society.	Bispebjerg Univ Hosp, Epidemiol Res Unit, Copenhagen City Heart Study, DK-2400 Copenhagen NV, Denmark; Hvidovre Hosp, Dept Resp Med 129, Copenhagen, Denmark; Univ Copenhagen, Dept Biostat, Copenhagen, Denmark	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; University of Copenhagen	Lange, P (corresponding author), Univ Copenhagen, Hvidovre Hosp, Dept Resp Med 129, DK-2650 Hvidovre, Denmark.		Vestbo, Jorgen/Y-2912-2019; Pistelli, Francesco/Y-8270-2019	Pistelli, Francesco/0000-0001-5612-6364; Vestbo, Jorgen/0000-0001-6355-6362				ALMIND M, 1992, DAN MED BULL, V39, P561; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; APPLEYARD M, 1989, SCAND J SOC MED S, V41, P1; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1990, MED CLIN N AM, V74, P547, DOI 10.1016/S0025-7125(16)30539-9; CONNOLLY CK, 1988, POSTGRAD MED J, V64, P422, DOI 10.1136/pgmj.64.752.422; Connolly CK, 1997, CHEST, V112, P994, DOI 10.1378/chest.112.4.994; ENARSON DA, 1987, AM REV RESPIR DIS, V136, P613, DOI 10.1164/ajrccm/136.3.613; FINUCANE KE, 1985, MED J AUSTRALIA, V142, P602, DOI 10.5694/j.1326-5377.1985.tb113530.x; FLETCHER C, 1976, NATURAL HIST CHORNIC; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Huovinen E, 1997, THORAX, V52, P49, DOI 10.1136/thx.52.1.49; JENSEN G, 1984, ACTA MED SCAND S, V602, P1; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Lange P, 1996, LANCET, V347, P1285, DOI 10.1016/S0140-6736(96)90937-X; LANGE P, 1988, AM REV RESPIR DIS, V137, P1119, DOI 10.1164/ajrccm/137.5.1119; MULLEN JBM, 1987, THORAX, V42, P843, DOI 10.1136/thx.42.11.843; OPENSHAW PJM, 1989, RESP MED, V83, P25, DOI 10.1016/S0954-6111(89)80056-3; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267, DOI 10.1164/ajrccm.155.4.9105065; PANHUYSEN CIM, 1997, AM J RESP CRIT CARE, V156, P674; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246, DOI 10.1164/ajrccm/154.6_Pt_2.S246; ROCHE WR, 1989, LANCET, V1, P520; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629, DOI 10.1164/ajrccm.150.3.8087330; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530, DOI 10.1164/ajrccm.153.5.8630597; VONESH EF, 1992, BIOMETRICS, V48, P1, DOI 10.2307/2532734; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806, DOI 10.1164/ajrccm/148.3.806	34	922	944	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 22	1998	339	17					1194	1200		10.1056/NEJM199810223391703	http://dx.doi.org/10.1056/NEJM199810223391703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	130QW	9780339	Bronze			2022-12-24	WOS:000076532400003
J	Soisson, SM; Nimnual, AS; Uy, M; Bar-Sagi, D; Kuriyan, J				Soisson, SM; Nimnual, AS; Uy, M; Bar-Sagi, D; Kuriyan, J			Crystal structure of the Dbl and pleckstrin homology domains from the human Son of Sevenless protein	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; EF-TS COMPLEX; ONCOGENE PRODUCT; DIFFRACTION DATA; KINASE-C; ASSOCIATION; ACTIVATION; BINDING; FAMILY; RHO	Proteins containing Dbl homology (DH) domains activate Rho-family GTPases by functioning as specific guanine nucleotide exchange factors. All known DH domains have associated C-terminal pleckstrin homology (PH) domains that are implicated in targeting and regulatory functions. The crystal structure of a fragment of the human Son of sevenless protein containing the DH and PH domains has been determined at 2.3 Angstrom resolution. The entirely alpha-helical DH domain is unrelated in architecture to other nucleotide exchange factors. The active site of the DH domain, identified on the basis of sequence conservation and structural features, lies near the interface between the DH and PH domains. The structure suggests that ligation of the PH domain will be coupled structurally to the GTPase binding site.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	Howard Hughes Medical Institute; Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kuriyan, J (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	kuriyan@rockvax.rockefeller.edu		Bar-Sagi, Dafna/0000-0003-2597-8948	NATIONAL CANCER INSTITUTE [P01CA028146, R01CA055360, R37CA055360] Funding Source: NIH RePORTER; NCI NIH HHS [CA55360, CA09176, CA28146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1998, IN PRESS ACTA CRYSTA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cherfils J, 1998, NATURE, V392, P101, DOI 10.1038/32210; Corbalan-Garcia S, 1998, MOL CELL BIOL, V18, P880, DOI 10.1128/MCB.18.2.880; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Freshney NW, 1997, FEBS LETT, V407, P111, DOI 10.1016/S0014-5793(97)00309-8; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HART MJ, 1994, J BIOL CHEM, V269, P62; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; KONISHI H, 1995, BIOCHEM BIOPH RES CO, V216, P526, DOI 10.1006/bbrc.1995.2654; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mossessova E, 1998, CELL, V92, P415, DOI 10.1016/S0092-8674(00)80933-2; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Raabe T, 1998, CURR TOP MICROBIOL, V228, P343; Ramakrishnan V, 1997, METHOD ENZYMOL, V276, P538, DOI 10.1016/S0076-6879(97)76077-4; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; RON D, 1991, NEW BIOL, V3, P372; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Wang Y, 1997, NAT STRUCT BIOL, V4, P650, DOI 10.1038/nsb0897-650; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	58	184	188	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					259	268		10.1016/S0092-8674(00)81756-0	http://dx.doi.org/10.1016/S0092-8674(00)81756-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790532	Bronze			2022-12-24	WOS:000076538300013
J	O'Brien, J; Ames, D; Chiu, E; Schweitzer, I; Desmond, P; Tress, B				O'Brien, J; Ames, D; Chiu, E; Schweitzer, I; Desmond, P; Tress, B			Severe deep white matter lesions and outcome in elderly patients with major depressive disorder: follow up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HYPERINTENSITIES; DEMENTIA	Objective To determine the difference in outcome among elderly people with major depression who do and do not have severe white matter lesions on magnetic resonance imaging. Design Follow up study. Setting Two psychiatric and two general hospitals in Melbourne, Australia. Subjects 60 depressed subjects aged over 55 referred to hospital psychiatric services with major depressive disorder meeting American Psychiatric Association (DSM-IIIR) criteria. Main outcome measure Proportion with good outcome as determined by full recover) from initial illness and no evidence of depressive relapse or cognitive decline during follow up among those with and without lesions. Results Mean (SD) follow up was 31.9 (9.9) months. Survival analysis showed a significant effect of severe lesions on time to poor outcome (P = 0.04), with median survival 136 days in those with severe lesions compared with 315 days in those without Conclusion Severe white matter change on magnetic resonance imaging is associated with poor outcome in elderly depressed subjects.	Newcastle Univ, Newcastle Gen Hosp, Dept Psychiat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Newcastle Univ, Newcastle Gen Hosp, Inst Hlth Elderly, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Univ Melbourne, Royal Melbourne Hosp, Dept Psychiat, Parkville, Vic 3050, Australia; Royal Melbourne Hosp, Dept Radiol, Melbourne, Vic, Australia	Newcastle General Hospital; Newcastle University - UK; Newcastle General Hospital; Newcastle University - UK; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital	O'Brien, J (corresponding author), Newcastle Univ, Newcastle Gen Hosp, Dept Psychiat, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.	j.to'brien@ncl.ac.uk	Desmond, Patricia/D-1966-2014	Desmond, Patricia/0000-0002-4803-6323; O'Brien, John/0000-0002-0837-5080				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; AMES D, 1991, INT J GERIATR PSYCH, V6, P477, DOI 10.1002/gps.930060702; CHIMOWITZ MI, 1992, ARCH NEUROL-CHICAGO, V49, P747, DOI 10.1001/archneur.1992.00530310095018; FAZEKAS F, 1993, NEUROLOGY, V43, P1683, DOI 10.1212/WNL.43.9.1683; FAZEKAS F, 1987, AM J NEURORADIOL, V8, P421; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [DOI 10.1111/J.2044-8260.1967.TB00530.X, 10.1111/j.2044-8260.1967.tb00530.x]; HICKIE I, 1995, BIOL PSYCHIAT, V37, P151, DOI 10.1016/0006-3223(94)00174-2; JACOBY RJ, 1981, BRIT J PSYCHIAT, V139, P288, DOI 10.1192/bjp.139.4.288; OBrien J, 1996, BRIT J PSYCHIAT, V168, P477, DOI 10.1192/bjp.168.4.477; ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698; Simpson S W, 1997, Int Psychogeriatr, V9, P257, DOI 10.1017/S1041610297004432	11	181	181	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 10	1998	317	7164					982	984		10.1136/bmj.317.7164.982	http://dx.doi.org/10.1136/bmj.317.7164.982			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	129EA	9765166	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000076449300023
J	Nightingale, SL				Nightingale, SL			Questions raised regarding benefit of albumin or PPF for seriously ill patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-24	WOS:000076210800006
J	Frank, E				Frank, E			Breastfeeding and maternal employment: two rights don't make a wrong	LANCET			English	Editorial Material									Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA 30303 USA	Emory University	Frank, E (corresponding author), Emory Univ, Sch Med, Dept Family & Prevent Med, Atlanta, GA 30303 USA.			Frank, Erica/0000-0001-7159-5417				Fein SB, 1998, AM J PUBLIC HEALTH, V88, P1042, DOI 10.2105/AJPH.88.7.1042; Gartner LM, 1997, PEDIATRICS, V100, P1035, DOI 10.1542/peds.100.6.1035; Scariati PD, 1997, PEDIATRICS, V99, DOI 10.1542/peds.99.6.e5; SPANGLER A, 1995, BREASTFEEDING PARENT; *US DEP HHS, 1990, US DEP HLTH HUM SERV, P379	5	9	9	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1083	1084		10.1016/S0140-6736(05)79752-X	http://dx.doi.org/10.1016/S0140-6736(05)79752-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	125PP	9798580				2022-12-24	WOS:000076246400005
J	Anaissie, EJ; Kontoyiannis, DP; O'Brien, S; Kantarjian, H; Robertson, L; Lerner, S; Keating, MJ				Anaissie, EJ; Kontoyiannis, DP; O'Brien, S; Kantarjian, H; Robertson, L; Lerner, S; Keating, MJ			Infections in patients with chronic lymphocytic leukemia treated with fludarabine	ANNALS OF INTERNAL MEDICINE			English	Review							LOW-GRADE LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PLUS PREDNISONE; PHASE-II; THERAPY; AGENT; MONOPHOSPHATE; LISTERIOSIS; PHOSPHATE; MALIGNANCIES	Background: Fludarabine, a purine analogue with activity in chronic lymphocytic leukemia, is usually well tolerated. Although serious infections after fludarabine therapy have been described, a systematic analysis of the risk factors for such infections in chronic lymphocytic leukemia is lacking. Objective: To determine the risk factors for major infection in patients with chronic lymphocytic leukemia treated with fludarabine. Design: Retrospective review of medical records. Setting: Cancer center. Patients: 402 patients with chronic lymphocytic leukemia not previously treated or treated with chlorambucil (with or without prednisone) who received fludarabine (30 mg/m(2) of body surface area per day for 5 days) with or without prednisone at 4-week intervals. Results: Infections occurred more often in previously treated (144 of 248 [58%]) than in previously untreated (53 of 154 [34%]) patients (P < 0.001). Listeriosis or pneumocystosis occurred in 12 of 170 (7%) previously treated patients receiving fludarabine plus prednisone, 0 of 78 previously treated patients receiving fludarabine alone, and 2 of 154 (1%) previously untreated patients receiving fludarabine plus prednisone (P = 0.003). Univariate analysis identified previous chemotherapy, advanced disease, failure to respond to fludarabine, elevated serum P, microglobulin level (P < 0.001), low serum albumin level (P = 0.024), elevated serum creatinine concentration (P = 0.008), and low granulocyte count (P = 0.003) as risk factors for infection. Multivariate analysis identified Rai stage III or IV (odds ratio, 1.98 [95% CI, 1.17 to 3.94]), previous treatment (odds ratio, 2.24 [CI, 1.43 to 3.51]), and elevated serum creatinine concentration (odds ratio, 1.98 [CI, 1.09 to 3.67]) as statistically significant independent risk factors for major infection. A baseline granulocyte count of more than 1000 cells/mu L was protective (odds ratio, 0.54 [CI, 0.29 to 0.99]). Five (26%) of 19 patients with a CD4 count less than 50 cells/mL developed cutaneous tester compared with 9 (6%) of 139 patients with a CD4 count greater than 50 cells/mL (P = 0.01). Conclusions: Fludarabine used in previously treated patients with chronic lymphocytic leukemia may be associated with infections involving T-cell dysfunction, such as listeriosis, pneumocystosis, mycobacterial infections, and opportunistic fungal and viral infections. Prophylaxis or presumptive therapy should be initiated in the appropriate setting.	Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Anaissie, EJ (corresponding author), Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, 4301 W Markham,Mail Slot 776, Little Rock, AR 72205 USA.							ANAISSIE E, 1992, ANN INTERN MED, V117, P466, DOI 10.7326/0003-4819-117-6-466; Angelopoulou MA, 1996, LEUKEMIA LYMPHOMA, V21, P321, DOI 10.3109/10428199209067614; [Anonymous], 1994, J CLIN ONCOL, V12, P2471; BASTION Y, 1991, EUR J CANCER, V27, P671, DOI 10.1016/0277-5379(91)90247-B; BERGMANN L, 1993, ANN ONCOL, V4, P371, DOI 10.1093/oxfordjournals.annonc.a058515; BOLDT DH, 1984, CANCER RES, V44, P4661; Briones J, 1996, MED CLIN-BARCELONA, V107, P86; BYRD JC, 1995, AM J HEMATOL, V49, P135, DOI 10.1002/ajh.2830490207; CHAPEL HM, 1987, SEMIN HEMATOL, V24, P291; Cheson B D, 1990, Oncology (Williston Park), V4, P71; CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; CHESON BD, 1995, J CLIN ONCOL, V13, P2431, DOI 10.1200/JCO.1995.13.9.2431; DEROSSI G, 1993, HAEMATOLOGICA, V78, P167; DIMOPOULOS MA, 1993, AM J MED, V95, P49, DOI 10.1016/0002-9343(93)90231-D; FAUCI AS, 1976, ANN INTERN MED, V84, P304, DOI 10.7326/0003-4819-84-3-304; FENCHEL K, 1995, LEUKEMIA LYMPHOMA, V18, P485, DOI 10.3109/10428199509059649; GIRMENIA C, 1994, BRIT J HAEMATOL, V87, P407, DOI 10.1111/j.1365-2141.1994.tb04932.x; GREVER MR, 1988, NOUV REV FR HEMATOL, V30, P457; Hequet O, 1997, HEMATOL CELL THER, V39, P89, DOI 10.1007/s00282-997-0089-1; HIDDEMANN W, 1991, ANN HEMATOL, V63, P1, DOI 10.1007/BF01714952; HOCHSTER HS, 1992, J CLIN ONCOL, V10, P28, DOI 10.1200/JCO.1992.10.1.28; KEATING MJ, 1993, BLOOD, V81, P2878; KEATING MJ, 1988, LEUKEMIA, V2, P157; KEATING MJ, 1989, BLOOD, V74, P19; KONTOYIANIS DP, 1993, CHRONIC LYMPHOCYTIC, P399; Montserrat E, 1996, LEUKEMIA LYMPHOMA, V21, P467, DOI 10.3109/10428199609093445; Morrison VA, 1998, SEMIN ONCOL, V25, P98; OBrien S, 1997, LEUKEMIA, V11, P1631, DOI 10.1038/sj.leu.2400816; OBRIEN S, 1993, BLOOD, V82, P1695; Papajik T, 1997, Vnitr Lek, V43, P25; Pillay GS, 1996, S AFR MED J, V86, P949; PUCCIO CA, 1991, J CLIN ONCOL, V9, P1562, DOI 10.1200/JCO.1991.9.9.1562; REDMAN JR, 1992, J CLIN ONCOL, V10, P790, DOI 10.1200/JCO.1992.10.5.790; ROBERTSON LE, 1992, BLOOD, V80, P29; SANDERS C, 1992, AM J HEMATOL, V39, P314, DOI 10.1002/ajh.2830390418; Schilling P J, 1991, Oncology (Williston Park), V5, P12; SCHILLING PJ, 1990, NEW ENGL J MED, V323, P833, DOI 10.1056/NEJM199009203231216; UZUN O, 1995, BLOOD, V86, P2063, DOI 10.1182/blood.V86.6.2063.bloodjournal8662063; WHELAN JS, 1991, BRIT J CANCER, V64, P120, DOI 10.1038/bjc.1991.253; WIJERMANS PW, 1993, EUR J HAEMATOL, V50, P292; YOUNG JL, 1981, NATL CANCER I MONOGR, V57, P10	41	215	231	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					559	566		10.7326/0003-4819-129-7-199810010-00010	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758577				2022-12-24	WOS:000076124500008
J	Sinai, MJ; Ooi, TL; He, ZJ				Sinai, MJ; Ooi, TL; He, ZJ			Terrain influences the accurate judgement of distance	NATURE			English	Article							VISUAL-PERCEPTION; LOCOMOTION; LOCATION; GUIDANCE	Mathematically, three-dimensional space can be represented differently by the cartesian, polar, and other coordinate systems. However, in physical sciences, the choice of representation system is restricted by the need to simplify a machine's computation while enhancing its efficiency(1). Does the brain, for the same reasons, 'select' the most cost-efficient way to represent the three-dimensional location of objects? As we frequently interact with objects on the common ground surface, it might be beneficial for the visual system to code an object's location using a ground-surface-based reference frame(2). More precisely, the brain could use a quasi-two-dimensional coordinate system (x(s), y(s)) with respect, to the ground surface (s), rather than a strictly three-dimensional coordinate system (x, y, z), thus reducing coding redundancy and simplifying computations(2-5). Here we provide support for this view by studying human psychophysical performance in perceiving absolute distance and in visually directed action tasks(6-11). For example, when an object was seen on a continuous, homogeneous texture ground surface, the observer judged the distance to the object accurately. However, when similar surface information was unavailable, for example, when the object was seen across a gap in the ground, or across distinct texture regions, distance judgement was impaired.	Univ Louisville, Dept Psychol, Louisville, KY 40292 USA; So Coll Optometry, Dept Biomed Sci, Memphis, TN 38104 USA	University of Louisville	He, ZJ (corresponding author), Univ Louisville, Dept Psychol, Louisville, KY 40292 USA.	zOhe0002@ulkyvm.louisville.edu						ATTNEAVE F, 1954, PSYCHOL REV, V61, P183, DOI 10.1037/h0054663; Barlow HB, 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; Cutting V. P JE., 1995, HDB PERCEPTION COGNI, V5, P69, DOI [DOI 10.1016/B978-012240530-3/50005-5, 10.1016/B978-012240530-3/50005-5]; ELLIOT D, 1987, J EXP PSYCHOL HUMAN, V12, P388; Gibson J. J., 1950, PERCEPTION VISUAL WO; HE JZ, 1994, NATURE, V367, P173; JIANG Y, 1994, PERCEPT PSYCHOPHYS, V56, P691, DOI 10.3758/BF03208362; LOOMIS JM, 1992, J EXP PSYCHOL HUMAN, V18, P906, DOI 10.1037/0096-1523.18.4.906; Loomis JM, 1996, CURR DIR PSYCHOL SCI, V5, P72, DOI 10.1111/1467-8721.ep10772783; Mark L. S., 1987, J EXPT PSYCHOL HUMAN, V13, P360; Philbeck JW, 1997, J EXP PSYCHOL HUMAN, V23, P72, DOI 10.1037/0096-1523.23.1.72; RIESER JJ, 1990, PERCEPTION, V19, P675, DOI 10.1068/p190675; Sedgwick H.A., 1983, HUMAN MACHINE VISION, P425, DOI [10.1016/b978-0-12-084320-6.50020-7, DOI 10.1016/B978-0-12-084320-6.50020-7]; Sedgwick H.A., 1989, SPIE P, V1198, P447; Shannon C. E., 1949, MATH THEORY INFORM; STEENHUIS RE, 1988, J MOTOR BEHAV, V20, P399; THOMSON JA, 1983, J EXP PSYCHOL HUMAN, V9, P427, DOI 10.1037/0096-1523.9.3.427; WARREN WH, 1987, J EXP PSYCHOL HUMAN, V13, P371, DOI 10.1037/0096-1523.13.3.371	18	161	165	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					497	500		10.1038/26747	http://dx.doi.org/10.1038/26747			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	124ZG	9774104				2022-12-24	WOS:000076212200055
J	Schaeffer, HJ; Catling, AD; Eblen, ST; Collier, LS; Krauss, A; Weber, MJ				Schaeffer, HJ; Catling, AD; Eblen, ST; Collier, LS; Krauss, A; Weber, MJ			MP1: A MEK binding partner that enhances enzymatic activation of the MAP kinase cascade	SCIENCE			English	Article							PROTEIN	Signal transduction is controlled both by regulation of enzyme activation and by organization of enzymatic complexes with nonenzymatic adapters, scaffolds, and anchor proteins. The extracellular signal-regulated kinase (ERK) cascade is one of several evolutionarily conserved mitogen-activated protein (MAP) kinase cascades important in the regulation of growth, apoptosis, and differentiation. A two-hybrid screen was conducted to identify nonenzymatic components of this signaling cascade that might be important in regulating its activity. A protein called MP1 (MEK Partner 1) was identified that bound specifically to MEK1 and ERK1 and facilitated their activation. When overexpressed in cultured cells, MP1 enhanced activation of ERK1 and activation of a reporter driven by the transcription factor Elk-1. Expression of MP1 in cells increased binding of ERK1 to MEK1. MP1 apparently functions as an adapter to enhance the efficiency of the MAP kinase cascade.	Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Ctr Canc, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Weber, MJ (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Microbiol, Charlottesville, VA 22908 USA.			Schaeffer, Hans-Joerg/0000-0003-2010-9153	NATIONAL CANCER INSTITUTE [R01CA039076, R37CA039076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NCI NIH HHS [CA39076] Funding Source: Medline; NIGMS NIH HHS [GM47332] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CATLING AD, 1995, MOL CELL BIOL, V15, P5214; CATLING AD, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Dang A, 1998, J BIOL CHEM, V273, P19909, DOI 10.1074/jbc.273.31.19909; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPER JW, 1993, CELL, V75, P805; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JELINEK T, 1994, MOL CELL BIOL, V14, P8212, DOI 10.1128/MCB.14.12.8212; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; SCHAEFFER HF, UNPUB	13	377	392	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1668	1671		10.1126/science.281.5383.1668	http://dx.doi.org/10.1126/science.281.5383.1668			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733512				2022-12-24	WOS:000075856500045
J	Liu, DJ; Ishima, R; Tong, KI; Bagby, S; Kokubo, T; Muhandiram, DR; Kay, LE; Nakatani, Y; Ikura, M				Liu, DJ; Ishima, R; Tong, KI; Bagby, S; Kokubo, T; Muhandiram, DR; Kay, LE; Nakatani, Y; Ikura, M			Solution structure of a TBP-TAF(II)230 complex: Protein mimicry of the minor groove surface of the TATA box unwound by TBP	CELL			English	Article							RNA-POLYMERASE-II; YEAST TFIIA/TBP/DNA COMPLEX; NUCLEAR-MAGNETIC-RESONANCE; URACIL-DNA GLYCOSYLASE; CRYSTAL-STRUCTURE; BINDING-PROTEIN; TRANSCRIPTION FACTOR; TERNARY COMPLEX; TRANSACTIVATION DOMAIN; PREINITIATION COMPLEX	General transcription factor TFIID consists of TATA box-binding protein (TBP) and TBP-associated factors (TAF(II)s), which together play a central role in both positive and negative regulation of transcription. The N-terminal region of the 230 kDa Drosophaa TAF(II)(dTAF(II)230) binds directly to TBP and inhibits TBP binding to the TATA box. We report here the solution structure of the complex formed by dTAF(II)230 N-terminal region (residues 11-77) and TBP. dTAF(II)230(11-77) comprises three or helices and a beta hairpin, forming a core that occupies the concave DNA-binding surface of TBP. The TBP-binding surface of dTAF(II)230 markedly resembles the minor groove surface of the partially unwound TATA box in the TBP-TATA complex. This protein mimicry of the TATA element surface provides the structural basis of the mechanism by which dTAF(II)230 negatively controls the TATA box-binding activity within the TFIID complex.	Ontario Canc Inst, Div Mol & Struct Biol, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; NICHHD, Lab Mol Growth Regulat, NIH, Bethesda, MD 20892 USA; Univ Toronto, Protein Engn Network Ctr Excellence, Dept Med & Mol Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Protein Engn Network Ctr Excellence, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Protein Engn Network Ctr Excellence, Dept Chem, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Toronto; University of Toronto; University of Toronto	Ikura, M (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.			Bagby, Stefan/0000-0003-2302-9511				ARNDT KM, 1995, EMBO J, V14, P1490, DOI 10.1002/j.1460-2075.1995.tb07135.x; ASO T, 1994, J BIOL CHEM, V269, P26575; Bagby S, 1997, J BIOMOL NMR, V10, P279, DOI 10.1023/A:1018359305544; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; Burley SK, 1996, ANNU REV BIOCHEM, V65, P769, DOI 10.1146/annurev.bi.65.070196.004005; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CLORE GM, 1994, METHOD ENZYMOL, V239, P349; COLEMAN RA, 1995, J BIOL CHEM, V270, P13842, DOI 10.1074/jbc.270.23.13842; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dikstein R, 1996, CELL, V84, P781, DOI 10.1016/S0092-8674(00)81055-7; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; Frankel AD, 1998, CELL, V92, P149, DOI 10.1016/S0092-8674(00)80908-3; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Geiger JH, 1996, SCIENCE, V272, P830, DOI 10.1126/science.272.5263.830; Guermah M, 1998, MOL CELL BIOL, V18, P3234, DOI 10.1128/MCB.18.6.3234; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kaiser K, 1996, TRENDS BIOCHEM SCI, V21, P342, DOI 10.1016/S0968-0004(96)10043-8; Kay LE, 1997, CURR OPIN STRUC BIOL, V7, P722, DOI 10.1016/S0959-440X(97)80084-X; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KIM JL, 1994, NAT STRUCT BIOL, V1, P638, DOI 10.1038/nsb0994-638; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOKUBO T, 1994, P NATL ACAD SCI USA, V91, P3520, DOI 10.1073/pnas.91.9.3520; KOKUBO T, 1993, J BIOL CHEM, V268, P17554; Kokubo T, 1998, MOL CELL BIOL, V18, P1003, DOI 10.1128/MCB.18.2.1003; Kosa PF, 1997, P NATL ACAD SCI USA, V94, P6042, DOI 10.1073/pnas.94.12.6042; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; LEE M, 1995, MOL CELL BIOL, V15, P5461; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; MERRITT EA, 1997, METHOD ENZYMOL, V277, P503; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; Nicholls A.J., 1993, GRASP MANUAL; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nyborg J, 1996, TRENDS BIOCHEM SCI, V21, P81, DOI 10.1016/0968-0004(96)30008-X; O'Brien T, 1998, MOL CELL, V1, P905, DOI 10.1016/S1097-2765(00)80089-1; Oelgeschlager T, 1998, MOL CELL, V1, P925, DOI 10.1016/S1097-2765(00)80092-1; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ORENGO CA, 1992, PROTEINS, V14, P139, DOI 10.1002/prot.340140203; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Tan S, 1996, NATURE, V381, P127, DOI 10.1038/381127a0; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMAZAKI T, 1994, J AM CHEM SOC, V116, P11655, DOI 10.1021/ja00105a005; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	67	172	181	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					573	583		10.1016/S0092-8674(00)81599-8	http://dx.doi.org/10.1016/S0092-8674(00)81599-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741622	Bronze			2022-12-24	WOS:000075851900005
J	Cave, H; ten Bosch, JV; Suciu, S; Guidal, C; Waterkeyn, C; Otten, J; Bakkus, M; Thielemans, K; Grandchamp, B; Vilmer, E				Cave, H; ten Bosch, JV; Suciu, S; Guidal, C; Waterkeyn, C; Otten, J; Bakkus, M; Thielemans, K; Grandchamp, B; Vilmer, E		European Org Res Treatment Canc Childhood Leuke	Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; DELTA-T-CELL; INVITRO AMPLIFICATION; GENE REARRANGEMENTS; QUANTITATION; INDUCTION; SEQUENCES; REMISSION; PROBES; END	Background and Methods The implications of the detection of residual disease after treatment of acute lymphoblastic leukemia (ALL) are unclear. We conducted a prospective study at 11 centers to determine the predictive value of the presence or absence of detectable residual disease at several points in time during the first six months after complete remission of childhood ALL had been induced. Junctional sequences of T-cell-receptor or immunoglobulin gene rearrangements were used as clonal markers of leukemic cells. Residual disease was quantitated with a competitive polymerase-chain-reaction (PCR) assay. Of 246 patients enrolled at diagnosis and treated with a uniform chemotherapy protocol, 178 were monitored for residual disease with one clone-specific probe (in 74 percent) or more than one probe tin 26 percent). The median follow-up period was 38 months. Results The presence or absence and level of residual leukemia were significantly correlated with the risk of early relapse at each of the times studied (P<0.001). PCR measurements identified patients at high risk for relapse after the completion of induction therapy (those with greater than or equal to 10(-2) residual blasts per 2x10(5) mononuclear bone marrow cells) or at later time points (those with greater than or equal to 10(-3) residual blasts). Multivariate analysis showed that as compared with immunophenotype, age, risk group (standard or very high risk), and white-cell count at diagnosis, the presence or absence and level of residual disease were the most powerful independent prognostic factors. Conclusions Residual leukemia after induction of a remission is a powerful prognostic factor in childhood ALL. Detection of residual disease by PCR should be used to identify patients at risk for relapse and should be taken into account in considering alternative treatment. (N Engl J Med 1998;339:591-8.) (C) 1998, Massachusetts Medical Society.	Hop Robert Debre, Serv Hematol Immunol, F-75019 Paris, France; Hop Robert Debre, Biochim Genet Lab, F-75019 Paris, France; Free Univ Brussels, Dept Physiol, Brussels, Belgium; European Org Res Treatment Canc, Ctr Data, Brussels, Belgium; Free Univ Brussels, Akad Ziekenhuis, B-1090 Brussels, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite Libre de Bruxelles; Vrije Universiteit Brussel; European Organisation for Research & Treatment of Cancer; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Vilmer, E (corresponding author), Hop Robert Debre, Serv Hematol Immunol, 48 Blvd Serurier, F-75019 Paris, France.			Bakkus, Marleen/0000-0002-0863-3369; Cave, Helene/0000-0003-2840-1511	NCI NIH HHS [5U10-CA11488-24, 5U10-CA11488-25, 5U10-CA11488-23] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA011488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BREIT TM, 1991, LEUKEMIA, V5, P116; Breslow N., 1984, CANCER CLIN TRIALS, P381; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAVE H, 1994, BLOOD, V83, P1892; Coustan-Smith E, 1998, LANCET, V351, P550, DOI 10.1016/S0140-6736(97)10295-1; COX DR, 1972, J R STAT SOC B, V34, P187; DAURIOL L, 1989, LEUKEMIA, V3, P155; HANSENHAGGE TE, 1989, BLOOD, V74, P1762; Henze G, 1987, Haematol Blood Transfus, V30, P147; MACINTYRE EA, 1990, J CLIN INVEST, V86, P2125, DOI 10.1172/JCI114951; NIZET Y, 1993, BLOOD, V82, P1618; OUSPENSKAIA MV, 1995, LEUKEMIA, V9, P321; PETO J, 1984, CANCER CLIN TRIALS, P361; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POTTER MN, 1993, BRIT J HAEMATOL, V83, P412, DOI 10.1111/j.1365-2141.1993.tb04665.x; REITER A, 1994, BLOOD, V84, P3122, DOI 10.1182/blood.V84.9.3122.3122; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; SHIACH CR, 1993, BRIT J HAEMATOL, V85, P431, DOI 10.1111/j.1365-2141.1993.tb03197.x; TRAINOR KJ, 1991, BLOOD, V78, P192; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879; YAMADA M, 1990, NEW ENGL J MED, V323, P448, DOI 10.1056/NEJM199008163230705; YOKOTA S, 1991, BLOOD, V77, P331	23	572	607	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 27	1998	339	9					591	598		10.1056/NEJM199808273390904	http://dx.doi.org/10.1056/NEJM199808273390904			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113LR	9718378				2022-12-24	WOS:000075552900004
J	Guo, ZH; Turner, C; Castle, D				Guo, ZH; Turner, C; Castle, D			Relocation of the t-SNARE SNAP-23 from lamellipodia-like cell surface projections regulates compound exocytosis in mast cells	CELL			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; GUANINE-NUCLEOTIDES; CHROMAFFIN CELLS; ENDOCRINE-CELLS; IDENTIFICATION; FUSION; SECRETION; MEMBRANE; TRANSPORT; GRANULES	For regulated secretion, mast cells and several other cell types utilize compound exocytosis, a combination of granule-plasma membrane and granule-granule fusions. The molecular machinery that controls this massive export process has not been identified. We report that SNAP-23, a t-SNARE related to SNAP-25, relocates in response to stimulation from plasma membrane lamellipodia-like projections to granule membranes in permeabilized mast cells. While relocation is a prerequisite for secretion, it can occur without membrane fusion and will expedite a subsequent secretory response. After relocation, SNAP-23 is required for exocytosis, implying a crucial role in promoting membrane fusion. Thus, relocation of this SNARE regulates compound exocytosis and links granule-plasma membrane and granule-granule fusions.	Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA	University of Virginia	Castle, D (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Cell Biol, Charlottesville, VA 22908 USA.				NIDCR NIH HHS [DE09655] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009655] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Abraham SN, 1997, INFECT IMMUN, V65, P3501, DOI 10.1128/IAI.65.9.3501-3508.1997; ANDERSON P, 1973, ACTA PHYSIOL SCAND, V88, P359, DOI 10.1111/j.1748-1716.1973.tb05465.x; Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; ARIDOR M, 1993, SCIENCE, V262, P1569, DOI 10.1126/science.7504324; Banerjee A, 1996, J BIOL CHEM, V271, P20227, DOI 10.1074/jbc.271.34.20227; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bock JB, 1997, NATURE, V387, P133, DOI 10.1038/387133a0; BRAND SH, 1993, EMBO J, V12, P3753, DOI 10.1002/j.1460-2075.1993.tb06053.x; Brown AM, 1998, MOL BIOL CELL, V9, P1053, DOI 10.1091/mbc.9.5.1053; BURRY RW, 1992, J HISTOCHEM CYTOCHEM, V40, P1849, DOI 10.1177/40.12.1453003; Chen FS, 1997, BIOCHEMISTRY-US, V36, P5719, DOI 10.1021/bi962331n; CHOCK SP, 1989, J BIOL CHEM, V264, P2862; DETOLEDO GA, 1990, J GEN PHYSIOL, V95, P397, DOI 10.1085/jgp.95.3.397; FERNANDEZ JM, 1991, BIOPHYS J, V59, P1022, DOI 10.1016/S0006-3495(91)82317-7; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; Gaisano HY, 1997, FEBS LETT, V414, P298, DOI 10.1016/S0014-5793(97)01013-2; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; GOMPERTS BD, 1992, METHOD ENZYMOL, V219, P178; Heidelberger R, 1998, J GEN PHYSIOL, V111, P225, DOI 10.1085/jgp.111.2.225; HESS DT, 1992, J NEUROSCI, V12, P4634; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; HohneZell B, 1996, FEBS LETT, V394, P109, DOI 10.1016/0014-5793(96)00931-3; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Kannan R, 1996, FEBS LETT, V385, P159, DOI 10.1016/0014-5793(96)00350-X; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P222, DOI 10.1016/0167-4889(93)90048-T; KOFFER A, 1990, J CELL BIOL, V111, P919, DOI 10.1083/jcb.111.3.919; KOFFER A, 1993, BIOCHIM BIOPHYS ACTA, V1176, P231, DOI 10.1016/0167-4889(93)90049-U; KRUGER PG, 1980, EXP CELL RES, V129, P83, DOI 10.1016/0014-4827(80)90333-X; Mariot P, 1996, EMBO J, V15, P6476, DOI 10.1002/j.1460-2075.1996.tb01038.x; Mehta PP, 1996, P NATL ACAD SCI USA, V93, P10471, DOI 10.1073/pnas.93.19.10471; MILLER SG, 1992, METHOD ENZYMOL, V219, P234; Mollinedo F, 1997, BIOCHEM BIOPH RES CO, V231, P808, DOI 10.1006/bbrc.1997.6196; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Norman JC, 1996, MOL BIOL CELL, V7, P1429, DOI 10.1091/mbc.7.9.1429; Oberhauser AF, 1996, BIOPHYS J, V71, P1131, DOI 10.1016/S0006-3495(96)79315-3; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; OSullivan AJ, 1996, MOL BIOL CELL, V7, P397, DOI 10.1091/mbc.7.3.397; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PALADE GE, 1959, SUBCELLULAR PARTICLE, P64; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PRICE LS, 1995, CURR BIOL, V5, P68, DOI 10.1016/S0960-9822(95)00018-2; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rossi G, 1997, J BIOL CHEM, V272, P16610, DOI 10.1074/jbc.272.26.16610; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tagaya M, 1996, FEBS LETT, V394, P83, DOI 10.1016/0014-5793(96)00932-5; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Veit M, 1996, FEBS LETT, V385, P119, DOI 10.1016/0014-5793(96)00362-6; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; Wang GY, 1997, J CELL SCI, V110, P505; Wong PPC, 1997, BIOCHEM BIOPH RES CO, V230, P64, DOI 10.1006/bbrc.1996.5884; Wu TT, 1997, J CELL SCI, V110, P1533	58	219	221	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					537	548		10.1016/S0092-8674(00)81594-9	http://dx.doi.org/10.1016/S0092-8674(00)81594-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727496	Bronze			2022-12-24	WOS:000075541100015
J	Stephens, RS; Kalman, S; Lammel, C; Fan, J; Marathe, R; Aravind, L; Mitchell, W; Olinger, L; Tatusov, RL; Zhao, QX; Koonin, EV; Davis, RW				Stephens, RS; Kalman, S; Lammel, C; Fan, J; Marathe, R; Aravind, L; Mitchell, W; Olinger, L; Tatusov, RL; Zhao, QX; Koonin, EV; Davis, RW			Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis	SCIENCE			English	Article							ESCHERICHIA-COLI; OUTER-MEMBRANE; HAEMOPHILUS-INFLUENZAE; PHOSPHOLIPID SYNTHASES; PROTEIN SEQUENCES; PSITTACI; GENE; CELLS; IDENTIFICATION; SYNTHETASE	Analysis of the 1,042,519-base pair Chlamydia trachomatis genome revealed unexpected features related to the complex biology of chlamydiae. Although chlamydiae lack many biosynthetic capabilities, they retain functions for performing key steps and interconversions of metabolites obtained from their mammalian host cells. Numerous potential virulence-associated proteins also were characterized. Several eukaryotic chromatin-associated domain proteins were identified, suggesting a eukaryotic-like mechanism for chlamydial nucleoid condensation and decondensation. The phylogenetic mosaic of chlamydial genes, including a Large number of genes with phylogenetic origins from eukaryotes, implies a complex evolution for adaptation to obligate intracellular parasitism.	Univ Calif Berkeley, Program Infect Dis, Berkeley, CA 94720 USA; Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; Stanford Univ, DNA Sequencing & Technol Ctr, Stanford, CA 94305 USA; NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; Stanford University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)	Stephens, RS (corresponding author), Univ Calif Berkeley, Program Infect Dis, Berkeley, CA 94720 USA.	ctgenome@socrates.berkeley.edu	Mitchell, Wayne P/C-5219-2008	Aravind, L/0000-0003-0771-253X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI039258] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 39258] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amann R, 1997, APPL ENVIRON MICROB, V63, P115, DOI 10.1128/AEM.63.1.115-121.1997; [Anonymous], 1984, BACTERIOL; BARRY CE, 1992, SCIENCE, V256, P377, DOI 10.1126/science.256.5055.377; BEATTY WL, 1994, INFECT IMMUN, V62, P3705, DOI 10.1128/IAI.62.9.3705-3711.1994; BRENNER SE, 1995, NATURE, V378, P140, DOI 10.1038/378140a0; COSTERTON JW, 1976, CAN J MICROBIOL, V22, P16, DOI 10.1139/m76-003; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; DUFOUR A, 1994, J BACTERIOL, V176, P1813, DOI 10.1128/jb.176.7.1813-1820.1994; Felsenstein J, 1996, METHOD ENZYMOL, V266, P418; FOX A, 1990, INFECT IMMUN, V58, P835, DOI 10.1128/IAI.58.3.835-837.1990; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Fraser CM, 1998, SCIENCE, V281, P375, DOI 10.1126/science.281.5375.375; HACKSTADT T, 1995, P NATL ACAD SCI USA, V92, P4877, DOI 10.1073/pnas.92.11.4877; HACKSTADT T, 1991, P NATL ACAD SCI USA, V88, P3937, DOI 10.1073/pnas.88.9.3937; Hatch GM, 1998, INFECT IMMUN, V66, P3727, DOI 10.1128/IAI.66.8.3727-3735.1998; HATCH TP, 1982, J BACTERIOL, V150, P662, DOI 10.1128/JB.150.2.662-670.1982; HATCH TP, 1986, J BACTERIOL, V165, P379, DOI 10.1128/jb.165.2.379-385.1986; HATCH TP, 1976, J BACTERIOL, V125, P706, DOI 10.1128/JB.125.2.706-712.1976; Hayashi M, 1996, FEBS LETT, V381, P174, DOI 10.1016/0014-5793(96)00114-7; Heinzen RA, 1997, INFECT IMMUN, V65, P1088, DOI 10.1128/IAI.65.3.1088-1094.1997; Hsia RC, 1997, MOL MICROBIOL, V25, P351, DOI 10.1046/j.1365-2958.1997.4701834.x; Hueck CJ, 1998, MICROBIOL MOL BIOL R, V62, P379, DOI 10.1128/MMBR.62.2.379-433.1998; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Koonin EV, 1996, TRENDS BIOCHEM SCI, V21, P242, DOI 10.1016/0968-0004(96)30024-8; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; KOONIN EV, UNPUB; LAGA M, 1991, AIDS, V5, pS55; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; Longbottom D, 1996, FEMS MICROBIOL LETT, V142, P277; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; MOULDER JW, 1988, MICROBIOLOGY CHLAMYD, P3; NEWHALL WJ, 1983, J BACTERIOL, V154, P998, DOI 10.1128/JB.154.2.998-1001.1983; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Ponting CP, 1996, PROTEIN SCI, V5, P914; POWELL BS, 1995, J BIOL CHEM, V270, P4822, DOI 10.1074/jbc.270.9.4822; Rockey DD, 1997, MOL MICROBIOL, V24, P217, DOI 10.1046/j.1365-2958.1997.3371700.x; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; SOLBRIG MV, 1990, MOL MICROBIOL, V4, P1535, DOI 10.1111/j.1365-2958.1990.tb02064.x; STEPHENS RS, 1992, INFECT AGENT DIS, V1, P279; Su H, 1985, KEXUE TONGBAO, V30, P695; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tatusov RL, 1997, SCIENCE, V278, P631, DOI 10.1126/science.278.5338.631; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; VOELKER U, 1995, J BACTERIOL, V177, P114, DOI 10.1128/jb.177.1.114-122.1995; WAGAR EA, 1995, J BACTERIOL, V177, P5179, DOI 10.1128/jb.177.17.5179-5185.1995; WAGAR EA, 1988, INFECT IMMUN, V56, P1678, DOI 10.1128/IAI.56.7.1678-1684.1988; WAGAR EA, 1992, FEMS MICROBIOL LETT, V98, P161; WALKER DR, 1997, INTELL SYST MOL BIOL, V5, P333; WEBSTER A, 1993, J GEN VIROL, V74, P1415, DOI 10.1099/0022-1317-74-7-1415; WEISBURG WG, 1986, J BACTERIOL, V167, P570, DOI 10.1128/jb.167.2.570-574.1986; YOKOYAMA K, 1994, J BIOL CHEM, V269, P12248; 1997, MORB MORTAL WKLY REP, V46, P193	53	1227	1743	1	85	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					754	759		10.1126/science.282.5389.754	http://dx.doi.org/10.1126/science.282.5389.754			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784136				2022-12-24	WOS:000076607500055
J	Iezzoni, LI				Iezzoni, LI			What should I say? communication around disability	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Iezzoni, LI (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, E Campus LY-326,330 Brookline Ave, Boston, MA 02215 USA.	liezzoni@bidmc.harvard.edu							0	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1998	129	8					661	665		10.7326/0003-4819-129-8-199810150-00018	http://dx.doi.org/10.7326/0003-4819-129-8-199810150-00018			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128WR	9786817				2022-12-24	WOS:000076431800012
J	Bondeva, T; Pirola, L; Bulgarelli-Leva, G; Rubio, I; Wetzker, R; Wymann, MP				Bondeva, T; Pirola, L; Bulgarelli-Leva, G; Rubio, I; Wetzker, R; Wymann, MP			Bifurcation of lipid and protein kinase signals of PI3K gamma to the protein kinases PKB and MAPK	SCIENCE			English	Article							PHOSPHOINOSITIDE 3-KINASE-GAMMA; WORTMANNIN; ACTIVATION; PRODUCT; BETA; AKT	Phosphoinositide 3-kinases (PI3Ks) activate protein kinase PKB (also termed Akt), and PI3K gamma activated by heterotrimeric guanosine triphosphate-binding protein can stimulate mitogen-activated protein kinase (MAPK). Exchange of a putative Lipid substrate-binding site generated PI3K gamma proteins with altered or aborted Lipid but retained protein kinase activity. Transiently expressed, PI3K gamma hybrids exhibited wortmannin-sensitive activation of MAPK, whereas a catalytically inactive PI3K gamma did not. Membrane-targeted PI3K gamma constitutively produced phosphatidylinositol 3,4,5-trisphosphate and activated PKB but not MAPK. Moreover, stimulation of MAPK in response to Lysophosphatidic acid was blocked by catalytically inactive PI3K gamma but not by hybrid PI3K gamma s. Thus, two major signals emerge from PI3K gamma: phosphoinositides that target PKB and protein phosphorylation that activates MAPK.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Jena, Res Unit Mol Cell Biol, D-07747 Jena, Germany	University of Fribourg; Friedrich Schiller University of Jena	Wymann, MP (corresponding author), Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland.		Pirola, Luciano/I-5250-2018; Wetzker, Reinhard/AAD-8713-2019; Wymann, Matthias P/C-3227-2008	Wymann, Matthias P/0000-0003-3349-4281; Pirola, Luciano/0000-0001-6539-5435				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; CARPENTER CL, 1993, MOL CELL BIOL, V13, P1657, DOI 10.1128/MCB.13.3.1657; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; PIROLA L, UNPUB; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rubio I, 1997, BIOCHEM J, V326, P891, DOI 10.1042/bj3260891; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Stoyanova S, 1997, BIOCHEM J, V324, P489, DOI 10.1042/bj3240489; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Wymann MP, 1996, MOL CELL BIOL, V16, P1722	19	296	305	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					293	296		10.1126/science.282.5387.293	http://dx.doi.org/10.1126/science.282.5387.293			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765155				2022-12-24	WOS:000076370200048
J	Kennedy, AK; Guhathakurta, A; Kleckner, N; Haniford, DB				Kennedy, AK; Guhathakurta, A; Kleckner, N; Haniford, DB			Tn10 transposition via a DNA hairpin intermediate	CELL			English	Article							ACTIVE-SITE; INTRAMOLECULAR TRANSPOSITION; TN7 TRANSPOSITION; IDENTIFICATION; RECOMBINATION; COMPLEX; PROTEINS; RESIDUES; CLEAVAGE; MUTANTS	We present evidence that excision of the nonreplicative transposon Tn10 involves three distinct chemical steps, first-strand nicking, hairpin formation, and hairpin resolution. This three-step mechanism makes it possible for a single protein-active site to cleave two DNA strands of opposite polarity, as appears to be the case in this reaction. We infer the existence of alternating bifunctionality within the active site with suitable modulation of substrate components between steps. DNA double-strand breaks are also made by a "hairpin mechanism" in V(D)J recombination, possibly reflecting the same basic constraints faced in the Tn10 system. Similarities in the basic chemical steps in Tn10 transposition and V(D)J recombination suggest that the V(D)J mechanism may have evolved from a bacterial transposition system.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada; Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Western University (University of Western Ontario); Harvard University	Haniford, DB (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	dhanifor@julian.uwo.ca			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM025326] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM25326] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal A, 1998, NATURE, V394, P744, DOI 10.1038/29457; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; Bao TH, 1997, EMBO J, V16, P3357, DOI 10.1093/emboj/16.11.3357; BENJAMIN HW, 1989, CELL, V59, P373, DOI 10.1016/0092-8674(89)90298-5; Berg D. E., 1989, MOBILE DNA; BOLLAND S, 1995, P NATL ACAD SCI USA, V92, P7814, DOI 10.1073/pnas.92.17.7814; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; Chalmers R, 1998, CELL, V93, P897, DOI 10.1016/S0092-8674(00)81449-X; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; COEN ES, 1989, MOBILE DNA, P413; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; Hiom K, 1998, CELL, V94, P463, DOI 10.1016/S0092-8674(00)81587-1; Junop MS, 1997, EMBO J, V16, P2646, DOI 10.1093/emboj/16.10.2646; KABOTYANSKI EB, 1995, NUCLEIC ACIDS RES, V23, P3872, DOI 10.1093/nar/23.19.3872; Kennedy AK, 1996, J MOL BIOL, V256, P533, DOI 10.1006/jmbi.1996.0106; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; Lewis LA, 1997, MOL MICROBIOL, V25, P517, DOI 10.1046/j.1365-2958.1997.4871848.x; May EW, 1996, SCIENCE, V272, P401, DOI 10.1126/science.272.5260.401; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; Melek M, 1998, SCIENCE, V280, P301, DOI 10.1126/science.280.5361.301; Mizuuchi K, 1997, GENES CELLS, V2, P1, DOI 10.1046/j.1365-2443.1997.970297.x; NADEL Y, 1995, J BIOL CHEM, V270, P28970, DOI 10.1074/jbc.270.48.28970; Namgoong SY, 1998, EMBO J, V17, P3775, DOI 10.1093/emboj/17.13.3775; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; POLARD P, 1992, EMBO J, V11, P5079, DOI 10.1002/j.1460-2075.1992.tb05615.x; SAEDLER H, 1996, CURR TOP MICROBIOL I, V204, P27; SAKAI J, 1995, EMBO J, V14, P4374, DOI 10.1002/j.1460-2075.1995.tb00112.x; Sambrook JFE, 1989, MOL CLONING LAB MANU; SAMOVSKY RJ, 1996, EMBO J, V15, P6348; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x	34	159	161	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 2	1998	95	1					125	134		10.1016/S0092-8674(00)81788-2	http://dx.doi.org/10.1016/S0092-8674(00)81788-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778253	Bronze			2022-12-24	WOS:000076242300016
J	Tsang, SH; Burns, ME; Calvert, PD; Gouras, P; Baylor, DA; Goff, SP; Arshavsky, VY				Tsang, SH; Burns, ME; Calvert, PD; Gouras, P; Baylor, DA; Goff, SP; Arshavsky, VY			Role for the target enzyme in deactivation of photoreceptor G protein in vivo	SCIENCE			English	Article							CYCLIC-GMP PHOSPHODIESTERASE; ROD OUTER SEGMENTS; TRANSDUCIN GTPASE ACTIVITY; CGMP PHOSPHODIESTERASE; RETINAL RODS; VISUAL TRANSDUCTION; ACTIVATION STEPS; GAMMA-SUBUNIT; RGS PROTEINS; FAMILY	Heterotrimeric guanosine 5'-triphosphate (GTP)-binding proteins (C proteins) are deactivated by hydrolysis of the CTP that they bind when activated by transmembrane receptors. Transducin, the C protein that relays visual excitation from rhodopsin to the cyclic guanosine 3',5'-monophosphate phosphodiesterase (PDE) in retinal photoreceptors, must be deactivated for the light response to recover. A point mutation in the gamma subunit of PDE impaired transducin-PDE interactions and slowed the recovery rate of the flash response in transgenic mouse rods. These results indicate that the normal deactivation of transducin in vivo requires the G protein to interact with its target enzyme.	Harvard Univ, Sch Med, Howe Lab Ophthalmol, Boston, MA 02114 USA; Columbia Univ Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA; Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA; Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA	Harvard University; Harvard Medical School; Columbia University; Columbia University; Stanford University; Harvard University; Massachusetts Eye & Ear Infirmary; Columbia University; Howard Hughes Medical Institute	Arshavsky, VY (corresponding author), Harvard Univ, Sch Med, Howe Lab Ophthalmol, Boston, MA 02114 USA.	varshavsky@meei.harvard.edu	Goff, Stephen P/K-6337-2014	Goff, Stephen P/0000-0003-0693-5547	NATIONAL EYE INSTITUTE [R01EY005750, R01EY010336, T32EY007105] Funding Source: NIH RePORTER; NEI NIH HHS [EY05750, EY10336, T32 EY07105] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ANGLESON JK, 1993, NEURON, V11, P939, DOI 10.1016/0896-6273(93)90123-9; ANGLESON JK, 1994, J BIOL CHEM, V269, P16290; ANTONNY B, 1993, BIOCHEMISTRY-US, V32, P8646, DOI 10.1021/bi00084a036; ARSHAVSKY VY, 1989, FEBS LETT, V250, P353, DOI 10.1016/0014-5793(89)80754-9; ARSHAVSKY VY, 1992, J BIOL CHEM, V267, P24501; ARSHAVSKY VY, 1991, J BIOL CHEM, V266, P18530; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARSHAVSKY VY, 1994, J BIOL CHEM, V269, P19882; Arshavsky VY, 1998, NEURON, V20, P11, DOI 10.1016/S0896-6273(00)80430-4; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P613; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BOURNE HR, 1995, PHILOS T R SOC B, V349, P283, DOI 10.1098/rstb.1995.0114; BOWNDS D, 1971, J GEN PHYSIOL, V58, P225, DOI 10.1085/jgp.58.3.225; BOWNDS MD, 1995, BEHAV BRAIN SCI, V18, P415, DOI 10.1017/S0140525X00039170; BURNS M, UNPUB; Calvert PD, 1998, J GEN PHYSIOL, V111, P39, DOI 10.1085/jgp.111.1.39; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRATZ EA, 1987, BIOCHEM BIOPH RES CO, V146, P379, DOI 10.1016/0006-291X(87)90540-7; Faurobert E, 1997, P NATL ACAD SCI USA, V94, P2945, DOI 10.1073/pnas.94.7.2945; FUNG BKK, 1981, P NATL ACAD SCI-BIOL, V78, P152, DOI 10.1073/pnas.78.1.152; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; HURLEY JB, 1982, J BIOL CHEM, V257, P1094; JOHNSON PA, 1988, BIOCHIM BIOPHYS ACTA, V950, P45, DOI 10.1016/0167-4781(88)90071-1; Koelle MR, 1997, CURR OPIN CELL BIOL, V9, P143, DOI 10.1016/S0955-0674(97)80055-5; LAGNADO L, 1992, NEURON, V8, P995, DOI 10.1016/0896-6273(92)90122-T; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAMB TD, 1992, J PHYSIOL-LONDON, V449, P719, DOI 10.1113/jphysiol.1992.sp019111; LEM J, 1991, NEURON, V6, P201, DOI 10.1016/0896-6273(91)90356-5; Lyubarsky AL, 1996, J NEUROSCI, V16, P563, DOI 10.1523/jneurosci.16-02-00563.1996; Natochin M, 1997, J BIOL CHEM, V272, P17444, DOI 10.1074/jbc.272.28.17444; Nekrasova ER, 1997, BIOCHEMISTRY-US, V36, P7638, DOI 10.1021/bi970427r; Nikonov S, 1998, J GEN PHYSIOL, V111, P7, DOI 10.1085/jgp.111.1.7; OTTOBRUC A, 1993, BIOCHEMISTRY-US, V32, P8636, DOI 10.1021/bi00084a035; PAGES F, 1992, J BIOL CHEM, V267, P22018; PITTLER SJ, 1991, P NATL ACAD SCI USA, V88, P8322, DOI 10.1073/pnas.88.19.8322; PUGH EN, 1990, VISION RES, V30, P1923, DOI 10.1016/0042-6989(90)90013-B; PUGH EN, 1993, BIOCHIM BIOPHYS ACTA, V1141, P111, DOI 10.1016/0005-2728(93)90038-H; SLEPAK VZ, 1995, J BIOL CHEM, V270, P14319, DOI 10.1074/jbc.270.24.14319; SUNG CH, 1994, J NEUROSCI, V14, P5818; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; TUTEJA N, 1988, FEBS LETT, V232, P182, DOI 10.1016/0014-5793(88)80413-7; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	47	166	167	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 2	1998	282	5386					117	121		10.1126/science.282.5386.117	http://dx.doi.org/10.1126/science.282.5386.117			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756475				2022-12-24	WOS:000076294900052
J	Grimes, JM; Burroughs, JN; Gouet, P; Diprose, JM; Malby, R; Zientara, S; Mertens, PPC; Stuart, DI				Grimes, JM; Burroughs, JN; Gouet, P; Diprose, JM; Malby, R; Zientara, S; Mertens, PPC; Stuart, DI			The atomic structure of the bluetongue virus core	NATURE			English	Article							INFECTIOUS SUBVIRAL PARTICLES; PROTEIN SECONDARY STRUCTURE; DOUBLE-STRANDED-RNA; PATTERN-RECOGNITION; VP7; CRYSTALLOGRAPHY; PURIFICATION; INTERFACES; ORBIVIRUS; INCLUSION	The structure of the core particle of bluetongue virus has been determined by X-ray crystallography at a resolution approaching 3.5 Angstrom. This transcriptionally active compartment, 700 Angstrom in diameter, represents the largest molecular structure determined in such detail. The atomic structure Indicates how approximately 1,000 protein components self-assemble, using both the classical mechanism of quasi-equivalent contacts, which are achieved through triangulation, and a different method, which we term geometrical quasi-equivalence.	Univ Oxford, Dept Biochem, Lab Mol Biophys, Oxford OX1 3QU, England; AFRC, Inst Anim Hlth, Pirbright Lab, Woking GU24 0NF, Surrey, England; CNEVA Alfort, Lab Cent Rech Vet, F-94703 Maisons Alfort, France; Oxford Ctr Mol Sci, Oxford OX1 3QT, England	University of Oxford; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; Pirbright Institute; Ecole Nationale Veterinaire d'Alfort (ENVA); University of Oxford	Stuart, DI (corresponding author), Univ Oxford, Dept Biochem, Lab Mol Biophys, Rex Richards Bldg,S Parks Rd, Oxford OX1 3QU, England.	dave@biop.ox.ac.uk	Zientara, Stephan/A-5336-2016; Zientara, Stephan/AAA-7661-2021	Zientara, Stephan/0000-0003-0089-8175; Zientara, Stephan/0000-0002-6733-8503; Mertens, Peter/0000-0002-3438-3738; Stuart, David/0000-0002-3426-4210; Grimes, Jonathan Mark/0000-0001-9698-0389; gouet, patrice/0000-0001-9485-6157				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Basak AK, 1997, STRUCTURE, V5, P871, DOI 10.1016/S0969-2126(97)00242-6; BROOKES SM, 1993, J GEN VIROL, V74, P525, DOI 10.1099/0022-1317-74-3-525; BRUNGER AT, 1992, X PLOR VERSION 3 1; BURROUGHS JN, 1994, J GEN VIROL, V75, P1849, DOI 10.1099/0022-1317-75-8-1849; Butcher SJ, 1997, EMBO J, V16, P4477, DOI 10.1093/emboj/16.14.4477; CALISHER CH, IN PRESS ARCH VIRO S, V13; CASPAR DLD, 1962, COLD SPRING HARB SYM, V27, P1, DOI 10.1101/sqb.1962.027.001.005; Caston JR, 1997, J CELL BIOL, V138, P975, DOI 10.1083/jcb.138.5.975; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; Frishman D, 1995, PROTEINS, V23, P566, DOI 10.1002/prot.340230412; FU H, IN PRESS J GEN VIROL; FURUICHI Y, 1976, J BIOL CHEM, V251, P5043; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; Grimes JM, 1997, STRUCTURE, V5, P885, DOI 10.1016/S0969-2126(97)00243-8; HARRISON SC, 1980, BIOPHYS J, V32, P139, DOI 10.1016/S0006-3495(80)84930-7; HEWAT EA, 1992, VIROLOGY, V189, P10, DOI 10.1016/0042-6822(92)90676-G; Holm L, 1996, NUCLEIC ACIDS RES, V24, P206, DOI 10.1093/nar/24.1.206; Holmes IHEA, 1998, VIRUS TAXONOMY CLASS, P208; HUISMANS H, 1987, VIROLOGY, V157, P180, DOI 10.1016/0042-6822(87)90327-8; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; JONES TA, 1985, DIFFRACTION METHOD B, P157; JUUTI JT, 1997, 6 INT S DSRNA VIR, pA1; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEBLOIS H, 1993, J VIROL, V67, P353, DOI 10.1128/JVI.67.1.353-359.1993; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LOUDON PT, 1991, VIROLOGY, V180, P798, DOI 10.1016/0042-6822(91)90094-R; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mertens PPC, 1996, VIROLOGY, V217, P582, DOI 10.1006/viro.1996.0153; MERTENS PPC, 1987, VIROLOGY, V157, P375, DOI 10.1016/0042-6822(87)90280-7; MOSS SR, 1994, VIRUS RES, V32, P401, DOI 10.1016/0168-1702(94)90088-4; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PRASAD BVV, 1992, J VIROL, V66, P2135, DOI 10.1128/JVI.66.4.2135-2142.1992; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Zhu YF, 1997, J VIROL, V71, P8899, DOI 10.1128/JVI.71.11.8899-8901.1997	40	456	480	4	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 1	1998	395	6701					470	478		10.1038/26694	http://dx.doi.org/10.1038/26694			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774103				2022-12-24	WOS:000076212200047
J	King, MA; Newton, MR; Jackson, GD; Fitt, GJ; Mitchell, LA; Silvapulle, MJ; Berkovic, SF				King, MA; Newton, MR; Jackson, GD; Fitt, GJ; Mitchell, LA; Silvapulle, MJ; Berkovic, SF			Epileptology of the first-seizure presentation: a clinical, electroencephalographic, and magnetic resonance imaging study of 300 consecutive patients	LANCET			English	Article							1ST UNPROVOKED SEIZURE; EXTENDED FOLLOW-UP; ADULT LIFE; RECURRENCE; EPILEPSY; RISK; CHILDHOOD	Background Prognosis and treatment of the first seizure depends on identification of a specific epilepsy syndrome, yet patients with first seizures are generally regarded as a homogeneous group. We studied whether it is possible to diagnose specific epilepsy syndromes promptly by use of standard clinical methods, electroencephalography (EEG) and magnetic resonance imaging (MRI). Methods 300 consecutive adults and children presented with unexplained seizures, We systematically collected clinical data from patients and witnesses. and attempted to obtain an EEG within 24 h of the seizure. Where the EEG was negative, a sleep-deprived EEG was done. MRI was done electively. Findings A generalised or partial epilepsy syndrome was clinically diagnosed in 141 (47%) patients. Subsequent analysis showed that only three of these clinical diagnoses were incorrect, Addition of the EEG data enabled us to diagnose an epilepsy syndrome in 232 (77%) patients. EEG within 24 h was more useful in diagnosis of epileptiform abnormalities than later EEG (51 vs 34%). Neuroimaging showed 38 epileptogenic lesions, including 17 tumours. There were no lesions in patients for whom generalised epilepsy was confirmed by EEG. Our final diagnoses were: generalised epilepsy (23% of patients); partial epilepsy (58%); and unclassified (19%). Interpretation An epilepsy syndrome can be diagnosed in most first-seizure patients. Ideally, an EEG should be obtained within 24 h of the seizure followed by a sleep deprived EEG if necessary. MRI aids diagnosis and should be done for ail patients except for those with idiopathic generalised epilepsies and for children with benign rolandic epilepsy.	Austin & Repatriat Med Ctr, Dept Neurol, Melbourne, Vic 3084, Australia; Univ Melbourne, Dept Med, Melbourne, Vic, Australia; Austin & Repatriat Med Ctr, Dept Radiol, Melbourne, Vic 3084, Australia; La Trobe Univ, Dept Stat Sci, Bundoora, Vic, Australia	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; La Trobe University	Berkovic, SF (corresponding author), Austin & Repatriat Med Ctr, Dept Neurol, Melbourne, Vic 3084, Australia.	sberko@austin.unimelb.edu.au	Jackson, Graeme D/A-9064-2013; Jackson, Graeme/AAD-9070-2019; jiang, yu/HGU-0029-2022	Jackson, Graeme D/0000-0002-7917-5326; Jackson, Graeme/0000-0002-7917-5326; Berkovic, Samuel/0000-0003-4580-841X				ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BERG AT, 1991, NEUROLOGY, V41, P965, DOI 10.1212/WNL.41.7.965; Brodie MJ, 1996, NEW ENGL J MED, V334, P168, DOI 10.1056/NEJM199601183340308; Brown W., 1987, SURGICAL TREATMENT E, P511; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; DELGADOESCUETA AV, 1984, NEUROLOGY, V34, P285, DOI 10.1212/WNL.34.3.285; Forsgren L, 1996, EPILEPSIA, V37, P224, DOI 10.1111/j.1528-1157.1996.tb00017.x; Gilad R, 1996, ARCH NEUROL-CHICAGO, V53, P1149, DOI 10.1001/archneur.1996.00550110089017; GOTMAN J, 1985, ANN NEUROL, V17, P597, DOI 10.1002/ana.410170612; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; HART YM, 1990, LANCET, V336, P1271, DOI 10.1016/0140-6736(90)92960-P; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HOPKINS A, 1988, LANCET, V1, P721; JACKSON GD, 1993, AM J NEURORADIOL, V14, P753; Kuzniecky R., 1995, MAGNETIC RESONANCE E; Kuzniecky Ruben I., 1993, P197; Lerman Pinchas, 1992, P189; MARSAN CA, 1970, EPILEPSIA, V11, P361, DOI 10.1111/j.1528-1157.1970.tb03903.x; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MUSICCO M, 1993, NEUROLOGY, V43, P478; SHINNAR S, 1994, EPILEPSIA, V35, P471, DOI 10.1111/j.1528-1157.1994.tb02464.x; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shinnar S, 1996, PEDIATRICS, V98, P216; VANDONSELAAR CA, 1991, BMJ-BRIT MED J, V302, P620, DOI 10.1136/bmj.302.6777.620	28	390	395	2	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	1998	352	9133					1007	1011		10.1016/S0140-6736(98)03543-0	http://dx.doi.org/10.1016/S0140-6736(98)03543-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759742				2022-12-24	WOS:000076121800008
J	Sokejima, S; Kagamimori, S				Sokejima, S; Kagamimori, S			Working hours as a risk factor for acute myocardial infarction in Japan: case-control study	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ENVIRONMENTAL TOBACCO-SMOKE; CARDIOVASCULAR-DISEASE; RATE-VARIABILITY; BLOOD-PRESSURE; MORTALITY; EXPOSURE; SEVERITY; TERM	Objective: To clarify the extent to which working hours affect the risk of acute myocardial infarction, independent of established risk factors and occupational conditions. Design: Case-control study. Setting: University and general hospitals and routine medical examinations at workplaces in Japan. Subjects: Cases were 195 men aged 30-69 years admitted to hospital with acute myocardial infarction during 1990-3, Controls were 331 men matched at group level fur age and occupations who were judged to be free of coronary heart diseases at routine medical examinations in the workplace. Main outcome measures: Odds ratios for myocardial infarction in relation to previous mean daily working hours in a month and changes in mean working hours during previous year. Results: Compared with men with mean working hours of >7-9 hours, the odds ratio of acute myocardial infarction (adjusted for age and occupation) for men with working hours of >11 hours was 2.44 (95% confidence interval 1.26 to 4.73) and for men with working hours of less than or equal to 7 hours was 3.07 (1.77 to 5.32). Compared with men who experienced an increase of less than or equal to 1 hour in mean working hours, the adjusted odds ratio of myocardial infarction for men who experienced an increase of > 3 hours was 2.53 (1.34 to 4.77). No appreciable change was observed when odds rations were adjusted for established and psychosocial risk factors for myocardial infarction. Conclusion: there was a U shaped relation between the mean working hours and the risk of acute myocardial infarction. There also seemed to be a trend for the risk of infarction to increase with greater increases in mean working hours.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Welfare Promot & Epidemiol, Toyama 9300194, Japan	University of Toyama	Sokejima, S (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Welfare Promot & Epidemiol, 2630 Sugitani, Toyama 9300194, Japan.							ALFREDSSON L, 1993, INT J EPIDEMIOL, V22, P57, DOI 10.1093/ije/22.1.57; APPELS A, 1991, BEHAV MED, V17, P53, DOI 10.1080/08964289.1991.9935158; BABA S, 1994, CIRCULATION, V89, P109, DOI 10.1161/01.CIR.89.1.109; Christensen NJ, 1995, ANN NY ACAD SCI, V771, P640, DOI 10.1111/j.1749-6632.1995.tb44716.x; HAMMAR N, 1994, INT J EPIDEMIOL, V23, P277, DOI 10.1093/ije/23.2.277; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; HAVASHI T, 1996, J OCCUP ENVIRON MED, V38, P1007; HAYANO J, 1990, CIRCULATION, V81, P1217, DOI 10.1161/01.CIR.81.4.1217; HAYANO J, 1990, AM J CARDIOL, V65, P84, DOI 10.1016/0002-9149(90)90030-5; HAYANO J, 1991, AM HEART J, V121, P1070, DOI 10.1016/0002-8703(91)90664-4; Hosmer D.W., 2004, APPL LOGISTIC REGRES, VSecond; IUOMILEHTO J, 1987, BRIT MED J, V295, P623; *JAP MIN HLTH WELF, 1991, SPEC REP VIT STAT 19; *JAP MIN HLTH WELF, 1993, NAT SURV CIRC DIS 19; *JAP MIN LAB, 1997, YB LAB STAT 1995; Kageyama T, 1997, LANCET, V350, P639, DOI 10.1016/S0140-6736(05)63328-4; MARMOT MG, 1976, AM J EPIDEMIOL, V104, P225, DOI 10.1093/oxfordjournals.aje.a112296; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; MORRIS JK, 1994, BMJ-BRIT MED J, V308, P1135, DOI 10.1136/bmj.308.6937.1135; MUKAI S, 1995, J APPL PHYSIOL, V78, P212, DOI 10.1152/jappl.1995.78.1.212; MUSCAT JE, 1995, INT J EPIDEMIOL, V24, P715, DOI 10.1093/ije/24.4.715; Naruse Y, 1997, J Epidemiol, V7, P71; OKAYAMA A, 1993, INT J EPIDEMIOL, V22, P1038, DOI 10.1093/ije/22.6.1038; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; PIEPER C, 1993, J HYPERTENS, V11, P177, DOI 10.1097/00004872-199302000-00010; REED DM, 1989, AM J EPIDEMIOL, V129, P495, DOI 10.1093/oxfordjournals.aje.a115160; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; *SAS I, 1996, SAS STAT SOFTW HANG; STENDER M, 1993, INT J EPIDEMIOL, V22, P644, DOI 10.1093/ije/22.4.644; Uehata Tetsunojo, 1991, Journal of Human Ergology, V20, P147; UESHIMA H, 1990, ACTA CARDIOL, V45, P311	32	165	172	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					775	780		10.1136/bmj.317.7161.775	http://dx.doi.org/10.1136/bmj.317.7161.775			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740562	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000076084200022
J	Martin, T; Obst, U; Rebek, J				Martin, T; Obst, U; Rebek, J			Molecular assembly and encapsulation directed by hydrogen-bonding preferences and the filling of space	SCIENCE			English	Article							SOLID-STATE; ORGANIC STRUCTURES; DESIGN; TAPES	Multiple copies of a molecule, held together in finite aggregates, give rise to properties and functions that are unique to their assembled states. Because these aggregates are held together by weak forces operating over short distances, a premium is placed on complementarity: The molecular surfaces must facilitate specific interactions that direct the assembly to one aggregate rather than another. Hydrogen-bonding preferences can be combined with molecular curvature to favor the assembly of four self-complementary subunits into a pseudo-spherical capsule. Filling the capsule with smaller, complementary molecules provides the final instruction for the assembly process.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Rebek, J (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Martin, Tomas/J-9222-2014	Martin, Tomas/0000-0002-9504-7287				BARR RG, 1986, J PHYS CHEM-US, V90, P328, DOI 10.1021/j100274a026; BURKE PO, 1984, J CHEM SOC PERK T 2, P1851, DOI 10.1039/p29840001851; CHANG YL, 1993, J AM CHEM SOC, V115, P5991, DOI 10.1021/ja00067a014; CHAPMAN RG, 1995, J AM CHEM SOC, V117, P9081, DOI 10.1021/ja00140a031; Conn MM, 1997, CHEM REV, V97, P1647, DOI 10.1021/cr9603800; CRAM DJ, 1994, CONTIANER MOL THEIR; DRIAN CM, 1993, J CHEM SOC CHEM COMM, P243; GALLANT M, 1991, J ORG CHEM, V56, P2284, DOI 10.1021/jo00007a007; GARCIAS X, 1995, TETRAHEDRON LETT, V36, P8535, DOI 10.1016/0040-4039(95)01829-7; HARRIS KDM, 1989, NATURE, V341, P19, DOI 10.1038/341019a0; LEISEROWITZ L, 1969, J CHEM SOC A, P2372, DOI 10.1039/j19690002372; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; Mecozzi S, 1998, CHEM-EUR J, V4, P1016, DOI 10.1002/(SICI)1521-3765(19980615)4:6<1016::AID-CHEM1016>3.0.CO;2-B; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; MORAT C, 1979, TETRAHEDRON LETT, V45, P4409; Rudkevich DM, 1997, ANGEW CHEM INT EDIT, V36, P846, DOI 10.1002/anie.199708461; Tokunaga Y, 1998, J AM CHEM SOC, V120, P66, DOI 10.1021/ja972885t; Vreekamp RH, 1996, ANGEW CHEM INT EDIT, V35, P1215, DOI 10.1002/anie.199612151; WHITESIDES GM, 1991, SCIENCE, V254, P1312, DOI 10.1126/science.1962191; YANG J, 1994, TETRAHEDRON LETT, V35, P3665, DOI 10.1016/S0040-4039(00)73066-8; ZERKOWSKI JA, 1992, J AM CHEM SOC, V114, P5473, DOI 10.1021/ja00039a096; ZERKOWSKI JA, 1990, J AM CHEM SOC, V112, P9025, DOI 10.1021/ja00180a083; ZERKOWSKI JA, 1994, J AM CHEM SOC, V116, P2382, DOI 10.1021/ja00085a018; Zimmerman SC, 1996, SCIENCE, V271, P1095, DOI 10.1126/science.271.5252.1095	24	123	124	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1842	1845		10.1126/science.281.5384.1842	http://dx.doi.org/10.1126/science.281.5384.1842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743495				2022-12-24	WOS:000076007100050
J	DiPaola, RS; Zhang, HY; Lambert, GH; Meeker, R; Licitra, E; Rafi, MM; Zhu, BT; Spaulding, H; Goodin, S; Toledano, MB; Hait, WN; Gallo, MA				DiPaola, RS; Zhang, HY; Lambert, GH; Meeker, R; Licitra, E; Rafi, MM; Zhu, BT; Spaulding, H; Goodin, S; Toledano, MB; Hait, WN; Gallo, MA			Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIETHYLSTILBESTROL; CELLS; MICE; EXPRESSION; APOPTOSIS; ESTRADIOL; EXTRACTS; GINSENG	Background Herbal mixtures are popular alternatives to demonstrated therapies. PC-SPES, a commercially available combination of eight herbs, is used as a nonestrogenic treatment for cancer of the prostate. Since other herbal medicines have estrogenic effects in vitro, we tested the estrogenic activity of PC-SPES in yeast and mice and in men with prostate cancer. Methods We measured the estrogenic activity of PC-SPES with transcriptional-activation assays in yeast and a biologic assay in mice. We assessed the clinical activity of PC-SPES in eight patients with hormone-sensitive prostate cancer by measuring serum prostate-specific antigen and testosterone concentrations during and after treatment. Results In complementary yeast assays, a 1:200 dilution of an ethanol extract of PC-SPES had estrogenic activity similar to that of 1 nM estradiol, and in ovariectomized CD-1 mice, the herbal mixture increased uterine weights substantially. In six of six men with prostate cancer, PC-SPES decreased serum testosterone concentrations (P<0.05), and in eight of eight patients it decreased serum concentrations of prostate-specific antigen. All eight patients had breast tenderness and loss of libido, and one had venous thrombosis. High-performance liquid chromatography, gas chromatography, and mass spectrometry showed that PC-SPES contains estrogenic organic compounds that are distinct from diethylstilbestrol, estrone, and estradiol. Conclusions PC-SPES has potent estrogenic activity. The use of this unregulated mixture of herbs may confound the results of standard or experimental therapies and may produce clinically significant adverse effects. (N Eng[ J Med 1998;339:785-91.) (C) 1998, Massachusetts Medical Society.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ 08901 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, New Brunswick, NJ 08901 USA; Canc Inst New Jersey, New Brunswick, NJ USA; Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	DiPaola, RS (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, Dept Med, 195 Little Albany St, New Brunswick, NJ 08901 USA.				NATIONAL CANCER INSTITUTE [P20CA057142, P30CA072720, R03CA077133] Funding Source: NIH RePORTER; NCI NIH HHS [CA57142, CA72720, R03-CA77133] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRIKIAN AG, 1994, BRIT J UROL, V74, P630, DOI 10.1111/j.1464-410X.1994.tb09196.x; Carraro JC, 1996, PROSTATE, V29, P231, DOI 10.1002/(SICI)1097-0045(199610)29:4&lt;231::AID-PROS4&gt;3.0.CO;2-E; CITRIN DL, 1985, CANCER, V56, P457, DOI 10.1002/1097-0142(19850801)56:3<457::AID-CNCR2820560307>3.0.CO;2-7; Cott JM, 1997, PHARMACOPSYCHIATRY, V30, P108, DOI 10.1055/s-2007-979529; Delos S, 1995, J STEROID BIOCHEM, V55, P375, DOI 10.1016/0960-0760(95)00184-0; DROZ JP, 1908, PROSTATE, V24, P62; Duda RB, 1996, ANN SURG ONCOL, V3, P515, DOI 10.1007/BF02306082; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; FAN S, 1995, Patent No. 5417979; Fielden MR, 1997, ENVIRON HEALTH PERSP, V105, P1238, DOI 10.1289/ehp.971051238; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; Halicka HD, 1997, INT J ONCOL, V11, P437; Hsieh TC, 1997, BIOCHEM MOL BIOL INT, V42, P535; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Risberg T, 1998, J CLIN ONCOL, V16, P6, DOI 10.1200/JCO.1998.16.1.6; Robertson CN, 1996, J NATL CANCER I, V88, P908, DOI 10.1093/jnci/88.13.908; See DM, 1997, IMMUNOPHARMACOLOGY, V35, P229, DOI 10.1016/S0162-3109(96)00125-7; SUCHAR LA, 1995, J PHARMACOL EXP THER, V272, P197; Volz HP, 1997, PHARMACOPSYCHIATRY, V30, P72, DOI 10.1055/s-2007-979522; WALKER BE, 1983, TERATOLOGY, V27, P73, DOI 10.1002/tera.1420270111; WALKER BE, 1983, J NATL CANCER I, V70, P477; Zava DT, 1997, ENVIRON HEALTH PERSP, V105, P637, DOI 10.2307/3433383; Zhu BT, 1997, CANCER RES, V57, P2419	24	257	274	0	27	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					785	791		10.1056/NEJM199809173391201	http://dx.doi.org/10.1056/NEJM199809173391201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738085	Bronze			2022-12-24	WOS:000075909200001
J	Salonen, JT; Tuomainen, TP; Nyyssonen, K; Lakka, HM; Punnonen, K				Salonen, JT; Tuomainen, TP; Nyyssonen, K; Lakka, HM; Punnonen, K			Relation between iron stores and non-insulin dependent diabetes in men: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Kuopio, Res Inst Publ Hlth, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Kuopio Univ Hosp, Dept Clin Chem, FIN-70211 Kuopio, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital	Salonen, JT (corresponding author), Univ Kuopio, Res Inst Publ Hlth, POB 1627, FIN-70211 Kuopio, Finland.				NHLBI NIH HHS [HL44199] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		OBERLEY LW, 1988, FREE RADICAL BIO MED, V5, P113, DOI 10.1016/0891-5849(88)90036-6; SALONEN JT, 1995, BRIT MED J, V311, P1124, DOI 10.1136/bmj.311.7013.1124; Tuomainen TP, 1997, DIABETES CARE, V20, P426, DOI 10.2337/diacare.20.3.426; Tuomainen TP, 1998, CIRCULATION, V97, P1461; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2	5	188	198	1	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					727	727		10.1136/bmj.317.7160.727	http://dx.doi.org/10.1136/bmj.317.7160.727			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732340	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000075995100021
J	Amend, JP; Shock, EL				Amend, JP; Shock, EL			Energetics of amino acid synthesis in hydrothermal ecosystems	SCIENCE			English	Article							EUBACTERIUM THERMOTOGA-MARITIMA; MOLAL THERMODYNAMIC PROPERTIES; GEOCHEMICAL CONSTRAINTS; ELEVATED-TEMPERATURES; PYROCOCCUS-FURIOSUS; HIGH-PRESSURES; STANDARD; SEQUENCE; SYSTEMS; 1000-DEGREES-C	Thermodynamic calculations:showed that the autotrophic synthesis of all 20 protein-forming amino acids was energetically favored in hot (100 degrees C), moderately reduced, submarine hydrothermal solutions relative to the synthesis in cold (18 degrees C), oxidized, surface seawater. The net synthesis reactions of 11 amino acids were exergonic in the hydrothermal solution, but all were endergonic in surface seawater. The synthesis of the requisite amino acids of nine thermophilic and hyperthermophilic proteins in a 100 degrees C hydrothermal solution yielded between 600 and 8000 kilojoules per mole of protein, which is energy that is available to drive the intracellular synthesis of enzymes and other biopolymers in hyperthermophiles thriving in these ecosystems.	Washington Univ, Dept Earth & Planetary Sci, Grp Exploring Organ Proc Geochem, St Louis, MO 63130 USA	Washington University (WUSTL)	Amend, JP (corresponding author), Washington Univ, Dept Earth & Planetary Sci, Grp Exploring Organ Proc Geochem, St Louis, MO 63130 USA.			Shock, Everett/0000-0002-4283-0163				Amend JP, 1997, J CHEM SOC FARADAY T, V93, P1927, DOI 10.1039/a608126f; Amend JP, 1997, GEOCHIM COSMOCHIM AC, V61, P11, DOI 10.1016/S0016-7037(96)00306-7; BACHLEITNER M, 1989, FEMS MICROBIOL LETT, V57, P115, DOI 10.1111/j.1574-6968.1989.tb03231.x; BAROSS JA, 1985, ORIGINS LIFE EVOL B, V15, P327, DOI 10.1007/BF01808177; BLAKE PR, 1991, BIOCHEMISTRY-US, V30, P10885, DOI 10.1021/bi00109a012; BUSSE SC, 1992, BIOCHEMISTRY-US, V31, P11952, DOI 10.1021/bi00162a038; ENGEL AM, 1992, EMBO J, V11, P4369, DOI 10.1002/j.1460-2075.1992.tb05537.x; HELGESON HC, 1991, CAN MINERAL, V29, P707; HELGESON HC, 1981, AM J SCI, V281, P1249, DOI 10.2475/ajs.281.10.1249; Huber C, 1997, SCIENCE, V276, P245, DOI 10.1126/science.276.5310.245; INGMANSON DE, 1977, ORIGINS LIFE EVOL B, V8, P221, DOI 10.1007/BF00930683; JAKOSKY BM, IN PRESS J GEOPHYS R; JOHNSON JW, 1992, COMPUT GEOSCI-UK, V18, P899, DOI 10.1016/0098-3004(92)90029-Q; KEIL RG, UNPUB; LILLEY MD, COMMUNICATION; LUTZ RA, 1994, NATURE, V371, P663, DOI 10.1038/371663a0; McCollom TM, 1997, GEOCHIM COSMOCHIM AC, V61, P4375, DOI 10.1016/S0016-7037(97)00241-X; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pennisi E, 1998, SCIENCE, V280, P672, DOI 10.1126/science.280.5364.672; RUSSELL MJ, 1997, J GEOL SOC LONDON, V154, P337; SANANGELANTONI AM, 1992, J GEN MICROBIOL, V138, P383, DOI 10.1099/00221287-138-2-383; SCHOCK EL, IN PRESS J GEOPHYS R; SCHULTES V, 1990, EUR J BIOCHEM, V192, P25, DOI 10.1111/j.1432-1033.1990.tb19190.x; SHOCK EL, 1992, GEOCHIM COSMOCHIM AC, V56, P3481, DOI 10.1016/0016-7037(92)90392-V; SHOCK EL, 1992, J CHEM SOC FARADAY T, V88, P803, DOI 10.1039/ft9928800803; Shock EL, 1997, GEOCHIM COSMOCHIM AC, V61, P907, DOI 10.1016/S0016-7037(96)00339-0; SHOCK EL, 1995, ORIGINS LIFE EVOL B, V25, P141, DOI 10.1007/BF01581579; SHOCK EL, 1990, ORIGINS LIFE EVOL B, V20, P331, DOI 10.1007/BF01808115; SHOCK EL, 1996, EVOLUTION HYDROTHERM, P40; SHOCK EL, IN PRESS THERMOPHILE; SVERJENSKY DA, 1989, COSMOCHIM ACTA, V53, P2157; TAKAHASHI T, 1980, CU180 LAM GEOL OBS; VONDAMM KL, 1990, ANNU REV EARTH PL SC, V18, P173, DOI 10.1146/annurev.ea.18.050190.001133; WACHTERSHAUSER G, 1988, SYST APPL MICROBIOL, V10, P207; Woese C, 1998, P NATL ACAD SCI USA, V95, P6854, DOI 10.1073/pnas.95.12.6854	35	158	162	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1659	1662		10.1126/science.281.5383.1659	http://dx.doi.org/10.1126/science.281.5383.1659			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733509				2022-12-24	WOS:000075856500042
J	Diez-Gonzalez, F; Callaway, TR; Kizoulis, MG; Russell, JB				Diez-Gonzalez, F; Callaway, TR; Kizoulis, MG; Russell, JB			Grain feeding and the dissemination of acid-resistant Escherichia coli from cattle	SCIENCE			English	Article							FOODBORNE PATHOGENS; O157-H7; DISEASE	The gastric stomach of humans is a barrier to food-borne pathogens, but Escherichia coli can survive at pH 2.0 if it is grown under mildly acidic conditions. Cattle are a natural reservoir for pathogenic E. coli, and cattle fed mostly grain had Lower colonic pH and more acid-resistant E. coli than cattle fed only hay. On the basis of numbers and survival after acid shock, cattle that were fed grain had 10(6)-fold more acid-resistant E. coli than cattle fed hay, but a brief period of hay feeding decreased the acid-resistant count substantially.	Cornell Univ, Div Biol Sci, Microbiol Sect, Ithaca, NY 14853 USA; ARS, USDA, Ithaca, NY 14853 USA	Cornell University; United States Department of Agriculture (USDA)	Russell, JB (corresponding author), Cornell Univ, Div Biol Sci, Microbiol Sect, Ithaca, NY 14853 USA.	jbr8@cornell.edu	Callaway, Todd/AAG-9380-2020; Diez-Gonzalez, Francisco/AAA-8401-2022	Callaway, Todd/0000-0002-3310-4979; Diez-Gonzalez, Francisco/0000-0002-8644-1397				Armstrong GL, 1996, EPIDEMIOL REV, V18, P29, DOI 10.1093/oxfordjournals.epirev.a017914; BENJAMIN MM, 1995, APPL ENVIRON MICROB, V61, P1669, DOI 10.1128/AEM.61.4.1669-1672.1995; Buchanan RL, 1997, FOOD TECHNOL-CHICAGO, V51, P69; CALDWELL DR, 1966, APPL MICROBIOL, V14, P794, DOI 10.1128/AEM.14.5.794-801.1966; Collins JE, 1997, EMERG INFECT DIS, V3, P471, DOI 10.3201/eid0304.970409; CRAY WC, 1995, APPL ENVIRON MICROB, V61, P1586, DOI 10.1128/AEM.61.4.1586-1590.1995; *CTR AGR SCI TECHN, 1994, 122 CAST CTR AGR SCI; GORDEN J, 1993, INFECT IMMUN, V61, P364, DOI 10.1128/IAI.61.1.364-367.1993; Hitchins A. D., 1995, FDA BACTERIOLOGICAL; Lederberg J, 1997, EMERG INFECT DIS, V3, P417, DOI 10.3201/eid0304.970402; LIN ECC, 1996, ESCHERICHIA COLI SAL, V1, pCH20; Ott, 1993, INTRO STAT METHODS D; RILEY LW, 1983, NEW ENGL J MED, V308, P681, DOI 10.1056/NEJM198303243081203; RUSSELL JR, 1981, J ANIM SCI, V52, P1177, DOI 10.2527/jas1981.5251177x; Sokal Robert R., 1969, BIOMETRY; SU CY, 1995, ANN INTERN MED, V123, P698, DOI 10.7326/0003-4819-123-9-199511010-00009; Tauxe RV, 1997, EMERG INFECT DIS, V3, P425, DOI 10.3201/eid0304.970403; WALDO DR, 1973, J ANIM SCI, V37, P1062, DOI 10.2527/jas1973.3741062x; WHIPP SC, 1994, J AM VET MED ASSOC, V204, P1168; Zhao T, 1998, J CLIN MICROBIOL, V36, P641, DOI 10.1128/JCM.36.3.641-647.1998	20	271	280	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1666	1668		10.1126/science.281.5383.1666	http://dx.doi.org/10.1126/science.281.5383.1666			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733511				2022-12-24	WOS:000075856500044
J	Cummings, SR; Browner, WS; Bauer, D; Stone, K; Ensrud, K; Jamal, S; Ettinger, B				Cummings, SR; Browner, WS; Bauer, D; Stone, K; Ensrud, K; Jamal, S; Ettinger, B		Study Osteoporotic Fractures Res Grp	Endogenous hormones and the risk of hip and vertebral fractures among older women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEMORAL-NECK FRACTURE; VITAMIN-D STATUS; POSTMENOPAUSAL WOMEN; ESTROGEN THERAPY; ELDERLY WOMEN; BONE; OSTEOPOROSIS; 1,25-DIHYDROXYVITAMIN-D; 17-BETA-ESTRADIOL; ENDOMETRIUM	Background and Methods. In postmenopausal women, the serum concentrations of endogenous sex hormones and vitamin D might influence the risk of hip and vertebral fractures. In a study of a cohort of women 65 years of age or older, we compared the serum hormone concentrations at base line in 133 women who subsequently had hip fractures and 138 women who subsequently had vertebral fractures with those in randomly selected control women from the same cohort. Women who were taking estrogen were excluded. The results were adjusted for age and weight. Results. The women with undetectable serum estradiol concentrations (<5 pg per milliliter [18 pmol per liter]) had a relative risk of 2.5 for subsequent hip fracture (95 percent confidence interval, 1.4 to 4.6) and subsequent vertebral fracture (95 percent confidence interval, 1.4 to 4.2), as compared with the women with detectable serum estradiol concentrations. Serum concentrations of sex hormone-binding globulin that were 1.0 mu g per deciliter (34.7 nmol per liter) or higher were associated with a relative risk of 2.0 for hip fracture (95 percent confidence interval, 1.1 to 3.9) and 2.3 for vertebral fracture (95 percent confidence interval, 1.2 to 4.4), Women with both undetectable serum estradiol concentrations and serum sex hormone-binding globulin concentrations of 1 mu g per deciliter or more had a relative risk of 6.9 for hip fracture (95 percent confidence interval, 1.5 to 32.0) and 7.9 for vertebral fracture (95 percent confidence interval, 2.2 to 28.0). For those with low serum 1,25-dihydroxyvitamin D concentrations (less than or equal to 23 pg per milliliter [55 pmol per liter]), the risk of hip fracture increased by a factor of 2.1 (95 percent confidence interval, 1.2 to 3.5). Conclusions. Postmenopausal women with undetectable serum estradiol concentrations and high serum concentrations of sex hormone-binding globulin have an increased risk of hip and vertebral fracture. (N Engl J Med 1998;339:733-8.) (C) 1998, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Kaiser Permanente Med Care Program, Div Res, Oakland, CA 94611 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; Kaiser Permanente	Cummings, SR (corresponding author), Suite 600,74 New Montgomery St, San Francisco, CA 94143 USA.			Ensrud, Kristine/0000-0002-9069-3036	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35582] Funding Source: Medline; NIA NIH HHS [AG05407, AG05394] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALOIA JF, 1985, AM J MED, V78, P95, DOI 10.1016/0002-9343(85)90468-1; BLACK DM, 1995, J BONE MINER RES, V10, P890; BROWNER WS, 1986, AM J EPIDEMIOL, V123, P143, DOI 10.1093/oxfordjournals.aje.a114208; COOPER C, 1989, BONE MINER, V5, P193, DOI 10.1016/0169-6009(89)90096-2; CUMMINGS SR, 1987, AM J EPIDEMIOL, V126, P796, DOI 10.1093/oxfordjournals.aje.a114716; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; CUMMINGS SR, 1995, J BONE MINER RES, V10, P1605; DAVIDSON BJ, 1982, J CLIN ENDOCR METAB, V54, P115, DOI 10.1210/jcem-54-1-115; DORGAN JF, 1996, CANCER EPIDEM BIOMAR, V5, P553; DUNSTAN CR, 1990, CALCIFIED TISSUE INT, V47, P270, DOI 10.1007/BF02555908; ETTINGER B, 1992, AM J OBSTET GYNECOL, V166, P479, DOI 10.1016/0002-9378(92)91653-R; Ettinger B, 1997, AM J OBSTET GYNECOL, V176, P112, DOI 10.1016/S0002-9378(97)80022-1; FURUYAMA S, 1970, STEROIDS, V16, P415, DOI 10.1016/S0039-128X(70)80124-6; Garnero P, 1996, J BONE MINER RES, V11, P1531; Genant HK, 1997, ARCH INTERN MED, V157, P2609, DOI 10.1001/archinte.157.22.2609; HESHMATI HM, 1997, J BONE MINER RES  S1, V12, pS121; HORDON LD, 1990, BONE MINER, V11, P247, DOI 10.1016/0169-6009(90)90063-L; KOCHERSBERGER G, 1988, Comprehensive Therapy, V14, P24; LAMBERG-ALLARDT C, 1989, EUR J CLIN NUTR, V43, P355; LANYON LE, 1993, CALCIFIED TISSUE INT, V53, pS102, DOI 10.1007/BF01673415; LAU EMC, 1989, GERONTOLOGY, V35, P198, DOI 10.1159/000213023; LAUFER LR, 1983, AM J OBSTET GYNECOL, V145, P585, DOI 10.1016/0002-9378(83)91201-2; LIPS P, 1982, METAB BONE DIS RELAT, V4, P85, DOI 10.1016/0221-8747(82)90021-2; LONGCOPE C, 1984, MATURITAS, V6, P309, DOI 10.1016/0378-5122(84)90002-1; LUND B, 1982, HORM METAB RES, V14, P271, DOI 10.1055/s-2007-1018990; MAYES D, 1968, J CLIN ENDOCR METAB, V28, P1169, DOI 10.1210/jcem-28-8-1169; Naessen T, 1997, AM J OBSTET GYNECOL, V177, P115, DOI 10.1016/S0002-9378(97)70448-4; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; Riggs BL, 1998, J BONE MINER RES, V13, P763, DOI 10.1359/jbmr.1998.13.5.763; RIGGS BL, 1983, AM J MED, V75, P899, DOI 10.1016/0002-9343(83)90860-4; RIGGS BL, 1973, J CLIN ENDOCR METAB, V36, P1097, DOI 10.1210/jcem-36-6-1097; RUDMAN D, 1989, J AM COLL NUTR, V8, P324; Speroff L, 1996, JAMA-J AM MED ASSOC, V276, P1397, DOI 10.1001/jama.276.17.1397; STEIGER P, 1992, J BONE MINER RES, V7, P625; Tomkinson A, 1997, J CLIN ENDOCR METAB, V82, P3128, DOI 10.1210/jc.82.9.3128; TONIOLO PG, 1995, JNCI-J NATL CANCER I, V87, P190, DOI 10.1093/jnci/87.3.190; VANDEWALLE B, 1989, MOL CELL ENDOCRINOL, V61, P239, DOI 10.1016/0303-7207(89)90135-4; VANHEMERT AM, 1989, CLIN ENDOCRINOL, V31, P499	38	520	528	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					733	738		10.1056/NEJM199809103391104	http://dx.doi.org/10.1056/NEJM199809103391104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731089	Bronze			2022-12-24	WOS:000075737800004
J	Song, HJ; Ming, GL; He, ZG; Lehmann, M; McKerracher, L; Tessier-Lavigne, M; Poo, MM				Song, HJ; Ming, GL; He, ZG; Lehmann, M; McKerracher, L; Tessier-Lavigne, M; Poo, MM			Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides	SCIENCE			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; DEPENDENT PROTEIN-KINASE; SEMAPHORIN-III; NITRIC-OXIDE; SPINAL-CORD; C-ELEGANS; INTRACELLULAR CALCIUM; AXONAL REGENERATION; GUIDANCE MOLECULES; KINETIC-ANALYSIS	Nerve growth is regulated by attractive and repulsive factors in the nervous system. Microscopic gradients of Collapsin-1/Semaphorin III/D (Sema III) and myelin-associated glycoprotein trigger repulsive turning responses by growth cones of cultured Xenopus spinal neurons; the repulsion can be converted to attraction by pharmacological activation of the guanosine 3',5'-monophosphate (cGMP) and adenosine 3',5'-monophosphate signaling pathways, respectively. Sema ill also causes the collapse of cultured rat sensory growth cones, which can be inhibited by activation of the cGMP pathway. Thus cyclic nucleotides can regulate growth cone behaviors and may be targets for designing treatments to alleviate the inhibition of nerve regeneration by repulsive factors.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, San Francisco, CA 94143 USA; Univ Montreal, Dept Pathol, Montreal, PQ H3C 3J7, Canada; McGill Univ, Montreal, PQ H3C 3J7, Canada	University of California System; University of California San Diego; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Universite de Montreal; McGill University	Poo, MM (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Ming, Guo-li/J-7880-2013	Ming, Guo-li/0000-0002-2517-6075	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS022764] Funding Source: NIH RePORTER; NINDS NIH HHS [NS22764] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANDTLOW CE, 1993, SCIENCE, V259, P80, DOI 10.1126/science.8418499; Behar O, 1996, NATURE, V383, P525, DOI 10.1038/383525a0; BIXBY JL, 1984, J PHYSIOL-LONDON, V353, P143, DOI 10.1113/jphysiol.1984.sp015328; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; Chen H, 1997, NEURON, V19, P547, DOI 10.1016/S0896-6273(00)80371-2; COLAMARINO SA, 1995, CELL, V81, P621, DOI 10.1016/0092-8674(95)90083-7; Cooper J.R., 1996, BIOCH BASIS NEUROPHA, Vseventh; EVERS J, 1989, J NEUROSCI, V9, P1523; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Fong JHJ, 1996, BIOCHEM BIOPH RES CO, V221, P19, DOI 10.1006/bbrc.1996.0537; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; IVINS JK, 1991, J NEUROSCI, V11, P1597; KATER SB, 1988, TRENDS NEUROSCI, V11, P317; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; LAUFER R, 1987, EMBO J, V6, P901, DOI 10.1002/j.1460-2075.1987.tb04836.x; Li M, 1996, J NEUROSCI RES, V46, P404, DOI 10.1002/(SICI)1097-4547(19961115)46:4<404::AID-JNR2>3.0.CO;2-K; LOHOF AM, 1992, J NEUROSCI, V12, P1253; Loschinger J, 1997, J NEUROBIOL, V33, P825, DOI 10.1002/(SICI)1097-4695(19971120)33:6<825::AID-NEU9>3.0.CO;2-B; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; MESSERSMITH EK, 1995, CELL, V81, P949; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Puschel AW, 1996, MOL CELL NEUROSCI, V7, P419, DOI 10.1006/mcne.1996.0030; ROSKAMS AJ, 1994, NEURON, V13, P289; ROTHERMEL JD, 1988, BIOCHEM J, V251, P757, DOI 10.1042/bj2510757; SATO S, 1984, ANN NEUROL, V15, P264, DOI 10.1002/ana.410150310; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; SCHWARZSCHILD MA, 1991, J NEUROCHEM, V56, P400, DOI 10.1111/j.1471-4159.1991.tb08165.x; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; Shirasaki R, 1998, SCIENCE, V279, P105, DOI 10.1126/science.279.5347.105; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Taniguchi M, 1997, NEURON, V19, P519, DOI 10.1016/S0896-6273(00)80368-2; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WOLIN MS, 1982, J BIOL CHEM, V257, P13312; WU HH, 1994, SCIENCE, V265, P1593, DOI 10.1126/science.7521541	45	675	698	1	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1515	1518		10.1126/science.281.5382.1515	http://dx.doi.org/10.1126/science.281.5382.1515			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727979				2022-12-24	WOS:000075738100043
J	Kors, JA; de Bruyne, MC; Hoes, AW; van Herpen, G; Hofman, A; van Bemmel, JH; Grobbee, DE				Kors, JA; de Bruyne, MC; Hoes, AW; van Herpen, G; Hofman, A; van Bemmel, JH; Grobbee, DE			T axis as an indicator of risk of cardiac events in elderly people	LANCET			English	Article							CORONARY HEART-DISEASE; DEATH; ELECTROCARDIOGRAMS; MORTALITY; PROGRAMS; MEN	Background The T axis was postulated to be a general marker of repolarisation abnormality, indicative of subclinical myocardial damage. The aim of this investigation was to assess the prognostic importance of the T axis for fatal and non-fatal cardiac events, in a prospective cohort study of men and women aged 55 years and older. Methods 2352 men and 3429 women from the population-based Rotterdam Study took part in the study. Electrocardiograms were done, and T axes were categorised as normal, borderline, or abnormal. Data were analysed with Cox's proportional-hazards models; adjustment for age and sex was done where appropriate. Findings During 3-6 (mean 4) years of follow-up of the 5781 participants, 165 (2.9%) fatal and 192 (3.3%) non-fatal cardiac events occurred. Participants with an abnormal T axis (n=609) had an increased risk of cardiac death (hazard ratio 3.9 [95% CI 2.8-5.6]), sudden cardiac death (4.4 [2.6-7.4]), non-fatal cardiac events (2.7 [1.9-3.9]), and combined fatal or non-fatal cardiac events (3.2 [2.5-4.1]); p<0.001 for each. Additional adjustment for established cardiovascular risk factors resulted in lower. but still significant risk for all endpoints. The risk associated with an abnormal T axis was higher than those for any other cardiovascular risk factor. Additional subgroup analyses indicated that the risk of cardiac death was not substantially modified by age, sex, or history of myocardial infarction. Interpretation The T axis is a strong and independent risk indicator of fatal and non-fatal cardiac events in the elderly.	Erasmus Univ, Sch Med, Dept Med Informat, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Univ Utrecht, Julius Ctr Patient Oriented Res, Utrecht, Netherlands	Erasmus University Rotterdam; Erasmus University Rotterdam; Utrecht University	Kors, JA (corresponding author), Erasmus Univ, Sch Med, Dept Med Informat, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BRISTOW JD, 1961, AM HEART J, V61, P242, DOI 10.1016/0002-8703(61)90582-8; CEDRES BL, 1982, CIRCULATION, V65, P146, DOI 10.1161/01.CIR.65.1.146; COOKSEY JD, 1977, CLIN VECTORCARDIOGRA; CULLEN K, 1982, BRIT HEART J, V47, P209; CUPPLES LA, 1992, CIRCULATION, V85, P11; de Bruyne MC, 1998, CIRCULATION, V97, P467; deBruyne MC, 1997, AM J CARDIOL, V80, P1300, DOI 10.1016/S0002-9149(97)00669-3; DRAPER HW, 1964, CIRCULATION, V30, P853, DOI 10.1161/01.CIR.30.6.853; EDENBRANDT L, 1988, J ELECTROCARDIOL, V21, P361, DOI 10.1016/0022-0736(88)90113-6; HOFMAN A, 1991, EUR J EPIDEMIOL, V7, P403, DOI 10.1007/BF00145007; KANNEL WB, 1987, AM HEART J, V113, P370, DOI 10.1016/0002-8703(87)90280-8; KNUTSEN R, 1988, J CLIN EPIDEMIOL, V41, P293, DOI 10.1016/0895-4356(88)90134-5; Kors JA, 1996, J ELECTROCARDIOL, V29, P83, DOI 10.1016/S0022-0736(96)80025-2; KORS JA, 1990, EUR HEART J, V11, P1083, DOI 10.1093/oxfordjournals.eurheartj.a059647; LARSON MG, 1995, STAT MED, V14, P1745, DOI 10.1002/sim.4780141604; LIAO YL, 1988, J AM COLL CARDIOL, V12, P1494, DOI 10.1016/S0735-1097(88)80016-0; MYERBURG RJ, 1992, CIRCULATION, V85, P2; Prineas R., 1982, MINNESOTA CODE MANUA; RABKIN SW, 1982, BRIT HEART J, V47, P546; ROSE G, 1977, BRIT J PREV SOC MED, V31, P42; Sigurdsson E, 1996, J AM COLL CARDIOL, V27, P1140, DOI 10.1016/0735-1097(95)00614-1; SILVERBE.SM, 1966, AM J CARDIOL, V18, P672, DOI 10.1016/0002-9149(66)90084-1; Tervahauta M, 1996, AM J MED, V100, P641, DOI 10.1016/S0002-9343(96)00042-3; VANBEMMEL JH, 1990, METHOD INFORM MED, V29, P346; WILLEMS JL, 1987, J AM COLL CARDIOL, V10, P1313, DOI 10.1016/S0735-1097(87)80136-5; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; World Health Organization, 1992, INT STAT CLASS DIS R	28	132	132	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	AUG 22	1998	352	9128					601	605		10.1016/S0140-6736(97)10190-8	http://dx.doi.org/10.1016/S0140-6736(97)10190-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	113TE	9746020				2022-12-24	WOS:000075567400008
J	Raschke, RA; Gollihare, B; Wunderlich, TA; Guidry, JR; Leibowitz, AI; Peirce, JC; Lemelson, L; Heisler, MA; Susong, C				Raschke, RA; Gollihare, B; Wunderlich, TA; Guidry, JR; Leibowitz, AI; Peirce, JC; Lemelson, L; Heisler, MA; Susong, C			A computer alert system to prevent injury from adverse drug events - Development and evaluation in a community teaching hospital	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CREATININE CLEARANCE; INFORMATION-SYSTEM; MEDICAL INPATIENTS; SURVEILLANCE; ERRORS; COSTS	Context.-Adverse drug events (ADEs) are the most common type of iatrogenic injury occurring in hospitalized patients. Errors leading to ADEs are often due to restricted availability of information at the time of physician order writing. Objectives.-To develop, implement, and evaluate a computer alert system designed to correct errors that might lead to ADEs and to detect ADEs before maximum injury occurs. Design.-Prospective case series. Setting.-A 650-bed community teaching hospital in Phoenix, Ariz. Patients.-Consecutive sample of 9306 nonobstetrical adult patients admitted during the last 6 months of 1997. Interventions.-Thirty-seven drug-specific ADEs were targeted. Our hospital information system was programmed to generate alerts in clinical situations with increased risk for ADE-related injury. A clinical system was developed to ensure physician notification of alerts. Main Outcome Measures.-A true-positive alert was defined as one in which the physician wrote orders consistent with the alert recommendation after alert notification. Results.-During the 6-month study period, the alert system fired 1116 times and 596 were true-positive alerts (positive predictive value of 53%). The alerts identified opportunities to prevent patient injury secondary to ADEs at a rate of 64 per 1000 admissions. A total of 265 (44%) of the 596 true-positive alerts were unrecognized by the physician prior to alert notification. Conclusions.-Clinicians can use hospital information systems to detect opportunities to prevent patient injury secondary to a broad range of ADEs.	Good Samaritan Reg Med Ctr, Phoenix, AZ 85006 USA; Samaritan Hlth Syst, Phoenix, AZ USA; Desert Samaritan Med Ctr, Phoenix, AZ USA		Raschke, RA (corresponding author), Good Samaritan Reg Med Ctr, 1111 E McDowell Rd, Phoenix, AZ 85006 USA.	robert@samaritan.edu	Tao, Youyou/D-2367-2014	Raschke, Robert/0000-0003-3495-7065				BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; BENNETT WM, 1994, DRUG PRESCRIBING REN, P19; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Classen DC, 1997, JAMA-J AM MED ASSOC, V277, P301, DOI 10.1001/jama.277.4.301; Dalton-Bunnow M F, 1993, Hosp Pharm, V28, P746; EDLAVITCH SA, 1988, ARCH INTERN MED, V148, P1499, DOI 10.1001/archinte.148.7.1499; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; Garibaldi RA, 1998, NEW ENGL J MED, V338, P259, DOI 10.1056/NEJM199801223380411; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; JELLIFFE RW, 1973, ANN INTERN MED, V79, P604, DOI 10.7326/0003-4819-79-4-604; JICK H, 1974, NEW ENGL J MED, V291, P824, DOI 10.1056/NEJM197410172911605; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; LARSON EB, 1987, ANN INTERN MED, V107, P169, DOI 10.7326/0003-4819-107-2-169; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; Lesar TS, 1997, JAMA-J AM MED ASSOC, V277, P312, DOI 10.1001/jama.277.4.312; OCONNELL MB, 1992, ANN PHARMACOTHER, V26, P627, DOI 10.1177/106002809202600503; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; SCHROEDER CG, 1986, AM J HOSP PHARM, V43, P355, DOI 10.1093/ajhp/43.2.355; SHAPIRO S, 1971, J AMER MED ASSOC, V216, P467, DOI 10.1001/jama.216.3.467; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; WHIPPLE JK, 1994, ANN PHARMACOTHER, V28, P655, DOI 10.1177/106002809402800517; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292	33	249	253	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 21	1998	280	15					1317	1320		10.1001/jama.280.15.1317	http://dx.doi.org/10.1001/jama.280.15.1317			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	129PQ	9794309				2022-12-24	WOS:000076472500022
J	Voinnet, O; Vain, P; Angell, S; Baulcombe, DC				Voinnet, O; Vain, P; Angell, S; Baulcombe, DC			Systemic spread of sequence-specific transgene RNA degradation in plants is initiated by localized introduction of ectopic promoterless DNA	CELL			English	Article							GREEN FLUORESCENT PROTEIN; GENE-EXPRESSION; VIRUS-RESISTANCE; CHALCONE SYNTHASE; TOBACCO; METHYLATION; SUPPRESSION; REPORTER; TRANSCRIPTION; MORPHOGENESIS	Systemic, posttranscriptional silencing of transgenes in Nicotiana benthamiana was initiated in localized regions of the plant by introduction of transgene-homologous DNA fragments, including those without a promoter. Following this initiation step, a sequence-specific signal of gene silencing spread from cells that had received the ectopic DNA via a relay mechanism that employs plasmodesmatal and phloem channels. The nature of this mechanism, the mode of its initiation, and the ability of the signal to move long distances indicate the existence of a sequence-specific signaling mechanism in plants that may have roles in developmental control as well as in protection against transposons and viruses.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; John Innes Ctr Plant Sci Res, Cereals Res Dept, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Baulcombe, DC (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England.			Voinnet, Olivier/0000-0001-6982-9544; Baulcombe, David/0000-0003-0780-6878				Ashe HL, 1997, GENE DEV, V11, P2494, DOI 10.1101/gad.11.19.2494; BARRY C, 1993, P NATL ACAD SCI USA, V90, P4557, DOI 10.1073/pnas.90.10.4557; BAULCOMBE DC, 1995, PLANT J, V7, P1045, DOI 10.1046/j.1365-313X.1995.07061045.x; Baulcombe DC, 1996, CURR OPIN BIOTECH, V7, P173, DOI 10.1016/S0958-1669(96)80009-7; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; CHAPMAN S, 1992, PLANT J, V2, P549; CHRISTOU P, 1991, BIO-TECHNOL, V9, P957, DOI 10.1038/nbt1091-957; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; Ding B, 1997, PLANT J, V12, P931, DOI 10.1046/j.1365-313X.1997.12040931.x; Elmayan T, 1996, PLANT J, V9, P787, DOI 10.1046/j.1365-313X.1996.9060787.x; English JJ, 1997, PLANT J, V12, P597, DOI 10.1046/j.1365-313X.1997.00597.x; English JJ, 1996, PLANT CELL, V8, P179, DOI 10.1105/tpc.8.2.179; English JJ, 1997, PLANT J, V12, P1311, DOI 10.1046/j.1365-313x.1997.12061311.x; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; HOBBS SLA, 1990, PLANT MOL BIOL, V15, P851, DOI 10.1007/BF00039425; Iglesias VA, 1997, PLANT CELL, V9, P1251, DOI 10.1105/tpc.9.8.1251; Jefferson RA, 1987, PLANT MOL BIOL REP, V5, P387, DOI [DOI 10.1007/BF02667740, 10.1007/bf02667740]; Jones Jonathan D. G., 1992, Transgenic Research, V1, P285, DOI 10.1007/BF02525170; JORGENSEN R, 1995, PLANT PHYSIOL, V108, P14; Jorgensen R, 1992, AGBIOTECH NEWS INFOR, V4, P265; Jorgensen RA, 1998, SCIENCE, V279, P1486, DOI 10.1126/science.279.5356.1486; Kuhn C, 1997, SCIENCE, V275, P1298, DOI 10.1126/science.275.5304.1298; Kunz C, 1996, PLANT J, V10, P437, DOI 10.1046/j.1365-313X.1996.10030437.x; LEISNER SM, 1993, BIOESSAYS, V15, P741, DOI 10.1002/bies.950151107; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; LUCAS WJ, 1995, SCIENCE, V270, P1980, DOI 10.1126/science.270.5244.1980; LUCAS WJ, 1993, NEW PHYTOL, V125, P435, DOI 10.1111/j.1469-8137.1993.tb03897.x; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Palauqui JC, 1996, PLANT PHYSIOL, V112, P1447, DOI 10.1104/pp.112.4.1447; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; PALUKAITIS P, 1987, VIROLOGY, V158, P239, DOI 10.1016/0042-6822(87)90260-1; POETHIG RS, 1990, SCIENCE, V250, P923, DOI 10.1126/science.250.4983.923; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; Roberts AG, 1997, PLANT CELL, V9, P1381, DOI 10.1105/tpc.9.8.1381; Ruiz F, 1998, MOL BIOL CELL, V9, P931, DOI 10.1091/mbc.9.4.931; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Sijen T, 1996, PLANT CELL, V8, P2277, DOI 10.1105/tpc.8.12.2277; Stam M, 1997, PLANT J, V12, P63, DOI 10.1046/j.1365-313X.1997.12010063.x; Vain P, 1998, THEOR APPL GENET, V96, P164, DOI 10.1007/s001220050723; Voinnet O, 1997, NATURE, V389, P553, DOI 10.1038/39215; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; WILLE AC, 1984, PLANTA, V160, P129, DOI 10.1007/BF00392861; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zupan J, 1997, CRIT REV PLANT SCI, V16, P279, DOI 10.1080/713608150	46	538	614	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					177	187		10.1016/S0092-8674(00)81749-3	http://dx.doi.org/10.1016/S0092-8674(00)81749-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790525	Bronze			2022-12-24	WOS:000076538300006
J	Roose, J; Molenaar, M; Peterson, J; Hurenkamp, J; Brantjes, H; Moerer, P; van de Wetering, M; Destree, O; Clevers, H				Roose, J; Molenaar, M; Peterson, J; Hurenkamp, J; Brantjes, H; Moerer, P; van de Wetering, M; Destree, O; Clevers, H			The Xenopus Wnt effector XTcf-3 interacts with Groucho-related transcriptional repressors	NATURE			English	Article							BETA-CATENIN; DEVELOPMENTAL EXPRESSION; SPEMANN ORGANIZER; FACTOR LEF-1; DROSOPHILA; EMBRYOS; CLONING; ENHANCER; COMPLEX; SPLIT	Tcf/Lef transcription factors mediate signalling from Wingless/ Wnt proteins by recruiting Armadillo/beta-catenin as a transcriptional co-activator(1-7). However, studies of Drosophila, Xenopus and Caenorhabditis elegans have indicated that Tcf factors may also be transcriptional repressors(6,8-13). Here we show that Tcf factors physically interact with members of the Groucho family of transcriptional repressors. In transient transfection assays, the Xenopus Groucho homologue XGrg-4 inhibited activation of transcription of synthetic Tcf reporter genes. In contrast, the naturally truncated Groucho-family member XGrg-5 enhanced transcriptional activation. Injection of XGrg-4 into Xenopus embryos repressed transcription of Siamois and Xnr-3, endogenous targets of beta-catenin-Tcf. Dorsal injection of XGrg-4 had a ventralizing effect on Xenopus embryos. Secondary-axis formation induced by a dominant-positive Armadillo-Tcf fusion protein was inhibited by XGrg-4 and enhanced by XGrg-5, These data indicate that expression of Tcf target genes is regulated by a balance between Armadillo and Groucho.	Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Clevers, H (corresponding author), Univ Utrecht Hosp, Dept Immunol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.							Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Bienz M, 1998, CURR OPIN CELL BIOL, V10, P366, DOI 10.1016/S0955-0674(98)80013-6; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Choudhury BK, 1997, GENE, V195, P41, DOI 10.1016/S0378-1119(97)00150-9; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Han M, 1997, CELL, V90, P581, DOI 10.1016/S0092-8674(00)80517-6; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARTLEY DA, 1988, CELL, V55, P785, DOI 10.1016/0092-8674(88)90134-1; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, MOL CELL BIOL, V18, P1248, DOI 10.1128/MCB.18.3.1248; Laurent MN, 1997, DEVELOPMENT, V124, P4905; LEMAIRE P, 1995, CELL, V81, P85, DOI 10.1016/0092-8674(95)90373-9; MALLO M, 1993, MECH DEVELOP, V42, P67, DOI 10.1016/0925-4773(93)90099-J; McKendry R, 1997, DEV BIOL, V192, P420, DOI 10.1006/dbio.1997.8797; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Parkhurst SM, 1998, TRENDS GENET, V14, P130, DOI 10.1016/S0168-9525(98)01407-3; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X	30	554	572	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					608	612		10.1038/26989	http://dx.doi.org/10.1038/26989			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783587				2022-12-24	WOS:000076362900050
J	Chan, A; McCaul, KA; Keane, RJ; Haan, EA				Chan, A; McCaul, KA; Keane, RJ; Haan, EA			Effect of parity, gravidity, previous miscarriage, and age on risk of Down's syndrome: population based study	BRITISH MEDICAL JOURNAL			English	Article									Australian Hlth Commiss, Epidemiol Branch, Pregnancy Outcome Unit, Adelaide, SA 5000, Australia; Australian Hlth Commiss, Epidemiol Branch, Hlth Stat Unit, Adelaide, SA 5000, Australia; Womens & Childrens Hosp, Dept Med Genet & Epidemiol, S Australian Birth Defects Register, N Adelaide, SA 5006, Australia		Chan, A (corresponding author), Australian Hlth Commiss, Epidemiol Branch, Pregnancy Outcome Unit, POB 6,Rundle Mall, Adelaide, SA 5000, Australia.		McCaul, Kieran A/B-8751-2008					HALLIDAY J, 1995, LANCET, V345, P704, DOI 10.1016/S0140-6736(95)90872-2; MCCULLAGH P., 1991, GEN LINEAR MODELS; *SAS I, 1993, SAS STAT SOFTW GENMO; Schimmel MS, 1997, BRIT MED J, V314, P720, DOI 10.1136/bmj.314.7082.720	4	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					923	924						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756811				2022-12-24	WOS:000076409000025
J	Giovannucci, E; Stampfer, MJ; Colditz, GA; Hunter, DJ; Fuchs, C; Rosner, BA; Speizer, FE; Willett, WC				Giovannucci, E; Stampfer, MJ; Colditz, GA; Hunter, DJ; Fuchs, C; Rosner, BA; Speizer, FE; Willett, WC			Multivitamin use, folate, and colon cancer in women in the nurses' health study	ANNALS OF INTERNAL MEDICINE			English	Article						folic acid; vitamins; colonic neoplasms; diet; dose-response relationship, drug	METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; NEURAL-TUBE DEFECTS; COLORECTAL-CANCER; LOGISTIC-REGRESSION; TRIPHOSPHATE POOLS; ALCOHOL INTAKE; PLASMA FOLATE; FOLIC-ACID; RED-CELL; RISK	Background: High intake of folate may reduce risk for colon cancer, but the dosage and duration relations and the impact of dietary compared with supplementary sources are not well understood. Objective: To evaluate the relation between folate intake and incidence of colon cancer. Design: Prospective cohort study. Setting: 88 756 women from the Nurses' Health Study who were free of cancer in 1980 and provided updated assessments of diet, including multivitamin supplement use, from 1980 to 1994. Patients: 442 women with new cases of colon cancer. Measurements: Multivariate relative risk (RR) and 95% CIs for colon cancer in relation to energy-adjusted folate intake. Results: Higher energy-adjusted folate intake in 1980 was related to a lower risk for colon cancer (RR, 0.69 [95% CI, 0.52 to 0.93] for intake >400 mu g/d compared with intake less than or equal to 200 mu g/d) after controlling for age; family history of colorectal cancer; aspirin use; smoking; body mass; physical activity; and intakes of red meat, alcohol, methionine, and fiber. When intake of vitamins A, C, D, and E and intake of calcium were also controlled for, results were similar. Women who used multivitamins containing folic acid had no benefit with respect to colon cancer after 4 years of use (RR, 1.02) and had only nonsignificant risk reductions after 5 to 9 (RR, 0.83) or 10 to 14 years of use (RR, 0.80). After 15 years of use, however, risk was markedly lower (RR, 0.25 [CI, 0.13 to 0.51]), representing 15 instead of 68 new cases of colon cancer per 10 000 women 55 to 69 years of age. Folate from dietary sources alone was related to a modest reduction in risk for colon cancer, and the benefit of long-term multivitamin use was present across all levels of dietary intakes. Conclusions: Long-term use of multivitamins may substantially reduce risk for colon cancer. This effect may be related to the folic acid contained in multivitamins.	Channing Labs, Boston, MA 02115 USA		Giovannucci, E (corresponding author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; BAILEY LB, 1982, NUTR RES, V2, P397, DOI 10.1016/S0271-5317(82)80048-1; Baron JA, 1998, J NATL CANCER I, V90, P57, DOI 10.1093/jnci/90.1.57; BENITO E, 1993, INT J CANCER, V55, P213, DOI 10.1002/ijc.2910550208; BENITO E, 1991, INT J CANCER, V49, P161, DOI 10.1002/ijc.2910490202; BIRD CL, 1995, CANCER EPIDEM BIOMAR, V4, P709; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; Chen J, 1996, CANCER RES, V56, P4862; CHU KC, 1994, JNCI-J NATL CANCER I, V86, P997, DOI 10.1093/jnci/86.13.997; COLDITZ GA, 1987, INT J EPIDEMIOL, V16, P392, DOI 10.1093/ije/16.3.392; Cravo M, 1994, Eur J Cancer Prev, V3, P473, DOI 10.1097/00008469-199411000-00004; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cuskelly GJ, 1996, LANCET, V347, P657, DOI 10.1016/S0140-6736(96)91205-2; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; FEINBERG AP, 1988, CANCER RES, V48, P1159; FENECH M, 1994, CARCINOGENESIS, V15, P1405, DOI 10.1093/carcin/15.7.1405; FERRARONI M, 1994, BRIT J CANCER, V70, P1150, DOI 10.1038/bjc.1994.463; Food and Drug Administration, 1973, FED REGISTER, V38, P20725; FREUDENHEIM JL, 1991, INT J EPIDEMIOL, V20, P368, DOI 10.1093/ije/20.2.368; FROSST P, 1995, NAT GENET, V10, P111, DOI 10.1038/ng0595-111; GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; GLYNN SA, 1994, NUTR CANCER, V22, P101, DOI 10.1080/01635589409514336; Glynn SA, 1996, CANCER EPIDEM BIOMAR, V5, P487; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195; Gregory JF, 1997, EUR J CLIN NUTR, V51, pS54; HUNTING DJ, 1985, CARCINOGENESIS, V6, P1525, DOI 10.1093/carcin/6.10.1525; ISSA JPJ, 1993, J NATL CANCER I, V85, P1235, DOI 10.1093/jnci/85.15.1235; JAMES SJ, 1994, CANCER RES, V54, P5075; KIRKE PN, 1993, Q J MED, V86, P703; Ma J, 1997, CANCER RES, V57, P1098; MAKOS M, 1992, P NATL ACAD SCI USA, V89, P1929, DOI 10.1073/pnas.89.5.1929; MEUTH M, 1981, SOMAT CELL GENET, V7, P89, DOI 10.1007/BF01544750; MEYER F, 1993, AM J EPIDEMIOL, V138, P225, DOI 10.1093/oxfordjournals.aje.a116851; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; PASPATIS GA, 1995, DIS COLON RECTUM, V38, P64, DOI 10.1007/BF02053860; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; ROSNER B, 1990, AM J EPIDEMIOL, V132, P734, DOI 10.1093/oxfordjournals.aje.a115715; SAUBERLICH HE, 1990, FOLIC ACID METABOLIS, P211; SENTI FR, 1985, J NUTR, V115, P1398, DOI 10.1093/jn/115.11.1398; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; Sturmer T, 1998, ANN INTERN MED, V128, P713, DOI 10.7326/0003-4819-128-9-199805010-00003; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; SUTHERLAND GR, 1988, MUTAT RES, V200, P207, DOI 10.1016/0027-5107(88)90084-X; Tseng M, 1996, AM J EPIDEMIOL, V144, P1005, DOI 10.1093/oxfordjournals.aje.a008871; *USDA, 1989, AGR HDB SERIES, V8; WEINBERG G, 1981, P NATL ACAD SCI-BIOL, V78, P2447, DOI 10.1073/pnas.78.4.2447; White E, 1997, CANCER EPIDEM BIOMAR, V6, P769; WICKRAMASINGHE SN, 1994, BLOOD, V83, P1656; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	54	543	562	0	32	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1998	129	7					517	+		10.7326/0003-4819-129-7-199810010-00002	http://dx.doi.org/10.7326/0003-4819-129-7-199810010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123KN	9758570				2022-12-24	WOS:000076124500001
J	Rosenthal, AN; Ryan, A; Al-Jehani, RM; Storey, A; Harwood, CA; Jacobs, IJ				Rosenthal, AN; Ryan, A; Al-Jehani, RM; Storey, A; Harwood, CA; Jacobs, IJ			p53 codon 72 polymorphism and risk of cervical cancer in UK	LANCET			English	Article								Background A polymorphism at codon 72 of the human tumour-suppressor gene, p53, results in translation to either arginine or proline. A recent report suggested that the risk of human-papillomavirus;associated cervical cancer in white women is higher for those homozygous for the arginine allele than for those who are heterozygous. We examined a similar number of cervical cancers and a larger control group for their p53 codon 72 polymorphism status to see if we could confirm this result. Methods Three different groups of UK white women were studied: 96 who had volunteered to take part in a trial of ovarian-cancer screening; 150 attending for routine antenatal care in the Oxford region; and 50 women with cervical cancer. DNA from peripheral blood samples and from archival tissue samples was examined by PCR with allele-specific primers. Findings The proportions of individuals homozygous for the arginine allele, homozygous for the proline allele, and heterozygous for the two alleles were 59%, 4%, and 36% among women screened for ovarian cancer; 65%, 8%, and 27% among the antenatal-care group; and 54%, 6%, and 40% in women with cervical cancer. chi(2) analysis showed no significant differences in these proportions. Interpretation In the population studied, individuals homozyous for the arginine variant of codon 72 of the p53 gene were not at increased risk of cervical cancer.	Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, Gynaecol Canc Res Unit, London E1 4NS, England; Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, ICRF, Skin Tumour Lab, London E1 4NS, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Rosenthal, AN (corresponding author), St Bartholomews Hosp, Gynaecol Canc Res Unit, London EC1A 7BE, England.		Jacobs, Ian J/F-1743-2013	Jacobs, Ian J/0000-0002-8112-4624; Jacobs, Ian/0000-0002-5005-2672; Rosenthal, Adam/0000-0001-6924-0721; Storey, Alan/0000-0003-2001-9772; Harwood, Catherine/0000-0002-1375-0965				BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; DELACALLEMARTIN O, 1990, NUCLEIC ACIDS RES, V18, P4963, DOI 10.1093/nar/18.16.4963; KAELBLING M, 1992, LANCET, V340, P140, DOI 10.1016/0140-6736(92)93214-8; SAMSBROOK J, 1989, MOL CLONING; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400	5	176	181	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 12	1998	352	9131					871	872		10.1016/S0140-6736(98)07357-7	http://dx.doi.org/10.1016/S0140-6736(98)07357-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118UA	9742979				2022-12-24	WOS:000075857300009
J	Jick, H; Vasilakis, C; Weinrauch, LA; Meier, CR; Jick, SS; Derby, LE				Jick, H; Vasilakis, C; Weinrauch, LA; Meier, CR; Jick, SS; Derby, LE			A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FENFLURAMINE-PHENTERMINE	Background. Recent case reports suggest that a combination of the appetite suppressants fenfluramine and phentermine is associated with an increased risk of cardiac-valve regurgitation. There are also reports of valvular disorders in persons taking fenfluramine or dexfenfluramine alone, particularly for more than three months. Methods We conducted a population-based follow-up study and a nested case-control analysis of 6532 subjects who received dexfenfluramine, 2371 who received fenfluramine, and 862 who received phentermine to assess the risk of a subsequent clinical diagnosis of a valvular disorder of uncertain origin. For comparison, we identified a group of 9281 obese subjects who had not taken appetite suppressants who were matched to the treated subjects for age, sex, and weight. All subjects were free of diagnosed cardiovascular disease at the start of followup. The average duration of follow-up for all subjects was about four years. Results. There were 11 cases of newly diagnosed idiopathic valvular disorders, 5 after the use of dexfenfluramine and 6 after the use of fenfluramine. There were six cases of aortic regurgitation, two cases of mitral regurgitation, and three cases of combined aortic and mitral regurgitation. There were no cases of idiopathic cardiac-valve abnormalities among the subjects who had not taken appetite suppressants or among those who took only phentermine. The five-year cumulative incidence of idiopathic cardiac-valve disorders was 0 per 10,000 subjects among those who had not taken appetite suppressants (95 percent confidence interval, 0 to 15.4) and among those who took phentermine alone (95 percent confidence interval, 0 to 76.6), 7.1 per 10,000 subjects among those who took either fenfluramine or dexfenfluramine for less than four months (95 percent confidence interval, 3.6 to 17.8; P = 0.02 for the comparison with subjects who had not taken appetite suppressants), and 35.0 per 10,000 subjects among those who received either of these medications for four or more months (95 percent confidence interval, 16.4 to 76.2; P < 0.001). Conclusions. The use of fenfluramine or dexfenfluramine, particularly for four months or longer, is associated with an increased risk of newly diagnosed cardiac-valve disorders, particularly aortic regurgitation. (N Engl J Med 1998;339:719-24.) (C) 1998, Massachusetts Medical Society.	Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, Lexington, MA 02421 USA; Mt Auburn Hosp, Dept Med, Cambridge, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Boston University; Harvard University; Mount Auburn Hospital; Harvard University; Harvard Medical School	Jick, H (corresponding author), Boston Univ, Med Ctr, Boston Collaborat Drug Surveillance Program, 11 Muzzey St, Lexington, MA 02421 USA.			Jick, Hershel/0000-0003-4270-5992; Weinrauch, Larry/0000-0003-1357-9528; Jick, Susan/0000-0002-2215-1067	FDA HHS [FD-U-001405-01] Funding Source: Medline	FDA HHS		Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Connolly HM, 1997, NEW ENGL J MED, V337, P1783; Graham DJ, 1997, NEW ENGL J MED, V337, P635, DOI 10.1056/NEJM199708283370911; Jick H, 1997, LANCET, V350, P1045, DOI 10.1016/S0140-6736(05)70451-7; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURZ X, 1997, NEW ENGL J MED, V337, P1172; Rasmussen S, 1997, NEW ENGL J MED, V337, P1773; ROTHMAN KJ, 1978, J CHRON DIS, V31, P557, DOI 10.1016/0021-9681(78)90043-7; Rothman KJ, 1979, EPIDEMIOLOGIC ANAL P; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1061; Weissman NJ, 1998, NEW ENGL J MED, V339, P725, DOI 10.1056/NEJM199809103391103	14	194	194	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 10	1998	339	11					719	724		10.1056/NEJM199809103391102	http://dx.doi.org/10.1056/NEJM199809103391102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116RF	9731087				2022-12-24	WOS:000075737800002
J	Nusser, Z; Hajos, N; Somogyi, P; Mody, I				Nusser, Z; Hajos, N; Somogyi, P; Mody, I			Increased number of synaptic GABA(A) receptors underlies potentiation at hippocampal inhibitory synapses	NATURE			English	Article							LONG-TERM POTENTIATION; ADULT-RAT BRAIN; RELEASE SITES; DENTATE GYRUS; VISUAL-CORTEX; SUBUNITS; CELLS; HETEROGENEITY; INTERNEURONS; TRANSMISSION	Changes in synaptic efficacy are essential far neuronal development(1), learning and memory formation(2) and for pathological slates of neuronal excitability, including temporal-lobe epilepsy(3), At synapses, where there is a high probability of opening of postsynaptic receptors(4), all of which are occupied by the released transmitter(5-9), the most effective means of augmenting postsynaptic responses is to increase the number of receptors(2,10,11). Here we combine quantal analysis of evoked inhibitory postsynaptic currents with quantitative immunogold localization of synaptic GABA(A) receptors in hippocampal granule cells in order to clarify the basis of inhibitory synaptic plasticity induced by an experimental model of temporal-lobe epilepsy (a process known as kindling)(10). We find that the larger amplitude (66% increase) of elementary synaptic currents (quantal size) after kindling results directly from a 75% increase in the number of GABA(A) receptors at inhibitory synapses on somata and axon initial segments. Receptor density was up by 34-40% and the synaptic junctional area was expanded by 31%. Presynaptic boutons were enlarged, which may account for the 39% decrease in the average number of released transmitter packets (quantal content). Our findings establish the postsynaptic insertion of new GABA(A) receptors and the corresponding increase in postsynaptic responses augmenting the efficacy of mammalian inhibitory synapses.	Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA; Univ Oxford, Dept Pharmacol, MRC, Anat Neuropharmacol Unit, Oxford OX1 3TH, England; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oxford; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nusser, Z (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.	mody@ucla.edu	Hajos, Norbert/U-2640-2019; Nusser, Zoltan/K-8587-2014	Hajos, Norbert/0000-0002-4582-2708; Nusser, Zoltan/0000-0001-7004-4111	NINDS NIH HHS [NS36142] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036142] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auger C, 1997, NEURON, V19, P139, DOI 10.1016/S0896-6273(00)80354-2; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brussaard AB, 1997, NEURON, V19, P1103, DOI 10.1016/S0896-6273(00)80401-8; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; Davis GW, 1998, NATURE, V392, P82, DOI 10.1038/32176; DE KONINCK Y, 1994, J NEUROPHYSIOL, V71, P1318, DOI 10.1152/jn.1994.71.4.1318; EDWARDS FA, 1990, J PHYSIOL-LONDON, V430, P213, DOI 10.1113/jphysiol.1990.sp018289; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; Hajos N, 1997, J NEUROSCI, V17, P8427; KOMATSU Y, 1994, J NEUROSCI, V14, P6488; KORN H, 1992, P NATL ACAD SCI USA, V89, P440, DOI 10.1073/pnas.89.1.440; Kosaka T, 1996, EXP BRAIN RES, V112, P237; Malenka RC, 1997, NEURON, V19, P473, DOI 10.1016/S0896-6273(00)80362-1; MODY I, 1994, TRENDS NEUROSCI, V17, P517, DOI 10.1016/0166-2236(94)90155-4; Nusser Z, 1997, NEURON, V19, P697, DOI 10.1016/S0896-6273(00)80382-7; Nusser Z, 1996, P NATL ACAD SCI USA, V93, P11939, DOI 10.1073/pnas.93.21.11939; NUSSER Z, 1995, EUR J NEUROSCI, V7, P630, DOI 10.1111/j.1460-9568.1995.tb00667.x; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; PERSOHN E, 1992, J COMP NEUROL, V326, P193, DOI 10.1002/cne.903260204; SIEGHART W, 1995, PHARMACOL REV, V47, P181; Silver RA, 1996, J PHYSIOL-LONDON, V494, P231, DOI 10.1113/jphysiol.1996.sp021487; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; Stratford KJ, 1996, NATURE, V382, P258, DOI 10.1038/382258a0; Stratford KJ, 1997, J PHYSIOL-LONDON, V505, P425, DOI 10.1111/j.1469-7793.1997.425bb.x; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; ZEZULA J, 1991, BRAIN RES, V563, P325, DOI 10.1016/0006-8993(91)91556-G	30	381	393	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 10	1998	395	6698					172	177		10.1038/25999	http://dx.doi.org/10.1038/25999			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118GK	9744275				2022-12-24	WOS:000075829900042
J	Johnson, AP; Warner, M; Woodford, N; Speller, DCE; Livermore, DM				Johnson, AP; Warner, M; Woodford, N; Speller, DCE; Livermore, DM			Antibiotic resistance among enterococci causing endocarditis in the UK: analysis of isolates referred to a reference laboratory	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFECTIVE ENDOCARDITIS		Cent Publ Hlth Lab, Antibiot Reference Unit, London NW9 5HT, England	Public Health England	Johnson, AP (corresponding author), Cent Publ Hlth Lab, Antibiot Reference Unit, London NW9 5HT, England.	ajohnson@phls.co.uk	Woodford, Neil/D-4123-2011; Johnson, Alan P/F-4420-2014	Woodford, Neil/0000-0003-1396-8953; 				[Anonymous], 1991, J Antimicrob Chemother, V27 Suppl D, P1; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; PRASAD A, 1995, BRIT J HOSP MED, V54, P341; Simmons NA, 1998, HEART, V79, P207; WILSON WR, 1995, JAMA-J AM MED ASSOC, V274, P1706, DOI 10.1001/jama.274.21.1706	5	14	15	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 5	1998	317	7159					629	630		10.1136/bmj.317.7159.629	http://dx.doi.org/10.1136/bmj.317.7159.629			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727989	Green Submitted, Bronze			2022-12-24	WOS:000075830200017
J	Kristiansen, BE; Tveten, Y; Jenkins, A				Kristiansen, BE; Tveten, Y; Jenkins, A			Which contacts of patients with meningococcal disease carry the pathogenic strain of Neisseria meningitidis? A population based study	BRITISH MEDICAL JOURNAL			English	Article							HOUSEHOLD CONTACTS; CLOSE CONTACTS; INFECTION; CARRIAGE; FAMILY; SPREAD	Objectives: To determine the prevalence of the pathogenic strain of Neisseria meningitidis in contacts of patients with meningococcal disease, and to determine which contact groups are likely to be carriers and warrant chemoprophylaxis, Design: Population based study. Setting: Norwegian county of Telemark. Subjects: 1535 primary contacts of 48 patients with meningococcal disease, and 78 secondary contacts. Interventions: Carriers of the pathogenic strain were treated with rifampicin. All household members and kissing contacts under 15 years of age were treated with oral penicillin. Contacts were taught to recognise the symptoms of meningococcal disease. Results: In 21 of 48 cases investigated, contacts carrying the pathogenic strain of N meningitidis were found. A total of 42 such contacts were identified. Contacts were stratified into three classes according to the assumed closeness of contact with patients. In class 1 (household members and kissing contacts) the prevalence of the pathogenic strain was 12.4% (95% confidence interval 5.5% to 19.3%). In classes 2 and 3 the prevalence was 1.9% (0.9% to 3.4%) and 1.6% (0.14% to 3.1%). Conclusions: There is a high rate of carriage of the pathogenic strain of N meningitidis in patients' household members and kissing contacts, and this supports the practice of giving chemoprophylaxis to these contacts. The prevalence of carriage among other contacts is 2-3 times that found in the general population (0.7%); the benefits of chemoprophylaxis to these contacts may be marginal.	Univ Tromso, Dept Med Microbiol, N-9037 Tromso, Norway; AS Telelab, Telemark Biomed Ctr, N-3705 Skien, Norway	UiT The Arctic University of Tromso	Kristiansen, BE (corresponding author), Univ Tromso, Dept Med Microbiol, N-9037 Tromso, Norway.			Kristiansen, Bjorn - Erik/0000-0001-8299-4624; Jenkins, Andrew/0000-0003-2588-8483				Achtman M, 1995, MENINGOCOCCAL DIS, P159; ANDERSEN BM, 1978, SCAND J INFECT DIS, V10, P277, DOI 10.3109/inf.1978.10.issue-4.04; [Anonymous], 1995, CONTROL COMMUNICABLE; BOVRE K, 1980, NIPH (National Institute of Public Health) Annals (Oslo), V3, P9; Cartwright K, 1997, BRIT MED J, V315, P757; Cartwright K., 1995, MENINGOCOCCAL DIS, P115; CARTWRIGHT KAV, 1991, EPIDEMIOL INFECT, V106, P133, DOI 10.1017/S0950268800056491; CAUGANT DA, 1994, J CLIN MICROBIOL, V32, P323, DOI 10.1128/JCM.32.2.323-330.1994; CAUGANT DA, 1996, ANN C I PUBL HLTH OS; *CDC, 1996, REC IMM PRACT ADV CO; COOKE RPD, 1989, BRIT MED J, V298, P555, DOI 10.1136/bmj.298.6673.555; DEWALS P, 1981, J INFECTION, V3, P53, DOI 10.1016/S0163-4453(81)80009-6; HOIBY EA, 1986, A VAN LEEUW J MICROB, V52, P255, DOI 10.1007/BF00555251; KRISTIANSEN BE, 1995, J CLIN MICROBIOL, V33, P1174, DOI 10.1128/JCM.33.5.1174-1179.1995; KRISTIANSEN BE, 1992, SCAND J INFECT DIS, V24, P165, DOI 10.3109/00365549209052608; KRISTIANSEN BE, 1988, J CLIN MICROBIOL, V26, P1988, DOI 10.1128/JCM.26.10.1988-1992.1988; *MEN DIS SURV GROU, 1976, JAMA-J AM MED ASSOC, V235, P261; MUNFORD RS, 1974, LANCET, V1, P1275; OLCEN P, 1981, SCAND J INFECT DIS, V13, P105, DOI 10.3109/inf.1981.13.issue-2.05; OLCEN P, 1979, J CLIN PATHOL, V32, P1222, DOI 10.1136/jcp.32.12.1222; Pearson N, 1995, J PUBLIC HEALTH MED, V17, P455; *PUBL HLTH LAB SER, 1995, CONTR MEN DIS GUID C; RELLER LB, 1973, J INFECT DIS, V127, P56, DOI 10.1093/infdis/127.1.56; *WHO, 1996, 105 WHO; Woods CR, 1996, J INFECT DIS, V174, P760, DOI 10.1093/infdis/174.4.760	25	32	32	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 5	1998	317	7159					621	625		10.1136/bmj.317.7159.621	http://dx.doi.org/10.1136/bmj.317.7159.621			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	118GN	9727987	Green Published, Green Submitted, Bronze			2022-12-24	WOS:000075830200015
J	Ishiura, M; Kutsuna, S; Aoki, S; Iwasaki, H; Andersson, CR; Tanabe, A; Golden, SS; Johnson, CH; Kondo, T				Ishiura, M; Kutsuna, S; Aoki, S; Iwasaki, H; Andersson, CR; Tanabe, A; Golden, SS; Johnson, CH; Kondo, T			Expression of a gene cluster kaiABC as a circadian feedback process in cyanobacteria	SCIENCE			English	Article							DROSOPHILA PERIOD GENE; CLOCK GENE; POSITIONAL CLONING; RHYTHMS; LUCIFERASE; SEQUENCE; FREQUENCY; TIMELESS; PROTEINS; ELEMENT	Cyanobacteria are the simplest organisms known to have a circadian clock. A circadian crock gene cluster kaiABC was cloned from the cyanobacterium Synechococcus. Nineteen clock mutations were mapped to the three kai genes. Promoter activities upstream of the kaiA and kaiB genes showed circadian rhythms of expression, and both kaiA and kaiBC messenger RNAs displayed circadian cycling. inactivation of any single kai gene abolished these rhythms and reduced kaiBC-promoter activity. Continuous kaiC overexpression repressed the kaiBC promoter, whereas kaiA overexpression enhanced it. Temporal kaiC overexpression reset the phase of the rhythms. Thus, a negative feedback control of kaiC expression by KaiC generates a circadian oscillation in cyanobacteria, and KaiA sustains the oscillation by enhancing kaiC expression.	Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Nagoya, Aichi 4648602, Japan; Vanderbilt Univ, Dept Biol, Nashville, TN 37235 USA; Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA	Nagoya University; Vanderbilt University; Texas A&M University System; Texas A&M University College Station	Ishiura, M (corresponding author), Nagoya Univ, Grad Sch Sci, Div Biol Sci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648602, Japan.	ishiura@bio.nagoya-u.ac.jp; kondo@bio.nagoya-u.ac.jp	Johnson, Carl H/I-4655-2014	Iwasaki, Hideo/0000-0002-3754-4955	NATIONAL INSTITUTE OF MENTAL HEALTH [K02MH001179] Funding Source: NIH RePORTER; NIMH NIH HHS [MH01179] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; BALDWIN TO, 1984, BIOCHEMISTRY-US, V23, P3663, DOI 10.1021/bi00311a014; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Bunning E, 1973, PHYSL CLOCK; BUSTOS SA, 1991, J BACTERIOL, V173, P7525, DOI 10.1128/jb.173.23.7525-7533.1991; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CROTHWAITE SK, 1997, SCIENCE, V276, P763; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; GEKAKIS N, 1995, SCIENCE, V270, P811, DOI 10.1126/science.270.5237.811; Golden SS, 1997, ANNU REV PLANT PHYS, V48, P327, DOI 10.1146/annurev.arplant.48.1.327; ISHIURA M, UNPUB; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONDO T, 1993, P NATL ACAD SCI USA, V90, P5672, DOI 10.1073/pnas.90.12.5672; KONDO T, 1994, SCIENCE, V266, P1233, DOI 10.1126/science.7973706; Kondo T, 1997, SCIENCE, V275, P224, DOI 10.1126/science.275.5297.224; KONDO T, UNPUB; Kutsuna S, 1998, J BACTERIOL, V180, P2167, DOI 10.1128/JB.180.8.2167-2174.1998; MCCLUNG CR, 1989, NATURE, V339, P558, DOI 10.1038/339558a0; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; MOHAMED A, 1989, PLANT MOL BIOL, V13, P693, DOI 10.1007/BF00016024; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; PRENTKI P, 1984, GENE, V29, P303, DOI 10.1016/0378-1119(84)90059-3; ROSE RE, 1988, NUCLEIC ACIDS RES, V16, P356, DOI 10.1093/nar/16.1.356; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Sweeney BM., 1987, RHYTHMIC PHENOMENA P; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; YOSHIDA M, 1995, FEBS LETT, V359, P1, DOI 10.1016/0014-5793(94)01438-7; ZEHRING WA, 1984, CELL, V39, P369, DOI 10.1016/0092-8674(84)90015-1	36	537	581	5	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	1998	281	5382					1519	1523		10.1126/science.281.5382.1519	http://dx.doi.org/10.1126/science.281.5382.1519			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9727980				2022-12-24	WOS:000075738100044
J	Seinela, L; Ahvenainen, J; Ronneikko, J; Haavisto, M				Seinela, L; Ahvenainen, J; Ronneikko, J; Haavisto, M			Reasons for and outcome of upper gastrointestinal endoscopy in patients aged 85 years or more: retrospective study	BRITISH MEDICAL JOURNAL			English	Article									Tampere City Hosp, Dept Geriatr, FIN-33500 Tampere, Finland		Seinela, L (corresponding author), Tampere City Hosp, Dept Geriatr, Kaupin Sairaala,Parantolankatu 6, FIN-33500 Tampere, Finland.							BRUSSAARD CC, 1988, GASTROINTEST ENDOSC, V34, P118, DOI 10.1016/S0016-5107(88)71275-4; COOPER BT, 1986, AGE AGEING, V15, P343, DOI 10.1093/ageing/15.6.343; GIBBINS F J, 1974, Age and Ageing, V3, P240, DOI 10.1093/ageing/3.4.240; JACOBSOHN WZ, 1977, GERIATRICS, V32, P80; LOCKHART SP, 1985, BRIT MED J, V290, P283, DOI 10.1136/bmj.290.6464.283	5	19	20	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	AUG 29	1998	317	7158					575	575		10.1136/bmj.317.7158.575	http://dx.doi.org/10.1136/bmj.317.7158.575			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721114	Bronze, Green Submitted, Green Published			2022-12-24	WOS:000075767800018
J	Zhang, J; Houston, DW; King, ML; Payne, C; Wylie, C; Heasman, J				Zhang, J; Houston, DW; King, ML; Payne, C; Wylie, C; Heasman, J			The role of maternal VegT in establishing the primary germ layers in Xenopus embryos	CELL			English	Article							BOX TRANSCRIPTION FACTOR; MESODERM INDUCTION; POLE BLASTOMERES; MESSENGER-RNA; LAEVIS; ENDODERM; GENE; EXPRESSION; OOGENESIS; BLASTULA	VegT is a T-box transcription factor whose mRNA is synthesized during oogenesis and localized in the vegetal hemisphere of the egg and early embryo. We show that maternally expressed VegT controls the pattern of primary germ layer specification in Xenopus embryos. Reduction of the maternal store completely alters the fates of different regions of the blastula so that animal cell fate is changed from epidermis and nervous system to epidermis only, equatorial cell fate is changed from mesoderm to ectoderm, and vegetal cell fate is changed from endoderm to mesoderm and ectoderm. Vegetal cells lose their capacity both to form endoderm and to release mesoderm-inducing signals. These results show that a single maternally expressed gene controls the patterning of the Xenopus blastula.	Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Paediat, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Cell Biol & Neuroanat, Minneapolis, MN 55455 USA; Univ Miami, Sch Med, Dept Anat & Cell Biol, Miami, FL 33136 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Miami	Heasman, J (corresponding author), Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA.				NICHD NIH HHS [1 HD33002] Funding Source: Medline; NIGMS NIH HHS [GM33932] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD033002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033932] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARER EL, 1994, EUR J CELL BIOL, V63, P255; El-Hodiri HM, 1998, DEV BIOL, V198, P174; GURDON JB, 1985, CELL, V41, P913, DOI 10.1016/S0092-8674(85)80072-6; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HEASMAN J, 1991, METHOD CELL BIOL, V36, P213; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Heasman J, 1997, DEVELOPMENT, V124, P4179; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; Henry GL, 1996, DEVELOPMENT, V122, P1007; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; Horb ME, 1997, DEVELOPMENT, V124, P1689; Hudson C, 1997, CELL, V91, P397, DOI 10.1016/S0092-8674(00)80423-7; JONAS E, 1985, P NATL ACAD SCI USA, V82, P5413, DOI 10.1073/pnas.82.16.5413; KELLER R, 1988, DEVELOPMENT, V103, P193; LAMB TM, 1995, DEVELOPMENT, V121, P3627; LEMAIRE P, 1994, DEVELOPMENT, V120, P1191; Lustig KD, 1996, DEVELOPMENT, V122, P4001; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Papaioannou VE, 1998, BIOESSAYS, V20, P9, DOI 10.1002/(SICI)1521-1878(199801)20:1<9::AID-BIES4>3.0.CO;2-Q; Sasai Y, 1996, EMBO J, V15, P4547, DOI 10.1002/j.1460-2075.1996.tb00832.x; SHI YB, 1994, DEV BIOL, V161, P48, DOI 10.1006/dbio.1994.1006; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; SMITH JC, 1989, DEVELOPMENT, V105, P665; SNAPE A, 1987, DEV BIOL, V119, P503, DOI 10.1016/0012-1606(87)90053-4; Stennard F, 1996, DEVELOPMENT, V122, P4179; STIEGLER P, 1993, MECH DEVELOP, V41, P163, DOI 10.1016/0925-4773(93)90046-Z; WHITFIELD T, 1993, DEV BIOL, V155, P361, DOI 10.1006/dbio.1993.1035; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4; WRIGHT CVE, 1989, DEVELOPMENT, V105, P787; Wylie C, 1996, DEVELOPMENT, V122, P2987; WYLIE CC, 1987, DEV BIOL, V119, P496, DOI 10.1016/0012-1606(87)90052-2; Zhang J, 1996, DEVELOPMENT, V122, P4119	35	373	378	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 21	1998	94	4					515	524		10.1016/S0092-8674(00)81592-5	http://dx.doi.org/10.1016/S0092-8674(00)81592-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727494	hybrid			2022-12-24	WOS:000075541100013
J	Li, TS; Tubiana, R; Katlama, C; Calvez, V; Ait Mohand, H; Autran, B				Li, TS; Tubiana, R; Katlama, C; Calvez, V; Ait Mohand, H; Autran, B			Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTED PATIENTS; ZIDOVUDINE	Background Highly active antiretroviral therapy (HAART) decreases viral load and increases CD4 T-cell counts in patients with advanced HIV-1 infection. Whether HAART can improve CD4 T-cell function, and the biological characteristics affecting immune reconstitution, remain unclear. We undertook an open prospective pilot study to address these issues. Both treatment-naive and previously treated patients were included. Methods 20 patients (seven naive, 13 previously treated) were treated with one protease inhibitor and two reverse-transcriptase inhibitors and followed up for 12 months. We measured CD4-cell proliferation in response to cytomegalovirus and tuberculin antigens and counted subsets of CD4 cells at baseline and months 1, 3, 6, 9, and 12, Patients who had no antigen-specific reactivity at baseline but developed it while receiving HAART were classified as immunological responders. Findings Four patients had antigen-specific reactivity at baseline compared with 14 at month 12 (p <0.001). Between month 3 and month 12 viral load fell by a median of 1.5 log copies/mL from baseline (4.6 log copies/mL) and CD4-cell count increased by a median of 63/mu L (from 93/mu L). Ten patients (six of seven naive, four of 13 previously treated) were immunological responders. They differed significantly from the ten non-responders in that their viral-load reduction was sustained for 12 months, the increase in CD4 count was greater, and they showed an early increase in memory CD4 T cells with an increase of naive T cells. Interpretation HAART can induce sustained recovery of CD4 T-cell reactivity against opportunistic pathogens in severely immunosuppressed patients. This recovery depends not on baseline Values but on the amplitude and duration of viral-load reduction and the increase of memory CD4 T cells.	Hop La Pitie Salpetriere, CNRS, URA 625, Lab Immunol Cellulaire, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Malad Infect, F-75013 Paris, France; Hop La Pitie Salpetriere, Serv Virol, F-75013 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Autran, B (corresponding author), Hop La Pitie Salpetriere, CNRS, URA 625, Lab Immunol Cellulaire, 83 Blvd Hop, F-75013 Paris, France.							Autran B, 1997, SCIENCE, V277, P112, DOI 10.1126/science.277.5322.112; CLERICI M, 1992, J INFECT DIS, V166, P723, DOI 10.1093/infdis/166.4.723; Collier AC, 1996, NEW ENGL J MED, V334, P1011, DOI 10.1056/NEJM199604183341602; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; DOLAN MJ, 1995, J INFECT DIS, V172, P79, DOI 10.1093/infdis/172.1.79; Emery S, 1997, CURR OPIN IMMUNOL, V9, P568, DOI 10.1016/S0952-7915(97)80112-4; FRENCH MAH, 1992, AIDS, V6, P1293, DOI 10.1097/00002030-199211000-00009; GIORGI JV, 1987, J IMMUNOL, V138, P3725; Gorochov G, 1998, NAT MED, V4, P215, DOI 10.1038/nm0298-215; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; HOY JF, 1988, J INFECT DIS, V158, P1971; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; LANE HC, 1985, AM J MED, V78, P417, DOI 10.1016/0002-9343(85)90332-8; Mathez D, 1997, Antivir Ther, V2, P175; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Reed JB, 1997, AM J OPHTHALMOL, V124, P199, DOI 10.1016/S0002-9394(14)70784-6; RINALDO C, 1991, J INFECT DIS, V164, P638, DOI 10.1093/infdis/164.4.638	20	461	495	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JUN 6	1998	351	9117					1682	1686		10.1016/S0140-6736(97)10291-4	http://dx.doi.org/10.1016/S0140-6736(97)10291-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZT448	9734884				2022-12-24	WOS:000074088900008
J	Weisfuse, IB				Weisfuse, IB			Gonorrhoea control and antimicrobial resistance	LANCET			English	Editorial Material									New York City Dept Hlth, Bur Sexually Transmitted Dis, New York, NY 10013 USA	New York City Department of Health & Mental Hygiene	Weisfuse, IB (corresponding author), New York City Dept Hlth, Bur Sexually Transmitted Dis, New York, NY 10013 USA.							[Anonymous], 1998, MMWR Recomm Rep, V47, P1; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P761; DILLON JR, 1977, 12 M INT SOC SEX TRA; Fox KK, 1997, J INFECT DIS, V175, P1396, DOI 10.1086/516472; Jones RB, 1998, AM J MED, V104, P28, DOI 10.1016/S0002-9343(97)00277-5; SIEGEL JE, 1997, HIDDEN EPIDEMIC CONF, P330; *US DEP HHS, 1997, SEX TRANSM DIS SURV, P1	7	4	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 28	1998	351	9107					928	928						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZE227	9734937				2022-12-24	WOS:000072770900008
J	Duan, Y; Kollman, PA				Duan, Y; Kollman, PA			Pathways to a protein folding intermediate observed in a 1-microsecond simulation in aqueous solution	SCIENCE			English	Article							MOLECULAR-DYNAMICS SIMULATIONS; MESH EWALD METHOD; FREE-ENERGY; VILLIN HEADPIECE; WATER; APOMYOGLOBIN; PRINCIPLES; KINETICS; BINDING; MODELS	An implementation of classical molecular dynamics on parallel computers of increased efficiency has enabled a simulation of protein folding with explicit representation of water for 1 microsecond, about two orders of magnitude Longer than the Longest simulation of a protein in water reported to date. Starting with an unfolded state of villin headpiece subdomain, hydrophobic collapse and helix formation occur in an initial phase, followed by conformational readjustments. A marginally stable state, which has a Lifetime of about 150 nanoseconds, a favorable solvation free energy, and shows significant resemblance to the native structure, is observed; two pathways to this state have been found.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Kollman, PA (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.	pak@cgl.ucsf.edu	Duan, Yong/D-3475-2013	Duan, Yong/0000-0003-3793-5099	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029072] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29072] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO DOV, 1995, J MOL BIOL, V247, P501, DOI 10.1006/jmbi.1994.0156; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Ballew RM, 1996, P NATL ACAD SCI USA, V93, P5759, DOI 10.1073/pnas.93.12.5759; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOCZKO EM, 1993, J PHYS CHEM-US, V97, P4509, DOI 10.1021/j100119a043; BOCZKO EM, 1995, SCIENCE, V269, P393, DOI 10.1126/science.7618103; Brooks III C. L., 1989, PROTEINS THEORETICAL; Burton RE, 1997, NAT STRUCT BIOL, V4, P305, DOI 10.1038/nsb0497-305; CHEATHAM TE, 1995, J AM CHEM SOC, V117, P4193, DOI 10.1021/ja00119a045; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; DAGGETT V, 1992, P NATL ACAD SCI USA, V89, P5142, DOI 10.1073/pnas.89.11.5142; DAGGETT V, 1994, CURR OPIN STRUC BIOL, V4, P291, DOI 10.1016/S0959-440X(94)90322-0; Daura X, 1998, J MOL BIOL, V280, P925, DOI 10.1006/jmbi.1998.1885; Demchuk E, 1997, FOLD DES, V2, P35, DOI 10.1016/S1359-0278(97)00004-7; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; DILL KA, 1995, PROTEIN SCI, V4, P561; Dobson CM, 1997, CURR OPIN STRUC BIOL, V7, P1, DOI 10.1016/S0959-440X(97)80001-2; Duan Y, 1998, P NATL ACAD SCI USA, V95, P9897, DOI 10.1073/pnas.95.17.9897; DUAN Y, UNPUB; Eaton WA, 1997, CURR OPIN STRUC BIOL, V7, P10, DOI 10.1016/S0959-440X(97)80003-6; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fox T, 1996, PROTEINS, V25, P315, DOI 10.1002/(SICI)1097-0134(199607)25:3<315::AID-PROT4>3.0.CO;2-E; Gilmanshin R, 1997, P NATL ACAD SCI USA, V94, P3709, DOI 10.1073/pnas.94.8.3709; Hagen SJ, 1996, P NATL ACAD SCI USA, V93, P11615, DOI 10.1073/pnas.93.21.11615; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; KARPEN ME, 1993, BIOCHEMISTRY-US, V32, P412, DOI 10.1021/bi00053a005; Kollman PA, 1996, ACCOUNTS CHEM RES, V29, P461, DOI 10.1021/ar9500675; KUMAR S, 1992, J COMPUT CHEM, V13, P1011, DOI 10.1002/jcc.540130812; Lazaridis T, 1997, SCIENCE, V278, P1928, DOI 10.1126/science.278.5345.1928; Li AJ, 1995, PROTEIN ENG, V8, P1117, DOI 10.1093/protein/8.11.1117; McKnight CJ, 1997, NAT STRUCT BIOL, V4, P180, DOI 10.1038/nsb0397-180; McKnight CJ, 1996, J MOL BIOL, V260, P126; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Plaxco KW, 1998, J MOL BIOL, V277, P985, DOI 10.1006/jmbi.1998.1645; PLAXCO KW, 1998, COMMUNICATION; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SALI A, 1994, NATURE, V369, P248, DOI 10.1038/369248a0; SCHIFFER CA, 1995, BIOCHEMISTRY-US, V34, P15057, DOI 10.1021/bi00046a011; Shakhnovich E, 1998, CURR OPIN STRUC BIOL, V8, P65, DOI 10.1016/S0959-440X(98)80011-0; Shakhnovich EI, 1997, CURR OPIN STRUC BIOL, V7, P29, DOI 10.1016/S0959-440X(97)80005-X; Sheinerman FB, 1998, P NATL ACAD SCI USA, V95, P1562, DOI 10.1073/pnas.95.4.1562; Sheinerman FB, 1998, J MOL BIOL, V278, P439, DOI 10.1006/jmbi.1998.1688; SIFERS RN, 1995, NAT STRUCT BIOL, V2, P355, DOI 10.1038/nsb0595-355; SKOLNICK J, 1990, SCIENCE, V250, P1121, DOI 10.1126/science.250.4984.1121; Thompson PA, 1997, BIOCHEMISTRY-US, V36, P9200, DOI 10.1021/bi9704764; TIRADORIVES J, 1993, BIOCHEMISTRY-US, V32, P4175, DOI 10.1021/bi00067a004; VERLET L, 1967, PHYS REV, V159, P98, DOI 10.1103/PhysRev.159.98; Williams S, 1996, BIOCHEMISTRY-US, V35, P691, DOI 10.1021/bi952217p	52	1127	1157	1	132	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 23	1998	282	5389					740	744		10.1126/science.282.5389.740	http://dx.doi.org/10.1126/science.282.5389.740			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	132AM	9784131				2022-12-24	WOS:000076607500050
J	Guo, L; Lim, KB; Poduje, CM; Daniel, M; Gunn, JS; Hackett, M; Miller, SI				Guo, L; Lim, KB; Poduje, CM; Daniel, M; Gunn, JS; Hackett, M; Miller, SI			Lipid A acylation and bacterial resistance against vertebrate antimicrobial peptides	CELL			English	Article							SALMONELLA-TYPHIMURIUM VIRULENCE; ESCHERICHIA-COLI; PHOP-PHOQ; CYSTIC-FIBROSIS; ANTIBIOTICS; EXPRESSION; REGULON; SYSTEM; GENES; LIPOPOLYSACCHARIDES	The Salmonellae PhoP-PhoQ virulence regulators induce resistance to host cationic antimicrobial peptides (CAMP) after infection of vertebrate tissues, and M2+ or Ca2+ limitation. The PhoP-PhoQ activated gene, pagP, was identified as important to inducible CAMP resistance and increased acylation of lipid A, the major component of the outer leaflet of the outer membrane, pagP mutants demonstrated increased outer membrane permeability in response to CAMP, supporting the hypothesis that increased lipid A acylation is a CAMP resistance mechanism. Similarly, in response to Mg2+ limited growth, other enteric Gramnegative bacteria demonstrated increased lipid A acylation. Compounds that inhibit the ability to increase lipid A acylation may have utility as new antimicrobial agents.	Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Texas, Hlth Sci Ctr, Dept Microbiol, San Antonio, TX 78284 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Health San Antonio	Miller, SI (corresponding author), Univ Washington, Dept Microbiol, Seattle, WA 98195 USA.	millersi@u.washington.edu	Gunn, John/E-3167-2011		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030479] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI30479] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANDA CMA, 1992, P NATL ACAD SCI USA, V89, P10079, DOI 10.1073/pnas.89.21.10079; Bechinger B, 1997, J MEMBRANE BIOL, V156, P197, DOI 10.1007/s002329900201; BELDEN WJ, 1994, INFECT IMMUN, V62, P5095, DOI 10.1128/IAI.62.11.5095-5101.1994; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; DARVEAU RP, 1991, ANTIMICROB AGENTS CH, V35, P1153, DOI 10.1128/AAC.35.6.1153; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; ELLIOTT T, 1988, MOL GEN GENET, V213, P332, DOI 10.1007/BF00339599; FIELDS PI, 1989, SCIENCE, V243, P1059, DOI 10.1126/science.2646710; FU R, 1991, GENE, V100, P195; GABAY JE, 1994, SCIENCE, V264, P373, DOI 10.1126/science.8153623; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GROISMAN EA, 1992, P NATL ACAD SCI USA, V89, P11939, DOI 10.1073/pnas.89.24.11939; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; GUNN JS, 1995, J BACTERIOL, V177, P5040, DOI 10.1128/jb.177.17.5040-5047.1995; GUNN JS, 1998, IN PRESS MICROB PATH; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hancock REW, 1998, TRENDS BIOTECHNOL, V16, P82, DOI 10.1016/S0167-7799(97)01156-6; Heithoff DM, 1997, P NATL ACAD SCI USA, V94, P934, DOI 10.1073/pnas.94.3.934; HELANDER IM, 1994, MOL MICROBIOL, V11, P481, DOI 10.1111/j.1365-2958.1994.tb00329.x; HILLENKAMP F, 1994, BIOLOGICAL MASS SPECTROMETRY: PRESENT AND FUTURE, P101; Hohmann EL, 1996, VACCINE, V14, P19, DOI 10.1016/0264-410X(95)00173-X; Hu KH, 1996, GENETICS, V143, P1521; JACOB L, 1994, CIBA F SYMP, V186, P197; KLECKNER N, 1991, METHOD ENZYMOL, V204, P139; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; MEKALANOS JJ, 1992, J BACTERIOL, V174, P1; MILLER SI, 1990, INFECT IMMUN, V58, P3706, DOI 10.1128/IAI.58.11.3706-3710.1990; MILLER SI, 1990, J BACTERIOL, V172, P2485, DOI 10.1128/jb.172.5.2485-2490.1990; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; MURRAY CK, 1996, ESCHERICHIA COLI SAL, P967; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RANA FR, 1990, FEBS LETT, V261, P464, DOI 10.1016/0014-5793(90)80616-Q; Sambrook J., 1982, MOL CLONING; Skorupski K, 1996, GENE, V169, P47, DOI 10.1016/0378-1119(95)00793-8; Smith JJ, 1996, CELL, V85, P229, DOI 10.1016/S0092-8674(00)81099-5; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; SORAVIA E, 1988, FEBS LETT, V228, P337, DOI 10.1016/0014-5793(88)80027-9; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Stolzenberg ED, 1997, P NATL ACAD SCI USA, V94, P8686, DOI 10.1073/pnas.94.16.8686; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wang HL, 1998, ANAL CHEM, V70, P205, DOI 10.1021/ac971036l; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	50	485	499	4	45	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					189	198		10.1016/S0092-8674(00)81750-X	http://dx.doi.org/10.1016/S0092-8674(00)81750-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790526	Bronze			2022-12-24	WOS:000076538300007
J	Panju, AA; Hemmelgarn, BR; Guyatt, GH; Simel, DL				Panju, AA; Hemmelgarn, BR; Guyatt, GH; Simel, DL			Is this patient having a myocardial infarction?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EMERGENCY ROOM PATIENTS; CLINICAL-PREDICTION RULES; CORONARY-ARTERY DISEASE; MULTICENTER CHEST PAIN; METHODOLOGICAL STANDARDS; THROMBOLYTIC THERAPY; CARE-UNIT; DIAGNOSIS; HISTORY; ELECTROCARDIOGRAM	When faced with a patient with acute chest pain, clinicians must distinguish myocardial infarction (MI) from all other causes of acute chest pain, If MI is suspected, current therapeutic practice includes deciding whether to administer thrombolysis or primary percutaneous transluminal coronary angioplasty and whether to admit patients to a coronary care unit. The former decision is based on electrocardiographic (ECG) changes, including ST-segment elevation or left bundle-branch block, the latter on the likelihood of the patient's having unstable high-risk ischemia or MI without ECG changes. Despite advances in investigative modalities, a focused history and physical examination followed by an ECG remain the key tools for the diagnosis of MI. The most powerful features that increase the probability of MI, and their associated likelihood ratios (LRs), are new ST-segment elevation (LR range, 5.7-53.9); new Q wave (LR range, 5.3-24.8); chest pain radiating to both the left and right arm simultaneously (LR, 7.1); presence of a third heart sound (LR, 3.2); and hypotension (LR, 3.1). The most powerful features that decrease the probability of MI are a normal ECG result (LR range, 0.1-0.3), pleuritic chest pain (LR, 0.2), chest pain reproduced by palpation (LR range, 0.2-0.4), sharp or stabbing chest pain (LR, 0.3), and positional chest pain (LR, 0.3). Computer-derived algorithms that depend on clinical examination and ECG findings might improve the classification of patients according to the probability that an MI is causing their chest pain.	McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, McMaster Med Programme, Hamilton, ON L8N 3Z5, Canada; Duke Univ, Med Ctr, Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA	McMaster University; McMaster University; McMaster University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Panju, AA (corresponding author), McMaster Univ, Med Ctr, 1200 Main St W,Room 3X28, Hamilton, ON L8N 3Z5, Canada.		Hemmelgarn, Brenda R./I-6894-2012					BERGER JP, 1990, J INTERN MED, V227, P165, DOI 10.1111/j.1365-2796.1990.tb00138.x; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; DAVIES LG, 1958, BRIT HEART J, V20, P153; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; GADSBOLL N, 1989, EUR HEART J, V10, P1017, DOI 10.1093/oxfordjournals.eurheartj.a059414; GJORUP T, 1992, J INTERN MED, V231, P407, DOI 10.1111/j.1365-2796.1992.tb00952.x; GOLDMAN L, 1982, NEW ENGL J MED, V307, P588, DOI 10.1056/NEJM198209023071004; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HERLIHY T, 1987, AM J CARDIOL, V60, P20, DOI 10.1016/0002-9149(87)90976-3; HICKAM DH, 1985, J CHRON DIS, V38, P91, DOI 10.1016/0021-9681(85)90012-8; Holleman DR, 1997, J GEN INTERN MED, V12, P165, DOI 10.1007/s11606-006-5024-6; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P313, DOI 10.1001/jama.273.4.313; JONSBU J, 1991, J INTERN MED, V229, P143, DOI 10.1111/j.1365-2796.1991.tb00322.x; KANNEL WB, 1984, NEW ENGL J MED, V311, P1144, DOI 10.1056/NEJM198411013111802; KARLSON BW, 1991, AM J CARDIOL, V68, P171, DOI 10.1016/0002-9149(91)90739-8; KEE F, 1993, BRIT MED J, V307, P1528, DOI 10.1136/bmj.307.6918.1528; KLAEBOE G, 1987, ACTA MED SCAND, V222, P27; KUDENCHUK PJ, 1991, J AM COLL CARDIOL, V17, P1486, DOI 10.1016/0735-1097(91)90636-N; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; MATHEWS MB, 1985, ANGINA PECTORIS, P2; NESS TJ, 1990, PAIN, V41, P167, DOI 10.1016/0304-3959(90)90021-5; Panju A, 1996, CAN MED ASSOC J, V155, P541; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PRYOR DB, 1983, AM J MED, V75, P771, DOI 10.1016/0002-9343(83)90406-0; ROUAN GW, 1989, AM J CARDIOL, V64, P1087, DOI 10.1016/0002-9149(89)90857-6; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SARASIN FP, 1994, J GEN INTERN MED, V9, P187, DOI 10.1007/BF02600122; Sgarbossa EB, 1996, NEW ENGL J MED, V334, P481, DOI 10.1056/NEJM199602223340801; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; SOLOMON CG, 1989, AM J CARDIOL, V63, P772, DOI 10.1016/0002-9149(89)90040-4; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; TIERNEY WM, 1986, MED DECIS MAKING, V6, P12, DOI 10.1177/0272989X8600600103; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; URETSKY BF, 1977, AM J CARDIOL, V40, P498, DOI 10.1016/0002-9149(77)90062-5; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WILLEMS JL, 1991, NEW ENGL J MED, V325, P1767, DOI 10.1056/NEJM199112193252503; YUSUF S, 1984, EUR HEART J, V5, P690, DOI 10.1093/oxfordjournals.eurheartj.a061728	43	168	192	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1998	280	14					1256	1263		10.1001/jama.280.14.1256	http://dx.doi.org/10.1001/jama.280.14.1256			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	127NR	9786377				2022-12-24	WOS:000076357900033
J	Cavallo, RA; Cox, RT; Moline, MM; Roose, J; Polevoy, GA; Clevers, H; Peifer, M; Bejsovec, A				Cavallo, RA; Cox, RT; Moline, MM; Roose, J; Polevoy, GA; Clevers, H; Peifer, M; Bejsovec, A			Drosophila Tcf and Groucho interact to repress Wingless signalling activity	NATURE			English	Article							SEGMENT POLARITY GENE; BETA-CATENIN; CUBITUS INTERRUPTUS; TRANSCRIPTION; MELANOGASTER; EXPRESSION; ARMADILLO; COMPLEX; PROTEIN; LEF-1	Wingless/Wnt signalling directs cell-fate choices during embryonic development(1,2). Inappropriate reactivation of the pathway causes cancer(3-5). In Drosophila, signal transduction from Wingless stabilizes cytosolic Armadillo(1), which then forms a bipartite transcription factor with the HMG-box protein Drosophila Tcf (dTcf) and activates expression of Wingless-responsive genes(6-8) Here we report that in the absence of Armadillo, dTcf acts as a transcriptional repressor of Wingless-responsive genes, and we show that Groucho acts as a corepressor in this process. Reduction of dTcf activity partially suppresses wingless and armadillo mutant phenotypes, leading to derepression of Wingless-responsive genes. Furthermore, overexpression of wild-type dTcf enhances the phenotype of a weak wingless allele. Finally, mutations in the Drosophila groucho gene also suppress wingless and armadillo mutant phenotypes as Groucho physically interacts with dTcf and is required for its full repressor activity.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Utrecht Hosp, Dept Immunol, NL-3584 CX Utrecht, Netherlands	Northwestern University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Utrecht University; Utrecht University Medical Center	Bejsovec, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA.	bejsovec@nwu.edu	Peifer, Mark/A-1152-2010	Bejsovec, Amy/0000-0002-8019-5789; Peifer, Mark/0000-0003-1412-3987				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEJSOVEC A, 1995, GENETICS, V139, P309; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; Bejsovec Amy, 1996, Advances in Developmental Biochemistry, V4, P1, DOI 10.1016/S1064-2722(08)60056-0; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; DECELIS JF, 1995, DEVELOPMENT, V121, P3467; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; Hepker J, 1997, DEVELOPMENT, V124, P549; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SCHRONS H, 1992, GENETICS, V132, P481; TIONG SYK, 1990, GENETICS, V124, P889; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; VonOhlen T, 1997, P NATL ACAD SCI USA, V94, P2404, DOI 10.1073/pnas.94.6.2404	26	576	596	0	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 8	1998	395	6702					604	608		10.1038/26982	http://dx.doi.org/10.1038/26982			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127QW	9783586				2022-12-24	WOS:000076362900049
J	Nightingale, SL				Nightingale, SL			New safety information added to antiretroviral package inserts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 7	1998	280	13					1128	1128		10.1001/jama.280.13.1128	http://dx.doi.org/10.1001/jama.280.13.1128			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124YR	9777799				2022-12-24	WOS:000076210800005
J	Block, JA				Block, JA			Prevalence of arthroplasty during the course of rheumatoid arthritis	LANCET			English	Editorial Material									Rush Presbyterian St Lukes Med Ctr, Rheumatol Sect, Chicago, IL 60612 USA	Rush University	Block, JA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Rheumatol Sect, 1653 W Congress Pkwy, Chicago, IL 60612 USA.			Block, Joel/0000-0002-0330-7353				AbdelNasser AM, 1997, SEMIN ARTHRITIS RHEU, V27, P123, DOI 10.1016/S0049-0172(97)80012-1; HAKALA M, 1994, J RHEUMATOL, V21, P1432; Pincus T, 1995, BRIT J RHEUMATOL, V34, P59; SHERRER YS, 1986, ARTHRITIS RHEUM, V29, P494, DOI 10.1002/art.1780290406; VANDERHEIJDE MFM, 1988, SEMIN ARTHRITIS RHEU, V17, P284, DOI 10.1016/0049-0172(88)90013-3; Wolfe F, 1998, ARTHRITIS RHEUM, V41, P1072, DOI 10.1002/1529-0131(199806)41:6<1072::AID-ART14>3.0.CO;2-G; WOLFE F, 1985, J RHEUMATOL, V12, P254	7	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	OCT 3	1998	352	9134					1086	1086		10.1016/S0140-6736(05)79754-3	http://dx.doi.org/10.1016/S0140-6736(05)79754-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	125PP	9798582				2022-12-24	WOS:000076246400007
J	Dolk, H; Busby, A; Armstrong, BG; Walls, PH				Dolk, H; Busby, A; Armstrong, BG; Walls, PH			Geographical variation in anophthalmia and microphthalmia in England, 1988-94	BRITISH MEDICAL JOURNAL			English	Article							INHOMOGENEOUS POPULATIONS; MATERNAL FEVER; TERATOGENICITY; MALFORMATIONS; ANOMALIES; EXPOSURE; COLOBOMA; UPDATE	Objective: To investigate the geographical variation and clustering of congenital anophthalmia and microphthalmia in England, in response to media reports of clusters. Design: Comparison of pattern of residence at birth of cases of anophthalmia and microphthalmia in England in 1988-94, notified to a special register, with pattern of residence of all births. Three groups studied included all cases, all severe cases, and all severe cases of unknown aetiology. Outcome measures: Prevalence rates of anophthalmia and microphthalmia by region and district and by ward population density and socioeconomic deprivation index of enumeration district grouped into fifths. Clustering expressed as the tendency for the three nearest neighbours of a case to be more likely to be cases than expected by chance, or for there to be more cases within circles of fixed radius of a case than expected by chance. Results: The overall prevalence of anophthalmia and microphthalmia was 1.0 per 10 000 births. Regional and district variation in prevalence did not reach statistical significance. Prevalence was higher in rural than urban areas: the relative risk in the group of wards of lowest population density compared with the most densely populated group was 1.79 (95% confidence interval 1.15 to 2.81) for all cases and 2.37 (1.38 to 4.08) for severe cases. There was no evidence of a trend in risk with socioeconomic deprivation. There was very little evidence of localised clustering. Conclusions: There is very little evidence to support the presence of strongly localised environmental exposures causing clusters of children to be born with anophthalmia or microphthalmia The excess risk in rural areas requires further investigation.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Dolk, H (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Environm Epidemiol Unit, London WC1E 7HT, England.	h.dolk@lshtm.ac.uk		armstrong, benedict/0000-0003-4407-0409				ALXEANDER FE, 1992, GEOGRAPHICAL ENV EPI, P238; BUSBY A, 1998, IN PRESS ARCH DIS CH; BUYS ML, 1990, EYE BIRTH DEFECTS EN; Carstairs V., 1991, DEPRIVATION HLTH SCO; CUZICK J, 1990, J ROY STAT SOC B MET, V52, P73; DIGGLE PJ, 1991, BIOMETRICS, V47, P1155, DOI 10.2307/2532668; DOLK H, 1993, BRIT MED J, V307, P203, DOI 10.1136/bmj.307.6897.203-b; DONALD JM, 1991, ENVIRON HEALTH PERSP, V94, P237, DOI 10.2307/3431317; EDWARDS MJ, 1986, TERATOGEN CARCIN MUT, V6, P563, DOI 10.1002/tcm.1770060610; FRASER FC, 1978, LANCET, V2, P634; HARTWIG NG, 1989, TERATOLOGY, V39, P295, DOI 10.1002/tera.1420390311; HOOGENBOOM ER, 1991, CURR EYE RES, V10, P601, DOI 10.3109/02713689109013852; *INT PROGR CHEM SA, 1993, ENV HLTH CRIT, V148; KNOX EG, 1991, EPIDEMIOLOGY CONGENI; KRISTENSEN P, 1994, BRIT MED J, V308, P205, DOI 10.1136/bmj.308.6922.205c; LAMBERT S, 1990, PEDIATRIC OPHTHALMOL, P91; Lyons Jones K., 1988, SMITHS RECOGNIZABLE; MARTUZZI M, 1995, AM J EPIDEMIOL, V141, P369, DOI 10.1093/aje/141.4.369; *MIN AGR, 1992, FISH FOOD PEST SAF D; PADUANO M, 1993, OBSERVER        0117, P3; ROMERO P, 1989, ENVIRON RES, V50, P256, DOI 10.1016/S0013-9351(89)80006-4; *SCOTT OFF, 1988, REP WORK PART MICR F; Sherman JD, 1996, ARCH ENVIRON HEALTH, V51, P5, DOI 10.1080/00039896.1996.9935986; SPAGNOLO A, 1994, REPROD TOXICOL, V8, P397, DOI 10.1016/0890-6238(94)90079-5; SPRAGGETT K, 1982, TERATOLOGY, V25, pA78; SULIK KK, 1988, DEVELOPMENT, V103, P213; VONHERZEN JL, 1976, OBSTET GYNECOL, V50, P728; WARBURG M, 1992, OPHTHALMIC PAED GEN, V13, P111, DOI 10.3109/13816819209087611; WARBURG M, 1991, OPHTHALMIC PAED GEN, V12, P57, DOI 10.3109/13816819109023675; WEILAND HT, 1987, LANCET, V1, P682; *WELSH OFF, 1985, INC CONG MALF WAL SP	31	66	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					905	909						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756803	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000076409000016
J	Saudou, F; Finkbeiner, S; Devys, D; Greenberg, ME				Saudou, F; Finkbeiner, S; Devys, D; Greenberg, ME			Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions	CELL			English	Article							DISEASE PROTEIN; CELL-LINES; LOCALIZATION; NEURONS; GENE; IDENTIFICATION; EXPRESSION; BRAIN; PRODUCT; SIGNAL	The mechanisms by which mutant huntingtin induces neurodegeneration were investigated using a cellular model that recapitulates features of neurodegeneration seen in Huntington's disease. When transfected into cultured striatal neurons, mutant huntingtin induces neurodegeneration by an apoptotic mechanism. Antiapoptotic compounds or neurotrophic factors protected neurons against mutant huntingtin. Blocking nuclear localization of mutant huntingtin suppressed its ability to form intranuclear inclusions and to induce neurodegeneration. However, the presence of inclusions did not correlate with huntingtin-induced death. The exposure of mutant huntingtin-transfected striatal neurons to conditions that suppress the formation of inclusions resulted in an increase in mutant huntingtin-induced death. These findings suggest that mutant huntingtin acts within the nucleus to induce neurodegeneration. However, intranuclear inclusions may reflect a cellular mechanism to protect against huntingtin-induced cell death.	Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, ULP, F-67404 Illkirch, Strasbourg, France	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Greenberg, ME (corresponding author), Childrens Hosp, Dept Neurol, Div Neurosci, Boston, MA 02115 USA.		SAUDOU, Frédéric/L-3454-2014	SAUDOU, Frédéric/0000-0001-6107-1046; Devys, Didier/0000-0001-9655-3512	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD018655] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS028829, R01NS028829] Funding Source: NIH RePORTER; NICHD NIH HHS [P30-HD 18655] Funding Source: Medline; NINDS NIH HHS [NS 28829] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; BESSERT DA, 1995, MOL BRAIN RES, V33, P165, DOI 10.1016/0169-328X(95)00124-B; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davies SW, 1998, LANCET, V351, P131, DOI 10.1016/S0140-6736(97)08360-8; DeRooij KE, 1996, HUM MOL GENET, V5, P1093, DOI 10.1093/hmg/5.8.1093; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; DRAGUNOW M, 1995, NEUROREPORT, V6, P1053, DOI 10.1097/00001756-199505090-00026; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Group T. H. D. C. R., 1993, CELL, V72, P971, DOI [10.1016/0092-8674(93)90585-E8458085, DOI 10.1016/0092-8674(93)90585-E8458085]; Gusella JF, 1996, COLD SPRING HARB SYM, V61, P615; GUTEKUNST CA, 1995, P NATL ACAD SCI USA, V92, P8710, DOI 10.1073/pnas.92.19.8710; HEDREEN JC, 1995, J NEUROPATH EXP NEUR, V54, P105, DOI 10.1097/00005072-199501000-00013; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kudo N, 1997, J BIOL CHEM, V272, P29742, DOI 10.1074/jbc.272.47.29742; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MARTIN JB, 1986, NEW ENGL J MED, V315, P1267; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; NISHI K, 1994, J BIOL CHEM, V269, P6320; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PORTERACAILLIAU C, 1995, J NEUROSCI, V15, P3775, DOI 10.1523/jneurosci.15-05-03775.1995; REINER A, 1988, P NATL ACAD SCI USA, V85, P5733, DOI 10.1073/pnas.85.15.5733; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; SAPP E, 1995, NEUROSCIENCE, V64, P397, DOI 10.1016/0306-4522(94)00427-7; Saudou F, 1996, COLD SPRING HARB SYM, V61, P639; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672	38	1287	1315	1	37	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 2	1998	95	1					55	66		10.1016/S0092-8674(00)81782-1	http://dx.doi.org/10.1016/S0092-8674(00)81782-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	125MX	9778247	Bronze			2022-12-24	WOS:000076242300010
J	Worrall, D; Elias, L; Ashford, D; Smallwood, M; Sidebottom, C; Lillford, P; Telford, J; Holt, C; Bowles, D				Worrall, D; Elias, L; Ashford, D; Smallwood, M; Sidebottom, C; Lillford, P; Telford, J; Holt, C; Bowles, D			A carrot leucine-rich-repeat protein that inhibits ice recrystallization	SCIENCE			English	Article							THERMAL HYSTERESIS PROTEIN; ANTIFREEZE PROTEINS; CRYSTAL-STRUCTURE; PLANTS; ELECTROPHORESIS; PATHOGENESIS; EXPRESSION; BINDING; TOMATO	Many organisms adapted to live at subzero temperatures express antifreeze proteins that improve their tolerance to freezing. Although structurally diverse, all antifreeze proteins interact with ice surfaces, depress the freezing temperature of aqueous solutions, and inhibit ice crystal growth. A protein purified from carrot shares these functional features with antifreeze proteins of fish. Expression of the carrot complementary DNA in tobacco resulted in the accumulation of antifreeze activity in the apoplast of plants grown at greenhouse temperatures. The sequence of carrot antifreeze protein is similar to that of polygalacturonase inhibitor proteins and contains leucine-rich repeats.	Univ York, Dept Biol, Plant Lab, York YO1 5YW, N Yorkshire, England; Unilever Res, Bedford MK44 1LO, England	University of York - UK; Unilever	Smallwood, M (corresponding author), Univ York, Dept Biol, Plant Lab, POB 373, York YO1 5YW, N Yorkshire, England.			Worrall, Dawn/0000-0002-9062-7987				Bertrand JA, 1996, EMBO J, V15, P2678, DOI 10.1002/j.1460-2075.1996.tb00628.x; COLLMER A, 1986, ANNU REV PHYTOPATHOL, V24, P383, DOI 10.1146/annurev.py.24.090186.002123; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DAVIES PL, 1990, FASEB J, V4, P2460, DOI 10.1096/fasebj.4.8.2185972; DEVRIES AL, 1986, METHOD ENZYMOL, V127, P293; DEVRIES AL, 1971, SCIENCE, V172, P1152, DOI 10.1126/science.172.3988.1152; Draper J., 1988, PLANT GENETIC TRANSF, P69; DUMAN JG, 1994, BBA-PROTEIN STRUCT M, V1206, P129, DOI 10.1016/0167-4838(94)90081-7; DUMAN JG, 1993, CRYOBIOLOGY, V30, P322, DOI 10.1006/cryo.1993.1031; Duman John G., 1993, Advances in Low-Temperature Biology, V2, P131; GRIFFITH M, 1995, BIOTECHNOL ADV, V13, P375, DOI 10.1016/0734-9750(95)02001-J; GROSS KC, 1982, HORTSCIENCE, V17, P933; HIGHTOWER R, 1991, PLANT MOL BIOL, V17, P1013, DOI 10.1007/BF00037141; HON WC, 1995, PLANT PHYSIOL, V109, P879, DOI 10.1104/pp.109.3.879; Huang T., 1995, Cryobiology, V32, P577; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; KENWARD KD, 1993, PLANT MOL BIOL, V23, P377, DOI 10.1007/BF00029012; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Logsdon JM, 1997, P NATL ACAD SCI USA, V94, P3485, DOI 10.1073/pnas.94.8.3485; MCMANUS MT, 1988, PLANTA, V175, P56; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PORWAL BL, 1989, INDIAN J AGRON, V34, P293; RAJESHEKAR CB, 1996, PLANT PHYSIOL, V111, P605; ROHRINGER R, 1983, J EXP BOT, V34, P1589, DOI 10.1093/jxb/34.12.1589; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SMALLWOOD M, UNPUB; SONNICHSEN FD, 1993, SCIENCE, V259, P1154, DOI 10.1126/science.8438165; SONNICHSEN FD, 1995, PROTEIN SCI, V4, P460; STOTZ HU, 1994, PLANT MOL BIOL, V25, P607, DOI 10.1007/BF00029600; URRUTIA ME, 1992, BIOCHIM BIOPHYS ACTA, V1121, P199, DOI 10.1016/0167-4838(92)90355-H; WISNIEWSKI M, 1987, PROTOPLASMA, V141, P160, DOI 10.1007/BF01272898; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; ZHENG LS, 1992, PLANT CELL, V4, P1147, DOI 10.1105/tpc.4.9.1147	35	205	271	1	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 2	1998	282	5386					115	117		10.1126/science.282.5386.115	http://dx.doi.org/10.1126/science.282.5386.115			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	126LM	9756474				2022-12-24	WOS:000076294900051
J	Messerli, FH; Mittler, BS				Messerli, FH; Mittler, BS			Framingham at 50	LANCET			English	Editorial Material									Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Hypertens Dis Sect, New Orleans, LA 70121 USA	Ochsner Health System	Messerli, FH (corresponding author), Alton Ochsner Med Fdn & Ochsner Clin, Dept Internal Med, Hypertens Dis Sect, New Orleans, LA 70121 USA.		Messerli, Franz/AAR-4783-2021					BRODY JE, 1994, HEART DIS PERSIST ST; GORDAN T, 1968, FRAMINGHAM STUDY; HAY, 1931, BRIT M J, V2, P43; WHITE PD, 1931, MED MONOGRAPHS, P400	4	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1006	1006		10.1016/S0140-6736(05)60073-6	http://dx.doi.org/10.1016/S0140-6736(05)60073-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759741				2022-12-24	WOS:000076121800007
J	Papayannopoulos, V; Tomlinson, A; Panin, VM; Rauskolb, C; Irvine, KD				Papayannopoulos, V; Tomlinson, A; Panin, VM; Rauskolb, C; Irvine, KD			Dorsal-ventral signaling in the Drosophila eye	SCIENCE			English	Article							PATTERN-FORMATION; LIMB DEVELOPMENT; NOTCH; FRINGE; GENES; CELLS; EXPRESSION; DELTA; AXIS; DISC	The development of the Drosophila eye has served as a model system for investigations of tissue patterning and cell-cell communication; however, early eye development-has not been well understood. The results presented here indicate that specialized cells are established along the dorsal-ventral midline of the developing eye by Notch-mediated signaling between dorsal and ventral cells, and that Notch activation at the midline plays an essential role both in promoting the growth of the eye primordia and in regulating eye patterning. These observations imply that the developmental homology between Drosophila wings and vertebrate limbs extends to Drosophila eyes.	Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA; Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Columbia University; Columbia University	Irvine, KD (corresponding author), Rutgers State Univ, Waksman Inst, POB 759, Piscataway, NJ 08854 USA.		Panin, Vlad/G-1583-2016	Panin, Vlad/0000-0001-9126-1481; Papayannopoulos, Venizelos/0000-0002-3741-8190	NIGMS NIH HHS [GM-R01-54594] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054594] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brodsky MH, 1996, DEV BIOL, V173, P428, DOI 10.1006/dbio.1996.0038; Brook WJ, 1996, ANNU REV CELL DEV BI, V12, P161, DOI 10.1146/annurev.cellbio.12.1.161; CAMPOSORTEGA JA, 1978, ROUX ARCH DEV BIOL, V184, P155, DOI 10.1007/BF00848224; Fleming RJ, 1997, DEVELOPMENT, V124, P2973; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; Heberlein U, 1998, DEVELOPMENT, V125, P567; HIGASHIJIMA SI, 1992, GENE DEV, V6, P50, DOI 10.1101/gad.6.1.50; IRVINE KD, 1994, CELL, V79, P595, DOI 10.1016/0092-8674(94)90545-2; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Ito K, 1997, DEVELOPMENT, V124, P761; Jarman AP, 1996, TRENDS GENET, V12, P121, DOI 10.1016/0168-9525(96)30015-2; Laufer E, 1997, NATURE, V386, P366, DOI 10.1038/386366a0; McNeill H, 1997, GENE DEV, V11, P1073, DOI 10.1101/gad.11.8.1073; MCNEILL H, UNPUB; Panin VM, 1997, NATURE, V387, P908, DOI 10.1038/43191; PARODY TR, 1993, GENETICS, V135, P527; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; RAUSKOLB C, UNPUB; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SPEICHER SA, 1994, DEVELOPMENT, V120, P535; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; STRUHL G, 1993, CELL, V74, P331, DOI 10.1016/0092-8674(93)90424-O; STRUHL G, UNPUB; Sun X, 1996, DEVELOPMENT, V122, P2465; TOMLINSON A, 1988, DEVELOPMENT, V104, P183; Treisman JE, 1998, CURR TOP DEV BIOL, V39, P119, DOI 10.1016/S0070-2153(08)60454-8; VILLANO JL, 1995, DEVELOPMENT, V121, P2767; Wehrli M, 1998, DEVELOPMENT, V125, P1421; WILLIAMS JA, 1993, DEVELOPMENT, V117, P571; ZHENG L, 1995, DEVELOPMENT, V121, P3045	31	184	186	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 25	1998	281	5385					2031	2034		10.1126/science.281.5385.2031	http://dx.doi.org/10.1126/science.281.5385.2031			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124BV	9748163				2022-12-24	WOS:000076161800057
J	Dirick, L; Goetsch, L; Ammerer, C; Byers, B				Dirick, L; Goetsch, L; Ammerer, C; Byers, B			Regulation of meiotic S phase by Ime2 and a Clb5,6-associated kinase in Saccharomyces cerevisiae	SCIENCE			English	Article							CELL-CYCLE; PROTEIN-KINASE; DNA-REPLICATION; BUDDING YEAST; START; G1; INHIBITOR; MEIOSIS; TRANSITION; ARREST	Cyclin-dependent kinase (Cdk) mutations that prevent entry into the mitotic cell cycle of budding yeast fail to block meiotic DNA replication, suggesting there may be fundamental differences between these pathways. However, 5 phase in meiosis was found to depend on the same B-type cyclins (Clb5 and Clb6) as it does in mitosis. Meiosis differs instead in the mechanism that controls removal of the Cdk inhibitor Sic1. Destruction of Sic1 and activation of a Clb5-dependent kinase in meiotic cells required the action of the meiosis-specific protein kinase Ime2, thereby coupling early meiotic gene expression to control of DNA replication for meiosis.	Univ Washington, Dept Genet, Seattle, WA 98195 USA; Univ Vienna, Ludwig Boltzmann Inst, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	University of Washington; University of Washington Seattle; Ludwig Boltzmann Institute; University of Vienna	Byers, B (corresponding author), Univ Washington, Dept Genet, Box 357360, Seattle, WA 98195 USA.				NIGMS NIH HHS [GM 18541] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM018541, R01GM118541, R37GM018541] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; Chu S, 1998, MOL CELL, V1, P685, DOI 10.1016/S1097-2765(00)80068-4; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DIRICK L, UNPUB; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Foiani M, 1996, MOL GEN GENET, V253, P278, DOI 10.1007/s004380050323; IINO Y, 1995, GENETICS, V140, P1235; KOCH C, 1994, CURR OPIN CELL BIOL, V6, P451, DOI 10.1016/0955-0674(94)90039-6; KOMINAMI K, 1993, BIOSCI BIOTECH BIOCH, V57, P1731, DOI 10.1271/bbb.57.1731; KUHNE C, 1993, EMBO J, V12, P3437, DOI 10.1002/j.1460-2075.1993.tb06018.x; MITCHELL AP, 1994, MICROBIOL REV, V58, P56, DOI 10.1128/MMBR.58.1.56-70.1994; Murray A, 1993, CELL CYCLE INTRO; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHUSTER EO, 1989, GENETICS, V123, P29; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tyers M, 1996, P NATL ACAD SCI USA, V93, P7772, DOI 10.1073/pnas.93.15.7772; Verma R, 1997, SCIENCE, V278, P455, DOI 10.1126/science.278.5337.455; YOSHIDA M, 1990, MOL GEN GENET, V221, P176, DOI 10.1007/BF00261718	24	112	113	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1854	1857		10.1126/science.281.5384.1854	http://dx.doi.org/10.1126/science.281.5384.1854			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743499				2022-12-24	WOS:000076007100054
J	Mastroberardino, L; Spindler, B; Pfeiffer, R; Skelly, PJ; Loffing, J; Shoemaker, CB; Verrey, F				Mastroberardino, L; Spindler, B; Pfeiffer, R; Skelly, PJ; Loffing, J; Shoemaker, CB; Verrey, F			Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family	NATURE			English	Article							INTERLEUKIN-1-DEPENDENT INTERLEUKIN-2 PRODUCTION; MONOCLONAL-ANTIBODY 4F2; XENOPUS-LAEVIS OOCYTES; EL4 THYMOMA CELLS; SURFACE-ANTIGEN; HEAVY-CHAIN; STIMULATION; EXPRESSION; PROTEIN; CLONING	Amino-acid transport across cellular plasma membranes depends on several parallel-functioning (co-)transporters and exchangers'. The widespread transport system L accounts for a sodium-independent exchange of large, neutral amino acids, whereas the system y(+)L exchanges positively charged amino acids and/or neutral amino acids together with sodium(2,3). The molecular nature of these transporters remains unknown, although expression of the human cell-surface glycoprotein 4F2 heavy chain (h4F2hc; CD98 in the mouse)(4,5) is known to induce low levels of L- and/or y(+)L-type transport(6-9). This glycoprotein is found in activated lymphocytes, together with an uncharacterized, disulphide-linked lipophilic light chain with an apparent relative molecular mass of 40,000 (M-r 40 K)(10,11). Here we identify the permease-related protein E16 (ref. 12) as the first light chain of h4F2hc and show that the resulting heterodimeric complex mediates L-type amino-acid transport. The homologous protein from Schistosoma mansoni, SPRM1, also associates covalently with coexpressed h4F2hc glycoprotein, although it induces amino-acid transport of different substrate specificity. The coexpression of h4F2hc is required for surface expression of these permease-related light chains, which belong to a new family of amino-acid transporters that form heterodimers with cell-surface glycoproteins.	Univ Zurich, Inst Physiol, CH-8057 Zurich, Switzerland; Univ Zurich, Inst Anat, CH-8057 Zurich, Switzerland; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Zurich; University of Zurich; Harvard University; Harvard T.H. Chan School of Public Health	Verrey, F (corresponding author), Univ Zurich, Inst Physiol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Loffing, Johannes/ABG-9973-2020	Verrey, Francois/0000-0003-3250-9824; Loffing, Johannes/0000-0002-9415-6588				BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; Broer S, 1995, BIOCHEM J, V312, P863, DOI 10.1042/bj3120863; Broer S, 1997, BIOCHEM J, V324, P535, DOI 10.1042/bj3240535; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DEVES R, 1992, J PHYSIOL-LONDON, V454, P491, DOI 10.1113/jphysiol.1992.sp019275; EISENBARTH GS, 1980, J IMMUNOL, V124, P1237; GAUGITSCH HW, 1992, J BIOL CHEM, V267, P11267; GEERING K, 1989, AM J PHYSIOL, V257, pC851, DOI 10.1152/ajpcell.1989.257.5.C851; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HEMLER ME, 1982, J IMMUNOL, V129, P623; HOFMANN K, 1992, COMPUT APPL BIOSCI, V8, P331; Isnard AD, 1996, J MOL BIOL, V262, P473, DOI 10.1006/jmbi.1996.0529; LUSCHER B, 1985, J IMMUNOL, V135, P3951; MACDONALD HR, 1985, J IMMUNOL, V135, P3944; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; PALACIN M, 1994, J EXP BIOL, V196, P123; Spindler B, 1997, PFLUG ARCH EUR J PHY, V434, P323, DOI 10.1007/s004240050403; TEIXEIRA S, 1987, J BIOL CHEM, V262, P9574; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	20	442	480	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					288	291		10.1038/26246	http://dx.doi.org/10.1038/26246			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751058				2022-12-24	WOS:000075974600054
J	Sussman, MA; Lim, HW; Gude, N; Taigen, T; Olson, EN; Robbins, J; Colbert, MC; Gualberto, A; Wieczorek, DF; Molkentin, JD				Sussman, MA; Lim, HW; Gude, N; Taigen, T; Olson, EN; Robbins, J; Colbert, MC; Gualberto, A; Wieczorek, DF; Molkentin, JD			Prevention of cardiac hypertrophy in mice by calcineurin inhibition	SCIENCE			English	Article							TRANSCRIPTION FACTORS; BETA-TROPOMYOSIN; TRANSGENIC MICE; CYCLOSPORINE-A; HEART-FAILURE; CARDIOMYOPATHY; CA2+; TRANSPLANTATION; MECHANISMS; MUTATIONS	Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease that affects 1 in 500 individuals. Here it is shown that calcineurin, a calcium-regulated phosphatase, plays a critical role in the pathogenesis of HCM. Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin Light chain-2, or fetal beta-tropomyosin in the heart. Cyclosporin had a similar effect in a rat model of pressure-overload hypertrophy. These results suggest that calcineurin inhibitors merit investigation as potential therapeutics for certain forms of human heart disease.	Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, Cincinnati, OH 45229 USA; Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, Dallas, TX 75235 USA; Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Univ Cincinnati, Dept Mol Genet, Cincinnati, OH 45267 USA	Cincinnati Children's Hospital Medical Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Case Western Reserve University; University System of Ohio; University of Cincinnati	Molkentin, JD (corresponding author), Childrens Hosp, Med Ctr, Div Mol Cardiovasc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Molkentin, Jeffery/0000-0002-3558-6529; Gualberto, Antonio/0000-0002-6590-839X	NHLBI NIH HHS [HL58224-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL058224, R01HL058224] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 1997, CIRCULATION, V96, P2755, DOI 10.1161/01.CIR.96.9.2755; CLIPSTONE NA, 1994, J BIOL CHEM, V269, P26431; Colbert MC, 1997, J CLIN INVEST, V100, P1958, DOI 10.1172/JCI119727; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; FEWELL JG, UNPUB; Gualberto A, 1998, J BIOL CHEM, V273, P7088, DOI 10.1074/jbc.273.12.7088; HAVERICH A, 1994, TRANSPLANT P, V26, P2713; HONGO K, 1995, AM J PHYSIOL-CELL PH, V269, pC690, DOI 10.1152/ajpcell.1995.269.3.C690; HUSI H, 1994, J BIOL CHEM, V269, P14199; James J, 1997, AM J PHYSIOL-HEART C, V273, pH2105, DOI 10.1152/ajpheart.1997.273.5.H2105; LEGUENNEC JY, 1991, EXP PHYSIOL, V76, P975, DOI 10.1113/expphysiol.1991.sp003560; Lim H. J., UNPUB; Maier LS, 1998, AM J PHYSIOL-HEART C, V274, pH1361, DOI 10.1152/ajpheart.1998.274.4.H1361; MARON BJ, 1995, CIRCULATION, V92, P785, DOI 10.1161/01.CIR.92.4.785; Maron BJ, 1997, LANCET, V350, P127, DOI 10.1016/S0140-6736(97)01282-8; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; MUTHUCHAMY M, IN PRESS J MOL CELL; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Palmiter KA, 1997, BASIC RES CARDIOL, V92, P63, DOI 10.1007/BF00794070; Palmiter KA, 1996, J BIOL CHEM, V271, P11611, DOI 10.1074/jbc.271.20.11611; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Schaub MC, 1997, J MOL MED, V75, P901, DOI 10.1007/s001090050182; Sussman MA, 1998, CIRC RES, V82, P94; Sussman MA, 1998, J CLIN INVEST, V101, P51, DOI 10.1172/JCI1167; Ventura HO, 1997, CURR OPIN CARDIOL, V12, P375, DOI 10.1097/00001573-199707000-00005; Vikstrom KL, 1996, CURR OPIN CELL BIOL, V8, P97, DOI 10.1016/S0955-0674(96)80053-6; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WIEDERRECHT G, 1993, ANN NY ACAD SCI, V696, P9, DOI 10.1111/j.1749-6632.1993.tb17137.x	29	390	409	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1690	1693		10.1126/science.281.5383.1690	http://dx.doi.org/10.1126/science.281.5383.1690			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733519				2022-12-24	WOS:000075856500052
J	Wang, CY; Mayo, MW; Korneluk, RG; Goeddel, DV; Baldwin, AS				Wang, CY; Mayo, MW; Korneluk, RG; Goeddel, DV; Baldwin, AS			NF-kappa B antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation	SCIENCE			English	Article							INDUCED CELL-DEATH; RECEPTOR-1 SIGNALING COMPLEX; INDUCED APOPTOSIS; CYTOCHROME-C; POLY(ADP-RIBOSE) POLYMERASE; CAENORHABDITIS-ELEGANS; ALPHA PROTEOLYSIS; CD95 FAS/APO-1; KINASE COMPLEX; PROTEIN	Tumor necrosis factor alpha (TNF-alpha) binding to the TNF receptor (TNFR) potentially initiates apoptosis and activates the transcription factor nuclear factor kappa B (NF-kappa B), which suppresses apoptosis by an unknown mechanism. The activation of NF-kappa B was found to block the activation of caspase-8. TRAF1 (TNFR-associated factor 1), TRAF2, and the inhibitor-of-apoptosis (IAP) proteins c-IAP1 and c-IAP2 were identified as gene targets of NF-kappa B transcriptional activity. in cells in which NF-kappa B was inactive, all of these proteins were required to fully suppress TNF-induced apoptosis, whereas c-IAP1 and c-IAP2 were sufficient to suppress etoposide-induced apoptosis. Thus, NF-kappa B activates a group of gene products that function cooperatively at the earliest checkpoint to suppress TNF-alpha-mediated apoptosis and that function more distally to suppress genotoxic agent-mediated apoptosis.	Univ N Carolina, Sch Dent, Lineberger Comprehens Canc Ctr, Dept Endodont, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Childrens Hosp Eastern Ontario, Mol Genet Res Lab, Ottawa, ON K1H 8M5, Canada; Tularik, S San Francisco, CA 94080 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Ottawa; Children's Hospital of Eastern Ontario; University of North Carolina; University of North Carolina Chapel Hill	Wang, CY (corresponding author), Univ N Carolina, Sch Dent, Lineberger Comprehens Canc Ctr, Dept Endodont, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA 75080, CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075080, R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1998, MOL CELL, V1, P782; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Maniatis T, 1997, SCIENCE, V278, P818, DOI 10.1126/science.278.5339.818; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1997, CELL, V88, P335; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Speiser DE, 1997, J EXP MED, V185, P1777, DOI 10.1084/jem.185.10.1777; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; Uren AG, 1996, P NATL ACAD SCI USA, V93, P4974, DOI 10.1073/pnas.93.10.4974; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C.-W., UNPUB; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wu BY, 1997, J VIROL, V71, P3161, DOI 10.1128/JVI.71.4.3161-3167.1997; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Xue D, 1996, GENE DEV, V10, P1073, DOI 10.1101/gad.10.9.1073; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; You MJ, 1997, MOL CELL BIOL, V17, P7328, DOI 10.1128/MCB.17.12.7328; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	58	2445	2571	0	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 11	1998	281	5383					1680	1683		10.1126/science.281.5383.1680	http://dx.doi.org/10.1126/science.281.5383.1680			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	118TR	9733516	Green Submitted			2022-12-24	WOS:000075856500049
J	Giovannucci, E				Giovannucci, E			Selenium and risk of prostate cancer	LANCET			English	Editorial Material							SERUM		Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Giovannucci, E (corresponding author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.							Clark LC, 1998, BRIT J UROL, V81, P730; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; COMSTOCK GW, 1992, AM J EPIDEMIOL, V135, P115, DOI 10.1093/oxfordjournals.aje.a116264; GRIFFIN AC, 1982, MOL INTERRELATIONS N, P401; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; Longnecker MP, 1996, EPIDEMIOLOGY, V7, P384, DOI 10.1097/00001648-199607000-00008; MAJEED FA, 1994, BRIT J UROL, V73, P377, DOI 10.1111/j.1464-410X.1994.tb07600.x; Rayman MP, 1997, BRIT MED J, V314, P387, DOI 10.1136/bmj.314.7078.387; SHAMBERGER RJ, 1969, CAN MED ASSOC J, V100, P682; Yoshizawa K, 1998, JNCI-J NATL CANCER I, V90, P1219, DOI 10.1093/jnci/90.16.1219	10	27	27	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					755	756		10.1016/S0140-6736(05)60674-5	http://dx.doi.org/10.1016/S0140-6736(05)60674-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737275				2022-12-24	WOS:000075762700004
J	Wolf, F; Geisel, T				Wolf, F; Geisel, T			Spontaneous pinwheel annihilation during visual development	NATURE			English	Article							OCULAR DOMINANCE COLUMNS; ORIENTATION SELECTIVITY; STRIATE CORTEX; MAPS; ORGANIZATION; ARRANGEMENT; PREFERENCE; DOMAINS; MODELS	Neurons in the visual cortex respond preferentially to edge-like stimuli of a particular orientation(1). It is a long-standing hypothesis that orientation selectivity arises during development through the activity-dependent refinement of cortical circuitry(2-4). Unambiguous evidence far such a process has, however, remained elusive(5-7). Here we argue that, if orientation preferences arise through activity-dependent refinement of initially unselective patterns of synaptic connections, this process should leave distinct signatures in the emerging spatial pattern of preferred orientations. Preferred orientations typically change smoothly and progressively across the cortex(1). This smooth progression is disrupted at the centres of so-called pinwheels(8,9), where neurons exhibiting the whole range of orientation preferences are located in close vicinity(10). Assuming that orientation selectivity develops through a set of rules that we do not specify, we demonstrate mathematically that the spatial density of pinwheels is rigidly constrained by basic symmetry principles. In particular, the spatial density of pinwheels, which emerge when orientation selectivity is first established, is larger than a model-independent minimal value. As a consequence, lower densities, if observed in adult animals, are predicted to develop through the motion and annihilation of pinwheel pairs.	Max Planck Inst Stromungsforsch, D-37018 Gottingen, Germany; Univ Frankfurt, SFB Nichtlineare Dynam, D-6000 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Wolf, F (corresponding author), Max Planck Inst Stromungsforsch, Postfach 2853, D-37018 Gottingen, Germany.		Wolf, Fred/D-5771-2011	Wolf, Fred/0000-0002-7068-3762				ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; BOCK GR, 1995, DEV CEREBRAL CORTEX; BONHOEFFER T, 1995, EUR J NEUROSCI, V7, P1973, DOI 10.1111/j.1460-9568.1995.tb00720.x; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Bosking WH, 1997, J NEUROSCI, V17, P2112; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DURBIN R, 1990, NATURE, V343, P644, DOI 10.1038/343644a0; ERWIN E, 1995, NEURAL COMPUT, V7, P425, DOI 10.1162/neco.1995.7.3.425; Frisch U., 1995, TURBULENCE; GERMAN S, 1997, SIAM J APPL MATH, V36, P86; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; Halperin B., 1981, PHYSICS DEFECTS, P813; Horton JC, 1996, J NEUROSCI, V16, P5510; Hubel DH, 1962, J PHYSL, V160, P215; LEVAY S, 1991, VISION VISUAL DYSFUN, P266; LOWEL S, 1987, J COMP NEUROL, V255, P401, DOI 10.1002/cne.902550307; Maldonado PE, 1997, SCIENCE, V276, P1551, DOI 10.1126/science.276.5318.1551; Miller AB, 1996, J PUBLIC HEALTH POL, V17, P367, DOI 10.2307/3343273; MILLER KD, 1994, J NEUROSCI, V14, P409; MOVSHON JA, 1981, ANNU REV PSYCHOL, V32, P447; NIEBUR E, 1994, NEURAL COMPUT, V6, P602, DOI 10.1162/neco.1994.6.4.602; Obermayer K, 1997, NEURAL COMPUT, V9, P555, DOI 10.1162/neco.1997.9.3.555; Rao SC, 1997, J COMP NEUROL, V387, P358; Renyi A., 1970, PROBABILITY THEORY; Sompolinsky H, 1997, CURR OPIN NEUROBIOL, V7, P514, DOI 10.1016/S0959-4388(97)80031-1; Swindale NV, 1996, NETWORK-COMP NEURAL, V7, P161, DOI 10.1088/0954-898X/7/2/002; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; von der Malsburg C, 1973, Kybernetik, V14, P85	30	83	83	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 3	1998	395	6697					73	78		10.1038/25736	http://dx.doi.org/10.1038/25736			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116JY	9738500				2022-12-24	WOS:000075722200049
J	Lord, GM; Matarese, G; Howard, LK; Baker, RJ; Bloom, SR; Lechler, RI				Lord, GM; Matarese, G; Howard, LK; Baker, RJ; Bloom, SR; Lechler, RI			Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression	NATURE			English	Article							ANOREXIA-NERVOSA; SERUM LEPTIN; MEDIATED-IMMUNITY; INTERFERON-GAMMA; DIABETIC MICE; OBESE GENE; RECEPTOR; MOUSE; WEIGHT; HUMANS	Nutritional deprivation suppresses immune function(1-3). The cloning of the obese gene and identification of its protein product leptin(4) has provided fundamental insight into the hypothalamic regulation of body weight(5,6). Circulating levels of this adipocyte-derived hormone are proportional to fat mass(6,7) but maybe lowered rapidly by fasting(8,9) or increased by inflammatory mediators(10,11). The impaired T-cell immunity of mice(12,13) now known to be defective in leptin (ob/ob)(4) or its receptor (db/db)(14,13), has never been explained. Impaired cell-mediated immunity(1-3) and reduced levels of leptin(7) are both features of low body weight in humans. Indeed, malnutrition predisposes to death from infectious diseases(16). We report here that leptin has a specific effect on T-lymphocyte responses, differentially regulating the proliferation of naive and memory T cells. Leptin increased Th1 and suppressed Th2 cytokine production. Administration of leptin to mice reversed the immunosuppressive effects of acute starvation. Our findings suggest a new role for leptin in linking nutritional status to cognate cellular immune function, and provide a molecular mechanism to account for the immune dysfunction observed in starvation.	Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Immunol, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Endocrinol, London W12 0NN, England	Imperial College London; Imperial College London	Lechler, RI (corresponding author), Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Immunol, Du Cane Rd, London W12 0NN, England.		Lord, Graham M/B-3797-2011; Abraham, Sabu/E-1144-2019; Matarese, Giuseppe/AAO-4077-2021	Abraham, Sabu/0000-0002-0916-5827; Matarese, Giuseppe/0000-0001-9429-0616; Howard, Jane/0000-0003-2754-8300; Lord, Graham/0000-0003-2069-4743				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Beak SA, 1996, ENDOCRINOLOGY, V137, P4130, DOI 10.1210/en.137.10.4130; Besedovsky HO, 1996, ENDOCR REV, V17, P64, DOI 10.1210/er.17.1.64; Boden G, 1996, J CLIN ENDOCR METAB, V81, P3419, DOI 10.1210/jc.81.9.3419; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CASON J, 1986, CLIN EXP IMMUNOL, V64, P370; CHANDRA RK, 1980, PEDIATR RES, V14, P544, DOI 10.1093/ajcn/33.1.13; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; FERNANDES G, 1978, J CLIN INVEST, V61, P243, DOI 10.1172/JCI108933; Friedman J M, 1998, Nutr Rev, V56, ps38; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gotoda T, 1997, HUM MOL GENET, V6, P869, DOI 10.1093/hmg/6.6.869; Grinspoon S, 1996, J CLIN ENDOCR METAB, V81, P3861, DOI 10.1210/jc.81.11.3861; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Janik JE, 1997, J CLIN ENDOCR METAB, V82, P3084, DOI 10.1210/jc.82.9.3084; Laufer TM, 1996, NATURE, V383, P81, DOI 10.1038/383081a0; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; LOMBARDI G, 1990, INT IMMUNOL, V2, P9, DOI 10.1093/intimm/2.1.9; POLACK E, 1993, J CLIN IMMUNOL, V13, P445, DOI 10.1007/BF00920020; Sarraf P, 1997, J EXP MED, V185, P171, DOI 10.1084/jem.185.1.171; SEMNANI RT, 1994, J EXP MED, V180, P2125, DOI 10.1084/jem.180.6.2125; SHEARS P, 1991, EPIDEMIOL INFECT, V107, P241, DOI 10.1017/S0950268800048895; Staite ND, 1996, BLOOD, V88, P2973, DOI 10.1182/blood.V88.8.2973.bloodjournal8882973; Young JL, 1997, EUR J IMMUNOL, V27, P2383, DOI 10.1002/eji.1830270937; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	1692	1793	1	98	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 27	1998	394	6696					897	901		10.1038/29795	http://dx.doi.org/10.1038/29795			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	114LW	9732873				2022-12-24	WOS:000075611800050
J	Bruner, AB; Fishman, M				Bruner, AB; Fishman, M			Adolescents and illicit drug use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21287 USA; Mt Manor Treatment Ctr, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University	Bruner, AB (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, 600 N Wolfe St,Pk 307, Baltimore, MD 21287 USA.	abruner@welclink.welch.jhu.edu						Brown SA, 1994, APPLIED PREVENTIVE P, V3, P61, DOI [10.1016/S0962-1849(05)80139-8, DOI 10.1016/S0962-1849(05)80139-8]; DAVIS P, 1997, WASHINGTON POST 1214; Elster AB., AMA GUIDELINES ADOLE; Fishman MJ, 1998, J ADDICT DIS, V17, P145; GILLMAN TJ, 1998, DALLAS MORNING 0527; Hicks, 1993, Adolesc Med, V4, P453; Kokotailo P, 1995, NIDA Res Monogr, V156, P112; *NAT CTR ADD SUBST, NAT SURV AM ATT SUBS, V2; *NAT CTR ADD SUBST, AD COMM REP AD ALC T; *NAT CTR ADD SUBST, 1997 BACK SCH SURV; *NEWS INF SERV U M, MON FUT STUD; *OFF NAT DRUG CONT, PULS CHECK SUMM 1998; *OFF NAT DRUG CONT, 1997, NAT DRUG CONTR STRAT; *OFF NAT DRUG CONT, 1998, NAT DRUG CONTR STRAT; Pope HG, 1996, JAMA-J AM MED ASSOC, V275, P521, DOI 10.1001/jama.275.7.521; Robins L N, 1985, NIDA Res Monogr, V56, P178; *SUBST AB MENT HLT, PREL RES 1996 NAT HO	17	24	24	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					597	598		10.1001/jama.280.7.597	http://dx.doi.org/10.1001/jama.280.7.597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718040				2022-12-24	WOS:000075384300011
J	Polanczyk, CA; Goldman, L; Marcantonio, ER; Orav, EJ; Lee, TH				Polanczyk, CA; Goldman, L; Marcantonio, ER; Orav, EJ; Lee, TH			Supraventricular arrhythmia in patients having noncardiac surgery: Clinical correlates and effect on length of stay	ANNALS OF INTERNAL MEDICINE			English	Article						tachycardia, supraventricular; arrhythmia; length of stay; surgical procedures, operative; risk factors	CORONARY-ARTERY BYPASS; ATRIAL-FIBRILLATION; CARDIAC-ARRHYTHMIAS; RISK-FACTORS; COMPLICATIONS; PNEUMONECTOMY; THORACOTOMY	Background: Few recent data are available on risk factors for perioperative supraventricular arrhythmia (SVA) after noncardiac surgery or on the effect of SVA on clinical outcomes. Objective: To determine the incidence, clinical correlates, and effect on length of stay of perioperative SVA in patients having major noncardiac surgery. Design: Prospective cohort study. Setting: Urban tertiary care teaching hospital. Participants: 4181 patients 50 years of age or older who had major, nonemergency, noncardiac procedures and were in sinus rhythm at the preoperative evaluation. Measurements: Preoperative clinical data, postoperative enzyme data, serial electrocardiograms, and clinical outcomes were collected prospectively. Outcomes were 1) SVA that persisted or led to treatment and 2) increase in length of stay attributable to SVA. Results: Perioperative SVA occurred in 317 patients (7.6%); it occurred in 83 patients (2.0%) during surgery and in 256 (6.1 %) after surgery. Independent preoperative correlates of SVA were male sex (odds ratio [OR], 1.3 [95% CI, 1.0 to 1.7]), age 70 years or older (OR, 1.3 [CI, 1.0 to 1.7]), significant valvular disease (OR, 2.1 [CI, 1.2 to 3.6]), history of SVA (OR, 3.4 [CI, 2.4 to 4.8]) or asthma (OR, 2.0 [CI, 1.3 to 3.1]), congestive heart failure (OR, 1.7 [CI, 1.1 to 2.7]), premature atrial complexes on preoperative electrocardiography (OR, 2.1 [CI, 1.3 to 3.4]), American Society of Anesthesiologists class III or IV (OR, 1.4 [CI, 1.1 to 1.9]), and type of procedure: abdominal aortic aneurysm (OR, 3.9 [CI, 2.4 to 6.3]) or abdominal (OR, 2.5 [CI, 1.7 to 3.6]), vascular (OR, 1.6 [CI, 1.1 to 2.4]), and intrathoracic (OR, 9.2 [CI, 6.7 to 13]) procedures. Among patients who had intrathoracic surgery, those receiving digoxin were at lower risk (OR, 0.2 [CI, 0.04 to 0.8]) for SVA than those not receiving digoxin. Patients with perioperative acute cardiac and noncardiac events had high relative risks for SVA. Supraventricular arrhythmia was associated with a 33% increase in length of stay after adjustment for other clinical data (P < 0.001). Conclusions: In this cohort, SVA was common after noncardiac surgery and was associated with prolonged length of stay.	Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, San Francisco, CA 94143 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; University of California System; University of California San Francisco; Harvard University; Harvard Medical School	Lee, TH (corresponding author), Partners Community HealthCare Inc, Prudential Tower Suite 1159,800 Boylston St, Boston, MA 02199 USA.		Marcantonio, Edward R/U-3929-2017; Polanczyk, Carisi CAP/D-6208-2013	Marcantonio, Edward R/0000-0002-2911-4250; 	AHRQ HHS [R01-HS06573] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CROSBY LH, 1990, AM J CARDIOL, V66, P1520, DOI 10.1016/0002-9149(90)90550-K; FROST L, 1992, INT J CARDIOL, V36, P253, DOI 10.1016/0167-5273(92)90293-C; FURBERG CD, 1994, AM J CARDIOL, V74, P236, DOI 10.1016/0002-9149(94)90363-8; GERSON MC, 1990, AM J MED, V88, P101, DOI 10.1016/0002-9343(90)90456-N; GOLD RL, 1985, J AM COLL CARDIOL, V6, P119, DOI 10.1016/S0735-1097(85)80262-X; GOLDMAN L, 1978, CHEST, V73, P450, DOI 10.1378/chest.73.4.450; GOLDMAN L, 1983, ANN INTERN MED, V98, P504, DOI 10.7326/0003-4819-98-4-504; HASHIMOTO K, 1991, J THORAC CARDIOV SUR, V101, P56; HILLIS LD, 1978, ARCH INTERN MED, V138, P972, DOI 10.1001/archinte.138.6.972; INCALZI RA, 1990, CHEST, V97, P1092, DOI 10.1378/chest.97.5.1092; Jakobsen CJ, 1997, J CARDIOTHOR VASC AN, V11, P746, DOI 10.1016/S1053-0770(97)90169-5; KROWKA MJ, 1987, CHEST, V91, P490, DOI 10.1378/chest.91.4.490; MICHELSON EL, 1979, AM HEART J, V97, P442, DOI 10.1016/0002-8703(79)90390-9; SHIELDS TW, 1968, SURG GYNECOL OBSTETR, V126, P743; SORENSEN O, 1986, ACTA ANAESTH SCAND, V30, P630, DOI 10.1111/j.1399-6576.1986.tb02489.x; Thomas EJ, 1997, AM J MED, V102, P277, DOI 10.1016/S0002-9343(96)00451-2; VONKNORRING J, 1992, ANN THORAC SURG, V53, P642, DOI 10.1016/0003-4975(92)90325-X; WAHI R, 1989, ANN THORAC SURG, V48, P33, DOI 10.1016/0003-4975(89)90172-0; WOHLGELERNTER D, 1984, CARDIOVASC MED, V9, P763; YOUSIF H, 1990, INT J CARDIOL, V26, P313, DOI 10.1016/0167-5273(90)90087-L	20	176	184	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					279	+		10.7326/0003-4819-129-4-199808150-00003	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729180				2022-12-24	WOS:000075329100003
J	Wallace, MB; Kemp, JA; Trnka, YM; Donovan, JM; Farraye, FA				Wallace, MB; Kemp, JA; Trnka, YM; Donovan, JM; Farraye, FA			Is colonoscopy indicated for small adenomas found by screening flexible sigmoidoscopy?	ANNALS OF INTERNAL MEDICINE			English	Article						colonoscopy; adenomas; sigmoidoscopy; polyps; colorectal neoplasms	COLORECTAL-CANCER; RECTOSIGMOID ADENOMAS; COLON-CANCER; POLYPS; RISK; NEOPLASMS; DISTAL; MORTALITY; HISTORY; SIZE	Background: There is controversy over whether patients who have a small tubular adenoma on screening flexible sigmoidoscopy should undergo colonoscopic examination of the proximal colon. Objective: To prospectively determine the prevalence of advanced polyps in the proximal colon among patients who have small adenomas on screening sigmoidoscopy. Design: Prospective cohort study. Setting: A health maintenance organization and a Veterans Affairs medical center. Patients: Asymptomatic patients older than 50 years of age who had no risk factors for colon cancer and underwent sigmoidoscopy. Intervention: At the time of sigmoidoscopy, all polyps were biopsied and characterized. All patients with distal adenomas were offered colonoscopy. Measurements: The size and histology of polyps identified by sigmoidoscopy and colonoscopy were noted. Polyps were considered advanced if they were larger than 10 mm or were tubulovillous, villous, or malignant. The prevalence of advanced proximal polyps was determined, and patients were stratified by the size and number of distal polyps found by sigmoidoscopy. Results: Among 4490 patients who underwent sigmoidoscopy, a neoplastic lesion was detected in 401 (8.9%) and colonoscopy was done in 301 (75%). Of 90 patients with a single tubular adenoma 1 to 5 mm in diameter in the distal colon, 0% (95% CI, 0.0% to 4.0%) had an advanced proximal polyp compared with 5.4% (CI, 2.4% to 10.4%) of those who had multiple distal polyps 1 to 5 mm or 6 to 10 mm in diameter and 7.9% (CI, 2.6% to 17.6%) of those who had advanced distal polyps (P = 0.013 for trend). The low-risk group with a single tubular adenoma 1 to 5 mm in diameter represented 44% of all patients with distal adenomas or cancers found at flexible sigmoidoscopy. Conclusions: Among patients undergoing screening sigmoidoscopy, those with single tubular adenomas of 5 mm or less had a low prevalence of advanced proximal polyps. These patients may not benefit from colonoscopy.	Med Univ S Carolina, MPH, Div Gastroenterol, Charleston, SC 29425 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Brockton W Roxbury Vet Affairs Med Ctr, Boston, MA 02132 USA	Medical University of South Carolina; Harvard University; Brigham & Women's Hospital; Harvard Pilgrim Health Care; Harvard University	Wallace, MB (corresponding author), Med Univ S Carolina, MPH, Div Gastroenterol, 171 Ashley Ave, Charleston, SC 29425 USA.			Farraye, Francis/0000-0001-6371-2441				ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BOND JH, 1993, GASTROINTEST ENDOSC, V39, P592, DOI 10.1016/S0016-5107(93)70184-4; BOND JH, 1993, ANN INTERN MED, V119, P836, DOI 10.7326/0003-4819-119-8-199310150-00010; Byers T, 1997, CA-CANCER J CLIN, V47, P154, DOI 10.3322/canjclin.47.3.154; Casella G., 1990, STAT INFERENCE; DINNING JP, 1994, ARCH INTERN MED, V154, P853, DOI 10.1001/archinte.154.8.853; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; Hofstad B, 1996, GUT, V39, P449, DOI 10.1136/gut.39.3.449; Lemmel GT, 1996, GASTROINTEST ENDOSC, V44, P109, DOI 10.1016/S0016-5107(96)70125-6; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; Morales TG, 1996, GASTROINTEST ENDOSC, V43, P25; Papatheodoridis GV, 1996, AM J GASTROENTEROL, V91, P1809; Read TE, 1997, NEW ENGL J MED, V336, P8, DOI 10.1056/NEJM199701023360102; REX DK, 1992, GASTROENTEROLOGY, V102, P317, DOI 10.1016/0016-5085(92)91817-N; SCHWARTZ E, 1995, GASTROINTEST ENDOSC, V42, P292, DOI 10.1016/S0016-5107(95)70124-9; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; STRYKER SJ, 1987, GASTROENTEROLOGY, V93, P1009, DOI 10.1016/0016-5085(87)90563-4; TRIPP MR, 1987, CANCER, V60, P1599, DOI 10.1002/1097-0142(19871001)60:7<1599::AID-CNCR2820600730>3.0.CO;2-I; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; WAYE JD, 1988, AM J GASTROENTEROL, V83, P120; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0	24	71	73	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1998	129	4					273	+		10.7326/0003-4819-129-4-199808150-00002	http://dx.doi.org/10.7326/0003-4819-129-4-199808150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	109NP	9729179				2022-12-24	WOS:000075329100002
J	Baxter, C; Jones, R; Corr, L				Baxter, C; Jones, R; Corr, L			Time trend analysis and variations in prescribing lipid lowering drugs in general practice	BMJ-BRITISH MEDICAL JOURNAL			English	Article									St Thomas Hosp, Dept Cardiol, London SE1 7EH, England; United Med & Dent Sch Guys & St Thomas Hosp, Dept Gen Practice, London SE1 9RT, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Baxter, C (corresponding author), St Thomas Hosp, Dept Cardiol, London SE1 7EH, England.	c.baxter@iaxnet.co.uk						Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; PEDERSEN TR, 1994, LANCET, V344, P1383; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; *SPSS, 1989, SPSS WIND REL 6 0 1	4	47	47	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 24	1998	317	7166					1134	1135						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	134QY	9784452				2022-12-24	WOS:000076755100034
J	MacLeod, K; Backer, A; Laurent, G				MacLeod, K; Backer, A; Laurent, G			Who reads temporal information contained across synchronized and oscillatory spike trains?	NATURE			English	Article							ENCODING NEURAL ASSEMBLIES; VISUAL-CORTEX; NEURONS; REPRESENTATIONS; BRAIN	Our inferences about brain mechanisms underlying perception rely on whether it is possible for the brain to 'reconstruct' a stimulus from the information contained in the spike trains from many neurons(1-5). How the brain actually accomplishes this reconstruction remains largely unknown. Oscillatory and synchronized activities in the brain of mammals have been correlated with distinct behavioural states or the execution of complex cognitive tasks(6-11) and are proposed to participate in the 'binding' of individual features into more complex percepts(12-14). But if synchronization is indeed relevant, what senses it? In insects, oscillatory synchronized activity in the early olfactory system seems to be necessary for fine odour discrimination(15) and enables the encoding of information about a stimulus in spike times relative to the oscillatory 'clock'(16). Here we study the decoding of these coherent oscillatory signals. We identify a population of neurons downstream from the odour-activated, synchronized neuronal assemblies. These downstream neurons show odour responses whose specificity is degraded when their inputs are desynchronized. This degradation of selectivity consists of the appearance of responses to new odours and a loss of discrimination of spike trains evoked by different odours. Such loss of information is never observed in the upstream neurons whose activity is desynchronized. These results indicate that information encoded in time across ensembles of neurons converges onto single neurons downstream in the pathway.	CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA	California Institute of Technology	Laurent, G (corresponding author), CALTECH, Div Biol 139 74, Pasadena, CA 91125 USA.	laurentg@cco.caltech.edu	MacLeod, Katrina/F-4595-2015; Laurent, Gilles/A-4583-2012	MacLeod, Katrina/0000-0003-0632-1158; Laurent, Gilles/0000-0002-2296-114X				ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; BACON JP, 1977, BRAIN RES, V138, P359, DOI 10.1016/0006-8993(77)90753-3; Fries P, 1997, P NATL ACAD SCI USA, V94, P12699, DOI 10.1073/pnas.94.23.12699; GEORGOPOULOS AP, 1989, SCIENCE, V243, P234, DOI 10.1126/science.2911737; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; HOMBERG U, 1984, J COMP PHYSIOL, V154, P825, DOI 10.1007/BF00610683; LAURENT G, 1994, J NEUROSCI, V14, P2993; LAURENT G, 1994, SCIENCE, V265, P1872, DOI 10.1126/science.265.5180.1872; Laurent G, 1996, J NEUROSCI, V16, P3837; Leitch B, 1996, J COMP NEUROL, V372, P487; Li YS, 1997, J COMP NEUROL, V387, P631; MacLeod K, 1996, SCIENCE, V274, P976, DOI 10.1126/science.274.5289.976; MILNER PM, 1974, PSYCHOL REV, V81, P521, DOI 10.1037/h0037149; MOUNTCASTLE VB, 1957, J NEUROPHYSIOL, V20, P408, DOI 10.1152/jn.1957.20.4.408; NEWSOME WT, 1989, NATURE, V341, P52, DOI 10.1038/341052a0; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SPARKS DL, 1990, COLD SH Q B, V55, P805; Stopfer M, 1997, NATURE, V390, P70, DOI 10.1038/36335; Victor JD, 1997, NETWORK-COMP NEURAL, V8, P127, DOI 10.1088/0954-898X/8/2/003; von der Malsburg C, 1981, CORRELATION THEORY B; Wehr M, 1996, NATURE, V384, P162, DOI 10.1038/384162a0	25	199	204	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 15	1998	395	6703					693	698		10.1038/27201	http://dx.doi.org/10.1038/27201			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790189				2022-12-24	WOS:000076472600051
J	Zhang, ZH; Hartmann, H; Do, VM; Abramowski, D; Sturchler-Pierrat, C; Staufenbiel, M; Sommer, B; van de Wetering, M; Clevers, H; Saftig, P; De Strooper, B; He, X; Yankner, BA				Zhang, ZH; Hartmann, H; Do, VM; Abramowski, D; Sturchler-Pierrat, C; Staufenbiel, M; Sommer, B; van de Wetering, M; Clevers, H; Saftig, P; De Strooper, B; He, X; Yankner, BA			Destabilization of beta-catenin by mutations in presenilin-1 potentiates neuronal apoptosis	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; IN-VIVO; MISSENSE MUTATIONS; PROTEIN; GENE; CELLS; LOCALIZATION; PLAQUES; BRAIN; MICE	Mutations of the presenilin-1 gene are a major cause of familial early-onset Alzheimer's disease(1-4). Presenilin-1 can associate with members of the catenin family of signalling proteins, but the significance of this association is unknown(5,6). Here we show that presenilin-1 forms a complex with beta-catenin in vivo that increases beta-catenin stability, Pathogenic mutations in the presenilin-1 gene reduce the ability of presenilin-1 to stabilize beta-catenin, and lead to increased degradation of beta-catenin in the brains of transgenic mice, Moreover, beta-catenin levels are markedly reduced in the brains of Alzheimer's disease patients with presenilin-1 mutations. Loss of beta-catenin signalling increases neuronal vulnerability to apoptosis induced by amyloid-beta protein, Thus, mutations in presenilin-1 may increase neuronal apoptosis by altering the stability of beta-catenin, predisposing individuals to early-onset Alzheimer's disease.	Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; Childrens Hosp, Div Neurosci, Boston, MA 02115 USA; Novartis Pharma Ltd, Preclin Res, CH-4002 Basel, Switzerland; Univ Utrecht Hosp, Dept Immunol, NL-3508 GA Utrecht, Netherlands; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany; Katholieke Univ Leuven VIB, Ctr Human Genet, B-3000 Leuven, Belgium	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Novartis; Utrecht University; Utrecht University Medical Center; University of Gottingen; Flanders Institute for Biotechnology (VIB); KU Leuven	Yankner, BA (corresponding author), Harvard Univ, Sch Med, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.	Yankner@A1.tch.harvard.edu	De Strooper, Bart/F-6507-2012; Saftig, Paul/A-7966-2010; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; 				Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Busciglio J, 1997, J NEUROSCI, V17, P5101, DOI 10.1523/jneurosci.17-13-05101.1997; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Guo Q, 1998, NAT MED, V4, P957, DOI 10.1038/nm0898-957; Guo Q, 1997, J NEUROSCI, V17, P4212; Kovacs DM, 1996, NAT MED, V2, P224, DOI 10.1038/nm0296-224; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; Li JH, 1995, P NATL ACAD SCI USA, V92, P12180, DOI 10.1073/pnas.92.26.12180; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Walter J, 1996, MOL MED, V2, P673, DOI 10.1007/BF03401652; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	28	457	501	2	15	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	OCT 15	1998	395	6703					698	702		10.1038/27208	http://dx.doi.org/10.1038/27208			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129PR	9790190				2022-12-24	WOS:000076472600052
J	Sidhu, H; Hoppe, B; Hesse, A; Tenbrock, K; Bromme, S; Rietschel, E; Peck, AB				Sidhu, H; Hoppe, B; Hesse, A; Tenbrock, K; Bromme, S; Rietschel, E; Peck, AB			Absence of Oxalobacter formigenes in cystic fibrosis patients: A risk factor for hyperoxaluria	LANCET			English	Article							OXALATE DEGRADATION; UROLITHIASIS; SATURATION; CHILDREN; HUMANS	Background Patients with cystic fibrosis have an increased risk of hyperoxaluria, and of subsequent nephrocalcinosis and calcium-oxalate urolithiasis. Oxalate homoeostasis is controlled, in part, by the intestinal bacterium, Oxalobacter formigenes, The loss of this bacterium from the gut flora is associated with an increased risk of hyperoxaluria and calcium-oxalate urolithiasis. We investigated whether the absence of O formigenes and the presence of hyperoxaluria are correlated in cystic fibrosis (CF) patients. Methods Stool specimens from 43 patients with CF aged 3-9 years and from 21 similarly aged healthy volunteers were examined for O formigenes by culture and DNA analysis. At the same time, 24 h urine samples were collected and analysed for oxalate and other factors that promote or inhibit stone formation. Findings 15 (71%) of 21 healthy volunteers but only seven (16%) of 43 CF patients were colonised with O formigenes. Detection of O formigenes in six of these seven patients required DNA-based identification, suggesting low numbers of colony-forming units, and the CF patient with normal numbers of O formigenes was the only one of the 43 patients who had not been treated with antibiotics. All seven CF patients colonised with O formigenes had normal urinary oxalate levels, but 19 (53%) of 36 patients not colonised with O formigenes were hyperoxaluric, with the most severe hyperoxaluria occurring in young patients. Interpretation Absence of O formigenes from the intestinal tract of CF patients appears to lead to increased absorption of oxalate, thereby increasing the risk of hyperoxaluria and its complications (eg, nephrocalcinosis, urolithiasis), Prolonged widespread use of antibiotics, and alterations of the gastrointestinal tract that occur in CF, may induce a permanent decolonisation in CF patients.	Univ Florida, Coll Med, Dept Pathol & Lab Med, Gainesville, FL 32610 USA; Ixion Biotechnol, Div Oxalate Res, Alachua, FL USA; Northwestern Univ, Childrens Mem Hosp, Div Nephrol, Chicago, IL 60614 USA; Univ Bonn, Div Expt Urol, D-5300 Bonn, Germany; Univ Halle Wittenberg, Childrens Hosp, Halle, Germany; Univ Cologne, Childrens Hosp, Cologne, Germany	State University System of Florida; University of Florida; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; University of Bonn; Martin Luther University Halle Wittenberg; University of Cologne	Peck, AB (corresponding author), Univ Florida, Coll Med, Dept Pathol & Lab Med, POB 100275, Gainesville, FL 32610 USA.	peck.pathology@mail.health.ufl.edu						ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; ALLISON MJ, 1986, J NUTR, V116, P455, DOI 10.1093/jn/116.3.455; ARGENZIO RA, 1988, J NUTR, V118, P787, DOI 10.1093/jn/118.6.787; BENTUR L, 1990, J PEDIATR-US, V116, P556, DOI 10.1016/S0022-3476(05)81602-6; BINDER HJ, 1974, GASTROENTEROLOGY, V67, P441; BOHLES H, 1982, HELV PAEDIATR ACTA, V37, P267; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DOANE LT, 1989, NUTR RES, V9, P957, DOI 10.1016/S0271-5317(89)80056-9; DOBBINS JW, 1977, NEW ENGL J MED, V296, P298, DOI 10.1056/NEJM197702102960602; GOLDKIND L, 1986, GASTROENTEROLOGY, V90, P1431; GOLDKIND L, 1985, AM J GASTROENTEROL, V80, P860; HAN J, 1985, J TONGJI MED U, V15, P249; HATCH M, 1996, CALCIUM OXALATE BIOL, P217; HESSE A, 1986, CLIN CHIM ACTA, V160, P79, DOI 10.1016/0009-8981(86)90126-9; Hoppe B, 1997, J UROLOGY, V158, P557, DOI 10.1016/S0022-5347(01)64550-6; Hoppe B, 1998, PEDIATR NEPHROL, V12, P275, DOI 10.1007/s004670050452; Joseph DB, 1996, PEDIATRICS, V98, P108; KATZ SM, 1988, NEW ENGL J MED, V319, P263, DOI 10.1056/NEJM198808043190502; KLEINSCHMIDT K, 1993, UROLITHIASIS, V2, P439; Matthews LA, 1996, J UROLOGY, V155, P1563, DOI 10.1016/S0022-5347(01)66126-3; MODIGLIANI R, 1978, SCAND J GASTROENTERO, V13, P187, DOI 10.3109/00365527809181746; PARRIES G, 1995, UROLITHIASIS LATE CO, P393; ROBSON AM, 1971, J PEDIATR-US, V79, P42, DOI 10.1016/S0022-3476(71)80056-2; SEFTEL A, 1990, UROL CLIN N AM, V17, P159; Sidhu H, 1997, MOL DIAGN, V2, P89, DOI 10.1016/S1084-8592(97)80015-X; STAUFFER JQ, 1972, NEW ENGL J MED, V287, P412; STRANDVIK B, 1993, ACTA PAEDIATR, V82, P306, DOI 10.1111/j.1651-2227.1993.tb12667.x; WERNESS PG, 1985, J UROLOGY, V134, P1242, DOI 10.1016/S0022-5347(17)47703-2	28	171	172	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 26	1998	352	9133					1026	1029		10.1016/S0140-6736(98)03038-4	http://dx.doi.org/10.1016/S0140-6736(98)03038-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	123JJ	9759746				2022-12-24	WOS:000076121800012
J	Gordon, PN; Williamson, S; Lawler, PG				Gordon, PN; Williamson, S; Lawler, PG			As seen on TV: observational study of cardiopulmonary resuscitation in British television medical dramas	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PATIENTS PREFERENCES; ELDERLY PATIENTS; SURVIVAL; RELATIVES; DECISION; VIEWS	Objective: To determine the frequency and accuracy with which cardiopulmonary resuscitation is portrayed in British television medical dramas. design: Observational study. Subjects: 64 episodes of three major British television medical dramas: Casualty, Cardiac Arrest, and Medics. Main outcome measures: Frequency of cardiopulmonary resuscitation shown on television; age, sex, and diagnosis of the patients undergoing resuscitation; rate of survival through resuscitation. Results: Overall 52 patients had a cardiorespiratory arrest on screen and 3 had a respiratory arrest alone, all the arrests occurring in 40 of the 64 episodes. Of the 52 patients having cardiorespiratory arrest, 32 (62%) underwent an attempt at cardiopulmonary resuscitation; 8 attempts were successful. Al 3 of the patients having respiratory arrests alone received ventilatory support and survived. On 48% of occasions, victims of cardiac arrest seemed to be less than 35 years old. Conclusions: Cardiorespiratory resuscitation is often depicted in British television medical dramas. Patients portrayed receiving resuscitation are likely to be in a younger age group than in real life. Though the reasons for resuscitation are more varied and more often associated with trauma than in reality, the overall success rate is nevertheless realistic. Widespread overoptimism of patients for survival after resuscitation cannot necessarily be blamed on British television medical dramas.	S Cleveland Hosp, Dept Obstet & Gynaecol, Middlesbrough TS4 3BW, Cleveland, England		Gordon, PN (corresponding author), S Cleveland Hosp, Dept Obstet & Gynaecol, Middlesbrough TS4 3BW, Cleveland, England.	patrickg@globalnet.co.uk						Ballew KA, 1995, RESUSCITATION, V30, P203, DOI 10.1016/0300-9572(95)00894-2; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Diem SJ, 1996, NEW ENGL J MED, V334, P1578, DOI 10.1056/NEJM199606133342406; EKSTROM L, 1994, RESUSCITATION, V27, P181, DOI 10.1016/0300-9572(94)90031-0; FLORIN D, 1993, J ROY COLL PHYS LOND, V27, P135; HEAP MJ, 1993, ANAESTHESIA, V48, P1027; HILL ME, 1994, BRIT MED J, V308, P1677, DOI 10.1136/bmj.308.6945.1677; JUDE JR, 1961, JAMA-J AM MED ASSOC, V178, P1063, DOI 10.1001/jama.1961.03040500005002; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; LIDDLE J, 1994, J ROY COLL PHYS LOND, V28, P228; Markert RJ, 1996, NEW ENGL J MED, V335, P1605; MEAD GE, 1995, J MED ETHICS, V21, P39, DOI 10.1136/jme.21.1.39; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; Turow J, 1996, LANCET, V347, P1240, DOI 10.1016/S0140-6736(96)90747-3; Valentin A, 1995, RESUSCITATION, V30, P217, DOI 10.1016/0300-9572(95)00898-5; WAGG A, 1995, J ROY COLL PHYS LOND, V29, P20	21	40	42	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 19	1998	317	7161					780	783		10.1136/bmj.317.7161.780	http://dx.doi.org/10.1136/bmj.317.7161.780			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740563	Green Published, Bronze, Green Submitted			2022-12-24	WOS:000076084200023
J	Chang, HY; Nishitoh, H; Yang, XL; Ichijo, H; Baltimore, D				Chang, HY; Nishitoh, H; Yang, XL; Ichijo, H; Baltimore, D			Activation of apoptosis signal regulating kinase 1 (ASK1) by the adapter protein Daxx	SCIENCE			English	Article							CELL-DEATH; RECEPTOR; CLEAVAGE; SAPK/JNK; PATHWAYS; MAPKKK; MICE	The Fas death receptor can activate the Jun NH2-terminal kinase (JNK) pathway through the receptor-associated protein Daxx. Daxx was found to activate the JNK kinase kinase ASK1, and overexpression of a kinase-deficient ASK1 mutant inhibited Fas- and Daxx-induced apoptosis and JNK activation. Fas activation induced Daxx to interact with ASK1, which consequently relieved an inhibitory intramolecular interaction between the amino- and carboxyl-termini of ASK1, activating its kinase activity. The Daxx-ASK1 connection completes a signaling pathway from a cell surface death receptor to kinase cascades that modulate nuclear transcription factors.	Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Bunkyo Ku, Tokyo 1138549, Japan; MIT, Dept Biol, Cambridge, MA 02138 USA; Japanese Fdn Canc Res, Inst Canc, Dept Biochem, Toshima Ku, Tokyo 170, Japan; CALTECH, Pasadena, CA 91125 USA	Tokyo Medical & Dental University (TMDU); Massachusetts Institute of Technology (MIT); Japanese Foundation for Cancer Research; California Institute of Technology	Baltimore, D (corresponding author), Tokyo Med & Dent Univ, Fac Dent, Dept Biomat Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.			Nishitoh, Hideki/0000-0002-8652-4109; Ichijo, Hidenori/0000-0002-5005-6438	NATIONAL CANCER INSTITUTE [R01CA051462] Funding Source: NIH RePORTER; NCI NIH HHS [CA51462] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Cahill MA, 1996, ONCOGENE, V13, P2087; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Golstein P, 1997, CURR BIOL, V7, pR750, DOI 10.1016/S0960-9822(06)90000-1; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang JK, 1998, NATURE, V392, P296, DOI 10.1038/32681	22	503	525	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1860	1863		10.1126/science.281.5384.1860	http://dx.doi.org/10.1126/science.281.5384.1860			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743501				2022-12-24	WOS:000076007100056
J	Herzog, CA; Ma, JZ; Collins, AJ				Herzog, CA; Ma, JZ; Collins, AJ			Poor long-term survival after acute myocardial infarction among patients on long-term dialysis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MINNESOTA HEART SURVEY; DIABETES-MELLITUS; TRENDS; HEMODIALYSIS; MORBIDITY; MORTALITY	Background Cardiovascular disease is common in patients on long-term dialysis, and it accounts for 44 percent of overall mortality in this group. We undertook a study to assess long-term survival after acute myocardial infarction among patients in the United States who were receiving long-term dialysis, Methods Patients on dialysis who were hospitalized during the period from 1977 to 1995 for a first myocardial infarction after the initiation of renal-replacement therapy were retrospectively identified from the U.S. Renal Data System data base. Overall mortality and mortality from cardiac causes (including all in-hospital deaths) were estimated by the life-table method. The effect of independent predictors on survival was examined in a Cox regression model with adjustment for existing illnesses. Results The overall mortality (+/-SE) after acute myocardial infarction among 34,189 patients on long term dialysis was 59.3+/-0.3 percent at one year, 73.0+/-0.3 percent at two years, and 89.9+/-0.2 percent at five years. The mortality from cardiac causes was 40.8+/-0.3 percent at one year, 51.8+/-0.3 percent at two years, and 70.2+/-0.4 percent at five years. Patients who were older or had diabetes had higher mortality than patients without these characteristics. Adverse outcomes occurred even in patients who had acute myocardial infarction in 1990 through 1995. Also, the mortality rate after myocardial infarction was considerably higher for patients on long-term dialysis than for renal-transplant recipients. Conclusions Patients on dialysis who have acute myocardial infarction have high mortality from cardiac causes and poor long-term survival. (N Engl J Med 1998;339:799-805.) (C) 1998, Massachusetts Medical Society.	Hennepin Cty Med Ctr, Dept Internal Med, Minneapolis, MN 55415 USA; Univ Minnesota, Minneapolis, MN USA	Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Herzog, CA (corresponding author), Hennepin Cty Med Ctr, Dept Internal Med, 701 Pk Ave, Minneapolis, MN 55415 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049540] Funding Source: NIH RePORTER; NIDDK NIH HHS [1 RO1 DK 49540] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOEMBERGEN WE, 1994, J AM SOC NEPHROL, V5, P1231; COLLINS AJ, 1990, AM J KIDNEY DIS, V15, P422, DOI 10.1016/S0272-6386(12)70360-8; COX DR, 1972, J R STAT SOC B, V34, P187; DONAHUE RP, 1993, J CLIN EPIDEMIOL, V46, P245, DOI 10.1016/0895-4356(93)90072-9; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HELD P J, 1991, Journal of the American Society of Nephrology, V2, P328; HERZOG CA, 1997, CIRCULATION S1, V96, P202; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KEANE WF, 1994, AM J KIDNEY DIS, V24, P1010, DOI 10.1016/S0272-6386(12)81076-6; KONG TQ, 1993, CIRCULATION, V88, P49; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MCGOVERN PG, 1992, CIRCULATION, V85, P172, DOI 10.1161/01.CIR.85.1.172; McGovern PG, 1996, NEW ENGL J MED, V334, P884, DOI 10.1056/NEJM199604043341403; NICOD P, 1989, CIRCULATION, V79, P528, DOI 10.1161/01.CIR.79.3.528; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V3; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V2; PUCKETT CD, 1997, ED ANNOTATION ICD9CM, V1; Rubin Timothy A., 1996, Journal of the American College of Cardiology, V27, p67A; SMITH JW, 1984, AM J CARDIOL, V54, P718, DOI 10.1016/S0002-9149(84)80196-4; SPRAFKA JM, 1991, DIABETES CARE, V14, P537, DOI 10.2337/diacare.14.7.537; *USRDS, 1992, USRDS NIH PUBL, P61; *USRDS, 1997, USRDS NIH PUBL, pD1; *USRDS, 1997, USRDS NIH PUBL, P35; *USRDS, 1997, USRDS NIH PUBL, P21; *USRDS, 1997, USRDS NIH PUBL, pC1; *USRDS, 1997, USRDS NIH PUBL, P69; *USRDS, 1997, USRDS NIH PUBL, P91	28	715	749	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 17	1998	339	12					799	805		10.1056/NEJM199809173391203	http://dx.doi.org/10.1056/NEJM199809173391203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119QT	9738087	Bronze			2022-12-24	WOS:000075909200003
J	Huang, MX; Zhou, Z; Elledge, SJ				Huang, MX; Zhou, Z; Elledge, SJ			The DNA replication and damage checkpoint pathways induce transcription by inhibition of the Crt1 repressor	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; COREPRESSOR COMPLEX; PROTEIN-KINASE; YEAST; P53; IDENTIFICATION; FAMILY; DOMAIN; REPAIR	We have identified the yeast CRT1 gene as an effector of the DNA damage and replication checkpoint pathway. CRT1 encodes a DNA-binding protein that recruits the general repressors Ssn6 and Tupl to the promoters of damage-inducible genes. Derepression of the Crt1 regulon suppresses the lethality of mec1 and rad53 null alleles and is essential for cell viability during replicative stress. In response to DNA damage and replication blocks, Crt1 becomes hyperphosphorylated and no longer binds DNA, resulting in transcriptional induction. CRT1 is autoregulated and is itself induced by DNA damage, indicating the existence of a negative feedback pathway that facilitates return to the repressed state after elimination of damage. The inhibition of an autoregulatory repressor in response to DNA damage is a strategy conserved throughout prokaryotic and eukaryotic evolution.	Baylor Coll Med, Howard Hughes Med Inst, Verna & Marrs Mclean Dept Biochem, Dept Human & Mol Genet, Houston, TX 77030 USA	Baylor College of Medicine; Howard Hughes Medical Institute	Elledge, SJ (corresponding author), Baylor Coll Med, Howard Hughes Med Inst, Verna & Marrs Mclean Dept Biochem, Dept Human & Mol Genet, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44664] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Aparicio OM, 1997, CELL, V91, P59, DOI 10.1016/S0092-8674(01)80009-X; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DESANY BA, 1998, IN PRESS GENES DEV; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P5373, DOI 10.1128/MCB.9.12.5373; Flaggs G, 1997, CURR BIOL, V7, P977, DOI 10.1016/S0960-9822(06)00417-9; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; GUARENTE L, 1984, P NATL ACAD SCI-BIOL, V81, P7860, DOI 10.1073/pnas.81.24.7860; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; REITH W, 1994, MOL CELL BIOL, V14, P1230, DOI 10.1128/MCB.14.2.1230; REITH W, 1990, GENE DEV, V4, P1528, DOI 10.1101/gad.4.9.1528; Sanchez Y, 1996, SCIENCE, V271, P357, DOI 10.1126/science.271.5247.357; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sun ZX, 1996, GENE DEV, V10, P395, DOI 10.1101/gad.10.4.395; TZAMARIAS D, 1995, GENE DEV, V9, P821, DOI 10.1101/gad.9.7.821; Varanasi US, 1996, MOL CELL BIOL, V16, P6707; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	30	412	423	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					595	605		10.1016/S0092-8674(00)81601-3	http://dx.doi.org/10.1016/S0092-8674(00)81601-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741624	Bronze			2022-12-24	WOS:000075851900007
J	Muscholl, MW; Hense, HW; Brockel, U; Doring, A; Riegger, GAJ; Schunkert, H				Muscholl, MW; Hense, HW; Brockel, U; Doring, A; Riegger, GAJ; Schunkert, H			Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ESTABLISHED HYPERTENSION; BLOOD-PRESSURE; DIASTOLIC FUNCTION; HYPERTROPHY; HEART; MASS; ECHOCARDIOGRAPHY	Objectives: To assess the relation between white coat hypertension and alterations of left ventricular structure and function. Design: Cross sectional survey. Setting: Augsburg, Germany. Subjects: 1677 subjects, aged 25 to 74 years, who participated in an echocardiographic substudy of the monitoring of trends and determinants in cardiovascular disease Augsburg study during 1994-5. Outcome measures: Blood pressure measurements and M mode, two dimensional, and Doppler echocardiography. After at least 30 minutes' rest blood pressure was measured three times by a technician, and once by a physician after echocardiography. Subjects were classified as normotensive (technician <140/90 min Hg, physician <160/95 mm Hg; n = 849), white coat hypertensive (technician < 140/90 mm Hg, physician greater than or equal to 160/95 mm Hg;, n = 160), mildly hypertensive (technician greater than or equal to 140/90 mm Hg, physician <160/95 mm Hg; n = 129), and sustained hypertensive (taking antihypertensive drugs or blood pressure measured by a technican greater than or equal to 140/90 mm Hg, and physician greater than or equal to 160/95 mm Hg; n = 538). Results: White coat hypertension was more common in men than women (10.9% versus 8.2%, respectively) and positively related to age and body mass index. After adjustment for these variables, white coat hypertension was associated with an increase in left ventricular mass and an increased prevalence of left ventricular hypertrophy (odds ratio 1.9, 95% confidence interval 1.2 to 3.2; P = 0.009) compared with normotensive patients. The increase in left ventricular mass was secondary to significantly increased septal and posterior wall thicknesses whereas end diastolic diameters were similar in both groups with white coat hypertension or normotension. Additionally, the systolic white coat effect (difference between blood pressures recorded by a technician and physician) was associated with increased left ventricular mass and increased prevalence of left ventricular hypertrophy (P < 0.05 each). Values for systolic left ventricular function (M mode fractional shortening) were above normal in subjects with white coat hypertension whereas diastolic filling and left atrial size Were similar to those in normotension. Conclusion: About 10% of the general population show exaggerated inotropic and blood pressure responses when mildly stressed. This is associated with an increased risk of left ventricular hypertrophy.	Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany; Univ Munster, Inst Epidemiol & Sozial Med, D-4400 Munster, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Epidemiol, Munich, Germany	University of Regensburg; University of Munster; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Schunkert, H (corresponding author), Univ Regensburg, Klin & Poliklin Innere Med 2, D-93042 Regensburg, Germany.	heribert.schunkert@klinik.uni-regensburg.de						Bidlingmeyer I, 1996, J HYPERTENS, V14, P327, DOI 10.1097/00004872-199603000-00009; CARDILLO C, 1993, HYPERTENSION, V21, P836, DOI 10.1161/01.HYP.21.6.836; CAVALLINI MC, 1995, HYPERTENSION, V26, P413, DOI 10.1161/01.HYP.26.3.413; Cuspidi C, 1995, J HYPERTENS, V13, P1707; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; Glen SK, 1996, LANCET, V348, P654, DOI 10.1016/S0140-6736(96)02303-3; GOSSE P, 1993, HYPERTENSION, V22, P766, DOI 10.1161/01.HYP.22.5.766; HAMMOND IW, 1988, J AM COLL CARDIOL, V12, P996, DOI 10.1016/0735-1097(88)90467-6; Hense HW, 1995, J HUM HYPERTENS, V9, P935; HIRAISHI S, 1983, AM J CARDIOL, V52, P1249, DOI 10.1016/0002-9149(83)90582-9; HOEGHOLM A, 1993, AM J HYPERTENS, V6, P282, DOI 10.1093/ajh/6.4.282; HOEGHOLM A, 1994, HYPERTENSION, V24, P101, DOI 10.1161/01.HYP.24.1.101; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; KEIL U, 1988, ACTA MED SCAND, P119; KINGWELL BA, 1994, CLIN EXP PHARMACOL P, V21, P31, DOI 10.1111/j.1440-1681.1994.tb02433.x; KUWAJIMA I, 1993, HYPERTENSION, V22, P826, DOI 10.1161/01.HYP.22.6.826; LEVY D, 1987, AM J CARDIOL, V59, P956, DOI 10.1016/0002-9149(87)91133-7; LEVY D, 1990, NEW ENGL J MED, V323, P1706; LEVY D, 1988, ANN INTERN MED, V108, P7, DOI 10.7326/0003-4819-108-1-7; MANCIA G, 1987, HYPERTENSION, V9, P209, DOI 10.1161/01.HYP.9.2.209; Mancia G, 1996, J HYPERTENS, V14, P1049, DOI 10.1097/00004872-199609000-00001; MUSCHOLL M, 1990, HERZ, V15, P377; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V229, P2892; SCHUNKERT H, 1994, NEW ENGL J MED, V330, P1634, DOI 10.1056/NEJM199406093302302; SCHUNKERT H, 1995, CIRC RES, V76, P489, DOI 10.1161/01.RES.76.3.489; SIEGEL WC, 1990, HYPERTENSION, V16, P140, DOI 10.1161/01.HYP.16.2.140; Soma J, 1996, J AM COLL CARDIOL, V28, P190, DOI 10.1016/0735-1097(96)00129-5; WALLERSON DC, 1990, EUR HEART J, V11, P67, DOI 10.1093/eurheartj/11.suppl_I.67; *WHO, 1983, PRIM PREV ESS HYP RE, P686; *WHO MONICA PROJ, 1989, INT J EPIDEMIOL, V18, pS29	30	74	76	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 29	1998	317	7158					565	570		10.1136/bmj.317.7158.565	http://dx.doi.org/10.1136/bmj.317.7158.565			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117EK	9721112	Bronze, Green Published, Green Submitted			2022-12-24	WOS:000075767800016
J	Perrett, DI; Lee, KJ; Penton-Voak, I; Rowland, D; Yoshikawa, S; Burt, DM; Henzi, SP; Castles, DL; Akamatsu, S				Perrett, DI; Lee, KJ; Penton-Voak, I; Rowland, D; Yoshikawa, S; Burt, DM; Henzi, SP; Castles, DL; Akamatsu, S			Effects of sexual dimorphism on facial attractiveness	NATURE			English	Article							PHYSICAL ATTRACTIVENESS; EVOLUTIONARY PSYCHOLOGY; PERCEPTION; SELECTION; BEAUTY; SHAPE	Testosterone-dependent secondary sexual characteristics in males may signal immunological competence(1) and are sexually selected for in several species(2,3). In humans, oestrogen-dependent characteristics of the female body correlate with health and reproductive fitness and are found attractive(4-6). Enhancing the sexual dimorphism of human faces should raise am-activeness by enhancing sex-hormone-related cues to youth and fertility in females(5,7-11), and to dominance and immunocompetence in males(5,12,13). Here we report the results of asking subjects to choose the most attractive faces from continua that enhanced or diminished differences between the average shape of female and male faces. As predicted, subjects preferred feminized ta, average shapes of a female face. This preference applied across UK and Japanese populations but was stronger for within-population judgements, which indicates that attractiveness cues are learned. Subjects preferred feminized to average or masculinized shapes of a male face. Enhancing masculine facial characteristics increased both perceived dominance and negative attributions (for example, coldness or dishonesty) relevant to relationships and paternal investment. These results indicate a selection pressure that limits sexual dimorphism and encourages neoteny in humans.	Univ St Andrews, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland; Kyoto Univ, Grad Sch Educ, Dept Cognit Psychol Educ, Kyoto 6068501, Japan; ATR, Human Informat Proc Res Labs, Kyoto 61902, Japan; Univ Natal, Dept Psychol, ZA-4001 Durban, South Africa	University of St Andrews; Kyoto University; University of Kwazulu Natal	Perrett, DI (corresponding author), Univ St Andrews, Sch Psychol, St Andrews KY16 9JU, Fife, Scotland.	dp@st-andrews.ac.uk	Burt, Michael/D-6684-2013	Burt, Michael/0000-0001-5627-6012; Perrett, David/0000-0002-6025-0939; Penton-Voak, Ian/0000-0003-4232-0953				ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Barber N, 1995, ETHOL SOCIOBIOL, V16, P395, DOI 10.1016/0162-3095(95)00068-2; BERRY DS, 1993, J PERS, V61, P497, DOI 10.1111/j.1467-6494.1993.tb00780.x; BOOTH A, 1993, SOC FORCES, V72, P463, DOI 10.2307/2579857; BUSSE W W, 1989, Drugs, V37, P1; CUNNINGHAM MR, 1990, J PERS SOC PSYCHOL, V59, P61, DOI 10.1037/0022-3514.59.1.61; CUNNINGHAM MR, 1995, J PERS SOC PSYCHOL, V68, P261, DOI 10.1037/0022-3514.68.2.261; CUNNINGHAM MR, 1986, J PERS SOC PSYCHOL, V50, P925, DOI 10.1037/0022-3514.50.5.925; DEUTSCH FM, 1986, J APPL SOC PSYCHOL, V16, P771; Gangestad SW, 1997, EVOL HUM BEHAV, V18, P69, DOI 10.1016/S1090-5138(97)00003-2; GRAMMER K, 1994, J COMP PSYCHOL, V108, P233, DOI 10.1037/0735-7036.108.3.233; JACKSON LA, 1992, PHYSICAL APPEARANCE; JOHNSTON VS, 1993, ETHOL SOCIOBIOL, V14, P183, DOI 10.1016/0162-3095(93)90005-3; JONES D, 1995, CURR ANTHROPOL, V36, P723, DOI 10.1086/204427; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANGLOIS JH, 1990, PSYCHOL SCI, V1, P115, DOI 10.1111/j.1467-9280.1990.tb00079.x; MANNING JT, 1997, EVOL HUM BEHAV, V18, P2223; MARTIN RD, 1990, NATURE, V293, P7; MOLLER AP, 1992, NATURE, V357, P238, DOI 10.1038/357238a0; PERRETT DI, 1994, NATURE, V368, P239, DOI 10.1038/368239a0; ROWLAND DA, 1995, IEEE COMPUT GRAPH, V15, P70, DOI 10.1109/38.403830; SINGH D, 1993, HUM NATURE-INT BIOS, V4, P297, DOI 10.1007/BF02692203; Symons D, 1979, EVOLUTION HUMAN SEXU; Thornhill Randy, 1996, Trends in Ecology and Evolution, V11, P98, DOI 10.1016/0169-5347(96)81051-2	24	881	893	6	391	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 27	1998	394	6696					884	887		10.1038/29772	http://dx.doi.org/10.1038/29772			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	114LW	9732869				2022-12-24	WOS:000075611800046
J	Bartsch, D; Casadio, A; Karl, KA; Serodio, P; Kandel, ER				Bartsch, D; Casadio, A; Karl, KA; Serodio, P; Kandel, ER			CREB1 encodes a nuclear activator, a repressor, and a cytoplasmic modulator that form a regulatory unit critical for long-term facilitation	CELL			English	Article							ELEMENT-BINDING PROTEIN; CAMP-RESPONSIVE ELEMENT; APLYSIA SENSORY NEURONS; TARGETED MUTATION; GENE-EXPRESSION; CRITICAL PERIOD; TRANSCRIPTION; MEMORY; PHOSPHORYLATION; DROSOPHILA	Although CREB seems to be important for memory formation, it is not known which of the isoforms of CREB, CREM, or ATF1 are expressed in the neurons that undergo long-term synaptic changes and what roles they have in memory formation. We have found a single Aplysia CREB1 gene homologous to both mammalian CREB and CREM and have characterized in the sensory neurons that mediate gill-withdrawal reflex the expression and function of the three proteins that it encodes: CREB1a, CREB1b, and CREB1c. CREB1a is a transcriptional activator that is both necessary and, upon phosphorylation, sufficient for longterm facilitation. CREB1b is a repressor of long-term facilitation. Cytoplasmic CREB1c modulates both the short- and long-term facilitation. Thus, in the sensory neurons, CREB1 encodes a critical regulatory unit converting short- to long-term synaptic changes.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, New York, NY 10032 USA; New York State Psychiat Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; New York State Psychiatry Institute	Bartsch, D (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, 630 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NIMH NIH HHS [MH45923-09] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; Deisseroth K, 1996, NEURON, V16, P89, DOI 10.1016/S0896-6273(00)80026-4; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; GALLIOT B, 1995, DEVELOPMENT, V121, P1205; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; Habener JF, 1995, VITAM HORM, V51, P1, DOI 10.1016/S0083-6729(08)61037-7; HARLOW E, 1988, ANTIBODIES; Hermanson O, 1996, BIOCHEM BIOPH RES CO, V225, P256, DOI 10.1006/bbrc.1996.1163; HUMMLER E, 1994, P NATL ACAD SCI USA, V91, P5647, DOI 10.1073/pnas.91.12.5647; KAANG BK, 1993, NEURON, V10, P427, DOI 10.1016/0896-6273(93)90331-K; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; Nibuya M, 1996, J NEUROSCI, V16, P2365; RUPPERT S, 1992, EMBO J, V11, P1503, DOI 10.1002/j.1460-2075.1992.tb05195.x; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; WAEBER G, 1991, MOL ENDOCRINOL, V5, P1418, DOI 10.1210/mend-5-10-1418; Walker WH, 1996, J BIOL CHEM, V271, P20145, DOI 10.1074/jbc.271.33.19668; Widnell KL, 1996, J PHARMACOL EXP THER, V276, P306; YIN JCP, 1995, MOL CELL BIOL, V15, P5123; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	34	285	291	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 16	1998	95	2					211	223		10.1016/S0092-8674(00)81752-3	http://dx.doi.org/10.1016/S0092-8674(00)81752-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790528	hybrid			2022-12-24	WOS:000076538300009
J	Randolph, GJ; Beaulieu, S; Lebecque, S; Steinman, RM; Muller, WA				Randolph, GJ; Beaulieu, S; Lebecque, S; Steinman, RM; Muller, WA			Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; PERIPHERAL LYMPH; HUMAN BLOOD; MACROSIALIN; GENERATION; MIGRATION; ANTIGEN; PROTEIN	Essential to the dendritic cell system of antigen-presenting cells are the veiled dendritic cells that traverse afferent Lymph to enter lymph nodes, where they initiate immune responses. The origin of veiled cells, which were discovered 20 years ago, is unclear. Monocytes cultured with endothelium differentiated into dendritic cells within 2 days, particularly after phagocytosing particles in subendothelial collagen. These nascent dendritic cells migrated across the endothelium in the ablumenal-to-lumenal direction, as would occur during entry into Lymphatics. Monocytes that: remained in the subendothelial matrix became macrophages. Therefore, monocytes have two potential fates associated with distinct patterns of migration.	Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; Rockefeller Univ, Cellular Physiol & Immunol Lab, New York, NY 10021 USA; Schering Plough SpA, Lab Immunol Res, F-69571 Dardilly, France	Cornell University; Rockefeller University; Merck & Company	Randolph, GJ (corresponding author), Cornell Univ, Coll Med, Dept Pathol, 1300 York Ave,Room C-420, New York, NY 10021 USA.	GJRandol@mail.med.cornell.edu		lebecque, serge/0000-0003-4006-8061	NHLBI NIH HHS [HL46849] Funding Source: Medline; NIAID NIH HHS [AI40045, AI13013] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI040045, R37AI013013, R01AI040045, R01AI013013] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; BUJDOSO R, 1989, J EXP MED, V170, P1285, DOI 10.1084/jem.170.4.1285; DESAINTVIS B, IN PRESS IMMUNITY; DREXHAGE HA, 1979, CELL TISSUE RES, V202, P407, DOI 10.1007/BF00220434; FREY JR, 1957, INT ARCH ALLER A IMM, V11, P81, DOI 10.1159/000228405; KELLY RH, 1978, ANAT RECORD, V190, P5, DOI 10.1002/ar.1091900103; Kurts C, 1997, J EXP MED, V186, P239, DOI 10.1084/jem.186.2.239; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; Matsuno K, 1996, J EXP MED, V183, P1865, DOI 10.1084/jem.183.4.1865; Mosialos G, 1996, AM J PATHOL, V148, P593; MULLER WA, 1992, J EXP MED, V176, P819, DOI 10.1084/jem.176.3.819; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; RABINOWITZ SS, 1991, J EXP MED, V174, P827, DOI 10.1084/jem.174.4.827; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Randolph GJ, 1996, J EXP MED, V183, P451, DOI 10.1084/jem.183.2.451; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SOKOLOWSKI J, 1978, LYMPHOLOGY, V11, P202; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; THOMAS R, 1993, J IMMUNOL, V150, P821; VANFURTH R, 1968, J EXP MED, V128, P415, DOI 10.1084/jem.128.3.415; ZHOU LJ, 1992, J IMMUNOL, V149, P735	26	633	669	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 16	1998	282	5388					480	483		10.1126/science.282.5388.480	http://dx.doi.org/10.1126/science.282.5388.480			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774276				2022-12-24	WOS:000076479600056
J	Hill, K; Model, K; Ryan, MT; Dietmeier, K; Martin, F; Wagner, R; Pfanner, N				Hill, K; Model, K; Ryan, MT; Dietmeier, K; Martin, F; Wagner, R; Pfanner, N			Tom40 forms the hydrophilic channel of the mitochondrial import pore for preproteins	NATURE			English	Article							OUTER-MEMBRANE PROTEIN; RECEPTOR COMPLEX; PRECURSOR PROTEINS; CELL VIABILITY; CONTACT SITES; TRANSLOCATION; IDENTIFICATION; RECOGNITION; PRESEQUENCE; MACHINERY	The mitochondrial outer membrane contains machinery for the import of preproteins encoded by nuclear genes(1-3). Eight different Tom (translocase of outer membrane) proteins have been identified that function as receptors and/or are related to a hypothetical general import pore. Many mitochondrial membrane channel activities have been described(4-7), including one related to Tim23 of the inner-membrane protein-import system(5); however, the pore-forming subunit(s) of the Tom machinery have not been identified until now. Here we describe the expression and functional reconstitution of Tom40, an integral membrane protein with mainly beta-sheet structure. Tom40 forms a cation-selective high-conductance channel that specifically binds to and transports mitochondrial-targeting sequences added to the cis side of the membrane. We conclude that Tom40 is the pore-forming subunit of the mitochondrial general import pore and that it constitutes a hydrophilic, similar to 22 Angstrom wide channel for the import of preproteins.	Univ Freiburg, Inst Biochem & Mol Biol, D-79104 Freiburg, Germany; Univ Osnabruck, Fachbereich Biol Chem, D-49034 Osnabruck, Germany; Univ Freiburg, Fak Biol, D-79104 Freiburg, Germany	University of Freiburg; University Osnabruck; University of Freiburg	Pfanner, N (corresponding author), Univ Freiburg, Inst Biochem & Mol Biol, Hermann Herder Str 7, D-79104 Freiburg, Germany.	pfanner@ruf.uni-freiburg.de	Pfanner, Nikolaus/AAV-7878-2021; Ryan, Michael T/C-6673-2011; Ryan, Michael/X-2152-2019	Ryan, Michael T/0000-0003-2586-8829; Ryan, Michael/0000-0003-2586-8829				Alconada A, 1995, METHOD ENZYMOL, V260, P263, DOI 10.1016/0076-6879(95)60144-9; ALLISON DS, 1986, P NATL ACAD SCI USA, V83, P9011, DOI 10.1073/pnas.83.23.9011; BAKER KP, 1990, NATURE, V348, P605, DOI 10.1038/348605a0; Bolliger L, 1995, EMBO J, V14, P6318, DOI 10.1002/j.1460-2075.1995.tb00322.x; Brix J, 1997, J BIOL CHEM, V272, P20730, DOI 10.1074/jbc.272.33.20730; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; DIHANICH M, 1989, EUR J BIOCHEM, V181, P703, DOI 10.1111/j.1432-1033.1989.tb14780.x; HILLE B, 1992, IONIC CHANNELS EXCIT, pCH9; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HONLINGER A, 1995, MOL CELL BIOL, V15, P3382; Juin P, 1997, J BIOL CHEM, V272, P6044, DOI 10.1074/jbc.272.9.6044; KIEBLER M, 1990, NATURE, V348, P610, DOI 10.1038/348610a0; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; Kunkele KP, 1998, CELL, V93, P1009, DOI 10.1016/S0092-8674(00)81206-4; Lohret TA, 1997, J CELL BIOL, V137, P377, DOI 10.1083/jcb.137.2.377; Mannella CA, 1996, J BIOENERG BIOMEMBR, V28, P163, DOI 10.1007/BF02110647; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; MAYER A, 1995, CELL, V80, P127, DOI 10.1016/0092-8674(95)90457-3; MORAN O, 1990, J BIOL CHEM, V265, P908; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Rapaport D, 1997, J BIOL CHEM, V272, P18725, DOI 10.1074/jbc.272.30.18725; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schmid B, 1996, FEBS LETT, V381, P111, DOI 10.1016/0014-5793(96)00080-4; Smart OS, 1997, BIOPHYS J, V72, P1109, DOI 10.1016/S0006-3495(97)78760-5; SOLLNER T, 1992, NATURE, V355, P84, DOI 10.1038/355084a0; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; VESTWEBER D, 1989, NATURE, V341, P205, DOI 10.1038/341205a0; VESTWEBER D, 1989, NATURE, V338, P170, DOI 10.1038/338170a0	30	403	408	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 1	1998	395	6701					516	521		10.1038/26780	http://dx.doi.org/10.1038/26780			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	124ZG	9774109				2022-12-24	WOS:000076212200060
J	McMasters, KM; Giuliano, AE; Ross, MI; Reintgen, DS; Hunt, KK; Byrd, DR; Klimberg, VS; Whitworth, PW; Tafra, LC; Edwards, MJ				McMasters, KM; Giuliano, AE; Ross, MI; Reintgen, DS; Hunt, KK; Byrd, DR; Klimberg, VS; Whitworth, PW; Tafra, LC; Edwards, MJ			Sentinel-lymph-node biopsy for breast cancer - Not yet the standard of care	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EARLY-STAGE MELANOMA; AXILLARY DISSECTION; PROGNOSTIC-SIGNIFICANCE; MALIGNANT-MELANOMA; GAMMA-PROBE; INTRAOPERATIVE RADIOLYMPHOSCINTIGRAPHY; PREMENOPAUSAL WOMEN; CUTANEOUS MELANOMA; OCCULT METASTASES; BLUE-DYE		Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40202 USA; John Wayne Canc Ctr, Santa Monica, CA 90404 USA; Univ Texas, MD Anderson Cancer Ctr, Houston, TX 77030 USA; H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Nashville Surg Associates, Nashville, TN 37203 USA; E Carolina Univ, Sch Med, Greenville, NC 27858 USA	University of Louisville; John Wayne Cancer Institute; University of Texas System; UTMD Anderson Cancer Center; H Lee Moffitt Cancer Center & Research Institute; University of Washington; University of Washington Seattle; University of Arkansas System; University of Arkansas Medical Sciences; University of North Carolina; East Carolina University	McMasters, KM (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, 529 S Jackson St, Louisville, KY 40202 USA.							Albertini JJ, 1996, ANN SURG, V223, P217, DOI 10.1097/00000658-199602000-00016; Albertini JJ, 1996, JAMA-J AM MED ASSOC, V276, P1818, DOI 10.1001/jama.276.22.1818; Alex J C, 1996, Surg Oncol Clin N Am, V5, P33; ATKINS H, 1972, BRIT MED J, V2, P423, DOI 10.1136/bmj.2.5811.423; Balch CM, 1996, ANN SURG, V224, P255, DOI 10.1097/00000658-199609000-00002; Barnwell JM, 1998, ANN SURG ONCOL, V5, P126, DOI 10.1007/BF02303845; Borgstein P, 1998, J AM COLL SURGEONS, V186, P275, DOI 10.1016/S1072-7515(98)00011-8; Borgstein PJ, 1997, LANCET, V349, P1668, DOI 10.1016/S0140-6736(05)62634-7; BYRNE J, 1992, EUR J CANCER, V28A, P658; CABANES PA, 1992, LANCET, V339, P1245, DOI 10.1016/0140-6736(92)91591-U; CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H; Chadha M, 1997, Oncology (Williston Park), V11, P1463; CHEN ZL, 1991, DIS MARKERS, V9, P239; Clare SE, 1997, ANN SURG ONCOL, V4, P447, DOI 10.1007/BF02303667; CLAYTON F, 1993, CANCER-AM CANCER SOC, V71, P1780, DOI 10.1002/1097-0142(19930301)71:5<1780::AID-CNCR2820710512>3.0.CO;2-2; Cox CE, 1998, ANN SURG, V227, P645, DOI 10.1097/00000658-199805000-00005; Crossin JA, 1998, AM SURGEON, V64, P666; DeCicco C, 1997, TUMORI, V83, P539, DOI 10.1177/030089169708300210; Dees EC, 1997, ANN SURG, V226, P279, DOI 10.1097/00000658-199709000-00007; DEMASCAREL I, 1992, BRIT J CANCER, V66, P523, DOI 10.1038/bjc.1992.306; Diab SG, 1998, J CLIN ONCOL, V16, P1655, DOI 10.1200/JCO.1998.16.5.1655; Dowlatshahi K, 1997, CANCER, V80, P1188, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H; ELSON CE, 1993, ANAL QUANT CYTOL, V15, P171; FISHER B, 1981, SURG GYNECOL OBSTET, V152, P765; Gershenwald JE, 1998, J CLIN ONCOL, V16, P2253, DOI 10.1200/JCO.1998.16.6.2253; Giuliano AE, 1996, J SURG ONCOL, V62, P75, DOI 10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N; GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016; Giuliano AE, 1997, J CLIN ONCOL, V15, P2345, DOI 10.1200/JCO.1997.15.6.2345; GIULIANO AE, 1994, ANN SURG, V220, P391, DOI 10.1097/00000658-199409000-00015; Glass LF, 1996, DERMATOL SURG, V22, P715, DOI 10.1111/j.1524-4725.1996.tb00623.x; GOLDHIRSCH A, 1990, LANCET, V335, P1565; Guenther JM, 1997, CANCER J SCI AM, V3, P336; Haffty BG, 1997, CANCER J SCI AM, V3, P2; HAINSWORTH PJ, 1993, BRIT J SURG, V80, P459, DOI 10.1002/bjs.1800800417; HAYWARD J, 1987, ARCH SURG-CHICAGO, V122, P1244; Kapteijn BAE, 1997, ANN SURG ONCOL, V4, P156, DOI 10.1007/BF02303799; Kirkwood JM, 1996, J CLIN ONCOL, V14, P7, DOI 10.1200/JCO.1996.14.1.7; KJAERGAARD J, 1985, BRIT J SURG, V72, P365, DOI 10.1002/bjs.1800720511; Krag D, 1998, NEW ENGL J MED, V339, P941, DOI 10.1056/NEJM199810013391401; KRAG DN, 1995, ARCH SURG-CHICAGO, V130, P654; Leong SPL, 1997, ARCH SURG-CHICAGO, V132, P666; MCCREADY DR, 1989, ARCH SURG-CHICAGO, V124, P21; McGuckin MA, 1996, BRIT J CANCER, V73, P88, DOI 10.1038/bjc.1996.16; Miliotes G, 1996, AM SURGEON, V62, P81; Morris AD, 1997, CANCER J, V3, P6; MORTON DL, 1993, J CLIN ONCOL, V11, P1751, DOI 10.1200/JCO.1993.11.9.1751; MORTON DL, 1992, ARCH SURG-CHICAGO, V127, P392; Mudun A, 1996, RADIOLOGY, V199, P171, DOI 10.1148/radiology.199.1.8633142; Mustafa IA, 1998, ANN SURG ONCOL, V5, P4, DOI 10.1007/BF02303756; NASSER IA, 1993, HUM PATHOL, V24, P950, DOI 10.1016/0046-8177(93)90108-S; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; NEVILLE AM, 1991, LANCET, V337, P1110, DOI 10.1016/0140-6736(91)91768-P; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Pijpers R, 1997, J NUCL MED, V38, P366; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RAMNATH EM, 1997, J MOFFITT CANC CTR, V4, P483; REINTGEN D, 1994, ANN SURG, V220, P759, DOI 10.1097/00000658-199412000-00009; Reintgen DS, 1996, ANN SURG ONCOL, V3, P327, DOI 10.1007/BF02305660; ROSEN PP, 1983, ANN SURG, V197, P276, DOI 10.1097/00000658-198303000-00006; ROSS MI, 1993, SEMIN SURG ONCOL, V9, P219; SIM FH, 1978, CANCER-AM CANCER SOC, V41, P948, DOI 10.1002/1097-0142(197803)41:3<948::AID-CNCR2820410324>3.0.CO;2-Z; Sosa JA, 1998, ANN SURG ONCOL, V5, P140, DOI 10.1007/BF02303847; Statman R, 1996, Adv Surg, V30, P209; THOMPSON W, 1996, SOC SURG ONC ATL MAR; Turner RR, 1997, ANN SURG, V226, P271, DOI 10.1097/00000658-199709000-00006; UREN RF, 1995, J NUCL MED, V36, P1775; VANDERVEEN H, 1994, BRIT J SURG, V81, P1769, DOI 10.1002/bjs.1800811220; VANLANCKER M, 1995, AM J CLIN ONCOL-CANC, V18, P267; VERONESI U, 1982, CANCER-AM CANCER SOC, V49, P2420, DOI 10.1002/1097-0142(19820601)49:11<2420::AID-CNCR2820491133>3.0.CO;2-2; Veronesi U, 1997, LANCET, V349, P1864, DOI 10.1016/S0140-6736(97)01004-0	70	250	263	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 1	1998	339	14					990	995		10.1056/NEJM199810013391410	http://dx.doi.org/10.1056/NEJM199810013391410			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	124MW	9753717				2022-12-24	WOS:000076186900010
J	Marsh, K				Marsh, K			Malaria disaster in Africa	LANCET			English	Editorial Material									Kenya Med Res Inst, Ctr Geog Med Res Coast, Kilifi, Kenya	Kenya Medical Research Institute	Marsh, K (corresponding author), Kenya Med Res Inst, Ctr Geog Med Res Coast, Kilifi, Kenya.							Trape JF, 1998, CR ACAD SCI III-VIE, V321, P689, DOI 10.1016/S0764-4469(98)80009-7	1	136	143	0	11	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	SEP 19	1998	352	9132					924	924		10.1016/S0140-6736(05)61510-3	http://dx.doi.org/10.1016/S0140-6736(05)61510-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121FG	9752813				2022-12-24	WOS:000076002200006
J	Silvestri, G; Pritchard, R; Welch, HG				Silvestri, G; Pritchard, R; Welch, HG			Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews	BRITISH MEDICAL JOURNAL			English	Article							LIFE YEARS; METAANALYSIS; ADJUSTMENT	Objective: To determine how patients with lung cancer value the trade off between the survival benefit of chemotherapy and its toxicities. Design: Scripted interviews that included three hypothetical scenarios. Each scenario described the same patient with metastic non-small cell lung cancer with an expected survival of 4 months without treatment. Subjects were asked to indicate the minimum survival benefit required to accept the side effects of chemotherapy in the first two scenarios (mild toxicity and severe toxicity). In the third scenario, subjects were asked to choose between chemotherapy and supportive care when the benefit of chemotherapy was either to prolong life by 3 months or to palliate symptoms. Subjects: 81 patients previously treated with cis-platinum based chemotherapy for advanced non-small cell lung cancer. Main outcome measure: Survival threshold for accepting chemotherapy. Results: The minimum survival threshold for accepting the toxicity of chemotherapy varied widely in patients. Several patients would accept chemotherapy fur a survival benefit of 1 week, while others Many would not choose chemotherapy even for a survival benefit of 24 months. The median survival threshold for accepting chemotherapy was 4.5 months for mild toxicity and 9 months for severe toxicity. When given the choice between supportive care and chemotherapy only 18 (22%) patients chose chemotherapy for a survival benefit of 3 months; 55 (68%) patients chose chemotherapy if it substantially reduced symptoms without prolonging life. Conclusions: Patients' willingness to accept chemotherapy for the treatment of metastatic lung cancer varies widely Many would not choose chemotherapy for its likely survival benefit of 3 months but would if it improved quality of life. The conflict between these patients' preferences and the care they previously received has several explanations, one being that some patients had not received the treatment they would have chosen had they been fully informed.	Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA; Dept Vet Affairs Med Ctr, Hematol Oncol Sect, White River Junction, VT 05009 USA; Dept Vet Affairs Med Ctr, VA Outcomes Grp 111B, White River Junction, VT 05009 USA	Medical University of South Carolina; VA Outcomes Group	Silvestri, G (corresponding author), Med Univ S Carolina, Div Pulm & Crit Care Med, Charleston, SC 29425 USA.							Brundage MD, 1997, J CLIN ONCOL, V15, P330, DOI 10.1200/JCO.1997.15.1.330; GINSBERG RJ, 1993, CANC PRINCIPLES PRAC, P673; GRILLI R, 1993, J CLIN ONCOL, V11, P1866, DOI 10.1200/JCO.1993.11.10.1866; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; MARINO P, 1994, CHEST, V106, P861, DOI 10.1378/chest.106.3.861; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; MCQUELLON RP, 1995, J CLIN ONCOL, V13, P858, DOI 10.1200/JCO.1995.13.4.858; NORD E, 1992, SOC SCI MED, V34, P559, DOI 10.1016/0277-9536(92)90211-8; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; READ JL, 1984, MED DECIS MAKING, V4, P315, DOI 10.1177/0272989X8400400307; RICHARDS MA, 1995, EUR J CANCER, V31A, P112, DOI 10.1016/0959-8049(94)00478-N; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SOUQUET PJ, 1993, LANCET, V342, P19; Sox HC, 1988, MED DECISION MAKING; STIGGELBOUT AM, 1994, MED DECIS MAKING, V14, P82, DOI 10.1177/0272989X9401400110; YELLEN SB, 1994, J NATL CANCER I, V86, P1766, DOI 10.1093/jnci/86.23.1766	16	273	275	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 19	1998	317	7161					771	775		10.1136/bmj.317.7161.771	http://dx.doi.org/10.1136/bmj.317.7161.771			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	122RA	9740561	Green Published, Bronze			2022-12-24	WOS:000076084200021
J	Cho, CH; Bunch, DO; Faure, JE; Goulding, EH; Eddy, EM; Primakoff, P; Myles, DG				Cho, CH; Bunch, DO; Faure, JE; Goulding, EH; Eddy, EM; Primakoff, P; Myles, DG			Fertilization defects in sperm from mice lacking fertilin beta	SCIENCE			English	Article							DISINTEGRIN DOMAIN; EGG FUSION; SURFACE PROTEIN; POTENTIAL ROLE; CELL-ADHESION; MOUSE EGG; METALLOPROTEASE; MOTILITY; IDENTIFICATION; TRANSPORT	Fertilin, a member of the ADAM family, is found on the plasma membrane of mammalian sperm. Sperm from mice tacking fertilin beta were shown to be deficient in sperm-egg membrane adhesion, sperm-egg fusion, migration from the uterus into the oviduct, and binding to the egg zona pellucida. Egg activation was unaffected. The results are consistent with a direct role of fertilin in sperm-egg plasma membrane interaction. Fertilin could also have a direct role in sperm-zona binding or oviduct migration; alternatively, the effects on these functions could result from the absence of fertilin activity during spermatogenesis.	Univ Calif Davis, Sect Mol & Cellular Biol, Livermore, CA 95616 USA; NIEHS, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of California System; University of California Davis; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Myles, DG (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Livermore, CA 95616 USA.	dgmyles@ucdavis.edu		Bunch, Donna/0000-0002-3638-0522	NICHD NIH HHS [U54HD29125, HD16580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016580, U54HD029125, R01HD016580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; BLOBEL CP, 1990, J CELL BIOL, V111, P69, DOI 10.1083/jcb.111.1.69; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; CHO CL, UNPUB; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; KLINE D, 1992, DEV BIOL, V149, P80, DOI 10.1016/0012-1606(92)90265-I; Lum L, 1997, DEV BIOL, V191, P131, DOI 10.1006/dbio.1997.8609; MYLES DG, 1993, DEV BIOL, V158, P35, DOI 10.1006/dbio.1993.1166; Myles DG, 1997, BIOL REPROD, V56, P320, DOI 10.1095/biolreprod56.2.320; MYLES DG, 1994, P NATL ACAD SCI USA, V91, P4195, DOI 10.1073/pnas.91.10.4195; OLDSCLARKE P, 1986, BIOL REPROD, V34, P453, DOI 10.1095/biolreprod34.3.453; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PHELPS BM, 1990, J CELL BIOL, V111, P1839, DOI 10.1083/jcb.111.5.1839; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; Rooke J, 1996, SCIENCE, V273, P1227, DOI 10.1126/science.273.5279.1227; Seed J, 1996, REPROD TOXICOL, V10, P237, DOI 10.1016/0890-6238(96)00028-7; SMITH TT, 1990, BIOL REPROD, V42, P450, DOI 10.1095/biolreprod42.3.450; Snell WJ, 1996, CELL, V85, P629, DOI 10.1016/S0092-8674(00)81230-1; SUAREZ SS, 1987, BIOL REPROD, V36, P203, DOI 10.1095/biolreprod36.1.203; WOLFSBERG TG, 1993, P NATL ACAD SCI USA, V90, P10783, DOI 10.1073/pnas.90.22.10783; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Yanagimachi R., 1994, P189; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105	24	416	441	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 18	1998	281	5384					1857	1859		10.1126/science.281.5384.1857	http://dx.doi.org/10.1126/science.281.5384.1857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	121HK	9743500				2022-12-24	WOS:000076007100055
J	Fernandez, I; Ubach, J; Dulubova, I; Zhang, XY; Sudhof, TC; Rizo, J				Fernandez, I; Ubach, J; Dulubova, I; Zhang, XY; Sudhof, TC; Rizo, J			Three-dimensional structure of an evolutionarily conserved N-terminal domain of syntaxin 1A	CELL			English	Article							PROTEIN-PROTEIN INTERACTIONS; SYNAPTOTAGMIN-I; VESICLE FUSION; NEUROTRANSMITTER RELEASE; CAENORHABDITIS-ELEGANS; RESONANCE SPECTROSCOPY; SECONDARY STRUCTURE; CALCIUM-FREE; C-2 DOMAIN; NMR	Syntaxin 1A plays a central role in neurotransmitter release through multiple protein-protein interactions. We have used NMR spectroscopy to identify an autonomously folded N-terminal domain in syntaxin 1A and to elucidate its three-dimensional structure. This 120-residue N-terminal domain is conserved in plasma membrane syntaxins but not in other syntaxins, indicating a specific role in exocytosis. The domain contains three long or helices that form an up-and-down bundle with a left-handed twist. A striking residue conservation is observed throughout a long groove that is likely to provide a specific surface for protein-protein interactions. A highly acidic region binds to the C(2)A domain of synaptotagmin I in a Ca2+-dependent interaction that may serve as an electrostatic switch in neurotransmitter release.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Rizo, J (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037200] Funding Source: NIH RePORTER; NINDS NIH HHS [NS37200] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; Betz A, 1997, J BIOL CHEM, V272, P2520; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; Bock JB, 1996, J BIOL CHEM, V271, P17961, DOI 10.1074/jbc.271.30.17961; BRENNER S, 1974, GENETICS, V77, P71; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P12, DOI 10.1021/bi00215a002; DAVLETOV BA, 1993, J BIOL CHEM, V268, P26386; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; Hanson PI, 1997, CURR OPIN NEUROBIOL, V7, P310, DOI 10.1016/S0959-4388(97)80057-8; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOSONO R, 1991, NEUROSCI LETT, V128, P243, DOI 10.1016/0304-3940(91)90270-4; INOUE A, 1992, J BIOL CHEM, V267, P10613; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J AM CHEM SOC, V115, P2055, DOI 10.1021/ja00058a072; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kee Y, 1996, J NEUROSCI, V16, P1975; KEE Y, 1995, NEURON, V14, P991, DOI 10.1016/0896-6273(95)90337-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1994, J BIOMOL NMR, V4, P871, DOI 10.1007/BF00398416; KUMAR A, 1981, J AM CHEM SOC, V103, P3654, DOI 10.1021/ja00403a008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Lin RC, 1997, NEURON, V19, P1087, DOI 10.1016/S0896-6273(00)80399-2; LOGAN TM, 1993, J BIOMOL NMR, V3, P225; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; RIZO J, 1994, J BIOMOL NMR, V4, P741, DOI 10.1007/BF00398406; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; Shao XG, 1997, NEURON, V18, P133, DOI 10.1016/S0896-6273(01)80052-0; Shao XG, 1997, J BIOMOL NMR, V10, P307, DOI 10.1023/A:1018349601965; Shao XG, 1996, SCIENCE, V273, P248, DOI 10.1126/science.273.5272.248; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Sudhof TC, 1996, NEURON, V17, P379, DOI 10.1016/S0896-6273(00)80171-3; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SUTTON RB, 1998, IN PRESS NATURE; Ubach J, 1998, EMBO J, V17, P3921, DOI 10.1093/emboj/17.14.3921; WISHART DS, 1994, J BIOMOL NMR, V4, P171; Wong SH, 1998, J BIOL CHEM, V273, P375, DOI 10.1074/jbc.273.1.375; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925; ZHANG L, 1994, CHIN J PHARMACOEPIDE, V3, P4	55	260	268	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					841	849		10.1016/S0092-8674(00)81742-0	http://dx.doi.org/10.1016/S0092-8674(00)81742-0			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753330	Bronze			2022-12-24	WOS:000076021200016
J	Fukumura, D; Xavier, R; Sugiura, T; Chen, Y; Park, EC; Lu, NF; Selig, M; Nielsen, G; Taksir, T; Jain, RK; Seed, B				Fukumura, D; Xavier, R; Sugiura, T; Chen, Y; Park, EC; Lu, NF; Selig, M; Nielsen, G; Taksir, T; Jain, RK; Seed, B			Tumor induction of VEGF promoter activity in stromal cells	CELL			English	Article							ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY; ANTIANGIOGENIC THERAPY; FACTOR EXPRESSION; TRANSGENIC MICE; MESSENGER-RNA; UP-REGULATION; ANGIOGENESIS; HYPOXIA; MECHANISMS	We have established a line of transgenic mice expressing the A. victoria green fluorescent protein (GFP) under the control of the promoter for vascular endothelial growth factor (VEGF). Mice bearing the transgene show green cellular fluorescence around the healing margins and throughout the granulation tissue of superficial ulcerative wounds. Implantation of solid tumors in the transgenic mice leads to an accumulation of green fluorescence resulting from tumor induction of host VEGF promoter activity. With time, the fluorescent cells invade the tumor and can be seen throughout the tumor mass. Spontaneous mammary tumors induced by oncogene expression in the VEGF-GFP mouse show strong stromal, but not tumor, expression of GFP. In both wound and tumor models the predominant GFP-positive cells are fibroblasts. The finding that the VEGF promoter of nontransformed cells is strongly activated by the tumor microenvironment points to a need to analyze and understand stromal cell collaboration in tumor angiogenesis.	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Melvin B & Barbara K Nessel Gene Therapy Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Gastroenterol Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Jain, RK (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.		Jain, Rakesh K/I-1384-2017	Jain, Rakesh K/0000-0001-7571-3548	NATIONAL CANCER INSTITUTE [R35CA056591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI027849, R01AI027849] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043031] Funding Source: NIH RePORTER; NCI NIH HHS [R35-CA-56591] Funding Source: Medline; NIAID NIH HHS [AI27849] Funding Source: Medline; NIDDK NIH HHS [DK43031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERSE B, 1992, MOL BIOL CELL, V3, P211, DOI 10.1091/mbc.3.2.211; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; BONDAR I, 1991, RES EXP MED, V191, P379, DOI 10.1007/BF02576693; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; CERFBENSUSSAN N, 1983, J IMMUNOL, V130, P2615; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Damert A, 1997, CANCER RES, V57, P3860; DETMAR M, 1998, IN PRESS INVEST DERM; DVORAK HF, 1995, AM J PATHOL, V146, P1029; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FIDLER IJ, 1995, J NATL CANCER I, V87, P1588, DOI 10.1093/jnci/87.21.1588; FLEENOR DE, 1993, BLOOD, V81, P2781; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Fukumura D, 1997, AM J PATHOL, V150, P713; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; Haas J, 1996, CURR BIOL, V6, P315, DOI 10.1016/S0960-9822(02)00482-7; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Helm R., 1996, CURR BIOL, V6, P178; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; HLATKY L, 1994, CANCER RES, V54, P6083; HOLLANDER GA, 1995, IMMUNITY, V3, P27, DOI 10.1016/1074-7613(95)90156-6; JAIN R, 1997, IEEE MULTIMEDIA, V4, P1; KERBEL RS, 1991, BIOESSAYS, V13, P31, DOI 10.1002/bies.950130106; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LEUNIG M, 1992, CANCER RES, V52, P6553; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MILSTONE DS, 1998, IN PRESS MICROCIRCUL; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; STEIN I, 1995, MOL CELL BIOL, V15, P5363; TISCHER E, 1991, J BIOL CHEM, V266, P11947	38	782	839	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					715	725		10.1016/S0092-8674(00)81731-6	http://dx.doi.org/10.1016/S0092-8674(00)81731-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753319	Bronze			2022-12-24	WOS:000076021200005
J	Russo, AA; Tong, L; Lee, JO; Jeffrey, PD; Pavletich, NP				Russo, AA; Tong, L; Lee, JO; Jeffrey, PD; Pavletich, NP			Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16(INK4a)	NATURE			English	Article							FAMILIAL MELANOMA; CRYSTAL-STRUCTURE; PROTEIN-KINASE; CELLULAR-TRANSFORMATION; RETINOBLASTOMA-PROTEIN; GENE-PRODUCT; TGF-BETA; P16; MUTATIONS; BINDING	The cyclin-dependent kinases 4 and 6 (Cdk4/6) that control the G1 phase of the cell cycle and their inhibitor, the p16(INK4a) tumour suppressor, have a central role in cell proliferation and in tumorigenesis. The structures of Cdk6 bound to p16(INK4a) and to the related p19(INK4d) reveal that the INK4 inhibitors bind next to the ATP-binding site of the catalytic cleft, opposite where the activating cyclin subunit binds. They prevent cyclin binding indirectly by causing structural changes that propagate to the cyclin-binding site. The INK4 inhibitors also distort the kinase catalytic cleft and interfere with ATP binding, which explains how they can inhibit the preassembled Cdk4/6-cyclin D complexes as well. Ttrmour-derived mutations in INK4a and Cdk4 map to interface contacts, solidifying the role of CDK binding and inhibition in the tumour suppressor activity of p16(INK4a).	Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Pavletich, NP (corresponding author), Mem Sloan Kettering Canc Ctr, Howard Hughes Med Inst, New York, NY 10021 USA.	Nikola@xray2.mskcc.org	Lee, Jie-Oh/AAG-4302-2020; Lee, Jie-Oh/C-1581-2011	Jeffrey, Philip/0000-0002-4351-5341; Lee, Jie-Oh/0000-0001-6519-6049				Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; BRUNGER AT, 1991, XPLOR SYSTEM CRYSTAL; Byeon IJL, 1998, MOL CELL, V1, P421, DOI 10.1016/S1097-2765(00)80042-8; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; Coleman KG, 1997, J BIOL CHEM, V272, P18869, DOI 10.1074/jbc.272.30.18869; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Fahraeus R, 1996, CURR BIOL, V6, P84, DOI 10.1016/S0960-9822(02)00425-6; GERBER MR, 1995, P NATL ACAD SCI USA, V92, P4651, DOI 10.1073/pnas.92.10.4651; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LI Y, 1994, CANCER RES, V54, P6078; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; Parry D, 1996, MOL CELL BIOL, V16, P3844; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; RANADE K, 1995, NAT GENET, V10, P114, DOI 10.1038/ng0595-114; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Stephen DB, 1996, STRUCT ENG MECH, V4, P1; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wolf SS, 1995, MOL BIOTECHNOL, V4, P269, DOI 10.1007/BF02779020; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YANG R, 1995, CANCER RES, V55, P2503; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734; ZOLLER MJ, 1981, J BIOL CHEM, V256, P837; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	51	390	408	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					237	243		10.1038/26155	http://dx.doi.org/10.1038/26155			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751050				2022-12-24	WOS:000075974600040
J	Yang, RB; Mark, MR; Gray, A; Huang, A; Xie, MH; Zhang, M; Goddard, A; Wood, WI; Gurney, AL; Godowski, PJ				Yang, RB; Mark, MR; Gray, A; Huang, A; Xie, MH; Zhang, M; Goddard, A; Wood, WI; Gurney, AL; Godowski, PJ			Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling	NATURE			English	Article							NF-KAPPA-B; DROSOPHILA TOLL; TYROSINE KINASE; IL-1 RECEPTOR; UP-REGULATION; ACTIVATION; PROTEIN; DORSAL; ENDOTOXIN; IMMUNITY	Vertebrates and invertebrates initiate a series of defence mechanisms following infection by Gram-negative bacteria by sensing the presence of lipopolysaccharide (LPS), a major component of the cell wall of the invading pathogen(1), In humans, monocytes and macrophages respond to LPS by inducing the expression of cytokines, cell-adhesion proteins, and enzymes involved in the production of small proinflammatory mediators. Under pathophysiological conditions, LPS exposure can lead to an often fatal syndrome known as septic shock(2). Sensitive responses of myeloid cells to LPS require a plasma protein called LPS-binding protein and the glycosylphosphatidylinositol-anchored membrane protein CD14. However, the mechanism by which the LPS signal is transduced across the plasma membrane remains unknown(3). Here we show that Toll-like receptor 2 (TLR2) is a signalling receptor that is activated by LPS in a response that depends on LPS-binding protein and is enhanced by CD14. A region in the intracellular domain of TLR2. with homology to a portion of the interleukin (IL)-1 receptor that is implicated in the activation of the IL-1-receptor-associated kinase is required for this response. Our results indicate that TLR2 is a direct mediator of signalling by LPS.	Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech	Godowski, PJ (corresponding author), Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA.	ski@gene.com	Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAZIL V, 1986, EUR J IMMUNOL, V16, P1583, DOI 10.1002/eji.1830161218; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Dangl J, 1997, CELL, V91, P17, DOI 10.1016/S0092-8674(01)80005-2; DELUDE RL, 1994, J BIOL CHEM, V269, P22253; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GAY NJ, 1991, NATURE, V351, P355, DOI 10.1038/351355b0; HammondKosack KE, 1997, ANNU REV PLANT PHYS, V48, P575, DOI 10.1146/annurev.arplant.48.1.575; HEGUY A, 1992, J BIOL CHEM, V267, P2605; KIDD S, 1992, CELL, V71, P623, DOI 10.1016/0092-8674(92)90596-5; LEE JD, 1993, P NATL ACAD SCI USA, V90, P9930, DOI 10.1073/pnas.90.21.9930; LEMAITRE B, 1995, EMBO J, V14, P536, DOI 10.1002/j.1460-2075.1995.tb07029.x; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lemaitre B, 1997, P NATL ACAD SCI USA, V94, P14614, DOI 10.1073/pnas.94.26.14614; Luoh SM, 1997, J MOL ENDOCRINOL, V18, P77, DOI 10.1677/jme.0.0180077; MARCHANT A, 1992, EUR J IMMUNOL, V22, P1663, DOI 10.1002/eji.1830220650; MARK MR, 1994, J BIOL CHEM, V269, P10720; MATSUURA K, 1994, J EXP MED, V179, P1671, DOI 10.1084/jem.179.5.1671; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, P NATL ACAD SCI USA, V95, P429, DOI 10.1073/pnas.95.2.429; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RIETSCHEL ET, 1992, SCI AM, V267, P54, DOI 10.1038/scientificamerican0892-54; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253	26	1072	1144	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 17	1998	395	6699					284	288		10.1038/26239	http://dx.doi.org/10.1038/26239			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751057				2022-12-24	WOS:000075974600053
J	Erikssen, G; Liestol, K; Bjornholt, J; Thaulow, E; Sandvik, L; Erikssen, J				Erikssen, G; Liestol, K; Bjornholt, J; Thaulow, E; Sandvik, L; Erikssen, J			Changes in physical fitness and changes in mortality	LANCET			English	Article							ALL-CAUSE MORTALITY; CORONARY HEART-DISEASE; AGED NORWEGIAN MEN; FOLLOW-UP; CARDIOVASCULAR MORTALITY; HEALTHY-MEN; EXERCISE; RISK; PREDICTOR; WOMEN	Background Point estimates of physical fitness give important information on the risk of death in healthy people, but there is little information available on effects of sequential changes in physical fitness on mortality. We studied this latter aspect in healthy middle-aged men over a total follow-up period of 22 years. Methods 2014 healthy men aged 40-60 years had a bicycle exercise test and clinical examination, and completed a questionnaire in 1972-75 (survey 1). This was repeated for 1756 (91%) of 1932 men still alive by Dec 31, 1982 (survey 2). The exercise scores were adjusted for age, The change in exercise scores between surveys was divided into quartiles (Q1=least fit, Q4=fittest). An adjusted Cox's proportional hazards model was used to study the association between changes in physical fitness and mortality, with the Q1 men used as controls. Findings By Dec 31, 1994, 238 (17%) of the 1428 men had died, 120 from cardiovascular causes. There were 37 deaths in the Q4 group (19 cardiovascular); their relative risks of death were 0.45 (95% Cl 0.29-0.69) for any cause and 0.47 (0.26-0.86) for cardiovascular causes. There was a graded, inverse relation between changes in physical fitness and mortality irrespective of physical fitness status at survey 1. Interpretation Change in physical fitness in healthy middle-aged men is a strong predictor of mortality. Even smalt improvements in physical fitness are associated with a significantly lowered risk of death. If confirmed, these findings should be used to influence public health policy.	Cent Hosp Akershus, Dept Med, N-1474 Nordbyhagen, Norway; Univ Oslo, Inst Informat, Blindern, Norway; Univ Oslo, Natl Hosp, Dept Med B, Oslo, Norway; Medstat Res AS, Lillestrom, Norway	University of Oslo; University of Oslo; University of Oslo; National Hospital Norway	Erikssen, G (corresponding author), Cent Hosp Akershus, Dept Med, N-1474 Nordbyhagen, Norway.			Bjornholt, Jorgen Vildershoj/0000-0002-0079-8062				Barinaga M, 1997, SCIENCE, V276, P1324, DOI 10.1126/science.276.5317.1324; BLAIR SN, 1995, JAMA-J AM MED ASSOC, V273, P1093, DOI 10.1001/jama.273.14.1093; Blair SN, 1996, JAMA-J AM MED ASSOC, V276, P205, DOI 10.1001/jama.276.3.205; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BOUCHARD C, 1986, MED SCI SPORT EXER, V18, P639; EICHNER ER, 1994, MED CLIN N AM, V78, P377; EKELUND LG, 1988, NEW ENGL J MED, V319, P1379, DOI 10.1056/NEJM198811243192104; ELLESTAD MH, 1975, CIRCULATION, V51, P363, DOI 10.1161/01.CIR.51.2.363; ERIKSSEN J, 1977, SCAND J CLIN LAB INV, V37, P243, DOI 10.3109/00365517709091489; ERIKSSEN J, 1986, ACTA MED SCAND, P189; ERIKSSEN J, 1978, THESIS U HOSP OSLO; Hardman A, 1995, J Cardiovasc Risk, V2, P285, DOI 10.1097/00043798-199508000-00001; LEMAITRE RN, 1995, ARCH INTERN MED, V155, P2302, DOI 10.1001/archinte.155.21.2302; LEON AS, 1987, JAMA-J AM MED ASSOC, V258, P2388, DOI 10.1001/jama.258.17.2388; MUNDAL R, 1987, EUR J APPL PHYSIOL O, V56, P245, DOI 10.1007/BF00690888; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; OCONNOR GT, 1995, AM J EPIDEMIOL, V142, P1147, DOI 10.1093/oxfordjournals.aje.a117573; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; PAFFENBARGER RS, 1986, NEW ENGL J MED, V314, P605, DOI 10.1056/NEJM198603063141003; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SANDVIK L, 1993, NEW ENGL J MED, V328, P533, DOI 10.1056/NEJM199302253280803; SANDVIK L, 1995, CORONARY ARTERY DIS, V6, P667, DOI 10.1097/00019501-199508000-00012; SANDVIK L, 1995, BRIT MED J, V311, P715, DOI 10.1136/bmj.311.7007.715; SLATTERY ML, 1988, AM J EPIDEMIOL, V127, P571, DOI 10.1093/oxfordjournals.aje.a114832; THOMPSON WG, 1994, SOUTH MED J, V87, P567; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801	27	341	352	0	20	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 5	1998	352	9130					759	762		10.1016/S0140-6736(98)02268-5	http://dx.doi.org/10.1016/S0140-6736(98)02268-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	117CH	9737279				2022-12-24	WOS:000075762700008
J	Meluh, PB; Yang, PR; Glowczewski, L; Koshland, D; Smith, MM				Meluh, PB; Yang, PR; Glowczewski, L; Koshland, D; Smith, MM			Cse4p is a component of the core centromere of Saccharomyces cerevisiae	CELL			English	Article							INNER KINETOCHORE PLATE; BUDDING YEAST; CENP-C; CHROMATIN STRUCTURE; PROTEIN; DNA; CHROMOSOME; ANAPHASE; MITOSIS; COMPLEX	Histones are fundamental structural components of chromatin and are expected to play important roles in chromosome dynamics. Here, we present direct evidence that Cse4p, a histone H3 variant, is a structural component of the core centromere of S. cerevisiae. In histone H4 and Cse4p mutants, the core centromere chromatin structure is disrupted at restrictive temperature. Overexpression of Cse4p suppresses this defect in the H4 mutant, implying that the two proteins act together in centromere structure. We show by chromatin immunoprecipitation experiments that Cse4p is specifically cross-linked to centromeric DNA. Furthermore, by immunofluorescence microscopy, Cse4p is found in discrete foci consistent with that expected for centromeres. These results suggest the kinetochore is assembled on a specialized centromeric nucleosome containing Cse4p.	Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Virginia, Ctr Canc, Charlottesville, VA 22908 USA; Carnegie Inst Washington, Howard Hughes Med Inst, Dept Embryol, Baltimore, MD 21210 USA	University of Virginia; University of Virginia; Carnegie Institution for Science; Howard Hughes Medical Institute	Smith, MM (corresponding author), Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041718, R01GM028920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM41718, GM28920] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allshire RC, 1997, CURR OPIN GENET DEV, V7, P264, DOI 10.1016/S0959-437X(97)80137-2; Baker RE, 1998, GENETICS, V149, P73; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; CUMBERLEDGE S, 1987, GENETICS, V117, P203; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EARNSHAW WC, 1989, CHROMOSOMA, V98, P1, DOI 10.1007/BF00293329; Espelin CW, 1997, J CELL BIOL, V139, P1383, DOI 10.1083/jcb.139.6.1383; FUNK M, 1989, MOL GEN GENET, V219, P153, DOI 10.1007/BF00261171; GAUDET A, 1987, MOL CELL BIOL, V7, P68, DOI 10.1128/MCB.7.1.68; Gorbsky GJ, 1997, BIOESSAYS, V19, P193, DOI 10.1002/bies.950190303; Guacci V, 1997, MOL BIOL CELL, V8, P957, DOI 10.1091/mbc.8.6.957; GUACCI V, 1993, COLD SPRING HARB SYM, V58, P677, DOI 10.1101/SQB.1993.058.01.075; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Hyman AA, 1995, ANNU REV CELL DEV BI, V11, P471, DOI 10.1146/annurev.cb.11.110195.002351; Jannink G, 1996, BIOPHYS J, V71, P451, DOI 10.1016/S0006-3495(96)79247-0; Karpen GH, 1997, TRENDS GENET, V13, P489, DOI 10.1016/S0168-9525(97)01298-5; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; Meluh PB, 1997, GENE DEV, V11, P3401, DOI 10.1101/gad.11.24.3401; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MURPHY MR, 1991, CHROMOSOMA, V101, P189, DOI 10.1007/BF00355368; NICKLAS RB, 1983, J CELL BIOL, V97, P542, DOI 10.1083/jcb.97.2.542; NIEDENTHAL R, 1991, MOL CELL BIOL, V11, P3545, DOI 10.1128/MCB.11.7.3545; NIEDENTHAL RK, 1993, NUCLEIC ACIDS RES, V21, P4726, DOI 10.1093/nar/21.20.4726; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; Rose MD., 1990, METHODS YEAST GENETI; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; SAUNDERS M, 1988, P NATL ACAD SCI USA, V85, P175, DOI 10.1073/pnas.85.1.175; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHULMAN I, 1991, ANNU REV CELL BIOL, V7, P311, DOI 10.1146/annurev.cellbio.7.1.311; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; Smith MM, 1996, MOL CELL BIOL, V16, P1017; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Straight AF, 1997, SCIENCE, V277, P574, DOI 10.1126/science.277.5325.574; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; Wiens GR, 1998, CELL, V93, P313, DOI 10.1016/S0092-8674(00)81157-5	42	303	310	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 4	1998	94	5					607	613		10.1016/S0092-8674(00)81602-5	http://dx.doi.org/10.1016/S0092-8674(00)81602-5			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	118QR	9741625	Bronze			2022-12-24	WOS:000075851900008
J	Wetzel, MS; Eisenberg, DM; Kaptchuk, TJ				Wetzel, MS; Eisenberg, DM; Kaptchuk, TJ			Courses involving complementary and alternative medicine at US medical schools	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARE	Context.-With the public's increasing use of complementary and alternative medicine, medical schools must consider the challenge of educating physicians about these therapies. Objectives.-To document the prevalence, scope, and diversity of medical school education in complementary and alternative therapy topics and to obtain information about the organizational and academic features of these courses. Design.-Mail survey and follow-up letter and telephone survey conducted in 1997-1998. Participants.-Academic or curriculum deans and faculty at each of the 125 US medical schools. Main Outcome Measures.-Courses taught at US medical schools and administrative and educational characteristics of these courses. Results.-Replies were received from 117 (94%) of the 125 US medical schools. Of schools that replied, 75 (64%) reported offering elective courses in complementary or alternative medicine or including these topics in required courses. Of the 123 courses reported, 84 (68%) were stand-alone electives, 38 (31%) were part of required courses, and one (1%) was part of an elective. Thirty-eight courses (31%) were offered by departments of family practice and 14 (11%) by departments of medicine or internal medicine. Educational formats included lectures, practitioner lecture and/or demonstration, and patient presentations. Common topics included chiropractic, acupuncture, homeopathy, herbal therapies, and mind-body techniques. Conclusions.-There is tremendous heterogeneity and diversity in content, format, and requirements among courses in complementary and alternative medicine at US medical schools.	Beth Israel Deaconess Med Ctr, Dept Med, Ctr Alternat Med Res, Boston, MA 02215 USA; Harvard Univ, Sch Med, Off Educ Dev, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Wetzel, MS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Ctr Alternat Med Res, 330 Brookline Ave, Boston, MA 02215 USA.	mwetzel@warren.med.harvard.edu			NIAMS NIH HHS [U24 AR43441] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [U24AR043441] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		*AM MED ASS COUNC, 1997, ENC MED STUD ED COMP; *ASS AM MED COLL, 1997, DIR AM MED ED; Association of American Medical Colleges, 1998, 1 ASS AM MED SCH, P7; Astin JA, 1998, JAMA-J AM MED ASSOC, V279, P1548, DOI 10.1001/jama.279.19.1548; Berman B M, 1995, J Am Board Fam Pract, V8, P361; BERMAN BM, 1994, ALTERNATIVE MED EXPA; Blumberg D L, 1995, Altern Ther Health Med, V1, P31; Breedlove C, 1997, JAMA-J AM MED ASSOC, V278, P1702, DOI 10.1001/jama.1997.03550200078038; Carlston M, 1997, Fam Med, V29, P559; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; *FED STAT MED BOAR, 1997, REP HLTH CAR FRAUD S; Fox E, 1997, JAMA-J AM MED ASSOC, V278, P761; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; MARTIN JB, 1997, CAB PRIM CAR SER HAR; MUEHSAM PA, 1997, GEA CORRES       SPR, P10; MUEHSAM PA, 1998, GEA CORRES       SPR, P24; MURRAY RH, 1992, NEW ENGL J MED, V326, P61, DOI 10.1056/NEJM199201023260113	18	274	281	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1998	280	9					784	787		10.1001/jama.280.9.784	http://dx.doi.org/10.1001/jama.280.9.784			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	114LA	9729989	Bronze			2022-12-24	WOS:000075609900006
J	Wu, WS; Holmans, P; Wavrant-Devrieze, F; Shears, S; Kehoe, P; Crook, R; Booth, J; Williams, N; Perez-Tur, J; Roehl, K; Fenton, L; Chartier-Harlin, MC; Lovestone, S; Williams, J; Hutton, M; Hardy, J; Owen, MJ; Goate, A				Wu, WS; Holmans, P; Wavrant-Devrieze, F; Shears, S; Kehoe, P; Crook, R; Booth, J; Williams, N; Perez-Tur, J; Roehl, K; Fenton, L; Chartier-Harlin, MC; Lovestone, S; Williams, J; Hutton, M; Hardy, J; Owen, MJ; Goate, A			Genetic studies on chromosome 12 in late-onset Alzheimer disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							APOLIPOPROTEIN-E; ALLELE; TRAITS; RISK	Context. - The only genetic locus universally accepted to be important as a risk factor for late-onset Alzheimer disease (AD) is the apolipoprotein E (APOE) locus on chromosome 19. However, this locus does not account for all the risk in late-onset disease, and a recent report has suggested a second locus on chromosome 12p11-12. Objective. - To look for evidence of linkage on chromosome 12 and to test for the presence of the new locus in an independent sample of familial late-onset AD cases. Design. - Retrospective cohort study. As part of a 20-centimorgan genome screen (approximately equal to 200 markers), we tested a series of 18 genetic markers on chromosome 12 and carried out multipoint, nonparametric lod score and exclusion analyses. Setting. - Clinic populations in the continental United States selected from the National Institute of Mental Health AD Genetics Consortium. Patients. - We selected samples for DNA analysis from affected sibling pairs, 497 subjects from 230 families with 2 or more affected individuals with probable or definite AD with onset ages older than 60 years (mean +/- SD, 75 +/- 6 years). Within the families, we used the 2 probable or definitely affected individuals. In families with more than 2 such cases available, we used all of them; in families with only 2 such cases in which unaffected individuals were available, we also sampled the oldest unaffected individual and used genotype data from this unaffected individual to check for nonpaternity and genotyping errors. Main Outcome Measure. - Presence of linkage or locus on chromosome 12. Results. - Although linkage analyses confirmed the presence of a genetic susceptibility factor at the APOE locus in these families with late-onset AD, we were unable to confirm the presence of a locus close to the marker D12S1042. A moderate lod score (1.91) was found near D12S98 close to the alpha(2)-macroglobulin locus in the affected pairs in which both members did not possess an APOE epsilon 4 allele. Conclusions. - APOE remains the only locus established to be a risk factor for late-onset AD. We were unable to confirm that a locus on chromosome 12p11-12 has a major effect on risk for late-onset AD, although an effect smaller than that for APOE cannot be excluded.	Mayo Clin Jacksonville, Neurogenet Lab, Jacksonville, FL 32224 USA; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Wales, Coll Med, Neuropsychiat Genet Unit, Cardiff CF1 3NS, S Glam, Wales; Inst Pasteur, INSERM, F-59019 Lille, France; Inst Psychiat, Old Age Psychiat Sect, London SE5 8AF, England	Mayo Clinic; Washington University (WUSTL); Washington University (WUSTL); Cardiff University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; University of London; King's College London	Hardy, J (corresponding author), Mayo Clin Jacksonville, Neurogenet Lab, 4500 San Pablo Rd,Bridsall Bldg, Jacksonville, FL 32224 USA.	hardy.john@mayo.edu	Hardy, John/C-2451-2009; Lovestone, Simon/E-8725-2010; Chartier-Harlin, Marie-Christine/L-4527-2018; Holmans, Peter/F-4518-2015; Perez-Tur, Jordi/A-2143-2010; Kehoe, Patrick/P-8760-2018	Hardy, John/0000-0002-3122-0423; Chartier-Harlin, Marie-Christine/0000-0001-6416-6526; Holmans, Peter/0000-0003-0870-9412; Perez-Tur, Jordi/0000-0002-9111-1712; Williams, Julie/0000-0002-4069-0259; Lovestone, Simon/0000-0003-0473-4565; Goate, Alison/0000-0002-0576-2472; Kehoe, Patrick/0000-0002-7542-1139; Newton-Bishop, Julia/0000-0001-9147-6802	NIA NIH HHS [AG14616, AG00634] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG014616] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Blacker D, 1997, NEUROLOGY, V48, P139, DOI 10.1212/WNL.48.1.139; CHARTIERHARLIN MC, 1994, HUM MOL GENET, V3, P569, DOI 10.1093/hmg/3.4.569; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Kang DE, 1997, NEUROLOGY, V49, P56, DOI 10.1212/WNL.49.1.56; Kruglyak L, 1996, NAT GENET, V14, P132, DOI 10.1038/ng1096-132; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; Lendon CL, 1997, NEUROSCI LETT, V222, P187, DOI 10.1016/S0304-3940(97)13381-X; Martin ES, 1997, ALZ DIS ASSOC DIS, V11, P163, DOI 10.1097/00002093-199709000-00009; PERICAKVANCE MA, 1995, TRENDS GENET, V11, P504, DOI 10.1016/S0168-9525(00)89161-1; PericakVance MA, 1997, JAMA-J AM MED ASSOC, V278, P1237, DOI 10.1001/jama.278.15.1237; PericakVance MA, 1996, ANN NEUROL, V39, P700, DOI 10.1002/ana.410390605; RISCH N, 1990, AM J HUM GENET, V46, P222; STRITTMATTER WJ, 1992, P NATL ACAD SCI USA, V90, P1971; TALBOT C, 1994, LANCET, V343, P1432, DOI 10.1016/S0140-6736(94)92557-7; WavrantDeVrieze F, 1997, NEUROSCI LETT, V227, P68, DOI 10.1016/S0304-3940(97)00304-2	16	90	91	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1998	280	7					619	622		10.1001/jama.280.7.619	http://dx.doi.org/10.1001/jama.280.7.619			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	110ME	9718053	Bronze			2022-12-24	WOS:000075384300030
J	Kimura, K; Hirano, M; Kobayashi, R; Hirano, T				Kimura, K; Hirano, M; Kobayashi, R; Hirano, T			Phosphorylation and activation of 13S condensin by Cdc2 in vitro	SCIENCE			English	Article							MITOTIC CHROMOSOME CONDENSATION; TOPOISOMERASE-II; PROTEIN; SEGREGATION; CYCLE; DNA; P34(CDC2); MITOSIS; KINASE; FAMILY	13S condensin is a multisubunit protein complex essential for mitotic chromosome condensation in Xenopus egg extracts. Purified 135 condensin introduces positive supercoils into DNA in the presence of topoisomerase I and adenosine triphosphate in vitro. The supercoiling activity of 13S condensin was regulated by mitosis-specific phosphorylation. Immunodepletion, in vitro phospholylation, and peptide-mapping experiments indicated that Cdc2 is Likely to be the kinase that phosphorylates and activates 135 condensin. Multiple Cdc2 phosphorylation sites are clustered in the carboxyl-terminal domain of the XCAP-D2 (Xenopus chromosome-associated polypeptide D2) subunit. These results suggest that phosphorylation of 135 condensin by Cdc2 may trigger mitotic chromosome condensation in vitro.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Hirano, T (corresponding author), Cold Spring Harbor Lab, POB 100,Bungtown Rd, Cold Spring Harbor, NY 11724 USA.		Hirano, Tatsuya/F-6008-2011	Hirano, Tatsuya/0000-0002-4219-6473	NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053926] Funding Source: NIH RePORTER; NCI NIH HHS [CA45508] Funding Source: Medline; NIGMS NIH HHS [GM53926] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; Hirano T, 1998, CURR OPIN CELL BIOL, V10, P317, DOI 10.1016/S0955-0674(98)80006-9; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; Jessberger R, 1998, CURR OPIN GENET DEV, V8, P254, DOI 10.1016/S0959-437X(98)80149-4; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; KIMURA K, UNPUB; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Lieb JD, 1998, CELL, V92, P265, DOI 10.1016/S0092-8674(00)80920-4; Masuda H, 1996, J CELL SCI, V109, P165; Murray A, 1993, CELL CYCLE INTRO; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nigg Erich A., 1993, Trends in Cell Biology, V3, P296, DOI 10.1016/0962-8924(93)90011-O; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; RUSSO GL, 1992, J BIOL CHEM, V267, P20317; SAKA Y, 1994, EMBO J, V13, P4938, DOI 10.1002/j.1460-2075.1994.tb06821.x; SAWIN KE, 1992, J CELL SCI, V101, P303; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRUNNIKOV AV, 1995, GENE DEV, V9, P587, DOI 10.1101/gad.9.5.587; TAAGEPERA S, 1993, P NATL ACAD SCI USA, V90, P8407, DOI 10.1073/pnas.90.18.8407	22	239	246	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 16	1998	282	5388					487	490		10.1126/science.282.5388.487	http://dx.doi.org/10.1126/science.282.5388.487			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	129TT	9774278				2022-12-24	WOS:000076479600058
J	Zhang, Y; LeRoy, G; Seelig, HP; Lane, WS; Reinberg, D				Zhang, Y; LeRoy, G; Seelig, HP; Lane, WS; Reinberg, D			The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities	CELL			English	Article							TRANSCRIPTIONAL REPRESSION; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; NEGATIVE REGULATOR; MI-2 AUTOANTIGEN; N-COR; YEAST; PROTEIN; RPD3; ACETYLATION	Histone acetylation and deacetylation were found to be catalyzed by structurally distinct, multisubunit complexes that mediate, respectively, activation and repression of transcription. ATP-dependent nucleosome remodeling, mediated by different multisubunit complexes, was thought to be involved only in transcription activation. Here we report the isolation of a protein complex that contains both histone deacetylation and ATP-dependent nucleosome remodeling activities. The complex contains the histone deacetylases HDAC1/2, histone-binding proteins, the dermatomyositis-specific autoantigen Mi2 beta, a polypeptide related to the metastasis-associated protein 1, and a novel polypeptide of 32 kDa. Patients with dermatomyositis have a high rate of malignancy. The finding that Mi2 beta exists in a complex containing histone deacetylase and nucleosome remodeling activities suggests a role for chromatin reorganization in cancer metastasis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Inst Immunol & Mol Genet, D-76133 Karlsruhe, Germany; Harvard Univ, Harvard Microchem Facil, Cambridge, MA 02138 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Harvard University	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucl Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.	reinbedf@umdnj.edu		Zhang, Yi/0000-0002-2789-0811; Reinberg, Danny/0000-0003-4288-2016	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019515] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-48518, 1F32GM19515-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; AIRIO A, 1995, J RHEUMATOL, V22, P1300; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Bulger M., 1994, METH MOL G, V5, P241; DeRubertis F, 1996, NATURE, V384, P589; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gibbons RJ, 1997, NAT GENET, V17, P146, DOI 10.1038/ng1097-146; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Harlow E, 1988, ANTIBODIES LAB MANUA; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HASSIG CA, 1997, CELL, V89, P331; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; QIAN YW, 1995, J BIOL CHEM, V270, P25507, DOI 10.1074/jbc.270.43.25507; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Seelig HP, 1996, ARTHRITIS RHEUM, V39, P1769, DOI 10.1002/art.1780391029; SEELIG HP, 1995, ARTHRITIS RHEUM-US, V38, P1389, DOI 10.1002/art.1780381006; Shorr AF, 1997, AM J MED SCI, V313, P249, DOI 10.1097/00000441-199704000-00011; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Toh Y, 1997, INT J CANCER, V74, P459, DOI 10.1002/(SICI)1097-0215(19970822)74:4<459::AID-IJC18>3.3.CO;2-H; TOH Y, 1994, J BIOL CHEM, V269, P22958; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Holde KE., 1989, SPRINGER SERIES MOL; VanLint C, 1996, GENE EXPRESSION, V5, P245; Vannier D, 1996, GENETICS, V144, P1343; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0; Verreault A, 1998, CURR BIOL, V8, P96, DOI 10.1016/S0960-9822(98)70040-5; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Woodage T, 1997, P NATL ACAD SCI USA, V94, P11472, DOI 10.1073/pnas.94.21.11472; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	60	631	652	1	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 16	1998	95	2					279	289		10.1016/S0092-8674(00)81758-4	http://dx.doi.org/10.1016/S0092-8674(00)81758-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	130UG	9790534	Bronze			2022-12-24	WOS:000076538300015
J	Ahmed, SH; Koob, GF				Ahmed, SH; Koob, GF			Transition from moderate to excessive drug intake: Change in hedonic set point	SCIENCE			English	Article							ADDICTION; COCAINE; TOLERANCE; DEPENDENCE; ABUSE	Differential access to cocaine self-administration produced two patterns of drug intake in rats. With 1 hour of access per session, drug intake remained low and stable. In contrast, with 6 hours of access, drug intake gradually escalated over days. After escalation, drug consumption was characterized by an increased early drug loading and an upward shift in the cocaine dose-response function, suggesting an increase in hedonic set point. After 1 month of abstinence, escalation of cocaine intake was reinstated to a higher level than before. These findings may provide an animal model for studying the development of excessive drug intake and the basis of addiction.	Scripps Res Inst, Dept Neuropharmacol, Div Psychopharmacol, La Jolla, CA 92037 USA	Scripps Research Institute	Ahmed, SH (corresponding author), Scripps Res Inst, Dept Neuropharmacol, Div Psychopharmacol, CVN-7,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		AHMED, Serge H/D-5236-2014	Ahmed, Serge/0000-0002-1225-9234	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA008467, R01DA004398] Funding Source: NIH RePORTER; NIDA NIH HHS [DA08467, DA04398] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Ahmed SH, 1997, PSYCHOPHARMACOLOGY, V132, P289, DOI 10.1007/s002130050347; Altman J, 1996, PSYCHOPHARMACOLOGY, V125, P285, DOI 10.1007/BF02246016; BOZARTH MA, 1985, JAMA-J AM MED ASSOC, V254, P81, DOI 10.1001/jama.254.1.81; DENEAU G, 1969, PSYCHOPHARMACOLOGIA, V16, P30, DOI 10.1007/BF00405254; EDWARDS G, 1986, BRIT J ADDICT, V81, P171; EMMETTOGLESBY MW, 1993, DRUG ALCOHOL DEPEN, V32, P247, DOI 10.1016/0376-8716(93)90089-9; EMMETTOGLESBY MW, 1992, BEHAV PHARMACOL, V3, P193; GAWIN FH, 1991, SCIENCE, V251, P1580, DOI 10.1126/science.2011738; GAWIN FH, 1988, NEW ENGL J MED, V318, P1173, DOI 10.1056/NEJM198805053181806; GOUDIE AJ, 1989, PSYCHOACTIVE DRUGS T; JOHANSON CE, 1976, PHARMACOL BIOCHEM BE, V4, P45, DOI 10.1016/0091-3057(76)90174-X; KALANT H, 1971, PHARMACOL REV, V23, P135; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; Koob GF, 1997, J NEUROPSYCH CLIN N, V9, P482; Koob GF, 1996, NEURON, V16, P893, DOI 10.1016/S0896-6273(00)80109-9; Leshner AI, 1997, SCIENCE, V278, P45, DOI 10.1126/science.278.5335.45; MARLATT GA, 1988, ANNU REV PSYCHOL, V39, P223, DOI 10.1146/annurev.ps.39.020188.001255; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; OBrien Cp E.R., 1986, BEHAV ANAL DRUG DEPE, P329; PICKENS R, 1978, HDB PSYCHOPHARMACOLO, P1; YOKEL RA, 1987, METHODS ASSESSING RE, P211; YOUNG SD, 1986, J ACCOUNT PUBLIC POL, V5, P5, DOI 10.1016/0278-4254(86)90003-7	22	818	836	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					298	300		10.1126/science.282.5387.298	http://dx.doi.org/10.1126/science.282.5387.298			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765157				2022-12-24	WOS:000076370200050
J	Dedysh, SN; Panikov, NS; Liesack, W; Grosskopf, R; Zhou, JZ; Tiedje, JM				Dedysh, SN; Panikov, NS; Liesack, W; Grosskopf, R; Zhou, JZ; Tiedje, JM			Isolation of acidophilic methane-oxidizing bacteria from northern peat wetlands	SCIENCE			English	Article							MONOOXYGENASE GENE-CLUSTER; METHANOTROPHIC BACTERIA; ATMOSPHERIC METHANE; CONSUMPTION; OXIDATION	Acidic northern wetlands are an important source of methane, one of the gases that contributes to global warming. Methane oxidation in the surface of these acidic wetlands can reduce the methane flux to the atmosphere up to 90 percent. Here the isolation of three methanotrophic microorganisms from three boreal forest sites is reported. They are moderately acidophilic organisms and have a soluble methane monooxygenase, In contrast to the known groups of methanotrophs, 16S ribosomal DNA sequence analysis shows that they are affiliated with the acidophilic heterotrophic bacterium Beijerinckia indica subsp. indica.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Russian Acad Sci, Inst Microbiol, Moscow 117811, Russia; Max Planck Inst Terr Mikrobiol, D-35043 Marburg, Germany	Michigan State University; Research Center of Biotechnology RAS; Russian Academy of Sciences; Max Planck Society	Tiedje, JM (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.	tiedjej@pilot.msu.edu	Dedysh, Svetlana/S-1655-2016	Dedysh, Svetlana/0000-0001-8903-8053; Liesack, Werner/0000-0002-9533-1552				Amaral JA, 1998, APPL ENVIRON MICROB, V64, P2397; BECKING JH, 1984, BERGEYS MANUAL SYSTE, V1, P311; CARDY DLN, 1991, MOL MICROBIOL, V5, P335, DOI 10.1111/j.1365-2958.1991.tb02114.x; Dedysh S. N., 1997, Mikrobiologiya, V66, P563; Dedysh S. N., 1997, Mikrobiologiya, V66, P569; Dedysh SN, 1998, APPL ENVIRON MICROB, V64, P922; DUNFIELD P, 1993, SOIL BIOL BIOCHEM, V25, P321, DOI 10.1016/0038-0717(93)90130-4; FELSENSTEIN J, 1993, PHYLIP VERSION 3 5C; FUNG I, 1991, J GEOPHYS RES-ATMOS, V96, P13033, DOI 10.1029/91JD01247; Hanson RS, 1996, MICROBIOL REV, V60, P439, DOI 10.1128/MMBR.60.2.439-471.1996; HANSON RS, 1991, PROCARYOTES, P661; Hein R, 1997, GLOBAL BIOGEOCHEM CY, V11, P43, DOI 10.1029/96GB03043; IMHOFF JF, 1991, PROCARYOTES, V2, P2141; KHALIL MAK, 1985, ATMOS ENVIRON, V19, P397, DOI 10.1016/0004-6981(85)90161-1; KING GM, 1992, ADV MICROB ECOL, V12, P431; KRUMHOLZ LR, 1995, FEMS MICROBIOL ECOL, V18, P215, DOI 10.1111/j.1574-6941.1995.tb00178.x; LIESACK W, 1994, INT J SYST BACTERIOL, V44, P753, DOI 10.1099/00207713-44-4-753; Maidak BL, 1996, NUCLEIC ACIDS RES, V24, P82, DOI 10.1093/nar/24.1.82; Matthews E, 1987, GLOBAL BIOGEOCHEM CY, V1, P61, DOI 10.1029/GB001i001p00061; McDonald IR, 1996, FEMS MICROBIOL ECOL, V21, P197, DOI 10.1111/j.1574-6941.1996.tb00347.x; MCDONALD IR, 1995, APPL ENVIRON MICROB, V61, P116, DOI 10.1128/AEM.61.1.116-121.1995; McDonald IR, 1997, APPL ENVIRON MICROB, V63, P1898, DOI 10.1128/AEM.63.5.1898-1904.1997; PANIKOV NS, 1993, J ECOL CHEM, V1, P7; STAINTHORPE AC, 1990, GENE, V91, P27, DOI 10.1016/0378-1119(90)90158-N; Strunk O, 1996, ARB SOFTWARE ENV SEQ; SUNDH I, 1995, FEMS MICROBIOL ECOL, V18, P103, DOI 10.1111/j.1574-6941.1995.tb00167.x; Wise MG, 1997, APPL ENVIRON MICROB, V63, P1505, DOI 10.1128/AEM.63.4.1505-1514.1997; *WORLD MET ORG WDC, 1997, 4 WORLD MET ORG WDCG, P47; YAVITT JB, 1990, SOIL BIOL BIOCHEM, V22, P441, DOI 10.1016/0038-0717(90)90176-Z	29	104	117	6	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 9	1998	282	5387					281	284		10.1126/science.282.5387.281	http://dx.doi.org/10.1126/science.282.5387.281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	127VA	9765151				2022-12-24	WOS:000076370200044
J	Thorns, A				Thorns, A			White lies	BRITISH MEDICAL JOURNAL			English	Editorial Material									Trinity Hospice, London SW4 0RN, England		Thorns, A (corresponding author), 4 Ashley Cottages,Crampshaw Lane, Surrey KT21 2TZ, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 3	1998	317	7163					939	939						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	128LV	9756819				2022-12-24	WOS:000076409000034
J	Butz, S; Okamoto, M; Sudhof, TC				Butz, S; Okamoto, M; Sudhof, TC			A tripartite protein complex with the potential to couple synaptic vesicle exocytosis to cell adhesion in brain	CELL			English	Article							TUMOR-SUPPRESSOR PROTEIN; ELEGANS VULVAR INDUCTION; POSTSYNAPTIC DENSITY; RECEPTOR LOCALIZATION; EPITHELIAL-CELLS; NERVOUS-SYSTEM; NEUREXINS; JUNCTION; MEMBRANE; HOMOLOG	We identify a complex of three proteins in brain that has the potential to couple synaptic vesicle exocytosis to neuronal cell adhesion. The three proteins are: (1) CASK, a protein related to MAGUKs (membrane-associated guanylate kinases); (2) Mint1, a putative vesicular trafficking protein; and (3) Veli1, -2, and -3, vertebrate homologs of C. elegans LIN-7. CASK, Mint1, and Velis form a tight, salt-resistant complex that can be readily isolated. CASK, Mint1, and Velis contain PDZ domains in addition to other modules. However, no PDZ domains are involved in complex formation, leaving them free to recruit cell adhesion molecules, receptors, and channels to the complex. We propose that the tripartite complex acts as a nucleation site for the assembly of proteins involved in synaptic vesicle exocytosis and synaptic junctions.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, Dallas, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet,Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NIMH NIH HHS [R01-MH52804] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH052804] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; COHEN AR, 1998, IN PRESS J CELL BIOL; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1, DOI 10.1152/ajprenal.1998.274.1.F1; DUCLOS F, 1993, P NATL ACAD SCI USA, V90, P109, DOI 10.1073/pnas.90.1.109; DUCLOS F, 1995, MAMM GENOME, V6, P57, DOI 10.1007/BF00350899; Grindstaff KK, 1998, CELL, V93, P731, DOI 10.1016/S0092-8674(00)81435-X; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Hata Y, 1996, J NEUROSCI, V16, P2488; Hoskins R, 1996, DEVELOPMENT, V122, P97; Hunt CA, 1996, J NEUROSCI, V16, P1380; Ichtchenko K, 1996, J BIOL CHEM, V271, P2676, DOI 10.1074/jbc.271.5.2676; ICHTCHENKO K, 1995, CELL, V81, P435, DOI 10.1016/0092-8674(95)90396-8; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JONES DH, 1974, BIOCHIM BIOPHYS ACTA, V356, P276, DOI 10.1016/0005-2736(74)90268-5; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Kim SK, 1997, CURR OPIN CELL BIOL, V9, P853, DOI 10.1016/S0955-0674(97)80088-9; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Martin JR, 1996, EMBO J, V15, P1865, DOI 10.1002/j.1460-2075.1996.tb00537.x; MAZOYER S, 1995, GENOMICS, V28, P25, DOI 10.1006/geno.1995.1101; Missler M, 1998, TRENDS GENET, V14, P20, DOI 10.1016/S0168-9525(97)01324-3; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; OKAMOTO M, 1998, IN PRESS EUR J CELL; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Sambrook J, 1989, MOL CLONING LAB MANU, V2nd; Simske JS, 1996, CELL, V85, P195, DOI 10.1016/S0092-8674(00)81096-X; Smith KV, 1996, NURS ETHICS, V3, P17, DOI 10.1177/096973309600300104; Tsukita S, 1997, SOC GEN PHY, V52, P69; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; WEINBERG RJ, 1998, IN PRESS J CELL BIOL; Woods D F, 1993, J Cell Sci Suppl, V17, P171; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141	41	439	464	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	SEP 18	1998	94	6					773	782		10.1016/S0092-8674(00)81736-5	http://dx.doi.org/10.1016/S0092-8674(00)81736-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	121NX	9753324	Bronze			2022-12-24	WOS:000076021200010
J	Clayton, NS; Dickinson, A				Clayton, NS; Dickinson, A			Episodic-like memory during cache recovery by scrub jays	NATURE			English	Article							NUTCRACKERS NUCIFRAGA-COLUMBIANA; BLACK-CAPPED CHICKADEES; FOOD PERISHABILITY; SPATIAL MEMORY; MARSH TITS; SITES	The recollection of past experiences allows us to recall what a particular event was, and where and when it occurred(1,2), a form of memory that is thought to be unique to humans(3). It is known, however, that food-storing birds remember the spatial location(4-6) and contents(6-9) of their caches. Furthermore, food-storing animals adapt their caching and recovery strategies to the perishability of food stores(10-13), which suggests that they are sensitive to temporal factors. Here we show that scrub jays (Aphelocoma coerulescens) remember 'when' food items are stored by allowing them to recover perishable 'wax worms' (wax-moth larvae) and non-perishable peanuts which they had previously cached in visuospatially distinct sites, Jays searched preferentially for fresh wax worms, their favoured food, when allowed to recover them shortly after caching. However, they rapidly learned to avoid searching for worms after a longer interval during which the worms had decayed. The recovery preference of jays demonstrates memory of where and when particular food items were cached, thereby fulfilling the behavioural criteria for episodic-like memory in non-human animals.	Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA; Univ Cambridge, Dept Expt Psychol, Cambridge CB2 3EB, England	University of California System; University of California Davis; University of Cambridge	Clayton, NS (corresponding author), Univ Calif Davis, Sect Neurobiol Physiol & Behav, Davis, CA 95616 USA.	nsclayton@ucdavis.edu	Clayton, Nicola s/A-2891-2010	Clayton, Nicola/0000-0003-1835-423X				[Anonymous], 1983, CANADIAN PSYCHOL; BAKER MC, 1995, ANIM BEHAV, V49, P1599, DOI 10.1016/0003-3472(95)90081-0; Clayton NS, 1996, IBIS, V138, P250, DOI 10.1111/j.1474-919X.1996.tb04336.x; CLAYTON NS, IN PRESS J EXP PSYCH; CLAYTON NS, IN PRESS ANIM BEHAV; GENDRON RP, 1995, AM NAT, V145, P948, DOI 10.1086/285778; HadjChikh LZ, 1996, ANIM BEHAV, V52, P941, DOI 10.1006/anbe.1996.0242; HAMPTON RR, 1994, BEHAV ECOL, V5, P44, DOI 10.1093/beheco/5.1.44; KAMIL AC, 1993, ANIM BEHAV, V45, P241, DOI 10.1006/anbe.1993.1030; KAMIL AC, 1985, J EXP PSYCHOL ANIM B, V11, P95, DOI 10.1037/0097-7403.11.1.95; KAMIL AC, 1990, J EXP PSYCHOL ANIM B, V16, P162, DOI 10.1037/0097-7403.16.2.162; REICHMAN OJ, 1988, ANIM BEHAV, V36, P1525, DOI 10.1016/S0003-3472(88)80223-9; SHERRY DF, 1982, ANIM BEHAV, V30, P631, DOI 10.1016/S0003-3472(82)80080-8; Shettleworth S. J., 1995, P NATO ADV STUDY I S, P158; SHETTLEWORTH SJ, 1982, J EXP PSYCHOL ANIM B, V8, P354, DOI 10.1037/0097-7403.8.4.354; STEVENS TA, 1986, IBIS, V128, P513, DOI 10.1111/j.1474-919X.1986.tb02703.x; Tulving E., 1972, ORG MEMORY, P382, DOI DOI 10.1007/978-1-4419-0463-8_37; TULVING E, IN PRESS HIPPOCAMPUS	18	859	878	6	336	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 17	1998	395	6699					272	274		10.1038/26216	http://dx.doi.org/10.1038/26216			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	120TZ	9751053				2022-12-24	WOS:000075974600049
J	Fukuda, K; Nisenbaum, R; Stewart, G; Thompson, WW; Robin, L; Washko, RM; Noah, DL; Barrett, DH; Randall, B; Herwaldt, BL; Mawle, AC; Reeves, WC				Fukuda, K; Nisenbaum, R; Stewart, G; Thompson, WW; Robin, L; Washko, RM; Noah, DL; Barrett, DH; Randall, B; Herwaldt, BL; Mawle, AC; Reeves, WC			Chronic multisymptom illness affecting Air Force veterans of the Gulf War	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OPERATION-DESERT-SHIELD; PERSIAN-GULF; US VETERANS; HEALTH; STORM; MISSISSIPPI; INFECTION; MORTALITY; PERSONNEL; DISEASES	Context.-Gulf War (GW) veterans report nonspecific symptoms significantly more often than their nondeployed peers. However, no specific disorder has been identified, and the etiologic basis and clinical significance of their symptoms remain unclear. Objectives.-To organize symptoms reported by US Air Force GW veterans into a case definition, to characterize clinical features, and to evaluate risk factors. Design.-Cross-sectional population survey of individual characteristics and symptoms and clinical evaluation (including a structured interview, the Medical Outcomes Study Short Form 36, psychiatric screening, physical examination, clinical laboratory tests, and serologic assays for antibodies against viruses, rickettsia, parasites, and bacteria) conducted in 1995, Participants and Setting.-The cross-sectional questionnaire survey included 3723 currently active volunteers, irrespective of health status or GW participation, from 4 air force populations,The cross-sectional clinical evaluation included 158 GW veterans from one unit, irrespective of health status. Main Outcome Measures.-Symptom-based case definition; case prevalence rate for GW veterans and nondeployed personnel; clinical and laboratory findings among veterans who met the case definition. Results.-We defined a case as having 1 or more chronic symptoms from at least 2 of 3 categories (fatigue, mood-cognition, and musculoskeletal). The prevalence of mild-to-moderate and severe cases was 39% and 6%, respectively, among 1155 GW veterans compared with 14% and 0.7% among 2520 nondeployed personnel. Illness was not associated with time or place of deployment or with duties during the war. Fifty-nine clinically evaluated GW veterans (37%) were noncases, 86 (54%) mild-to-moderate cases, and 13 (8%) severe cases, Although no physical examination, laboratory, or serologic findings identified cases, veterans who met the case definition had significantly diminished functioning and well-being. Conclusions.-Among currently active members of 4 Air Force populations, a chronic multisymptom condition was significantly associated with deployment to the GW. The condition was not associated with specific GW exposures and also affected nondeployed personnel.	Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA; ABT Associates Inc, Cambridge, MA 02138 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; ABT Associates	Reeves, WC (corresponding author), Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Mail Stop A-15,1600 Clifton Rd, Atlanta, GA 30333 USA.	wcr1@cdc.gov		Fukuda, Keiji/0000-0002-9598-9565				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; American Psychological Association, 1994, DIAGN STAT MAN MENT, V4th; [Anonymous], 1983, FACTOR ANAL; ASH LR, 1987, PARASITES GUIDE LAB, P51; BASILEVSKI A, 1994, STAT FACTOR ANAL REL; CAMARGO MARIO E., 1966, REV INST MED TROP SAO PAULO, V8, P227; *CDCP, 1992, MMWR-MORBID MORTAL W, V41, P131; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P443; DEFRAITES RF, 1992, INVESTIGATION SUSPEC; *DEP DEF, 1996, COMPR CLIN EV PROGR; Floyd FJ, 1995, PSYCHOL ASSESSMENT, V7, P286, DOI 10.1037/1040-3590.7.3.286; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; GOW JW, 1991, BRIT MED J, V302, P692, DOI 10.1136/bmj.302.6778.692; Gray GC, 1996, NEW ENGL J MED, V335, P1505, DOI 10.1056/NEJM199611143352007; GREEN GM, 1994, JAMA-J AM MED ASSOC, V272, P391, DOI 10.1001/jama.1994.03520050071033; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P231, DOI 10.1001/jama.277.3.231; Haley RW, 1997, JAMA-J AM MED ASSOC, V277, P215, DOI 10.1001/jama.277.3.215; HARMAN HH, 1976, MODERN FACTOR ANAL, P268; HYAMS KC, 1995, CLIN INFECT DIS, V20, P1497, DOI 10.1093/clinids/20.6.1497; HYAMS KC, 1991, NEW ENGL J MED, V325, P1423, DOI 10.1056/NEJM199111143252006; Hyams KC, 1996, ANN INTERN MED, V125, P398, DOI 10.7326/0003-4819-125-5-199609010-00007; HYAMS KC, 1993, J INFECT DIS, V167, P986, DOI 10.1093/infdis/167.4.986; Institute of Medicine, 1996, HLTH CONS SERV PERS; Kang HK, 1996, NEW ENGL J MED, V335, P1498, DOI 10.1056/NEJM199611143352006; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MAGILL AJ, 1993, NEW ENGL J MED, V328, P1383, DOI 10.1056/NEJM199305133281904; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; MELVIN DM, 1982, PUBL CDC; MURRAYLEISURE KA, 1994, 34 INT C ANT AG CHEM; NEWHOUSE VF, 1979, AM J TROP MED HYG, V28, P387, DOI 10.4269/ajtmh.1979.28.387; Nisenbaum R, 1998, AM J EPIDEMIOL, V148, P72, DOI 10.1093/oxfordjournals.aje.a009562; Penman AD, 1996, MIL MED, V161, P1; RONALD MG, 1995, ARCH INTERN MED, V155, P262; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; *STAT AN SYST I, 1990, SAS STAT US GUID, V1; *STAT AN SYST I, 1990, SAS STAT US GUID, V2; STRETCH RH, 1995, MIL MED, V160, P131, DOI 10.1093/milmed/160.3.131; Tabachnick B.G., 1983, USING MULTIVARIATE S; Tsai Theodore F., 1995, P980; TSANG VCW, 1991, CLIN LAB MED, V11, P1029, DOI 10.1016/S0272-2712(18)30533-X; *UN SPEC COMM IR, 1995, REP SECR GEN STAT IM; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEBER R, 1992, NEW ENGL J MED, V326, P161, DOI 10.1056/NEJM199201163260304; Writer JV, 1996, JAMA-J AM MED ASSOC, V275, P118, DOI 10.1001/jama.275.2.118	45	506	515	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 16	1998	280	11					981	988		10.1001/jama.280.11.981	http://dx.doi.org/10.1001/jama.280.11.981			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	119JC	9749480				2022-12-24	WOS:000075891400031
J	Owen, L; McNeill, A; Callum, C				Owen, L; McNeill, A; Callum, C			Trends in smoking during pregnancy in England, 1992-7: quota sampling surveys	BRITISH MEDICAL JOURNAL			English	Article									Hlth Educ Author, London SW1P 2HW, England		Owen, L (corresponding author), Hlth Educ Author, Trevelyan House, London SW1P 2HW, England.			McNeill, Ann/0000-0002-6223-4000				CAMPION P, 1994, ADDICTION, V89, P1245, DOI 10.1111/j.1360-0443.1994.tb03303.x; CAMPION P, 1994, HLTH ED J, V53, P163; Department of Health, 1992, HLTH NAT STRAT HLTH; Foster K, 1997, INFANT FEEDING 1995; Royal College of Physicians, 1992, SMOK YOUNG	5	71	73	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 12	1998	317	7160					728	728		10.1136/bmj.317.7160.728	http://dx.doi.org/10.1136/bmj.317.7160.728			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	121CT	9732341	Green Submitted, Bronze, Green Published			2022-12-24	WOS:000075995100022
J	Cook, P				Cook, P			Duplicating a tangled genome	SCIENCE			English	Editorial Material							RNA-POLYMERASE-II; DNA-REPLICATION; NUCLEAR MATRIX; RAT-LIVER; TRANSCRIPTION; DOMAINS; SITES; VISUALIZATION; PHASE		Univ Oxford, Sir William Dunn Sch Pathol, Dept Cell Biol, Oxford OX1 3RE, England	University of Oxford	Cook, P (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, Dept Cell Biol, S Parks Rd, Oxford OX1 3RE, England.			Cook, Peter/0000-0002-6639-188X				BEREZNEY R, 1977, J CELL BIOL, V73, P616, DOI 10.1083/jcb.73.3.616; FOX MH, 1991, J CELL SCI, V99, P247; HASSAN AB, 1994, J CELL SCI, V107, P1381; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Jackson DA, 1998, MOL BIOL CELL, V9, P1523, DOI 10.1091/mbc.9.6.1523; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; NAKAMURA H, 1986, EXP CELL RES, V165, P291, DOI 10.1016/0014-4827(86)90583-5; NAKAYASU H, 1989, J CELL BIOL, V108, P1, DOI 10.1083/jcb.108.1.1; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Pederson T, 1998, J MOL BIOL, V277, P147, DOI 10.1006/jmbi.1997.1618; TUBO RA, 1987, J BIOL CHEM, V262, P5857; WANSINK DG, 1994, J CELL SCI, V107, P1449; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; Wei XY, 1998, SCIENCE, V281, P1502, DOI 10.1126/science.281.5382.1502; Zink D, 1998, HUM GENET, V102, P241, DOI 10.1007/s004390050686	17	14	14	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	SEP 4	1998	281	5382					1466	1467		10.1126/science.281.5382.1466	http://dx.doi.org/10.1126/science.281.5382.1466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	116RJ	9750117				2022-12-24	WOS:000075738100028
J	Weiland, O				Weiland, O			Can HCV infection be cleared?	LANCET			English	Editorial Material							HEPATITIS-C; INDIVIDUALS; RNA		Huddinge Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden	Karolinska Institutet	Weiland, O (corresponding author), Huddinge Hosp, Karolinska Inst, Div Infect Dis, S-14186 Huddinge, Sweden.			Weiland, Ola/0000-0002-6934-9724				ALBERTI A, 1992, LANCET, V340, P697, DOI 10.1016/0140-6736(92)92234-7; Hawkins A, 1997, J CLIN MICROBIOL, V35, P187, DOI 10.1128/JCM.35.1.187-192.1997; Haydon GH, 1998, GUT, V42, P570, DOI 10.1136/gut.42.4.570; Lindsay KL, 1997, HEPATOLOGY, V26, pS71, DOI 10.1002/hep.510260713; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; Mason AL, 1998, HEPATOLOGY, V27, P1736, DOI 10.1002/hep.510270638; REICHARD O, IN PRESS J MED VIROL	7	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	1998	352	9129					669	670		10.1016/S0140-6736(05)60815-X	http://dx.doi.org/10.1016/S0140-6736(05)60815-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	116MT	9728977				2022-12-24	WOS:000075729700005
J	Herman, ST; Pedley, TA				Herman, ST; Pedley, TA			New options for the treatment of epilepsy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							NEWLY-DIAGNOSED EPILEPSY; PHARMACOKINETICS; CARBAMAZEPINE; LAMOTRIGINE; VIGABATRIN; SAFETY		Columbia Presbyterian Med Ctr, Inst Neurol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University	Pedley, TA (corresponding author), Columbia Presbyterian Med Ctr, Inst Neurol, 710 W 168th St, New York, NY 10032 USA.			Herman, Susan/0000-0002-6556-083X				Bergey GK, 1997, NEUROLOGY, V49, P739, DOI 10.1212/WNL.49.3.739; Biton V, 1997, EPILEPSIA, V38, pS42, DOI 10.1111/j.1528-1157.1997.tb04518.x; Blum D E, 1998, Adv Neurol, V76, P57; BRODIE MJ, 1995, LANCET, V345, P476, DOI 10.1016/S0140-6736(95)90581-2; Chadwick DW, 1997, EPILEPSIA, V38, pS59, DOI 10.1111/j.1528-1157.1997.tb04522.x; DEVINSKY O, 1995, ANN NEUROL, V38, P670, DOI 10.1002/ana.410380418; Dooley J, 1996, NEUROLOGY, V46, P240, DOI 10.1212/WNL.46.1.240; Dreifus FE, 1998, NEW ENGL J MED, V338, P1869, DOI 10.1056/NEJM199806253382602; FEUCHT M, 1994, EPILEPSIA, V35, P993, DOI 10.1111/j.1528-1157.1994.tb02544.x; KALVIAINEN R, 1995, ARCH NEUROL-CHICAGO, V52, P989, DOI 10.1001/archneur.1995.00540340081016; Krauss GL, 1998, NEUROLOGY, V50, P614, DOI 10.1212/WNL.50.3.614; LEPPIK IE, 1990, NEUROLOGY, V40, P456, DOI 10.1212/WNL.40.3_Part_1.456; Macdonald RL, 1997, CURR OPIN NEUROL, V10, P121, DOI 10.1097/00019052-199704000-00009; MOTTE J, 1997, NEW ENGL J MED, V337, P1801; Pellock JM, 1997, EPILEPSIA, V38, P1261, DOI 10.1111/j.1528-1157.1997.tb00061.x; RITTER FJ, 1993, NEW ENGL J MED, V328, P29; Sachdeo RC, 1997, EPILEPSIA, V38, P294, DOI 10.1111/j.1528-1157.1997.tb01120.x; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Shorvon S, 1997, EPILEPSIA, V38, pS45, DOI 10.1111/j.1528-1157.1997.tb04519.x; Vigevano F, 1997, EPILEPSIA, V38, P1270; WALKER MC, 1995, PHARMACOL THERAPEUT, V67, P351, DOI 10.1016/0163-7258(95)00021-6	21	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 26	1998	280	8					693	694		10.1001/jama.280.8.693	http://dx.doi.org/10.1001/jama.280.8.693			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	111PM	9728627				2022-12-24	WOS:000075446900013
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Tissue cork borer	SCIENCE			English	Article																		Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844	1	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 21	1998	281	5380					1163	1163						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	113CE	9735032				2022-12-24	WOS:000075531200042
J	Zou, JY; Guo, YL; Guettouche, T; Smith, DF; Voellmy, R				Zou, JY; Guo, YL; Guettouche, T; Smith, DF; Voellmy, R			Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1	CELL			English	Article							PROGESTERONE-RECEPTOR COMPLEXES; DNA-BINDING ACTIVITY; AMINO-ACID-ANALOGS; STEROID-RECEPTORS; GLUCOCORTICOID RECEPTOR; IN-VIVO; RETICULOCYTE LYSATE; MOLECULAR-CLONING; PROTEIN-SYNTHESIS; GENE-EXPRESSION	Heat shock and other proteotoxic stresses cause accumulation of nonnative proteins that trigger activation of heat shock protein (Hsp) genes. A chaperone/Hsp functioning as repressor of heat shock transcription factor (HSF) could make activation of hsp genes dependent on protein unfolding. In a novel in vitro system, in which human HSF1 can be activated by nonnative protein, heat, and geldanamycin, addition of Hsp90 inhibits activation. Reduction of the level of Hsp90 but not of Hsp/c70, Hop, Hip, p23, CyP40, or Hsp40 dramatically activates HSF1. In vivo, geldanamycin activates HSF1 under conditions in which it is an Hsp90-specific reagent. Hsp90-containing HSF1 complex is present in the unstressed cell and dissociates during stress. We conclude that Hsp90, by itself and/or associated with multichaperone complexes, is a major repressor of HSF1.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA; Univ Nebraska, Med Ctr, Dept Pharmacol, Omaha, NE 68198 USA	University of Miami; University of Nebraska System; University of Nebraska Medical Center	Voellmy, R (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.				NIGMS NIH HHS [GM31125] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Baler R, 1996, CELL STRESS CHAPERON, V1, P33, DOI 10.1379/1466-1268(1996)001<0033:EFAROH>2.3.CO;2; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; BALER R, 1993, MOL CELL BIOL, V13, P2486, DOI 10.1128/MCB.13.4.2486; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P1472; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; HATTORI H, 1993, J CELL SCI, V104, P629; Hedge Ramanujan S., 1995, Journal of Cellular Physiology, V165, P186; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; HUANG LE, 1994, J BIOL CHEM, V269, P30718; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; LAI BT, 1984, MOL CELL BIOL, V4, P2802, DOI 10.1128/MCB.4.12.2802; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; LEPOCK JR, 1993, J CELL BIOL, V122, P1267, DOI 10.1083/jcb.122.6.1267; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; Morimoto R I, 1996, EXS, V77, P139; MOSSER DD, 1993, MOL CELL BIOL, V13, P5427, DOI 10.1128/MCB.13.9.5427; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; NUNES SL, 1995, BIOCHEM BIOPH RES CO, V213, P1, DOI 10.1006/bbrc.1995.2090; OREILLY DR, 1992, BACULOVIRUS EXPRESSI; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1994, MOL CELL BIOL, V14, P6552, DOI 10.1128/MCB.14.10.6552; RIEHL RM, 1985, BIOCHEMISTRY-US, V24, P6586, DOI 10.1021/bi00344a042; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SANCHEZ ER, 1990, J BIOL CHEM, V265, P20123; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Voellmy R, 1996, EXS, V77, P121; Whitesell L, 1997, ONCOGENE, V14, P2809, DOI 10.1038/sj.onc.1201120; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Whitesell L, 1996, MOL ENDOCRINOL, V10, P705, DOI 10.1210/me.10.6.705; Xiao NQ, 1997, MOL ENDOCRINOL, V11, P1365, DOI 10.1210/me.11.9.1365; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0; ZOU J, 1998, IN PRESS CELL STRESS; ZUO JR, 1994, MOL CELL BIOL, V14, P7557, DOI 10.1128/MCB.14.11.7557	54	907	951	2	71	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	AUG 21	1998	94	4					471	480		10.1016/S0092-8674(00)81588-3	http://dx.doi.org/10.1016/S0092-8674(00)81588-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	113GB	9727490	Bronze			2022-12-24	WOS:000075541100009
J	Nightingale, SL				Nightingale, SL			Thalidomide approved for erythema nodosum leprosum	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	17	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					872	872		10.1001/jama.280.10.872	http://dx.doi.org/10.1001/jama.280.10.872			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739956				2022-12-24	WOS:000075666600006
J	Nightingale, SL				Nightingale, SL			FDA seeks input from stakeholders	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	17	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 9	1998	280	10					872	872		10.1001/jama.280.10.872	http://dx.doi.org/10.1001/jama.280.10.872			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	115LN	9739956				2022-12-24	WOS:000075666600045
